Content-Type: text/html

#

    Reference sequence (query): batch____
    Identities normalised by aligned length.
    Colored by: property

    HSP processing: ranked
    Search cycle: 3

                                                                                                          1 [        .         .         .         .         :         .         .         .         .         1         .         .         .         .         :         .         .         .         .         2         .         .         .         .         :         .         .         .         .         3         .         .         .         .         :         .         .         .         . ] 392
         batch____                                              bits   E-value  N 100.0%  1:392             MIWIMTMARRMNGVYAAFMLVAFMMGVAGALQAPTLSLFLSREVGAQPFWIGLFYTVNAIAGIGVSLWLAKRSDSQGDRRKLIIFCCLMAIGNALLFAFNRHYLTLITCGVLLASLANTAMPQLFALAREYADNSAREVVMFSSVMRAQLSLAWVIGPPLAFMLALNYGFTVMFSIAAGIFTLSLVLIAFMLPSVARVELPSENALSMQGGWQDSNVRMLFVASTLMWTCNTMYIIDMPLWISSELGLPDKLAGFLMGTAAGLEIPAMILAGYYVKRYGKRRMMVIAVAAGVLFYTGLIFFNSRMALMTLQLFNAVFIGIVAGIGMLWFQDLMPGRAGAATTLFTNSISTGVILAGVIQGAIAQSWGHFAVYWVIAVISVVALFLTAKVKDV
       1 UniRef50_C9MEZ4        Sugar efflux transporter n=...   209     1e-52  1  13.9%  1:388 391:772     MSLYLKAEKIQSWRVLIMACAGFIFNTTEFVPVAMLSD-IAQSFDMQTADTGLMMTVYAWTVLIMSLPA-MLATGNMERKSLLIKLFIIFIVGHILLVIAWNFWILLLARMCIALAHSVFWSITASLVMRISPKHKKTQA--LGMLAIGTALATILGLPIGRIVGQLVGWRVTFGIIAVLALSIMFLIIRLLPNLPSKN--AGSIASLPLLAKRPLLLWLYVTTAIVISAHFTAYTYIEPFMIDVGQLDPNFATAVLLVFGFSGIAASLLFNRLYRLAPTKFIVVSMSLLMFSLLLLLFSTETIIAMFSLVFIWGIGISCIGLSLQMRVLKLAPDATDVATAIYSGIFNAGIGAGALFGNLATTYLGLNEIGYTGAALGLIGLIIFIT----
       2 UniRef50_A0RA52        Quinolone resistence protei...   198     3e-49  1  14.1%  5:388 113:489     ----VKREPLWTKEFIALILANLCMFLGFQMLIPTLPVYV-KEIGGTSSNIGFVVGMFTVAALFVRPLTGNALQKF-SKKIILMIGTAICLLAMGSYLFASTVFLLLAVRILHGAGFGITTTTYGTVVSDLIPQARRGEGM--GYFGLSGTIAMALGPLIGLWLMQTYNFTILFL-CALSCTIVSLILTKLLQIKKSPQPPKQTSGTFLDGFIERKALLPSLLILCITLMYGGIGSFITLFATEV---GIADISLFFLFNALAIAVTRPFSGKLYDAKGHSFVIIPGVIITFTGIILLSYTTTIPSLIIAAACYGSGFGAIQPALQAWMIdvAPHRRGVATATFFSAFDLGIGAGAIIFGFIAHFTNYATVYRYSSLLLIAFLFIYIT----
       3 UniRef50_A6Q5H8        Multidrug-efflux transporte...   197     5e-49  1  14.1% 15:391   8:382     --------------VLPLSLIVALRFFGLFIVLAVLSQYALQLKGGTAFLAGVAVGGYAFTQALLQVPFGVLSDKIGRKKTILI-GLLLFAAGSVICAVADNIYVLLLGRFLQG--SGAIGSVVTAMIADYVREDER--AHAMAVMGMVIAMSFAAAMIIGPIIGGLYSVKALFWLTAILAILALGILFTAVPEPPKIVHhsEEEAKIKEVFKDKDLVRMYITFLFHSSTMAIAFFIIPILMKQKFGLGPEHYWKVYLPAVIFGILSMGPAAVFGEKYHKGkvFIVSILFIAVSFALMGFSSSFLLFTIGAVFFFIGFNMFEPLLQSFVSKFArhQKGAALGVANTFAYIGIFLGGAIGGLLYQYGHEKAVAIFVLIVSMVWIYWIVGMRN-
       4 UniRef50_Q31IV1        Major facilitator superfami...   192     2e-47  1  16.1%  6:389   7:392     -----SMAPIERRAAFSVAGIFSTRMLGLFMIFPVFALFAHEEfgVTATQIGIAMGIYGLTQAVLQIPYGMLSDRFG-RKPLIIVGMLVFMLGSIVCAMADSIEMMIVGRAIQGM--GAVAAVLMATVADLVTEQFRLRAM--SIVGMTIGLSFTLSLVVGPMLGELFGVRGIFWVIAGLGVLGIVLVLFAVPKIENqrEAEADPSQFKDVIKNPQLLRLDIGVFVLHAILTAMFIAIPFMIRDNAGLDSLHHWELYLPVMLLSFVLMVPFIIQAESKGRMKPIFVGAILTIALmgFLFEANGFWTMFVLLLIFFTAFNLLEASLPSLVVKLSpdKKGTASGVYSSSQFLGAASGGFIGGWFYEMYGLEGLFFFTASIGFVWFLIAMSM---
       5 UniRef50_C4LKD4        Permease of the major facil...   192     3e-47  1  13.2%  3:387 213:592     --QTEMGSRRALFALIALSIGGFGIGTTEFVSMGLL-KYIGADYGISDGAAGRIVTAYAMGVVVGAPLITALTGKI-PRRRLLLLLMGAFTVGNGLSVFAPNYPFLIAARFIAGIPHGAFFGVSSLVAVSLSKPGKRGQA--IAIVNLGLPIATLIGVPLAQAIGQAMSWHYAYAMVSLIGLATLVSIWIALPHMTLMLTTNPLTE--LSALIKPQVLLTLLMGTVGFGGMFAVYTYISWTMTEVAGLPASLMWIVLMSYGVGMIIGTWFGGKLVDYNPERGIFFSLIVMMVILTAFFFTSHNPWLGTINFALIGMSGSLLTPNLQSRLMDTAGEAQNLASALNQSALNLANAGGAMVGGWVVSafGYSSGGLAGALMALLSMIVWA-----
       6 UniRef50_B0MWI8        Putative uncharacterized pr...   190     8e-47  1  15.3%  1:391   1:381     MKGTTTQDRLWTGSFLRICLVNLFIFVNFHALLPTFPFFVT-YLGGDAVTIGLATALFSIASIVSRPFVGWLIDTRGRY-AILVLGLIGMTLIPMGYFVSAGIATAVILRTAHGVFHAASSNASSTWVTDIIPHKRMGEG--LGMYGLSMAISTAVAPALGLAVMNAWGFR-PLFAIAALTALAALLTGMGIRSRNYAVSDAPLRIRE---LFEPMSLPAAVTQFFFMMAYGVVEVYMAIYAASCR---LPGGGIYFIFIALATVATRILLGRAVDRYGEARLVYTGNAAIVIGILLLVFAHNVPCYLLSALLLGYSFGAIQPSLQTMAMhvAPERRGAASSTFFVAFDFGIASGGFLAGILVKQLGYDAMFLCMIVPCLLSSGYYYAFGR-
       7 UniRef50_Q3J6T2        Major facilitator superfami...   188     4e-46  1  15.0%  4:389  11:397     ---TLGMTLLERRSLFSLAGIYSLRMLGLFLILPVFSLYAHDLQGATPALIGLALGAYGITQALLQIPFGLLSDRIG-RKPIITAGLILFALGSIVAAMADTIAGVIIGRALQG--TGAIAAAVMALVADLTREEQRTKAM--ALIGLSIGMSFAVALAAGPVLNQWIGVPGLFWLTAILAVLGIAVLHLGVPQVTAPRHhePAPQQFLRVLGDFQLMRLALGIFFLHLLLTASFVVLPISLRDESGLDPAYHGYVYLPVLVTSIIAMVPFIILAEKKRRMKEVFIgaVLGLAELAWRFFHPSLAGTIVALWLFFTAFNLLEATLPSLVSKQSpgSKGTAMGVYSTCQFLGAFVGGWAGGAVYGYFGFEGVFTFCAGIVALWLIFAATM---
       8 UniRef50_B4EX10        MFS-family transporter n=5 ...   187     8e-46  1  14.4%  7:387   1:380     ------MKLSIRSLFYLVCFSALLGSLAQNIYTPVLPL-IQQQFNTTLSLVNLTVSAFTFAMAVMQLCYGSLIDKWG-RKPILLSGLTISIIGALICIWANSINLLIFGRVIQAIGIAAIPVVAATILGDLYQGNERAKAM--GSYQMLLALAPASGPLLGGYLAQHYHYQSIFVFLSMVGLVLLIAHLFYLPETRPEQKQskSLSAMRQVLAAPEGKSVFVISFMVFYNYFCLLVFLPLIAFHLYHLNSSEIGGLYVPMSIALVLGSYLYRKVCHLFSagVIITSCINLAMLSLFALFWQISLPIMLILTVLYGLSLGLTMPTHTTLITSHFSSVRATAMGIYNFIRYCGMAAGPMVASYFVTDNHYQYVFYSCVILTSLALCFAI-----
       9 UniRef50_C6PTG8        Major facilitator superfami...   185     3e-45  1  15.7% 12:386   8:384     -----------KLPLFILMINLFIALLGQGMVIPILPEYLKQ-FNAAGSAAGYLVAAFGAAQFLFSPIGGRLSDRYG-RKIMIFSGMILTVISDFIFAVSPYLMLLYIARFIGGIGLGIMIPSVLAYVSDVTSKD--TRAKGMGYLSAAMNLGMVLGPGIGGMIAN-FGIRVPYFFAAALGIASTLLTL-ILPETLPIEKRTASKGsqLVKSAHTSYFRYLILIFIMTFGLVNYETVYSLFVEHKYGFTTQQVSVLITLGAAIGIIVqwLIDKVIKRYGEYKTIRFSLVMAAIALVLMLLKVNFIYLILVSSVFFTFNSLLRPTVNTMLSKEAGDQQGFVSGLNNMYTSLGNIIGPILAGNLFDK-QINLPYILGAFILLITTCLV------
      10 UniRef50_A0RG90        Quinolone resistence protei...   183     9e-45  1  13.7%  4:389   2:383     ---TMQSEKLWTKDFLGTCFSSLFLFLTFYMLMTTLPVYVIDGLKGKPEEIGLVATVFLISSVLCRPFTGKWLDDLGRKK-ILFISLSLFLAATVMYFGAQSLFLLLALRFLHGIGFGMATTATGTIVTDVAPAHRRGEA--LAYFGVFMSLPMVIGPFLGLTIISHFSFTVLFIVCSVFSLLAFLLGLLVNIPHEAPVSKQKQEKMKWKDLLEPSSIPIALTGFVLAFSYSGILSFIPIYAKEL--GLADIASYFFILYALVVVISRPFTGKIFDRFGENVLVYPAIIIFTIGMFILSQAQTPFWFLGAGMLIGLGYGTLIPSFQTIAISAAphRRGSATATYFSFFDSGIGFGSFILGIVAAKSSYHNMYFIAAIIVAFTLLLYYGL---
      11 UniRef50_A5VHZ1        Major facilitator superfami...   183     1e-44  1  13.8%  7:391   1:390     ------MTKEVKRIIFVVLFCEFLICLGMSLIFPVEP-FIKNEYHFTAFDMGVMSSLFAFVQFIASPIVGRISDKVG-RKPMLVWGLLIFAIAEFVFALAQHLWLFDLSRAVDGLSAAMFVPTSMALAADITSEKDR--AKVIGWLSAAFSG-GLILGPGLGGMLAHVNYKFPFWVAGILGLISTVVAWRFLpkSETKNPENELLTGGWSQLKqpILITLFGMIFVASFGLAGFESIYSLYVNEVHNFDLNAIALVLTLNGIISLILqfFFDRLVRWLGEVRLMRYSFFLSLVGTIMVIYDHNHWHIIIATLFVFEAFDLLRPTITTLLTKMSKTNQGLLNGVNMSLTSVGNIIGPLISGYLLD-VNYQYPYWFVSIFLIISWVITLILGR-
      12 UniRef50_A3WJW9        Sugar permease, MFS-like n=...   183     1e-44  1  12.9%  4:391  10:398     ---TVSDSARFDFVVIILALLTAFAPLSIDMYLPAFTA-IAADYQTDTHRVELSLSAFFFGLFIGQLLYGTATDKFGRKKPLYI-GLAIYVVTSIACAWAPDIEWLIVLRFFQAIGACAGIVIARAVVRDLYTPQ--ASARVFSFLILVMGVAPILAPLFGNYVTEWFGWRAIFWIVSVLGVACAFVIHLVLPETRGRrrMRHSGRTYWDVLKDRSFLRYSLTGGIAQAGLFAYITGSPLMFIELFDFTPSAYSWLFGANAVGIIGFSQLNGWLLKYYPARKILNVSLPILAVVSVGMAVaaPVWGILVPLFAYISTLGLVFPNAMAGALANQQERAGSASAVTGSLQFLIAGLVSMGVNSVSGLTDYAMAWVIGS--TGIIAVVTYRLMR-
      13 UniRef50_C6IV54        Major facilitator superfami...   183     1e-44  1  15.2% 11:386  20:405     ----------WKINLIVLWFGQFLVNAGMTMITPFLSLYLARDLHVQglWAGMIFAANFATSFIFQPIWGKLADKYG-RKIMLLRSGFGMAIVITLMGFATQPWHLLGLRLLNG-TISGFNPASVALISGTAPKERMGFAM--GTIQSGNVAGTILGPLIGGLMAEQIGFRPIFYITGVLLFIASMLALLFVReeALHTPQPSVLQGFLELNKTPQLTALFAVTFLLQFAMLSPMSLLPLYVEKLHGQTAdwAGFVSAVTGISNMITSPVLGRISDKLGAHRILTYCLIGAAATLIPQAFVQTVWQLIAVRFLMGVFMGGLLPSVNALIRYYTPDGmsRAFGFNSSTLALGNMMGSLIGGFLAGYIGIEGLFVISGILLLINMLWV------
      14 UniRef50_D2LTY2        Major facilitator superfami...   183     1e-44  1  15.2% 12:392  43:432     -----------KRNLVIMCIVNFFVAASATMILPFLSIYIDTFGEFTDawAGFVFGITFLIAFFVSPFWGRFGDKFGRKRILLITGYGI-AISIFLMGYIQSVLGLFILRLIMGIVTG-FIPTSIALIAAQTKKEEAGK--VLGTLQMGTVSGGLFGPMIGGVLADSFGFAYTFIITAIIIAAATTIVHFGIKENRnrNKRHSMREVLKMIFTNKVLLIVMFVSFIIQTANFSIQPQLALYVDQLIQAeaFLAGMAFSVTGLGNLMATRFWGILGDRIGHEKVLLTCLILAGLFFLPQAFVTNIWQLVFLRFLFGIQIGGVIPVVTAYIRKSVpsIQGEVLGYNQSFRFLGNVAGPVVGGLISGYWTIASVFYFSTSLFLIAAICLFICLRV
      15 UniRef50_B8G1J2        Major facilitator superfami...   182     2e-44  1  18.4%  7:386   1:376     ------MQKQYLRPMVILVIIQFLVMVGFGIVIPILP-FLIEELGGGAFSLGLFMSAYSIMQFFFAPFWGRLSDRIG-RRPVLLIGLSGYGITFFLYGMAGNLPLLIAFRALSGVVSSATLPTAMAYMADITEGADRSK--SMGMLGAAMGLGMVFGPALGGFLG-HYSFTLPFYFAGTLALLVLPFAWKLLPETLKEpeSKPKVRFHPGVIRDPLF-PLFIFNFVLSFTMAMFESTFTLFAAERVGFGPQEMGIVFMIIGITGVIVqmLIGKVVRRFGDAKPAKVGALLCAVAFLWLLWAPNAILLVLGTVVFMIGNSFMVPTGSSLVSKNSHTGQGASLGVFQSFGSLGRIAGPLVGGGIY-GLSMNTPYVIGAATLVLCLIFF------
      16 UniRef50_D2TTN7        Major Facilitator Superfami...   182     2e-44  1  14.4%  9:391  17:404     --------PAWWVTIFLFWLGWIFMYADRTILNPVMGE-LEKEFGLSGTQLGILNSVFYFSYALLQVPAGILGDKIGKKK-VLVPGFILFGVFTAVTGWAKSWYTLLFARVVTGAGEGTYYGPQYGLSSEQIPKKYRSLGS--AIINSGMAFGIALGLMTSSWLvqGYSWRMPFYAMAIPSVLVGLAIWFLVKEKKRAagKQVKKGKFSDLLKNRNLILTYIMVFCSLFGFFVILTWLPYYLQNERGIAGSDTGFISSLVAWISIPGALLFSSLSDKLGKRKPLIMFLvvAIISMLSIIWMPNMTGVIIALCVYGlgKLALDPVLVALVADSVDenYSTAFGLFNFIGMSSSILAPIIAGAARDITglASSFYVSATLLAIGLVAMLFLKE-
      17 UniRef50_C6XPM3        Putative uncharacterized pr...   182     2e-44  1  12.5%  8:390  30:419     -------SPLSIPTYRNLWTATAFSNMGSQ-IQVVAASWLMASLTDSPQLIALVQTAMSLPVMMFSIFGGALADRWDRRKLMLLSQTVMFCAAVTLMTATytPWFLLLFTAIIASGNAINNPSWHASVRDLIPRNILGRA--VALNSMSMNLARTLGPAIGGLIVAISSAATAFLVNVLSYIGLIITLLIWRpdIPSEPILQAVGAGMRFAIRSPYIRTAMVRGAMGGMTNSAILALAPVLVSQRYDGTALSFGFLLGGYGVGAVMGAISGGILREKWTSENVVRLGTVCIFIGLLLLAFAPVYLVSVMGMLLAGSGWVVKHTSLNTTVQLCAPRWvaRALSTYQMATFGAMVVGSWTYGFIAEYGSLSTAYFVASIILASSAILALGMK--
      18 UniRef50_A9VPP3        Major facilitator superfami...   181     5e-44  1  17.5%  1:388   1:394     MKEGVKMAS-WKRNLMICWLGCFTTAAGMSLVIPFLSFYI-EELGVtaQWSGLAFGVTFLMGAIVSPIWGKLGDIHG-RKLMLIRASLGMAIIMTLMGFVTDVYQLVALRFLMG-SVSGFLSTAMTLIAAETPQEHSGWA--ISTISTGGVSGSLLGPILGGYLSELIGMRHVFLVTGAFLFLSFLIVFFFLHEEKHSAkkAQPKKVWTMVPAKHLIISLFVATFIIQLANMSIQPIITLYVKHLAGPGTDHigAVMSATGLAVILAAPKLGRLSDHIGPQKTLVVALFAAGIIFIPQAFVTSAWQLLILRFLLGIAQAGLLPSVQTLLKQHTPTHvgRIFGYNQSFQFLGNMIGPVLGGQIAAHAGFQYVFFSTSSLLFIACIWVYF----
      19 UniRef50_C5F257        Multidrug-efflux transporte...   180     5e-44  1  15.6%  5:389   1:382     ----MIKKESLIKQTIPLSLILAGRFFGLFVVMPVLSLYALSMEGMSPILVGIAIGGYALTQVLFQIPFGFLSDKFG-RKSIIALGLIIFIIGSAVCAMSDDIYMLILGRFLQG--AGAIGGVVSAMIADLVKEEKRTKAM--ALMGATISLSFTTALIVGPILSAYFGVASLFWITCFLGVLSLGILLLFVPEAPKIQYsiSSSDKYSFILKNKNLQIMNLTNFLQKGFMTLAFLIIPIALVKGFEMPKENLYQVYVPASLLGLIAIAPAAIFAEKKGKFKSVLVVGILFFVVAYLLMLSQNLWVFVAGILVFFVGFSVHEPIMQSLASRykAHQKGSALGVFTAFGYFGSFVGALVGGHLYEYFGMLSISLFVVVVSFLWILALGFL---
      20 UniRef50_UPI0001C1603A General substrate transport...   179     1e-43  1  16.5%  1:387   1:382     MRNSPSLDPDLRKNLVVIFTSGLLFWSALASLLPTLPLYI-ESLGSTKQQIGMVMGSFAVGVLAFRPQVGKLADHQG-RKLVLLIGMVVATIAPLGYLAVKSLVGLMLIRAFHGISIAAFATAYIALVSDLAPDDRRGE--IIGYMSLVNPIGVAVGPALGGYLQAIAGYTPLFIFSGLLAGLGLICVIPITNPPRWKNNKQETGDDFWGILISPRVRVPAIILLMIGFSIGTIHTFIALYIKSI--GVDLNPGLFFAAAAISSFVIRLFVGRASDKYGRGLFVTLSLISYTVAMLIIWQANSSPTLLLGAIMEGAASGIAIPMISAMMTDRapHERGRIFSVSLTGFDLGLGIAGPVVGYIAQSTSYRHVFGLSFGLTLLAILIFI-----
      21 UniRef50_C6CRW4        Major facilitator superfami...   179     1e-43  1  13.5%  4:389  17:415     ---TLLKEKIWTRNFVTICVSSFFMFLTFYVLTTAFPLYVRDSLHGGQQQMGLVITIYVIGGVLIRPFSGQWVDRFGKRK-MAIIGMIIFLLACFSYFGTKGIILFLIVRFIHGMSYAVASTAMSTVAATIVPVSRQGEGM--GYYTMFMSIAMVVGPALGLFLWKDQNINVLLLAICIIAALSLGFAFVLkeAEPLVQEQPEKKGWRLSSFLEPAALPISLVGFILSFAYSSLSSFMASFTDEIHQ--SQVTGTFFMVFAVMIVVFRPVIGKVFDRYKEHYLYYPGIGLFAVGMFLLSQAHSAAMVLSAGVIMGIGYGALLPCFQTLAIKLSphRRGSANGTFFLMFDLGYGLGSYFMGMIASLTDYRMMYLVAGIVAVICAGGYYIL---
      22 UniRef50_A4VH19        Major facilitator family tr...   179     1e-43  1  14.8%  2:392  86:475     -SHTEKGTPRFTRTALALFAGGFATFALLYCVQPMMP-MLSQAFGINAAQSSLILSLSTLTLAVGLLITGPISDAIG-RKQVLVASLLAAAVFTVGSALAPSWHGVLLMRALVGLALSGVAAVAMTYLSEEIHPHHLGLAM--GLYIGGNAIGGMSGRLLSGVLVDYLSWHSVLGLMGGLALLAALLLWRFLPEspRPLRPQGLLQGYRLHFRDAGLPWLFLQGFLLMGSFVTLYNYIGYRLiePFHLSQTMIGL-LAVLYLSGIYSSAQVGALADRFGRRRVFWLVIALMLAGVGLTLF-DRLPLVLLGMLLFTFGFFGAHSVASSWIGRRARQARGQASSLYLFSYYLGSSIAGTLGGVFWHAAGWDGVGLFIASLLLIAFAVALHLARL
      23 UniRef50_C6CZM5        Major facilitator superfami...   179     1e-43  1  14.1% 10:386   2:378     ---------NRKFVLYIVAFAAFFGPFTQTIYTPILPE-VASQLHSTSFVVNLTISVFTLFLAIMQVVYGPLTDLKGRRKVML-FGITLYVIASIGCFFSETITFLLVFRALQAIGIAAGTVVAVTVISDLFEGKERGEAM--GTFQMLVSLGPVLGPVIGGFLGGKFNFHSVFLALAATGMIVLVFNYLYLKETKpvQAGRFQLRDFTGILQNRIGSSIIYLGFIQYYVFYYFLVFMPNILTDRYGLSGEQKGLVFLPMSLGIVIGSYLGGKIQSRIDGEKLLVLTSFLNAVsfFLLFYSISLPWLLAAIIFFGLSLGLSLPVQTTLLTGAFTNNRATAVGAYNLFRYMGMALSPILGSLFYNMGGYVLLYGFIIIVYLAFALLL------
      24 UniRef50_A6LRB1        Major facilitator superfami...   179     2e-43  1  12.6% 10:391  11:382     ---------LWTKNFVIINVINLLIFFGFQMLLPTLPLY-AKKLGGTNSIIGLVTGAFVVSSVIIRPISGLLLDKLGRQKVFLV-GLFIFIISVFSYSIVPFISAIIMIRFIHGFGWGAVSTASNTIASDNIPNDRFGEGM--GYFSLTSSLAMAIAPTIGLFVISKYSFQALFLTSTILAVLGGIIAFKL----EYKKIENKEQTKIKASLYEKISINPSIIVFFVTITYGALTSFLPLYASQK---GIENIGIFFTVYAISLFISRPIFGKIIDKLGFDYAIIPGFICVIISMLLLSESSNISMFLIAAFIYGIGFGATQSTLQTMAmgVPPSRLGAANATFFTAFDCGIGLGAVILGVVSSNVGYAQMYLWASGAAIIAFILYFIIGR-
      25 UniRef50_B0RY73        MFS transporter n=9 Tax=Xan...   179     2e-43  1  15.6%  4:387 100:491     ---MTPTTPSTRRMALLLAGLAMFGPFSIDTIFPAFSQ-LSRSLAVDEVAIQQTISVYLLAYGLMSIAHGPLSDAWGRKRVIL-GGLVLFIAGTIGCALSRDLPTLLAFRALQGLSAGVGMIVGRAVIRDLFQGHDAQR--LMSQVSMIFGIAPAIAPIIGGwlLSGAGWPLIFWFLAVFGLVLLIATVTWLPETHPVEArrRLLHDYVRIGFNPRFQRLAAAGAFNFAGIFLYIASAPVLVMRHLHLGEGDFAWLFIPTIGGMTLGSFLSGRMAGRMDPVRQVRIGFIYCGVAAllAVAQISLPWAVLPIFLAGLGMALIFPILALAVLDMYPQQRGLASSLQAFTQLMTNTVVAGVLSPLLSEHPRHLAFGMTGFFLLGWLFWRW-----
      26 UniRef50_C3BKF2        Multidrug resistance protei...   178     2e-43  1  16.0% 12:387  23:397     -----------KSMLRILAVIAFFIGLDSLIVSPLLPA-ISQTIGMPAEKGGLLITAYALCYGITAPFFGPLSDKVG-RKQMIVTGLIIFSAATFCTGLTNHFEILLLFRGLTGLSGAMIMPSVFALVGDKVPYQSRGKAM--GMIMGAMVGSTVLGVPIGAFLSEVGNWQWTFYIIGLLALLVTLITSRLlkNQLSISAPKAMIGSCKIVFTNFSVFFALLATFLWTVGLHGMFSYIGVYYGINFGFTIGQIGIVIFFAGLGSVIGNIAGGKLADKIGKKVVVSIASIFASISVILFSviGNVKYAITAHMIWSICIGFGQASLTALISELNPAIRGTVMALNSSAMYIGMTIASSVASFALSK---GLPFFVLGIICAIASLLIL-----
      27 UniRef50_A0RMF6        Multidrug-efflux transporte...   178     2e-43  1  15.6% 11:389   1:375     ----------MIKTVLPLSFIVASRFFGLFVVLPVLSLYALNLKGANELLVGLLVGGYALTQMALQVPFGSLSDKFGRKNTM-TFGLIVFIIGSLICAQATDIYTMLIGRLVQG--SGAVGAVATAMISDFTTEEKRGHAM--AIMGGMIGVAFAISMVVSPILSSKFGLASLFYLSAALTFACIVLLYTVVPKESKIHHHDA-KAPFLNLITQKNLFIMNITNLMQKMLMSAAFVAIPIVLVNHLGYDSSRLWIVYLAAMVFGFISMGLAGFLGDAKGhkKLLLIGVVLFIISYLDFAFSENSLAFIIGVTLFFIGFNLHEPIMQSCASKFaaSQKGAALGVFNAFGYAGSFLGGAVGGYFLHKFNITYLAIFYSILSVFWLVLLFML---
      28 UniRef50_C5SGU6        Major facilitator superfami...   178     3e-43  1  16.7% 12:389  42:422     -----------NGALSVMFAVVFINLVGFGLLVPLMP-FFAQTLNAGPWQVTLMFAAYSLGQFFAEPLWGSLSDKWG-RKPVLLITTASNILFYVLLAFAPNVWWAIAIRFLNGIGSG-NVSCIQSYVSDMSEPHQR--AGRMSLIGAAFSLGFVIGPVMGGFlaGAAGFRLPLFLAAGLSAVATLGILFYVREsrTHAAPQNFRATFAEARRHPIISRLILSTLFYMAALAGLEATFGLWAKARYDWGPREVSLVFLFIGVTAALMQMVFTrlVRRYGEARILVLGLTVFGLGFFLQGINQVPWLVTPLVMVAALGQAVIFASISAIISKsaTDRQGAMLGLNQSTGAIARIAGPVVAGFLFSQLGADGPLWFCALMCFTAALLALRV---
      29 UniRef50_P39637        Uncharacterized MFS-type tr...   177     4e-43  1  14.6% 13:390  18:396     ------------LLALALTMGVFAAGSEELVISPLLPD-LAKAFSSDVSVLALSISIYGVMIFIGAPLLVPLGDKY-SRELSLLAGLMIFIIGTVICALAQNIFFFFLGRALSGLAAGAFVPTAYAVVGDRVPYTYRGK--VMGLIVSSWSLALIFGVPLGSFIGGVLHWRWTFWIFALMGVLVVLLILLEMRRHAQHKNSgePAGTFRDALKVPRVPVYITITFCNMIGFYGMYSFLGTYLQDVFTGGNTAAGLFIMIYGIG-FSMSVITGKIADRIGKMRSLLIALGVISVLLACLPYApsMFLLIASLFIWGLMQSLTVTLLSTILSDCSERHRGKVMVFYSLASNLAVTLGSALMGPVYVAYGYAAVGLICAAITVLGFVLSVFAY--
      30 UniRef50_A5IHN8        Major facilitator family tr...   177     4e-43  1  15.4%  7:390   1:386     ------MKYSWNKTVFPIAAIFSFRLLGLFLLIPVFTLYATNLKGATPTLIGLALGSYGLAQGLLQIPFGMLSDKLG-RKPMIAIGLLLFAGGSLLGAVTHSIAGMITARILQG--AGAIGSVLIALLADLTLDEQRTKAM--AIVGITIGTSFSLAMIISPALTHYYGLSGVFYLTAALAVLGIMILYLIIPNPSkhADSEPSLSLIKPVVTDQHLQRLNFGIFCQHFILTATFFAIPMLLKYQIETglHQQWHFYLPLMLFSFILMVPFIIISERKKRLKTVFVISVLLTTfgLLVFTSQNWYWFCILMFVYFVSFNVLEATLPSLVSKLapGSKGTAMGIYSTSQFLGIFFGGSLAGILYQWYDNQAIFLINMILSCLWLIISLSMK--
      31 UniRef50_A4IK11        Multidrug resistance protei...   177     5e-43  1  17.3% 11:391   3:387     ----------WKRSVRILWLCNFMVSAGMTMVIPFLSLFlvTEHHALSMWTGLVFSATFLSAAIMAPIWGMFADKYGQRANLIRAG-IGMGLLTACMAFAASPMALLVLRFLVGFFSG-FITVSFSYLARIVPKDHSGEA--LGTLQTGSIAGNIIGPLIGGALSDLFGFRPVFLVTGLCILLTLLPVMFWLEKDPVVPQTKKNKASFKEVFEHRPLIILFIATFLVQIAVLGVNSMMTIFVQSLVGNTSNLagLASSITGIATIIGAPYLGKLGDRIGQEKTLPILLVLSGLFALPQVWTDNIYALYVWRFLQGLVVGGVWPAIQALINVQSPRrqGRVFGVTASSRFLGNLTGPTAAGAIASLFSIAYIFAFSSLLLIVTGALVGYAHR-
      32 UniRef50_C2YTE4        Permease (Major facilitator...   177     6e-43  1  18.5%  1:390   1:388     MTKFQRLKKNPLTGLLVIAMAVFIDMLLYSLVVPIVPLYVSK-FGASQTTVGILISCYAFTFIFFTPILGVVSDKFGRRGSML-WGMVVLIASTLMFAFANNMYILILARLLQGIAAAATWTAGLALITDLYPANKRGKA--LGTVITFMSAGTLLGAPVGGLLYEWGGYQLPFLLAAGIALLDGLARMFLLED--PPKDKETSSVDIAKIFKDFEVLKIFGVVLLGSSAISILEPTLPIYLMENLGASTVHIGFLFGITTLAYGLASPIAGWLSDKSGTFHIMMIGLLILAVCLPFVTIPNTLVLEGVVLFFLGAAAGLVLTplANSVDRLGGGAYATAFAVFNVAYSVGMMIGPIFGGFFADMFNVSIALYILSAFLVCYSISLRIMK--
      33 UniRef50_Q5WGK5        Major facilitator (MFS) sup...   177     7e-43  1  18.0%  4:391   1:392     ---MKALATRNRGAILLLMFNIFIGFVGVGLVIPIMPTYM-NVLGISGTIVGLLVAVFSLTQFLVAPYAGSWSDRYG-RKWIIVAGLLLFAVSELLFGLATNAVLLFISRLLGGVSVAFIMPAVMAYVVDITTEEDRG--MGMGWINAAISTGFIIGPAIGGFLVE-YGMRVPFFAAAGAAALSAVVSMSILPEspAPEARMDRKESQLAQLarTPYFTGLLIILITSLGLSQFETVLGLFVDHKYSYTPNEIAWLIMIGAIVGAVMQllFGRLINWIGEKKLTVYCLLVMAVFMVATIFSAQYWMMVVSVTLVFLAVDFVRPAISTYFSRIAGNEQGLVAGLNASYTSLGNIGGPILAGALFD-VQINSPFLVGSLIALGGWILSLRWMR-
      34 UniRef50_A4J552        Major facilitator superfami...   177     7e-43  1  15.4% 14:389  18:401     -------------TLAALAGVPLIMVLGNSMLIPVLPQ-MAKSLNVSQMQISLIITLFSVPAGLVIPFAGFLSDRFGRKKIIIPGLFLYGLGGLLAGAAanAFPWILGGRILQGIGAAGTAPIAMAFCGDLWKGKER--AKSLGVIEASNGLGKVASPILGALIG-LIAWWYIFFFFPVVIAVVILGVWFICKEpkQPKKVNEYVGSIKNIfkSPLLLTSFFAGSAALLILFGVLFFLSDYLEKKFGLDGVIKGAALAIPVLFMSTTSYVTGakKKIKLMKWLVVIGHGLIGASLVTLPLFNNVYIFFAGISVAGIGTGLVLPCLNTLITSStkDERGLVTSLYGSVRFLGVAAGPPLFGWLVEK-GSDMMFWASASLAVISAVLAFFF---
      35 UniRef50_C2QNT4        Major facilitator superfami...   177     7e-43  1  12.4%  2:388   1:382     -MSTLNSDVNPRLALISLMISTFAIGTTEFIIMGILPD-VAKDLNVSISSTGLLVTGYAIGVAIGAPLLTALTGKMQRKKLL-LMLMLLFVIGNTLCAVAPTYEFLLVSRVLAAFAHGTFFGVGSVVASKLVPPEKQSSA--VAMIFTGVSVANIVGVPLGTFVGQALGWRASFWIISALGVVAILCITKFIP--QMALTSVPSFRQEIRVLKKPQVQLTLLMTILSFVGVFAAFTYIAPTLTDITKFSASAITPILLLYGLGLTIGNTVAGRLSDWKPMPTIIGMLALLTLVMGSFYITSEYKILAVITVFLWGFTSFGHVPGLQMRVIAKAKGAPNIAASLNISAFNLGIALGSFVGGVVitSLGLKAIPLVAALLTVLCIGVVLV----
      36 UniRef50_A1T6H1        Major facilitator superfami...   176     1e-42  1  17.1%  6:391  30:416     -----ATKQPLPREVWVLVAANFVVALGYGVVAPVLPQY-ARHFGVSISAATFVITAFAVMRLVGAPPAGMLVQRLGERR-VYISGLIIVALSTAACAFAETYWQLLLFRSLGGIGSAMFTVSSLGLMIRISPPDARGRVA--GLFSSGFMVGSVGGPILGA-LTAGFGLSAPFLIYGAALLVAATVVFVSLRHSTVVGQqpEEPVPFRTVFRHRAYRAALFSNFATGWASFGliALVPLFIVEVLGQSPGAAGLALTAFAVGNISVVIPSGHLSDRLGRRKLMIFGLTLAAASTALVGFTTSLPVFLVAAYIAGAATGIFVSPQQAAVADVVGnrGGTAVATFQMMADFGSIGGSLLVGLIAQYTSFGWAFLISGVILAVAAVGWIFAPE-
      37 UniRef50_B9JYK2        MFS permease n=25 Tax=cellu...   176     1e-42  1  14.5%  6:390   7:398     -----SLAPFKNQIFLTIWLASITSNFG-GLIQDVGAAWMMTSISSSESMVALVQASNTAPIMLFSLVAGALADGFDRRRVMLFAQVFLLTVSALLSLFTwtPWSLLAFTFLIGCGTALNSPAWQASVGDIVGREDLPSA--VSLNSMGFNITRSVGPAIGGLIVAVAGAATAFAINAVSYLAMIYALFRWKPVYPKNTLPRENlaGLRYMAMSPNLMKVLFRGFFFGFCATAILSLLPLVVKDNLGGGPLAYGGLLGAFGIGAIAGAISNARIREKLSSEQIVSCSFAGFALASVLTGISHHFWLTAPALVLAGACWVLSLSLFNTVVQLSTPRwvGRALSLYQTATFGGMAGGAWIWGLLAESGSAGHALVMAAGLMALGVGIGLALP--
      38 UniRef50_B7HDG2        MFS transporter n=77 Tax=Ba...   176     2e-42  1  10.8%  5:392   1:387     ----MMKNSKLTFILYVVCISALFGSFAQNIYTPILP-MIQNSFHTSLYLVNITVSLFTFVLAIMQLVYGPLIDTKG-RKSVLIPSLVISTIGSIGCAFSANIYLFLFFRAVQAIGIAAIPVVSATIIGDLFEGKERGEAM--SLYQMLLALAPAMAPLIGGYLGSIHGHLSVFLFLSTLGIILLIINISLLPETKPNikQAKAQKNYSLILKNKTGFSITLIGFIQFCIYFCFLVFLPSILTNSFHLTVNKIGLMFVPMSLSIMLGSFCYKFLQKRLTTKQALFITSFFNIICVVLFSFiiNIPFIIIVTSLYGFSMGLSMPTHTTLLTEEFVQERATAIGMYNFIRYLGMGTGPLIGGFLLFNQNYFWIFFLGAIMFLLVILYTMKMLSL
      39 UniRef50_A6LYL4        Major facilitator superfami...   175     2e-42  1  14.3% 11:388   4:387     ----------WKRNLKVCWFGMFVTGIGMSQIAPVLPLYI-QHLGIQDAAsgIAFGSTFIISAIFSPIWGHAADKFG-RKPMLLRASLGMAIVISCMGFAPNVYVLIALRLLQGAITG-YSTACTTLIATQTDKEHAGYA--LGTISTANIAGSLLGPTIGGFVGETFGLQNVFFITGGLMLIAFITTVLFVKESFSREDNksFKEVWNTVPEKGLTITLFITFFILSVAMYSVEPIVTVYVTqeASHIALIAGITFSASGFANIIAAPRLGRISDKVGAHKVMLICLIIAGIIFIPQAFVTNTWELMGLRFLLGLTVGGLNPSVNILVKKITPSatGRVFGFSMAAGYLGVFAGSVLGGQIAGYLGIKCVFFVTSALLLINAVLVYF----
      40 UniRef50_A9AXN0        Major facilitator superfami...   175     2e-42  1  18.7% 12:390   3:381     -----------RSPLLTIFLIAFVGTMSYGVVIPITPFY-AQEFGASEVQVGMIVGSYALMQFIFAPILGQLSDRYG-RRPLLILSLIGTVCSLLLFGFANSLIWLFVGRMFDG-ATGGNISIAQAYVSDITTDKDRARGM--GMVGAALGLGFIAGPAIGALLSKDGNYQLPIFVAAGIAVLSLILTIVVLPEPERHAPQQGrpMKLLAAVRKPNVGRLLSITLLINLAFVAFETTFALFAARRLEFGSHQTGYTLAGVGIVVAIVqgLIRRLAARFGEATLIVSGSLLLALSLAGLGFIQNVWHLVAICIVLAVGEGLLTPSLSSLVSRNSPaeRGENMGLYQSMSSLARIFAPLYATWMLSNVGEASPYLMGSVLVVAGALIAVGLP--
      41 UniRef50_C1EU34        Drug resistance transporter...   175     3e-42  1  14.1%  8:391  16:404     -------KTNRLWMILVLGTLTAIGPLSIDMYLPSLPK-LTDDLQTGASLAQLTLTACLLGLSVGQLFVGSISDIYGRRKPLIIA-LIIYVASSLLCAVAPSIWTLVLLRFLQGASGSAGIVISRAMVRDMYSGSEMTK--FFSLLMLVNGAAPILAPIIGGQLLQFTTWRGVFIVLGAISVFMLISATFVLRETLPPEErsGTLATYGKLLKDRLFMGYALSQGLVTAAMFAYISGSPFVLQNIYGASPQQFSLFFAINGIGIIIASQVTGRLAGKVNEKTLFVSGIVIAAVGGLSLLLTILLGIGLisLFLVVSSVGVVSTTGFSLAMRNQKQAAGTASALLGLLQFISGALVAPLVGIGGSNTALPMGVVIALCEIGAVLCYLFMARR-
      42 UniRef50_A6LUR3        Major facilitator superfami...   175     3e-42  1  15.6%  1:392   1:391     MSYIQKGTREFRHASIALFAGGFNTFAILYCTQPLMP-YLSKEFGISPTMASLSLSVTTCTLAVSMLIFGSLSEVLG-RKPIMCFSLFASSILAVLTAIVPNFNSMLVIRCLQGFVLAGLPAIAMAYISEEIDKSSLG--LVMGLYISGNSIGGMSGRIIIGVINDFFNWRLALAVIGILGLISSFLFWRKLPLSKHFEArkNLIKSSFNHLKNPNLLCLYCIGFLIMGSFVSLYNFIGFQLIEryNLSQTLVSFIFVIY-IVGTFSSTFMGRLADKHGQYIMLCISIFIM-LFGISITLNVSLLLKIIGIALLTFGFFAGHSIISSWIGKIATHDKAQASSLYLLFYYVGSSVGGTAGGTFWSLYGWEGVVIMISCFLAVAFFILIGLSSV
      43 UniRef50_Q6GIU7        Quinolone resistance protei...   175     3e-42  1  13.3% 11:387   1:374     ----------MNKQIFVLYFNIFLIFLGIGLVIPVLPVYL-KDLGLTGSDLGLLVAAFALSQMIISPFGGTLADKLG-KKLIICIGLILFSVSEFMFAVGHNFSVLMLSRVIGGMSAGMVMPGVTGLIADVSPSHQ--KAKNFGYMSAIINSGFILGPGIGGFMAE-VSHRMPFYFAGALGILAFIMSVVLIHDPKKSTTsqKLEPQLLTKINWKVFITPAILTLVLAFGLSAFETLYSLYTSYKVNYSPKDISIAITGGGIFGALFqyFFDKFMKYFSELTFIAWSLIYSVIVLVLLVIADGYWTIMVISFAVFIGFDMIRPAITNYFSNIAGDRQGFAGGLNSTFTSMGNFIGPLIAGALFDVH-IEAPIYMAIGVSLAGVVIVL-----
      44 UniRef50_Q9KDN7        Multidrug-efflux transporte...   175     3e-42  1  16.2%  7:389   1:383     ------MTRSERKPLLMLMVNMFVVMMGIGLVIPILPYYI-EAFGASSVELGLLIAIFSFMQFLLAPFWGRLSDKVG-RKPLIAVGMFGFAVAEFIFAFATQFWMLFVSRILAGAFGSAVMPAAMAYVSDRTSEEKRGHGM--GLLGASMALGIVVGPGIGGWLAE-FSLATPFLFAGFAASFAAIFSLLWLPESLPLEKRKTEVEPVNQFVqrSPIGFLLFLVFGLSFGLANFQTIFGIFALHRFHYNPSEVGFIMVLTGIVGAIAQglVGRLTERYGEEKVVLGSLSLSGIGFLIMMLAFNYWTVIATTCLFFLGNSILRPAVQSFLSKMAGDQQGMIMGLNNSILSLGNVVGALLAGLLFE-WNMFLPYTVGAFVMFASLGATFRW---
      45 UniRef50_A7ZBP2        Multidrug-efflux transporte...   175     3e-42  1  16.9% 11:389   1:375     ----------MLKSVLPLSFIVASRFFGLFIVLPVLSLYALNLSGANEFLVGLIVGVYAISQMIFQVPFGALSDKIGRKKA-LTIGLLIFVAGSIVCALASEIYTMLFGRFLQGV--GAVGAVATAMISDFVAEENRSKAM--AIMGAFIGLSFTLSMVLGPLLVKDYGLSSLFYLSAALSLLCVVLLYTVVPKEIKVSAKAE-KVPFGKLFLQKDYMIINFTSFMQKMLTSIAFLVIPIVLVKEYGYESSELYKVYTLGAVLGFLAMGLAGALGDGKGLSKVILigTLLFALTYVIFALSFTKFIFVVGIAIFFIGFNLHEPIMQSTATKFVKSSqgTALGIFNSFGYFGSFVGGAFGGYIMHAFGFKVLAIICVVLCVIWLVLLFSL---
      46 UniRef50_P77726        Inner membrane transport pr...   175     3e-42  1  14.0%  6:391   5:390     -----KMTPGERRATWGLGTVFSLRMLGMFMVLPVLTTYGMALQGASEALIGIAIGIYGLTQAVFQIPFGLLSDRIG-RKPLIVGGLAVFAAGSVIAALSDSIWGIILGRALQG--SGAIAAAVMALLSDLTREQNRTKAMAF--IGVSFGITFAIAMVLGPIITHKLGLHALFWMIAILATTGIALTIWVVPNSSThrESGMVKGSFSKVLAEPRLLKLNFGIMCLHILLMSTFVALPGQLAD-AGFPAAEHWKVYLATMLIAFGSVVPFIIYAekRKMKQVFVFCVGLIVVAEIVLWNAQtfWQLVVGVQLFFVAFNLMEALLPSLISKESpgYKGTAMGVYSTSQFLGVAIGGSLGGWINGMFDGQGVFLAGAMLAAVWLTVASTMKE-
      47 UniRef50_UPI0001C35CA2 arabinose efflux permease f...   174     4e-42  1  13.5%  7:390  17:392     ------PDKIWNASFISVFIANMLMFMGQQMMNTLVAKY-ANHLGAAPIIVGLVTSAFAYTALIFKIFAAPAIDTF-NKRYILVFAMLIMAASYAGYSFSGSIPVLLASRLLQGAGQAFSATCCLALATDTLPPDRLGTG--ISYFSLAQVICQSIGPTIGLSLSRTIGYHYTFMIGAVTMCLAAVAASRIRNKHVKSVKRYSISLDSIIA---REAILPAVLMFLLCMVYYNITTFLVIYAEER--GCGVNIGYFFTVYAVTLLVTRPVIGRFGDKHGLVKIFIPAMFCFALAFLLISFATNIWMFLLAAFVSAFGYGACQPSVQTLCMKCVpeKRGAGSSTNYIGQDLGNLVGPLIAGSLAGRFGYAAMWRIMILPVALALVIVLMFR--
      48 UniRef50_Q1H3C0        Drug resistance transporter...   174     5e-42  1  15.3% 26:391  30:401     -------------------------PLSIDMYLPGFPA-IEKSLLAQAGSAQLTLASYFIGLAIGQLFYGPLSDRFGRRLPLLI-GLVIYILASFGCAFTSSIPELIFWRFLQALGGCAGMVITMAVIRDRCSAND--AARAFSMLILVMGLAPILAPLIGGWIVTSFDWRVLFITLGVAGILGLIAVYFWLEETHDTRHEPPllRNYGRLFMDRRFIGYTLSGGLARAGMFAYIAGSPFVFIEYYHIPAQHYGWIFGMNAAGLILVSQINVWRLKKHRATVLLSRALWLPGGIGVLLLGLstLPLLLIGIFLFVASIGYIGPDAGAATLATHGQQAGTASALMGSLQFGLATIAGGLVNLLHDGTTFPMVTVMAGCGIGAWLAHRLIIVR-
      49 UniRef50_UPI0001745101 tetracycline resistance pro...   173     6e-42  1  16.7%  8:390   3:391     -------AASRKTQFTVIFITILLSTIGFGVCIPVLPLY-AKTFGASEFLNGLLIGVFPMMVFLASPLWGKLSDRVG-RRPVLIFSVLGSAAGYFLMGFAHTLPLLFLARIVDG-ASGGNVAAAQAYIADITSPQERSRAM--GMIGAAFGIGFIIGPALGG-IAAQISPNAPFFLVGILCLINAVLIWTSLPESLTQERrpQPLTALPRHADGPVYFTVAASYLVCLAAFSIMTTVFSLFAQERFGMDEQHVGYVMAAIGFVGVIMqgVMRKLLPAYGDIRLALSGMSILLVSFVLLPLDTGLYGLYAVSCLIAVGNSLVQPTLNGLASRCVTNaqGRAMGLLQSSASLGRTVGPVLGGWLldAHYGRTPFWVAAALMAVTLAIASRLR--
      50 UniRef50_C0Z656        Probable multidrug resistan...   173     7e-42  1  16.1% 11:388   4:390     ----------WRRNLYVLCGSLFFVMVAMSMIMPFLPLYIQQDFGIEdaWAGIIFGANFLTAGLVSPIWGNLADKHG-RKIMILRSGFFMSITMAMTGFAGSLWQLLALRLLN-GLVGGIIPASTALVASSVPKERIGYAT--GLLQSFITAGTIMGPLFGGVLAEKIGFRMIFVITGCVLLLATLVITFTVKepPEKKEQSSLREDFQMIFSSKELPALFFVTVMIQFALFSIIPVLPIYISQLLGSEGawAGIVQACMGVANVFASPQLGRLGDRFGSQKVLLFSLLAAAIIFIPQGLVHTVWQLVALRFLLGLSLGGLLPSVNALLRRATphMVSRVYGYNNSFVSIGSMLGPMIGGFLAGYVSISGVFYMTSAFLFINAGWVYY----
      51 UniRef50_C1D5T9        Major facilitator family tr...   173     1e-41  1  13.8%  9:391  17:405     --------PGWWITVFLFWLGWVFMYADRTILNPIM-KDIQLEYGLSATQLGLLNSVFFLSYAFLQVPAGVLGDKIGKKK-VLVPGFIFFGVFTAVSGMMKSFTALLFARVMTGAGQATYYGPQYGLSSEQIPPERRTFGS--AIINCGMAFGLALGMMVSSYLvqGYNWRVPFFVMSVPTVVIALLIWFLVKepVAQQAADTKKGSFMDLLKNRNLMVTYLMVFCSLFGFFLMVTWLPYYLQNERGIDGSQIGNISSLIAWVSIPGGLLFASISDKLGRRKPLIMFMvvAIISLISIVQMQDVNMMIVALCVYGLFGKLAmpVLVATIADNApeSYSSAFGMFNFVGMSSSILAPTIAGAITDVTglAAGFYLSAGLLVMGLVGIMFLKE-
      52 UniRef50_Q1YRM8        Major facilitator family tr...   172     2e-41  1  17.4% 10:389  19:398     ---------LEKRAVASLASLYGFRMLGLFMVLPILALYMDDYPGFSPLLLGVCLGIYGLTQAALQIPLGLLSDKIG-RRPVIVGGLLVFIFGSLVAASAETSAGLIVGRAIQG--AGAIASTLMALVSDLTREENRTKAMAN--IGASIGVSFVLAMIFGPVIATALGLSGVFWVTALLGCLGIIIFLRWVPKaqRNRETHTDLQQIRGLLKDPSLLRLNFGVFALHLILMAAFVVIPALLSEELGIVGADLWWVYLLLLGGGFVAMLPAMIIGEKLQRQKlfTTAVVCVTLAMLLLALFRGPLLTPIMLLLFFAAFNLLEASLPSWLSKVCPAGrgTAMGIYSTCQFFGAFVGGVLGGWSVQQLGVDSLFLLLAAIGFVWWLLALGL---
      53 UniRef50_B3QY61        Major facilitator superfami...   172     2e-41  1  18.0% 12:389   3:384     -----------KSPLVVLFFTVFIDLVGFGIVLPLLPTY-AKDIGATPLEIGLIAASFSVMQFFFSPIWGSKSDQIG-RRPIILISVAASAISYLIFSQSDTVALLLISRVLAGIG-SANISATQAYITDVTDSANRSKAM--GMIGAAFGLGFVLGPPLGGFLKTFYGISMVGYVATALTLLDLILAFIFLPESIKEKKPKtsFDKMLDAFKRPAVSRIMITNFLFLFAFVNMQVSAALLWKEYFSVTDQSIGYLFAFVGVVSVIVqfLIGKLTKKYGERKVFLLGNIIMALGLIFIPYIPTDSLflIFLAMLAIGNGLAVPVSTSLISLYTPHhqGEILGISQSVGSFARILGPFSGSLLY-GVEIHAPYLVGGALVLVGSLVASTL---
      54 UniRef50_Q03TF8        Permease of the major facil...   172     2e-41  1  17.2%  5:377   3:382     ----TRQPEQWRRNLAVLWLGTFIAGMGFSEVMPFISLYVDDLGHFTKGQlgLTYAVTFLVIALVSPLWGKLADRKG-RKLMLLRSSLGMAVVIGLMGFVTNVWQLIGLRFLQGFFAG-YIPNASALIAAETPQAKSGNA--LGILTTGYVSGNLIGPVLGGILAQVFSIRWTFILTGIFLVIVFILSATLVHetPISKEKQAQAGFWLGQVKNPTLIIVLLvtMFIQMGNNSITPIISLYVRQLMGNqtLVAGIVAALPGISTLMAAPKLGEYGDRKGTQRVLIFGYAFAVLMYFPQGFVTSVWLLGLFRFMIGISDGALFPAVQTMLTKNVPhlTGTVFSWNQSFQALGSMLGSMLGGFVANWFNYNGVFIFTAF---------------
      55 UniRef50_Q4L4B7        Quinolone resistance protei...   172     3e-41  1  12.7% 11:388   1:375     ----------MKKQLFTLYFNIFLIFVGIGLVIPVLPVYL-KDLGLKGSDLGILVAVFALSQMIISPFGGTMADKLG-KKLIICIGLVLFAISEFLFAIGHHFPVLIASRILGGFSAGMVMPGVTGMIADISPAKD--KAKNFGYMSAIINSGFILGPGIGGFLAE-FSHRAPFYFAGTLGVLAFIMSLLLIHNPRKETTehSLEPEVFTKINWKVFITPIILTLVLAFGLSAFETLFSLYTAEKANYTPRDISIAIVGGGVAGAVFqfFFDKFMKYMTELTFIIWSLLYSAIVLGLLILSHSYWTIMFISFIVFIGFDLIRPALTNYYSNIAGNRQGFAGGLNSTFTSMGNFVGPLVAGALFD-VNVEFPLYMAIIVMLFGIVIIFV----
      56 UniRef50_Q1BYA8        Drug resistance transporter...   171     3e-41  1  15.3% 24:390  76:448     -----------------------CGPIATDMYLPSLPS-IAAGFSVSAGAAQRTLTSFMAGFSIGMLLYGPLSDTWG-RRPVLLGGIALFTLASIGCFVAGSIDMLIVVRFLQALGAGAASVLARAIARDAHEPSD--AAKVLSMVAIVTAVGPLLAPLIGGQILRFSGWRGVFVVLAVFGALCATTAYLRVPETWPKERRkaSFASYGRILSDPVAWGHMLCGGMAFASMFSYITATPFVYIEYFHVSPQHYGLLFGLNVVGIMIGNFANSRLVGRIGSLRIIAAASLvlAVAFVALTGLGGLWSIVVCLFFVVGVVGILSANCTTDLMHRYPHNAGASAAVFGAMQLALGALASVAIGALADGTPFAMGVTIGVSGLLCFAGRYLVLR--
      57 UniRef50_C0ZI14        Probable multidrug resistan...   171     3e-41  1  17.3% 12:392   3:382     -----------KKHLALLFFIAFFIMLGFGIIIPILP-FFAEKLGATSLQIGVLFASYNIMQLVFAPIWGALSDKIG-RKPLLSFGLFGFSITFILFGLADSYTEMLLYRILGGIVSAAALPTVTAMVADLFPSEER--AKGMGVIGAGIGLSFVFGPVIGGLL-SKFGFAVPFYASGIVALLTFFLILFSLPESLPKEKRANLQKEQRqvSLFGSMSLLYGILFTVSFAFSGLETTFALYISDLYGFTSIDLGYMFLVMGLIAAAVQglIGRMVKQLGEASVLVIGMILYGIGFFAIPLSGNFWVLALILSLFGAGQGMIRATATAMITQRTTQGQGVTSGAISSMDSLGRILGPLAGGAVYQVSHGGPFFLGGVLMVLLLLWFVSSYRRL
      58 UniRef50_C3AL28        Permease (Major facilitator...   171     4e-41  1  16.0%  1:388   1:386     MEARLKMSRVQKASLWVVAVAVFTDMLIYGMIVPILPRY-AETLGASQTEIGFLFGSYAITLLLATPILGVVSDKVGRRLPMIL-GLFGLAAATLLFGLANSFWLLVLARMLQGISAAATWTAGLALLADVFPLQERGKAMGLAL--SGQAAGMLLGPTIGGALYQWGGYHLPFIIAASIALIDGILRITLLHNEPK--SSSNQRISYRSILNMRSLFIMIGIIILGSALPSALEPTLPLYLQDTLHLSPGTIGLLFAVPTLAYGFTAPIIGTLSTKIGRKQTMAVGIALAALCFPFTVIVSHTALEIFVLAILGISFSLLLAPALPELTYLAdhAYGILFAIYNTAYSIGMFFGPMLSGSLSDLFGFTNAFYIFSVLLLCYLCLFLW----
      59 UniRef50_C0RLS8        Major facilitator superfami...   171     4e-41  1  15.5% 11:391  95:486     ----------WKQNLVICLLGSFTTLIAMSLLLPFLPLYVEQLGVISHAAigIAYGATFLAAAFVAPLWGRLGDRYG-RKLMLIRASLGMAVAMSLIGMVTCVWQLVALRLFVGIA-GGYSSGSMILVATQTPKDKTGWALgsAGIMAGIMAGNLAGPLLGGALPPLIGIRATFWLAGGVIFLTFLATTFLIREERKPPKPTREEKtwAAIPDKGPVVAMLVTGILLLFANMSIEPILTIYVMQLMDDQTKVtgVVMAAAALGSILSSSRLGQLADRIGHTRVIIGALAVSALLLVPQAFVTDAWQLIGLRFLMGLALGGLLPCITSVIRHNVPDraGGILGYSVSAQYVGQVAGPVAGGFVGGHFGMRAVFLGTCLMMAAGAIYNWAVLR-
      60 UniRef50_Q63BE3        Multidrug resistance protei...   171     4e-41  1  16.4% 11:389   5:386     ----------LKSMIRILAIVAFFVGLDSLLVAPLLPV-ITETISIPDGSGGLLITIYALCYGITAPVFGMMSDRVGRKR-MIIIGFIIFSISTFCTGLAKNFEILLLFRGLTGLSGAMIMPSIFALVGDKVTYESRGKAM--GTIMGAMIGSTVIGVPIGAFLSEIGNWQWTFYSIGLLTLFLTLLINHILRNEKERDDVHVSlaPLKMTVVNISVLFALLATFLWTIGLHGMFSYIGVYYENNFGISVGKIGIVIFLAGVGSVAGNILGGKLADKIGKKNVIVIASIVSSISVMLFSLStnLVIAIIVHIIWSLFIGFGQASLTALISELKPAVRGTVMALNSSAMYIGMTIASGVASliSNGFPFSSLGTICAIASLLVLPIIFVL---
      61 UniRef50_C2QJH8        Multidrug-efflux transporte...   171     5e-41  1  13.9% 11:390   2:378     ----------MKRNIVPLMIVQFFIFLGFGMIIPVLPEIITN-LHVPSHHLGMLLSSYSLASFLTAPLWGKISDRAGRRPVLLIGILGYSISFFLTGLLIDNLTGLYIARSLNGLFAGALYTAATASIVDMTNETERNR--YIGMMGACIGMGFIVGPAIGGML-SHFGNAVPFQIASNLLVILFLYTCFTFKESLNNADEKDTGNPFKRFIHLPAsiGLFFITFTISMALAGLEGTYQLFGKQAIGITPLQIGIIFLASGLVDAFIQGGLIRYIRNGDEKRYIIIGQIISATGLFLIPFITNLLWAGICLSIFTAGNALVRTCTLSFLTKQVKSDHGTISGLNYSFDSLGRIIGPIFFTMIFTSQGAVSFIVGGMMTMLSIGLVILFSK--
      62 UniRef50_C0WNC9        MFS family major facilitato...   171     5e-41  1  13.0%  6:391   4:396     -----SKTPQWKKNLWALWFGNFSTGAGASMALPFLPLFISEFGNFPKWElgLAFSSVFLSQAIVSPMWGNLADRTG-RKPMLLRASIGMTVSATLCGLAPNVWTLILIRFIQGTFSG-YINNAYALMASEVPQEESGHTM--GTLTTGNVGGNLIGPIIGGYLSGMFGYRLPFYIFGFMMFLAAVSTWLFVKEDFKPIKKSAKLgaFAGIQKKWVVSAMIVSSMLIMAATMSINPIISLFVRELMHGHGNVagVVAALPGIATILTAPTLGKLGDHIGPEKILLAGLIFSAVVFFPMTFVTTVLMLGILRFLIGIANAALMPITQTVMTLETPasVSRIFSYNQSAQAVGAVIGPMMASGVAGILDYRYVFLMTTLLVLINLGVVLIAYR-
      63 UniRef50_A7BTL7        Major facilitator family tr...   171     5e-41  1  16.2%  1:390   1:388     MSFNNRMTPSELKATLALASIMSIRLLGLFMIFPVFTLYAQQLPDVTPILIGLALGIYGLTQGILQIPFGMLSDRIG-RKPIIYLGLLIFALGSVVAATSTSIVGIIIGRALQGC--GAIASTMLALTADLTREEQRTKGM--AIMGISIGTSFILALTIGPLLNGWIGVPGIFWLTAIFALMAIVILHFAVPQPAnhSHHGKFLVQLKGILQDTQLLRLNIGILFLHLLLTSLFVVLPIALLDN-QLPANEHWQIYVSVLIASVIAMVPVIWMAEKYRqkPVFVGAVVILGLSQLGLsfYHNLTSIILMLFLFFTAVNILESNLPSLISKMAPAnkGTAMGVYSSSQFFGAFLGGLLGGWLHQHYGIGAVFSFCATLTVIWFIFAVTMQ--
      64 UniRef50_B1MZI6        Permease of the major facil...   170     6e-41  1  17.3%  6:386  11:399     -----SENTLWQRNVFVLWFGVFMTGVALSEVMPFLSLYIDTLGHFNKDAlgAVFAISFLVTAVVSPFWGKLADRKG-RKLMLLRAAFGMSVVLFLMGNVTNVWELLLLRALQG-AMGGFISNANALVATQTPKQHAGKA--LGILVTGMTAGNLIGPFFGGVLATFFSYRTSFHITGIILFLVFILTLCLVKEEARPVSLTVAKSSTRVLWAGLpiVGLFVTTMLVQTVNTSINPIISLFVRELMHntTFMAGIVAAMPGIATVIAAPPFGRLGDRVGTERMIKIGFMIAVIAFIPTAFVTSISMLMLLRFIVGISDATMLPAIQTLLSKNSpeMTSRIFSYNQSFQSLGSVMGPMIGAIIASLFDYRGIFIVSALIIILNAVLF------
      65 UniRef50_A4IKQ8        Antibiotic resistance prote...   170     7e-41  1  17.4%  7:391  13:388     ------KEKIWTRNFVLICLANFFIFLGFQMTLPTLPLFV-EYLGGNDQLIGLVVGVFTFSALIVRPFAGHALETRG-RRFVFLFGLLIFVISVGSYSFISSIFLLFLMRVVQGIGWGFSTTASGTVATDIIPANRRGEGM--GYYGLSGNIALAFGPSLGLVLAAAIPFSHLFMICAALGVASLLFAAAI---TYKKAEAGHDKGEKKWDLYEKTALIPSVLLFFLTVTFGGIASFLPLYTAQKQIGGLQLY---FLLYALALMVTRTFAGQLYDRKGHRAVFLPGAGLVLLAMLMLAWLPGEWALLTAAVLYGFGFGMVQPGLQAWSVERAphRKGMANATFFSFFDLGVGIGAIVFGQISHWFGYPSIYLAAAGSVLISMLVYLSVLR-
      66 UniRef50_Q603V5        Major facilitator family tr...   170     8e-41  1  14.6%  7:390   1:385     ------MTRTEIRAATSLAAIYMFRMLGLFMILPVFSIYARDLPGATPVLIGLAISAYGLTQAVFQIPFGIWSDRFG-RKPLIVIGLLMFAGGSVMAAVADSIYGIVAGRALQG--AGAVAGVIMALAADLTQEEHRTKAM--ALIGVSIGISFAFSMVAGPVLSGWIGVRGIFWSVAGLALLGIAVLYSVVPTPQrhRDTEAQPARFSSVLTNPELVRLDFGIFALHAILTATFVVLPLILRDELRMDTPEHWKIYLPVFVLSMISMVPFVIVAEKKRQMKPVFLSFILLTAavILAGFTPTTLGIGLLLYLFFTAFNLLEATLPSMVSKVApdLKGTAMGVYSTTQFLGAFVGGAGAGWIQGHHGIPAVFLFCAGIALLWLAVAFGMQ--
      67 UniRef50_D1Z1Q5        MFS transporter n=1 Tax=Met...   170     9e-41  1  12.2%  9:392  10:395     --------PAYDRRLWILFFGMALNQFGMSIVMPFISIYLYYYQGVSAGLVGFAMFASSFVGAIFQFVGGEMCDRMGRRFTFILGLSILITSFLLLGWAVghYGLYLLILCMTRVATGLFRPIPNIIATDLVPPQKRLEA--FSLLRIGQNAGFALGPMVGGVMA-MLSYSSMFYFTAVTSTIYLLLVIFFISDTRtiPARRFTLKDLRRIPDDRPFMVFSILVFLVSVVYSQMYSPLSVYSKGFVGIPEVEIGMLFAINGIMVVVAQYFVTRLTDRYRLTLSMALGVTLYALGFGLVAFSHNFLMLALCIFIVTLGELTYMPPQTTLTANLSteNRGRYQGFSGLTSTLGFAVGPLLGGVLLDHLPGMYVWLIVGTAGLGCALSFIYLRKL
      68 UniRef50_B5I5W3        Bicyclomycin resistance pro...   170     1e-40  1  15.9% 26:370  57:410     -------------------------PLAMDMYLPSLPE-VTDSLHAPAATVQLTLTACLLGMALGQLVVGPMSDRWGRRRPLL-AGLLVYVVATALCAVAPTVEFLVGFRLVQGLAGAAGIVIARAVVRDLYDG--VAMARFFSTLMLIGGVAPIVAPLIGGQILRVTDWRGVFVVLTAIGALLAVLVWARLPETLPAAERHtaLHSMRRLLADLPFTGYMLTGGFAFAALFAYISASPFVIQEIYGASPQTFSLLFGVNSVGLVVVGQINGklVGRVGLDRVLGVGLLTVTAAAAALLLMtgLFPVAAGLFVLMSAMGVTLPNAQSLALLRTKHSAGSASALLGTSSFLIGAVASPLVGMAGEGTAVPM----------------------
      69 UniRef50_B1XLE3        Transporter, major facilita...   170     1e-40  1  16.0%  1:388   1:392     MKVFLQLQPEMRWNLGLLFLAALGFWLSMTSLLPVLPAYI-QDLGATDQQVGFVMGCFAIGLLLARTRLGKMVDEQGRKRVILIGAVVV-AIAPWGYIFLNSIPQMMVWRAFHGISIAAFTTGYSALVVDLAP--ERNRGEVISYMSLAIPVGMSIGPVLGGYLLGVVDYPWIFAASGLCGVGALLLavIAIDKNSLTPNQGETNRDYPELFRHKGLYIPSLIMLCIGLVFGVLVTFLPLYIRE-LGLN-FNTGLFYGAAAISSFSSRILVGRASDTLGRGLFISGSLLCYAATMLILNHAISTPWFVVAGAVEGLGAGTLVPMMIALMSDRSSSarGKVYSICIGGFDVGIALAGLLLGTVTQTVGYQGIFAIAAGLALFSFFIFLT----
      70 UniRef50_Q04DH7        Permease of the major facil...   169     1e-40  1  14.9%  1:389   1:398     MFKKLNDLPNWQRNIYILWFGTFMIGVGSGEVLPFLSLFTETLGNFTKAEvgIAFSSTFLMTAIVSPIWGKLADRVG-RKPMLIRAALGMAVVYTLTGFSTSVWVLIGLRFLMGFFNG-YVSNANALVAKDTPKIYSGHA--LGIVVTGYTSGALIGPLLGGFLANIFGYRMPFFITGSILFLLTFLTLIGVHEDKSTLVTKKTTGKQPSALKSAkvFGLFITSMIVNLVTNSINPILSQYVRQLLEPNEShaGLIAAAPGMTAIIFAPRFGRLGDRIGSEKLVIGGFLIGIVSMIPMAFVSNVWVLFVLRLFIGLTTAAMNPAIQAILAHETPQetSRIFSYNQSFLAMGNVFGPLLGSLVANIFDYRGVFIVSGIMIMINLISFFTF---
      71 UniRef50_B6J233        Transporter, MFS superfamil...   169     1e-40  1  14.8%  7:390   1:385     ------MYTKERSAVTSLAAIMSFRILGLFMLLPVFALYVNRIPYATPALIGVAIGVYGLMQAFFQIPFGMLSDRIG-RKPIIAGGLLLLGVGSAIAAFSHSIYGIIFGRALQG--AGAIGSTVLAMIADLTRDEERSKAM--ALVGMTIGFSFAVAIILGPIINAWFHLEGIFWATLAFAILGLILLFTVVPTPPQTLAHPEVESefKNVLRNTQLLRLDFGIFSLHCILTAMFIGIPIMLSQRLNLTeeQVLLYLIIMALAFIAMMPLIIVAEKKRQLKPFFIISIVLLIACQLSLLFFhsVIQIVGLLFVFFTAFTLLEASLPSWISKIAprHKGTAMGVYSSAQFFGIFIGGSIGGWVFGHFHLAGLFFFCAAIGFIWLLVALTMQ--
      72 UniRef50_D0XBZ8        Putative uncharacterized pr...   169     2e-40  1  13.9% 10:391  23:399     ---------KMPLQVWILTLAAFAIGTAEFVIAGILPQ-VANSLSITEGQAGYLISAYALAIVFGGPLLTIYLARF-NKKAVLAGLMVLFILGNVLSAFAPNYFVLMVSRVITGLVQGPFYGIGAVVATNLVSEKMAGRA--VGQMFAGLTLANVLGVPGGTWIGLQFGWHTTFLTVAAFGLVALFFITSVIKSTG--HGEAKDVKAQLAAFKNPMLLISLAITVFAWSGFMTLYGYIAPIAMHITGFGESAVTWILVIVGVGLIVGNTMGGRSSDKNLQKASMFWAIAMIVSLVLVGLTVDSKVLFIATAFVFGIASFANVPAMQLRVMNHGGEGQELAATANISAFNLANAFGGFLGGMVLdqMGAGMIPYAAIIVPLIGLLFIAKANR-
      73 UniRef50_D2EHP0        MFS transporter, DHA1 famil...   169     2e-40  1  13.5%  7:390   1:389     ------MDAKNKKTLWILIAGNLLICLGIGLVIPVTP-FIKNYYHYSTTQMGIMTSLFAFSQFIASPLVGRLSDRIG-RKPLIVAGLFLYAVSEVIFALSNSLIWFNVSRVIGGLSAALFVPTSMALAADVTTPAQR--ARVIGWISAAFSGGLILGPGIGGVLAN-ISYKTPFWAAAALGLISTIFTYAVMpeEHDDEPQAVKKTGALRDVLTAPLIILFTMIFVAAFGLQGFESIYSIYVNQVFNFGLGTIALVLTFNGIFSLILqfIFDWLVRKMGEVNLIGACFLIGAIFVFWITQAHTQIEVIIATLVVFSAFDILRPAITTLLTKEGKNNQGLINGLNMSLTSVGNVIGPILAGMLMD-YNTHIPYLLVALILFISYGITFAVK--
      74 UniRef50_B2J4Z8        Major facilitator superfami...   169     2e-40  1  15.2%  8:389   3:393     -------SKNNSRPILVLFLTVFIDLLGFGIILPILPLY-AEQFGAKPNEATLLVAIYSLMQFLFAPLWGRFSDRYG-RRPILLLTLFGSVIAYAGLGFANSLWMLFLARSLAGI-MAGNISTAQAYIADITTPANRARGM--GIIGAAFGLGFILGPAIGGFLidNANFHLPSLFSGGLSLFALLCALTLLPESLNSETKAKMQANRHRRrqRPQFCVLVGIYFFVTFAVAAMDSTLALWSKQQLNWGPQQTSYLFAFMGIVSTIVqgLIGFLKKHFGEIKLLTLGILGLGLGLLLIGFSQSLILLLVATTLVAWGISVSQPILNSLISQmaPEEQGQILGIASSCSALARIVGPTWAGISFMKFGSDSPFLSGFLVMIVALALSLRV---
      75 UniRef50_Q6MQR5        Drug resistance transporter...   168     2e-40  1  12.3%  1:390   1:393     MQSSAKPNTPFALLILLLASLTAFGPLSIDMYLPAFPA-IAENLNVPLSSVQMSLASFFIGLATGQIFYGPITDRFGRKKPLYV-GLGIYALASLVCAFTKNVEMLILFRFLQALGSCAGVVISRAIVRDLFTHQE--TARVFSLLMLVMGVAPILAPFFGGYISEFFGWRAIFALMVIISTSCIVMLAIFLPETHQPDQrkDSLKNYVQIIKDRHFMGYALAGGAAQAGLFAYITGSSFVFINLFEIPAKSFGWVFGSNAIGLIACSQINARLLKRLSYDVILEKIFVVLGVLGVILAMAggFWGLAIPLFLFIAALGMTFPNATAGAMATQRKAAGSASALLGTLQYGIAALSSAAVSRLHDGTTLPMCAMIGFCGVLALALHRLLVK--
      76 UniRef50_C8Q9F9        Putative uncharacterized pr...   168     2e-40  1  14.3%  7:390  23:413     ------WQPLHQPVFRMLWLATVVSNIGSWMNDVGV-NWSMLTLSADPLSVALVQAASSLPMFLFALPSGVMADIVDRRKYLLFSQLWVFIAAAGLTLLsvTPWVLLVAAFLLSTGAAMSSPPFQAIVPDLVDKHELGPA--IALNSLGINISRAIGPALGGLILSFAGPWMVFLLNALSVLGVAWVLYRWKAAppPEHFFPAVRVGLRYVHAAPVFRNVLVRTCAFFLFGSAGWALLPLVARRELGLGPGGYGIMLACIGVGAICGAVLLPGLRKKFSADRLMVLASIMFGLTMLALAFIRHFWWLNACEFFTGFAWIAVLSTLNLGAQRSAAKwkARALAVYLTVFFGSMTVGSALWGQLAAHFSIPLSLTFAAVGMFLSCVTVWRWR--
      77 UniRef50_C5ACF6        Drug resistance transporter...   168     2e-40  1  15.2% 24:392 159:528     -----------------------CGPIGTDMYLPSMPS-VAESLGTSAAAVQWTLTSFIAGFSLGMLLYGPLSDALG-RRPVLLGGIVLFTVAGVGCFVAPSIGALIVLRFLQALGAGAASVLSRAIARDAHEPAD--AARVLSMVAIVTSVGPLLAPLLGGQILRFAGWRTVFVVLAVFGLGCAIAAFLKVPETWPKERRRssFASYGRIIGDPVAWGHMLCGGMAFASMITYITATPFVYIEYFHVSAQHYGLLFGLNIIGIIIGNFINTRVVGRLGSLRLISAASLvfAVAFFALTGIGGLWSIVAGLFFVVGVIGLLSANCSTDLMHRYPHNAGAAAAVFGAMQLGLGAVASAVVGLLADGTPFGM-----GVTIAITGALCLMGRRL
      78 UniRef50_B1HPN2        Multidrug-efflux transporte...   168     2e-40  1  16.4%  5:389   1:384     ----MTQQKSNKAALYILMFNMFIAMGSIGIIIPVMPEYL-RIFGAAGQVLGMLIATFALAQFVFSPIAGNLSDQYG-RKNLIIFGLILTGLAQIGFGLSTDVWMLFLARFLGGLGSAFVAPPIMAFVADVTTYEERGKGM--SLLGAAMSFGFMIGPGIGGFLA-KVSLHFPFFMAGAAAILAAILSYFLLPSTKPnrQKQDNLVKQMARSVHMPYFVMLIIMMVFSFGIANFQTTLSLFVTEKFNYSPGDIAIILVVGGAFGVIVqfIITPLFKRFGEMKVVLVNLFIAAVAIFLILFVSGFALILVVATIFSTATTLIRPAVNTLISKLAEKEQGFAAGLNNAYMSLGNMIGPALAGFLFD-WNMNSPYIFGAIILLACFFLALIW---
      79 UniRef50_Q7M899        MULTIDRUG-EFFLUX TRANSPORTE...   168     2e-40  1  16.8% 11:391   1:378     ----------MIKQVLPLSGILALRFFGLFIVMPVLSLYALEMEGATPILMGIAIGGYALTQVLLQIPFGLVSDRIGRKKT-IFFGLLVFVLGSVVCAMAESIEMLIVGRFLQG--AGAIGGVVSAMIADLVKEERRTKAM--AVMGATISMSFTAAMILGPIIGSSFGVDKLFWLTALLASLAILVLFINVPEAPLVSYseAEESRWQEVLHDKNLQLMNLTNFLQKAFMTLAFLIIPLALVKGMHFEHQDLWKVYIPAAILGVLSMAPAAILAEKKGYFKGVLLFGIVMFALSYTCMVSREPWLFILGVMLFFIGFSAHEPIMQSLASKYaaHQKGAALGVFTSFGYLGSFFGGLLGGHFYQWFGIFSIACFVGSVSIIWLILIFRMKN-
      80 UniRef50_Q65F99        Blt n=4 Tax=Bacillus RepID=...   168     3e-40  1  18.8% 15:391   7:387     --------------LYMLMLNVFIVMLGIGLIIPLMPTFI-EEFGASGSTLGLLIAASGITQLLFSPVAGEMTDKYGRRK-MIILGIGAFAVSQLLFALASQMWLLFVSRLLGGAGAAFLVPAMFAYIADITSEKDRSKGM--GLISAAMSLGFVIGPGAGGYLAA-FGLTFPFYVSAGLAGLATVLSLLVLPEtrRSVQKREPLAKQMARALRSPYAFLFILVFILNFGIMNFEAVFSLYVDHKHGFTPGDIAFVITAASLIGVFVQAVagMLTNRFGEKKLMNMTLIGSAGALAVCSIAGSYWLVFGATIVFFMLTSILRPAINTLISKMAGDEQGFAAGMNNAFMSLANIVGPTVAGLLFD-VNVEIPYIFGVVVLVLSFLAAVSWGR-
      81 UniRef50_Q2S940        Permease of the major facil...   168     3e-40  1  14.6%  1:390   1:390     MQKTQRFMPQERRAVSALASLYAMRMLGLFMVLPVFMVLGRELEGATPALLGLAIGVYGLSQAVMQVPFGALSDRFGRKK-LIFIGLGVFCLGSVVAALSDNIYGVIFGRLLQG--AGAIASVLMALLSDLTQEENRTKAM--ASVGMTIGLSFALALVLGPLISGFAGLAGLFWATACMALSGMILLYKVPTPLQQRRNLEtlRSALRNVFQHKELMRLNWGIFSLHMILTAMFVAMPVTLADKFNMVADRHGWFYLAVMGAAFVFMIPLIIIGEKKRLLRQVFTGalMAVALMIVMKGVNDFIGFTLAVFGFFLAFNFLEATLPSLVSKVApgMRGTAMGVYSSSQFFGAFLGGVLGGLAYQKFGLMGVYGLCTVMAVVWGGVSLFMP--
      82 UniRef50_Q49VL8        Putative sugar transport pr...   168     3e-40  1  13.6% 10:392   2:378     ---------KYPIAIWMLAIGAFAIGMTEFVIMGLLPN-IARDFDVTVSQAGQLITGYALGVAIGGPIIVMLTIKW-NRKYLLIVLMGIFIIGNLTASFSPNYGFMMTSRIITSLAHGSFFGIGSILAASMVRPEKR--ASAMALMFMGLSMSNILGVPFGTLIGQNFGWPMTFIIISIIGALALIGIIIFVP--MQRETIKSSVLNELQILKEKRLWLTLAVTLFGFSSVFAYFTYISTVLIDVSNVQENLISYLLIIFGIGVTLGNVVGGKLADWNLNKALKIIFIVFILYFILLYFVQMNSILMVAGIFFFGLIGFSMSPSLQFKSTLISQDAPTLASTLNQSAFNLGNALGAFIGGVVVTNLPIASLSLIAPILTVIGLIFLLVSIRV
      83 UniRef50_C6NXL9        Major facilitator superfami...   167     5e-40  1  17.2%  3:391  59:450     --RMPPLADGPSWWFPLLCGAGFGGRLSYEMIRSPLTSLYARHLGAPTAVIGLLVAAVTITGIFIKLPAGSLADQFGFRR-LMLAGMMVTAVGPFLYLLVWVWPQLLAVRFFHGLSTALYAPAASAQVAKSFPAQ---RGRRLGLYGAAENAGVVLGPVIGAAALAHLGFAAAFVVSGGIGLLALLTILPFPRDALVHDGrrVAAQGVRQIIGDPAIRLVGLIEAALYFGVGTLQAYLPLYALDQ-HIPILNIGFLFGAQGIASILFRPVFGMASDRVGRGPFIVAGIGLCATVLATIPHMGQFLPLLGLSTLFGLGTAMVTPATTAMLGDLVrrDFGAAMGVFGSIWDAGHACGPLISGVFIAWIGYRSAFAIIAGVMVTALGIFLYGNR-
      84 UniRef50_Q04U94        Permease n=3 Tax=Bacteria R...   167     5e-40  1  13.0%  7:391   5:404     ------MNPQRPAALGFIFITVLIDVIGFGVIIPVLPKLIQELTHGSLSDvgLLMFAYSFVQFISAPFVGGLSDRYG-RRPILLASLFGFTLDYLFLAFAPSIFWLFVGRVVSGI-MGASFTTGYAYIADISPPEKR--AQNFGILGAAFGLGFIIGPVIGGSLGQ-FGSRAPFLAAAALTLVNWLFGFFVLPESLTDENRRkpIDSLINLKRYPMIVGLIIAFFLINTAAHAVQGTWNYYTMEKFQWNEAMIGYSLGVVGLVYAVTQGGLIRIipVLGQNRSIYLGLALSALGYALFAIATQSWMMFVFLIPYCLGGIAMPPLQGIMSSQVPPREQGELQGALTSLMSVTAIVEPILMTGLFSYfsPEAPLWMGTILTAASLWISVGSLR-
      85 UniRef50_C1SLV9        Arabinose efflux permease f...   167     5e-40  1  14.5%  5:389   1:383     ----MDKAKLWTKDFVIGTSINFLLMMNYYLLVVIMTVYAIEVFEASPGGAGLASSIFVIGALVSRLFCGMLIEQIGRRK-MLLCGAALNVFMTLLYFEVTDIVPLLFIRFIHGVSYGVAATAVATIVSDLVPVDRRGEG--IGYYMLSITLASAIGPFLAMYLLQHGSFSLVFAICTGLAILCClmLLRVPVIKLSAEDVSAMKKIRLENFIEIKAVPISIVCSMVYFCYSGVLAFLSPYAKEI--NLTGAASFFFIVYSAAIFFSRPFTGRLFDRKGENVAIYPALLIFIFGLVLISQAHHGVTLMFSAVLLGFGVGVVQSCGMAIAVKVTPQHrgLANSTFYMFLDAGVGFGPVVLGMFIPFSGYRGMYMDMVVVVLICTFIYYLL---
      86 UniRef50_UPI0001C33615 arabinose efflux permease f...   167     6e-40  1  16.0%  7:388   6:388     ------LDSRQKQNLGLLLGVSLFFWISITVLLPTLPTYV-EYLGGTKPEIGLIMGSFAVGSLFSRTLLGYLADTK-SRKLVLYIGVIIAALSPLNYLFVQTILPLSIVRAIHGISISAFTTAYSALVIDFSPIKHRGR--VIGYMSLVTPIGMSIGPVFGDLLKENFGYTTLFIVSSICGFLGLFLVVAMQKESNSNSYSsdSSHSFHKILSSHSLVIPTLVLLLIGLLFGTIITFLPLFLEEK--GLEFSAGLFYTLASITSFLSRIFLGRVADKFGRGLFITTSILCYFSSMILLTQATGSQQLYLAAIFEGIGAGILMPMIITLVSDrsPQERGQVYSVCLGGYDLGIALAGPIVGILGSELTYQTIFTFSSNLALIAFILFIV----
      87 UniRef50_C7PNP9        Major facilitator superfami...   167     6e-40  1  13.6%  7:388   1:391     ------MQTTKQSAIGFIFITLLIDVMGWGLIIPVMADLIAQLKHIPVNQAslLLSVFAITQFIFAPVVGNLSDKYG-RRPVLLLSLLGFGIDYIILALAPSYGWLFIGRVIAGM-TGASFTTATAYIAD-VSIDETTRAKNFGMIGAAFGLGFVLGPALGALLA-HWGIRAPFYAAAVLCLLNCLYGFFLLPESLKKENRRppLGSLKFLTTHPEIGGLAFAFFLIYLGAQSVQGNWNFFTIYRFQWSEKMVGISLAIVglVGAVQAGLTRIIIPKIGNEKSIYLGLSLYSLGLVLFAFATQSWMMFAFLIPYCLGGICGPSLQSVISGHVPPNQQGELQGALTSLMSLTTIVGPLImgTFAYFTTDKAPFYFPGIHFLIGAVCMLL----
      88 UniRef50_Q3AD23        Putative transporter n=1 Ta...   167     6e-40  1  13.0% 11:388   9:378     ----------WSKDFTLLWIVNFLMAAGFYFLLPTMPVYATKVIGANESQVGLVTGVYTLSAVAIRPLGGYALDSVGRRKVFL-WALALFALFMGSYYFATNLFFLLMLRLLHGFCWGVTTVGGSTIAADILPPQRRGEG--IGYFGLTMTLAMAVGPLIGLQLMGEANQYGRLFFTASGLVVLALIIANFIRYPKLPLTKRPIS---LDAFIEKKVLPVSMVMFFSALVYGGIVSFITLFSKE---IGIKNGGTFFLAYAAALSLVRPTSGKLLDRRGPAPVITVGFLCTAAGFLLLSLSKGLTGFLTSAVIIGAGNGMVWPSIQTMVINMvpQRRGVANSTYFSAVDLGIGIGSILLGWLANRTSIATMYFISTIILFVPLAYFIL----
      89 UniRef50_UPI00017F6010 Permease of the major facil...   167     8e-40  1  17.7% 12:389   3:379     -----------KKPIFALNLATLVIALGYSLILPVMPFYM-ENLGAGGRELGWLTAVYALAQTVCAPFWGALSDRIG-RKPIISIGIIGYSISLFLFGLASSFWTLFIARSLSGILSSATSVASLAYVGDSSSEEERSK--NMSQLGASMSVGVMMGPLLGGILAG-YSLALPFFTGAGISFIAFLLILTLLPESIERSGQTEKRKPflKSIIFGSAGMVLILIFVVHFCQTGLQGITGLYVVDKFGFSTKQVGVIWMVLAGILIVVqfLTGPLAKKIGEKRLILIGMFCKALVAFAMVLTTGFVSVLVVFGLFAVSSAITVPTLNATLSKTDNQHKGTLMGFASTAGNLSKVIAPLLTGYLYES-NIELPYITTGGIALIGVVICYIW---
      90 UniRef50_C2G4A4        Bcr/CflA family drug resist...   167     9e-40  1  13.5% 10:388   8:392     ---------KRSTIIFILGLLSAIGPFSIDMYLPAF-KTIATDFDTSVDRVQLSLSSFFIGIAIGQLVYGPLLDKFGRKKPLIV-GISLYIFASIMCIFSTSIEQLIVFRFIQALGSCSGMVASRAMVRDYFGPQE--SAKIFSMLMLIVGISPILAPSVGAFVMSHFEWHMIFTILTVMAVLILISVIFLLPESFAGnaPKQVTINFWTVCKNPQFLSFCLVSALTASALYAYLAGSPFVMQELYGLTESEYGIVFAIIASALILATQINRIALNRWSSSDISKFASRLQVSISALFIVVttLPTMVGFIFLILLAQGFIFPNTSALALAPFKELAGSASALLGCFQMGIGALASGAVSILHNNTSLPMVIVMSACSFLGLIIYSYL----
      91 UniRef50_A0QVE8        Major facilitator superfami...   166     1e-39  1  13.6% 10:391  23:429     ---------LRYWILGWLLLAGILNYMDRSSVSIAAPHMIA-ELGLTKTDIGLMGAVFSWTYALCQLPAGYLIDKLGARR-MYFAAVGIWSVATALMSVGQTMAHFLTFRFLLGVGESPNSPNSSKITTEWFPREERGQAA--GIWDSGSKWGSAIAPPVLTVLSLAFGWRAMFLIIGLAGLVLALAFWAYYRAPESSRhqPKAHLPWGKFFTYPQTWGMMLGFFSSIWIWNIFITFLPLFLQDTLDVSIAQTGWVAAIPYLASAITGIYAGrlVRRRgkKTVLIGGSVGLGILLAVVPLVHNPVLAIVVLCAALGLVAAVQSQSWALTSDIVPdhAAQFGGIMNFGGYFGGALAPLVTGVIVDKTgyTPSFLVSGVIAVLGACVYGFMVR-
      92 UniRef50_A1VXC0        Drug resistance transporter...   166     1e-39  1  14.4% 13:387  14:393     ------------KLIVILALMSSIAPLSTDMYLPALS-HVEQSFQTNSFLTQLSIASFFIAFALGQLIYGPLSDIFGRKIPALV-GIFFFIVSSLFCVIIDDIYAFIALRFFEALGGCAGVVIARAIVNDLF--EIKEAAGIFALMMVFSSLAPMLSPTFGGFLLEYFSWHSIFATLFALGILLFLMILFGLKESAPHLkhHEAMKSYKFVLSDKRFLVYILCASFALAAMFAYITGSSFVFTQFFGLSEQKFALLFGANALGFVICANINARLVLKYESEKILAKALMIMFISTVILlfHPNFLLFELSIFTSIAMLGFIAPNTTTLAMARFKEHSGTASAVLGTVQFGFAGLISFVVGAINANTPIILAFVMCACVLVANMIYFL-----
      93 UniRef50_Q9CKS3        Bcr n=1 Tax=Pasteurella mul...   166     1e-39  1  15.4%  1:390   1:393     MPVATNTTWNQTALICFLGTLVGFGPLSIDMYLPSLPT-IAKALHTSIEWVQLSVSTFLTGFCVGMLFYGPLSDKYG-RRIILLIGMTIYIVASIACSIATSIEQLLVARFLQAFGGGVGPVLGRAIVRDSFPPQRIT--HVLSMMQLVTMLAPLLAPFIGGIVLLWFGWETQFLLLALIGVVCWLIAYFFLAETNQDRHQRPlfQAYCGILKQPQSFGNILCLSAMFGGMFAYVAGTPFVYIDYFHIPPQDYGFYFGINVVGIVLATLINNYCVKRYAVQRVLMagLVALAGMAFFLADPDSLFAIMLPLFIFVGLTGALTPNVMTSLLKQHSHAAGAAMALVASMQFAGGFVASGALSYFFNNSPQTMLWVMSTCAGVAIVGFMITLK--
      94 UniRef50_UPI0000E87E47 MFS family transporter n=1 ...   166     1e-39  1  14.0%  1:385   1:385     MSNREKMSSLEIRTSFILASIYALRMLGMFLILPIFAIYASgeGNPTSFQIGLALGIYGLTQALFQIPFGMSSDYFGRKK-VIYFGLLLFVIGSIVAALSSTIEGIIIGRSIQG--AGAISAVLTALLADLTRDEHRTKAM--AIIGGGIGLTFALSLVISPWLNTLIGVTGIFLLMAVLSVLAFFIVHFFIKEPRSEGKKTptQADFLSLIKDIHLNRLNFGIFVLHATQISMFMIVPIYLISQGGIDLSSHWYIYLPVLIVSFLLIIPVIIFSERYHKNKLTFLGAILFLLAatFMVFSATLTGIIVALLIYFVGFNFLEASLPSLVSRVApnKKGLALGVYNTSQSLGIFIGGSVGGLITKFYGYNGSFLFCIILIGVWFAF-------
      95 UniRef50_C5QNX1        MFS family major facilitato...   166     1e-39  1  14.9%  8:389  21:399     -------TRLWTKDFLSVTFVNFFMYLIHYMLIVTITEYTIDEYHASESVGGLAAGIFIIGMLAGRLGSGRIIDNLQP-KLVLLSGTIFSVIAVALYFTINSLWVLMLIRLIHGIAFGFSSTATGTISSRIVPEDRKGEG--IGYYGLSVTLASAIGPFLGLVFNKNLGFESIFGISLISIVVALILTFFIKkpVLGNTTENEERPKGIHAYLQKEALPISMVIVLVGVAYASVLSFLSIYAEKINLVTAS--SFFFVVFAIVTFVTRPFTGKIYDNYGENKVMYPVLFSFMIGLVILGCTHSSLVLLIAAAFIGFGYGTIVPTAQAiiQQSPPNKMGLATSTFYIFTDFGAGMGPFILGMIIPFLGYRNLYILMGVVVIIAIIIYFFV---
      96 UniRef50_C6PMM3        Major facilitator superfami...   166     1e-39  1  15.2%  1:388   1:383     MEQSEEEEKLWNFSFILMLMINSLIFIGFTMMTPILPKY-AISLGAAMSIAGLVAGVFAITSITIRPFAGFATDRF-NKKHLLIVSTIFLAISALGLKISYSISTLFFFRIIQGISFSISVTVINALSTSYMPKKRIGEG--IGFMGLGYILATAISPNLGLEISTRFGFKYVFYLSCVIVMIAVALMTMIPYNPPNKKNLTANKFQIknDFFAKELVIFAIIACLFTFMNGVIGSFLALLGDERH---ISNIGYYFTINAIVILIIRPLSGKLLDNKGLSIIAFPAFIMAMAAALLLAISTSLWMILAVAILYGIGQSSLSPALQAtvKRLGPSRVGVATSTYFIGYDAGQGLGPIIGGTIAGKFGLTSVFYICGALLFAGIVIYYL----
      97 UniRef50_A6M098        Major facilitator superfami...   166     2e-39  1  13.6%  5:387   1:381     ----MDKPKLWTKNFLIVSTANFFLYFTFYLLMVTITTFATERFHASPSEAGLASGIFVIGVLLSRIFSGRYIDQVGWKK-MLYIGFILFLATTFLYFLVNSMVFLFINRFLNGAAMGIASTATGTIVAKIIPNERRGEGT--GYYALSLTIAAAIGPFLGMFITEHSNFYMNFVVCIIFLILSFFAVFfiPKLEIVKGHSNNNKDFSLHNFFEIKAIPISIIAGVIALGYSSILTFISSYSKEINLMSVG--SLFFIVYAVFVLLSRPFTGQMFDKKGENFVMYPAIALFALSLFFLSQTHGSLTLLLAAAILGLGYGTTSSSVQAIAIKVSPKHrgLATSTNFIFQDLGVGIGPFILGYFVPLIGYRGLYMMMAAVAVLCIFLYY-----
      98 UniRef50_D1BR56        Drug resistance transporter...   166     2e-39  1  13.6%  4:386  10:394     ---MLTISNKGWLFTSILSALMAFTSLSTDIYLPAMPE-MGRDLNGDAE---LTLTGFLIGFALAQLFWGAVSDKIGRKKPLII-GIVLFIIGSVGCALSSSMMELLAWRVFQAFGACVGPMLSRAMIRDLYGRTE--AAKMLSTLAIVMAIAPIAGPMLAGHLLVWYTWHSIFWLLVAIGILMLVAVLVIPETHPLEKRSKKSIgnYWILLRNKGFMKYTLCVSSFYIAIYAFLTGSPYVYIDVYEVPKEYFGYLFSVNIIGVMLLSAINRRIvdRLLKYATLFAAICVSIVMGLMFLGYHSLWLIVIGCFLFFSMNGIIAAVTNALALDRAGRMAGSGAALLGAMQYGSGIVSSLILTFLPNDTAYPMMGVIAIFVIICAMIAF------
      99 UniRef50_A0KLA9        Bicyclomycin resistance pro...   165     2e-39  1  14.8%  4:388   1:391     ---MPHAPLSPRFLFILLGALAGLTPLAVDMYLPAIPA-IARDLATSIDGAQLTISAFLGGFAIGQLFYGPLADSYG-RKPVILAGLSMFAVASVGCAMADSLPELLAWRMLQAAGGAAGSVVVNALLRDLFEKDAFSRAM--SFVILVMTLAPLVAPVVGGYISAHSDWRVIFWLLVGISLFICLVLQWKIPETLKPEHKQPLrrNYWGVLSHRGAMGYVLCGALSSSGMFAFLSASPYVYIEYFHVPTEHYGWLFGLNILLMMVVTFVNSRLVKGVGAERMLQYGLTMLPLAGALlsQTGGLWGIVIPVVLFVGHISLVGANAMTGLMGHFPQSAGTASALAGTLRFGVGALVGILVNLDPPESPLPMAIAIASCGFGSALCYWLL----
     100 UniRef50_P39843        Multidrug resistance protei...   165     2e-39  1  15.7% 11:391   8:391     ----------QKTIFIILLSNIFVAFLGIGLIIPVMPSFM-KIMHLSGSTMGYLVAAFAISQLITSPFAGRWVDRFGRKK-MIILGLLIFSLSELIFGLGTHVSIFYFSRILGGVSAAFIMPAVTAYVADITTLKERSKAM--GYVSAAISTGFIIGPGAGGFIAGFG-IRMPFFFASAIALIAAVTSVFILKESLSIEERHQLSSHtlKRSIHPVYFIAFIIVFVMAFGLSAYETVFSLFSDHKFGFTPKDIAAIITISSIVAVVIqlLFGKLVNKLGEKRMIQLCLITGAILAFVSTVMSGFLTVLLVTCFIFLAFDLLRPALTAHLSNMAGNQQGFVAGMNSTYTSLGNIFGPALGGILFD-LNIHYPFLFAGFVMIVGLGLTMVWKE-
     101 UniRef50_Q3ZXW4        Major facilitator family tr...   165     2e-39  1  15.9% 10:392  22:408     ---------RFDRGVWMLTLIGLINSAAFSLSLPFISLYLYQERGLSMTQVGLVILLSGFVSAIVQMVAGALADTYGRKPVMLlgSAVIYGAMAVLIGFNMPVMLIILSYVLLRCTLVATRPASQAMIADLTPKDRLTET--YGMVRIGNNLGWAIGPMLGGFLLIGLPYAYLFGVGAVVCLITLYITAKYINESLSNSVEWVSLTKIFSAGKDRAFLWFTILSILLFIVVGQFISTLSVFTVDRLHFSEADYGMLLTLNGLMVFALQYPVTRILHNVSKSHMVVMGSLIYAVGYLMFAWTTNLGMAFLAMSVITMGEIVFAPTTLAVVGDLspQQRGRYMGFYGFSEMLGFSLGPMVGGALLDAhsSLSVWGTLAALAVMSAVGFYIWGRV
     102 UniRef50_Q1LE12        Drug resistance transporter...   165     2e-39  1  14.8%  1:384  19:410     MTSTKGAPSSSRFPLWLlaSLTAIAPLSIDMYLPSFPA-LAADLHTDIGQVQLTLGTFLVGLAIGQAFYGPISDRFGRKPPLYV-GLTIYGAAAAGCAMASTVDSLMLWRFLQALGGCTGLVVSRAVIRDRMEAHESARA--YSSLMLVMGLAPILAPLIGGAVLAASGWRAIFWIHCGAAVLLLWFVHVRMEESLDVQRRraVLRSYWELLRDREFLGYSLAAGCVQGGMFAYIAGSPFVLIELHGIDPSHYGFVFGANAFGLIGMSQVNTRLvdDVLRVALFAPCVAGLVLAGTALIGWATLPVLLVCFFAFLSGLGCITPNASALALSHQSHRAGTASALMGTLQFGFGTLAGAAVSLWHDGTALPLAVVMAVCGSGAVVL--------
     103 UniRef50_B0TJI4        Major facilitator superfami...   165     2e-39  1  13.9% 11:391   1:377     ----------MNPKVYLLALITFATGMDENIAGGIVP-FIAEDLGVSISAAGQLTTVFSLTFALAAPVLLFATAKFNRLR-LLQVALFTFCLGNLFSALSPSYAFLFGMRIISAASCALIVVLVTTIATEMVEAEFKGRA--IGIIFMGISGSLVLGVPVGLLFCNWLGWRAPFAFIALMALLLCIIVPLMLPN-VSSNGQRIPLSKYAEHLKNPKLLTAQLVSILMIGGHFVLFAYLAPYLQATIGASKSELTFYYFLFGAAAITGGYMGGWLSDKLGHITAIILIPSIFILFLGAIPFtnSLVLFIPCMMLWGGLSWTISPIVQNYLIQSDHANAGVSIAVNNTSMHLGVALGSLLGGVVIKYSSVNWTPAIGVFVVVLSLLCALYSTR-
     104 UniRef50_A8FAL5        MFS family major facilitato...   165     2e-39  1  15.2% 13:386   8:376     ------------LLIILLAVGSFVTGTSEFVVSGIL-DMISVDLNISIPAAGQLITVYSLFYAVGALFLVMATSKLNRKK-VLLSAIFMFILGNVVAFFSHHFMLLLLSRVIMAMSGGLYIVVATNYAAQIAPPEKKGSAM--ATVITGFTVSLVLGVPIGTFLSGHVDWHYIFLIIALGTACLLFLLYQLLP--RMEGHSHLPLKQQLHLLQDSRVISGLATTVFWILGYTMVFAYISPLLRQTAGFSLEMTSIALLILGIAAFIGSRFGGFAVDQWGPNRTISISIMIQMFTLFTLFFTqsTISVLITLAIWGIATWTTTPAKQFYLISLKPQASETVLSFNTAIMNIGMMLGSSMGGVIIQYTNVTNLSWIGGIASFAALMLI------
     105 UniRef50_Q4MIT7        MW2376, putative n=9 Tax=Ba...   165     3e-39  1  13.6% 11:363   1:349     ----------MNFKVFILALATIAVGLVELIVGGILPD-IAKDFNVSLSSAGQLITIFAFTYAIAGPVLLIFTNKVERKK-LYIISLYIFLIGNILTYFSPNFTFMMIARILTAMSTALVVVLSLTIAAKIVNPSYR--AKALGLIYMGISSSLVLGVPLGILISNTFGWRVIFLCIAILSLGSIILISVFLEKIPGEENRIPLSIQLKAV-CSPKLGAAHLATMFMLAGHYTLYAYFTPFLEDKFHLSPYWISIFYLVFGIAAVSGGAFGGVLSDKIGAPKSIVIVITLFALILFILPFTtsIILFVPVMIVWAALSWGLAPPQQSYLIQTAPDTSDIQQSFNNSALQIGISLGSAVGGIAL-----------------------------
     106 UniRef50_B5GBY2        Bicyclomycin resistance pro...   165     3e-39  1  14.5%  6:390  47:440     -----TARRTSLLTTFVLGGLTATPPLSMDMYLPALPK-VTEALGSPAATVQLTLTACLTGMALGQLVVGPLSDRFGRRRPLLV-GLVIYVLATAACALAPGTAPLIAFRLIQGLAGAAGIVIARAVVRDLYDG--LAMARFFSTLMLISGVAPIVAPLIGGQILRFTDWRGIFLVLTVVGTLLTLLVVRSLPETLPPARrrEALATMRGLLADRVFTGHVLVGGFTFAALFAYVSASPFVIQEIYGASPQVFSLLFGINSVGLIVMGQVNGRlvGRVSLERATGVGLSLITAAALALLLMTslVPLAVGLFVLMSSMSLVMPNAQTLGLQRAPHAAGSASALIGTSSFLIGAIASPLVGIAGEDTAVPMALVQLVSVLVAGAAFVLLCR--
     107 UniRef50_Q0AK80        Major facilitator superfami...   165     3e-39  1  14.7%  5:391   1:403     ----MSARTPGKHAIIFIFVTVLIDMIGFGLIIPVMPDLIEELTGlaAVLGAWLMVSYAGMQFVFAPIIGGLSDRFG-RRPVLLAALGGFAIDYLIMGFAPVFWLLIVGRILAGIF-GASYSTANAFIADITPPEQR--AARFGLIGAAFGVGFTLGPAIGGFLGDSFGPRAPFFAAAVLAGANFIYGLIILPETLKAENRRppLGSLLQMRKYPAVLVLMSAIFLMLLGHSVYPAIWSYYTDFKFGWSSRDIGLSLMAVGLSSAIVQGGLTrlVPKLGEWRAIALSLSLAVIAYALYGLATTGWMVYAIILFAALG-GIGQPALQGVMSRIVPaaQGELQGAMTSLQSLSMIVGPLVMSRIFSHFspGMPFLVASGLTLLALFIGLSARR-
     108 UniRef50_D0SE80        Major facilitator superfami...   165     3e-39  1  14.1%  7:376  10:374     ------PTSHLSVIILALALGGFCIGTTEFVAMGLI-QEISQSFNLSIPVTGHFISAYALGVTIGAPVIAILAAKV-PRKTLLIGLMLFYGIANASTALANSYESMLVSRFIAGFPHGAYFGIAALVVAEFAGKQKR--ASAVAMLMMGLNVATVIGVPFATWLGQLYGWRAGFEFSASIAFLTVVAICFGLPKMQL--DHTASIQNELRGLKNTQMWLTLAVGAIGFGGLFSVYSYVSPILTEYTHASIQVIPFALACIGLGLVVGGVVAGHFADKNLNKAIIWVLVSNACSYVLCALSMDHLATAFIALFLVSFSIAGLGPLLQTRLMDVAGNAQGLAASLNHSAFNIANAFGAFLGGWLiqGLGWLAPIWVGV----------------
     109 UniRef50_UPI000169463E multidrug-efflux transporte...   165     4e-39  1  16.0% 11:392  26:404     ----------LKKPILLIMIMLFFVYVGFGIIIPVLPVFVQEE-GVDPAGLGLLLSIYSIVSFLVAPFWGALSDRKG-RRPILLTATFGFALSFVLLALsrHIWLLYLSRVLGGLFSGALSGVAMAYVADITSHEERTK--SMGFVGMSIGLGFIFGPALGGLLSSW-SLTLPFWVSAGACTAVFAGTLLVLPESlkSVQPAEHSHSSRWKAFSGLLRYLYILTFVVSVSLAGLESTFQYFEMEVFQVTSSQIGLMFMFSGFADALVqgLIRPIAKRKWEKQAIGTGLFFSVMGFIMILQSAGFWTATVALTIFSMGNAMVRPCVSSLLTQRTTGGQGITTGLNSSMDSLGRIAGPLLGTSLFGWKS-GAPYLAGILLSLAAGYWLWKFHEL
     110 UniRef50_C6WNJ4        Major facilitator superfami...   165     4e-39  1  14.4%  3:391   5:395     --TTERTAQRLPAEVWVLVVASFIIAIGFGIVAPALPIF-ADSFGVGSTAVALVISSFAVVRILFAPVSAKLVTRFGEPKT-YIAGIVIVALGTAACGFAVTYWQLLFLRAFSGIGSTMFTVASVGLLIRITPPAQRGQAT--GLWSTGFLLGNIFGPIIGAALVG-VSVQLPFVSYAAALLVAATFVWWFLRKSTLAaaRPESPVTVRQALRNSSYRAALASNFANGWAVFGlvSMVPLFVEKALHGSPEMGGISMSVFAVGNVCTLMVSGKLSDRIGRKPLGIAGLAISAAGTLWFGFSTTVPVFLVASFVAGLGAGLLNPPQNAVVADvpKGKGGPLLATFQVIADLGAIVGPLLAGLLADNFSYTTAFTVTSGIMVVALLMWITMPE-
     111 UniRef50_O31762        Bacillibactin exporter n=71...   164     4e-39  1  15.4% 13:388   2:386     ------------KNIIALSSVPLVMTLGNSMLIPVLP-MMEKKLSVTSFQVSLIITVYSVVAIICIPIAGYLSDRFGRKK-ILLPCLLIAGLGGAVAAFASTyaMILAGRVLQGIGSAGAAPIVMPFIGDLFKGDDEKVSAGLGDIETANTSGKVLSPILGALLASWY-WFVPFWFIPFFCLISFLLVLFLVAKPEEDEDAPAVSEFIKSVKKirWLYTVFIIGCVIMFLLFGVLFYLSDTLENKYAIDGVAKGGLLAIPLLFLSTSSFIAGKKidKGRMKFCVVTGMILLTLSFIALWWNHSFYFLFVFLSFGGIGIGMALPALDALITEGIESEqgTISSFYNSMRFIGVALGPPVFAALMSNANW-IIFILSAFCSIVSLFLVLF----
     112 UniRef50_Q3BM88        Drug:H+ antiporter-1 family...   164     4e-39  1  17.1% 10:366  41:405     ---------RRRAALIFIFITVLIDVLSFGVIIPVLPDLVRHFTgvAAGWIGWFGFLFAAIQFVCSPLQGALSDRFG-RRPVILLSCLGLGLDFILMAIAHSLPMLLLARVISGVCSASF-STANAYIADVTPPDKR--AGAFGMLGAAFGIGFVAGPLIGGWLGS-IGLRWPFWFAAGLALLNVLYGWFVLPESLPAERRTapLGALKLLRRYPQVFGLASVVFLANLAHYVYPSIFVLFAGYQYHWGPREVSWVLAGVGVCSIIVnlLVGRLVRRLGERRALLLGLGCGVIGFIIYGLADSGTAFLIGVPISALWAIAAPSAQALITREVGADAQGRVQGALTGLVSLAGIAGPLLFANVFAWF--------------------------
     113 UniRef50_P73784        Quinolene resistance protei...   164     4e-39  1  15.3%  7:386  10:391     ------LSPSTQKTFALLFASVLMFWLSLTALLPTLPMY-AQDVGATKQQVGWIMGSFALGLLGSRIWIGQLVDRRG-RKIAIVIGALVVALAPLGYLLTATVGALMAIRAFHGICLAAYTTGYNSLVVDLSPPQQRGE--IIGYMSLAVPIGMGFGPAVGAYISQSIGYEFLFIASSLLGFISLVLALQVRENRPPDQSsrPRPRSIGKLLTSRSMAVPTLVLLLIGLLFGNLATFLPLFVREID--LATYAGVFYSVAAIASFVPRLFLGSLADTYGRGLFIVGSLICYLLSMVCLAQADNSWELLTAAALEGAGSGILLPTTIALISDRSseERGRVFSVCMSGFDGGIAIAAPIMGVLNEIFGYRHVFWLSGGLALAAIMVF------
     114 UniRef50_Q5QU78        Probable arabinose efflux p...   164     5e-39  1  11.6% 13:390  10:381     ------------LAIFAMAIGSFAIGIGEFVIMGLLPD-VAADFNTDTRETGHLISLYALGVVIGAPLITILFARL-PRKPMLLALMLAFSLGNFASASADNYTLLQVLRFLTGLPHGAYFGIACLVAADMVRKNQRG--MAVTMVMMGLTVAILVGNPLATWLGQLIDWRTVYHTVGALGLLAFVMIFIVVP--KHPNEKKTSARGEMQALQNPQVWLTLAIGAIGFGGMFAVLSYIAPTLINATGLDSHWIPVALFIYGLGSLAGSLVGGWAADR-NLKLTIGGSLVWSAIVLAIFPLTLQSLWTVMPMVLLLGSSAALVPALQVRLMDVAGEAQTLAASLNHSAFNAANALGAWLGGliISPLSWQGTGWVGCALSLAGLLLFWVTK--
     115 UniRef50_A6LDK1        Putative transmembrane tran...   164     5e-39  1  15.1%  6:389   4:379     -----TKPVLWNRNFVQCCISYFLMNFAFYMLMPTMPVYLVEELGISTSEVGMVLSSYTIGLLCVRPFSGYLVDCF-SRKPLYVFAFTIFACLFAGYWFAMTVYTIMAVRFIQGGFMGLTSVSGNTITIDVIPSKRRGEGM--GFYGLTINLAMSLAPLVAVGLYDRHGFFWIIGVALVIALVGIGSVGLICYPKREKVPRPAFSLDRFILVK---ALPAALAYLLVAIPYGMLLSFVVLYGKE---IEVPNPGYFFICMAIGVGTARLISGRLVDHGKIHVVSIVSLVSLAISFSVFATVHTSFVFFACALAIGIGFGVSVPAFQCLFVNVAPHhrGTATSTYLTSFDFGMGIGMLSAGFIATHTNLATAYGVGAVCCLLSLFVYIRL---
     116 UniRef50_A7HKI1        Major facilitator superfami...   164     5e-39  1  18.6% 12:376  15:378     -----------KKVLTTLFFIVFADMLGFGLIIPLLPYY-AKEFGAKDIVIGFLSMIYPLGQIFASPLIGRMSDKFG-RKIALLLSVGGTFLSLLLLGFAKSLTLIFISRLLDGL-TGGNITVAQSYISDFT--DKKSRAKSLGLIGAAFGLGFILGPAIGGFL-SRWGFHVPAFFAAGLSFVNLLNIIFLLPDSKPVEDAKRvfEEMKKTISRPVVFYLLLTKFFYSFGFTTFESTFALFALRRLNLPLSQTSFVLAYVGILIAFTqfLVGKITKKYKEDDIIKSLIFVVVPFLILYSFSANLITLILLLTPLSVISGLIGVSVNSIATKTvrDRLGGTLGIFNSVDSLTRIISPLFGALIIQYIGPKYLGLFIG----------------
     117 UniRef50_C6D395        Major facilitator superfami...   164     5e-39  1  13.8%  8:390   9:390     -------KPHYHLTTLILFWCSLIVVSALYLTIPLLSVF-EDVFQVSSSGAAWAGSAFSFAFAGGGLLFGGLSDRYGRKK-MMIAGLCLLMASTPFIGTVHEFHWLIVLRVIQGLAASMFPPAVLAYAMEMFPANK--KVTILGFISTAFLMASIVGQIYSSTVEMAIGWENVFYILGIVYFVSLFLIALGIPKDITQKPEGNFFSPLKRifKKKNLPFCYIVSSTLFISLVGFFSTLGSYLSshFGLSHQEILWVRAA-GIIGMFISPFDGKLVTRFGVKNVLWCGLIMAGIGLGLVGVSENLALLIPTSIIFTAGIAMALPALISLIGTLAGELRASALSFHMFMLFIGASLGPIISIYLIDTQGHRSTFEVLAGLLLISTVVPLFIR--
     118 UniRef50_D1RSQ6        Putative uncharacterized pr...   164     6e-39  1  14.8%  7:390  26:416     ------WQPLRQRVFRMLWIATVVSNIGSWMND-IGVNWTMLTLSADPLSVAMVQVASSLPMFLFALPSGVMADIVDRRKYLLFSQVWVFIAAAGLTLLSVtpGVLLVAAFLLSAGAAMSSPPFQAIVPDLVSKNEMGPA--IALNSLGINISRAIGPALGGLILSFAGPWMVFLLNAISVLGVAWVLYRWKAEppPEHFFSAVRAGFRYVHAAPVLRNVLVRTVAFFTFGSAGWALLPLVARRELGLGPGGYGIMLAFIGVGAIFGAVLLPRLRKSFNPDRLMVLASLMFAVTMLALAFVRNVWLLNAFEFFTGFSWIAVLSTLNLGAQRSAAKwkARALAVYLTVFFGSMTAGSAIWGQLASHFGIPVSLCVAALGMVLASTTVYRWR--
     119 UniRef50_B9XJZ1        Major facilitator superfami...   164     6e-39  1  13.2%  9:387  15:395     --------ARERLLLLTLAAIQFTTILDFLIIMPLGPQYM-RVFSIDPKQFGLIVSSYGISAGVAGLAAGFFLDRFDRKRALL-WLYLGFGVGTLFCAMAYNYQLLVASRFFAGAFGGVVGAVILAIVGDVIPMERRGAAM--GMVMSAFSVSSIVGVPLGLLLASHYNWHVPFYALTVLSFIILIIAAWITPPLRGHLAHHQDQHPFARTLthPDHQKAFLFMAALTCAGFAVFPYISTYMVSNVGLTETQLPLIYLCGGLCTLYSMNWVGRWADRAGKLRVFTITSLTTAVPILllPRVPVVAAVATSTLLMVCMSARMVPAMAMMTGAVEARYRGGFMSINSAVQQLSMGVTAFLGGYIVQQKTPTSPVTHFPINGFISIACAY-----
     120 UniRef50_Q6V4U1        Putative multidrug efflux p...   164     6e-39  1  18.3%  5:392   1:392     ----MISKPSKIKTLFLLMVCVFIATAAFGLIIPILPDFMGK-FNTNGQMMGLLVATYGIIQLFLSPIAGRFADRYGRKR-IIEIGLICLTLSQLVFAFSVHFWLLFLGRFLTGIAVSLLIPGAMACIIDITTEEER--AKGLSFLNASISFGFVIGPGIGGFL-TTYGLYVPFYFATVLSFVSFLLSFFLLPETLEKKtpQPMVQQILRSIRVPYVVPLLLV-FLYSVSLYIFEAIFGLFVAKQFGYTAKDIAMVITIAAFVSVMVQLLLtkLVSLFGESKVMNGTMIAGGVSFLFLLFTTRIWSILLLTCLLYTATSILRPVINTVLSKLANNEQGFIAGMNNAYVSLGSVVGPILGGILFDINTYFPYVIGVLAFLTGTVLLTWKHRSL
     121 UniRef50_B2UQK8        Major facilitator superfami...   163     7e-39  1  15.9%  7:389  17:395     ------KAPLWTRDYILACCANLMTGLAFYELVPVLPLYLTGQLQVSSGWLGWIMSIYVLAAIISRPWFAHRVD-TGDRKKIYITVYIMLALSFSGYAAAATALAFFLTRFIQGLIWGGMTTSGPTMAVDIIPPARRGEG--LGFFGMTMTLGMCLGPVIGLQVYQQYGFYVITWSSLLLCLAGaiASLIRVPRSPVQEPVYETPKKVLDRLVLRVGIPLAVNVMIATFSYGVVAVYSALY-GEMHGF--KYAGLFYALMGLGMLVSRFMVGRQIDRGRVAELSVISLSILTVSFGALALAPLEWIYYASAILIGFGFGIFIPTFQTMKLNMarGHRGAVNSTFFTAFDIGVGTGMFLGGKIYAYLNLNWAFGTGALLNLLAIVYFYRI---
     122 UniRef50_A5FFZ3        Drug resistance transporter...   163     7e-39  1  13.0%  8:385   3:386     -------TKKYLKLILILGSLTALGPFSIDMYLPGFSG-IAKDLNTSVAKVSMSLSSYFIGISAGQLLYGPLLDRFGRKKPLFLGLMV-YILASLGCSYVTDIDTFIFLRFIQAIGSCAATVASVAMVRDLFPVKDIPK--VFSLLMLVLGLSPMLAPTIGGYVTEDYGWHTVFSILMFMGIAILIAAQIGLPNSYKPdkPKPIISNFLKVLKEPQFYTYAFTGAIAFSGLFTYVAASPIIFMDIYHVDAKTYGWIFAFMSVSFIGSSQLNSVLLKRFSSEQMIFGALILQSVVSIIFLILsgLYETIAILFIFLGCLGISNPNTAGLTMAPFAKNAGSASALMGAIQLGLGSLASFAVGIFVKDSVAPMVLIMTVTTIIAFIVL-------
     123 UniRef50_C6XSM5        Major facilitator superfami...   163     9e-39  1  12.9%  7:387   1:390     ------MHTSKKAAISFIFITLLIDVMGWGLIIPVMADLIAQLKGISINQAslLLSVFAVTQFLFSPVMGNLSDRYG-RRPILLFSLLGFGIDYIILALAPTYGWLFLGRIIAGI-TGASFTTATAYIADVSTDET-SKAKNFGLIGAAFGLGFVLGPALGAFLATW-GIRAPFYAAAALCLLNCIYGYFFLPESLSKEHRRepFGSLKFLTNNPKIGSLALGFFLIYLGSQAVQSNWNFFTIYRFNWSEKMVGISLAVVGVMVGAVQGGLTRIvpKIGNEKSIYLGLSLYTLGLVLFAFATQGWMMFAFLVPYCLGGICGPSLQSAISGHAPANQQGELQGALTSLMSLTAIIGPLIMNNSFAYfsSKAPFYFPGIHFLIGGVCML-----
     124 UniRef50_A9VRX5        Major facilitator superfami...   163     9e-39  1  12.9%  2:390   5:392     -SKEVNSERNYTIMTAVLCWAGMVVMSSLYVTIP-LTALFSDLFKVSLAQSAATGSIFSVGFAIGCLLFGAISDKYGRKKVIFIGLLALSIVSFFL-GIVDSLFWLVILRGLQGIAAATFSPVALAYVVEMFPVEK--KVTTIGFVSTGFLVAGIAGQVISTAVSQHFGWHMVFFLLSIVYIITAVWIHYSLPKGEMSQSNTDILGPIKqvFTHKSLVLSYMIAFVLLMAFVNMYTVLGNYLSSPTYNLIPEQILYFRLAGLFGMLLSPLAGRLTKRFGVRQVLQGGLLVAIFSLSSMGFISNLPLLVMMSICFVIGIAISVPSLVSLVGQLGGKSRGIAVSIYTFVLFLGTSIGPIISIYLMKIGDYAQTFILLGLILFIGFVSTLFIQ--
     125 UniRef50_Q6MQK5        Multidrug resistance protei...   163     1e-38  1  17.5%  8:390   3:395     -------ATSNKSQLAIIFFTVFLYLVGFGVVIPILPI-LSRNFGATALETGLLLSVYSLMQFLFAPFWGRLSDRMG-RRPILLFCLVGETLSYIMFAWARSLEWLFVARILAGFF-GASLSTASAYISDITPKHERSKGM--ALIGAAFGLGFVVGPALGGGlaPHFDTSFASYWVAALCFANFLFGVKFLKESLSeaAKRKRFSIMWQYLNKKTVGPLMTVFLLSSLAMSSMEATLILFMGEKYQWDVKQVSFGFAYIGVIIIFTqfLVRRLLPKWGERKVLRLGVLLLALGLTGIAIADSITGMAITMTLLSLGNGLANPSTLGSISLLsaNEQGAAMGVTQSMASLGRILGPALGGALYGTVAITAPFWASGLMAFLGLAIVIIIY--
     126 UniRef50_A5Z5Z5        Putative uncharacterized pr...   163     1e-38  1  12.6%  9:390   7:379     --------KIWNAAFISIFVANALMNLGQQMVNSLVAKY-ADYLGAAATLVGFLSGLFAATALIFKIFSGPAIDSFSRKK-ILVLSMIVMIISYVGYGISDSVPMLIGFRLLEGSARAFTATCCLAIASDTLPTEKFGSG--IGIFSLAQAACQAVGPTIGLTLYRYIGYNKTFLLGAACVVLGAIATANMKLEEKKNTKKFKISISSIAA---PEATVPALLLFLLSGTFFTVNSFLAIYGTN---MGVMNIGFFFTVYAGVMLISRPIIGKLSDKYGLVKVVIPALICFALSFYIISIAENLFMFLVAAFVSAFGYGAAQPAIQTLCMKSVpeRRGAGSNTAYIGNDLGNMAGPLVAGYVIEAFGYRLMWRIMIIPMVVAFVLLIVFK--
     127 UniRef50_B5E903        Major facilitator superfami...   163     1e-38  1  14.7%  3:391  13:399     --QHQTPGERQAAQVLICCAIGFVCFLGAYMRIPVLPL-LASGIGASTTQIGLINAAFMLSAGLLAVPSGLISDKVGI-TPVLLAGLALMSAASLLIPLSGNWVALGAIYLVFGVGLAAFTPTMMSSVARIVPRSHVGRA--YSWYTTAVYLAMTIGPAAGGWFGQRLGFRQVFLVSGVLIAVALIAVLCFLPKDTHATHRTHGEgpPSSIFSNGRLMAALAGTLGGCFGFGMYLSFLPLH-ARAAGLSVDQIGIVFAAQALVNVLLRIPFGHLSDRIDRGAMSGIGLVVCAVALALTGASHTLAAMILGACLLGAGMGTSFTALSSLVAIVMpgQRGLGMGLYNSCVYLGMMLSSATMGVVIKRTGFATGFLAAGCITFAATLLFLLLYR-
     128 UniRef50_C6CSA6        Major facilitator superfami...   163     1e-38  1  14.4%  5:386   1:387     ----MTQPYSWKRNLIVLWIGVFFCSTAYSVSIPFIPLFLHNDLGVneMWSGFAFGITFLASALIAPYWGSLADKYGRKPMLIRSGFSLAAL-YFITFFVHDPYVFLILRVFQGL-LAGYVPAAIALVATNTPEEKSGYA--LGIMATSGATGGIMGPLIGGTVSHYIGNRESFVFSGCIVLVAALIATFFATEHkrSGVRSSVLDDLKHASHNKAFLTLLGMSGLAMFSVMILEPLLTVYVLQLghDASLQAGIVFSAVGIATLIAAPQWGKFGSRIGFSKVLFIGLLGGGIGNCLQFFVGHIAEFGILRFVYGLFFAGVTPAINAMIVKSTETsrGRAFSLNQSATQFATMLGPVIGGVLGGIIPIKWVFIINGLMLMLAAILV------
     129 UniRef50_A8GEQ9        Major facilitator superfami...   163     1e-38  1  11.2%  7:391   6:414     ------PNTRWLRVIAPILIACIISFMDRVNISFALPGGMESDLGITSQMAGLASGIFFIGYLFLQVPGGRIA-VNGSGKRFIAWSLCAWAVVSVATGFVTNHYQLLILRFVLGISEGGMLPVVLTMISNWFPEKELGRANAF--VMMFAPLGGMLTAPISGAIINQLDWRWLFILEGLLSLVVLAVWWLLISDRPQEArqPVSKAPLRDVFRNKGLMKLVLLNFFYQTGDYGYTLWLPTILKNLTGGNMASVGFLAILPFVATLLGIYLISVLTDKTGKRrvMVSLFCFAAALLASVVLRHNVVAAYIALVVCGFFLKAATSPFWSMPGRIaaEVAGGARGVINGLGNLGGFCGPYLVGVMIYLYGQNVAVCALAVSLIIAGIIAWRLPR-
     130 UniRef50_B8GFY3        Major facilitator superfami...   163     1e-38  1  14.9%  1:389   1:399     MNQHRQIPPAEKRQFLLFLILCSIGGLAIFSsnPVLPI-LAQTLGANLQTIGLIAAASTVTGIVTSLWAGSLSDRYGRRPMLILSGIVFFT-APVLYLLVHTPLDLALVRVYHGLATAIFGPVAMAYVTDLTP---VRRGERLGYFSSFQLAGRSVAPLAGGAILAIGVWQLVYLVCAVAGALTLAGMVLLPeePAPESDTTSMGSAFRAVISDRTILITSLAEASGFFAFGAIEAFLPLYALN-AGIDTLMIGLLFLVQVGVRTLTRPLFGKVSDQRGRKAQITAGLLLTAATAALFPYTTAWPVLLCLSALFGMGFSVASAATSAFVADLAPSrrGTALGLMSTIMDIGQAAGPILMGGLLALFSYHTGFGVTGAVVLVCAILFQWL---
     131 UniRef50_B8FSV1        Drug resistance transporter...   163     1e-38  1  13.9% 11:390  19:400     ----------RKGLIAFIVLMNMFIPLSMDLYLPALPK-MNEYFGSSAAITNLTLSLFFLFYAIAILVWGPLSDRYG-RKPIIMVGSAIYIVSSIACALSTNITLLIISRACQGIGSGGITSASMAIIKDCFTGKSRE--TILAVTQAISGLAPMLAPIVGAWILYFTDWRGSFWLLAFISVINLVLTILYQETLREEERYRGSLIGSWSRLanKSFIIPTLIFALGSIHFMGYIAVSSYVYIDYFGLSEQMYSYFFAANAFISILGPAIYIRFFLNFNKKRLAVLCFGLSALSGILIMTLgsPYIFLMGIVLMSLAGTVMRPFSTNILMEQQKGDAGSMSSILNMSFTLFGSLGMAIASISWGNIVAGLGALIAVGSGISILAWYAFMK--
     132 UniRef50_B6BW60        Major facilitator superfami...   163     1e-38  1  16.2%  7:389   1:381     ------MTSFEIKSTLGIAFIYMLRMLGLFIVLPIMSIYLSegAGASTFLIGLTFGIYGLTQALFQIPFGILSDRFGRKK-IIIIGLCIFLIGSLVIFFSESLIMITLGRALQGAGA----ISAVLLALLADLTTDKARTKSMAIIGASIGLTFGISIVLSPILNTYLGFQNIFMLIAILSLIAIAVVIYYIPNPIRYSRNEKIDYPIKKIIFDKVFLKLDYGIFALHASQIIMFMMIPLML-NKIGYPIKYHWQIYLPVFFLSMLAIIPMIILSSKKKMLRSFFLlfLLIFVQYLFISWSDSKQSVMITLLIYFIAFNFLEATLPSLISRLSPKnkGLVLGAYNTSQSLGIFVGGILGGFIATQFNDQAIFILSAALLAGWLVLMIRF---
     133 UniRef50_C6VW73        Drug resistance transporter...   163     1e-38  1  13.7%  1:386   1:392     MSERKSMSRKQYfiILILGSLATVSPFSIDMYLPGFPR-IASDLQTTIDKVQLSLTSYLIGICIGQVLYGPLLDRFGRKKPLYV-GLALYVIASFGCAMTSSVDALIAMRFFQAMGGCVGLVASQALVSDLFPADKR--AEVFSLITLVIAVSPMIAPTIGGYVTASIAWYWIFVILAGIVSLIILAIYFFLPTGRDAdrPEAVLGGYLTVISQPQFLIYTLAGGLATAAPFAYISGSSDVFMNIYKVSEQQYGWIFAFLAVAMIGSTQLNHFLLKKYSSEQIIRFTLIYQSVVGVVLILGvgLYSLIGTMFVFLTGQGLTGPNASALSLAPFRKHTGSASALMGSWRMGAGAVISAIVSFLHNNTAMPMVG-MMAFCAFGGLVIL------
     134 UniRef50_C7MU50        Arabinose efflux permease f...   163     1e-38  1  16.4% 11:387   1:372     ----------MPIALLALAIGAFGIGTTEFVLMGVLPE-IAHDLGISISEAGNFITAYALGVVVGAPLLTAVAVRL-ARKTMLLSMMGVFIASNALFAFAPTPEVGMLFRFAAGLPHGAFFGAGAVVAATLVGAQRR--AKAVSMMFLGLTLANVIGVPAGTFLSQQVGWRATFGVVALIGVVALVSIAKLIPHQRPTSNV--SLRGELGAFRKPEVWFALAIVTFGLGGGFASLSYVAPVLTDVAGFDGTSVTLLLSLAGLGMTFGNVIGGRLADRFPLTGLYGALTALAVVLLLFTVTANSKIGAAVMLFLVGMTSFMVGPMMQSRIMEKAGGAQSMVSAAVQSAFNIANSIGAYLGGliAGGFGLVSPNVVGAMLALVGLTLTV-----
     135 UniRef50_A3WP52        Permease of the major facil...   162     2e-38  1  12.3%  2:391  30:419     -MSQQQLNRTEKRAAFALASVFGIRMLGLFLIMPVMAIYAHEYPDYTPALMGIALGAYGLTQAFFQIPLGMLSDRIG-RRPIIVGGLLVFALGSMIAAQADSLVGVVVGRAVQGIGA--IAAAILAMAADVSRDNQRSK--VMAIIGMCIGLAFALALIIGPLLADHIGLQGLFWFTAASALVGIGLLLVAVPKALTKSARREALpeLKHLVRHRQLWLLNGGVFVLHAVLTSWFISLPTLLAAHEIRTEYHALFYLPTLVLSIALMVPMIIHGAKTNQHVTWFRLSILLLMVGATLiwWGASLIVIAIALVVFFTGFNFLEATLPSLLTRIApgSKGSASGIYSTCQFSGAFVGGALGGWLLQTYQLKGIGVASLAILALWFVLSRLMQN-
     136 UniRef50_Q8GFB9        Orf16 n=7 Tax=Enterobacteri...   162     2e-38  1  14.5% 12:383  11:384     -----------RWLIPLLGALVAFGPLSIDMYLPALPE-MARQLQATQGQMQHTLGVFFAGFCIGMLLYGPLSDHLGRRK-LLLSGIALFVVASALCTLVTQVEQLILLRALQAFGSGAAVVMGRAIARDIYSPQELPR--VLSLMTLVTMIAPLIAPLLGGFLLTYFNWQAIFTLLGLFGCISGILLLFFLPETLPAQSNNgaFKNYGKLLTDGEAMATIGTLAFTCAAMFAFISGSPFVYINYFQVPANYYGLLFACNALGMMAIVLLNVRLLKVYDVSRLLFisAQLLFGILLVIFYQQSLTVVVILVVLFISLVNAIGTNSLSLLLQHRGQLAGSASALAISAQFGMAALASVAVSLLQDETPFAMAFVMAVCAGLCWL---------
     137 UniRef50_Q4BWJ5        Major facilitator superfami...   162     2e-38  1  17.1%  7:391  13:397     ------QSRNIHPNVWILGLVSLFTDFGTKAIQSVLPLFLLSVLGANLTTIGLIEGIAESTASTLKLFSGVLSDYWGRRKELAILGYGLSAAIIPVFALANSPFWILVARFGDRLGKGIRVAPRNALVADVTPTEQRGAA--YGLRQTLDTIGAFSGPLAATLILLISgfRLVFWVALIPGIISVALLVKGIRETPSSQGKRGQPIQWSFCQQlrNYWALVGVAALFNLGNFS--DAFLLLKAQEIGIAAAWIPLSMIVMNFSYMLSAYPLGLLSDRIGRKQLLVAGFWLFALVYLGFAWVEQPWQIWGLFAFYGVYLGMSQGILLALVADLTPGerGTGFGIINLVIGIILLPASLLAGFLWQTVNPQAPFILGSLLAIAASVLLLLAVR-
     138 UniRef50_C9RNG6        Major facilitator superfami...   162     2e-38  1  13.5% 10:387  12:382     ---------LWTRTFITVAAANFLLFFSFYQLLPILPLYIIDKFQTDNATAGFIISLYTIGALACRPFAGFLVDTF-SRKPLYFWTFFAFTLCFLGYKTVGLLPILAVVRFAHGLFFGISSTASNTVAIDALPASRRGEG--IGYFGISVNLAFATGPMTGMFLYEAFGDGIVFAISTILCVIGLVLVQTL---KVKPREKKVCAPLSLDRFFLTRAVPQFANFIFVGFAYGPVTNYIAIYANE---LGIGGTGWFYALIASGLILNRIMTGRLIDRGYLIHLVGSGMTLIVVAYFILAFSHSPITFFLSAFLIGTSLGLIFPGYQTMCVNLARhqRGTANSTYLSGWDIGIGAGILVGGAMANHFGMhqVFFVCGIALAIADIMFL-----
     139 UniRef50_A1AMA2        Drug resistance transporter...   162     2e-38  1  15.9%  5:387  23:411     ----PMPRGQMVRMVLILGVLTAFGPMSIDMYLPAFPQ-IARDLGVPLGTVQLSISAFLFGSAAGQLLYGPLADRFGRRRPLL-CGLTLYIAAALGCACVHTGEGLLIWRLVMAVGGGAGMVISRAVVRDLYDTAE--AARMFSLLMLVMGAAPILAPIAGGQILLITGWRGIFAFLGLFALVSIAAAARWLPESLPPERraEMVAGYGQLLANRDYIRYSIALGCVAGFTFAYIAGAPFFFIELHGMSPQRFALLFGANAVGLIGASQLNRRLLHRFSAQRIMKTCfaTLLLVAVVMAGIGGFPGQGLLIFFCVSMTGFLYPNVTALTLAPFGKAAGSASALLGTIQYSIGASAGALVGALHNGTALPMTASMALCGVVGWLAVAL-----
     140 UniRef50_C8WTB2        Major facilitator superfami...   162     2e-38  1  15.9% 15:391  16:402     --------------VVLMMFFTFGFVFMERLSVVYLFPYLAPDLKLNNAQLGMIVSVLAICWALSGFFFGTISDFLGSRKNVLVPITLAFSLLSFLTGLAKNFGQMLGIRALMGVSEGPVLPIAQAAV--MADSTEARRGFNMGFVQSALgiGSTFGPLILTWAATKYSWHAGFYVAGIPGLIMFFVLLFFMKEplAKSEHRLRKEDFPVVFRTWNIWFTLLIAVLMMTWLFAFTSFAPTFLVEYDHYTGEQMGVISAAMGLGTFFWGFMGPYISDKWGRRPTLVLFSFIAVLSPLVLIFVHGSVALMCVLGFLTCAGQACFPLFMVVieSLSPKYVGTAVGLVQMVGElgGAVMPTVAGVAADHFGLPAPMWIAAAGAFVSGIMAFFMRE-
     141 UniRef50_A9VP23        Major facilitator superfami...   162     2e-38  1  13.5% 11:388  42:414     ----------LNFRVYILAIAAFVVGTVELIIGGTL-DLVANDLGVSISAAGQLITIFSVVFALSGPVLLALTGKFERKK-LYVVALSIFLIGNIISAFSVNYGMLMFSRVICAASGSLIIALSVTLASSVVEPHFRARA--IGIIFMGISGSLVLGVPLGLVLGNAYGWRAPFVLISILTVMAIACISLFL--TKVPATSVLSIREQIATLKDKKIVSAQLTSFLFLTGHLTLYAYLTPFLKDVMHVEANWISVFYFIFGIAAVLGGGLGGWLADKWGSKKSIISIIIVFACAIFMLPMMtsFPLFIIMMGLWSMLSWAISPAQQNYLIEIAPESAGIQQGLNNSALHLGIALGSTVGGVVIEKSSVIYNAWVGGVFIILALLCAVF----
     142 UniRef50_Q089J4        Major facilitator superfami...   162     2e-38  1  15.5% 25:392  15:382     ------------------------IGTTEFVIVGLIPT-MAQDLNVSLPSAGLLVSLYALGVAIGAPVLTALTGKW-NRKHVLLAVMSLFVAGNLLAWQAPGYETLIAARIITGLAHGVFFSIGSTIATGLVPKEK--AASAIAIMFTGLTVALVTGVPLGTYIGQTFGWQATFLTVAILGFVALIGSSLLVPNNLP-QPPAAKLSSQLKVLTQPRLLLVYAITALGYGGTFTAFTFLAPILEQVSGFESQSIGLIMLVYGVSVAIGNIWGGKMADKMGPIKALSIIFSGLATILVIFNFTanPIAAVITILVWGAFAFGNVPGLQVYVVSLapDAVDVASGLNIAAFNVGIALGSWGGGLIVANAGLMHTPWVGAVIVVIALALTRFSGSL
     143 UniRef50_B8H4G8        Tetracycline resistance pro...   162     2e-38  1  16.4% 10:387 179:572     ---------RRQAALGFIFVTAILDVLSLGVMIPVLPNLVKAFGGGDTAAAalFATTWGVMQFICSPILGLLSDRFG-RRPVILTSIFGLGIDFLFMAFAPNLWWLFIGRIFNGM-TAASFSTASAYVADVTTPENR--AKGFGLMGAAFGIGFTFGPALGGWLWE-FDHRAPFLVCAALALTNWLYGFFVLPESLPPERRQppIGSLQLLRHHPGLMGLAGVGFLFQLAHNVLPSVFVLYMGFRYGWSPQTIGLTLMASGIASILIqfVVGPAVKRLGERGVLLIGLFAGFLGFSIYALAPTSLLYLAGLPIFAFSGLIQPGLQGLMTRRVGPNEQGQLQGANAAMMGIASIIGPPLFLIPFalHLPGLPILIAAVLMLAATLLAY-----
     144 UniRef50_C6CSG5        Major facilitator superfami...   162     3e-38  1  14.8%  4:387   1:391     ---MKPAEKLWTKNFILLACSNLFLFFGLEMLLPTLPLF-ADEKGGSGSQIGMMLGIFTFSAVVSRLLIGIGLKHFGKRK-LLLIGVTICLIGMACYYAADSISALLALRVVHGFGFGIATALYGTLVSDAIPAERRGEGM--GYFAMGNAVSFSIGPMLGLWLLDQYDYAGLFGAGVVFLAITLVLTLLVRQKSAQSVeaAGVKPSPWAEVIEPKVLVPSMLGSLVGFAFGGMLSFVTLFTKD---IGITQTGYFFLVVAISEVLIRFISGPLFDRKGPFWVLFPTAILCMIGCVLLYYTDSMAMLLLAGVFYGAGFGAMFPALQAWVINLvpERRGVATATYYNFFDIGIGLGSILLGVVVTATSYTTMFLLSGILYVIYLAVYF-----
     145 UniRef50_A8FB28        MFS family major facilitato...   162     3e-38  1  13.8% 14:389   6:376     -------------VVYLLALAAFLIGTIEYIITGII-QMVADDLHVTTSAAGLLVTSLALSAAIGAPIVIALTINIDRKK-ILSWMLMIFILSNVITSVSHSFEMVMMTRVLQGISGGTAIVVAMAVATRLVEREKRGTA--IGIILMGLSSSLVLGVPIGTFLSSMIGWKALFAAIGLITLIPLIVVYRRIPSMK--EQEPVTLRMQLSILKDKRILLAVAVTLFYVGGYSTLFTYLTPFLQASANLSITEISGILLLAGICSFLGSSLGGMTADKKGPIFTIFSGIILQIIMLMLLSFVtnLVVMVAVIMIWMIATWSTSPAQQLYLVTLVPKSPDIALSVNTSFIQFGFALGSGLGGFVLSRTSILHLSWISAGTVLLALLMTILM---
     146 UniRef50_D0RZF1        Major facilitator transport...   162     3e-38  1  14.6%  1:391   1:407     MSDVDTSISIPRRYAWLVFALTFGLLISDYmvLNAVFPLLKTEWLLSDSQLGLLSGIVALMVGLLTLPLSLLADRFGRVKS-LAIMAALWSLATLGCALAENYEQMFIARFMVGVGEAAYGSVGIAVVVAVFPREMR--ATLASAFMAGGVFGSFLGMALGGVLAQHFGWRWAFGAIALFGLILAFLYPVLVKEKRIASSHQNKNRslKTLYSSRSVIATYIGSGLQLFVGGTVIVWMPSYLNRYYGMSTDTAGVMAAVIVLCSAVGTILCGMLCDYLGRnlAITYCLVSCVLLLIAFAVPTGRSQLLLICLGMFIALGTNGPSSAMVANLTHNSVHGSAFATLTLanFLGLALGPLVVGKISDVIGLHSAFQLMPLVSIAAAAVFFYAKR-
     147 UniRef50_A8TRZ5        Drug resistance transporter...   162     3e-38  1  16.5%  9:390   4:390     --------KPISPPIWILIAATATGPLALNIFVPSMPG-LVHVFNTDYATIQLTLTLYLVGVALAQLAYGPLSDRFGRRPAMLY-GLAIYAAASLLCAVAWSVETLIVGRILQAVGGCAGMVLGRAIVRDVYERDR--AAGAIALITMAMAVAPAIAPTLGGYLETGFGWHATFLAPMVMGLVVLAASFRGLNETNLTPIPraMLRHYGELLRSRAFIGYAGNSAMSVGAFFAFLAGAPYVVIEILHRPPGEYGLYFVLISVGYMIGNFGASRLSQRLGVDRMIPLGVASSTVGGllLADIITPASVFLPMMLVAVGNGLSQPNSIAGAISVNPRIAGAASGLMGFGQMTVGAIFTVIVGHLQNDHDHAAMAGMILFSCVASYLFYLLAK--
     148 UniRef50_D2QPT5        Major facilitator superfami...   162     3e-38  1  14.6%  8:390  15:395     -------PSLYTFSFWLLCVSNFLFSASFQMMIPELPAYLTKLGG--QEYVGWIIALFTLTAGISRPFSGKITDTVGRVPVMAFGSLVCFLCGF-LYPYLLTVGGFLTLRLIHGFSTGTKPTATSAYVADIVPATRRGEAM--GTLGLFTAMGMSLGPAIGSWVANDYSMNVMFWTSSAFALLSIGILLQMTETLPKPQPFRFRLLRLKKdiFDRNALPPFLVLLLQSFSSGVILTVVSGL---STSLGIANKGLFFTVYTVASLVVRLVFSKSSDRYGRLPVLFISTVVLAVSMVLLIITESPFMFWVSAVFYGMSWGMNSPTVTAWTADLSDEkrGRAMATMYIALEAGIGLGAVAAGWLLNhaGIDASFAVSGVLALVAVTYLGWLW--
     149 UniRef50_C6PN18        Major facilitator superfami...   161     4e-38  1  13.6%  8:389  12:392     -------TKSYSLITLILFWSGLVIMSSLYVTIPLVSTF-SQIFSVEVSKAVWSSSGFSLCFAIGCLCHGPLSDRYGRKKVIIIGLSALTIISFLL-GTVHNLVTLITLRGIQGAAAATFSPVALSYAVELFPPKKR--VVAIGFISTGFLMAGIIGQVFSSFVNQHIGWNFVFYILGLIYLITTLLIILFIPNLPISQPdsKVFKQMKNVFKIKSLKYAYIIALVLLLSFVGMYSALGNFLSSPKFNFTTQQILYVRLIGIIGMVLSPYAGKLVEKFSIISVLRGSLLLSIIGLALIGISRSALFMIIMSVIFVIGIAITTPTLISLIGVLGGKTRGSAVSMYTFILFLGASIGPVLTMRLLKTGSYTITFTSLAACLVIGILATFFI---
     150 UniRef50_Q119R9        Major facilitator superfami...   161     4e-38  1  15.9% 32:389  39:396     -------------------------------ISPLLPS-IAKNWNISPEHIGWVISAFFIPITIGTPISGILADRYG-RKQILIPALILFAISGTLCSLAPNFQTLIGLRFVQGIGAAPLESLTLTLISDFYSGKLLTTAMAFKTMSVGLSL--VIYPLISSGL-TTWGWRYPFLLY-LIAIPLSIWILFSLKNPAIPKQkkKYLRNIWQSFNNYQVRSLLIVIIVNffSLGPCLTYIPLFADRQLGASYIVIGIILASRGIFLAFASSQLGIFAKYLSELTLIKISFIIYCIAFIMIPTINNIWLLFIPGILLGLAHGMLVPSTQSLLGQLSPEnrAGFMAVTSSALSFGRTLGPILAGSMFYIGGMAGVFYSSSIVSLVIFVFISYL---
     151 UniRef50_C8SZ68        MFS family major facilitato...   161     4e-38  1  14.8%  7:337   1:331     ------MARVSLSWALILGLLSGIGPLCTDFYLPALPE-ITQQLQATSTQTQLSLTAALIGLGLGQLFFGPLSDRIG-RLKPLALSLLLFIFSSAMCALTRDINMLIVWRFLQGFAGAGGSVLSRSIARDKYQGTLLT--QFFALLMTVNGIAPVLSPVLGGYVITAFDWRILFWTMAAIGGVLLVMSLAILRETRPATAAHASRQRPGqvLKNRRFLRFCLIQAFMMAGLFSYIGSSSFVMQSEYGMSAMQFSLLFGLNGIGLIIAAMIFSRLARRFSAERLLRGGLTLaaAIMLLFAWLHLPVLALVGLFFTVSLMSDISTVAGAEAMSAVDAAQ-------------------------------------------------------
     152 UniRef50_C0ACE7        Sugar permease (Arabinose p...   161     4e-38  1  14.4%  2:391  12:407     -TQASTRPYKEGWLLLTLAAVQFTHIMDFMIMLP-LGSYLMEIFSITPGQFSRIVASYGLSAAVTGFIAGVFIDYIPRRRALLI-LYAGFAISTLGCAIAPTHHWLLLARIVAGAFGGVAGSVVVAMVGDVIPIERRGRGM--AVVQAAFPLASILGLPAGLYLVAHLGWHSVFFLLAVLSAIVWGIAWRSLPHVSMHTASQQPLRQMREMLTHRVHVRGFVVTAVLIFGGAATGPFMAPSMVANVGFSKDQLSWIYLCGGGATFATTYLFGWLSDRFDKLHVLACVSIFTITTVLymGPTPVPVALIVTTLFFVTMSGRFAPTMTMVANAVEPRYRGGFMSVNSAIQQASGAFATIFAGWMMslLGYDRVGIISSVGFLLTVVAAAWLRR-
     153 UniRef50_P43531        Inner membrane transport pr...   161     4e-38  1  15.1%  8:391  31:413     -------TPQFMRVTLALFSAGLATFALLYCVQPILPV-LSQEFGLTPANSSISLSISTAMLAIGLLFTGPLSDAIG-RKPVMVTALLLASICTLLSTMMTSWHGILIMRALIGLSLSGVAAVGMTYLSEEIHPSFV--AFSMGLYISGNSIGGMSGRLISGVFTDFFNWRIALAAIGCFALASALMFWKILPESRHFRppKTLFINFRLHWRDRGLPLLFAEGFLLMGSFVTLFNYIGYRLMLSPWHVSQAVVGLLSLAYLTGTWSSPKAGTMTTRYGRGPVMLFSTGVMLFGLLMTLFS-SLWLIFAGMLLFSAGFFAAHSVASSWIGPRAKRAKGQASSLYLFSYYLGSSIAGTLGGVFWHNYGWNGVGAFIALMLVIALLVGTRLHR-
     154 UniRef50_Q65P24        Putative uncharacterized pr...   161     4e-38  1  15.1%  1:391   1:393     MFAQFKAFSRLHPLIRFLLIGTLVTKAAKSMTTPFLALYLHMKTGADFGTIGLVIGLGYFSSTVGGVVGGALSDKIGRKKVML-SSIFIWSFVFILFGLVHDFMWFLLLNILSWLCHSCFEPVSKALMAELSEREMRFR--IFSLRYLAINVGAAVGPLLGAYFGLAKT-GTPFIITGLVYFGYAILllTTVKETKIAPEKVQAGSVLKTLKQDKALRLYIAGGILFLFSYSQMESTLLQYLNNDFANGVKIFSTLITLNAVTVILLQVPLTRLFERYKSLTTISIGTVFCILGNIGFSIANGWIVFMLSMFVLTIGEILCFPSMNVLLDELAPDHMKGAYYGMQNLYNIGEFLGPWLGGMMLALYGGKAVFLIAACSVFLALGAYHVGRR-
     155 UniRef50_B9E9H8        Putative uncharacterized pr...   161     4e-38  1  15.1% 11:387   1:372     ----------MKQQFKLLMMIQFFIYFGFSIVIPVIPA-LVHSLNLNAFHMGLLLASYSIVSFIVAPMWGYLSDKYGRKKILIIGLIGFTLSFVLFGLFIDNLPMLYTSRILGGLFSGACFSTTTSMVSDMTTHEERNK--YMGLMGMMIGLGFIFGPAVGGLLSG-ISYQIPYFVTAAILTVIALFCLFTIQETLQHSTDSEQATVNPKLLT-PAVYMLLLSTFIVTFTMSGMESSFQLFEIEKINITATQMGMLFMIGGLVNAGLQGGYLRKVKHGQEKPVIITGQLITIVAFIMLPFSMNLFYAGLCLVLLMSGNALVRTLLTslTKETSSNKMGKLTSISYSMDSLGRILGPLLFTALLSRH-LEMPFYFGALTSVFGLILLF-----
     156 UniRef50_C6XQ76        Major facilitator superfami...   161     4e-38  1  16.9% 14:367   9:369     -------------AFFFVLIVVLMDMIGFGLVMPVMPQLISELTGlaVAWAGPIIAVYALMNFIFGPLLGGISDRFG-RRPVILISVAMLGVNFLISGLASSIWMLFIGRVLSGI-SGATFSTANAYIADVTEPENRGKA--FGMIGAMFGLGFIIGPALGGILGD-IHMRAPFFAAAALSFISFLYGLFVLPESLDPENRRspFGAFKHFVKLPHIAWLLLAVGLFSLAHNVYPAIWSFHGEIRYNWTAKEIGISLSIMGLTAAIVQglIGIVIKRFGSANTVWLGLSVSILCYIGFAFAGLPWIVYMIIPFSALGGLTMPALNAITSSQTAKNAQGELQGAQSSLQALAQIIAPIMMTQVLSSFS-------------------------
     157 UniRef50_D0KBI4        Major facilitator superfami...   161     5e-38  1  14.1%  9:384  21:418     --------SRLRWNIIFILLIAAVVNYLDRANLSIANTTISKEFGFSSTQMGLLLSAFLWPYAIANLPAGWLVDKFGPKK-MFSWALGLWSGFTILAGFVNGYAMFYGLRMLLGVSESPFFTSGIKITHRWFPSNERGLPT--AIINTGSQIANAIAPPILTILLLTMGWRGMFIAIGLAGIPLLLVWMKLYRNPTPQekPDAPKASWGSLFKHKTTWFMILGNFSIMFTIWVYLTWLPSYLERSLGFSLMKTGWVASIPFMAGILGVLCGGIISDRLIRRGtiVCGAALAACCVAPVPFVTDTTLCIALLSLGYFFSQMPSGVIWTLATDIAPKTqaSLGAIQNFGGFLGAASAPIVTGIILDMTgfTNVFIFGASLLMLGAI--------
     158 UniRef50_Q2BCG6        Quinolone resistence protei...   161     5e-38  1  15.3%  7:391  12:393     ------KEKLWTKSFVMLMAGNLFVFMSFQMLIPTMPPYI-KSIGASGLEIGLVTTLFSAGAILCRPFIGYMLE-YRTRKPLVLAGAAALLLITLVYPLSSVVVMFLLFRLVHGLAWGWSTTVNGTAAVDVVPNSRLGEGM--GYYGLSVTLGMIIAPSLGIYLFQVTTFENLVYISAGLGIISIILLSLvtPQSVKEAKKEELAFSYLGSLIEKTSWYPALITVIVTFGYGSIVTFIVIFGEER---GIEQIFLFYLFNAVLASASRPAAGKWFDRNGPRGLVLFCTLITFAGMWVLSFAHSNVLIAAAGVLFGIGFGSLIPTLQSWTLSlpPNRRGVANGMFFSAIDLGIGLSGLVFGVIAQYVETGRLFQISSIFLLIAIAMIMAEGR-
     159 UniRef50_C6QMY1        Major facilitator superfami...   161     5e-38  1  14.4%  8:382  61:434     -------TREYKKASLALFFGGFVTFAILYTTQPLLPVF-AKEFHVSAASASLTVSVSTGTLAVMMLIAASLSDRVGKKKVMMISMLLTSMLA-LAMSFSPNFISLVLARMFLGMAAAGIPSLAMAYVAEEFHPA--GIGKVMGLYISGTSLGGMAGRILTGLLTDLFSWRTALFAIGIISLLLSLIFALILPAPRHSVNKptALRAYAVHLHNKPLMALIVLGFLFMGGFVTLYNYIGFLLGDPPYSFSQSVLGFLFIVYLFGSFSSVYMGKKADLSGHALVLSISVALTALG-AVVTLVPSVVVKIIGLSLFTFGFFGCHSIASAWIGECANVNKAQASSLYLLFYYLGSSLAGTAGGYFWTHFHWLGVITFIVILLLLS----------
     160 UniRef50_Q0ADB4        Major facilitator superfami...   161     5e-38  1  13.8%  6:390  16:401     -----KMSRVELRASISLAGVYALRMFGLFIILPVFTFFAKDLPGgsYTLIGIALGAYGLTQAILQIPFGWLSDRIG-RKPVVYLGLILFAVGSFVAASATDIYWVIFGRVIQG--AGAISAAVMALAADLTREEHRTKAMAM--IGVSIGAVFALSLISAPILNQWVGVPGIFAITGCLAILAMLVVYKVVPDprFHSDTEVTTSRFGNVLRDPQLLRLNYGIFALHAVLMALWLVVPVSLRET-GLAAAHHWQVYLPVMVGAVILMVPAIIYAEKKARMKPVFIAAVALLLLAQVLlfNTSFWGLVFALLVFFTAFNLLEATLPSLISKIApgAKGTAIGVYSSTQFLGAFVGSALGGYLFQHFGFYAMAIMCSGLLIIWLILATTMQ--
     161 UniRef50_A5VH86        Major facilitator superfami...   160     6e-38  1  17.0%  4:391   1:396     ---MEAENRRYERIATAVLGLTFGIVFFDRNALNFLMPFILRDIALTNTQIGLAASGLALTWALSGMMIGRLSDRIGRRKPLLIGAVLAFSASSFVTGITWSFATLLGARLLMGLAEGPVLPISQTLMAAASSPERRGRNMGLMQNVLSNLMGSLVAPLVVVALATSYGWRYAFFLTALPGFVAAALIWRYIEEPEPRARQAADraSVRDVLRHRNIRLCLFISPLIVGWMISGWVFLPIYFTSVAGFTPTQMSALLSVLGLTGAIAGYLVPALSDRFGRRLVVAAGCLLGILtlAAMWGVHSGAVAIAVLVATGWMAGGTISIVMATIPAESSDavTTAMALVMGSGElgGTLAPTIVGWTMDRWGPTAPLMGQVIMIASASVLALFLRN-
     162 UniRef50_Q8CXK1        Antibiotic resistance prote...   160     6e-38  1  17.8%  5:391   1:383     ----MNLEKIWTKSFISISLVQLLIFLSFYALLTTLPIYVMDQLGGNEAEGGLVVTVMLLAAIIIRFFSAKLLDKIGKKRGLII-SVALFMITSFLYLLVETYTSLLALRFLHGFSFGIITTATGAIAADIIPASRKGAG--LGYFAMAMNVAVVLGPFIGLTLIQYVSFHTLFFILGVLMIVALINSMMVQVEEQIVEVNDNRQRLSIHDFIETRALPIAIIASLVSLSYASVMSFISVYASSI--GLASTASFFFLVFAAVMLITRPSIGRSFDLKGPRFVLLPCLMIFSVGLIALSITNSSWMLLLAAGLIGLGYGSILPGFQTIAIQLSPDSRSsaTSTFFILYDLGIAIGSFVWGLIVSEIGFSNLYLVAAAIVVIALFLFEFYYR-
     163 UniRef50_C6RM88        Transporter, major facilita...   160     6e-38  1  13.9%  8:389   7:385     -------SRLWNKFFIFCLFNNMFLFIFYFAQTAVLPVYIISDLNGTVAQAGLAMTLFMVSSIVVRPFSGLIIEKFGKKKTFLVSEL-IFCLFSFAYLLADNLSVLLVIRFLHGIWFSILTTVCVPIANDFIPEKRKGEGM--GYFIMSINLGLVLGPLLGLSLIQPLGYTTVALILATIICLGFAFCLLiiREIKKLPEVTEKKKISLQDFVEKRALPASLMVMLLAFGYSSIMSYISTFAETKGLLSS--AGLFFVVFAVAMMSIRPFTGRLYDIKGPNIIIYPSIILFIMGLILLSQIETLTGLMISAIFIGMGFGSLQPCLQTLAIQRSPRYrgHTTSTFFTLYDTGIALGAVLLGYVVALYGYTVMYLLCAFIIALSLIFYKFV---
     164 UniRef50_C6XXZ3        Major facilitator superfami...   160     6e-38  1  14.5%  5:391   3:385     ----PSSHSIYTLQFGLVCLSSFLFSASFNMLIPELPAYLTAMGGAAYK--GLIIALFTLTAGISRPFSGKLTDTIGRVPVMAVGSLVCFLCGF-LYPLLTTIAGFLFLRLIHGFSTGFKPTATAAYVADLVPPGKWGEAM--GVHGVCFSTGLAIGPAIGSTITDHYSINVLFYCSSLFALLSIVILANMKETLPGKQkrAAHLKINKKDIIEWRVIPAVVIIFLSYISYGSILTVISDW---SAHLGTSNKGLFFMVFTLTSLLIRFVAGKASDRYGRTLILRISLGLLAVSLMLIAIASSSFTLMMASALYGVATGMLSPTATAWTVDLspTQRGKAMATMYIALEAGIGLGALLAGWLfnIRMIPVTFYCCTGITLIALVYLQFFYR-
     165 UniRef50_A6T249        Drug (Bicyclomycin) resista...   160     7e-38  1  15.1% 12:389  20:400     -----------SALAIMLALLSMLGPFSIDTYLPAFPN-IQASLDASALEVQQTLTAYLFSFAVMILWHGALSDAFGRRNIILV-SLAVFAVATLACAAVHSIEYLWVFRMLQGISAGAGVVIGRAIIRDLYAGSAAER--LLSLVTMIFSIAPAIAPILGGWIVKHSNWRNIFLALFAYAVLLLIYCYKRLPESLPPEKRQplYHSYKRVFRSPLFHLKGGTVAFNFAGMFLYVAAAPVFLVQHLGLGPDQFGWQFIPTVAGIFCGALAANRLAGNIPISRQVLIGFVFLIGAGIfaLFPPALPWSVAPLFFYTFGMSMVAPGATLLVLDLFPNIRGTVASCQSFTLTL---LGALVAGVIAPALSHSPLALAAGQMIFTLIALSLWL---
     166 UniRef50_D0KAF8        Drug resistance transporter...   160     7e-38  1  14.6%  1:390   1:396     MSDSSLLASRSFVLIGILGILCAFDAMSIDMYLPAFPA-IQQDIGADAAGMQTSLSVFLIGLALGQLVYGPLIDRYGRKGPLLL-GIVLFSISSLLIAHASTLSWFVFFRLMQGLGGAAGLVIPRAIVADLY--SERDAAKVFSLLMQVMAIAPIIAPPLGGVLLGTLGWSAIFWVLTFVGMLMLFATWRCVPESLPRRDRtsALTGYAVLLRQKKFMGYTLSGSFVMGGLFTYIGASAFIFIEYFHLSPTTYSYIFASNALGMVLLGQINIFLLNRWREYQILPIGIAlvALCGVLLAGITSLWIITGLIFLTMSFLSLVFGNGVAVAMNAAPGQTGSASSLLGVLQYVFGGVAGVIMGIVHDGTLLPPVMLLTVYAIGALLSWWYAWR--
     167 UniRef50_C4LL17        Permease of the major facil...   160     8e-38  1  15.6%  2:386  41:432     -SNVPKKNQLTAAVLTSLALLSAAGPLGTDMYLPTF-IDIAKDLSTTASSVQLTLSAFMIGLAVGQLFAGPISDGVGRRRPLAIGSLLFF-LFSAGCALTPSIGLLIAFRLLQGIAGGTTVVVARSVIPDVA--HGRAAASAFSALMAIQGLAPAIAPLLGGFLSPIIGWRGIFWVIAVFNVIMVVVSRFVVPESLPADRRTPglPTIFRCFGRPAFIGYCFAFAVGFGTFFSYISASPFVLQDQLGLPTHVYSITFAINSLAIAGMSALNGKLVNRFEVRSVLVFGLILYVATSVIllLGPRLWPTLICLFVMTSATGLLLGNATALGVEAVRdgAGAGSGAMGALQFLAAGIVSPLVGIGSdsLSMALCMLVCSIIAIVGCVTL------
     168 UniRef50_A9BS78        Putative uncharacterized pr...   160     8e-38  1  14.0%  7:391  67:463     ------WAPLSGPTFRMLWLIWMAANTCMWMNDVA-AAWLMTSLTTSPVLVALVQSASTLPVFLLGLPSGALADILDRRRYFIVTQFWVAAVALVLCLFVLsaHWLLVLTFANGIGLAMRWPVFSALIPELVPKHHLPSAM--ALNAVAMNASRIIGPLVAGAIIASLGSAWVFVLNAVLSILSGIVLIRWKRRHvrERLPSAMRVGLQFVRESPRMHAVLARTVCFFLQCTAVMALLPLVAQRLhgGGAETFTLLLASMGAGAIVGAMFLPRLRQAMSKESLIRSGSAVHALATLAVALSPNVYMAVPAMMLAGMALISTANVLGVSAQMALPNwrARGMSIYQMSIMGGTATGAALWGQVASMVGVRGSLMVAAASGVVCMLLVQRLVR-
     169 UniRef50_B7IW40        Major facilitator family tr...   160     8e-38  1  16.2%  7:389  19:388     ------MERLWTKSFIKMTFAMLFLFTGFYLLVPTLPLFI-KEIGGNESQVGLMMGMFTIAAVVIRPIIGGMLDQYG-RRSFIIFGLIFFGLTMYSYNIASTIVLLAVLRVIHGVTWAVSTTAVGTAITDIIPDSRRGEGM--GWYGMAMTIAMAIGPMIGLWVVQNYSFNGLFLLATLLSFMAVVLSLITKMPFTLQKEKGKIQ------LFEKSVLTITIVVFFLSFAYGGITTFLPLFASSIH----VNPGTFFLVYAIALTIVRPISGKLLDKCGEVFIILPALCITILAIVVLTISNGLIGVIIAATLYGIGFGSAQPALQAAMLTIvpSKRGVANASFFTAFDLGIGLGAIVLGVVSQMFGYRILFSGSAISALIALIIFVFF---
     170 UniRef50_D1WY20        Major facilitator superfami...   160     8e-38  1  15.9%  9:391  15:400     --------SGMPREFWWLWTSTLVNRLGAF-VATFMALYLTLDRGYSASYAGLVAALHGLGGVISSLGAGVMTDRLGRRPTMLIAQ-VSTAVSVAVLGFMVHPVAIAAVAFLVGMASNASRPAVQAMMADIVPPKDRVRA--FSLNYWAINLGFAISSAGAGFIAE-YSYRAGFLGEALMTLVCAVLVFVKVPESRPARarPQDEVRLTTVLRDGRYMGVVGLSFLVSLIFQQGYVGLP-VAMGTDGLSSSDFGTAIAVNGVLIVVLQIPVTRFIQHRDPRRLLIISSVLAGYGFGLTAFAGSVAAYALTVCVWTLAEIVNAPTQTGLVVQLSpeGRGRYQGVYTMSWSVAALVAPLMSGFVIDHYGAAWLWAACAVIGTVAGLGYWLLMR-
     171 UniRef50_C9PNB3        Bicyclomycin resistance pro...   160     8e-38  1  13.3% 15:391  39:420     --------------IVTLGILSMLPPLGVDMYLPAF-LLIAQDLNVTPEKVQHTLTFFAAGMAIGQLFWGPVGDSYG-RKPIILLGVTISAIAALILTNIQSIGNFTALRFVQGFFGAAPVVLVGAILRDLFNKNELSK--IMSSITLVFMLAPLLAPIIGGHLVSWFHWHSIFYVISFMGLLSCLLVLVLIPETHHKEKRIPLrrNFLSLCKQKEVLGYMFASAFGFGGLFALITAGSIVYVGLYGVPVDQFGYFFMLNIGVMTIGSALNGKIVNKVGTETMLRVGLAIQFIAGIGLIMVsgFWTMTCFLAIFAGQNPLISSNAMASILEKFPTMAGTANSMVGSVRFGTGAIVGSLVALMPMKTPAPMLLTMALCSIIGVSCYYFLTYR-
     172 UniRef50_D0SX27        Predicted protein n=1 Tax=A...   160     8e-38  1  13.6%  5:386   3:382     ----VSAERLWNRSFILCLFNNFFLFVYYFALLTILPIYIMKDLGGSVKEAGLALTLFLASSIAIRPFSGMIIEKLG-KKISMRGAGVIFALFAFSYLLVDSMWSLLLVRFLHGIWFSILTTVSVPVANEFIPEQRKGEGM--GYFVMSTNLGVVFGPLLALTVIQFTSFKVLFGVLAVIISLGLIFCWMLkeLPKPEVISTEKISLSLQDILEVKVLAVSFVALLTAFAYSGIMSFITAFSETKQLL--AYTSVFFIVFAASMLLVRPWVGKIYDRKGPSAVIYPSFIFFAIGLVIVSLISNQWILWLSAVFIGIGYGSLFPCLQTLAIQSVDKQrgHAISTFFTLFDLGLAIGSVAMGVLIAHWGFETTYVLSAVLVIVTILVY------
     173 UniRef50_O34307        Uncharacterized MFS-type tr...   160     8e-38  1  12.8% 13:387  10:386     ------------LILYTVCFSAFFASLSQNIYSPILPI-IKESFHVSTAMVNLSVSVFMIVTAIMQIILGAIIDFKGAR-IVLITGILATAAASIGCAVTTDFTLFLIFRMIQAAGSAALPLIAATTIGQLFTGNERGSAM--GTYQMLLSVAPAIAPVLGGFIGGAAGYEGIFWILAAISIVLLVTNSITFPKDSPTeaKGNVFAHYKSIFTNRTGNVILTLSFVLFFIYFAVIVYLPILLTEHYHIDVGIAGLLYLPLALSTIAGTFLFKRIQAKIGLHTLFIGSNVIAACSIILFAVTHslVLMALTLALFGISMGVIPPLYSTMITNEFEHNRGSAIGMFNFIRYTGMAAGPMVSAYLLTMMPSAMSFSLLGLGFAALSFCLL-----
     174 UniRef50_B7LJR0        Lactose/glucose efflux syst...   160     9e-38  1  51.7%  2:392  30:419     -SPAVSTPKAFDLTATAFLIVAFLTGIAGALQTPTLSLFLTDEVHARPGMVGFFFTGSAVIGILVSQFLAGRSDKKGDRKKLIVFCCLMGTLACVLFAWNRNYFILLFLGVFLSSFGSTSNPQMFALAREHADRTGREAVMFSSFLRAQVSLAWVIGPPLAYALAMGFGFTVMYLSAAVAFIVCGVMVWLFLPSMRKDAPLAVGTLEAPR-RNRRDTLLLFAICTLMWGTNSLYIINMPLFIINELHLPEKLAGVMMGTAAGLEIPTMLIAGYFAKRLGKRLLMIIAVAAGFAFYAGMLLAHSPMVLLGLQLLNAIYIGILGGIGMLYFQDLMPGQAGSATTLYTNTIRVGWIIAGSLAGIAAELWSYHSVFWFALAMTVAAVFCLFKIRDV
     175 UniRef50_C9RTA0        Major facilitator superfami...   160     9e-38  1  14.5% 12:391   4:380     -----------RRDLSLLFLVMFLVMAGFGIIIPVLPFY-AEKIGATPTQLGWLMAVYSLMQFLFAPMWGKLSDRYG-RKPMLLVGIFGLALSFFLLAAATTLWMLFAARIIGGCLSAATMPTAMAYVADVTTEEDRGKGM--GIIGAAVGL-GFIFGPGIGGIFSKTSLTAPFWIAGSLALLTAIFVFVFLHESLPREKRaqGKRPSLTAALRSPLARLYILQLIVTFSLAGLEATFAYFAAERAGLSSTELGYIFMIMGLAGAVVQglLGKLIRSFGEGAVIRFGLFLSAVGFFLILFVHSFWTAALYLTIFGIGNGVIRPCVSALLTKHTTDGQGSATGVLSSFDSLGRIGGPAIAGWLFTLKS-SLPYMAGIVLTFISFAVFQSFQR-
     176 UniRef50_Q6AJB3        Related to quinolone resist...   160     9e-38  1  16.1% 13:391   4:384     ------------RTLITLLLSIFIALLGIGIIVPVMPIY-AETLGAGGFALGMIIASFSVSRCILQPIIGNLSDSLGRKR-FLIAGLLIYALVGLLIPEAESIQSLIFIRLLHGMGSAMIVPIAMAYVSQMAPYGHEGR--YMSFLNIAIFSGMGCGPIIGGIFFDTLGFKAVFYMMAAMSFLAAILITANLpeTKSIKLQASLLSSMKRMVANRHTRGVLITRYATMTALVPSMAFLPFIMTESGYSSGTLVGLVIACRTLVNAALQFPCGKLADRYNKLTLLFIGVWVMVIATSLIPEAEKITSFFLIYALLGCGEAIVWPTLAAYASLDGREnhGTMMGVFNLAMSGGVFTGALLAGYSMDSIGLRWAFYIPAiiATIASLGMALIYR-
     177 UniRef50_A1S0R8        Major facilitator superfami...   160     9e-38  1  16.6% 13:392  11:387     ------------RNVYALGFVSLFTDVSTEMINGYLPVFLVQELGATRALLGLIEGIGELANYFFRLVSGYISDRLGRRKALVFAGYSLSAVSKPLFAFAHSPWDALVVKALDRTGKGIRTSPRDALISQSIDEESSGKA--FGLHRTIDQSGAMIGPLLATLLLPLIGPRNLFLVSFIPAVIALAILLAFVVDVKTESREARILKGARQVLGNKRLLLVLAAFAVMGLGYYDF--SFLLVRSREVGVAADLVPLVYLAINLFHTAVGYPSGVLSDRVGKEKVLVGSLVFFALASIALARTENLAGFAVAVVLYGVFFGSYETVSRAILPRFapELRGTVYGVFYIATGLATLAGMTVVGYLWDTAGRAVAFTYSATLSLIAALLFAYSTRI
     178 UniRef50_B1HWY6        UPF0226 protein n=2 Tax=Bac...   160     1e-37  1  12.3%  5:387   1:375     ----MKKQTIFTSAFLLLFMSNFLTFIGFEMLLPILPAYLM-SLHASPFQVGLVTTVFTIGAIIIRPFVGylVD--NNRKGLAMGAGITLMIITIIYPFMNTIWLILLLRFFHGATWGVSTTANSTMAVDLIPKTRLGEG--IGYFSISTTVGAIIAPSLGILIYHSFSFSILIYSSCMLCLLAVIALQFVYSAEPVKHEKQPF--QFMEAIFEKEVWFQALLTVMTTLGFGAIITFLVLYGEQR---GLDHIFLFFLINAIVSTLLRPFTGKWFDKTGPWSIIIVSAVVGFLSLMVLSYATNSWLLIIAAILFGAGYGTVMPCLQTwvQKVSEAKSGAANATFLSSFDSGVGISAFLLGLLAEWMSVEMIFRLVSLSFLLVALFVY-----
     179 UniRef50_B5ELK1        Major facilitator superfami...   160     1e-37  1  16.2%  8:390  25:406     -------TRSFRNTSLALFAAGFATFSMIYCVQPLMPAF-SREYGVAATSSALSLSLTTGILAFTMLLVGNWSDRLG-RKPIMVWSLFMSAFLVLATGFAPNWDVFLLARALLGISISGLPAVAMTYLNEEVHADSIGIGM--GLYISGSAVGGMSGRLVAGVLANYWGWHVAIVSIGVISLIAAVLFVRSLPDSLHFSPQHVSWNgiRMLFKDSGLPWLFAEGFFLMGIFVTFYNYLTYRltSPYDFSQAQVGLIFSVYGVG-IFSSPVMGHIAGWVGRRKVLWMAFALVITG-VLLSFAGAVWAIMLGTILLTFGFFGGHSIVSSWVGRRAHGAKAQAASLYLFFYYLGSAVLGSSGGYFYSGWGWDGVAGLLTFLAASGLLIAWKLR--
     180 UniRef50_A7HM59        Major facilitator superfami...   160     1e-37  1  14.9%  5:387   1:409     ----MSKDINRKRTVIFLFILLVILNADQMVMSPVIG-MIEKEFNVTDSHIGLVGGVFSIVGAIISLFWGFLSDKYNRKK-LLVGSILVGEIPCLLTAISGSFGQLFFWRVLTGIGVGASFPISYSIVGDLFGHKERGK--VVSILGLASTVGSILGMLVAGYTANILGWRIPFILVSAPNIILIPLIWYYLDEPKRAAHEEgkLSDYANLVKIKTNLLLFFQGIAGTVPWGAIPYFMIEFFRREKGMDLNQATTMFLIFALGSIAGNVIGGIVGEkiSRRLVPLVSAVTTILGVFFTVWvgTFLIFGLLGFVAAMMDSYTGPNVKMMLLNvePKNRGRIFSIFNLTDSVGTGIGRFVGGALSVSLglSAYFWFICGFFLMLTAWYF-----
     181 UniRef50_C0Z5S7        Conserved hypothetical memb...   160     1e-37  1  17.0% 12:388   3:380     -----------RLFLMIFFFTMFLIGTNTFIISPLLPT-LRELYHVSTNQAAWLIGTYALGFALAALIAGPLSDNR-NRKHVMAVGMLGFALSTLACAFAPSFTAMLFFRFLAGICSAFIGPQVWAAIPVLFPPARIGKAM--GVVMAGLSVSQVIGVPIGSFL-SAYHWSFPFLAVGIASLGAFVLIIRKLPDLLPPttTNAIFARYKDLLRLPQASRSFIGYFVFMTGVYAVFSFYGVWLSDQYQQSVTEIGLITLVIGLGNTVGSLLSGWLLERWKRSTILTVGFLGSALLYLVLPYIPGIGLLQVVLFFMYCFGGVLVPVLMGYLQSLSDTSRGTISSLANACMYIGTFIASSFAGSLYSIFGFVGVSTFATFTFLIAYFLFVW----
     182 UniRef50_Q0W1D9        Permease (Major facilitator...   160     1e-37  1  17.1%  5:391   9:393     ----LNMDKNQKLALLVVFIAIFTDMLIYCMIVPILPEY-ASGLGASQQMIGLLFASYAITFLLAAPVVGVLSDRVGRKLPMLVGLLGLFG-STLLFAFSSDLTMLFVARALQGVSAGATWTAGLALLSDLFPPKMRQQAIGIGI--SGSFAGTLLGPLFGGALYEYGGYALPFLAAAGLVLIDGIARLLLLKDPPRLPAEQQV--SLKSMLKNRTILLMAGVIVLVSAATALLEPVLPLYLSDVLKVSPTMIGLLFAVTVVASLIASPLSYKVAERFGRKRVIIAGLICSALILPTLALSGSFILEVVLMAALGGVLAIGLAsmTDVIDRLGQGGYGAVYAIYNLALSFGMMAGPIAGGLLAGSFGITAGLGIGGAFMIGYAMLLLIVMR-
     183 UniRef50_Q1R0S4        Major facilitator superfami...   160     1e-37  1  13.0% 12:388   5:380     -----------KAIAYSVSFAAFLGPFTQTVYVPILPE-LQDTLATSQLLINASISVFTFIIAFMQILYGPLTDTWGRKKVLLP-GIALYVGASIGCFYADHIASLLFFRVFQAVGIATGSVVAVTVIGDLFRDEERLKAM--GTFQTMVALGPVIGPVAGGFIADQLDYHYVFLALAVAGTLIGILNLALLRETKPapARRIDMAEYVRIARDRQGLTIGILGFVQFYIYYNFLVYLPVILDQGYTLSVAQKGLMFLPLSVALMLGSFLSSRVQKRLSTESLLVITALLCAvmAFLATSMHSLASLITTTCLFGFLLGLSLPAQTALLTRVFVTHRATAVGLYNFFRFMGMASGPFLGALLFDLGGLTLLFSIAALLFLLIAMLAHR----
     184 UniRef50_D1UB26        Major facilitator superfami...   159     1e-37  1  14.4%  9:390   2:386     --------KQESRIVWIAAIIQLINIVDFMMVMPLGPD-ISKDLPVTNSDIGIICGCYTLAVGISGIACAKFLDRFD-RKHVALVAVLGLSLATLGATFSWDLTTLTGARVLAGLFGGPAAAIAFSIVCDVVPPERRGKAM--AIVMGTFSVSAVAAIPFGLELAEKGTWRTPFYAISILGFIVFWLILRLTPSLKEHLKGEPRTLELTRLFSNGKFLLAFIMMATAMISSYAIIPNISAYFQLNLGYPRSSLGFLYLVGGLFSLILIQIGGRASDKIGPIPTNILGTILLVVFLygFMHQPTSSLLVVFSMFMGMVCFRNVSATTEASKIPQPHERAAFMSLFSSIQHLGNGIGAFLASAIldLINMKWVGLLSIVMALIQPLILIMIR--
     185 UniRef50_C6IVP9        Major facilitator superfami...   159     2e-37  1  15.7% 15:390   8:394     --------------LIALASIPLIMTLGNSMLIPILPQ-IARELHVNSFQVSMLITVYAVVAILLIPIAGYLSDKFG-RKAIIVPSLIIAGVGGCISGVADWfwLILGGRFLQGIGAAGAFPIVLPLVGDLYESEE-EVSHNLGLIETSNTFGKVLSPILGALLGAWI-WYVPLLSIPVLCLISLLLVLFLVREPKDREKAKPLrsAVKAVLKqrWLYAIFAIGCISMFLLFGVLFYLSEQLEAKHGLDGVIKGLVLAIPLAALCLASYVTGKKidKKLMKWSGVAGLILSTGALFGIGFFNNIYFVIVCLIVCGAGIGIVLPSSDALITevDKEMRGTITSLYSSMRFIGVSAGPPVMSLLMKAGHMTMFFVIAGVSLVAVILLLTMVK--
     186 UniRef50_D2NPF3        Permease of the major facil...   159     2e-37  1  12.2% 10:386  12:393     ---------LSPLFIVVLALLTAIAPLATDMYLAALPA-VAENLNTTSTNASLTLSGFMVGMALGQLVVGPLSDKTGRRKPLLIGAVICF-IATVACGFAPNIELLIFARFMMGFTGSIGAVLARSIVADTT--EGLATAKLMGVMMMINGFAPVLAPLFGGWVLSWGSWRDIFHVLGVVTAIMMLGVVFVVKETLPVEERYQGTaeLPKVFKIRRYLGFMLTMCFAFGALFSYISGSTFVLQKILGMSETEFTVVFGVNSIGIVLFSAIATKLVGRVAQRRIVNVGVVSLLVVSSLLVVSfsLVPTLILLFLLTSSCGLIFGNASALALNEARHMAGSASAVMGTVQAMLGALAAPLVSFAGEHEYLPMGFSILGFAVLTALVLW------
     187 UniRef50_A6H0E2        Major facilitator superfami...   159     2e-37  1  15.0%  9:375  14:382     --------RGFSREIWILAIVTFINRAGV-MVVPFLSKYLKENLHFTYSEVGWIMVGFGVGSVCGSWLGGKLSDKIGFYKIML-FSLFVSGIVLILLQFVNSFWGLVLGLFVLMVIADMFRPAMFVAIGAYAKPENRTRA--LTLVRLAINIGFAAGPALGGLIIMYIGYSGLFWIDGSTCIISIILFGLLVKEKKkpEIETVTIAEVNSVFHDKPFWIFSVACLISGVLFFQLFTTIPLYHHEQFNLTELQTGLLLTLNGLIIFFLEMPFVSYIEriSKLKVCGWGLLLMTISLSLLMINFWSGILIVMMVFMTFGEMFVFPFSNSFALSRApgHEGRYMAIFTMSYSCAHIFSSKAGLDVVSNFGYQKNWFLM-----------------
     188 UniRef50_C7PTI1        Major facilitator superfami...   159     2e-37  1  14.1%  3:349   7:355     --ETIQFSSYQKLIIFMLAVAQFSVLLDFMVIAP-LGDLLIKSLSLKPAQFGIAVSAYAFSAGISGLLIAGFADRYDRKK-LLLFFYAGFILGTLCCAIASSYIYLVAARIVTGLFGGVISSIAMAIIADIFPLQQRGR--VMGYLQLGFSASQVLGIPLSLLIANLWGWQYPFVLVSAIGLIGLIMIATRLQPLQQhqQTRSPLLHLKHALSIGRYHIGYIATALMSIGGFMMMPFSSSFAVNNLHVTQTQLPGLFMASGITTLVVMPLIGKLSDKMDKFKLFTLASILMMAIVVIylGPTPFWIVVALNMLMMSSIMSRMIPSSALTSAIppQDRGAYMSVTASLQQ-------------------------------------------
     189 UniRef50_Q6ML57        Sugar transport protein n=2...   158     2e-37  1  15.4%  8:389   3:393     -------SKQEKFLLAILASIQFSSIVDFMIMMP-LGPQLMRMFAINPHQFGLLVSSYTFFAGLSGFAASFFLDKFD-RKACLLFFFVGFSVGTVACGLAPNYEMLLLARGLTGVFGGVLGSLVLSIVSDAISYERRGSAM--GVIMTSFSMASILGVPFSLFLANQFNWHAPFIFLGCTSLLLCVVIWFKVPSMSKhvNKEPMWNTISRIANNKNQRRGLYFMSSVMFGHFAIIPFLSPSLVANAGLSESQLPLMYMIGGAFTIFSSPFIGRMADRYGKHKVFLWGALVTLIPYWvlGPSPLWVVLAICAFFFVVSGGRMIPATALVSGTAKPQNRGSFMSIVSCVQQLSSAVSSYIGGLIVTTghYPVVGYIAIAFTFVAIFLSRRI---
     190 UniRef50_C0Z5D0        Multidrug resistance protei...   158     2e-37  1  16.0%  5:391   1:392     ----MALLLKNQGALLILMFNIFLVFTGIGLVIPIMPKYM-ESLGITGGTIGLLVAAFSLTQLLFSPIAGRWADSFGRKK-IIVIGLVVFAISEVMFGIANSPVLLFVSRLLGGISAALIMPAVMAYSADITTNEER--AAGMGYITAAITTGFIIGPGIGGYIAE-FGIRVPFYSAGIAGLIAACITLLILKESKPTEESLADSSSSEKQRsrEPYFFSLIIVFVMSFGLANFETVFSLFVDHKFGFEPKDIAFIITFGSIAGAVVQlaFSWIMNRFGEKRVISICLLFAGLFIILTLFVHGFWMIFAVTFIVFLAIDILRPAISTQMSMLAKDQQGYVAGLNSAFTSLGNIAGPIVAGFLFD-IDINYPYGLACLILLICFVLSLGVKN-
     191 UniRef50_C7M7F9        Drug resistance transporter...   158     2e-37  1  14.1% 15:391  17:398     --------------ILIMGLLSMLTPLAIDMYLPAF-VKIANDLNVSEEMISQTLALFTLGFAFGQLFWGPLSDSYG-RKPIILIGIITSALVSLVITQIHHIHHFYILRFVQGFFGASPAVVTGALLRDLFAKNE--FARQMSMIMIVTMIAPLIAPVLGGHLTDWFHWHIIFYVLMVLGLLAALLVSYKIPETLPKFKRVPllRIYGKLLSNKKVLGYIFCNSLSYSGMFCFITTGSIVYTKLFGVAPQHFGYFFLLNVIVMMTATSLNGKFVTKIGVEKSLRLGLTIQLIAGAWLvfHLGLWATVAGVSMFVGLVSVVSSSANAAILDMYPEVAGTANSLTGMLRFGIGSVVGAVLSLFAITSERPMVFAMAICIGVGALSYLLLVAR-
     192 UniRef50_B9YYL5        Drug resistance transporter...   158     2e-37  1  16.3%  1:392   1:401     MPSQTVTSPSATRSRGLALVLALLATLGPFSIDTFLPAmiGASLGASPVEIQQALTVYLFCYGMMMLWHGSISDAVGRRPVVLVTTL-LFGAASVGCALADNLTTLLIFRGLQGLCGGAGLVVGRAIIRDRFDGAEAQR--MMSQVTMLFSLSPAIAPVVGGWLFGAFGWHSIFVFMALIGFGLFVMSWFSLPETHGHERRqtLLANYTRVARQREFQLLAAAVSFNFAGFFVYIPAAPVFLMQHLGLGPEQFLWMFGPAVGGIMLGAFLSGRLAGRRGAREIVNLGYGVMFTALAclLFPPALFWNVAPLMLYTTGMSLVAPSITLILMDQFPELRGTVSSLQGFTQTMMSSLVAGVIAPLVWGSPLTLALTMACFLCLGFAFRMAFRRRL
     193 UniRef50_D2UC81        Probable major facilitator ...   158     3e-37  1  15.2% 12:387   9:392     -----------RRMTLLLAGLTMFGPFSIDTIFPAFPQ-LAQRLHEDPVAIQQTVSVYLLAYALMGLAHGPLSDAWGRRR-VIVGGLTLFILASVGCALSHDLPTLLAFRALQGICAGVGMIVGRAVIRDLFHGDDAQR--LMSHVSMLFGIAPAIAPIIGGLILSSggWPMIFWWLVGFSSLLLLATLRWLPETHPPQVRTPllRDYLGIAFNPHFQRLAAAGAFNSAGVFLYIASAPAFVIDLLGMSEQDFAWLFMPTIGGMTLGAFLSGRMAGRLGPLRQVRIGFICCGASVaaLAPQIALPWAVLPIFGGGLGMALIFPILALAVLDMYPRQRGLASSLQAFTQLMVSVAVAGGLAPLLSGHPLHLALGSGGFFLLGWAFWRW-----
     194 UniRef50_UPI00016C4DCC Sugar permease (arabinose p...   158     3e-37  1  18.5%  8:390  16:404     -------SRGEWGLILLLMAIQFTHMVDFVIIMP-LGGRLIDELSLKEAQFAHIVSAYAWAAGVASLAASFVMDRFD-RKTVLLTMYAGFTLSTLFCGLAGGYELLLLSRTLAGAFGGTAAVALMSVIGDVFPPEKRGRAS--GAVMSSFAVASIAGLPAGLMLAEWFGRGAPFLVLAALSALVWALVWSKLPPVRGhdNRPNRWAEFGEVVSNRTYLGAFAFSFFLVLGTFTVASFIGPYLKALNGWTERQLAQLYFVAGACTLVGMTVVGRLSDKLPRlrVIGSAAIVMALVVTHLPAGPLWVAAIAMSAFMVVAAGRMVPVQALLLGVASPKNRGAFMSVNTAVQHAATGLAPLIAGALVTlvGFENVGWVAAVTAAISLVLAGVLK--
     195 UniRef50_B7BGD8        Putative uncharacterized pr...   158     3e-37  1  14.3% 12:388  10:393     -----------WELIIMLWIAYFLNQGDRQIFNVVIPL-IKEDLHLTDVQLGLVASVFTIVYGCLVPFGGYMGD-FLKRKWIILISILIFSIGTLCTGFSGGVISLIVLRGitGGGEAFYYPAATSLISQY---HHKTRAMAMSIHQTSLYVGIVASGFIAAYIGEHFGWRMSFFTFGLGGLLLCIYLFFRMEDTpkEEERYSIGYVIKEIFKKKTVWMLCLAFGGMCFVNIGYVTWMSTFYHEKYHLSLSTAGFTSMFFHFAAAlgVLIGGKLSDKYAQKRKTvvGLLLGAPFIFFMGYTSNLYVSYVMLALFGFFRGIYDSNLYAALFDvaPDLRASSVGVMTAFAFIVGALAPLLLGYLKTDYGLSFGISFLSIFYLLGALAVFV----
     196 UniRef50_B5ZXF6        Major facilitator superfami...   158     3e-37  1  14.2%  5:392   1:403     ----MLDPKFVRRGLFLVFIILFLDIIGIAIIMPVLPAYLEQLTGGGVSDagWLMLVYAGMQFLFAPLLGNLSDRFG-RRPILLLSVLTFAIDNFICGIATSFWMLFVGRVLAGISGGSF-ATCSAYIADISTEENR--AKNFGLIGIAFGVGFTIGPVIGGVLGE-FGPRVPFLGAAALSFVNFIAACFLLPETLEARNRRrpLGALRQMRHYPGIGWVSLVMFLFFLAHAVYPSVWSFVSTYRYGWSEGQIGLSLGIYGIGAALVmlVLPRVVPLLGEWKTALLGLCFSAAGLTGYAFAWEGWVVYVVIVATVMENVADPPLRSIAAGKVPPSAQGELQGALTSLSSITTIVGPLIFTQLFSYFtaGAPYLTAALFILVAAGVFLVRVRV
     197 UniRef50_C6D6R2        Major facilitator superfami...   158     3e-37  1  13.6% 10:391   9:384     ---------PFPISVLSLTVGAFAIGMTEFVIMGILPN-VASDLNVSISAAGQLITMYALGVAVGAPIMTILTSRIPQKK-LLCILMLLFILGNGLSVVAPNYAVLMIARIITALTHGTFFGVGAVIASKLVRADKQ--AGAVSIMMAGLTIANIIGVPIGTYIGQNWGWRASFGAIAVMGVLALIGIIIFIPKLKLSKQVSVLKQ--ISAIARPKLLVYLLIAALGNAGLFAVFTYITPLLTDITGFAEHSVTWILILFGIGVTVGNMVGGKLADWKLMPSILGLYLTIAVVLTIFTFTVHNEIAAVITIFLWGAASFAVFPGLQVRIMSLAQSAPALASTSSHSAGNLGNASGAFIGGWVITHLSLGALPWVGAILVGLALILGLFTAR-
     198 UniRef50_B2G7W0        Multidrug transport protein...   158     3e-37  1  13.8%  6:390  13:404     -----KFPHGWHRTFYTLWLGAFITGMGYSMTMPFISLFIAELGNFTRFQlgLAFGVTFISQAIVSPFWGSLADRKG-RKLMCMRASGVMACTICAIGFAQSVWMIIGMRFLQGVFSG-YINNATALMAGETPHNKSG--WVMSAMTTAGVAGNLVGPLLGGFLSGLFGYRIPFFITGALMFCVFLSTWLLTVepIKKEAMKPMKEIIHNLDNPPLIFVMFLTTMIVTSSTMSIDPIISLYVRQLMGGhaFVAGIVAATPGLGTLLAASKVGHTMDRIGPEKVLQIGILTAFILFIPMTITKSPWALAFWRFLLGLANAALMPATQTVLTLDVPTEagRIFSYNQSFQAAGAVLGSILGSFISGISSYEMVFVITGLTLLLNFILVMLVR--
     199 UniRef50_Q8NSK1        Arabinose efflux permease n...   158     3e-37  1  14.3% 17:387  50:415     ----------------ALALGGFAIGVTEFVSMGLLSA-IASDFEISEDQAGHIITIYALGVVVGAPLITAFTGKLPR-RRLLLILVAFFVVGNALSTLNASYEVLLIARFIAGLPHGAYFSVAGLAAASMAPDGQRGRA--IAYVGMGLSVGTVAGVPAAQALGDAFGWSTAYVLVTVLGVLTLLALWFLMP--HMTEMKPTSPLTELSALKNSQVWLTLGIGSIGFGGMFAVYTYISWTMTDQAGMPSSLIWIVLMAYGVGMICGNYVGGRIADWNVDRGILLALICIVVALIGFYFTSNNAILGTINFGLVGFFGSTLIPSLQIRLMDVAGRAQTLAASLNQSALNIGNALGAAIGGVVIGaySYSTPALAGAGLAFLAIVVWF-----
     200 UniRef50_C7PNJ6        Major facilitator superfami...   158     3e-37  1  12.6%  2:390  12:400     -TVSPSHNRASKGEVVIVSLATFIIFFQAFMVAPLLPE-LASLFGSTVRQTSFIEPVYLLGYGVFTLVYAPLSDRYGRFK-IIVYSLCLFIIFSACTAFVESTNQMILLRLLTGISAAGIAPTTISWISDRFPYAERGYA--LGIFFGCMAGGMAFGSSVGALLAEFVGWETLFLLVAFSGSIVLLLNvrLYPDMPKSSSQVSLLTIFREILSTPGAKGTYFFVFENGLFHSGVFAWLGVYFYNVYHLNERGIGLALLGYGIPGLLLGPALGRMADRIGRKRIIPLGIVLGGVTVMLLSCIPSLSIACMLVAILSLSFDLTHPSLATIVTSFSKKNAGGSTGLFAFFLFMGYGFGSLLFSLLVSIGLVETLRIFGLIAITASFVANRFFR--
     201 UniRef50_B5IE15        Transporter, major facilita...   158     3e-37  1  13.9% 11:391  17:404     ----------LNRKLLHISIAFLLINMGWGMAWPYLPN-LVKLLGGGVIAVGMLSILFNITSSFGQFFWGRSSDKMGKRKIFALFGVFSSGFFFLLIGFASSVFLVLLLRTLQGFFISAQTPAISALVSEIS----KDVGKGFAVFNSFSNIGFMLGNFAGGFVTSVFPIHFVYYFSSIPIFSGLILLIFFKEEKKNPqrPGRTLFKWKNVkrNRNISLFSFSIFISMIGSGMVYTYLSLLIGARFG--SSWVGTYFGVDGLASIPLIILFGYLADKYGSKPVLIYGLVGYMATFYLYYYSTTIPMLILTAMVSGSKWGSYFNSANTYVSRMskKERATALGLMNSSMALGWVVGPLLGAYFIPMLGLAETMLVAIIPEIISLILVLFIKN-
     202 UniRef50_Q032Y5        Permease of the major facil...   158     3e-37  1  17.3% 23:391  16:381     ----------------------FLVFLGAGLVIPVLPT-LKEQMHFSGTTMGMMISIFAIAQLIASPIAGALSDKIGRKK-LIAIGMIIFSFSELLFGLAQAKTGFYISRALGGVAAAMLMPSVTAYVADMTTISERPKAM--GLVSAAISGGFIIGPGVGGFIA-HFGIRVPFYVAAILAFIGFILTITILKEPEreANHETEKVSFLDILKNPLFGSLFIIILISSFGLQAFESIYSIMASINFGFSMGEIALVITVSGILALFFQLFLftIVNKIGELGLIQLTFFASAIFIAIIAFTKTNLVVALSTFVVFLAFDLFRPAVTTYLSKHAGNRQGAINGLNSAFTSFGNILGPMAAGYMFDINHL-FPYYISAIILLGTGFLSLFLNR-
     203 UniRef50_UPI00016AE76E drug resistance transporter...   158     4e-37  1  16.0% 16:352   2:339     ---------------VVVSLLCACSVLPLSIFLPSLPN-IFSDLHVDYAVMSLSLAGYAGLSAILELFMGSLSDRFG-RRPIILLSLALFTIGSLGCALATNAWSFLASRFVQAAVTSSY-PVSIAAVRDVFGKEAAGK---IGYAATAAALAPMLGPALGGFLDEIFGWRANFWVLAGVGALLFVFCWIDLDETKTNISrkAQLEAYPILLRSNRFWGYTVCLACSTGAFYAFLTGVPTTAKISFNLSPAALGAYMGAITLGFMSGSFLSGRYSKRWSLARTMVWGRILACFgtIALLGTSEVFWVLAPCMLVGIGNGLSSPCANAGAVSVHPTLAGSAAGLAGCITIGGI----------------------------------------
     204 UniRef50_C9NP72        Major facilitator superfami...   158     4e-37  1  13.0%  5:390   1:381     ----MAMTQS-RAAINAVVFASTVGFMGIGLVDPIL-VAIADGLNATPSEVSLLFTSYFLITAVMMLITDIAATRIGLKNTIMLGAFVV-ALFALGSGNSNTVGQLVGYRSGWGLGNALFVATALTLIVTLSQKKGKESVR---LYEAALGVGIAIGPLVGALLGQ-GSWRYPFWGTALLMLIGFVSIAYFVPATPVQRQQRHSLAAPFQALKQPKLRLISLSAFFYNFVFFAILAYSPFVLQ----LGVLEIGAVFFGWGLALAITslITPRWQSRLHPVSIIIRCQWVLVVLMLIMGYFAAPapLVIAIIVSGALFGVVNTLFTELAIETHPTSTSIASAAYNFVRWLGGAIAPILITHIGEHYGSAYSFSLAAVFALIACAIISRAK--
     205 UniRef50_Q2FS41        Major facilitator superfami...   158     4e-37  1  17.0% 11:387  14:384     ----------RRLLFISLYVAVFSTMLGIGIVIPLLPRF-AETLGASGFGIGMIFSSFALSRAFAMPFFGRYSDICG-RRQFIIIGLLLYAIFSLLYVPAGSVLELSGIRFLQGIASAMVFPIAMAYIGDIAPPGMEGR--YLGTFTSSLFLGMGLGPFLGGIVTDIAGMDTAFICMGALTGVALLTCIFFLP---GYQGSRKEQSSILHLLIHPGLRIPLLYQMMNAFANGTFMVFLPVIAAHVGNLSAGETGLVISVSVLSTALLQRVCGRLADRFDKYLLIATGCLTVTVALALVPGFEGLWSYLFFALLMGIGGGISVPAMYALVTIAGRdgQGAAMGTINMVMSMGMIISPVVCGLFMDQTGISSVFYLSAVIVLVVTPVFL-----
     206 UniRef50_Q9K9Q3        BH2592 protein n=4 Tax=Baci...   158     4e-37  1  13.8%  9:386   2:385     --------KGWKRNLYILVVCQFLVVSAMTMIIPFLPLYL-QELGVTdlWAGIIFAANFLTAFLFSPLWSRLADRYG-RKMMILRSGFGMALIIGLTGFAQGPLSLLCLRLLNGV-ISGFIPASIGLVATNTPKEKAGYA--LGFLQAGAVSGGICGPLIGGIMAQAFGYRMIFFLTGLCIFIAALVVLLFVNepNPKEEKTNTWGEFKKITAIRPIFSLYVVVFLIQFAVMGVNPLISLFVEELVSGvaLFAGLAISATGFANMLSSMQLGKLSDKAGAHHVLFFCLLGTVIFMIPQAFVQQLWQLIVLRFFVGLSLGGLLPAANALVRMHAPKGmsRTYGFSTSALYLGNMVGPTVGGAVVATVGIRGLFLISAFTLLLTVWIV------
     207 UniRef50_Q30UI0        Major facilitator superfami...   158     4e-37  1  14.9% 15:391   5:379     --------------VFPLSAILSLRFLGLFLVLPVISIYALELKGSTPFLVGIVVGGYALTQAIFQVPFGSMSDKIGRKPTLLV-GLLIFLVGSVLCAYSTDIYTLMIGRFLQG--AGAIGSVITAMISDLVQEEIRGKAM--AIMGASIALSFALAMGLGPVLGAKYGVEFLFILTALFAVLAIILLFTKVPTPPKIKHTYHATAKTSDILKDSNLLNMIVINAMQKGLMTIAFVLIPIILTSafAWQKSDLYMAYLPAMLFGLAAMGPAAVFGEKHNKPkiFLLSIALFIVSFLIMGLTTSSSVFVVGVVLFFIAFNMMEPLVQSMITKFAkhQKGAALGISNSIAYFATFIGGTSAGLLLGISDRETIGISVGVVALLWFLWTLKLQN-
     208 UniRef50_C5U4J9        Major facilitator superfami...   158     4e-37  1  16.9% 11:389   1:372     ----------MKSEAYVIWIVTFTTMLGIGLIAPILSFY-AKTLGANNFQVALIFSIFMIARTITQIPAGHLSDIYG-KKLFLTLGTFFYGLTTFFYNFVSNIFELLIVRFFTGVFSAFVTPIAGSYISAIAPKEKMG--QYMGFFNSAIGMGFGVGPIIGGFLAEHFSIKAPFYFCGFLGILASILSYFKLRDIKFKNKSRGI--NLKLYLKNKKFLIPFIFNTVILMGNSSVIVFLTIY-AYRFGIGLDGSGFLIAFTNIISALLQRKLGSLYDKYGL-NIIIVGLLLVSLGFFYLSLADNFYKIMLSLILQAIGSSLISTSLMSYVANLIpeRRGEGLGLFTTSLNFGFMFGSLFFGAIANVIGIGEMYKVVSLFSLIMGFSLFKI---
     209 UniRef50_C5A6T3        Tetracycline resistance pro...   157     5e-37  1  17.7% 12:390  19:398     -----------SWNVFVLGLVSFLNDMSSEMINPVIPKYLTDVLGTGELLSGTLMGAIESLSSLFKVAFGYFSDRFKKRKAFIFAGYALSTFAKGALAFTRHWWDFLSLRVLDRVGKGIRTAPRDALIAESSEKGKTGK--SFGFHRMMDTLGAVAGPLVGIGLLHLmaYRYLFLSAAVPGLLSLLIIVFLVKDRGREVKKKITGVS---ALKSRSLRLFLLVIAVGALGRYSY--AFTLWKAGELGYSLKGEMAFYALFNLMYALAAYPIGVYSDRVGKKTLITAGFLISALASLAFAYARGLGTLILAFVLYGIYIAIEDTVPRAYMADLAKdeKGTVIGAYHTVFGVFVFPASVIAGWLWQSYSLTYSFLYAAFMNLLAFVLMILIR--
     210 UniRef50_C1DP43        Drug resistance transporter...   157     5e-37  1  15.5% 24:377  42:400     -----------------------FASVSTDMYLPALPT-ISRALHTTSASIELTFSAFLVGFSLGQLLWGPISDRYGRRLP-IAIGLVLFTIGSVGCALSTTVTQMMVWRVVQALGACVGPVLSRAMVRDLYGREQ--SARMLSTLILIMGVAPLVGPLLGGQVLAFWSWQGIFWTLAGIGVLTLASLAALPESLPPARRSATPLrsYWELLGDVRLMGYALSGGFFYGGAYAFIVGTPFAYIDYYHVSPQAYGWLFGLNIVGMMVANFVNRRLLERFGSERLFHIGTWILALTGIVLAiwGGLPGLVVPIFFYMSMNGLIVANSVAGALSAFAHKAGSASSLLGAMHYGSGILSAAMLGWFSDGTPWTMAWIMALA---------------
     211 UniRef50_UPI0001C4273A hypothetical protein BpOF4_...   157     5e-37  1  13.6% 11:386   4:385     ----------WKRNLRILVVCQFIVMSAMTMIIPFLPLYL-KELGVTNPqaGIIFGANFLTAFLFSPFWGRMADRHG-RKMMILRSGFGMALVISLTGFATGPVSLLILRLLNGV-ISGFIPASIGLVSTNTPKEKVGYA--LGVLQSGTVAGAICGPLIGGVMAQAFSYQMVFFLTGLCILVAALGVLFFVRepVSKEQKTSTKEDFIAVTKQKPVLSLYLVIFLIQLAIMGVNPLLSLFVTELTPAeaFFAGLAISVMGFANMMTAPFLGKLSDKKGAHHVLIYSMLGVAMFSIPQAFVADIWQLIALRFMVGLCLGGLLPAANTLIRLHAPNGmsRTYGFSNSAMYLGTMIGPIIGGWIIANVGVRGLFLVCAAILLVNVAIV------
     212 UniRef50_Q2JNV3        Transporter, drug:H+ antipo...   157     5e-37  1  14.9%  1:389   1:384     MRVFGQLQPAQRRNLGILFVAGLLFWASLSSLLPTLPLYV-RDAGGTSQQVGWVMGAFSIGLLAFRPALGRLADGH-SRQIVLLIGMGVVGMAPIGYWLSDWIPWVALVRAFHGVSIAAFATAYVTLVVDFAPEEKRGE--ILGYMSLVNPIGAAIGPALGGFLQEFAGYGPSFLFSALLGLVGFLCTQLVREQRREHWGSLPMDGAFWSFLGSPKVRSLAWVMFLVGLAFGTQTTFVALLIQEA--GAPLNPGLFYTAVAFASFGVRLLTGRASDRYGRGPFISLSLVTYALAMGILIVANSSGAFLAAGVAVGCGFGTLIPLISALVADRspAERGRLFSLVMCGFDLGIGLAGPLLGTLAAGSGYRAMFGYAALLSLASLGSFLFF---
     213 UniRef50_A1TNE2        Drug resistance transporter...   157     5e-37  1  14.3%  7:391   9:399     ------WRAPRWTLAVLLAVLGMLGPFSIDTYIPAFSG-IAAALGATPVEMQQTLSAYLFGFAFMTLFHGALSDSFG-RRPVVLWGIAVFTLASAGCALSQSIGQLVLFRALQGLSAGAGIVVSRAVIRDMFPPAQAQ--QVMSQVTIYFGVAPAIAPIVGGWLFVHAGWHSVFWFLTGVGLLLWIANYRLLPETLHADHRQplLQGYWQLGSSPRFLLLALASGVPFNGMFLYVLAAPAFLGEHLHLSPTHFFWFFILTISGIMGGAWLSGRLAGRIAPKRQIRHGFLIMFIMSMlaLFTAHVSWALLPIAVFAFGWALMVPVVTLLVLDLYPERRGMASSLQAFVGSTANGLVAGVVAPLVMHSTLLLACASLAMMCVGLVAWVYLHHR-
     214 UniRef50_C3Q2R4        Molybdopterin biosynthesis ...   157     6e-37  1  14.7% 14:388  11:378     -------------ILVVIGIVSAFGPFVTDFYLPALPV-LAGYFDTTASLIQLSLTFSMVGLAVGQLVIGPLSDKYGRKKTLM-ASLVLFCISTIGCLYASDIYVFIFFRLLQGLSGAGGVVISKSIATDLY--EGRELTRFFSMLSSVQGIAPVCAPVLGGVLLEVTDWKGIFWILVLIGILLIMALAFFKESLNNEQQHCGVFATFrpVFQNAQFMRYVLVQAFAMGVMFTYIAASPFIFQEHFNMSPLAYSLCFGANAIAIMLGSLTVSLFHDATDALRVGSIGFGIMSLfaAALFFSTSVWPVEVSLFVFMLFLGVILPSSTTLALDLERKNSGNASALLGFLMFL-------FGGVLSPLTGLGNMLYTTGIIIVACCIGTWF----
     215 UniRef50_A6U8Y2        Major facilitator superfami...   157     6e-37  1  15.5%  5:390   1:400     ----MIDQKFVKRGLFLVFMILFLDIMGIAIIVPVLPSYLEELTGADVGEagWLLLVYSAMQFFFAPLIGNLSDRFG-RRPILLASVLTFAIDNLICALATSYWMLFIGRSLAGI-SGASFGTASAYIADVSNDENR--AKNFGLIGIAFGTGFALGPVIGGVLGE-LGPRVPFYGAAALSFLNFVMGAFLLPETLDParRANPFGALKQMRHYPGIGWVGLVFFLYWLAHAVYPAVWSFVASYRYGWSEGQIGLSLGIFGVGgiVMALVLPRVVPALGERRTAALGLTFTALGMAGYAAAWEGWMVYAVIVATALESLADPPLRSIASVHVPPSAQGELQGALTSISSMTTIIGPLMFTQIFAYfaFSGAPYAVAGCLIIAALLIFLAK--
     216 UniRef50_B8DEA1        Multidrug resistance efflux...   157     6e-37  1  13.6%  5:387   1:378     ----MMTDKEMNTGKWITAAASLLAFMGIGVVDPLLPS-IAESIGASHSQVEMLFTAYIFTMAIMMIPIGIVAGKLGDKK-LIVIGLFIVTIFALLCGLSDTIGALSIFRAGWGFGNSMFMATAMTMLIALSETP----GHAIGIYEASMGLGMAFGPLLGGILGN-ISWRYPFFATACLIFIAFLLILFKVKEPKKVAPAPTEkkQMLHLFKYRPFLQIAFSGMFYYYCFFTILAYSPLIL----GLSAIQIGFVFFAWGLCLALGSAKVSHALerFNSKQILKGSLLACAVILALLGFIDNTAVDIGLIVISGLILGINNALFTTTVMEHSPYARSVTSGAYNFVRWLGAAFAPLCSGLLSEAFGMKMPFIVASVICLAGMGLLF-----
     217 UniRef50_A3I2R5        Drug resistance transporter...   157     7e-37  1  15.6% 40:385   1:353     ---------------------------------------MSKDLGTSIANIQLSLTAYLVGIAIGQLFYGPLLDKFGRKKPLYV-GLGIYVIASIGCAFTDSVNTLIIMRFLQAVGGCAGMVAAQAMVRDIFPITK--TAQVLALLTLVIAVSPMIAPTLGGFLTAYYEWHWVFIVLALLTIIIWMAVIWVLPDGANPdrPKQVWKNYILVMQNRQFLVYMLAGGLAGAAPFAYIAGSADVFMNIYGLSETQYGWIFAVLAFAMIGSTQLNHLLLRRFSSQQIINFSlvGLALVFGIYFQWLDVGSLLVLMFIFLTAHGLNGPNTAALSMAPFSRNAGSASAILGSIRMAFGGLASAGVSFFHDGTSLPMVSGMAACALAGFIVL-------
     218 UniRef50_B3PG88        Drug resistance transporter...   157     7e-37  1  14.2% 10:383   5:379     ---------SHPWLIVLLAAIIATTPLAVDMYLPAMPV-IAGDLNAHIGSVQQSLSIFLAAYAAGMLLFGPLADMIG-RRPLALFGLGGFTLSSVALAFSSQIDQFLLLRVIQAFCGAAATVVAPGVVRYLYQEH---TAKGMSYISMMMMLAPLLAPGVGSLVLWVSDWRSIFWLLAVYGLLIWVLIWRYLPEIPRAepKPNLLSGYRTVFGHSGARPLIVSMMFGSFAFFCFITAVPFVYIQYFGASEQQFSLLFGFNVVMLMLANWVNSRWVIRVGSLTMLRAGLVLATVSALVLAGVnnLWFTVFSVAPLMMGLTLIGTNTDALVLMQFPHNTGTATAVNGTLRFGSGAFAGPLLAWFYNGTALPFALLMLTGVLGVML---------
     219 UniRef50_C6D4Y4        Major facilitator superfami...   157     7e-37  1  12.2%  9:392  15:398     --------KMRDKRLLIVMAILMTTFIGFGIIIPVMPEMIKasPGNAEHHTGLMLALYSAVSFILSPYWGGLSDRIGRRPIIIIGVTGFAISFFLFGLSSDNLTMMYLSRILGGLFSGAVTSVIVAYVADITPPEQRTKGM--GLVGMSIGFGFTIGPGVGGLLSQ-VSLEAPFYAASIMALITLFFAITKLKESLPPEKRRAAgrESRWSAFTGPLKFLYVLAFFVTFTLAGMEATLQFFGIQRFDVTPVQVGMLFFVCGFVGALVqgVVRRRIKRGQEPQYIALGLIISAVGFFLLLAAHSLWWATLSLAVFGIGNSLIRPCVTSLITQKTQVGQGVASGLSSSMDSLGRILGPLVGSFLFT-LDLRLPYVSGGILCLLALILLVQFRRM
     220 UniRef50_B7JLE0        Major facilitator family tr...   157     8e-37  1  14.5%  1:392   1:409     MKNTWRELREMDRNVWIRFIGETLNGIAMMMLMPFFALYLKDKVD-SLLQVGVIMALSPIAASFGSIIGGRIADIYG-RKPIMIFSMTSNALLMLGFLFIEGFIPYAILSVFLGLSNSLFHPAASAMVADVTAPEKRTEA--YGLLRMGHNIGAAIGPIMGASVV-MLSKNLVFIIASSTMLFYALLVFVLIQETMPKSaeKESGVVWKIVLRDKALMIYLLAGIIISMGFSQTEGMLPLHFDNEmfGTNNPYPYLMALNGLLVVLFQFQISKWATDKPVGKTMLYGACLFGIGLFFIGWLPklIMLLFVYAIYTLGEMIMSPVQMTFVANLAPEhrGTYMGAASLQWITGNAFGPLLGGFLLDRLLGHFLFTILAIGCVVAGVVYISLDRL
     221 UniRef50_B1HS27        Probable glucarate transpor...   157     8e-37  1  13.6%  1:389   1:397     MTTNDVTKKSRNVILALLFLGWSLGNLDRYIMN-YAVVSITGDLQLDASSTGIILSAFFLGYAIMQIPGGWLADKFGAKR-ILLMAVIMWSIFTGLTAIAWSLTAMIVIRFLFGIGEGGFQPSSSKIIATIFPKEERGRAM--SIMLTSGGIVSLIVPLLAAYLLGTIGWRMMFIIIGAIGAIIAYLYWKYIQLPKAETADAavKVSFKELLKTPLMWNLIIAYFCIYAVNWGLVSWIPTYLQKNRGLDLMSIGWAQTIPAITTIIGVYGSGYIIDKLpeKVLGSISCAVIGILLYLMFTAKTVTLFIGYQTVVSIFIAFVITLLPVIVLKKLPSstGSAMGIANTGGQLAGFVTPMAIGFMVDAfsFDAAFWMLIGFALICIVSLVTL---
     222 UniRef50_C4L8C2        Drug resistance transporter...   157     8e-37  1  14.9% 17:385  27:397     ----------------ILGALMAFTSLSTDIYLPAMPQMASELQG----NVELTVTGFLLGFMVAQLIWGPISDHLGRRIPLFI-GMVLFVIGSIGCAGSQSLEQIVFWRVFQALGACTGPMLARAMIRDLFSRTEG--ARMLSTLVIIMAIAPIAGPVLGGQIIKFSTWHSIFWLLAIIGSLMFV-SLFWLPETLAAEKraSVFTNYQRLLKNGAFMKYTLCVTLYYVGAYAFITGSPAVYISYFGIDAQYYGWLFAVNIVGVMTVSFINRSLVRHISLQRLLRVSSLVAAVAMIIMALsgGLYIILVMVFIYFSMNGVIAASSTAAALDEVPEIAGSASALIGALQYGSGIISSLLLAYFGNDTPWTMTWIMMLFTCGSALVV-------
     223 UniRef50_D1BPI8        Major facilitator superfami...   157     8e-37  1  13.2%  1:380   1:396     MSTSVYDARGGMRNVWIITASMTVLAICYTMIIPFLPIYLL-ELGVpaLWSGLVFGITFLIAGIMAPIWGKIADNKGKKRMALRAGFAI-AVSYVLIGMVTDQYQLLMGRALVGFANG-FYPAAMTMVSLSVDEKQVGRA--LGIFQTGLILGNVIGPFLGGAVESVVGMRPVFYISGIAVFIATLAVLFLVKEpkQPVKATSLREDFKLVQEQPVLVRLLWIYFFMQCVIMMLQPILALYVGDMQGTMEGAagTILSIGGLAGSLTTNIWVRLGERRGYFRTISYCMLGSGVVLLLQSLPVGIWWFGVLQVLIGSCIVGINPSLSAAVtnTEPGFRGRMFGMTTTAQQFGSMVGPVFASIVSTYIGISYVFSITGLLLL------------
     224 UniRef50_A8FIK1        MFS family major facilitato...   157     8e-37  1  13.7%  9:388   2:375     --------KNFPIAIFALTLGAFSIGMTEFVIMGLLPN-VANDLHVSISASGQLITGYALGVAVGGPIL-TLSTGKMSRKRLLILLMILFVAGNAVAAVSTSYGLLMAARILTSFAHGTFFGVGAIMAARLVPKEK--SASAISFMFTGLTVANVLGVPFGTFIGNQFGWRMSFLVIAVIGLISLIGIISLVPNQSKEEV--LDIRNEVSVLKKPQVLVSFAMTIFGFAGVFTAFTYISPILLQVTGFQENGVTLILVLFGLGVTIGNLVGGKLADWKLMPSIIVSLILLIAVLLLFTITSEFKVPAVLTIFVWGIISFILVPTLQYRTMNMAHEAPTLASTLSHSAFNIGNAGGAALGGLAIELTHLQLVPLFAAAVTFIGLIITIM----
     225 UniRef50_C3IB14        Putative uncharacterized pr...   157     8e-37  1  16.3% 11:390  12:391     ----------FHPLVWQLLGGTTFARTASFMTIPFLALYLQNDLHASPIMIGLAVGISQLTATFGGFFGGFFTDRFGRKK-IIIISMFCWSIVFYGFAFANSVWIFVLCNALNGICRAFFEPASQALMIDYTDEDRRRR--LFSIRYTAINLSAVIGLLLGIVISKASSISFPFLITalLYAIFLVITLRRIEEQNTVNVTQDIGDLMRVLLQDSTLMLLIIASVICNFVYMQTEATMPQLLNLTMADGVALYSVLIVINAATIVILQLPLGILSEKVAIKTSLIFGGGLLALGMLIFHFADNWTLFIVGMVVFSLGEIFVFPMTSAIVEMIAPAHQKATYLGFMQFQNLGGFLGPVLGGWLIIHFAPQLYLVMVSLCLVVIICYIAALR--
     226 UniRef50_C8WRR5        Major facilitator superfami...   157     9e-37  1  17.6% 11:391   4:390     ----------WQRNLVVLWIGTLLTSASYSMVIPFLPLFLLkvHQHTDIWSGALYSAAFVAGAIAAPYWGSLGDRYGQKPMIVRAGFVLFVI-YGLTAFVQHPWELLVLRTLQGLLSG-YIPGSVALVGSNTPEDKVGYA--LSTISAASSAGGIVGPLLGGTIARLFGNRVAFGSASVLVLISTLLALVFVRekRRATSRPSVLGAIGGALHNKPLVTALSLNMVVSFSIMTIEPVLTLYIAesAKNASFLAGLVFSLAGIASVVFAPLWGKYADRIGFAKVLTIGLAGGAVWTFMQIPFHNIIAFAAVRFVYGAFFCAVYPAINGLIVRSTEAtrGRAFGLNQTANQIGNTVGPLVGGAIADATSIHGVFWVTGALLASVTAGAYALLR-
     227 UniRef50_Q5ZTC8        Multidrug resistance protei...   157     9e-37  1  13.6%  8:388  60:446     -------PKIDPWLIFVILMLMALMQTTTDQYIPSLPA-ITTALNSTEASIQLTISMFMLGLSLSHIFYGPLSDKIGRKPPLM-FGVGLSILGSLVCFVAPNVSVLILGRFLQGFGIGCCNSVGRSLVRDLFT--DRLLAKIGSYVGVVSIFIMAASPTLGGFIQEMAGWKANFMFLFVFGILVWLLAFCILPETNKHLNPEamAKNYFTLLRSKIFVGYTMCACFAFAGMVSYLTIAPFLFQNTMGLSPLEFGRLTFFIAGAICFSGIVNSQLVMRKGISFMVCTGVLFMIVGGLSLLLItqIYFIMISMTLFSAGAGFTFINAFAGAFHPFPQMAGTVGALYASMQDLSAALTSGFIAGIKGYGQYSLAIILLILGLSSLVAWYYL----
     228 UniRef50_B9Y630        Putative uncharacterized pr...   157     9e-37  1  12.3%  9:391  16:392     --------RLWTVPFILVLFVNALNGISSYMVNPAMPEFLVSK-GIPFALTGLISSLLSWVALAMRPFSGAMSDRFNKKKIMFV-SYLATAACMLGYALVQKSAAVIGVRILHGVAFAVSGTISMVFATSFVPEKRI--AEGISYIGIASLLGTMIGPQLGSSISQQLGMRNLFLTAGGLCLICLLMIVVIPYQFVEQKGKRAGKKITFSDFFAKELLIYVFLIGLFSFGNGIISYYLINFGEVR---GIANIALFFTVYSVAMLIMKPFVGKLQDARGIRVILIPAFLIYAVGMVLLANAYSLTPVLIAAVFKAIGQGNGSPAIQAESVKKLgeRNGVAISTCLIGQDLGNALGPIFASYVVNFSNYGSMFMLYALMLLGGLGIYIGTTR-
     229 UniRef50_Q64DZ9        Permeases of the major faci...   157     9e-37  1  16.9% 13:390  14:390     ------------KQLLLFSIVILLFCSFIGAVITVHPLYL-EQFVEHPALVGLIAAISSFAGLTFSLPIGTLSDREG-RKPMLIVSFGFVSVVLLAFFINTRLYPLILLQITFGVFMAPIWVVGEAFIKDISPTERRGEFR--SFFGTFANAGLLIGALIGGFLAEAFGIRSPYLFAAILLVVPLILVFGMKdnTNKNQAVMDFLPVLKEFLQQRELKLLALCTVSLYFWYAARWIFGPLFLHD-LGYSPYIIGVWLAVSVLPFLLFQIPIGKLSDKIGKSRIMYLGFLISAVSLIPLGFMSSISSLLATIFIVSIGTAFVEPLIEARVTDIVPKErgAYSGIFEFTKTLGLMLGPVGSAIFVYSFGISYAFIPAVVFFILTSALFVTTR--
     230 UniRef50_Q7M9C7        PUTATIVE EFFLUX PROTEIN n=1...   157     1e-36  1  13.2% 14:391  13:395     -------------LIIILGMMTSLAPLSIDMYLPALP-FLQGFFHADASAIQLTLASFFVAFALGQLFYGPLSDAYGRKKP-LYAGVILFIVASIGCVWAKSVEMLIFLRFLQALGACAGIVIARAIVSDLFRAEE--AAGIYSSMMMISGVAPILAPIIGGSILGTIGWEAIFYLLAFLGAIVLLSSFLGISETREPSKRSaaLESYSSLLHHRHYLTYTLTGGLAMAGLFAYIAGSPFLFIEHFGLSEQGYAILFGANAVGLVLGSQINARLLRRYSSTSILSRALLCQSLCALLLLvtHELFSFVIPLFGYITALGFILPNTTALAMAHFTSHAGSASALLGTIQFVLAGILTWGVGSLGATTPLMLGFLIAVCGWSAIAVFLMLKKR-
     231 UniRef50_C8WT67        Major facilitator superfami...   156     1e-36  1  11.8% 10:391   3:385     ---------AWRRTLVILWCANFCAAAGMSQIIPFIPLYLAELGLHTERSisWVFSAQFVTSFMFQPIWGSLADRYG-RKPMLLRAGFGMGVMTALMGLVGAPWQLLVLRLVNGVFSG-FIAMAISLQASVTPAENAGRA--LGTLQTGNIAGSLIGPLVGGLLAEWLGFRGCFFFTGAMLVLASLIVLLFVHEPKGARRARAKVRGSWKSLA--GLWPVFLGSFMTQLAMMSIEPIVTIFTRSIYHGatLAAGLVVATSGIANLIGTPTLGRVGDRVGQQRVLLLALFGAACAFLPQALAHALWLLLLGRFLLGLFVGGMLPSLQALVRKLAPekQATAYGLNSSATFFGNLVGPLIGGQVAAMYGIRSVFYVTMALLLLNAAVIAANQR-
     232 UniRef50_B1HXA6        Putative uncharacterized pr...   156     1e-36  1  12.8%  5:386   1:382     ----MKLSNLFHPLVWIILGGTVFTRIASFMAMPFLAIYLHNEIEATPLQIGLTIGIAPLISTVGGFFGGYLTDRFG-RKSVILITIIVWSLVFFGFATVHTVWLFILFNALNGLCRSFFEPSTQALMIDFTPADKRKR--LFSLRYTAINIAAVIGPIIGVYISQLASPSIPFMLTGIMYIIYAVFLFFVLNrqQKAVTQTKILHTFTILLTNRVLLSFIFGAILINIGYSQFDSTLPQVIELTVENGTKLYSLLISLNAAVVLLLQLPISIVSERFSSSATLLVGILFFAIGLFMFGFSSNYTLYIIAMIIFTIGEIFAFPTMNVMIDEIAPdqKATYLGAAQ-FKNLGGFIGPIIGGWLLTHY-MGAMFAIIAILVLCSCIFY------
     233 UniRef50_A4ING5        Multidrug-efflux transporte...   156     1e-36  1  15.6%  5:388   1:385     ----MQLLFKKRGAMLILMFNLLLIFIGIGLIIPIMPTFI-EQLGISGGTVGLLVAVFSLTQFLFSPVAGRMADAVGRKK-LIVSGMLLFAFSEWQFGYADHVFEMFFSRVIGGISAALTMPAVMAYAADITTNEER--AAGIGYINAAITMGFMIGPGIGGYMAEW-GIRVPFNCAAAVGVMAAVITALFLPESHSSASTGTVQKdqLAQVHRQPYFFSLLIIFALSFGLANFETIFSLFVDHRFGFSPKEIALIITIGSIGGPLVQLtfGWLLGHFGEQRVVSACLLLSALFIVLTLLASTWTMLLVATVLVFLAIDILRPAVSTQMSKIDETQQGYIAGLNSAFTSLGNIIGPAVAGVLFD-VDIRFPYILASVVLFLCFVLSLR----
     234 UniRef50_Q133Y5        Drug resistance transporter...   156     1e-36  1  13.5% 21:391  46:423     --------------------MNGAAPIALYIFVPALPI-LASDLGSDISVAQMTVSLYMVGLACSQLIMGPLSDRFG-RRPVLLGGLMLMVAASIGCIFAQTLPQLIAARFLQALGGASGMVISRAIIRDLYSRDRVG--GMISLVIAVMMIAQMLSPLFGGVIETALGWRAIFYVVTAGAIIVTVAIALALPETRrpTAPGGFRGDVGSLFRSRTFVGYVLCQVLASAIIFTFAGGGPYVVVTQMGRSSAEYGAWFASSGFAYLIGNLFCVRFSPRYSLDRLIWFGLALQIGGALllGYNQVPSWLFITHMVIMFGNASVMANAAAAAISVRPQAAGTASGLMGFTQMGFGALCSQFGAWLGGHFATPLPlaVMGLAIACASAMIFLVPR-
     235 UniRef50_B8HL77        Major facilitator superfami...   156     1e-36  1  16.0%  1:388   1:383     MPFLSFLPAPIRRNLAILLGSSLLFWCSLSSLLPIIPLY-AESLGGTPQQIGWITGAFAVGLITARPWLGQLADQR-SRKLVLLIGMGVAAIAPLGYLLAPSPNWLMLFRALHGISISAFATAYLTLVADFSPVQYRG--TILGYMTLGNPLGTAIGPAIGGLLLAHSSFAFVFMMAAGFGLAGFLSSSQVEPPPLPAISEADRGKPFWYSFDRAGLAIPTLAMLLVGMAFGVLHTFIALFIKSLEI--DLNPGIFYTAAAMGSFCVRILVGRIADRWGRGLFFTLSLSCYTLSMLLLSLAQNSFHFLLGGLVEGMSMGILIPIVSALIADRspQERGRLFGFCITGLDLGIAFAGPIFGFLGAWLSYRQMFSIATVLPGLAIVLFMT----
     236 UniRef50_C7PJW2        Major facilitator superfami...   156     1e-36  1  14.8%  6:390   4:385     -----SPGRVYTFHFIMLCLSNALFSASFNMLLPELPAYLTRMGGEDYK--GYILALFTLMAGLSRPFSGKLTDTIG-RVPVMIFGSLVCVVCSLLYPLVSSVGAFLLLRFFHGFSTGFKPTGTAAYVSDIVPATRRAEAM--GMVGLFSTIGLALGPAIGGYISTQWNIQVMFQISAVFALLSVVILVGGMRETLADKqrLSTLRISKSEIFEPLVLAPVIVTFLTYLSYGALFTIIPDF---SSHLGIQNKGLFFTFFTAASIGIRLLAGKVSDKYGRVPILKISSFTMAIAVFVLAVAHTPAMMLTAAIIYGVSVGLNSPAITAWTIDlhPQFKGRALASMYIAMEAGIGLGAYLSAFIYHNDtfALTFYCTAVVTLLASVYLLFIY--
     237 UniRef50_B5XRH7        Transporter, major facilita...   156     1e-36  1  11.1%  1:386   1:383     MTIAVSRTAGLPAAVYALSVGSFGIGTTEFVIMGLL-LDVAHDFHISITLAAWSITAYACGVVIGAPLLTPLLSRY-PKKPALLFLMILFSIGNLGCGIAGNMTMLIIFRVITALAHASFFGISSVYAAELAPVDKR--ASAVSAVFLGATLANILGVPLGAWVGQYLGWRYTFFMVTLIGILSALAVIALVPGRQAQPAVQSRIRDELKVLRHPTVLRSLLITALGFSGVFAAFTYIAPMLKTVTGMSEHLIPPVLVLFGVGMVAGNHLGGRLTDGGVRRALLLTLALLIVVLCLFPFAIQTLPGACAAVFLLGAAMFSTIPPLQMQALDSSETGKSMVSSCNIAAFNLGNAAGAWFGGLLLTAgsLSHIPLAGACLTASGFVIA------
     238 UniRef50_C9M8D4        Major facilitator superfami...   156     1e-36  1  14.1% 12:387  17:390     -----------WGLLFVLSMSLCICMLGIGIVNPLLPLYAVR-MGAGGAFLGAVMGAFSLSRMTATFFSGPMADRF-PRRTLMLGGLSLYAAASVGYIFASKAWHLMAVRLLNGVGSAFVIPVAMAIGAEVAPPGKEGR--FFGTMQMATYLGVGLGPLLSGVTYEHWGVKAPFLVMFVSCSVAVVASLIKVPKGIGDSShkSLWRSMGGILADPVLFRVMLYQLMTTFGRGMTMLLIP-ILANRHGLSVSQIGYLVAGVSISSALLQQVSGWLADRISKRWLAVVSCILTGSVLLALPLPRTFAGFMLVSVLYGGANAIGIPATLAFVSQRShyGSGVSMGAYNIAFGIGMTAGPILGGSLESHGMEGTAVAIVAACLAVVSAVMA-----
     239 UniRef50_A6G4P6        Multidrug resistance protei...   156     1e-36  1  14.2%  5:390  13:436     ----PMSEADKRRALMTVAFTLFLDLAGFGIILPILPYY-AESMDASATMVALLSTTFSAAQFVMSPVLGRISDRYG-RRPIMLVSIAGSALAALVLGFATALWLVFVARLVAGSSKA-NVSTAHAYVADLVPQEQR--AKYMGMMGAAMGLGFVFGPGIGGMLALH-SPHMPFFVSAGLSAVNFLMAAKWLPETHFPQAKRDTGHAPAAslRGTHMAWLIAIAFGFYISFAGMESTMALFTEHLFDWGAPETGVFMTFIGVNMVIFqlLVGRAVDRMGEAKTLALGLLCLAIGLPLlaSTSSLVFMALGGVLLSGGNGLSNATLSALVSRvsPEEQGWNMGLKESASSLARVCGPALAGPLFQHVDEGAPMLLAGLVALINFKVALFLR--
     240 UniRef50_C1MAF1        Major facilitator transport...   156     1e-36  1  10.6%  5:390  12:416     ----PKTWKARYTVLTLIWLAWLLSFLDRMVMSVSLP-YIGKDLNLDTTQQGLIISAFFIGYAAFQIPGGLLADKFGSRK-IMAIGIAWWSVFTSLTGAVMTLPLMLAVRFFFGIGEGCFPSASWKMISTYFPSKERGRAT--AIQSTVNTLGPALAVVVAASIIGAFGWHMVFIVLGIPGLFIAAGIYLFTRDNPKDHpqNTSAIAFKDVLKMPVLWQMASIWFLFDITFWGFSTWLPSYLITVREFSLAKTGVMAAIPFLFGAGGTLLGGYCSDKFkrKTLYVVTSVIAAGFLYLTFSVSSADMAVVYQCVSALFMFFAMATFWGILMDTIPSnmGRASGIVNFGGQMAGVVSAPIIGWLIQSSgyNSAFIFMIAALLCSAVVTLTVK--
     241 UniRef50_C6B457        Major facilitator superfami...   156     1e-36  1  15.8% 10:382  29:401     ---------AYRRASLALFLSGFSTFSLLYCVQPLLPIF-SQQFSVSPAESSLSLSLSTGFLAVAIVCAAAVSEGLG-RRSLMSISLVGAALLTIATAFAPNWHLLLVIRALQGLVLGGVPAVAMAYLAEEIDP--RGLGATMGLYVGGTAFGGMSGRVLTGIFAEYLTWRPALFLIGAIGLAPAIGFIALLPPSRNFVRRPghAKAWLGHLSNPALPFIFAIAFLAMGSFVTIYNYAGFRLVApyGLNQTELGLIFTVY-LFGIGASSIGGLLGDRIGHFSVLLFGLALTAAGSALTLFA-SLPVIILGIIVLTTGFFMSHSIASGLVGKLAHGTKGHASSLYMLAYYVGSSLMGSAGGWFFAVEGWVAVVIFTLAMLGLA----------
     242 UniRef50_B4F1R5        MFS-family transporter n=5 ...   156     2e-36  1  10.2%  9:391  14:406     --------PYWVKLTIIFFFGWIALYGSRAIVGPLM-VNIGAEFDLTKAQLGSIMSIFFIGYTALNIPSGIIGDYLGKKK-VLVTGVVLFGGFTIIAGMMPTYVTFMFAWVMVGVFQGFYYGPQYGLSSEAIPKHRITLGS--AIINSGMAFGLSIGYYISSISVGEMgwRAPFYIIGVPIIIIGLMMLWIIKdtAPNAPKQKTKLTFKDLFGNRNINLAYITIFCSIYGFFVLVTWLPYYLETERGITGTQISTIASLMPWFAIPGSLLFSWFSDKLGRRkvLLIMLPLSLVAILAVPMSDSMPVLIGALILYGigKISTNPVLVAVVADNSPRHagTSFGVYNCIGMLGSVFAPTLTGFLSDKTgmDSGFYFAAILICIGIVASLFIKE-
     243 UniRef50_D1X4W1        Drug resistance transporter...   156     2e-36  1  14.8%  6:390  62:455     -----TARRTGLLVTLVLGGLTALPPLSMDMYLPALPA-VTDSLSAPAATVQLTLTACLAGMALGQLVVGPMSDRWGRRNPLLL-GMVVYVLATAICALAPTAELLIGFRLLQGLAGAAGIVIARAVVRDLYDG--VEMARFFSTLMLISGVAPVIAPVIGGQVLRITDWRGIFVVLTAVGLVLTLVVWKWLHETLPPADRHtaLRTMRGLLADRVFTGYMVAGGLAFAVLFAYIAASPFVVQEIYGASPQTFSLLFGLNSIGLITVGQINGKlvGRISLDKVLGFGLAVIVLAAVALLLMtgLVPVAAGLFVLMSAMGLAMPNTNAQALMRTKHAAGSASALLGTSSFLIGAVASPLVGIAGEDTAVPMAVVQVVCAVAAVGCFLLLCR--
     244 UniRef50_P33026        Sugar efflux transporter B ...   156     2e-36  1  50.4%  2:392   4:393     -SPAVSSAKSFDLTSTAFLIVAFLTGIAGALQTPTLSIFLTDEVHARPAMVGFFFTGSAVIGILVSQFLAGRSDKRGDRKSLIVFCCLLGVLACTLFAWNRNYFVLLFVGVFLSSFGSTANPQMFALAREHADKTGREAVMFSSFLRAQVSLAWVIGPPLAYALAMGFSFTVMYLSAAVAFIVCGVMVWLFLPSMRKELPLATGTIEAPR-RNRRDTLLLFVICTLMWGSNSLYIINMPLFIINELHLPEKLAGVMMGTAAGLEIPTMLIAGYFAKRLGKRFLMRVAAVGGVCFYAGMLMAHSPVILLGLQLLNAIFIGILGGIGMLYFQDLMPGQAGSATTLYTNTSRVGWIIAGSVAGIVAEIWNYHAVFWFAMVMIIATLFCLLRIKDV
     245 UniRef50_Q796Q1        Uncharacterized MFS-type tr...   156     2e-36  1  13.5%  4:389   1:394     ---MESSKQNNGMTIVAIGSIPLILTLGNSMLIPILPK-MKSELHLSQFQVSLVITVFSLIAAFAIPIVGYLADRF-SRKVIIIPCLILYGAGGLLAGFAAGfpWVMAGRALQGIGAAGTGPIAMALTGDLFKGAQESK--VLGLVEASNGMGKVLSPIIGSLIALLV-WYGAFFAFPVFCIISIVLTWIFIKEKKKEKEpgQYAKGLLSVFKhrWLFTAYLAGATCLFTLFGILFYLSDVLEKTYDTDGVKKGLILAIPLLVMCVTSYTTGSKIGQklMKKLIVLGLAFMTVSYAALSFIENLVLFISVLVLSSIGSGLVLPCVNSFITGAVgeRRGFVTSLYGSVRFLGVAIGPPIFGRLMQWSRPGMFLSIAGLTLVVGILVMMLI---
     246 UniRef50_Q3JW60        Major facilitator family tr...   156     2e-36  1  14.7%  3:390 102:484     --TSTRMSAPELRATTSLAAIFALRMLGLFMIMPVFSVYAKTIPGgnVVLVGIALGAYGVTQSLLYIFYGWASDKFG-RKPVIAAGLLIFALGSFVAAFAHDITWIIVGRVIQGM--GAVSSAVLAFIADLTSEHNRTKAMAM--VGGSIGMSFAVAIVGAPIVFHWVGMSGLFAIVGALSVAAIGVVLWVVPDAPRPVHVPAP---FAEVLHNVELLRLNFGVLVLHATQTALFLVVPRLLVD-GGLPVASHWQVYLPVMGLAFVMMVPAIIVAEKQGrkPVLLGGIAAILIGQLLLGVATHTILIVAalFVYFLGFNILEASQPSLVSKLAPGSrgAATGVYNTTQSIGLALGGVVGGVLLKHGGPDTVFFACSALVAVWLIIAAGMK--
     247 UniRef50_UPI0001788EDD major facilitator superfami...   155     2e-36  1  14.4%  7:388   1:380     ------MTRQQKFLTMNLFLLTFILGTSEFLMVGLLSE-VATDMKIAISTAGFLVTAFAFTFAICTPVFTALFSRF-SKFPLILVLLSIFIVGNIVTALSGSYGMLLVSRIITAVVTGVLIALAMSVASQVMPPEKRG--PVISIIFTGFTVASVLGVPLGTFIGQWGGWHLAYWFTTLLGIISLIASIATIPRGLK--GKHSSLTKQLRLLAYPRIVLAFAIMMLSIAATYSIYTYLAPLLQDVLFVPARYISLIFLLYGVVSIFSTLIGGKLAVGDGMKKMRYVLLAQAVILVSLYFTSGSLVGGLVSISFMALVVYLMNSTMQLYFIDYapEARDLASSLTSVANNVGIAIGSALGGIITTNMKLIDLSWSGGIVAVLAAVLAWV----
     248 UniRef50_P94577        Uncharacterized MFS-type tr...   155     2e-36  1  14.3%  4:388   1:380     ---MKKADAIWTKDFIMVLLVNLFVFVFFYTFLTVLPIYTLQELGGTESQGGLLISLFLLSAIITRPFSGAIVERFGKKR-MAIVSMALFALSSFLYMPIHNFSLLLGLRFFQGIWFSILTTVTGAIAADIIPAKRRGEG--LGYFAMSMNLAMAIGPFLGLNLMRVVSF-PVFFTAFALFMVAGLLVSFLIKVPQSKDSGTTVFRFAFSDMFEKGALKIATVGLFISFCYSTVTSYLSVFAKSVDLSDIS--GYFFVCFAVTMMIARPFTGKLFDKVGPGIVIYPSILIFSVGLCMLSFTHSGLMLLLSGAVIGLGYGSIVPCMQTLAIQKSPAHrgFATATFFTFFDSGIAVGSYVFGLFVASAGFSAIYLTAGLFVLIALLLYTW----
     249 UniRef50_Q8CX74        Multidrug resistance protei...   155     2e-36  1  16.6% 18:390   1:383     -----------------MWLANFFISGSMTMVVPFISLYIESMGDFSetWSGLTFAVTFITAFIFSPIWGRIGDRYGRKK-IMIASAFGIGFSVFLMGFADTVWQLFLLRLFMGIVTG-FIPMSQAFIATQTPKE--VAGKVLGTLQTGTITGSLMGPLLGGALADAFGYTSTFKWVAITIFISGLLVLFGVKELKMktKKYSRKEVLQHILQKPVLFVVMLLSALVQIAHFSIQPILSLFVAEIHgnLAFFAGIAFSAAGLGNLLMARRWGIIGDNHGYVKILIILLFAAGFVYLPGIFVTNIWQLVILRFLLGLSIGGIVPLRIAYIRQEApsMQGEVLGYNTSLRFLGNIIGPALGGTIAASFGFSAVFIITSMLLILSGMIMLYVW--
     250 UniRef50_A8ZZ81        Major facilitator superfami...   155     2e-36  1  16.1%  4:388   1:384     ---METMTTGDKKIFAAIFVSIFGAVMGVGIVVPLLPVY-AQNLGASGFYIGLIFAAFSLSRTFLLPLFGSLSDRTG-RKPYITIGLFGYALVSVAFIYSDTVGGLIWLRFLQGIASAMIMPVAQAYIGDITPKNR--EGFTMGLFNLSMFTSLSIGPLLGGVINDLAGLDAAFAGMGVLSLAACLASLFLLPPVREEhtRGSVPAKWSLLLTDRFLYGLFCLRFVYVFCIGTIWCFLPVFASSI-GLSSSRIGVLIMLGVFVSGLLQMPMGMLADRTDQKRMAICGGLMTAGAMVVYTWAVDFWGLFAASVAFGIGGGVAMPPLMAMAVVKGGETrgSVMSLLTVAHSMGMLFGAAIGGVAMDFFSLRQAFPFAGLIMVAGVVIFAV----
     251 UniRef50_Q7UXZ3        Tetracycline-efflux transpo...   155     2e-36  1  14.9% 34:389  83:454     ---------------------------------PVLPELIKEFVGGDTSRASWYVGvySLMQFFFAPVLGALSDRFG-RRPVILASLFGLGVDFIVTGLAPTVGWLFVGRIVAGV-MGASFSTANAYIADVSTQE--TRARNFGLVGMMFGLGFIIGPALGGVLGG-IHIRLPFFVAAGLSLVNWLYGFFVLPESLPPEKRGspLGTIARLRNYPMIAGLAVAFMFSSLAQRGLENVWVLSMGYRFGWNEVTNGLTLALVGLMAAIVQGGMVrtIKRLGERRTAVLGTCVSCLAFLGYGLASQGW-MIPCIVVFGSLAGLAGPAIQSLVarVSPEEQGKVQGALTSLISLTNIPAPLLfgLLGYFTspGAPFVFGSLLLAIAVIVLARV---
     252 UniRef50_A7GX73        Drug resistance transporter...   155     2e-36  1  11.5%  4:384   1:381     ---MRKKHNSRLFLLLFLGALSAFGPFVTDLYLPALPS-ITTWFDTSVSATQLTLSTSMAGLAIGQLIIGPISDKFGRKRP-LTISLIIYTISTICIFFAQSIEIFIFMRVIQGLASAGSLVISRAVVSDLYSGHEMTK--FFGLMMVINGIAPIISPIGGSFLLEFTDWRGIFVVLSIIGVLLFVANFNFKESLDEPRRIKAPlgVYKQILINKTFMLFVAIQTCALGTMFAYIACSSFIFQDFYGLSSMSYSVCFASNGLALVIGSRTASLLKDKMALRIGVYGIFASSIVVGLILTAKFHVYAVIVAFFIMLLFIGFILPTASSLAMNSARRYAGSASAVLGFCPFFLGGIVSPLVGLGDIFYSSSLTMLVCTLLALTAFF--------
     253 UniRef50_B4RKU4        Drug resistance translocase...   155     2e-36  1  13.4%  7:388  20:403     ------MFPHEWRASTTLSGVYALRMLGMFLVLPVLAIYAASLPGanKTLVGLAMGIYGLTQALLQLPLGIASDKFGRKKTIYV-GLVVFAAGSFLAAAADTLPMLVAARAIQG--AGAVSAAVTALLADLTRDGVRTRAMAM--IGLSIGLTFSVSLVVAPMIADVAGVRGLFMLTGILTVISIGVVAWMTPDpkLHEDTQAQPSRIGEVLKNRRLLTLDFGIFALHAAQMALFTALP-FAMTRLGLEKIQHWKVYLPSTITGLVVMVPLIIVGerNKLKQVFVLGIVCIAAalGLLSGMHSIWLITAYLVVYFIGFNVLEASLPSMVSKIApdLKGTAMGVYNTMQSLGLFAGGAAGGLLFQKYGFAGVFAFCSILMLLWLVIAVL----
     254 UniRef50_C4DP25        Arabinose efflux permease f...   155     2e-36  1  13.4%  1:389   1:388     MEQSPATVTSLRAVVPTVYLPAAIYSVGQGAIAPVV-VLSALELGASTGVAAFIGALSGVGMLIGDVPAGAFAARVGDRRAML-WATVLVGVALVGCVVAPSVAVLAVAIAVVGMCNSVWMLARHSYLTEVVPLRLRGRAM--SVLGGVQRVGRFLGPFIGAAAMQVWdgAYGVYVVAAVGAAVAVACVRDPQPAEPADEPVAPSGSSRTLREHLPVFRTLGVAVMILGAVRAANNVVIPLWGAHIELDATTTSLIFGIAGAVEMLLFYPAGSIMDRFGRRAIALPCLGIMAVALAWMPFTSGFATLLAASILLGIGNGVGSGIVMTLGADAAPagRAEFLGGWRLCVDLGFAMGPAVIGGVTAAASLGPAILVMAGLSVAGAGAMARW---
     255 UniRef50_C7ILS8        Major facilitator superfami...   155     2e-36  1  15.2%  8:389   6:384     -------TTELKKKIPLFYLTTVLYWFSLYTYVPTLPIYV-RSIGASYKMVGLIIGSYGFTQMLFRIPIGIISDRLNKRKVFIIGALLIALFSGLGLWFFDSPSMVLISRGLSGVSAAGWVVFIIQYTS-YFDVKDTPRA--IGVINAFNSTGIMLAIILGGIFSNYLGLKISFLL-AVFGAILGLIFSIYIYEPNNLKSTSVKISDLISITKDKNLLKISFLGVLSQFIIFATVYGFTPILAKQIGANNFQISILTTLSTMPGIVSSIlsSFFAKRFGERKTIIWGFILTSIFCTVIPYIKNISVLYITQVFGGFAWGGVFPLLMGiiRNIETDKRATAMGFFQAVYGLGMFVGPLVIGFLSDFAGLTGGFWVTGFVGLMAALFSMFF---
     256 UniRef50_B2HY14        Permease of the major facil...   155     2e-36  1  14.6%  1:391   1:396     MSEQTAQRQYSIGWIMLLALLTALGPLSIDMYLPALPQ-MAHDFGVSTQMVANTLPAYFFGLAIGQLVYGPLSDRIGRKKP-LYFGLALYAVASLFCVLATNEWSLIAARILQALGGCVGVVMARAAIRDRLDVQ--GSAQAFSSMMIVMGLAPILAPMIGAWILIWFPWQAIFIALSIVGAICWLCVHFFFKETLAVDKRlqVATLYGAIFKDASFRLPMFAGCLTGAALFCYISSAPAVFMDQYGLNQQEFAYVFGLNAFGIMLMSSLNKHLTTRVEITKRLKAGSMvsIVLIAGLISAAPLWLVMLGLFLAISGIGLTGPNAMALAMSKQGARAGTASAIMGSMQFACGLLGGVLLNFLIWSASLN-MGVMMVLFTLSGFIVVLKAIR-
     257 UniRef50_A3IDX7        Chloramphenicol resistance ...   155     2e-36  1  17.1%  6:368   7:367     -----TLSKKHKILAFTLILLTFVMGTSEFVIVGLLTE-VSTSIGISIATAGTLVSGFAIAYAIGTPIVTGFVSRF-PKYPLMLVLIAIFILGNIISALSSTYVVLMGSRITTAVVSGVLTALSMSIANTVIPKEKRS--TIIASIFAGFTIANVMGVPLGTMIGQWSNWHMTFWLTAFLGGVAFIISMFVLP--KRLSGENGSLSDQLSLLKHPKVILAFLIPIFTIAGTYTIYTFITPILENKLGVPTKYIAIVLLIYGFFSIFSNVLAGKIAQRNGLSKLRYIFIIQAFILFSFYFTMSSLWLGILSILLMAVILYAVNATIQLYFMDLapSAKDFASSLTPVAVNVGIALGAAIGGFVINSGSL------------------------
     258 UniRef50_P31436        Sugar efflux transporter C ...   155     2e-36  1  46.3%  2:392   3:394     -KTATTPSKILDLTAAAFLLVAFLTGIAGALQTPTLSIFLADELKARPIMVGFFFTGSAIMGILVSQFLARHSDKQGDRKLLILLCCLFGVLACTLFAWNRNYFILLSTGVLLSSFASTANPQMFALAREHADRTGRETVMFSTFLRAQISLAWVIGPPLAYELAMGFSFKVMYLTAAIAFVVCGLIVWLFLPSIQRnpVVTQPVEILPSTHRKRDTRLLFVVCSMMWAANNLYMINMPLFIIDELHLTDKLTGEMIGIAAGLEIPMMLIAGYYMKRIGKRLLMLIAIVSGMCFYASVLMATTPAVELELQILNAIFLGILCGIGMLYFQDLMPEKIGSATTLYANTSRVGWIIAGSVDGIMVEIWSYHALFWLAIGMLGIAMICLLFIKDI
     259 UniRef50_B9KZL8        Transporter, major facilita...   155     2e-36  1  17.7% 10:388  19:402     ---------RINRVLVWISAIVGINQLGFGSIVPVVPLY-AQAYGVSEALIGLAIAVYGLARFTSSAPAGWIADRAGRRWSLFAGGLA-TVLGNILCALAPSYPIFLVGRFVAGSGASMVLTSGQIVLADITEPATRGRTM--AIYQAVFLFAVGFGPIPGGFLAQYGGLSAPFWVYGFVGAIVAVLALWRLPETRPAGAREParRQLVSVLRHRPLVLIGLVTFGNFFatGALFTLVPLRAEREIGLSPSQIGFGLAAVSVVSLVMAYPAGVLLDTFGRKVVIAPATLFSGLGLVGFAFASSYPWFLLACVTWALASGIGGGAPAAYAADVspGMTAAAMSAYRMLSELGYVVGPTVLGLAAETIGIRATLVATAVLIVGLGGLFWL----
     260 UniRef50_C3PFK9        High-affinity glucose trans...   155     2e-36  1  16.7%  1:390   1:390     MKNTAEPQVKIPREIWVMVTAGFIIALGYGLIAPLLPQFIV-SFDVSMAAAGLVVSVFSASRLVFAPAAGFLIDRVGTRR-VYVTGLFTVAVTTGLVGVAQEYWQIVALRTIAGIGSTMFTVAAMGLIVRLAPPSIRGR--CSATYATSFLLGNVIGPLVGASL-SFLGFRWPFFIYGVGVAIAALVVWILMPSVNEADERRRHLTPMreAWEDTAYRAVLTSNFAQGWINMGvvAVLPLFAAAIFANGASTSGVALAAFAAGNAIVLQFSGSWSDRVGRRPLIVAGLVGSALFVGTLGLATNIVSLLILSALSGAASGLIAPSQQAAVADIVGSKrgQVLSTFQMAGDFGQILGPIVIGLLADKYGFETAFGFCAVVAAAGVVAWIFGR--
     261 UniRef50_B1HYQ3        Quinolone resistance protei...   155     2e-36  1  13.5%  5:390   1:383     ----MKAGNFMKKAILLLMSVQFLVYLGFGIIIPVLPEVIVQQ-NWDNLHVGGLLTVYSLASFFTAPLWGMLSDKVGRKQLILTGLIGFSLSFVIFSLFIDNLAILYVSRIVGGLFSGALYTAVTGFIADMSSEETRNK--YMGFMGMSIGLGFIFGPAIGGMLG-HISLQLPFIASAILIGLLFIYASFVlpEKRKDSNKRAIVPKGAGKMLQYRVRYLFMFSFLVTFMLAGVEATFQLFQIEKIQITPLQIGYLFMFSGFVDAAIQGGVVRRIKNGSETTWLIGAQIVTAVGMLLFTLTANLFIAGLALCVFTAGNALARTCVVSLSSKESGGQYGTAAGLSYSMDNLGRILGPLFFTWLFTMH-ASLGYYTSAVIAILSISLIFIFK--
     262 UniRef50_B1HYF6        Multidrug-efflux transporte...   155     2e-36  1  14.8% 14:357  12:357     -------------VLYALSISTFFASLNQNIYTPIIPL-IRDSFEVSISWVNFTVSSFIFIIAVIQIVLGTVVDHQNKKR-LLLISLVLMGVSAVICAYTNSFILFTLFRMIQAIGAGIIPLVAISMIAQLFEGEARGSAM--GTYQILLTLAPAVSPVVGGFIGEFFGYEGIFLFLLFMAVSLLMFIVYLLPSEKqeKQSKGFIHSYKAIFSHYIGTSIMTVSFLVFFIYFAILVYLPVLLHDHYHVSLQLIGLLYLPLTVSMIVGSILFKRLQKKISLNTLFILLLIVMPLQVVLFGvaQSLVALSIILFGYGIMVGFSAPLFSTLISNEYSEHRGTALGVFNFVRYSGMAIGGM-----------------------------------
     263 UniRef50_Q21M22        Major facilitator superfami...   155     3e-36  1  16.4% 13:372  29:390     ------------RAVSSLALLYAFRMLGLFMVLPILVLYAGDYPGATPFTLGLALGIYGLTQAVFQIPLGLLSDFIG-RKPVIIAGLLVFCAGSVLAGTAESVEWLIIGRALQG--SGAIASTIMAMVADLTSEQNRTKAM--AAIGASIGLSFSLAMILGPTVGAFGGLSVVFYFSAVLALIGVCIVIFLVPRPPQVGHSHRDSGAVPEllKNTELLRLNFGIFTLHALLMACFLAIPVVVESSLGIPRGKHWQVYLPMLAIALGVVLPLIMVAERNRkkPVFLFAIAVLVVSQASLAVVpaGWPFLLLMLLFFVAFNLLEACLPSLVSKLApgAKGTAMGVYSTSQFLGAFIGGSVGGYIFTLWGMDGLF--------------------
     264 UniRef50_Q02YV3        Arabinose efflux permease n...   155     3e-36  1  16.9% 14:386   8:377     -------------TVTGLFLGVFVVGVDSFIITPLLPQ-IAQDFHATISQTTLGVTTYALCEMIGAPLFGPLGDRFSKRK-LLITGMSLFLGANLLCAIATNLATFYIYRAAAGLGAALFLPNVWAFIGSYFNGQLMNKIMGIS--MAGLSLSVAVGVPLGSFLSQLSNWHSAFWASAVLTVFSLILIIAIIPNTTAQNQKISYLVNFRNVFKAKNVIHTLLLDFFWMFGFYLVYTFLGSFLAEHFHFSSGKAGLVFLIYGTANFIAASTGGVIMNKLGRVKSILfaCASLSFTLALGLFSNSILGLIIFLILLAFSMGWGVTAISAYLVTLSTQNRSTLMSFNSSALYLGLTLASIVGGLIYQGLGFWILGIISSFSYAIVILLI------
     265 UniRef50_UPI0001788632 major facilitator superfami...   155     3e-36  1  18.4%  1:376   1:376     MNDINTKQPLWTKEFITLMVSNLFLFLTLQMMLTTLPAYAKEAFTASPLQVSLITSLFAFSAIASRFVSSKALEK-GKLRLLLYVGLLISLAATLGYYWASGIAFLLLMRILFGIGFGMTSTSFPTMASDVIPIKRLGEGM--GYFGLSTTLAMSIGPMIGLTLLQSGGFTPLVFITVIINLLIFPLAYLlkRNAERPAAVQPRVEDKPKGSFNKKLILPSILNFLMSITYGGLLSFMALFGAEAHLRNPQ---YFFLFNAIAIILVRPFSGRIYDRYGHKALVIPAAILMVSGLLLLTFATSTGSMLLSALCYGIGFGAMQPSIQTwiQEVHPLQRGMANGMFFNSLDFGVAIGSIALGAIAKSTSYAIMYRYSA----------------
     266 UniRef50_A1U797        Drug resistance transporter...   155     3e-36  1  15.3% 13:391   8:392     ------------WTTILLAAAVALGPLAVDMYLPALPQ-IGADFHAGTDQVQLTLSVYLAGFAIAQLICGPLADRFG-RKPIMIGGFLLFTVASIGCAMANNIETLQLFRFLQALGGSAGPVLGRAIIRDIYTP--REAAKILALLASIMALAPAVAPTLGGLMVGGLSWHWIFIAMGGYALVMAAVTAFGIPEPLKPEYRQPLraNYRRISTDASFIGYTLTNAAIYGGLFAFLSGASFVLIDVLGVQPEHFGFYFAAIVVGYIAGNLGSIRLARYLGPDQILFYGLITALAGGAIMALLasPWAVMIPQAIFMAGTGLVLPQCMAGALANFPTMAGSASALFGFTQMTAAAIAGAIVGALHNGTPMVMATVIAACAGLAMIGYLLLVQR-
     267 UniRef50_A8U143        Permease of the major facil...   155     3e-36  1  16.3%  6:391   5:396     -----SFHATRPGSIALLTFMVALNQMSMGLYLPSMPT-MAGALGTSVGQVQLTLTVFIAGFAVSQLVWGPVTDRFGRRPALLV-GLACFTAASVACAFAETIEQLIVYRFFQALGACAGQVVSRSIVRDTTEGAE--SAKVMSYIALAMSLSPAVTPSIGGQLHAFFGWRSNFVLLAAIGLILAAITVVRLPETTRRKVpvPMLRNYGSLLRDRRYVGYILMIGGMFGCLMAYQTGSPFVLMTELGWSPQAYGLLILFNVFGFLTGSLIAARIAPRFGIPRMVRLSSIVVLVSGFLLLAFpsTVAVIAPMMLFLFGMGIGIPSAMAGTLQGFPYIAGSASALMGFSQMGVGVLTSLAVSRIDGDHHLVMGAVFAASGLMCFLSQALVLPR-
     268 UniRef50_A0KDI0        Major facilitator superfami...   155     3e-36  1  16.5% 12:392  64:438     -----------WWGVLALALTAFIFNTTEFVPVALLSA-IGDSLQMQPTAVGLMLTIYAWAVAVVSLPLTFVTRHVERRK-LLSVALLVFIGSHVVTGVAWNFTVLMIGRLGIACAHAVFWSISIPLAVRLAPSDRKSRA--LSLIAMGSAIAMVAGIPLGRVIGEAFGWRVTFLIIAGTAGIALLLLRATL--PLLPSQGAGSLSSIGVFLRKPALVALYAITVLVVSAHFTSYTYIEPFVQSINHASNSRITYVLILFGIAGLPAAVCFNRVYPHRPDDFLLASIVALSGCLLILFPCALNIVTLSVHTLVWGGAIVCFGLAMQAWVLKLAPDATDLAVSIYSGLYNVGIGAGALLGNHIAGDFGLPWIGTFGGVVAIFAAGVAWAALRL
     269 UniRef50_Q0AX92        Multidrug-efflux transporte...   155     3e-36  1  15.6% 33:390   1:357     --------------------------------MPILPYY-AESMGASAFQLGLLMTVYALCQFIFAPFWGSYSDRVG-RKPVLLVGMFGFTLTFFIFALANSLWVLFVARIAGGALSCATVPTAMAVMGDTSSPEKRGA--SMGMVGASMGMGMIFGPAIGSGLA-HISLAAPFVMAGSLSVVICFCILFLVKESLPVEDRVSEAQKIDRAPLLkpLAFLFTAMFLASMAEATNMGTFALFAEGKLGFGPTSMGLIFSCAGLASVLVqfVVGRAINKWGEEKTSGAGIILMASSFALFLQAKSLLELIIYMGIFSAGTGLIRPSISAATSKRTTGSQGTAMGVLQGYDSLGRVIGPSLGGYLLDM-NLSYAYFSAIFFSGLAFLTLLFNR--
     270 UniRef50_A6CRK0        Quinolone resistence NorA p...   155     3e-36  1  16.6%  6:390   4:384     -----TRPALWTRNFISISISNFFLFMTFYFLLVTIPIYVVDYLDGEKSEAGLMITVFLISAIIIRPFTGRWIERFGSKR-ILLCSMFVFFVSALLYFAADSVGFLLIVRFLHGIGFGMATTAAGSIAAATVPGSRRGEGM--GYFILSSNFAMVIGPFLGLTALHQWGVSTMLIIAGAAAFAGLLSGLSITMSNEKKEDGRPAQLSWKDAIFEGKAIPVALAGAFFAIVYSAILSFVSVYAGE-LGLS-HAASYFFVVYAAVLLLSRPLTGKWYDIHGPNFIVYPAILLFAVGMIVLGTANSAILFLTAAAFAGLGWGTLFPTFQTIAIQAspKRAAMATATFLSIFDIGIGLGSFLVGLAAAKISLGDLYTYSSLYVLAGLLLYYFLQ--
     271 UniRef50_Q1N2F2        Major facilitator family tr...   155     3e-36  1  15.7%  7:375   1:369     ------MTPTEKRSVSTLALIYALRMFGLFMVLPVLALYAADYEGASAALVGVAIGAYGLTQACLQLPFGMWSDRIG-RKPVILMGLALFTLGSLIAGLADSIVWLIVGRALQG--AGAIASTLMALMTDLTREENRTKAM--ASIGASIGLAFTLAMVAGPVLSNWLGMSGLFLMTAVLSIMAMILLVRAVPTPvrSRESRAFLHQLADVFKDRQIMRLSFGILVLHAVLVACFVAMPVLLEQS-GLNKQAHWKVYLPIMITAFMAMVPFIIIGEKKQKMKPVLAMAVGLLLVSVLFMWQAGlwALVAALWLFFVSFNILEASLPSLVSKFAPAgkGSAMGIYSTCQFLGAFIGGALGGVITETWGLSAVFVAT-----------------
     272 UniRef50_Q2IM75        Major facilitator superfami...   155     3e-36  1  14.7% 12:391   4:381     -----------RSALAILFVIVFIDLLGFGMVIPVMALY-AERLGAPDAQIGWLMTGYSAMQFVFTPIWGRLSDRHG-RRPLLLVSIVMTAVGFLGYALAPSFAWLLVSRLFAGAATA-NIAIAQAYIADVTPPE--GRARGMGLIGAAFGLGFVLGPAIGGLL-SAISLSAPGYAAAALAAVNGVAAFFVLPEPAAhaERRPHLEALLGGVSRPGIRRLILIYFIAILAFSGMEATFALLAVHRYGLDQRQVSYVFALIGVVATVVqgLIGPLSRRFGERALLVAGLLLQAAALAALPYAGSVAGLLVATVPLAFGSSLTTPSLTSLISRSAreDQGGTLGIGQSAAALGRIAGPISATHAYSQLWFAAPYLGGATLMLAGAAVGSTLRR-
     273 UniRef50_A3IH26        Multidrug resistance protei...   155     4e-36  1  16.2%  1:390   1:406     MKQIRRQPFDLPPIFWLVTAIAFINSVSFTIVIPLLYPY-AKQFGLSDFQASLLTTAFALSQFLGTPILGSLSDRLG-RKSILIVSLAGTVVANMVASFATVAWLLYAARVLDGL-TGGNTSVARAVISDITDASQRTKA--FGIFSATFRLGFVVGPFLSYlfAGISSLGMSFVVSAAIASIALLLTIVFLPEKRSRRDPHSGTQKEKFRLSwpKLGQLFILTFLSGSTFTIFTFAFQPFFLNVLNQNTKRLAIMFAIVGMLGFISQVFAlpLSKRFNLINIIAVTLAIRGLTFILMPAFPTFTAFVIILSIFALVNSFPMPLitVLSLNTSPQKQGEVLGINAAYLSIANAIGPMISGLLVS-FDYQTPLWITGGLTLLVAGFATHLK--
     274 UniRef50_Q26IA3        Drug resistance transporter...   155     4e-36  1  14.9% 10:385  15:396     ---------RKTSVILVLGTLIAIGPFSIDAYLPAF-KQIAGDFKVETSAIGFTLTTYFIGIGLGQLAYGPLMDRYGRRRP-LIAGLILYITTSVLSAYAWDVSSLATLRFFTALGACAGMVASKAIVRDLFDDDKV--AEVLSTLMLIMGIAPIIAPTIGGFIIEHYHWDMIFYGLAGFAALMLFNVIFILPESSKPNppVPVLKEYWTIYKDKAFFLFSTARGFVIGALLGYVAAAPFIFLDFFNMAQSDFAIIFGSNAAGLIAGSQINRFLLRRFTTFQITYTISILLVVTTLLlfFEPEFWVVYPLLFLMMTFIGFQNPNVTALALQPFTVRAGSASAFVGAVSMIFGSFASWYVSRYVTVSVLPLALMLAGCALLGYAAI-------
     275 UniRef50_Q3M7N1        General substrate transport...   155     4e-36  1  18.6%  1:388   1:384     MKAFNTFDASLRLNLLILFTAGLLFWSSTATFLPTLPLYI-EDVGGSKQEIGIVMGGFAIGLLVFRPMLGRMADQNG-RKLLLLIGTIVATIAPFGYLAFKSIPLLMLVRVFHGISIAAFTTGYSALIADLAPIAIRGE--IISYMSLTAPIGLAIGPALGGYLQASIGYPILFLIASELAFVGLLGTIQVspPVPQGRQATEKDSNFWQLLSSPRVRVPTLVMLLIGIAIGAVHIFLPLFIKST--GVEFNAGLFFTIAAIGSFSLRVFAGKASDRFGRGLFITFGIMAYMLSSFLLWQANSAISFAIAAIAEGCGGGTMISMITTMMADRspQERGRIFSICIAGLDLGIAIAAPILGFIAEATGYRSMFAYTTALTFLALLIFLT----
     276 UniRef50_C1A5F8        Multidrug resistance protei...   155     4e-36  1  14.1% 16:385  13:390     ---------------LTVLMVTAFIDMLGLLMILPLLPFYAENLGAGGFVVGLLVSSFSVAQLLSAPLWGRFSDRYGRRPALMV-GLGASAVAYVVFAYADSLWLLFLSRIVQGAG-GGTVSVIQAYVADATRPEDR--AKSLGWLSAATNAGVALGPVIGSWV-QHWSPHTPGLVAAALCVVNMAFARKYLNEIRKppVRRSSREAVFRVISHppASRLILIYAIAIGAFQGTTAILALFLGWRFGVTADTIGYFFMYIGVLSVVvaLILGRLVDRVGEPRLSRIGVVFLAIGLTGVSLSHDYVTLALAVGMLPLGTAFTFPCVTAMLSRVVSseRGLYMGVQQTYGGITRVAFPVILGAAYDSLGQPTPFLISAVLVLATLAM-------
     277 UniRef50_B1HWQ5        Putative transporter n=4 Ta...   155     4e-36  1   9.5%  2:389   1:387     -MEVTARKKLWTKDFLIVSLINFTITLIFYLLMVTIAAYAVEHFNASTSTAGLVSSIFIIGTLLGRLGTGRIIGDWGSKKT-LFCGLLLFMLSTMSYFIAGNLPLLMLNRLIQGIALGVASTATGTIIAQILPPERRGEG--IGYYSLSAILATAIGPFVGILLTQLfdYRMIFAVDSVLAIICFFmfIVTVPDAPKKTVDAAVKAGFKMtfIELRAVPIAFVALVIGFAYSGVMSFMTFYAKELDLVSAG--SYFFIIYAIVILATRPFTGKLLDTRGANIIIYPCLVIFAIGMYAFSSASTTIAFLIAAACIGIGYGNFNSVAQAVAIKVTPNErgLATSTYFIFYDLGLGVGPYFLGLFVPSAGYSAIFFAMVFVILLSIVLYYFL---
     278 UniRef50_C6XBF1        Putative uncharacterized pr...   155     4e-36  1  14.9%  2:390   9:405     -TAASAFAPFKYRIFTVLWMATLISNIGTWMFN-VTSGWIMTELSPSPFMVSLVQVATALPIFIFALPAGALGDIFDRRKLLLVtaAALFVFAAILWAGHVSAWGLLLFTFLTGAGSAFAMPAWQAIVPRLVAKEALQPA--IALNGVSVNIARAIGPALGGFILVAAGATATVLFDAVTYLFVAAALLWWRASapREHMVGAMRAGLRFSLRSQALRSTIIRALAFFTFASAYWALLPLIAKELLHGGPGLYGIILTALGAGAVAGTFLIGKLRKQLGANAVVALGTLGTALAMGFFAYGGNATLGVLAGVLAGLSWIMVISSLNVSAQTALPDwrARGLAIFQMMFWGAMTAGSLLWGKLAMSLGLPHALILAAAISLLCIPLTWRFK--
     279 UniRef50_C6D475        Drug resistance transporter...   154     4e-36  1  13.7%  6:391   4:394     -----NKKSNFIRQALLLGLFSTLGPFTIDMYLPAFPE-IVEQLGSSASLVQFSLTACLLGLGIGQLVMGSLSDVYGRRIPLLI-SMAFYVASSLACAFSPNIVLLILFRFIQGVAASAGIVISRAIVRDLYSGHELTK--FFSLLLLVGNLGPLVAPVAGSGVLSVTSWIGVFIFLAVLGIYLLSVTKWSLKETLPVDRRSPslRNYGSLLRDRQFVGYMLAQGIMIAGVFAYVSGTPFIYQNIYGVSPTVFALLFGSNGVSLIIGSQIVGRLAHRVSErfGLCLALLASMIVVVVTLVHGPLFTLVIPLFIFVASIGITSTAAFPLAMESQANQAGSAAALLGVVPFLLGAVVAPLVGIAGEDTAVPLGIIILITSIAAMLAYFLLVRR-
     280 UniRef50_B3E9G6        Major facilitator superfami...   154     4e-36  1  16.0%  5:379   1:373     ----MTHTKHGRASFVLLCLIGSATFFSSYLRIPVLPLFAAT-LGAGPAQVGLINGAFMVTAGILSIPAGLLVDRLGRTKPVI-GGIVATAASSLLVTQCSSPLQLVAVYLLFGAGLAAFAPAMLSLVADIVPSERLGRA--YGWYTTAIYVAMTIGPATGGYLAKTVGLRNVFLVSGTMLATMALLALLVLPRTAARHKTELHAALAASLTlnRPLRACLLATTGSCIGFGLFLTFLPLFAAS-HGLDPGQVGLVFAAQAITNVVGRVPIGMIADRLERRLLVSAGLFCLALALPALGQTTQLSWMVLCAVGMGIGMAFTFTAISALIVEQVPtqRGLAMGMYNSCIYLGMMTGSTAMGIAFKWVDYPTGFVAAGVIA-------------
     281 UniRef50_B4WMG6        Transporter, major facilita...   154     4e-36  1  15.1%  8:390   9:425     -------KPRLPLQFWIVALIAFINSVSFTIIIPTLYPY-AKQFGLSDFEASLLTTAYSLSQFVGTPILGQLSDRWG-RKPLLVISLIGTVISNLLAAIAGVPGLLFCARIFDGL-TGGNNSVAQAVISDITTPEQRTQA--FGIYSGLFRLGFVAGPPMSYLalEVSSLGMSFLVSAAIALVAAAMCFFFLKETQVDHqkKFDFVSLFTALGRPVIGRILLMTFLNGATFTIFTFAFQPFFINVLGQDAKNLAIAFVAFGILAFVSQVFAlpLRKRFTLVNVLVGALIARGFLFLLMPALPNIVAFSLLLACFGLVNAFPMPLIDSILSTRSNQaqGEVLGLNASYLSISNAIGPAISGLLVTTFGYSFPFWVAGALTMMVAGFALTLK--
     282 UniRef50_D1Z2E1        MFS transporter n=2 Tax=Eur...   154     5e-36  1  14.0%  6:392   4:385     -----NWLKKDTIALMALSLVGFTASFTGHLISSNLGNYMG-SYGSSMTVIGLVIGSLAIAEVLLKTPFGILSDRVGKLK-LMLGGLALLVIVSLMFPMFQTPLLLFVIRFMQGIAIAAFSTTSTALVADLFTD---RKGEAMGTYNSFKGAGYALGPILGGLVTQYFDFFDTFLLCAIAGAVVLVLCFVSVRESFTPPKKKQSVGLMLKESNKLDFFSCYFIGMSGMLAFYSIISFLPVYGTQN-GIGAGVTGAILGVQAVVYVLAQYYSGKLADKYGSRVPIMTGSILLAAGVLMIALVPDPLVWGAAVILSGLGISALWVVSNSYLAYAAPSamGTVMGLSGTFKEVGDGGGPILIGLLGDWIGLKGAFLCILVFLAISFLMALTLDNM
     283 UniRef50_Q8NRI3        Permeases of the major faci...   154     5e-36  1  14.7%  9:388   8:383     --------KLFTPTFVMGWFANLFQFLVFYFLITTMALYAIKEFQASEVEAGFASSSIVIGAVFSRFFSGYIIDRFGRRKIVLI-SVLVTTIACALYLPIESLPLLYANRFLHGVGYAFAATAIMAMVQELIPASRRSEGT--GYLALGTTVSAALGPALALFVLGTFDYDMLFIVVLATSVISLIAVVFMYFKTSDPEPSGEPAKFSFKSIMNPKIIPIGIFILLICFAYSGVIAYINAFAEERDLIT--GAGLFFIAYAVSMFVMRSFLGKLQDRRGDNVVIYFGLFFFVISLTILSFATSNWHVVLSGVIAGLGYGTLMPAVQSIAVGVvkTEFGTAFSTLFLFVDLGFGFGPIILGAVSAAIGFGPMYAALAGVGVIAGIFYLF----
     284 UniRef50_Q7MLK0        Permease n=69 Tax=Gammaprot...   154     5e-36  1  15.4%  2:390  29:422     -SQAVSQSQISLFLFAVLGAIGALTPLAIDMYLPAMPT-IARDLGVDAGAVQFTLTAYTAGFALGQLIHGPLADSFG-RRPVLLLGVLFFGLAAVVSATTNGIDALTYVRTAQGFAGAAAAVIIQAVVRDMFDREDFARAM--SFVTLVITIAPLVAPMIGGHLAIWFGWRSIFWVLAFFAVIVIALVWWQIPETLKVENRQPLrrNYLKLCCNKTAMGLILSGAFSFSGMFAFLTAGSFVYIDIYGISPDQFGYLFGLNIVAMIIMTSLNGRMVKKVGSHFMLRLGLTVQLIAGLGLFVSwgLWGTVPFVVLFIGTLSTIGSNAMALLLSGYPNMAGTASSLAGTLRFGTGSLVGALVAILPSGVTWPMVLVMSACSVLSALFYWIFGR--
     285 UniRef50_O34367        Uncharacterized MFS-type tr...   154     5e-36  1  14.5%  4:390   1:386     ---MTSANKSNIPALLALAVSAFAIGTTEFISVGLLPL-IADDLDIPVTTAGLTVSLYALGVTFGAPILTSLTSSM-SRKTLLLWIMFIFIAGNTMAATASSIGILLAARVISAFSHGVFMSIGSTIAADIVPEDKR--ASAISIMFTGLTVATVTGVPFGTFIGQQFGWRFAFMVIIAVGIIAFITNGILVPSKLRKGTKTTMRDQLK-LVTNSRLLLLFVITALGYGGTFVVFTYLSPLLQEVTGFKAGTVAVILLGYGIAIAIGNMIGGKLSNRNPIAALFYMFIVQAIVLFVLTFTAPYQAAGLITILCMGLLAFMNVPGLQVYVVMLapSAVDVASAMNIAAFNAGIALGSYLGGVITDSIGLIHTAWIGGLMVVGAVILTGWSR--
     286 UniRef50_Q11I19        Drug resistance transporter...   154     5e-36  1  17.9%  2:392   1:394     -MIIPTFDKTTPPHILTLVAVAATASSATNIFLPSLPG-MAEQFGADYGIVQMTVSLYLAATAVLQLGIGPASDRFGRRPVMLV-SFAVFCIATLAGAYAPTIEALLACRVLQAFSASGL-VLSRAIVRDIVGTDE--AASRIGYVTMGMTLGPMVAPLVGGILDEAYGWRSTFLLTFGFGIVALILIYVDLGETNRHRSSsaQFRGYRELVRSHRFWGYVATAGFASGTFFAFLGGGPYVAAEILGLSPFTYGLYFGVVSLGYMLGNFISGRYSRAIGINRMMLSGNAIAALGmlFLGGYDHPLSFFGPTFFVGMGNGIALPSATAGMVSVRPHLAGSASGLGGALqgVGAALATLAGGLLSQETGAYPLMVLMLASSSLGIAATLYVIRV
     287 UniRef50_Q0BNX0        MFS family major facilitato...   154     5e-36  1  15.3% 18:389  12:383     -----------------ISLIYSFRMIGLFIIFPIFSLYINHLEYATPFLIGLALGVYGLSQAMLQIVLSILSDKFG-RKPIIFVGLIFFIIGSIVAACSSTIYGIIIGRAIQG--AGAIGSTLTALVADSTKEENRLKAM--SLIGMSIGFSFLVAMMFSSILNSIIGLSGIFWLTAVFGGLSIFMLTKIPTPKAphHEAKPVFKLIKDVISHKELLKLNYGIFTLHATLTALFIVIPPILTNILNIDADYQWLVYLPVLIISFSIMFPFVMIarKMKKYFVIAVALLGICLALLVISYRHTFLLSIILTFFF-AAFTFLESCLPSWVSKIApgSKGTAMGVFSSCQFFGIFIGGMIGGITYHHFGITGVLILCTALSVSWFIISLIM---
     288 UniRef50_C2CZ37        Major facilitator family tr...   154     5e-36  1  15.0%  8:367  25:398     -------RRYWWKVVALCFVGWILIYADRTILNPV-QEQIGAQFHIGNTQLGLVNSIFFLTYAICQIPFGILGDRVG-RRLVIMGGFIVLGIMTFFSGFAFSFGIFLLFRALAGAGQGTYYGPQYALSTEAIPTKDLTLGT--AIINSGMAFGTSGGYLLSSSMVLQHgwQTPFYVMALPTIIVGVLFYVVLKetAEVKKSEESKVQLKDLFKNRNLVFAFILCFCSIYANFVILTWLPQFLQVERGFQGSSVGFISSLVPWASIPGAIVFARIYDKLKKTKLMIAFLviSLVAVFGIAFVTNKLLLIVLLIVYGlgKLAIDPILVAFVTKNSpgSLSTALSAYNFIGMSGSILAPYLTGWISDQFG-------------------------
     289 UniRef50_A5GB53        Major facilitator superfami...   154     5e-36  1  20.3%  9:367  17:371     --------SGITGNVLILGMVSFLTDVSSEMIYPLLPLFLTTVLGAGPAFLGVIEGVAESTASLLKLFSGIASDRVSDRQKLVLFGYTVSACARPLIALAATPAFVLFVRFFDRVGKGIRTSPRDALIADSVDSSLRGKA--FGFHRSMDHAGAIVGPLIATLLLTFfdIRTIFWLAAIPGLLAVLLIILRVRD---VSRKRGENGAFMRMVPRGKLRAYLIILFLFTLGNSS--DAFLLLKAGQLGVTPARIPLLWMFFHLVKMFSSMPFGALSDRIGRRSIIVSGWCVYALAYAGFSLAATELHVWLLFAFYGLFYGLTEGVEKALLVDIapGERGGAFGWYNFAIGAGALPASLIFGIIWQKAG-------------------------
     290 UniRef50_UPI000178907F major facilitator superfami...   154     6e-36  1  16.0% 10:391   3:388     ---------SWKKNLWILWFGSFIVSSSFSMVIPFLPLFLI-ELGVteLWSGLLFSSAFFAGALSSPFWGAVGDKYGRKPMIIRAGLVLFVIYVLMAFVTNEYQVLILRLLQG--LLSGFIPGAIAIVGTNTPEKKVGYA--LSMMSTATATGGIMGPMIGGTLASLFSNRMAFGLAGMLCFAATLLVIFWVKEEkpSKERVSVMNTFKVAGHNKALMTVLMLTVLTQFSVMTIEPVLPLYIAQIGGSSSHtaGFVFSIVGIASILFAARWGRLADKIGFQKVLLIGLLASGIGSLAQILFSNIWAFSAIRFAYGAFFCAVFPALNGLVVKHTPSerGRAFSLNQTANQIGGMAGPLAGGMISGIFNIHSVFLMTGVLMLITTAITYWTMR-
     291 UniRef50_B0SY01        Major facilitator superfami...   154     6e-36  1  12.5%  6:389  14:408     -----TTPDASPRALYVLLLVVFINLVGFGLVIPLLPFY-AKSLNASPWQVTALFSAYSLGQFVAEPFWGRLSDRIG-RRPVLIVTILANTVSYVALAFAPNIAWAFAIRLASGFGSG-NISTIQGYMADVTPPEKR--AGRMGLLGAAFGMGFVVGPTLGGLltGRLAFQIPLLTAAVLAAIASLGVFLFVVESRAPSAKDAPRPHRREAlaHPVLSRVLLVTLISTAAFAGMEAVFGLWTQARFDWGPRQVGLCFAVIGIIASIGqlITGRLARRFGEAKVLTAGLSIIAVSLALTPFVPTSAFVPVVVGCTAFGQSLVFPCVAALISRapPDKQGAMLGLNMAAGSLARMAGPMLAGPLF-GLAIGGPYWLGAVLMIPAIAFALTI---
     292 UniRef50_UPI0001AEBDF9 MFS permease n=1 Tax=Altero...   154     6e-36  1  12.6% 16:389  36:403     ---------------FWLAFGTFVIGCSEFAAMGLLP-YFAEDFGITENVAGHAISAYAIGVVVGAPLITIFFSRL-ARRTMLISLMVFYAGGNLLTALAWSEWTMNIARFIAGLPHGAYFGIAMLFAADIAGKNKR--AQAVSNVILGLAIANIIGVPSISGIGQMFGWRTGFFIISAFALVTALMVWKTAPYRGPNPDAKPLTE--LKALKNKDVLLVLLMGAIGFGGMFSVYSYFSASYLNTTSSPEWGISATLLIYGIGVTLGNIIAGRYSEGRLLTSAITFQVLLGLSAAAYAASMGNPYLMAASLFFIGIGGGMVVP-LQTRLMDVAGEAQTLAGAMNHAAFNTANALGPWLAGmlSAGYGYTSTGWVGLALAGGGVLVWLAI---
     293 UniRef50_C6WVS2        Major facilitator superfami...   154     6e-36  1  13.5%  2:386   1:392     -MPTVTPVHNERSVLLTLAGIQFTHILDFMIMMP-LGPMIMKEFSINTHEFGLLVAAYSFSSALSGLLGAAFIDRF-ERKQLLVAMSICFGIATVACGLASSYAALLVFRGLAGVFGGIMGAMVQTMVGDIIPFTRRGKA--NGIISTAFSISTVAGVPLSLWIATHYVWRSPFFLIAVVTAIFVLIAQRLLpdHHLSIKRSHPFAPMLAVLRDTNHIRALLFSALIIFSSFTVIPYLTVYAVNNVEISQHDIPLIYLAGGAATLITARLIGRWTDKSGKVLVYRLVALAAVFPIICITQSGPVpwLLYTTAFFVLVSGRMIPAMTVIISAAQPKLRGTFMLLNSTVQSLAMGLSTTLGGFIVTqsGYESAGYIAVLLNILAIIFV------
     294 UniRef50_B8FCI3        Major facilitator superfami...   154     6e-36  1  18.0%  7:368   1:365     ------MRSKLPKTVFILGLVSFFNDLSSEMIYPLLPLFLSSTLGAGAVALGVVEGVAESASSILKAVSGIAADRWNKRKPLILSGYGLSGLVRPLIGLAWAWPLVLAARFFDRVGKGLRTSPRDALISMSVKPEMRGRA--YGFHRAMDHSGAVAGPLAAAFLLSvlGLRHVFLLAAIPAMVVIALIVFGVKDPKDQQPEEDACAPPFSKHDWKRLGPDylLTAVVIFTLGNSTDAFILLKLSAAGVSGAWIAGLWSLHHVVKSIATYWGGLFSDHLGRRRMILVGWLFYAAVYFCFAFASSPGWIVALFLLYGVYYGLTEPCEKAWVADMAPKElgAAFGFYHAAVGFAALPASLIFGVIWHAWGM------------------------
     295 UniRef50_C7RMR7        Drug resistance transporter...   154     6e-36  1  14.0%  5:348   1:353     ----MADSQLSPAPRGIAFMLAALAALGPFSIDTYLPSfiGASLHATPLQVQQTLTAYLLPFALMTLWHGAISDALGRRRVILVT-VALFALASAGCMLATRIEHLWLLRALQGMTGGAGIVISRAIVRDLYDGPPAQR--LISQITMMFAVAPAVAPVLGGWLQAWFGWRSVFAFLALSSAALWLASWYLLPETLPRHRRQSlvRSYWQVLTSRPFLLVCGALAFNFAAFFIYVLSAPVFLMHHLGVAATGFLWLFGPAMGGLMIGAWLSGRCAGKLSLPRTIAAGYLVMGLAVVllAWPPALPWSVLPIFVFTLGMSLAMPCLTLQALDLFPEKRGLAASCQGFLQ--------------------------------------------
     296 UniRef50_B5FNS1        Quinolone resistence NorA p...   154     6e-36  1  15.7%  7:388  11:388     ------KEKLWTKDFWAITIVSFIIFFVFYVLLTLLPIYIADRLHASADKAGLLVTCFLAAAIVIRPFAGQWVGKYSNKKILVLSSLA-FLVITALYPVCHSIESLLFIRVLHGITFGVITTVKGTISARLIPASRRGEG--ISFFSLAMGLAMVVGPWIGLNMARWNAFTAAFWLCSAVAALGIVLSLIVTVPPVIRHADGSKPNLGFAAMFDRAALPFALVTFFMTFSYAGVSAFLALYARELDLM--AAASNFLLCYAIFLMICRTFTGNICDKKGPKYVVFPCLLAFTIGLVALGYTNGSIMMIISGGLIGIGYGSVTPVFQtiISSVEPHKIGVANSLFFNAMDAGMAIGAFIMGMMVESVGYRMIYVAGAVLVVLAGALYAV----
     297 UniRef50_P45123        Bicyclomycin resistance pro...   154     7e-36  1  14.2%  5:391   1:392     ----MNQQKSTFIFILTLGILSMLPPFGVDMYLPSF-LEIAKDLDVSPEQVQHTLTSFAYGMAFGQLFWGPFGDSFG-RKPIILLGVIVGALTALVLTEINSVGNFTALRFVQGFFGAAPVVLSGALLRDLFSKDQLSK--VMSTITLVFMLAPLVAPIIGGYIVKFFHWHAIFYVISLVGLLAAALVFFIIPETHKKENRIPLrrNFLLLWKQKEVLGYMFAASFSFGGLFAFVTAGSIVYIGIYGVPVDQFGYFFMMNIVTMIFASFLNSRFVTKVGAETMLRIALAIQFLSGMWLILTagFWPMAIGVAFFVGPNPVISSNAMASALERCPQMAGTANSLIGSVRFAVGAIMGSLVASMKMDTAAPMLFTMGACVVISVLAYYFLTSR-
     298 UniRef50_C0ZGX2        Conserved hypothetical memb...   153     7e-36  1  13.8%  1:391   1:393     MSWIKMRLQEFHPIVWSLVVGTVFVRAASSMSMPFLFLYLSNQTDMSLAMIGLTIGAGPLAGTIGGFFAGAWSDRIGRRRVML-GALYVWTLVFVGFALSKDPWVLLFLNIAGGLCRSFYEPVSQALMADVTPQEKRLR--VFGIRYMAINVGVAVGP-IAGVVLAKSSVALPFLVTALIYLIYVISLQGLLNkeGQKKEVVTFSRAFSVIVNDKAFRLYMLAGVLGAIGYSQMSSTLAKFAEMTVVNGTELFAILMTVNAIVVVMMQLPLTTWAEKKTPLTAILVGNVMYAVGDVGYAFANSWLIFIVAMVFFTIGEILTFTAGDVLIDRMAPENMRGSYYGAKSFSNLGQFIGPWMGGLLLAHYGGTTLFLVVAATSMMSSAFQWAGAR-
     299 UniRef50_A1BFH5        Major facilitator superfami...   153     7e-36  1  17.4% 28:389  35:422     ---------------------------GFGIVLPLLPTY-AKDLGASPLMIGLIAAIFSIMQFIFSPLWGKLSDKIGRRPVMLI-SIFITAVSYFVFSQAVTIPLLIFARGLSGIG-SANIAAAQAYITDVTDNQNRSKAM--GMIGAAFGIGFIIGPLIGGLLKHNYGIAMVGYVASALITLDFILAIFLLPESNKHAIkqAYIDGLKLAFTSRPLALLMIANYVFTFAIVNMQVASILLWKEYFHASDQAIGYLFAYVGFFSVVVqgLISKLIKALGEHKLFFWGHLFTFVGVFFIPFLPSDTLflFILFFFAIGTSLVAPINISLISLYtkQKQGEILGLSQSINSFARIMGPFSGSVLY-GLNVHAPYILAGVLTLFGAVISLML---
     300 UniRef50_Q12IY6        Major facilitator superfami...   153     7e-36  1  12.8%  7:389   6:388     ------LSSLEKKVAFSLAGVFGLRMMGLFMIMPIFALYGQHLEGFSPLWVGIAIGAYGLTQALLQIPMGILSDKYG-RKPIILIGLVLFAVGSIIAAMSDHIYWVVFGRAVQGMGAIAAAVLALAADLTR----DEQRTKVMAIIGMCIGLSFALSLLAGPLVAQYLGLSGIFWLTAVLAVLGMAIVHFLVPNPISQAPKGDTLAalRRMLLDPQLFRLDAGIFILHLVLTAVFVALPFNLVDAGLVKEQHWLLYFPAFVAAFVLMVPMIIIGVKRNNTKTMFQLsvIMMLSLLLMGLYAQNLWLLSAAVVLFFTGFNYLEASLPSLIAKFSpgEKGSAMGVYSTSQFLGAFCGGMLGGGAYQYLGAEGVFFVASALMVIWLFLSFGM---
     301 UniRef50_Q469F0        Membrane transport protein ...   153     7e-36  1  13.5%  6:391  13:398     -----KLQKNLKLTVPLLALLSAFPPLTTDMILPALP-YLAKSWNVSLSLINLNLVFFFVTYGLFLLFYGPISDRYGRRRPLLV-GLAVYIVTSLLGAFVSGAPMLIGTRILQAAGAAAGSSISMAMTKDIFVGQERER--ILAYIAVIMGLAPMFAPIIGGWILLYLSWHWIFLMEAFMGIIAMFGVLRFPepEVSETPLSQVINTYGRLLLNTPYMIMVLVMSVSFFPLFSFIAGSSAIYINEFGLSEQKYSYFFAFNALAIMTGAFFCLRLIKSVNSKHLMTIGFAGVFLGGIFLLFMggPWSFALPMFMVSFSLGLSRPPSNNLVLEQVDRDIGSASSLLIFTYFTFGAVSMWFISLEWADKIPVLGTTAVGCGALVLAAWFIIQKR-
     302 UniRef50_A6GTB8        Major facilitator superfami...   153     7e-36  1  18.0% 29:390  42:411     ----------------------------IDLYLPSLAA-IGAELQAPAGRVQQTVTVFLAGFALGMLFYGPLSDRFGRRR-MIFAGTTVFVLASVACMLAQTIEQLLVFRLIQAFGGGAAAVISRAVIRDLFGETD--SARVMAMVAMVTSLAPMIAPLLGAYILELGSWRYEFLALALFGALCTVAAYALLPETLSKVRSQSSlrGYRTVWEQRDARLLIIAGGAHFAAMFAYITGTPFVYIEFFGLSEKTYAVLFGSNILTLIGFGYASTRLVKRTGTTPLVKTGSALGLLGALMVLVSanLGLMVAGFLLCVGSLGFVAPNTTAQLLGKHPKNAGAASALYGCAQFGLGGLASWAVSVVHDDTSLPMAATVVAFAALACWASIRLKR--
     303 UniRef50_C8PWH1        Major facilitator superfami...   153     8e-36  1  11.0% 16:388  63:433     ---------------IMIGMIGAFAFLQVYSIQAILPI-IMQAFSATETQVGMTVAATVIAIAIMSPFMGMLSDAVG-RKNIIVASIAFMAIPTMMIGLSNSLSSIVIWRFMQGLAVPGITVVTIAYVGEEYAGKE--MAKMMSYYVSGTVFGGFLGRFILGHLEELIGWEKGFVFMGVLTVLGAALVAWLLPRSRHFHAnaSALHMLSKHVRNRYVVTAGLLGACVLFSLVGCFTYVNLHLADtyNLSSAGLANIFAVY-LIGVVVTPIASSLIAKYGAARMVRVAVMISMMG-VLMTLAAPISLVVVALAVMSTGVFITQSATITYIAVNVKEGRSLASGLYYMAYYIGGSIGAWACGLAYAQGKWLYTVYTLLAVQVIALLIAFF----
     304 UniRef50_C1ZH60        Arabinose efflux permease f...   153     8e-36  1  15.2%  2:389  11:413     -PQSPESKAHKQAGIQFILCTLLLDVLGIGLIIPVLPDLVKMLAGKDNSDASllITAYATMQFLFAPLIGALSDRFG-RRPVLLTSIAVLTFDFLLTAFAPNLWWLLVARILSGMTA-ANITAANAYIADISDET--TRVRNFGLAGAMFGLGFVLGPLLGG-IAGSYSSRLPFLLAALLSAVNFLYGWLVLPESLPAEQRHWPRKslRSLRVEPVVFGLAIAYFCVSFGEMTLRSTWILFTEERFQWDAFQNGLALSMVGLMTAFVqvLVRRFNNRFGERAALLTGLFISMLAYIGYALATRGEMMFAIIMLSSLGGISGPTAQSIIAKRVDPKTQGQVQGALSSIASLTAILAPSLGTGAFWYFtpGIPFVIAAIFAFLALLITAWV---
     305 UniRef50_A1ZQV8        Quinolone resistence NorA p...   153     8e-36  1  14.2%  4:389   1:386     ---MRHKETLWTRDFVLFCLSYLLMAAGFYFLLPVLPLYVTQVLEEDKTKIGYIIGLYALSALLIRPFSGYALDTFGRRKVYII-SMVLYAFSMFLYSYATTFLLLLSLRFLHGFAWGMVTTGGGTIPADLVPARRRGEG--IGYFGLSVTLSMALGPLAGLWILGNNNFSLLFYIGFGVSIASLILAYMVKYPSIAQATSeaPAPRKKGQMFEAKASHASVVVFLFGFAYASIFAFAAVYGTET---GVGHSGMFFLLLAIGVSISRPYAGKLMDKKGPQQIMLLSFILGFVGFLLlaTGHSLIVYLTAGFIIGLGCGSIIPTLQTMVMNMvpERRGVANATYYAAVDLGIGLGSIILGYVANWASTAQMFQFCALMFVFAGIYFFSM---
     306 UniRef50_Q1ISJ8        Major facilitator superfami...   153     8e-36  1  13.7%  2:388   3:387     -SSAPNPDRSTSMSLIAVMLAGACTFLNVYCTQPLLP-FLRRLFHASELQVSLTVSATTFGVAIAAPIVGLMAERIGRKK-VIVPALFWLTVPTLLAATSTGIWSMVLWRFLQGICVPGIIAVMIAYIGEEF--SGINVGSVMASYVTGTVFGGFLGRFIAGLVATHWHWRAAFVVIGVINLCGAIAVRQWLPKArkAEDINATLNDMRMHLRNPRLLATVAMGFGVLFSLVGAFTYVNFYLAApfHLSSAALGTIFCVYLLGLII-TPLSGRFLDRSGFRNTAIVATAFALTGLAC-TLSQHLSIVIVGLALFSSGIFIYQAAATVQTGINAGRARSSAAGLYVTLYYIGGSVGATALGWVWLWRGWHACVAAIAVASLLTLVCAFL----
     307 UniRef50_C2HEP2        MFS family major facilitato...   153     8e-36  1  13.7% 12:391  30:401     -----------KSSALVVAATCMIAFMGVGLVDPIL-KTIAAQLNATPAETTLLFTSYMLVTGVVMLFTGFLSSRIGLKKTLM-TGLFIIVVFAGLGGLSGNIGMLIGLRAGWGVGNALFVSTALATIVSILVGN---TEKAIMMYEAALGCGMAVGPLVGGVLGS-GSWRYPFFGVAFLMFCGFIALAVLLPETEKPKRKVGLWEGVK-ALSNHKLRSVGLIALLYNFGFFTLLAYAPFLLI---GYSELEVGFVFFGWGVLLAIAsfVAPALERKFTTYRTILAAFVLFIICLLLLGAGTSMPVLviSIVLAGFFQGIINTLLTTIAMEIPGLQRNVASSSYSFVRFFGGALAPFIAGVVGEHIGESYAFYFAGAIVLISVCCIIYHRN-
     308 UniRef50_B1HV30        Antibiotic resistance prote...   153     8e-36  1  14.2%  8:388  10:386     -------TQIWTKRFISLFLTNISVFFVFYGLVTTLPLYAIGELHQTDKEAGLLLSGFLLSAIIVRPFSGKLLDVFGKKK-LLVLSIAGYFACTVLYLFIHPFGLLLGLRFIQGIFFSIITTAAGSLAADIVPAKRKGAG--LGYFTMSTNLAVVIGPFIGLLLIQYSTFNVLFIVMSFCILAGGILALTVHTDDLPQPAHKGKLTFTFHDLFERKALPVAAIASLVAFSYASVLSFLSVYAQQKGLM--AVASLFYAVFAAAMLITRPYTGKLYDTKGPQFVIIPGIISFAIGLIMLAFVEGPMLFLSAAIFVGFGYGAVTTSLQALAVQSTaqRSGYATATYFTMFDLGIALGSYILGMVAVQAGYASVYLSGAGLLGVVFIIYLL----
     309 UniRef50_B4W7V9        Transporter, major facilita...   153     9e-36  1  15.1%  1:391   1:415     MIQTPSPPAVRAPALAVLFSVVFINLVGFGLVVPLLP-FFAQSLKAEAWQITLMFSAYSLGQFFAEPFWGRLSDRIG-RKPVLLATLAANTVGYLMLAFVPNIWLAIAVRLFTGLGAG-NISTVQGYVADVTPPEQR--AGRMGLIGAAFGLGFIVGPGLGGLllGRLGYQLPIFLAAALAAMAAVGVIVFLRESrpAAARPPFLAGLKDARTNPVVSRVLVVTLVYMAGFSAMESVFGLWSESRYAWGAREVGLSFMIVGVISTLNqfFAGRLARRFGEARVLATGMLLFGASLVLQVLApqGWVIPLVMAVGACGMSLAMPNISAMISRAspDRQGAMLGLNMASSSVARIFGPMVAGALFSGLGHDWPFLVGALLTIPAAVMAINAGR-
     310 UniRef50_B8FQQ3        Major facilitator superfami...   153     9e-36  1  16.0%  3:377   8:372     --NTVTKPRLWTRNYLFTLFANQFVCLSFHMLLPTLPLFV-RHLDATEDIIGLIMGVFTVTALGIRPFAGRAVDTKG-RKVIFLWGAAIIVSSVFAYSLFPVIPFILTFRLIHGLGFGLSTTAVGAMVTDFVPNSRLGEGM--GYYGLATVISMAVSPAVGLFIFHSWGASALFHVSAFIAGLGAFSAMFVKYPQKITPRPNEPTSFFLE----KNAYLPTVMILLVIITHASIIAFVSLYADS---LNISNIGIFFTLYAISSLLTRPVFGLLSDRKGFSYSIIPGIILTSTALIVLYFARDFSHFMIAAICYGIGYGGLLPAFQTMAVraSPARRGAATSTFYCGMDIGSAFGMIACGFIAKATGYSTMFLLLVI---------------
     311 UniRef50_A6WT42        Major facilitator superfami...   153     1e-35  1  14.0% 13:391  24:396     ------------WVLLALALGTFALGTTEFASMTLVP-YIASDLGVDVAHVSYAISAYALGVVVGSPIIMVLAVRV-RRRTLLIALAALMAVANGLSALAPSLNWLIFFRFLSGLPHGAYFGVAMLLAASLVPPEM--KARAVSRVIIGLTLATIIGVPFATWMGQTVGWRSGIGIVAILATITAVMVYFLAPDQAVAADASPRKE--LQTLKNREVWLTLGIAAIGFGGIFCVYTYLAETLIQVTQVEPFKIPIMMAVFGIGATLGTLVCGWAADKSALAAAFWSLVLSTLVLAIYPSLTGHYWALMPVVFFVGCGLGLA-TIVQARLMDVAPDGQAMTGALVQCAFNLANAIGPWVGSliLSGQGIAATGYAASLLSLGGLVMWWLTHR-
     312 UniRef50_C3XHU5        Major facilitator superfami...   153     1e-35  1  13.1% 15:389   5:377     --------------ILPFLSILIFRFIGLFIVLPVISLLIATMPHANIWSVGMAIGAPYLLQMICQPFFGRWSDIYG-RKPILILGLVIFLIGTIICMFESSIYYLILGRCVQGM--GAIGGILTALVADSVKEEKRTSAM--ALMGVGIFVSFVIAMILGSILGAHYGLNSLFALSAVVTIISLIITFVFVKPTPKIayPNHDEDKASESMIKRSIFAVSLSGFIEKLLMVLTFALVPIILNE--HIDKTHFWYVYVPAMFAGIIALGPTSVISEKKGKSkvLLVSIAIFFIAYFCMALwdNIIIFAIGLACFFAAFSMQEALLQSMISKYaaKNRGGVIGDFSAAGFGGSFVGAMIGGFFSQYEAIVAWHWVLFGTLMASMILWIFI---
     313 UniRef50_A5IVN3        Major facilitator superfami...   153     1e-35  1  14.6% 15:391   6:385     --------------LFTFILSIFIVGMVEMMVAGIM-NLMSQDLHVSEAVVGQLVTMYALTFAICGPILVKLTNRFSSR-PVLLWTLLIFIIGNGIIAVAPNFSILVVGRIISSAAAALIIVKVLAITAMLSAPKNRGK--MIGLVYTGFSGANVFGVPIGTVIGDLVGWRYTFLFLIIVSIIVGFLMMIYLPkpVNHEAPSHENHVTSKILRPAEVAKYLIITFLVLIANSVTFVFINPLILSN-GHDMSFVSLALLVNGIAGVIGTSLGGIFSDKITSKRWLMISVSIFIVMMLLmlILPGSGLLLAGLFIWNIMQWSTNPAVQSGVIQHVEGDTSQVMSWNMSSLNAGIGVGGIIGGLVMTHVSVQAITYTSAIIGALGLIVVFTLKN-
     314 UniRef50_C1B433        Putative MFS transporter n=...   153     1e-35  1  12.4%  2:387  16:407     -PDRTSLDRAARITVILLFAAWVVDYIDRLAINLALPS-IGAEFDLGHTEQGMVISAFFLSYALCQIPGGLLADRFGSRRVV-CWSLLIWSLFTALTGTAWAFVVLLAIRFVFGVGQGVFPAAAMKAVAERTVPHQRMTAT--GWAQSSNAFGAVLAPLIAAPIIALWGWRMSFFAVAGLGVLVWAAIQLWLPAALPQSADTSPrgGLRTVLASWVMWRFTLMFFGYGIIVWGLNSWIPSYLQTVRGISLTGSGLLSAIPALVGGGAIIAGGKLIDRLghRLIVFPAMTVCAVCILFLNRVTSLAEFVALLSLATASATLCYMPIFAIPLRTLPGavGTGSGMINLGGQAAGFITPMVMGALVDRYSYTAAFAFLVVGAVVAGAFAL-----
     315 UniRef50_Q46ST6        Drug resistance transporter...   153     1e-35  1  15.5%  7:386  24:412     ------QPKALPGIAAMAAIAAGLSMLGQFAIATYLPAfmSDALHATNAQVQQSLTAYLLPFALMLPWHGAISDAVGRRRMVLL-GCALFTIGSLVCAGATGIDMLHAGRVLQGISAGIGVIVGRAMVRDVFDGMQAQ--QVMALVAMIFALAPAIAPVCGGWLLLWTGWRSIFVFLALVSASLLVACWRWVPETLPPARRHPlaRGYGSMLTHWRFVALTLANAGVNVGIYVYIFAAPTFVTRHLGLGAQSFGWLFIPIVAGIMLGSLVSHRMAGRISPVRSVLLGHAVMLFAGIlaLHAPAMPWALIALPVYGAGMTITQPSLQLLALDCFPERRGLASSGYVTVQQLGNFLMSALLVPLLLDSTVKLAVCMAALQLFGLAMFM------
     316 UniRef50_C6XDZ4        Drug resistance transporter...   153     1e-35  1  14.4% 30:384  25:387     -----------------------------FTIDTYLPAflAQDFHTDNLAIQQSLTAYLLPYALMTLWHGAISDAIGRLRTIYI-GLGIFTLASIGCAFATNVETLWFFRVIQGLSAGAGNVVARAMVRDLFEGVMAQR--VMAQLQMMFGLAPAIAPIMGGWLLG-IHWQAIFVFLALYAGLAMLCVQRWLPETMPPEKRRPLSagYAQVFGDREYLKLVVAVGANFAGFFVYVLAAPVFLVEHLGLGPQQFGWMFIPTVCGMMLGSYLARHSAGRYSAHRIIRLGYGWMAMAAIlwLLPPQPLWNIAPIVLYNIGSALVLPNLSIAALDRMPKLRGTASSGQAFMQMVLATVSAGLLIPLLWHHPAGLALGMAGYLLLGFLA--------
     317 UniRef50_C8S9K1        Major facilitator superfami...   153     1e-35  1  15.8% 13:391   2:376     ------------RQLIYLAFICFILMFSVTMIYPVVKHYVMDKYEATVSQASMFVAVNLIAYAIFAPVWGSLSDKLGKRKVFITTGLLGNSAMLFLQAIAPNLSLLMLFRFVEGIFTVMVYSIAMTLVLDIARKEAYGRGM--GVIGMGIATGTAFGAPFGGFLGS-LNPVMPFYSASLLIFLAFVFALIIL-EDVEVESSKSVLEGIAVAKKRKELLIPYLFSFVDRFTAGFFISVFPIMLGTLYQMTPKEIGIYLSSFLMPFALLQYPGGFISDRFGRIKPLILGSIIYGICISSVGFL-TPPAIAISMLVAGVAAAIILPASSALSGDLApdLKGAAIGGFNFSGSLGFALGPAVAGFIAEKYGFSQTFYIAGISVFMVTFAAVLLLR-
     318 UniRef50_C9PIZ4        Major facilitator superfami...   153     1e-35  1  11.9% 27:388   1:362     --------------------------MAEFVVVGILPV-IAGDMNVDIPTAGQLVSYYALGVAVAAPILTALSSKYDRRK-LTVGLMLLFALANLLTTLAPSYSLLLFGRVLAGVVQGVFYSIATVIAADLVSKDKSGRA--IGIVFSGMTVAIVSGVPAGAFITEWLNWRAAFALISVLGFVSMVSLWFLLPANLKRPKPASVFKQL-SVIGVPRMLLVFLITGIGYGGSFIAYTYLSEILGKITGFSTSAIGTILIFYGIAVVFGNTYAAKWADKQGPLKASAGIFISLALTLLLFGfaTNKYYVIPLVMIWGAAAFGSVPVLQLYVVQQapQAIDASSSMNIAAFNLGIAVGASVGGLVVTKYGLLATAPAAAVVVAISVLLIVY----
     319 UniRef50_C0YUQ3        Bcr/CflA subfamily drug res...   153     1e-35  1  13.6%  7:389   1:390     ------MKKNLNIVVFILALLNTLESLSIDLYLPAFPN-MAKIFNTDIGHIQISISVFFAGFAFGQLLWGPLSDKKG-RKPVLYSGLLLFITGATAIYFTSDIYVLWGMRFLQAFGGSAGIVVGRAIIIDLYDKHK--AVTIFSQQSQISGIAPIVAPLLGSVFLKFWGWNSSFAFLCIMGLITFFMVYKYVPETNtaTDEKKLKDQLKMIISNRDFISSTMVGSIAFASLIIYISNAPFLFMEIHGFSSSVFSFIFAFNSLALITAAYITPKLIKRISNSTLLFVATVILLVVCTLHILIasVALEIAMLYLSLLAIGILFPITSAHALSPFKEGRGTAAALLGFMQLMVTFLMSALLGFL-EADSIIPMVVTRSAMALIAVWFGYRI---
     320 UniRef50_B2JBG5        Major facilitator superfami...   153     1e-35  1  15.5%  2:389  11:399     -TVTRKTFQTIPRNVWVLGFVSLLTDISSEMIHSVLPLFLVSALGADLLTVGWIEGIAESTASVFKVFSGALSDYLGQRKRLAVAGYGLSTLVKPLFALATSPGWVLMARFGDRVGKGIRVAPRDAIVADVTDSANRGAA--YGLRQSLDTIGAFTGPLIAFMLMSFSgfRLVFWLAVLPGILAVALLAIGVREPSNINSQRQNNPLQWSALQSLGKSYWVLVAVALLFNLGNSSDAFLLLQAQQAGISASLVPLTLVVMNVAYSLSAYPVGLLSDRIGRLGLLVGGFCVYALAYLGFAFVDAPWQVWGLFGLYGLHQGMSQGILLALVADRVPShrGTAFGLINLAIGVALLPASLLGGILWQTISPKATFIAGSVFAASAIVLLLVF---
     321 UniRef50_C5SFH9        Major facilitator superfami...   153     1e-35  1  18.4%  8:371   5:374     -------KAHLKPGVMFIFITVCLDMMALGLAIPVLPRLIETFVgaASWWSGVFNSLWGFTQFICSPILGSLSDRFG-RRPIILMSNLGLALDYLIMALSGNLMWLLIGRLLNGV-TSSSITTAYAYISDISEPDER--AQMYGYIGAAFGVGFVMGPALGGMLG-HIDLRLPFWVAGGLSLLNALYGALVLPESLDKDHRKppIGSILFLWQAKSVMRLALISMVSNFAHHVIPATFVLYASYRLGWSGREVGLAMAYYAVWAVIVQglTGLVVKRIGEKATLVIGLLCGVVGFISYGYHTDWRVFLITIPIMS-CWGMTNAALQSLMTTRVGTsqGLLQGAVNSLMSLSGIIAPFVFGYILSVMTRPGV---------------------
     322 UniRef50_B7VM20        Permease n=26 Tax=Vibrional...   152     2e-35  1  12.7%  5:390  81:469     ----MSATFPLAKLTFLIAILTAVGQMTQTMYVPSIG-HMAGEFLVSASSLQAVMACYLIPYGLSQFAYGPLSDRLG-RKPIIVVGLIIYIIGTLVALFAHEYEWFLAGSFIQGLGIGCGGAMSRTLTRDCFEGAELHRA--NSLISMCVIFSPLMAPVLGGYLTEAFGWRSSYLFLALFGIAVVITMMTSMMETLPKERRksVANSYKFVLSDKRFQGFLLVLVATFAGVAVFEAAAGVLLGGVLGLPATTVSLLFVLPIPGYLVGAGLSSYIAQRSSERRALNVGLVAILVGSTVVLIptTALTLIGGATIYFLGAGILFPAATTGALSPFPYHAGTGGAILGGMQNLGAGIATLLASFFPAQDQLPLGCLMIAMSFIAMLGLRWVNR--
     323 UniRef50_Q5FSF5        Putative efflux protein n=1...   152     2e-35  1  14.9% 16:390  21:404     ---------------VLIGVIFILGPVSTDMYLPAFPA-LEHDLGHGPGSAQLTLTAWLAGLAIGQFTLGPLCDRYGRKLPLL-CGLVVYALASVGLALTTSFHMFCALRFIAALGGAISSVAPRAMVRDVATGAAG--VKLMSQLMLIFGLGPLLAPSIGSFLLDLGNWRLIFWANVVFGVVMFLGTLFLLPETLPMERrsGMAARYRDLLREPLFCSAVMVVSFGTFTMFAYLSNAPALFENILHFSPHLFAIFFGLNGVGFILGSQINARLANRfgMLAVLMFCVLAVAVCLSGLAGPKDPWILCALIWCTTFSLGFIGPNAGILALTHHGHQAGAASALMGTMNWTIAGLAGVMMSFLPTHWVGSTSIGMLVGISCCWLCDLWRRR--
     324 UniRef50_Q5WED2        Antibiotic resistance prote...   152     2e-35  1  16.9%  5:389   1:377     ----MAKQRLWSPTFLYLCFSAFTLFSIFNLFIPTLPLFAMDVLHASEQQVGIIVGVFIAASVIARLFAGLLLDRFGE-KNMLLVSFLVVVITAILHIWSFSFGWLLFLRFLQGLGFGVATTAAGALAIMIAPKTRQGEA--VGYYSMFMSLAMVIGPVVGLQVVQHISYTALFLTTVFLSVIGLLLALFIVYKPVRKAPEPLSVDRFIAI----KAVPVSLCSSLASFAYGGILSFITLYAVSL--GMESAASAFFLVYALVLLGSRMITGRIFDRFGENVVVYPTLVLFAIGLFTLSQAGSLSIFLIAAVLMGAGFGSVLPSFQTLAVQSVPPKQaqATSTFYIFYDLGIGLGSYVLGLIVTGSTYSFMYIISASIVILAIVAYRVL---
     325 UniRef50_C0ZB03        Hypothetical membrane prote...   152     2e-35  1  17.8%  1:388   1:386     MSIFTQMTKQQRIGLLFVILILFIDMLLYSLLIPIVP-YFTEKLQPSSTMMGVLFSSYAIAMLIATPIFGPISDRMG-RRTMLLIGLLGLAASTLLFAFSETMGLLITARFVQGIAAAATWPTALALLADLFPSKMRGTVMGIAL--TAISTGTLLGAPIGGWLFEISDHRMPFLAAAAFTVINIVLVYLFLKED--ATKTVSEKLHVGGFIRNPQVIFIAGIVLLAEISLCLLEPTLPVFFTEKLSMTPTTIGLLFGVMTLAYGMIAPVAGSLSGRMNPYKLMFGGIMTLAVFLPFLAWADSLWQAMLAMALIGASIGFTLstLGAIIDQGGSGAYGTAYSLFNMFHGIGMVAGPLAGGILTDLLPVSSALLIVAASILGFGILLFV----
     326 UniRef50_D0SP70        Predicted protein n=1 Tax=A...   152     2e-35  1  13.0%  8:392  27:410     -------SKSFTAILWSLFFAGFASFSSLYCVQPMMPIF-AKFFQVTPTHSSFPLSFSTIALAIGLLFTGFISDRYGRKR-IMVFALFFVSVLLLISASFPIWEIFLTTRIFIGLAVSGVAAVAMTYIGEEI--AQKDIGFAMGLYISGTAIGGMGGRLIAGVLVDFISWQSATYIIGFLNLIIACLFYFLLPKSQHFKPYPFRFSRFKDalKDSKLRILFAQGFILMGCLVTVFNYISYHLLEafHLSQAWIGVI-SIAYLAGIYSSPKAAQWGFKYGRDKVLPMMLMTMMIG-LWFTLIPSLWSILIGLIIFAFSFFAAHSTASSWVSVQAVQYRAVASSLYLFCYYIGSSLLGSFGGLVWEQFGWIGINLSVSVVLVIGLVSALYLGKL
     327 UniRef50_Q1MQW7        Permeases of the major faci...   152     2e-35  1  13.0% 14:389   6:382     -------------NIILIMSIALMGVMGVSIILPVLPL-LAHIFELTPTEVGLIITCFSLPSALFTPVAGIIADLYGRKK-ILLLGLALFALGGVGCALSTSFKGLLFCRAIQGLGAAPLGILYSTIIGDLYNEEERPK--MMGIAGATISIGTAIYPALGGFVGE-IHWTLPFWFSLllPVAIIALIYPYPYKGTKTSIKDYTKISGKLIFHSHSVGLLSITFLCFSILYGPILTYFPLIANLLYQASPIQIGITFSIACLGTAIIAINLAQLSRTYSHKKLLIIAAGCygLVIILPLQSQNIWLLTLPIFVLGIAQGISFPLVNSHITSLApsNRAIVMAINSTFMRLSQSISPIVFGIGWSFFGWPGPFIFGLFTSIILALLIMKV---
     328 UniRef50_Q4FUU0        MFS multi-drug efflux pump,...   152     2e-35  1  16.6% 15:358  28:379     --------------IMMLGLIVAVGPLSIDMYLPALPS-MADDFGVSTAFMANSVPAYFVGLVFGQLFYGPFSDRVGRVKPLYI-GMVLYVIASIICATTNNEYVLFTGRTLQALGACVGAVVTRAAIRDRLTAKQ--TAKAFSIMILVMGLAPILAPSLGAVFLQFFSWHSIFWFLAAFGTLNLLLTKFFfeENRNVRPAKEILSQYWELLKDPTFNYPAIGGGLLMGAMFVYISSASELIMDTYGLSATHFGWLFGMNAAGFVALTQLNQWLTNRFRILSILRFGAMMQVISAGALFTLgwLPLVLACIFFCIAGLGLTQPNSSAIALAFQQRRAGMASALQGSLMFSVGIFGGLL----------------------------------
     329 UniRef50_A6LZS3        Major facilitator superfami...   152     2e-35  1  15.2% 12:387  18:404     -----------KHALIFGLISVFLCGIGFTIIAPVVPFLvtSNPGEQAIVVTLLTSVYAVCVFLAAPGLGALSDRYG-RRPVLLVCLLGSAIGYVVFGIGGALWILFAGRIIDGI-TGGTISTIFAYFADIIPSNQRTK--YFGWVSAIVGVGTVIGPTLGGLLA-KFGYSVPMYFGAIITLLNVVYGIFFMPESLHNEDRLepFTQLASILSMKSIKMLLISGFLLWIPNGSLQAVFSQFTIDTFSWKPTVIGLMFSIMGFQDIISqlIMPKLLLKLNDKQIAILGMGSEIMGYAFIALSALlpLFIIGMFIFGFGDSIFGPSFNGMISKSvsSEQGRIQGGSQSIQALARMIGPIIGGQIYVSLGHSAPAFMGILLIALAIPVLY-----
     330 UniRef50_A1ZFX4        Major facilitator family tr...   152     2e-35  1  14.4%  7:388   2:380     ------KKNSLPHNVILLGFVSLFSDISSQMVYPLLAPFL-KSLGATVVLIGLIEGIAETTAALCKTFAGRLSDLWQKRKIFVLLGYGLSNLSKPFLYGASVWSHVLGVRFADRVGKAVRNPPRDALIAGSVDKTQRGKA--FGWHLALDRTGALLGPLIALLILSLsnMRLVFLLSIVPGVIAIGLV-FWVKEVKIHQPKQPAQKQTRALLGNRSFMLFWIACMLFTLGNSS--NAFLILKAQEVHFSTTAIVLLWTLYNLVCTLAAPVLGNLSDKVGRKPLIALSFLYYAGLYALFAFAQAQWMIWTLFGAYGIYYGLSKGIFKAYIADLVPDhrATAYGLFNTGLGIALLPASLLMGAIWTQWSSQWAFLVSACFSLLGCSIFLV----
     331 UniRef50_A0LD21        Major facilitator superfami...   152     2e-35  1  16.8% 10:390   2:396     ---------KRKSTISIIFFTVFLDLLGFGLVLPLLPNYASdmFHASTMEIGVLMGIYSLMQFLFAPLWGRLSDHIG-RRPVLIIGLFGSALSYLIYGLAESLMVLILSRALAGF-MGANIAAAQAAMADLTPPEKR--AQAMGIIGAAFSLGFVLGPAMGGYLASTYGISAAPLAAALITGLNAVAALFLLSETrsKRAHPLSLHPWKQARNYPGALMVCLFMGLFITLFAAFEMALPLWTQIIMGWDsaENGHLFAFVGVVMAIVqgIVRRLVPKIGEVRTAYSGLICIALGLMLLGQASNYTTLLIALGLAATGAGLVHPAFSSLVsnTDKDKQGLMMGLFQSMGALGRVLGPLWAGIAFVSLKGNLFFVSAMGMTVLLGALIPLSR--
     332 UniRef50_C8WEY6        Major facilitator superfami...   152     2e-35  1  14.3% 11:388   1:373     ----------MPIALLALAIGAFGLGTTETIVMGILPE-LSDNLHVSIAKAGLLVSGYAIGVTIASPLMAIITNRYSRRQTLLL-MMAIFVVGNICSALAPNYNLLMASRFLTSLSHGTFYGAASIVACQLVPPQKRAEA--LSIVYIGLTLAMVLGVPLGTLVAQFTSWRVSFWLIGGVGSLAWISIWYLIPHDNQTNTSIRLYDQFRS-LTHPMVILMMLVSMCTSAGMFGLFTYITPFLEIRTGLSAHATDWVLLLIGAGLCLGNLLGGRLADWKMLPSCGGLLAMTIIIQLLLISGSLHVWSCILLLFFWGVFIYAPMAPLQSYVVTCAESAPNIAAAVNQSSFNLGNAIGSWSGSLLVGTLPSTYGKLPILASAFLAAGVLLV----
     333 UniRef50_C5SEM7        Major facilitator superfami...   152     2e-35  1  17.9%  5:390  23:408     ----VPMLALERRAAAGLAAIFSTRMLGLFMVLPVLALYAHDLPGATPLLVGLAIGAYGLTQALFQIPLGLLSDRIG-RKPVIYGGLVLFLVGSLVAALADSIQWVIIGRALQG--SGAIAAAIIALTADLTRDEVRTKGM--AAIGISVALSFAAALVLGPPLTGLIGISGLFWLTALLALGGMLLLAAVVPDpkVHRDAQPVLDQLAGVVRDPTLIRLDLAIFMLHLTMVSLFVVLPLSLRE-AGLPVTEHWMLYLPAVLVAILAMVPFIVLAERGGRVRSVLIgaVLALSMLGFYLFNQTLWLVGVLLAVVFTIFNLLEAVLPSLVSKAAPAgkGTAMGVFSSSQFVGAFLGGLLGGLAHEQFGGEAVYLVGMLTALLWLRLVWTLP--
     334 UniRef50_A0R3Q3        MFS permease n=5 Tax=Actino...   152     2e-35  1  15.2% 11:366  21:371     ----------RWLAVFALALGGFGIGTAEFVAMGLLPD-IATGFGITEPTAGHVISAYALGVVVGAPVLAAVTARV-PRRVLLLGLMAVFTLGNVASMVAPSYPTLVVARFVAGLPHGAYFGVAALAAAHLMGPANR--AKAVAHVLSGLTIATVLGVPMASWLGQALGWRSAFGLVVFVGVLTLAALWFWLPEQLRTMHISSPL-TELGALRRPQVWLAVLVGMIGFGGMFAVYTYISTTMTDVAGLSRGLVPLALMVFGFGMVIGNLLGGRLADLSVVRALYVSLAALGILLAVFVAASHHPWSALLVLFGIGVAGSAVGPALQTRLMDVAHDAQTLAAALNHSALNIGNATGAWVGGLVIAAG--------------------------
     335 UniRef50_UPI00016C47A1 drug resistance transporter...   152     2e-35  1  14.2%  5:391   1:393     ----MPAKRSGLFVISLLGALSVVSPFAIDMYLPAFPE-LATGFGVPSTTIALTLSSYFIGLALGQVVYGPLLDRFGRKPP-LVVGLVLFIVTSVGCAFAPDVYTLIGLRFVQALGGCVAQVASVAMVRDFFPRKE--AARVLSRLFLFIAVSPLLAPTVGTLVIEAGGWPAAFLALAVVVAGILALVVTLLPEGHKPdrPGPILSEYGSILRHPRFHTFAGAGAFSFAGLFTFVAGSPILFRDGFGVDGKTYSLIFALLAGGFIGASQLNVALLRYWPSEVLFRRFLTAQVVFGWLFLAGTVAGWllAVLFAFLCCVGVTNPNASALAIAPFSKNAGSASALLGFFQLGTGAVISMAIGAVEPNNQVPIVAIFGTTASIGLAILVVGRKR-
     336 UniRef50_P28246        Bicyclomycin resistance pro...   152     2e-35  1  14.2%  4:390   1:392     ---MTTRQHSSFAIVFILGLLAMLMPLSIDMYLPALPV-ISAQFGVPAGSTQMTLSTYILGFALGQLIYGPMADSFG-RKPVVLGGTLVFAAAAVACALANTIDQLIVMRFFHGLAAAAASVVINALMRDIYPKEEFSR--MMSFVMLVTTIAPLMAPIVGGWVLVWLSWHYIFWILALAAILASAMIFFLIKETLPPERRQptIGNFAALFRHKRVLSYMLASGFSFAGMFSFLSAGPFVYIEINHVAPENFGYYFALNIVFLFVMTIFNSRFVRRIGALNMFRSGLWIQFIMAAWMVISagFWSLVVGVAAFVGCVSMVSSNAMAVILDEFPHMAGTASSLAGTFRFGIGAIVGALLSLATFNSAWPMIWSIAFCATSSILFCLYASR--
     337 UniRef50_C6VMY6        Transport protein n=3 Tax=L...   152     2e-35  1  15.6% 12:371  52:409     -----------NWLIIGLFCGAFVTGADAFIISALLPA-IATSLHVPTNTAAYGVTVYALCYAIGAPLFGPLGDRF-NKRFLLINGCGIFLLGTLLCGLANSLLTFYLYRAIAGIGAALFVPNIWAFIGTYFNGQRLN--QVMGIVMSALSLSIATGVPLGALLAQLSSWHMAFWGSAMLTLIALSILTIAIPSLPSqaQPDGYFTSFKTLVHTPHAIAALLITLTWMTGFYGVYTFLGVFATATFHFNTMQTGLIFITYGSANFVASFFAGKLISLLGKKQSVTigLVSATLVLSLGIWGQHLAVLLIILVVLALSQGWGVTALTATIVNIVPSNRSTIMSFNSAFLYYGLTLGSAAGGLLLTKIGFYAV---------------------
     338 UniRef50_Q9X4X4        DitE n=2 Tax=Pseudomonas Re...   152     2e-35  1  16.8%  6:386  22:409     -----AWAPIRNRSFRWLWCGGAMVNLAIWM-QTVGAAWIMTLLSTSPLMVSLVQTAISLPAFLFGLPGGVIADLVDRRKWLMMTQGVMLIAAAALSVLSssDWSLLAFTFLLGTGSALSMSAWMVTIVSVLPRDQVPAA--ISLNGISTNAARALGPALAGGLIAYWNAASVFVIITVCLALVIVLVAAFTPRQTPHALPAelRSGVRYIRHSAVLVSALKQVFIFTLSASALWALLPLVAKHELGMDAGGYGLLMGFLGAGAVAGALNLTAMYRRFPLRVLIIAGTAGFALATLVAALSHSRWAVCGTLMIAGMSWMAVNATISTVVQTCAANwrARVASVYLLMLMGAMAIGGAIWGTLAEYLGLQNSLVLAAVTLGVGLILT------
     339 UniRef50_A6W364        Major facilitator superfami...   152     2e-35  1  18.4%  7:387   1:381     ------MDLLERRSVLALALIYLFRMLGLFLIMPVISVAADGLTGADAALIGTAIGIYGLTQASLQIPMGMWSDKIGRKR-VIVIGLLLFAVGSLICANASDINTLIVGRAIQG--AGAIASTLMALLSDVTREQNRTKAM--AIVGISIGASFMLSLVLGPWIFALVGLSGLFYLSFALSLLGIVLIIFAVPNIVQHTFRrpSLLALGLVLKDPRLRFLNVSVLLLHASLTALFVTVPNLLVQQFDLPLSQHSWLYLAIMGFAFAGMLPLVIIAESKGKTkvLIAVMILLGLSSILLQWTPYLWVFGALLWAYFVGFNSLEAVLPSLISKLApgYRGTAMGVFSTHQFMGSFLGGVGGGWLLQHHSNSGVFWVVGVVFLAWSLVCA-----
     340 UniRef50_P37498        Uncharacterized MFS-type tr...   152     2e-35  1  15.6%  1:391   1:390     MTYIRKGTPVFRKITFAFFAAGFNTFAILYCVQPLMEEF-TREFHVTPTAASLSLSVTTMLLAVSMLVFGSLSEVWG-RKPIMGISMLAASVLCLASAFSPSFHTLLVLRTIQGVALAGLPSIAMAYLGEEIEPGSLGSAM--GLYISGNAIGAVFGRIVSGLLSEYLNWHMAMGTIGVISLIASVIFFINLPPSRHFTPRKLKLgsLIGHLRDRKLFSLFLIGFLLLGSNVALFNYIVYVLLGPPYSLNKAFSSWIFIVMIVGIFSSSFIGRMVDRYGYPKILVMNIFIVIAG-ALFTINNMLAVKILGIALFTFGFFGGHSVASSWVGRRALHNKAQASSLYLFFYYAGSSVFGTIGGLFWSGFHWLGVVGMITFMLLVALWLSGYLAR-
     341 UniRef50_Q5HKS2        Major facilitator superfami...   152     3e-35  1  12.2%  5:390   1:385     ----MEESKNYNLITTIMFISGIIVMASLYTALP-LTATFAEDFHVPESIATLNGVLFSLTYSISCLFYGTISEKYGRIKTILVGMSALVII-CLMIGIVHSFTVLLILRALQGVFAASFSPVVMTYTTETYP--RVKRVTAISFISTSFMLSGVLGQNMSELVVSYLNWQWVYFILTILYLILVLVIYKNVPESPHKNPDIQLIknFKDFKDNLKVFYCLFISLTLLIMFISMYDILNEYVTSHQVGGDMSVSSMMKLFGVIGMLLSLLAGRVSSRIGIKRLLTIALTTCIVSIILMGVTTNIILITTFSVLFVAGIAFAIPTVISKIGVVVKNNQGFFLSVNTFVLFLGTAIAPILMLFVGELSNFFLQFLMIAIVGLIALVVSIFMP--
     342 UniRef50_Q7NZZ8        Probable MFS transporter n=...   152     3e-35  1  16.8%  7:369   1:373     ------MSRTSRNHFGLAALLAALSTLGPFSIDTFLPAmiGDTLSASPLEMQQALTVYLFCYALMMLWHGSISDAVG-RRPVVLATTLLFGLASVGCALSNTLGQLLLFRALQGLCGGAGLVVGRAIIRDRLEGAAAQR--LMSQVTMLFSLSPAVAPVVGGWLFGAFGWHSIFAFMALIGFALFALCWFGLPETHPKAArrPLLASYWRVGRTVNFQLLTAAVSFNFAGFFLYVPSAPVFLMQHLRLGPTEFLWLFGPAVSGIMFGAYLSGRMAGHFSSREVVSRAYWLMFAAAllLAPEQALPWAVLPLALYTTGMSLAAPSITLNLMDQFPELRGTASSLQGFCQTMVSSLVAGVIAPLAWASPLR-----------------------
     343 UniRef50_C6BK10        Drug resistance transporter...   152     3e-35  1  16.1%  7:391   1:389     ------MPGPIPGWLLLLGALTAIGPLSVDMYLPSLPT-IARDLNTSSAAAGLTLTVFLISLAIGQLIYGPASDRFGRKPPLYI-GLAMYVAASIGCAFAKDATMLAVLRGVQGFGGCAGMVIARAAVRDRMDPA--GAAQAYSTLMLVMGVAPILAPMIGGAVLQFTTWRVIFALLTAFGVLSLVAVHYLMRESLAPEQArhVLRDYWELLRDHHYAAYMGCGAVFLSGMFAYITVSSFVLIDGYGLTPSQYAWVFGSNAAGMIAASRVNVRLVRKYSPARVLRRALWVPAITSVLAAAatPLPLVLAALFCYIASIGCISPNTGALAMAGQGARAGTGSALMGAMQFGLGMVTGTVVATIGQTA--LPLLGMMAVCAIVALLLGLRITR-
     344 UniRef50_Q0FFS7        Drug resistance transporter...   152     3e-35  1  15.0% 13:391  16:396     ------------PSMLTLVLLASISALAMNSFLPSLPN-MAEHFGSSTALMGLSVGVYLGTSAVFQILVGPLSDRIG-RRTVSLWSLIIFIVVSISCVYAPNTFVFMCLRALQAIAACTF-VVARAIVRDTT--ETQASGSKIAYISMGTAICPMFGPALGGLMDGWFGWEANFWFIGGLGLLILVIAYFDLGETVPENTqrQQFSEYPELLLSRRFWGYCLASAFGAGAFFAYLGGGPFVGSIVYNLSPEMLGLYFGAPAIGYFFGNFLSGRFTIRFGIDAMILWGLWIIFSGLSlyIGYGTVETFFGFMIFVGLGNGLTIPNATAGMLSVRPHLAGTASGLGGAMMIAIGAALSTLAGAFLVPGSNEMPLLMLMWFSSLSGVAVIIYVR-
     345 UniRef50_C7MV11        Arabinose efflux permease f...   152     3e-35  1  13.6% 10:391  36:412     ---------KLDKRIYLLTAIAFAVGLVELIIGGIL-DLVAADLGVSEGRAGLLITAFALVFGISGPVLLFLFGRFDRKRVTL-AALVVFVVGNVIAVLSPTYVLLLLSRVISAASGGLLTVMSLTMAARISAPELRGRA--IGLVVMGISGSIVLGLPVGVSMGHAFGWRSPFVLVIVLALLLMWAVAARF--GTMTAEPPAPLGRQVAALGNSRVLSAHLTTSFFLAGHYTLYGYLTPFVITTMGFGGALITAVYFVFGAAAVTGGGLSGALSDRFGARRTLLTATALFALCLVAIPHTTSVpaFWVVLALWGVLSWAITPPIQSHLVQLAPRTADIQQSLNNSMLHLGIALGSFVGSTVIDRFGVMYNARVGALFVLLALGAALVSFR-
     346 UniRef50_C2QV90        Multidrug resistance protei...   152     3e-35  1  14.5% 10:389   6:388     ---------RKNLALVLALFNVFIVFLGIGLVVPVMPSYM-RALHLGTDTMGYLIAMFAFFQLLTSPIAGIWVDIFGRKK-MIIAGLILFSFSEFLFGVGNQIWVLFLSRALGGVSAACMMPAVTAFIADTTTLENR--AKALGYLSAAISTGFIIGPGIGGFISD-FGIRAPFFFAAVISGIAACFSVFILKEPVSKEQrqVSFLKEIKQSFHPLYFIPLLLVFVLGCGLSAYEHMFSFVVDKKFGFTPKDISIIISVSAILGVIAQifFEKLVKKFGEKGIIKYSLFIAAIIIVVSTFVGNYWMVAILTFIIFLAFDLLRPAITTLLSKIAGENQGFIGGMNSTYTSLGNIIGPATGGILLN-VNVNLPYIFAGLILTIGFGITVYW---
     347 UniRef50_C2QNT2        Multidrug resistance protei...   152     3e-35  1  18.5% 11:388   1:376     ----------MKKIMAVFFLIMFVIGTDTFLISPLLPS-LREKYDVTVELSGWLVSAYALGYALFALIAGPISDGFNRKKVMI-FGLFSFSIFTFLCGLASSFELMLIFRFLSGISAAFLTPQVWASIPILLPPNKVLRGMGIAT--AGLSVSQMLGIPIGSYLAS-INWNTPFFIISIFSLLLLIPTFLLVPSIQPTEkkTSIFKNYQGLLSSSKVRKTFFAYFIFQLGNFCAFSFLGTWLSDDYHFSVSQVGTAMLILGLGNTLGSLLGANVIQKIGELSSLIYGMIILSVFYSVLAYLPNILMVEVTFLLMFLFTGMIFPLLMSLLQSLSSTARGTIASLSNTVMYSGTTIGGYIGGILYGTYgfAAIGFFTTAMFLLSLILFIT----
     348 UniRef50_D1XEN6        Major facilitator superfami...   152     3e-35  1  12.6%  9:366  27:378     --------STMPLALLALAVSAFGIGTTEFVMMGLLPN-VADDLGTSVPTAGYLVSAYAIGVVLGAPLLTGLGSRIPRKR-MLLLLMALFTVGNLASAFAPGYGWLLAGRVLAGLPHGAFFGVGAVVAARLVPDGRQARA--VATMFLGLTVANIVGVPAATLLGQHLGWRATFMVVAVIGLAAMAALARLVPQIPREAH--QDVRHEIRALGNRQVVLGLLTAVLGFAGVFAVYSYLSSMTTEAMGFGESSVTLVLALFGIGMTLGALAAGPLTDRALRPTLYGSLAALSVVLVVFPFAAHVKWAALVMVVLLGAVGFMTTTPLQMLVMNKAKDAPTLASASNHSAFNLANAGGAWLGGVAISAG--------------------------
     349 UniRef50_Q2S5E9        Transporter, major facilita...   152     3e-35  1  18.5%  6:388   4:389     -----TKTSNPYLILFALWLMMFSASSQLIIMVPILPE-IAATLGVNAFWQGMLLTAYALSLGVSALITGPASDRIG-RRLILLYGTILMAVTLTLHTVAESYVLLFSMRLLAGIGGGMLTSGSVAYVGDYFPYEQRGWA--NGWVMSGTAFGQVAGIPIGKVLATGFGYRWPFLMFAVPMAVSAVLIWLYVPQPDarLTPARLVEKYRAVLQGSDAVNAVASYLLMFSGFGLFTSFLPSWLESTVGVSSYEIALLFAIGGTANILASPLGGRVSDRIGRKPIVVWASLVLGLLMALAPliTGFLIAAVLFFLAMGLIGIRVGPLQSLITALVPDrrGLLMGLAMSVGQAGFGFGSFVASITYGPYGFFSNAVGGALAMIGMAGLVHW----
     350 UniRef50_C0Z8B1        Putative transporter n=1 Ta...   152     3e-35  1  14.9% 10:384   2:371     ---------LNSWKIYILAIVSFLVGTSEFVIAGIL-DRVASDVGVTLAAAGQLITVYSLAYAIGTPILIAITAKMDRRK-LMLAALVLFLLGNLVTITTTGFAMLFGARIILAIGTGVFMVVALTVASKIAQPGKQGGA--IATVLLGFNLALILGVPLGRVIAGSYDWKIIFTGIGVLSLIAMFVLLLTIPKSKGEIPV--PIREQLSLLKTPRISIALSISFFWILGYTIIYTYISPFLLTITGMSDRMVSIGLFVFGIASLLGSQVGGYGADKWgpRTMIGGLLLHSGILLLITVFSHSSVFVLPLLMLWSFFAWSTGPVQQVYLIGMAPKASGIILSLNTSIVQLGMAVGSVIGGMVVENISLQAVGWIGAIGVAIALL--------
     351 UniRef50_A0B6G9        Major facilitator superfami...   151     3e-35  1  16.5% 11:392   4:387     ----------LPKSIFPLYLSVFVSVLGFAVVAPIFPLYVL-DMGATHLMLGMIISIYGAVQLLTQMPAGRLSDQRG-RKPVLLIGLLTFTIMPLLYIYASNAYQLLLIRIFGGIGASMVWPVTMALIVDCVDPSHRGLAM--GWYNASFYSAVAVGPVIGSLLYGSFGINAPFIFWSLFAVASLIMVTFVVREPPVRGEvnTPRTPKARLIVDGSMITFIICCSVVmgIIGGFNMTLLPELALSVGVGVSQLGILYMAYAGSNALANIYFGRVADLGHRRLLISGGSLGCVLGFLVLGHGQGILPQLIALTILGLSSGICTPAATVVVSYisPERRGEIFGIFNTSRMLGVVIGPIIAGLTADLGGLAGAITAFLAVSLLISAMTLSLREI
     352 UniRef50_C9A449        Major facilitator superfami...   151     3e-35  1  14.4% 16:377  36:397     ---------------LLLGTLSAYGPLLMDAYLPAFPV-IQEELGISASLTQMSLTMCLIGLALGPLAIGTLSDRIGRKKP-LAIGITVAILCCLLVPFVRNIWLFLALRLLQGIASSAGIVLTRAIAKDLFTGERLTK--FFAMLIAVNGIFPIISPLLGSAILAVASWQTIFLFLGGLGILLLLGILFGYQETLQPQEhhQMESGWRAVLSDRIFMLLVLIQGFIYGALFSYISGSSFMFQNVYGLSDQMYSLLYGINGIGIIVTAELSGILSRRLSLVQQLGSGLVIGFIGSVLVMLSgsIALAIIGLFLVVATLGIVNSVVTTLAMDRQGEHAGVASSILGIGMYSIGIICTPLVGIMGSHTYLPLALLIFLC---------------
     353 UniRef50_D1J9U2        Putative uncharacterized pr...   151     4e-35  1  15.7% 13:387   5:377     ------------KEVAIYAVLMFIAMLSLTLMAPVIQEFIIDRFNASNTEASMFFSLEMLAYVIFAMIWGSLSDKCGKRKFFIVFGFAGSAVLYFLMAQANTLPILLILRFIQGAITVMAWSLVMTSALDSVPKT--SYGKTMGVIGMAMMLGMAFGAPLGGFLAERYNVFVPMYLTSSLFLMGTLISATQIHDVRIENKPDTMLESIKVLIDEKRLAVPYIFSFVDRFTIAFFIFAFPLYLAHAFGFGGAERGMYQALLLFPLVVFQYPFGRLSDKIGRAPLLVTGSLFYGLEMCLVCFV-GKTILIALILSCGVFAAMMFPSSTALAGDIspNKRGAAIGGFNVFGSLGFVVGFSAAGILSDMYGYSTSFVFGGISEILVALIAI-----
     354 UniRef50_Q03Z75        Permease of the major facil...   151     4e-35  1  15.2%  6:392  23:408     -----TDQRLFTKDFIILMMINFLVMTAVTTQMGTLPLYVTH-LGGNSIMSGLVVGIWGLAALCARIPVGKLLDTYGRKKLIFIGLAILMADFSMLIFYS-TIASLIVLRALQGIGNGTQSTSVATMVADKLPKQKLSIG--LGYFSISQTLPAAIGPAIGLVVVENFGFQSLFYFSLSLICLAFVLSFFVKDNYTHVEKSKHVvtGFLDLIRLKSVWVPSLIVFVVCFANAAVTAFLVQFGEQK-NLSATIVGFSFTMQAIIGALVRVWFAKLYLYFRSYVLVIAGILMIASAYFMIAFGATVEWLVLAGALNGFGFALLIPLMNAVVLkvSSAQRGRATAIFSSGTDVAYGLGAFMWGVVANFIGFFGMYCLTATMVIATLLLVIAHNRL
     355 UniRef50_Q4QP52        Probable sugar efflux trans...   151     4e-35  1  13.7%  1:388   1:382     MSLYLKAEKIQSWRVLIMACAGFIFNTTEFVPVAMLSD-IAQSFDMQTADTGLMMTVYAWTVLIMSLPA-MLATGNMERKSLLIKLFIIFIVGHILLVIAWNFWILLLARMCIALAHSVFWSITASLVMRISPKHKKTQA--LGMLAIGTALATILGLPIGRIVGQLVGWRVTFGIIAVLALSIMFLIIRLLPNLPSKN--AGSIASLPLLAKRPLLLWLYVTTAIVISAHFTAYTYIEPFMIDVGHLDPNFATAVLLVFGFSGIAASLLFNRLYRFAPTKFIVVSMSLLMFSLLLLLFSTEAIIAMFSLVFIWGIGISCIGLSLQMRVLKLAPDATDVATAIYSGIFNAGIGAGALFGNLATTYLGLNEIGYTGAALGLIGFIIFIT----
     356 UniRef50_Q395I2        Drug resistance transporter...   151     4e-35  1  14.0% 27:391  24:394     --------------------------VTIDAYLPSLPA-MADALHGTDAQLQLTLTLYMVGYALSMLVSGPLSDRYG-RRPVLLGGLCLYVVASVACAWSTSITAIVAARIFQALGGCSGTVIGRVIVRERFPTAMQ--ATMLGRISAGMALSPVIAPLAGSAVAEWLGWRGVFGLLAAGGLVATAMVLRYLPETrrPAPDKGLLRTYAGLLRDRSFLRYSLAISFAYCTYYPFIAESSTLFQRQRGVSGPVYAAIFGLTVLGYLIGSNLFARTGTRWKADSVIAAAAGVNLASAAVLWIgtAVAALVVPMFFVMVAVGIAIPACQFAVMQPYTTIAGTASGLFFFIQMAITAACGGVLAWLSDGTARPmvVTVGASVAFLAVAVGLRERR-
     357 UniRef50_C0X6B1        Major facilitator family tr...   151     4e-35  1  14.8% 11:389  17:407     ----------WIKVVAIFFVGWILMYATRTIFNPVMGV-IGEQFGLSNTQLGLANSIFFLTYAVAQIPFGMIGDKIG-RKLVIAVGFIVLAISTYFSGLATTFVMFLVIRAIAGIGQGAYYGPQYALSTEAIPASKRTIG--NAIINSGMAFGTSGGYLLSSKLVLENgwSKPFFIMAIPTFIVGILFYTILKEKVIRPggPQEKISLKEIFSNRNLLAAFILCFTSIYANFVIITWLPQFLIAERGFTGASVGFISSLVPWASIPGALIFARLNDKTGATKKLVFTLvlAILSVFAIAFVTNRTLLISVLILYGlgKLALDPIMVTFVTKHAPKAagTTLSAYNFIGMSGSILAPYVTGYLADTAgmQVGFYLSCVLLVIGLLAFAFL---
     358 UniRef50_B9QVG0        Drug resistance transporter...   151     4e-35  1  15.1%  2:391   6:406     -TAHTTREPKRIAFVVMLMGISTLSPFAMNIYLPSV-DGMMSAFSATAAEIQLTLAFYFIAIAVAQIFLGPISDQFG-RRPVIVAGMVLFVIGSVLCLMAPTVEALIAARIVQAIGGGAGLVLARAIVRDVYGRDK--AASMIGYVAMGMAVAPTIGPAIGGFLDAHYGWRGGFVLMLIFGIGVTICAWLFLPETNQHKKakQIGQGYADLFKEKMFWVFCGASTFMAWLYFAYLGGAPFVAAGVFNMAPAEIGLYLMVVSIGYIIGNFITGRIAARAGIARMIALGVITGVFGVSLLVVGttGPLFFMPMFFIGLGNGLGIPSAISGAVSIRPDLAGTASGMLSFLQVGAGALVSSAVAYMFSamPMILVMVVGGVFGLACVLAVFLGER-
     359 UniRef50_C5LE52        Tetracycline resistance pro...   151     4e-35  1  15.9%  3:373  33:417     --ETSAKSMPIDRRVWPIALSTGLMGVSIGLVQPVLPL-LATSLNISTAQFGQVIAVVGLSRIFctIPTSILADVSG-RRPLLVYGAAASALSMAGLGAASSFNQLLFWRLLGGAASAGQMTGAHLYLADISQPENRSRTM--APVVAAWGVGFAAGPALGGLLAEAFGTQMPFYGTAAVIAAVAAVNHRMLPETHKRspLRVTLGNYRKLLEHPTIRQASLITGTFWFMQTGCqcLLPLLLIQEFSFSAGGVGVVYATLAATGALLSQPAAHISDRVSRRSCIVPGSLLVAASVATlaAAGSTPLLYCSLSGWAVGSALVGTAPTALVADSVNeeRASALALLRTAQDFGGLVGPLALAWAADMFGMGVPLW-------------------
     360 UniRef50_Q21Z49        Drug resistance transporter...   151     5e-35  1  13.5%  7:391   9:399     ------WRAPRWALAVLLAVLGMLGPFSIDTYIPAFSG-IAQSLGATPVQMQQTLSAYLFGFAFMSLFHGAISDSVG-RRPVVLWGLAAFTLASMGCALSQSIGQLVFFRAVQGLTTGAGIVVSRAVVRDMFAPAQAQK--VMSQITIYFGVAPAIAPIIGGTLFVHLGWHSVFWFLTAVGVLLWVANYKLLPETLHLTQRQplLQGYWQLGLDPRFLLLALASGVPFNGMFLYVLSAPAFLGGILGLAPTQFFWFFVLTISGIMGGAWVSGRMAGKLAPKQQIKYGLLIMLLIASlwLFKAHVAWSLFPIAIFAFGWAMMVPVITLLVLDLHPERRGMASSLQAFIASSANGLVAGLIAPLVMHSAVSLAVASLSMMCVGLFAWLYLHRR-
     361 UniRef50_A8IJC5        Transmembrane efflux protei...   151     5e-35  1  14.6%  9:392  27:407     --------SAMPVALYALAAGAFGIGVTEFVIMGLL-LDVGADLGVSLSAAGLLISGYALGVVVGAPVLTILTARW-PRKAVLLGLMAVFTLGNLACALAPDYELLMAARVLTAFAHATFFGVGSVVATGLVPANK--KASAIAIMFTGLTVANILGVPFGTWLGQHYGWRSTFWAVTLVGVLAFAVIALLVPANAAKPEASNLKKDL-AVLTRAPLLLGLLTTVLSWVGVFAAFTYIAPMLTKITGFAESAVSPILLVFGAGLVVGNLAGGRLADRWLVPTVYGSLVVLAAVLGALTFALHNAVAAVIFVGLLGAVAFATVAPLQMWVLEKagAGQSLASSFNIAAFNLGNAIGAWLGGVVIDhlGLGAVPWVAALVPLAAVPVAWWAGRL
     362 UniRef50_Q5FSN5        Putative drug transport tra...   151     5e-35  1  15.3%  3:388   4:409     --QNMTFRRGDPLPAWllGIFTAVGPVSTDVYLPALPE-MERQLHTAAGSGSATMAAWVIGLAIGQITIGPISDRFGRRWPLLL-GMLGYTLGEIGCALAPSMTFLCICRVFSAIMASAGLVVPNACIRDLTEGDASSK--MMSRLIVIQGTVPILAPMLGGFALKFVDWRVIFWVTAVYGGICTLLLMTIFPETLAPHDRRDLreRYVYILRTRSFVTNGLVWSFLGFVTFTYLTAAPMLFEDVFGMSPFHYGMLFGLFAICMIGASAINGQLVGRVSTGRMLFSALGVSLAGCAILLLLAvlWPLIIALIITMGPTGIIGPNSMVGVLSEQSDRAGSASALAGTMQYLFGAVASALFGLMPSGTAVPMALFLSFAFVAAMGFALLR----
     363 UniRef50_B2KCW9        Major facilitator superfami...   151     5e-35  1  13.1% 10:392   2:386     ---------KMTREIFIITLANALILAGYGMSVPFFAIYLNVERALPASMVGAVIAISTIGRAFASGISGELSDIFGRKKLmlVLGAVFLALMGLGMILDAHYIWIIIFHMIASFFGAFFRPSSNAWVADNVAPKNRLEA--FGYIRIGLNLGWAAGPALGGLIAN-YSFGAAFIITAVSYIGTAAMLQAKIKEtvRSKEHKSKFTDMILELKNQRLAKLCALIFLISVVAAQLVTGLSLHGVKYIGLTQAQIGLLFTIDGSIVVLLQYHASKIMTDMRITTALIIGCIIYGSGYILVGAAHGFTLAAIGIALVATGEMAISPGSNTLISNIAPeaRGRYLGMQEVSRHIGTAAGMFGAGVMIEYLSPISQIIPWLLIGFISFTVAFLFYKI
     364 UniRef50_C6QL36        Major facilitator superfami...   151     5e-35  1  14.1% 17:391  12:385     ----------------LFLIASFIFWFSNFIYMPILSPYI-ELLGGTYTFIGIVLSSYGFMQFLFRLPIGMISDFMKRRKPFIILGMLMTMSSGLMFALTNSLGWALVSRSLAGVA-AATWVAFTVLYCSYFSDEKIYKAMSN--ISFAVVLAQLMGMSISGYIVDKWGWHAPFWIGGILGMIGVILSLFIypKDKDIKQASIQMKDLILVMREPLLLRASLLSILAHSIIFTTMFGFIPMYVLQIGFQENDLSMIVFSFMIPHALATLFMEKlvPVFGKWKSLMLAFLCSAVFTLVTPIIKDKELLCIIQAFNGFSLGLLFPLLLGMAIESIDDrrATAMGIYQAIYAIGMFGGPYIAGKLNSAIGIQASFYFAGILGIAAMMLILAWNR-
     365 UniRef50_A0RFY9        Major facilitator family tr...   151     5e-35  1  12.3% 10:392   5:407     ---------SWDRNLKTRLIGETMFNTLFWMYFPFMAIYYSDAFGKTIG--GVLMAIIPLVGIIGNLLGGYLADRLGRRPVMLL-GTIIQVAMFAVFALSHSHWINYLAYIGIGISGAIYSPASSAMIADIVPEKDRR--VVFATFVTANNIGAVFGPVLGSFF--FFHYRslLWTCTIVTFIYFIAIYFIIRETLPEASkkEQWNNYIKIFSDKIFSLYIVAGVLIMIAFMQLDLYLALYVKesFSLSNTQigWMMGLNGILFVLCSLPVAKYFENWGDRNVLLISNVLFGTGMFLIGLTTNIWLLFGFMAILTIGELIRSPVVHSFVSKYAPeaRGQYMAASNLQFTIGRFIAPIMI-VFSTWLSPSVVFGIILLCALVSAVFYVKVFRM
     366 UniRef50_A5VLW9        Major facilitator superfami...   151     5e-35  1  14.4%  9:389   2:380     --------SKFRLQSVVFVLTAFLLGCNEFMIVGVISD-IAKSYHASLSTVGFLVTSFAIIYAICTPLITTLTGKFDRFKVLMV-LMLIFLIGNTLTAVAPNLFWLFVSRIVTAAVAGTIISLILVFVSMIAPIEKR--AMLVASTFTGFSIATIVGVPVGTAISNAFSWRDSFALISVLTVIICGFLYW--PTPRDSRQENASLSNQVQLFKDRRIILGVIVMVTLMSAEYTFYTYVRPIITNVLGFSTTNLTWLLGLIGITFILGNICAGVIANRFGITKLTIISSTVLICLLLMNAMFHVAWLGILLLCVICFVLGMPGSILQVMFLNIapEAMNLASSLNPICTNVGVSIGSLTASISINFVQINQIGYVGAIYALVAVFGSFYL---
     367 UniRef50_Q2BHQ6        Putative uncharacterized pr...   151     5e-35  1  15.9% 13:390   8:389     ------------PPIAYFTVMSMVSPIALNILLPALPD-VAENLGVTTSEVQLSLTLYLFSLAIGQLICGPLADRFG-RRPILLTGIALHFIGCLLGAYADDLNSLLAARVLQALGGCTGMVLARTIMLDRYTRDQ--AAGKIGYITLSIALSQAIAPTLGGHINLQFGWQYLFHFSLLLSTVSWLIVMFMIPETAKEKTDsrVLSQYWQVLKAPNYLGYALSTTFIACAFYLFIGSAPYIVDSEMGGTSADFGNWFLIVSLGFMLGSFTAAKISARLGIQRMIILglAAVTMLLCILSFGLHYFTLFIPMALFTLGRGFSQPSGQSAGISCSQGSPSTASGLMGFIQLLTGAVIAQVTPFILAAGSV-WIIVTLLLCPLLAFVAFYTTR--
     368 UniRef50_A4CGZ2        Multidrug-efflux transporte...   151     5e-35  1  16.0% 15:390  10:401     --------------IFLILLSLFVVMLGYGILLPILPYylKDNLDAdnFHIGMLTSIYPLFQLIFVIVWGRLSDKYG-RKPIILVGLIGFITMNLLTGLATSLTMLYSARIFGGIFTSSVIPVSNAYLSDITSQKRRTKTMAWS--GVAISSGVIFGPVLGGLLSQtfgfSIPFLFAAILGLIILFVIIKWLKNTAIVTRIREKTIKFDFTLSN-YFIILLLLSFVMQFVVTLFETVFSIYGKDELAFNSSQVGIGFMLCGSVMAVLQPVFATYGEkiTSKQQITLGLLITGVSLLMFPFLQSELSVYGMIILFASGGAMVTPNLLSAVSLLSKEDTGRNISIQSSSNSIGQILGPVLGTWLL-AGGFYYPFIIAGLIILMAIGLVYYLQ--
     369 UniRef50_Q1QXI0        Drug resistance transporter...   151     5e-35  1  16.3% 12:391   7:391     -----------RRLALLVAANTALAPFAIDAYLPAMPT-LAEAVNASVHHTELSLSVFLFGFAIGQLLCGPLSDRFG-RRPVLLTGLVVFLVASLGIMQVSSLETLWGLRFVQALGGGACVVNSAAIVRDCF--SGREAAKVMSTMAMILMLAPLVAPTVGSVLLGFFNWQSIFLFLALYAAFLLFFLGTRLPETHGRDPDAPslRNYASVIRHREAMGYICAVSMSFAGMFAFITGSPYLYMEHYGISAAVYPFVFGANILVMASSNRLNIYLLKRRTPQQNLVVGlaGVALVALILSGMDSIYSVAPLMVVFVGMQGLIAPNAMSSMLDHFPNMSATATALQGCLQFSSGAFAGMLVGAFEIASAWPTVLTMLGASLLGNIGVRVLAGR-
     370 UniRef50_A4B9G3        Possible MDR-type permease ...   151     5e-35  1  13.9%  1:389   1:393     MKAIWQQYQGLNRDLYILALARAIASAGAF-VLPMLTLILTQKIGLSVAQSGLLVSAASASFVPGSLIGGRLADRYGRKKVM-VFAESMAGLSWIVCGFYPESTLVIPFVFVANFCWGMIEPSSTALVTDLTRPEQRKAAFSLAYL--GHNLGFAVGPLIAGFLFLNHA-HWMFWGDGATALIGAMLVLWLVQdpQTEAEADVVGSVWPILWARRYLLWFTAANFLLVFTYAQMSFSLPLQLEQTFgqGARNFGLVMTVNAITVLVFTPIMIALTRRLHSIFNVAVTGVFYVVGFGMIFWLDALWLFFVSTLIWTLGETLHHINANAYIASHSPrhRARINSILPLIYGTGYGIAPMVMGQFIGWQGIRAVWLLVILLAAVGTLCMVLL---
     371 UniRef50_C6D8H8        Major facilitator superfami...   151     5e-35  1  13.9%  1:368   2:368     MSYLQSGQPGYTRASMALFGGAFVTFAELYSTQPLMPE-LTERFEVTPALSSLSLSVATISLAIALPLVAGFSDRWGRKRVM-SLSLLASAAVSILVACSPNFQALLILRAIQGIAISGFPAIAMAYVNEEFDPAENARAM--GLYVSGTSVGGMSGRIVISALADLFSWRIALLAVGLISLAIAVWFLRALPKapKRIAPSETLGMSIRALRNRSLAGIYALGFLLMGGFVAMYNYVGYLLTGEPYRLSQTVVSFVFVVYLMGTFSSAWMGKLADRLGRPQAIRLAIVISLAG-CLLTLLPSLYVKILGLACFTFGFFGAHSVASGWVGRIAAGYRAQASSLYLLFYYGGSSAAGFAGGLFWGRYGW------------------------
     372 UniRef50_Q797E3        Purine efflux pump pbuE n=1...   151     6e-35  1  11.9% 11:389   1:374     ----------MNFKVFLLAASTIAVGLVELIVGGILPQ-IANDLDISIVSAGQLISVFALGYAVSGPLLLALTAKIERKRLYLIA-LFVFFLSNLVAYFSPNFATLMVSRVLAAMSTGLIVVLSLTIAPKIVAPEYRARA--IGIIFMGFSSAIALGVPLGILISDSFGWRILFLGIGLLALISMLIISIFFE--RIPAEKMIPFREQLKTIGNLKIASSHLVTMFTLAGHYTLYAYFAPFLEETLHLSSFWVSICYFLFGISAVCGGPFGGALSDRLGSFKSILLVTGSFAIIMFLLPLStsMIFFLPVMVIWGLLSWSLAPAQQSYLIEIAPDSSDIQQSFNTSALQVGIALGSAIGGVVLDQTGTVVSTAWCGGSIVIIAVLFAFI---
     373 UniRef50_O34724        Uncharacterized MFS-type tr...   150     6e-35  1  15.3% 16:381   4:367     ---------------IWLFFSVMFVIGTDTFLLSPLLPLLQDQFHVSTDLSGWMVSAYALGYALFAFIAGPISDRL-NRKTVMLWGLAGFIVSTFLCGIAPSFAAMCLFRFAAGVSAAFVTPQIWASIPVIVQPSQIIKGMGIAT--AGLAASQMLGLPIGGFLAS-FTWHTPFFVLSACSLILLLILAAVMPGIRPSEprPSIVNPYRELFSLPKTSVILLAYFLFQTGNFASFSFLGTWLSADYHLTVSQIGAAMLVLGLGNMLGSLIGSRVSEKLGMFKTLISGMLLMGALYFALPFFPNLFLVEAGFFLTFFTAGIIFPLMMGVFQSIAPNARGTIASLSNAAMYAGTTVGTSIAGFLYQSTQHFGAVTGFTAILFI-----------
     374 UniRef50_D1YWI8        MFS transporter n=2 Tax=Eur...   150     6e-35  1  14.7%  9:390   7:391     --------RRYDRQVWILVAGSLLNTFGTSIAYPFVSLYLYKYQGVSMTDIGLALLAAAAAGGLVSVGAGELCDRFG-RKIMLNIGLFFQMVSFALLGYawGYSEFMMLMVLKEISGGLYRNVPQVMVADTVEPGDRNGA--FSLLRIGGNLGFALGPIFGGILAS-YSYAAMFIITALTSGAYMLISLYLLHDTRPDERDIAAHPHHDPMWSNTPFIIFCAASAIGSLVYSNLFTTFGTFSGGFIDVSESMIGLIFSLNGFMVVVFQLPVAYYLERFRMTTSLILGSLIYASGFALVGFCNSVWMLFMSMFIITVGELVVTPASQTLLSEMapEARGRYMNVAGFIGSGGNACGPAVGGFLMDGFsiIMMWLILGALEVVCAGGYLALR--
     375 UniRef50_P94131        Cis,cis-muconate transport ...   150     7e-35  1  16.8% 40:385  43:398     ---------------------------------------IKAEFNLSTVEAGMLGSFTLAGMAIGGIFGGWACDRFGRVR-IVVISILTFSILTCGLGLTQSFIQFGVLRFFASLGLGSLYIACNTLMAEYVPTKYRT--TVLGTLQAGWTVGYIVATLLAGWLIPDHGWRVLFYV-AIIPVLMAVLMHFFVPEppSKQTETVKTSAFKLIFQDKrfILWALTAGFLQFGYYGVNNWMPSYLESELGMKFKEMTAYMVGTYTAMILGKILAGFMADKLGRRFTYAFGAIGTAIFLPLIVFYNSPDNILYLLVIFGFLYGIPYGVNATYMTESFPTarGTAIGGAYNVGRLGAAIAPATIGFLASGGSIGLGFVVMGAAYFICGVI-------
     376 UniRef50_UPI0001BC2E9A MFS transporter n=1 Tax=Bre...   150     7e-35  1  15.1%  9:386  18:391     --------SRAKLALLALSIGGFGIGLTEFVIAGLLTE-VATDLSVTIPAAGHLVGAYALAVVPGALILTPFLMRRPP-KVALVALLALFVIGNILSAWSPSYEVMFAGRIVAALAHGGYFGIGAVLAGSLVPKSRQ--ASAISIMFAGLTIANVLGVPLGSFIGQQLGWRAVFWIISVIGVLALIGLMALVPRTDPEQDQLPVRQQFATLAK-PQVLSSLITTALIFGGMFGVFTYIEPLLRNETGFSAGAIPWLLVLFGGGLFLGNVIGGRAADRNPDKAVVVLSILLPIVILALGMAAGIPWATAVLLTLMGAVGFATVPGLQARVMRHAQGAATLASATNIAAFNLGNTIgsLAGAAIGAGWGFRSPTVVGAGLTVIGLIIM------
     377 UniRef50_Q03N75        Permease of the major facil...   150     7e-35  1  18.6%  8:384  29:410     -------RRRRIWLTLLLGTVSATGPLAIDLYLPALPQ-MKAQFATTASLMQLSITACLIGLALGQLIAGPLSDQYGRRKPLII-GFVIFGLVSLAMAFIHSVTLLIALRFIQGLAGATGQVLARAVARDLFSGKKLTR--FYALLNTVNGVFPIIAPIIGGFMIQYVDWEAIFILLALIGLLIALAVTFGLHESLPPEKRQtsLLAMGKLVVQPSFWPLILATGLVYGGLFSYISASTFVFQTGFGMAPQTFSLLYAFNGLGIVVGSNLPGRLASRFSNRqmLAIAAGVSALLIISLLFPANVWVVSGLILLLVILIGALLTLTVTIIMDQATSNAGGASAVIGLSQNACGGLASPLVGLSGKSYAAMAIMLFVCNVGAYGLV--------
     378 UniRef50_A3MZ73        Bicyclomycin resistance-lik...   150     7e-35  1  16.0%  5:391   1:392     ----MVTQRPHPCFFIILGMMAMLPPLAIDMYLPSF-LDIARDLQVSQEKVQTTLAVFTFGFAVGQLFWGPMADSFG-RKPIILFGLTGSALAAYFLTQVMTIENFYLLRLIQGLCAAAPAVVLGALVRDLFDRNM--FAQMMSVIMIISMLAPLLAPILGGYIAKYFHWHSIFYTLVLMGISCVLLISWKIPETLAIEKRQPLrkNFWTLLSDKATLGYVLVGGLTFAGMFCFLTSGSLVYIGIYGVSQEYFGYFFGLNMIVMVSMTALNGRIVVKVGSEKMLKIGLLVQLLAGIWLACVagFWAMAIGIPFYVGMLSTIGSNATAAILDRYPQMAGTANGLAGTARFGIASLVGAMLSHIAVTSERPMLYAMAMCTIAASIAYYLLCKN-
     379 UniRef50_B4CWN5        Major facilitator superfami...   150     7e-35  1  12.6%  1:389   1:419     MSETPSGATHVRYALLGVATANAFLLYLDrmTTVVHSPSFLRELHLSEADVGNVLSSFFFAYALGQLPAGWLADRFGPRR-MLVAYIVLWSACTALTGLATSIAAIVIVRLACGLSEAGAYPASARVISRWFPFGHRARA--NSFVAFGGRLGLALAPWLTvvIARLNGWRPVLWIYGGIGLTLAAATFFTFRDEppPPSKPDYRFPWLELLCHRGLWLLSLGAIGLNFGWALLVTWLPKYLQSVRGLDEEDANFSVTIVLACGVAGVLFGGWWCdrWGRRLPIIIGGLIGTAAYLVCPSLHSARGVIIACGLVAFATDSANPAIWTLSQDIGRGHVAATLAWSNMWGNLGASAvpLALASTMHRADWSEVFWMCAASFLIFAGCALFI---
     380 UniRef50_Q03E32        Arabinose efflux permease n...   150     8e-35  1  13.0%  4:371   1:368     ---MINQKSKANFALFALAVIFFAVGVTEFISVGVLPA-ISKSFMITTSTAGLITTIYALGVALGAPILTILTAKF-QRKGTILGAIIIFIIGHLIIGFATNFGEVIFGRLIAGASHGLLFALSSTIAAELVDESRQ--ASAIAYIFTGFTIATALGAPLGTAVSTYWGWRIPFLAIATLGIVAWILNRVALPKQARKNVEISSIADQVKLILHPHVLLTLLITILGYGGTFATFTYLSSILQKITHVPANQVSLFLVIYGIAIAIGNTLGGKLGNAKPINALFGIFIVQGLALFAFYFTVTNIYLSTLNIVLLGLVAFMSVPVLQSYILILAkkAVDVASSLNISAFSFGIVGGSFLGGVALDTYGLRST---------------------
     381 UniRef50_C4DJ48        Arabinose efflux permease f...   150     8e-35  1  13.9% 11:392   1:379     ----------MPVAIYLLGAAIFAQGTSELILSGLLTD-IASDLNITIPQAGLLTSGFAVGMAIGAPILAVLTLRWDRRKTL-LALLAAFTAAHILGALAPTYELLLLTRFAGAFAYAGFWAVASVTAITMAGPQARGKAM--SIVAGGLTIATVVGVPAGTVIGQHFGWRAAFWTVAALTALSALGVAKTVPSQKSTPEDRPRLRTELRTFAGGRIWIAYVATAMSSGAVMATFTYLGALLTGVTDIPTTWVPAVLVLFGLGSLLGITLGGRFADAHPFATLYTGFGGVIAAAVLLFTGATNPTLTLIASFLLAVSGFATNPAVNVLVFSLANNAPTLAGATNITAFNVGITLAPWASGLLiaHLGLPTITWISATLATIGLTATLTSQSL
     382 UniRef50_B6ESH9        MFS transporter n=18 Tax=Pr...   150     8e-35  1  15.2% 10:391   5:381     ---------KMPFQVWILTLAAFAIGTAEFVIAGILPQ-IAVSLSITEGQAGYLISAYALAIVIGGPILTIYLARF-NKKIVLIGLMVLFIIGNILSALAPNYNLLLVSRVVAGLVQGPFYGIGAVVATNLVSEKMAGRA--VGQMFAGLTLANVLGVPAGTWISLQFGWHITFFTVAAFGAIAMVFILTSIKSTGHSEAK--DIKTQLVAFKNPMLLISLAITALSWSGFMTLYGYLAPIAMHITGYGEAAVTWILVIVGAGLIIGNILGGRSSDKNLAKASMFWAVAMLISLILVGLSVDNKILFVVTAFVFGIASFANVPAMQLRVMKHGGEGQELAATANISAFNLANAFGGLLGGLVLdhVGASMIPYAAVVVPIIGLFFIAKANR-
     383 UniRef50_C5SHV1        Drug resistance transporter...   150     9e-35  1  11.0%  1:392   1:400     MSAPEAAPPALKNPFLVIFTLGALSTISPFAIDMYLPAfiAADFKTSSAAVGLSLSSYFAGMALGPLIYGPLLDRYGRKPP-LYAGLALFVLTSVGCVFAPNIDVLIWLRLFQALGGCAASVAAMSLVRDLFPPKD--TAKIISLIILTIGVSPLLAPTLGGLVTTWLDWHWVFAFLAAIVGLTLILVITVLPDGKPADPSvpILKTFLGLYRNPAFVTYLFAGGFSFGCLFIYVSASPVIFMEIFHIKPEIYGLIFAGLSVGFIGSSQLNVFVNRRYSSKQILRVGLSVQCVFVLAFLLAanVWGTVIMLFLILSCLGFIGPNSSATAIGSLTRDIGSGSALMSFTQIGLATIVSAVVSAL-QAQTLTPIVVVMTMSVVIGRVVLFVGERL
     384 UniRef50_B0C5I9        Major facilitator superfami...   150     9e-35  1  15.5% 11:390   1:383     ----------MKREVWIVSAIALVNSLSFTVLLPTLYPY-GRQFGLNDFETSFLFSIFSIAQFIATPVIGQLSDRWG-RRPLLLVSLAGTMLANLMAGLATAAWVLFLARFLDGI-TGGNNSVIQAVIADVTDAENRARG--FSLFGAAFGVGFVLGPLI-SLGAQAISLGASFLVSAWIAGIALGVTYFFLPETLEERSQPrgLAKLVTGLTIPKVGILLLINFLIGTTFTIFTYAFQPYFLNVLNQTPQSLALIFIVYGVLGVLMQTFgpNLTKRFNLLLILFVALLIRSVAFLAMPIWPNVTYFVSITIFFSIFNSLVQPIINTLIsnVDAQQQGMAMGLNSSYLSISNGIGPVIAGVLIHqaSYGYPLYLAGACTFGVLLLAIQTR--
     385 UniRef50_A5FNK2        Major facilitator superfami...   150     9e-35  1  11.9% 11:389   1:375     ----------MKKSLIALSFGGLTIGITEFVMMGLLPD-IASDMKVSIPVAGYLISAYALGVVIGAPLLVILGRNFPPKK-MLLILAAMLAVFNALSIIAPTYNILFASRFLSGLPHGAFFGVGAVVASRLADKGK--EAQAIAIMFSGLTLANLIGVPIGTYIGHNFIWRYTFVLIAVVGLLTFLFISLWMP--HLDKGESVNMKKQLEFFKRREAWLIIGITAIGFGGLFAWISYIAPLLINVSKFAEGDVSYILILAGLGMVVGNFAGGKLADKYSPAPTTLALLFIMSvlILVYFLSSNQYVSLFLTFLTGAISFSVIAPIQMLMIRTAKGAEMIASASLQGSFNIGNALGAFLGGllSAGYSYASPNLIGVGMSVIGMLITLTL---
     386 UniRef50_C8WUC9        Major facilitator superfami...   150     9e-35  1  14.8% 18:388   1:388     -----------------MCAVQAIMMMAFSSMNPFLALFIGQLGVHNplWAGVVASANFLMSAIMSPVWGSVADKRGKKLMVMRTTLAI-AIATSLMGFSRNVYELLFIRMLQGAFSG-FSASANALVASTIPEERLG--FALGWLSTFAMVGSLVGPLLGGVLVDAfnYRIVFHLTAAFATTAFLLTWAMIRESKTStrRIGLIGQFKAVRDLRTVQVMFFVLFAAQFSVMSVQPVLPLYIRELVGRDPQLFGVifAVTGIADLIFSPFLGKRSDRIGYRKVLSISLVGAALCYIPQALAPNVWVFMLGRFLLGAFIGGILPTANALVGRMTpeMRGRVYGLTASSTFLGSFAGPLVGGAVSAGFGIRVMLAAVILLYLANFAWVRW----
     387 UniRef50_A6VI88        Major facilitator superfami...   150     9e-35  1  14.9% 15:389   8:380     --------------IYVLWITIFVTMLGIGLIAPLLAIF-AKSYGLSNFQIGLIFGSFALVRTIFQLPAGTLSDTYG-KKIFLVAGTLLYGVTTLFYGLVSGFASMLIVRTFTGVFSAFVNPVAGSYIAQVSPKSKLGE--YMGVFNSAVSLGFGVGPLLGGLLADMYGIMVPFYVCGILGIIASIIAYYKLEDISKSQEKQKLSGksLEFLKMRNFSAAFIINIAITISRGALLAYLAIYAYD-YGVSAFKIGIMLAAMNMVLAVTQKKFGKIFDKNGNRIILNGIIIGNLGMYIL-AMSTSFTSMFFSLIIASIGASMSTPGINSIAIRDIPHErgEAMGLYTASINVGIFVGAVLLGYISDIVGISNMFKIGAVFSFLISYIAYVL---
     388 UniRef50_C3PLC0        Permease of the major facil...   150     9e-35  1  16.5%  3:347  16:354     --QTEISTTRRTIVMIAMALGAFAIGTTEFTSMGLLPL-IADDFGITEDTASVVISVYALGVVVGAPVIAALTGKLPRRRLI-ILLIGFLLVGNLLTALAPNYGVLLVARFIAGLPHGAYFSVANLAAVSMAPPGRQGFAM--SMVGMGLSIATVIGVPAAQALGQGLGWHAAYFLVVAIAGLTMILLFFLFP--HMTRMPQTDMFTELGALKNSQVLLTVFLGTVGFGGMFAVYTYITWTMTDVAGMDPSHTWIVLMAYGIGMTTGNVAGGWLADRNLEFGIIFALICMVGVSVTFYFVAHSAWAGTVVFGVLAFFGSILVPSLQLRLVNVAGDAQTLAAALNQSA---------------------------------------------
     389 UniRef50_A1HQS7        Major facilitator superfami...   150     9e-35  1  15.1%  8:391  12:382     -------EQLWTRDFILICTTNLFIFCGFQMLMPTLPVY-AKHLGGSDAAAGLIVGSVSVAAVLMRPVAGQALDYYG-RKGIFLAGLVVFISAVLAYIWAPSLGVLLLIRFIHGFGWGATSTAASTVAADIIPKARLGEGM--GYFGLTTTVAMAFAPALGLYLTSHFSFTVLFLASAFIVAIAAGLALSI-------GYRHINAAKAKTFLLEKAALRPALVIFFVTMTYGAVVSFLALYAAQQ---GIDNIGPFFTVYAIALAVARPLSGRLADRRGFDIVVIPGVVLIMVAMFLLYLANSFAWFLAAGIVYGIGFGAVQPGLQAmvLKAPPNRRGAANATFFIGFDLGIGFSSVLWGLVSQAFGYKAMYLWTVVPALLALSIYIIIGR-
     390 UniRef50_A4J1M4        Major facilitator superfami...   150     1e-34  1  12.2%  7:390   1:414     ------MSQKSTNMRWILGFSLFLIGFVAYmnLSVAGPLIMKDFGFDKVQFGLVQTLFFIGYSLMQVPGGLIAERFGARKAMALA-IGWWSSFTILTAYASNFLTFGIVRALFGVGEGPLYPGASVLVSKWFNKKERGTA--NSFILAGSFVGPVLAPAITVYIMTAFGWRAVFWLFGAVGFLVALGWWLLARDNPANHpeKKEFAPLGKFINSVQFWAIGFQYFVADYIMYVYLAWLPIYLMEAQHFSLKEMGIMAAFPWLALAITTLSTGVISDRLVSRGVSvlGLVISSIALYFAAVSVKPMITVLWLTLSLGILGFTFNASWASCNDLGQKFTGTVSGWMNLCGNLGGVLAPTLTAIVATHWGWQSALVFTAGIGLTGVIAWFLVK--
     391 UniRef50_C0EUN7        Putative uncharacterized pr...   150     1e-34  1  14.8%  6:389   4:382     -----KMTLKEWLPLLGITVSAFIFNTSEFMPIGLLTD-IADSFHITEAHAGVLITVYSWIVMLLSLPLMLLLNKIDFKR-LLLGTIALFGIFQMLSAFSASYGMLMISRIGVACTHSVFWSIASPAAVSVVSEKFRSLA--LSMVVTGTSIAMILGLPLGRIIGLHMGWNMAFFCVGIIAFITTAYLIFVFP--KVPGGESFSIKQMPEIFKNKTLMGIFLVTFLFATSYYTGYSYIEPFLQKVAGLSANWVTTTLTIFGAAGLLGSFLFSHYYDKNKYLFVKLVMISVAAALLLLYPISKAHMAVVLLCAFWGMAVMAFNVTFQSEIITYAPAAASsaMAIYSGIYNLGIGSGTWIGGSICTHLSISYIGIAGGMIAVVAALLCIFV---
     392 UniRef50_B9XIE9        Major facilitator superfami...   150     1e-34  1  14.2% 11:391   2:395     ----------RKPSVGIIFLTVFIDLIGFGLVIPLLPIY-AKNFNATGWQIALVMAAYSFMQFVFAPFLGRLSDRIG-RRPVLLTSTAGAAVSYLIFAYatALILLIASRAFAGVC-GANITVAQAYIADITPPENRSK--RMGLIGMAFGLGFIFGPILAAVARTYFGDSGPGWAAFALCAINFFLALTILPESWKPsaPRPHLAQWMHTLSRPKVGLLIGIFFLATFCFTCFESTLGLLILSKFSlgIRTVSYLFIYAGLVGALVQgaTGRLVKALGEPKLIALSLFLVAISLGPLPFAQNWTQVLILLALLSIGSSLTRPPVFGMISnsSAQEQGVTIGVAQSAGSLARIIGPLFALPLFTYQQSYPYLICGAISLLTGILAWQRLSR-
     393 UniRef50_D2QFD2        Major facilitator superfami...   150     1e-34  1  11.8% 11:390   1:376     ----------MKKSLLPLAIGGFGIGMTEFVIMGILPD-VASSLQISIPVAGHLISSYALGVVLGAPLLVGIAGNYPPKK-ILLGLMALFTFCNALSSFAPNYEIMMITRLLSGLPHGAFFGVGAVVASRLAGKGK--EAQAISMMFAGLTVANIIGVPLGTYIGHTMSWRITFIIIAAVGLATMFCIQKLLP--VMPVVGESSLRKDLKLFTRVEPWLILGITAIGTGGLFAWFSYIAPLLTEVAHFGSSQITWILILAGLGMATGNLISGRTADLISPSKATALFLLLMTCSLIGVYFVAQyiPLLIMTFITGAIAFSLGAPIQILMIRAANGSEMLASSVSQAGFNMGNALGAYLGGliAAGLGYASPEWVGAALAFAGFGLAMVVY--
     394 UniRef50_C1PBG0        Major facilitator superfami...   150     1e-34  1  14.0%  5:389   1:383     ----MDKPKLWTKDFIMISSTNFFTHVVFYLLMTSIAMYVITAYHASQGMAGLAAGIFVLASLIARLFAGKYLDKIG-RKQMLVGGLIVFLAVMLLHFKADSLLYLMVLRFIQGAMHGVITTAAGAIVADIIPNERRGEGT--GYYATSMNLAMAIGPFLGILITRFADFHMIVLVSSIIAFIDLigILLSVPKPAAGHAKVTEMARFKViyFEPAAVPISGAVFAVTLAYSSVLSFLSLYAKDI--GLTGAATYFFLVYAAALVITRPFTGRWFDERGANVVVYPLFILLIAGFVLLSQAHSGWMLLTAGALIGIGYGTVQSSFQAIAIQLSPPNraLATSTFFIFLDLASGSGPYLLGTVAGLMDFRMLYLAVSGWVVLCIAVYYAV---
     395 UniRef50_C7R2E6        Drug resistance transporter...   150     1e-34  1  12.6% 15:386  26:403     --------------ILMLGAIAAIPAITTDIYLPSLTD-VRDELATTDAMVAMTMSGMLIGGAVGQLMWGPLTDRYGRKAPLLV-GLALHIITSLLCAIAPNITILVTLRIMQGFFNAACAVAAISVIRDRFVGA--TAARLLSQLMLVIGVAPLFAPSVGGAIASFGSWRTVFLALAIIGAIMAVIVARFLPETLAEDHrgRVAKGYWTLAKDRKFLALAMLPALAMTTIFAYVVGSPFVFQEHYGLSTSQYAVLFAMNGLAMVFSAQLNASLVRKFSPESLLRVGLGLQLVLAlgATGWGGFWTFEVTLWLLLGCQGLIGANAQVLALANYGHMVGTAAAVLGSLQSGVAGAVSPMVGVFGGDALAMAAVIAAGLILANLIVVF------
     396 UniRef50_A4WAE6        Probable sugar efflux trans...   150     1e-34  1  15.3%  1:391   1:385     MTTNTVSRKVAWLRVVTLAIAAFIFNTTEFVPVGLLSD-IAQSFQMETAQVGIMLTIYAWVVALMSLPFMLLTSQMERRK-LLIGLFVLFIASHVLSFLAWNFNVLVISRIGIAFAHAIFWSITASLAIRLAPAGKR--AQALSLLATGTALAMVLGLPIGRIVGQYFGWRTTFFAIGLGALITLLCLIKLLPKL--PSEHSGSLKSLPLLFRRPALMSIYLLTVVVVTAHYTAYSYIEPFVQVVAGFSANFATVLLLILGGAGIIGSVLFGKLGNKHASLLVSSAIGLLLACLLLLMPAAQSETHLAILSIFWGVAIMIIGLGMQVKVLALAPDATDVAMSLFSGIFNIGIGAGALVGNQISLHLSMSAIGYLGAIPALAALIWSILIFR-
     397 UniRef50_Q0BZG6        Transporter, major facilita...   150     1e-34  1  13.3%  1:390   1:397     MTDAPAPSPFSIPLFKRIWVANIASQFG-GLIQSVGAAWLMVQLGGSETQIALVQASVTLPIMILSLLSGAIADNYPRRTVMLLSQVYMFIVSAVLCVFalSPWLLLTFTFLLGCGTALNAPSWQATVGDIVP--RQTIAAAVSMNSLGFNIARTAGPALGGAIVAAAGAAAAFAVNVLSYLGIIYVLLAWKPEKPLKParTAIGAGVRYVSMSPPIRQVMARAALFGIAASAVLSLLPLVAQELVGGGAVTFGILSGAFGIGAVIGALSNARLRRRFTAESILRMTISMIIAGVVIVAFSRVLPLTVVGLVICGSGWLLSMATMNVTVQMAAPRwvGRALSLYQMAVFGAMAVGSWITGQLAENYGVMQALLTMAAVQSVSLFAGLFLR--
     398 UniRef50_UPI0001AED2A9 integral membrane transport...   150     1e-34  1  14.1% 33:380   1:346     --------------------------------MPLLAFYVTDELGRDAAFAGTVVAATGVGSLAAGPFGGILADRLGH-KPTLVGAQAATAVCMVALAYARSPWALLLGAFAVGLANNATRPAHNALISEVVTPEHRARA--YSLNFWAINIGYSVA-MLSVGLVTFTGYTALFWLNGATTLIGGILIAARVPGGRPTPPpaEKGEGFGAVLRDRTFVGFVVAEFLVLTILYQSEAGLPIAMGQD-GFSPSTFGQVAALNGIVIVLVQLPLTRFYKRFPESGVLAGSSALIGVGYSVLLLGDSAWIYGLSVVVWTLGEIGNTPTSFTIVARISPDhrGRYQGLYQMAWTGSLVVAPLIGGGVIHNWGATPLWIGCLIVGL------------
     399 UniRef50_Q56RY7        TetA(39) n=13 Tax=Bacteria ...   150     1e-34  1  17.1% 11:390   1:387     ----------MKKSLSVILITIFLDAVGIGLIMPILPELLRSLAGAEAGGvgALLAVYALMQFIFAPILGALSDRFG-RRPVLIISIAGATADYLLMAAAPSLLWLYIGRIFAGI-TGANMAVATAYVSDITPAHER--AKRFGLLGAVFGIGFIAGPVIGGVLGEW-NLHAPFFAAAFMNGINLIMTAVLLKESKhkVQEQSILKKLSYLITQPNMAPLLGIFLIITLVSQVPATLWVIYGQDRYGWSIFIAGVSLASYGICHSIAQAFaaPMVKRFGEKNTLLCGIACDAIGLLLLSIAVEEWVPFALLPLFALGGVAVPALQAMMSRGISDERQGELQGLLSSFNSLGAIIGPVLVTSLyqASAPGMVWALAAILYVITLPLLLKYR--
     400 UniRef50_B6YSG1        Permease n=6 Tax=Thermococc...   150     1e-34  1  16.4%  1:391   1:392     MGEKEKKIFGVSRNVFLLGIVSFLNDMSSEMIAPVVPTYLTEILGISKVVSGSIMGLIESLSSLFKVLFGYFSDHFRKRKLFVAFGYLFSTIAKGALAFVHSWWDFVTLRVLDRVGKGIRTAPRDALIAESSEKGKTGK--SFGFHRMMDTLGAVAGPLAAIAILELlaYRYLFLLSAIPGLIGVVIVILLVKDKG---GEVKKKVKGISALKSRNLRLFLVVVAIGALGRYSY--AFTLWKAEELGFSVVQGLGFYALFNLIYALSAYPLGTYSDTFGKKRMIALGFGIAALASLAFAYARDFYTLIAAFVLYGLYIAIEDTIPRAYMADLAEeeKGTIIGAYHTVFGVFVFPASVIAGWLWQNYSLTYSFIFAALMNAIAMVLMAFVRE-
     401 UniRef50_Q080G5        Major facilitator superfami...   150     1e-34  1  13.2% 12:389  14:384     -----------TAILLVLALGTFILGLSEFSMMPMLPL-ISETFSSTPSQSGYAISAYAIGVVVGAPIL-MLTTANMKKRHALAIFLTLMFISNGLSAMATSLEQLIVFRFLSGLPHGAYFGAAILLAADIAPQNKR--ASYMSKVFMGLTIATIVGVPIVTLVGQNLSWRYCLAGASVLALVALVCVYVVIPKI--ENNQPSNLINEFSVLKNKLVWSILGIVIIGFGGVFCIYTYIADTILVVTETPAYTISIAMVMFGIGCTLGNYVLGKAADRAALKTTGIALVCTIIFSLAYVSASHNIWLLYAVIFFIGCSVGLA-TLIQTLLMDVSPNGHAMIGALVQCSFNTANAIGPWVGGMFIAQGAMPNETGYVAAVLFAGGLMMWLL---
     402 UniRef50_Q49V98        Putative permease of the ma...   149     1e-34  1  12.6%  9:389   4:381     --------KLWSKDFISITFVNFLMYLIHYTLIVTVTIFTIDKFHASESMGGLAAGIFIIGMLFGRLASGRVIDNLQPKK-VLLFGIIFSIITVGLYFLISSLFLLMLVRLLHGIAFGLASTATGTISSRIIPEKRKGEG--IGYYALSVTTASAIGPFCGIVLNQRFGFESIFIVSLVIIIIAFIAALFilPKPPVENNDEVENKGIRAYI-QKEALPISFVVIFVGIAYSSVLSFLTVYTEQI--NLATASSFFFIVYAVSTFVTRPFTGKIYDAYGENKVMYPVLCSFAIGLVLLAITHTSLLLLISAIFVGIGYGTIVPSAQAIAIQQSpdKIGLATSTFYMFTDFGAGIGPFVLGIMVPIMGYRYLYITMAIVVIASIILYYFM---
     403 UniRef50_Q6MQ30        Tetracycline-efflux transpo...   149     1e-34  1  16.8% 52:390  16:366     ---------------------------------------------------GYFISIYALMQFLASPLLGALSDRFG-RRSVLLISLLVAGFDYILMAYAPTLEILFAGRIIAGL-TGANITVAMAYIADVSNDENRSA--NFGMVGAAFGLGFIIGPAIGGLLG-HLGPEYPFLVAAALNLLNFFFGLFILPESLPKnrRTNPLYSLLGVLRSKHLLALLLVYFFFQLAGQTHPSIWTLYTETRYGWTTAQVGLSLAVVGLLSALAQGWLTRLvpKFGEHRTVVIGAFGYAVSFIFYGMATEGWMMYAILILSAVFWTSPPALQSLISHKTPPQEQGELQGSLVSLSSLAAIITPLVTTKLFAHFspGAPYYFGALICFVSWAIMYRRK--
     404 UniRef50_A7HNZ9        Drug resistance transporter...   149     1e-34  1  16.8%  5:386   1:387     ----MKLAPGTAAFTVFLASLTAVGPLSTDMYLPSLPA-IGEDFNADAGTVQLTLSTHLIAFAGSQLFYGPLSDRYG-RRPVLLGGFLLFMAGCFASLFVTSIEQLILARLLQAVGGGASVVLARAIVRDLFEGPE--AGQMLAKMAAIMGLVPALAPMLGGVVQDLYGWKANFIAMGAFGAVLALMVAVNLDETLPRDRRQSalRSYRRLLADRHFLKYLAIATVAFCGLFAFVSGSSFVLQGLYGYSPIAYGLCFGAMAGGFVAGSLAGGRLVRRRGIDGTLRFGGFCAalMLSGLFLTPSAMAIVLPVVIYGFSMGVTMPQAMAGALTPFPDIAGTASSLLGFLQSFAGALAGLYVGYGAEASALPMAGTIAAGGVLSFVIAM------
     405 UniRef50_P40760        Uncharacterized MFS-type tr...   149     1e-34  1  15.5% 18:392   1:383     -----------------MWLANFFVSASTTMIVPFLSLYIETLSSFSNgwSGYVFGITFLMAFLVSPFWGRFGDKRGYKKILMATGTGI-ALSIFFMGFVTSVYQLFFLRMAMGLVTG-FIPTSLAMISAQTPKS--SAGKTLGTLQMGQVSGSLFGPLLGGMLADRFGFTYTFFITSFVIFSSVLLVLFGVKEKHLAEKTasRKEVLSYIFHHPALWVMMLLTMLIQTGNFSIQPLLALYVNELHgnLAFFSGMAFSATGLGSLLLARKWGDLGDRYGHRRILIGLLLAASFFFIPQALASSLSVLLVFRFLFGMAMGGLLPCITAAIRVQAPGsqGEVLGYNVSFRFLGNVLGPLLGGIISSHFTISATFYVTAFLFFAGACMLWIMQKL
     406 UniRef50_C6DDP2        Drug resistance transporter...   149     1e-34  1  14.8%  1:391   1:394     MTQVQTRPEKTPGLFFilSALMAFTSLSTDIYLPAMPVMAKDLQG----NAELTITGFLIGFCIAQLIWGPLSDHLGRRMPLFI-GMVLFIIGSVGCALSTDMSQIVFWRVFQALGACTGPMLARAMIRDLFSRTR--AAQMLSTLIIVMAIAPIAGPLLGGQLIKVTSWHAIFWLLAVIG-IAMLMSLRWLPETLPEDRrpSAFRNYYALLTNTSFMRFTLCLTFYYVAAYAFITGSAFVYITYFGIDPQHYGWLFALNIVGVMGMSVVNRRLVQRYSLEKLLKFAVLIATVASFILAVggGIVLIVVSVFIFFSMNGIIAATSTAAALDAVPNIAGSASALIGSLQYGSGIISSLLLALLSDGTPWTMA-WIIALFTAASAVIALTTRE-
     407 UniRef50_B2V655        Major facilitator superfami...   149     1e-34  1  14.1%  9:348   8:351     --------PEEKKITLGLAFIFALRMLGLFLALPVLSIYAKNMPGSDAFLAGLAIGAYGLTQAIFQIPYGLWSDKIG-RKPIIITSTIIFILGSFLSAYAASIelLIIGRFLQGI--GAVSSVVIALLADMTREEIRTRAM--ATIGASIGMAFAFGMVLGPLIASHFGLAGVFTFTGILGLISLPYIIFGIKEPPIVKHHDDAEFtlGIVLKDKNLLKMDFGMFVLHMTLTAVFTAVPIIFAHQYTIDVKDLWKIYLLMFFVGLTIMVPSTIIAEKKNKIkvKMLGILVLIVSFIMFlfKNNFYLTVLAIVVYFTGFMMLEPIMPSLMSKYapHVKGTASGVFNTAQ--------------------------------------------
     408 UniRef50_D1JCU2        Putative uncharacterized pr...   149     1e-34  1  16.0% 12:385   7:380     -----------KRTLFTLYFSIVAAILGLSIISPLLPT-IAEDLGATGFWVGMIFSGYAISRAIIMPVMGGLSDKYG-RRIFIASGLLLLAVISLLYLPAHNVYSITAVRLLNGLAAGMIIPVAMAYAGEVAQEGKEGRAM--GIITMIFYLGIAVGPFIGGIFWHSFGATSVFYVMSGISAFALLLVLPFLPEIKNPKASKTEEHELFKNLIKRDAVKIVLIIGFISAFRTGVLLSFLPSHASGFNINVAQVGIIISVGVIFTGVLQPFFGNVADKLSKYNmiIIGSFIGTIGLFMVPLCNDFITLLLVNVLIGIGAAISIPVLADIAVVIGKkgIGSWMGIFNTTISLGIIVAPLMSGVVMDYSGINSVFYYSGIVSLLCTFI-------
     409 UniRef50_A7ZZ10        Multidrug resistance protei...   149     1e-34  1  15.2% 10:391  11:400     ---------NWKRNLIVAWLGCFLTGAAFSLVMPFLPLYV-EQLGVtnMWSGIVFSITFLFSAIASPFWGGLADRKG-RKLMLLRSALGMGIVMVLMGLAQNIWQFLILRALL-GLLGGFVPNANALIATQVPRNKSGWA--LGTLSTGGVSGALLGPMAGGLLADSYGLRPVFFITASVLILCFFVTLFCIREKFQPVSKKEMlrEVVTSLKNPKLVllFVTTLIIQVATGSIAPILTLYVRELAGNVSNVagMIASVPGVAALLLSAplGKLGDRIGPEKILITALIFSVLLLIPMSYVQTPLQLGILRFLLGAADGALLPAVQtlVYNSSNQIAGRIFSYNQSFRDIGNVTGPLMGAAISANYGFRAVFLVTAGVVLFNAVYSWNSLR-
     410 UniRef50_C5BXU7        Major facilitator superfami...   149     1e-34  1  16.4%  2:391   8:401     -MPRATRTTRWWVVALLFFLGWLFIYADRTILNPVMSE-IGSEFGLDKAGLGLLNSVFFLVYALVQVPSGMLGDKYGRLK-FIVFGFIVFGLFTGLTGIAGAVGVLFLMRAMAGFGQGFYYGPQYSLSGEMIP--ERFRTVGSALINSGQAFGISIGLIASSYIalDLGWRGPFYVFALPTIVVGLAMWVFIKEPARPTPSaePKPTVLSLFKSKNLVRTFVMVFCSIYGFFVMITWLPTYLNEVRGVALEDTGFVSSLAAWTSVPAALVFAYFSDRIGRRklLLIVFPAAIASILLLVFAPSMPLVIVALVLYGlgKLATDPLLIALCGVNSPKatATAFGLFNFIGMSASILAPYITGFLVEATgwNVGFYLAIGLLVVAILAALGIKE-
     411 UniRef50_C0QVC3        Arbinose efflux permease n=...   149     2e-34  1  14.5%  6:384  13:389     -----STSENRLLAIISLVLLSFALGTSEFIVIGVLTE-IAEGFNITEVKAGGLVSMFALAYSVCTPFSAAIAGKF-NRFHFIIFAGILFIVGNFLCSLASNYTFLLIVRMFIAIISGALISVSISFSPYISTKDKRP--MVVAWIYSGFSIASIFGVPIGTSISYYFGWRASFIFISIFSAVMLILMFITLPKNTPTHKVK--LLGQFILFKDARFILSTFTILFGAASSYVLYTYLKPIFLNYIHIPNKYVSAALLVFGVTVLFSNLLSGKLAEHNGVYRlmMQFLCMIVLPFALLNAVSSSIVILIIGFLMYLMNSPVQLNILDFTEREYPSCLTLASSNNSFSFNFGIALGSFVGSSIFDNFGIRWVGFGGAVLSVLAFI--------
     412 UniRef50_A0LYZ9        Bcr/CflA family drug resist...   149     2e-34  1  16.6%  6:390   5:397     -----TSERNKKQEYIILLVLGTMIALGPFSIDAYLPGfiAKDFNTSISQIGITLTSYFIGISIGQLAYGPIMDKYGRKKPL-LIGLLLYLLSALSCMYSPNLEWLIISRFFLAVGAAAGMVAAKAIVRDIFPVNEV--AGAISVLMLIMGGAPIIAPTVGSFIIDSFGWKTIFLFLAVFSALMIISVSRFLPESIIPDrpKQVAIKYFGILTHPKFMNFAFAGSFAIGAMFAYISDAPKLFMGNFGLTQKEFGILFGLNAAGLILGSQINRLFLRKYSTFQITLFNSVILVVLSLLffFEFGFITTVVLLFLMLFLLGFQNPNTTALSLEPFEKKAGRASALIGSLKMILGALTSFIISLFHSSSAIPLAIILSTCLFISSLLLFSFAR--
     413 UniRef50_B3QQM7        Major facilitator superfami...   149     2e-34  1  19.5% 11:375  10:375     ----------LSGNVFFAGLVSFCMDVSSEMIYPLVPLFLASALGVNKSMIGLIEGSAESMASLVKVFSGWYSDRLGKRKRLMLAGYSVSTLSRPLIALAGGWHQVLVARLVDRFGKGVRTAPRDAIIADSAEPAWLGRA--FSFHRSMDTMGAVVGPAIAFIALQIYhyRHLFWLSIVPGILAVLLIIFFIREKQAPPVQAEAETPQTSGSRKLDRRAWFFIVIVAIFALGNSSDAFLILRAGQLGVPAAMIPVVYLLFNLVYSITAIPAGIAADRYGRKRLILAGFVLFAALYAGFAVAGSALAVWVLFALYGVFMGLTEGIQKAFLATLIPEgkGTAFGLYAGAVGFAALPSSLIAGMLWDSFSAAATFWFG-----------------
     414 UniRef50_Q15ZK9        Major facilitator superfami...   149     2e-34  1  16.1%  7:384   1:377     ------MNRTEIRASLALAAVYVLRMLGLFMVMPVLAILAVHYPDYSALMLGLAIGGYGLTQAILQIPMGVLSDKIG-RKPVIVGGLLMFAIGSGVAATADSMLWIVIGRFLQ--GAGAIAGAIMALAGDVSREQQRPK--VMAIIGIAIGFSFYIALLIGPVIADNYGLHGIFSITGILAISCIPLVIWVVPSaaPKGDTLPVLTDVKILFFDPQLRRLNISVMLLHMMITVLFVQMPILL-SALGWQLESHWQLYLPILAASVVGLVALMMLTKRMSQAGVIRLCILLLGGALLGLHFSHsvLAVMVFGWLFFTGFNFLEASFPAMVSSIApgKKGSAMGIYASFQFLGAFLGGTLSGLASQYIGPQWVFVIAGGACGIWWL--------
     415 UniRef50_C0ZKD4        Conserved hypothetical memb...   149     2e-34  1  13.1%  6:388   4:382     -----SRERLWTRDFVLLTVCNLLLFLTVQMQTPTFPAYVKETYQANDFVVSLVISLFSLAAVIARVFTGEAL-KTKSSKLLAIVALGFVAIFSAGYYWAGSIVFFLLLRILVGIGFGMGSTTFPTIVSNVIPARRIGEGM--GYFGLSTSLAMALGPLIGLGVLNGFGFGSMLMVLVLLVAIIFPLMHFIRanQLPVSSGNTQTVTGIRRFYDKKLLLPAGLNFCLSITYGGILSFLALYGKEAH---IENVGWFFLTNALAMVLIRPFSGKLYDRKGHIAVLPPGAIFVGISLLLLSLTTTESLLLVSAAFYGLGYGMIQPSIQAWMVKVvpEQRGMANGLFFNSIDLGIAVGSMLLGVIATHSSYSVMYRWSAACLLLFLIVYFL----
     416 UniRef50_C6XPG3        Drug resistance transporter...   149     2e-34  1  14.2% 12:391  28:413     -----------WELICIIAGLMALNATAVDIMLPALSDIQNTFQFEDDNNRQKMVIVYLMGMGLSQIFYGPLIDRFG-RKPILVVSLIVYIIASVACLVAPDYQMLIFARAVQGAAAGATRVVAAAVVRDCYTG--RAMAEIMSIVMLIFMAAPILAPSLggILFFFGDWRAIFWALVVLGSVMMIWSYVRLPETLAPEDRRPLkrSYYTVFTNRYAMGYSIASALIFGTLFGYISASEQIYVEAFNKGAS-FPLWFAGVSAGMAVSNLLNSRLVRNLGMRFLSHWALIIMILVNILHAIVssFVVFYVLMIISFVCIGFIGPNFSSTAMEPLGHIAGSASALYGFAT---TFLAAAIGGFVADQYdlGPLFAVNAICLILALVVILWTER-
     417 UniRef50_A6VW64        Drug resistance transporter...   149     2e-34  1  15.1% 13:390   6:389     ------------PIILVLGLLSGLTPLAIDAYLPSIPT-ISKSLNTDIGLIQMTLSIYLLVFAFLQILFGPISDAIGRRKVV-VGGLTVFAIGSFVCALTQSYELLMIGRAIQALGGAAVAVCVPALVKD--GMSINQFAKAMSMIMLVMSLAPLAAPIIGGAILTILNWHYIFVMLGILAIIAIALFLRTIPETLPVEKRTpaIRNYITLLKNRSVMGYIAASAFYFAGMMSFITGCSFVYIEIYNVDPANFGFLVGLNVISMMLASTINGRYVEKLGTEAliYIPLIASILMIVLSFFSHPPLWLIIISSMLFIgmGILGGGFMAGALKYAGNNNGSVTALAGTSRFAFGALGGVVISILHNGTFVPMLGTIAACGIIAFVCFKVTVR--
     418 UniRef50_UPI0001AF423C major facilitator superfami...   149     2e-34  1  15.4%  8:391  37:418     -------ATSFALTLALLTSTAFLLFAQIFMVAPILPA-LARDFGSTEGMVGLGVPAFLVPYGWTVLVWGTVSDRWGRRRVILMSLCA-FVVLTIVTPLATDVGQFIALRFVTGVAAGGVVPISVALIGDLVPYRRRGR--VLGWVFGGAAGGMAFGAAGGALGEPLVGWHGLFGVVAVGGLVLLVLGLWLVPDTAAAPHprQVAAGFAELLSTSRGRRTYGYVLVNAVLHAGVYTWLGVYLHDHVQLDEEQIGLVLLGYGIPGLVLGPAIGRLADRYGRARVIPLGLALTAACAAVFASEPSLLFLQAAVVSLSLGYDMTQPALVVIVTDLSG-QRGQAIGLNSCVLWVGMGIGSLVFQAILLPLGFSGAFAWFAGLSLLAGAVAIPLFR-
     419 UniRef50_C4LEH8        Major facilitator superfami...   149     2e-34  1  45.3% 18:392  17:389     -----------------FMGVTFLTGLAIAFLVPVLSLFLSDELHVRPLLVGAFFTVNAVMGIIIGQVLAKYSDNLNNRKPLIMICGIAGILGSLLYAFDRHFGVLISLGIVLMSLCGSMTPQLYALAREYTDAENKQAITFSTVMRAQFSLAWVIGPPLAFFIVANFDFTRLFTGVAVLYLLCVLIIVRYLP--VIPRQIVAPDKSAGSIWQNQRLCLLFLSSFLLWTCNSMYLITMPLYISKVLHWQQGLAGWLMGLAAGLEIPVMLLAGRYSLRIGNRRLMLISGVSAVVFYVVLLLSQQPLILFLAQIPNALFIGILAGIGMTCFQDLLPGYAGQASTLFSNSIRCGGIVAGMLAGTITEWFRFDGVFLCALGLSACALLALWRISSL
     420 UniRef50_B9L669        Major facilitator superfami...   149     2e-34  1  15.7% 18:392   4:373     -----------------LSLLMAIRFFGLFIVMPLLALYAMNLQNANAFNVGIALGAYALSQVFLQIPFGKAA-DKFDKKKILIFGLSLLALGSLVCAFSTNIYMLIFGRLLQG--AGAIGGVILAYIADLTDEN--TRAKAFARMGQFIALSFALSMILGPTIGANWGVDKLFILTALLALFSIWLVIAKIPNPPKIVHHQQH-SSLKEILTHKELLKLFLSGFLQKGLMTVFFMLTPIIFTTKLGWDKTDLWKVYIPALVLGIFALPLGAILAEKKQKAKTVFVMSATAITLSLILFLIGNKYTYFAAVIVFFFGFNLLEPVLQSFVSKIArhEKATALSTSNTIQYIGIFLGGASAGYFVHHNMLSLFLIISVIIGLIWTFLLIKMKPV
     421 UniRef50_C0Z6H0        Conserved hypothetical memb...   149     2e-34  1  14.5%  1:392   1:396     MSKMRQVLEAYHPIVHLLMAGTVFVQLTQSMSIPFLAIYLGETTKLSHAYIGLIIGAGPLAGTVGGFVGGILSDLFGRQK-LMFFSLLAMACSMIGFITLAHPIGLLVISMVMGLAASIFATVSKALMGDLTPEQKRFR--VFSNRYLASNLGFAIGPMLGAFWG-ISGSNLAFVLTGVSLVSFAVILVVACRreNGEVERASLGEIWQVLRRDVVLLTFVTGGILLVTVYGQMSVTLSQYLRENFSEGVALFGTLMSVNGFTVLLLQIPVTRLVERYSLFARIAGGAVLMAIGEVGFAFSSNWVWFITAMIVFTLGEILIIPAEYAQIDEISPAnrGTYYGA-QSATMLGSFLGPWAGGMVLTAYGGPVMFGVMGVLALVSLIFYWLGRRM
     422 UniRef50_A9AT81        Major facilitator family tr...   149     2e-34  1  14.7% 11:363   1:348     ----------MDRRLSILAVGMFAMGTDNFVVAGILPG-VAASLHTSVALAGLMVTCYAFTYAIAAPIMAALAGRW-PRKLLLVSALGIFVAGNVLSALATDLGVVLFSRALAGFGAALFSPTALGVASALATPERRGRA--LAAVTAGLTGATALGSPLGTFIGGFGGWRSTLWFVAALGAVAMIGVWTMLPAVPRPAPVG--LRERIAPMRDARIALTLLTSLFAFGGFLMVYTYAGVVLQRVTHGDERMLAALFLLWGVAATAGNFIAGRLVDRFDSRRVIDAMLWIAIVNFCLLPwaAHVFGAIVALTIWGLCGWGLIVPQQHRLVHAAPQVAPLVLALNNTATYIGLAGSGVLGGLVL-----------------------------
     423 UniRef50_B2T9D8        Major facilitator superfami...   148     2e-34  1  13.3%  8:390  25:416     -------ERYWRRNLAVCVFGSFTTLVSLSMLLPFLPIYVQQLGVQSQSAvgIAFGATFLGTAVTAPVWGRLADRYG-RKPMLVRAAVGMAVVMSLIGVAHNVHQLVALRLLAGLV-GGYSSASTVMVGTQAPKERAGWA--LGVLSTGALAGNLIGPLVGGFLPGWLGIRGTFFAGGAMIAVAALLTIFVvpATHSSRRPPEHATASTHRNNYPVIAALLVTAMMVLLANMSIEPVITVYVGSLGVQsaRVAGIVMACSAFGSMLTAARLGALADRVGSWNVIVACLVLTGLVMIPQAFVHAWWQLAGLRALMGMTLAGLLPAIAKLARHAVEEHkgQMLGYLQSAQFSGQVVGPIIGGVIAVHLGLHSVFFVTGSLLVACAALAQWAR--
     424 UniRef50_A0JT57        Major facilitator superfami...   148     2e-34  1  14.8% 11:388   1:379     ----------MPIGLLALALGGFGIGLTEFVIMGLLPE-VAADFSVSEATAGWLISGYALAVVVGALLLTAAVTRF-ERKPVLAVLLVLFIAGNLVSAIAPDYSMMMIGRIVAALAHGAFFSIGAVVAADMVAPTK--KAGAIAIMFTGLTAANVLGVPFGTMLGQAAGWRSTFWAITGIGVLALAGILTLVPRTGpaQAASGGLRGELRAFRSGQVWLSILVTILGYGGMFGAFTYIAYTLTEVTGFAASTVPWLLILFGVGLFIGNTVGGKAADRNVDRTLLVVLAALVVILVAFALAAGNQPLTIASMVLMGGFGFATVPGLQMRVMKYASSAPTLASGANIGAFNVGNALGAWLGGviTAGLGYTSPIWAGAGITLLGLGVMAF----
     425 UniRef50_P37597        Inner membrane transport pr...   148     3e-34  1  11.3% 12:391   5:383     -----------KRFLVWLAGLSVLGFLATDMYLPAFAA-IQADLQTPASAVSASLSLFLAGFAAAQLLWGPLSDRYG-RKPVLLIGLTIFALGSLGMLWVENAATLLVLRFVQAVGVCAAAVIWQALVTDYYPSQKVNR--IFAAIMPLVGLSPALAPLLGSWLLVHFSWQAIFATLFAITVVLILPI-FWLKPTTKARNNSQDGLTFTDLLRSKTYRGNVLIYAACSASFFAWLTGSPFILSE-MGYSPAVIGLSYVPQTIAFLIGGYGCRAALQKWQGKQLLPWLLVLFAVSVIATWAAgsLVEILIPFCVMAIANGAIYPIVVAQALRPFPHATGRAAALQNTLQLGLCFLASLVVSWLISISTPLLTTTSVMLSTVVLVALGYMMQR-
     426 UniRef50_B5WJ08        Major facilitator superfami...   148     3e-34  1  17.1%  5:391   1:393     ----MQMTDRRSKLVLLLLFLTWGTVFLDRMSQLYLAPYMIHDLDLDSAKVGNLAGVTGICWAISTLLFGALSDRIGRRKVLLPA-IFSFSILSWLSGVVQSYEQMLIVRALLGIAEGPCFSVIMAITEETAEPQHRGRNVGI-VVSAASLIGLAVAPVLTTQVAAHAGWRAAFFVAGTPGIILGLLIWKLVPEPTRKDGAKkaLGDYLSVLTYRNIWLCCLGAVGVICWLFEVNVFAPLYITQVAGQSGTTAGFLLGAAGFGAFVLGMIFPALSDRIGRKAALIIMSVLIAaaMLTQSLYANLWLLAGIFFVTNAQQGIVALMMVLVPTETVPAraATAIGMVTMVafIGATAAPAIGGALAQQYGLAVPLYMALGGASVVFIVGLLLKE-
     427 UniRef50_B4SSK8        Major facilitator superfami...   148     3e-34  1  15.9%  2:390  44:431     -TRIQQGTPAFRRTALALFLAGFSTFGLLYTVQPLLPEF-SRHFGVSAAGSAMSLSLTTGTLAVAMLLAGLLSDAVG-RRPMMIVALLASATLSLCTALVDDWTTLLVLRTLLGLALSGVPAVAMTYLVE--EMDSRALGLAMGLYIGGNAIGGMSGRLLAGIIADHWGWRWGIGVVSIIAIASTVLLWLQLPPSRHFHPRRDGLrrWRTLFADPGLPWLFATSFVLMGVFVTLYNYLGYHLLApyHLSQTVVGLIFSVY-LVGTFSSAWMGQQATRYGRGRILSISFALIGAGIVLLA-MPWLSAMALGIALVTFGFFGGHSVASSWVGSRAGAMRAEASALYLFAYYLGSSVLGAVGGLAYAAWDWLGVCVFAAVLTLIGGGIVWALQ--
     428 UniRef50_B9CPQ5        Chloramphenicol resistance ...   148     3e-34  1  14.6% 15:392   6:386     --------------IATFILSVFIVGMVEMMVAGIM-NLMSHDLNVSEAVIGQLVTMYALTFAICGPILVKLTNRFAVR-PVLLWTLFTFIIGNGIITIAPNFTILVIGRILSSAAASLIIVKVLALTAMLTKPKNRGK--MIGVVYTGFSGANVFGVPIGTMIGDWVGWRFTFLFIMAVSVLVGILMIIYLPKerSNHSSDNDSEIPSRIIRPMEIVKYLIITFLVLVANSVTFVYINPLILSK-GHELSFVSLALLVNGVAGVIGTSLGGVFADKNTSKRWLMISVSIFIIMMLVLnlLAGTVILLIGLFVWNIMQWSTNPAIQSGIIEHVEGDTSQVMSWNMSCLNAGIGFGGIVGGLVISHINVQAITYTSAIIGLLGLIVVLTLKNI
     429 UniRef50_B1JAC1        Major facilitator superfami...   148     3e-34  1  15.9% 14:390  19:390     -------------SILILTMAAFAVLTTEFIILGILPG-LARDLGITVPKAGQLVTVFAFTVMLVGPFLTAAISHWDRKKVFL-GVLLIFAASNALSAVATDFWTMALSRILAAATLPVFWGTASESAAQLAGKGNEGKA--VARVYLGITAAFVFGIPLGTLAADALGWRGTFWLISGLCLVIALLMWVFLP-QLPDAPKRAGGERQTVILRDPKFVFHVALSVVVFTAMFSAYTYLADLLERLAHVPSAQVGWWLMGFGAVGMIGNAIGGRLVDRSPLGATIVLLTVLGAGMAGAPPAVDTLWLLVVALAAWGIAYTALFPVCQVRVMIAGAKAQALAGTLNVSAANAGIGLGAVIGGVTIEQLGLAALGWVGALIAVLAVGLSLLLW--
     430 UniRef50_A6T2X4        Transporter of the MFS supe...   148     3e-34  1  14.7%  9:390  11:403     --------KNERLFLLTIAGIQFTHILDFMIMMPLGPQLI-RVLHIDTHQFGLLLSSYTFTAAASSLLAATYIDRFDRRKLMLV-LYACFIIATLCCGLAPNFTFLLIARALAGAFGGILGGLVQTMVADVIPFERRGKA--LGTVMAAFSISTVAGVPLGLLLASTfgWRAPFFFIVLLAGIFWVIGYKLLPNMTAHLHNKPLGNVFQRIfrEPRHLTAFAFIAMIMMAGFTVIPYIALYMTTNVGLPESFITVVYLCGGAATFFTSQLIGRMADKYGKLKVyrVALASFIPLLITTHLVPIAWWLVlsTIFFILVPGRMVPGMAMVSAVPEAHVRGTFMTLISSVQMLSSGLATLIAGLIITRTpyDTVGYLAVACGVVTIWLAQRLR--
     431 UniRef50_A6H1H8        Major facilitator superfami...   148     3e-34  1  13.1%  7:387   1:396     ------MKSNHKSTLIFVLIVVVIDTAGFGLIFPVLPQLLINLLHSDISTagWLSFAYAIMQFVFAPVLGNLSDQYG-RRPVLLSSLFGFSIDCIFLAFAPSILWLFVGRTIAGI-TGASYSVASACVADISTDDNRTK--NFGLINAGFGL-GFIIGPIIGGTLGQFGTHTPFIVAAILSFINFIFGYYFFPESLKANNRRkpFGSLKHLQKFPLIKTLVLPMIFVSIANHSMESVWAFFTIEKFKWSTSLVGYSLAFIGILSIIVqwLVSILAKKLSDKRMAVLGFVLMMTGFFLFAFTPWQWLLFTALLLFIVGGIQGTAVQSIMSSAMPDNEQGELQGALGSLMGLTTLIAPPLMTSSFSYFtpGIPFLIASILTLISLILFL-----
     432 UniRef50_B8CUJ6        Transporter, putative n=17 ...   148     3e-34  1  14.5%  7:391   6:390     ------LSKTEKKVAFSLASVFGLRMMGLFMIMPVFALYGQHLEGFSPLWVGIAIGAYGLTQAILQIPMGILSDKYG-RKPIILIGLLIFALGSLVAANAETIYGVVAGRALQGMGAIAAAVLALAADLTR----DEQRTKVMAIIGMCIGFSFALSLLVGPIVAQHLGLSGLFFMTAGLAVLGMLIVQLLVPNPISQAPKgaAPEKLRRMLVDPQLFRLDAGIFILHLVLTAVFVALPLDLVDAGLAKEEHWMLYFPAFMGAFFLMVPLIIIGVKRNNTKAMFQVALLIMMMALGSMafANNLMVLSFAVVLFFTGFNYLEASLPSLIAKFCpgDKGSAMGVYSTSQFLGAFCGGILGGGAYQLVGAEGVFAVALVLMGIWFLLTFGMKN-
     433 UniRef50_B2A615        Major facilitator superfami...   148     3e-34  1  14.6%  7:390   1:394     ------MQQETKKYLAALSGVPFIMVLGNSLIIPAFPE-IQNQLNLTQLEVGLLVTTFSIAAGITIPIVGFISDKYG-RKVVLVPSVFLYAIGGLISGFApaYPWIIFGRVVKGIGAGGTGPIAMALAGDLFQSGERSEAM--GVLEAANGIGKVVSPILGAIIVVWI-WYSVFFVYTIFSLPVAIMLWVVLKEPEQKaeEKGYFTRIFDVFKDKklIATYLAGFTVLFSLFGTLSYLSDILEIRYNLEGAPKGIVIALPVIVMAVTSYTTGHFIqkLLMSKLVVTGLTIIGLSFgiILLLDNDYALFAGIILIGVGTGLVLTSVNTLVTSTagRARGGVTSLYGSVRFFGVAFGPPAFGLLVEISRIAMFGTAGIIAILVMGVNLIMIK--
     434 UniRef50_B0JY88        Major facilitator superfami...   148     3e-34  1  18.8%  6:389  14:396     -----SLTAETRSQLLFLFVTALFFWISITTLLPTLPTYI-DSLGGSKQDIGFVMGAFAIGLILSRSWLGNLVDRR-SRKLVVLFGTIVAATAPLGYLFFRDLSSLFAVRAYHGLSIAAFTTGYSTLVVDFSPV--RQRGEIIGYMSLTAPLGMGIGPALGSYLYQSIGYNGLFLVSAASGAIAFLFGFSIQEPDFKkaENQTIERSFWALCQERAFLVPTLVFLLVGTLFGGLVAFLPLFLLEN--QLPFSAGLFYSCAAVSGVIGRILSGGASDRYGRGLFITISVFCYGLSMLVLSSARSSSALILAAILEGTGGGILFPMLLALISDRspQERGRAYSICIGGFDVGTALAGPILGVLA--ISYETMFSLSSGLAVIALFLFFTL---
     435 UniRef50_B5WBD0        Major facilitator superfami...   148     3e-34  1  11.0%  9:389   6:406     --------RHRYLVLLILFAIYLLCYMDRMIMAAAIP-FIASEFHLSAMEMGGILSAFFFSYALCQIPAGLLADRFGPR-LMTTIGITWWTIFTALTGLCNSLGLMLVVRVAFGVGEALFPPAAFKALSAWFPKREVGRAT--GLMMTTNALGPALAPLFVAAVMAVWGWRAIFTSLFIPGIAMAVFGWIYIRNSPNQSKhsAGTADFSGLIKTPLVWWCFVTLFVFSIASWGIMSWFPTYLLKARGLSTARMGIMASVPFLVGTIAYCITGFLSDKfrRELLVVLGCIVAAIFAYLTAHAETAETAVFYQTIGYFFSTMAGCSLYTIPNAALPNkvGSAIGFVNAAGQLAGFLSPLIVGYILTRTnfNIVFHLFVGCFLLASVSAWFI---
     436 UniRef50_D1BQN1        Major facilitator superfami...   148     3e-34  1  13.6% 11:386   4:387     ----------WKRTVYISLICVFCTSFGVSQLAPILPLYFHDLGVQTPSAmgLATGATYLIVCLVAPFWGRVADKKGRKITLIRSS-FGMALCNLLLAFQTTPEGVVIIRLIQGLVSG-FYSATITLIASESPIERTGWA--LGLLASANLAGSLIGPLLGGYIADTIGIRNGFILVGILMGFAGLLATIFIHENYVPKPNVEKLSISKLKEQIPEfvALCIASFIYAICIMSLQPVISVYIksNTENLAFIAGTVFSAMGIAQLISSSPLGKLVDKIGPRKVLVVSLIYVGLFNIPQAYVTDVYQLALIRFLQGFGLGGMLPALNTYLSSKTPRetGQVFSYNQSSLFLGYFLGAVGGASLMAWLGFTTLFWASGGLFIISALWI------
     437 UniRef50_B7JH26        Drug resistance transporter...   148     3e-34  1  14.0%  7:384   1:385     ------MKKVSVPSLLLMIILVAFPQISETIYTPSLPD-ISRALHVSNNEVQLTLSVYFAGFALGVFFIGWLSDIIGRRPAML-FGIVVYGIGSFLCFIANSIEVLLVSRFIQAFGASAGSVVTQTILRESVEGHKRH--VMFAQISAVIAFTPAIGPLIGGFLDQMFGFKIVFLSLVVMSVGIFLYTFVSLPETKTSSVTNkvFSVLKRLITNPKVVTYGLLIGGANGVLFSYYAEAPFIFIEYFRLSPSMYGFLGIVVASASIIGAKVSKRLLATYKPEKIIYIGCLVMVVGAVALSIITSviGFLVAMFILLLGIGIALPNCLSLALVDFQDVIGTAGALFSLGYYVIVTMTIWGMSQLHTGSLLVMPLYFLAIVVIMMVF--------
     438 UniRef50_P0A4K5        Multi-drug resistance efflu...   148     3e-34  1  13.4% 10:391   5:391     ---------NWKDNLRIAWFGNFLTGASISLVVPFMPIFV-ENLGVGSQQvgLAISVSAISAALFSPIWGILADKYGRKPMMIRAGLA-MTITMGGLAFVPNIYWLIFLRLLNGVFAG-FVPNATALIASQVPKEKSGSA--LGTLSTGVVAGTLTGPFIGGFIAELFGIRTVFLLVGSFLFLAAILTICFIKEdpVAKEKAIPTKELFTSVKYPYLLllFLTSFVIQFSAQSIGPILALYVRDLGQTENLLfgLIVSSMGFSSMMSAGVMGKLGDKVGNHRLLVVAQFYSVIIYLLCANASSPLQLGLYRFLFGLGTGALIPGVNALLSKMTPKaiSRVFAFNQVFFYLGGVVGPMAGSAVAGQFGYHAVFYATSLCVAFSCLFNLIQFR-
     439 UniRef50_A1VCX1        Major facilitator superfami...   148     3e-34  1  14.9%  6:387   5:383     -----APTLRIGRHLLLVFGITLMVVMGVSSIMPILPD-LARTFDMPMSSVGMVFMAFTLPGVVLTPLGGILADRIGRKKVLIP-SLLLFAAGGVACAFAPSLPVLLACRFVQGIGAAPLGVLYTTIIGDLYDGNQRMQAM--GFNAGVLSLGTAIYPAVGGLLGE-LGWRVPFLLPLLALPLCFAIARTTFPEPRSSQGMGEYFRSTWGIISSPRAITLFLLTLFTFLILYgmVTFFPVLADQQFHATPSQIGFVFSIASAGTVLTAVRLGTLARLIRPVRLLLASHGLYALAMVTMPFVPSLWWALAPVFIFGLAQGLNIPNTATLLTDLApeGRAAIMAVNGTVLRLAQTIGPVLAGIAFATGGLSGVYTFGAFMAASMAALIL-----
     440 UniRef50_A6E9P1        Major facilitator superfami...   148     3e-34  1  16.4% 17:389   1:372     ----------------MLSLATFIVMFQGFMVAPLLPTF-SEQFGTTVRHVSFIEPAYLLGYGLFTLVYAPLSDRIGRFR-IVAFCLIMFSLFTLLTAFVDGINQMIFLRLLTGIGAAGIAPTTISWISDTYPYEKRGHA--LGIFFGSMAGGTAFGASTGSLITALIGWHWLFIGVAIIGIVVFTLILifGKTQTMTETKEKILVSFHKILSTGRARRTYFYVLFNGMFHSGIFAWLGYFFYKNYGLNQLHIGLALLGYGIPGLLFGPLLGRLADRYGRNKIIPLGLFLSAVTVLLLSQSLSLAISCVLVALLSLGFDLSHPLFAAIVTTFS-SKKGAATGLFAFFLFSGYGLGSLVLSLIVN-IGLDRAFQLFGIGILVAAVCSIFV---
     441 UniRef50_Q2G767        Major facilitator superfami...   148     3e-34  1  17.3% 15:389  27:405     --------------VTALLSLNFGILFFDRNAVNFLMPFVQPDLKLTNTQVGMFSSALSLTWALSGLLVGRISDKLGSKKPVVVIATIAFCLCSFISGAASSFLMLLGARLLMGAAEGGVMPVSHAMIVSEVAPERRGLAMGVAQNLGSNLLGSGLAPILLVPVAAAVGWRTGFYLAALPGLVTAALIWFTLREPPAEVheATPKVTLREAFAHRNVILCALIAILLVSYLVVCWAFMPLYLTKARGFAPETMGWLMATLGISAGIGSFVVPAISDAIGRRPVMIFFSFLGVILPLGALYYQGSTLVLAAIFFIGWGLNGLFPMFMATieSVDPRLTATLTGVVMGTgvLGGVLSPFFAGALADSYGLSAPLWLMLVCTVLAGMLTLGL---
     442 UniRef50_A4A910        Drug resistance transporter...   148     4e-34  1  12.9%  7:387  27:411     ------LDPGSKATLMFLAALVALGPLSVDMYLPAMPA-MQQAFNTDIVHMHFTLSAYLWGFAVFHLACGPLADRFG-RKPVLLGGTGLFVLASAGCALANSVEELTTYRFMQGVGACVGPTLARTITRDIFGPK--GAARALSLIAMLMALAPAVAPGLGGLMLRYVEWPAVFVFLSVYGSIVMVIIGFRIPETLAEprPGNIAANYLVLLRDPVFLPIAAASALVYAGLMAYLACSGFVFIDMLGVPVEYFGFIFLSSVFGYMGGSAVSARLAVRYATSELLLLGGVIATVAVLSmlAPTSILALILPMSFYSAALGLVLPQAMAMAMEHFPRIAATNSSLFGFLQMGLSAVITVAVGSVLVSSPLPMIITMAVTQVLALLLMVY-----
     443 UniRef50_C6D2A8        Major facilitator superfami...   148     4e-34  1  16.9%  7:391   1:384     ------MEPSTRSQRLLFMTVTLMFWIAMYTYVPTLSPYLS-SRGLTLDLIGVVLGSYGFVQLLIRFPLGMLSDRYGKRKPFILLGMLAASISCLLFIIPGSWLWPLAGRAMAGLCAS-TWVAFTVMYANYFAAEDATKAM--GNISVMTVSGQMIGMLLSGWMSEGFGADAPFVLGAIIGGMGLLLALVIhpAKPLHERSGISFSKIQSVIRTKLLLQVALLSLLAHCVLFITMFGFTPLKAEDMGSSGVELTLLVFAFMAPHALASMFTARwaPRFGNWTTIGTGFILSAICTVSICYVHSIWILMLTQMINGFAQGLHIPLLLGLAidVDPSGRATAMGLYQAVYATGMFAGPFLAGWLNESWGLNSGFALGGIFGFIAAVLCLLYYR-
     444 UniRef50_B5S1P8        Drug transport protein n=1 ...   148     4e-34  1  16.0%  1:387   1:393     MTHTRDGRSLPAFFALLVAGLSMIGPFSIDTYLPALPA-IATSLGTSPLHAQQTLTAYMLPFAFMILWHGALSDALG-RRVVILAGLALYVLASLLCATAGRIEVLLLGRALQGLVAGAGMVVARAMISDLLDGAAAQR--MMAQVTILFATGPAVAPILGGRIFLAFDWHAIFIFMALFGALMLALCIRYLPETLPPEKrrDMGRAYRQIFGHGPFRGISLTLAFNLNGMFVYALSAPAFMMLLLGFRPDEFGWLFIPSIAGMMVGSWISGRLAGNWPGRRTIVLGMGIMLATALaaLVPTSRLAALLPMPFYTLGVGLAMPSLQLMTLNDFPERRGMASSCQGAIQTGLNVISGGIVAPLVWGSVLSLSLASLAFISLGWLAFGL-----
     445 UniRef50_C0ZIX2        Putative transporter n=1 Ta...   148     4e-34  1  15.1% 12:388   4:375     -----------KFLILLLALGEFMIGTAESIVTGIIG-MIADDTHVSLSLAGQLVTAFSLAFAFGAPVLIALTAGVERKK-LILWTLFSFIVANLLASISQSFSLLMVSRILLGLCGGIYTVVALAQAANMASPEK--KGSSIAIILMGFSLSLVLGVPLGTMLGDIWGWRPVFALIAVLTLIPFFAILAFLPKQQGEETV--PLRKQLAALRNKRVIHALCISLFFVTGYSTVYTYITPLLQSTSAMTTAWVSTTLFLAGLASVAGSRIGGVSTDKWGIRTTLYVSLLLHAAILLILPLSSQltWAIITVMFWVAAVQTTVPAQQYYLITLSPHSSQVALSMNTSVFQLGLALGAGLGGVIVDHVGIVHISWVGGLLVLVGFGFAWV----
     446 UniRef50_A4C850        Putative efflux protein n=1...   148     4e-34  1  15.3% 21:387   1:371     --------------------MAAIPAFSLDIYLPLL-EQIREQLATSVTSAQMTISLFVISFAFIQLVIGPLSDNYGRKKVLYV-GLLLFILGSLVAIFSADINTLMFARVLQGAGACTGVVSAFAIARDGFSLDER--ATVLATIGMYVALAPIIAPVIGGLLSESMGWRYIFLLLAVLSFIILLLVTVKLPETLAQKNskSLLLNYKEMLCHRDFVVFTAIGMCAFTSLFCFISMSPHIFINQLGYNSNDFGFIFAFNALVFFAGSKLSIKLSKTKTHSFSITLGLTLLISGGVVMALlpKMELVLLPMALASVGISIVLPNATSLMLEPFGDKAASASALNGFIRFVFAGSASVLVTFLDFPPHLILAFSLVSLSVLSWFIWLV-----
     447 UniRef50_Q11YA1        Sugar efflux transporter n=...   148     4e-34  1  17.3%  1:392   1:402     MQPTQKSAINEGLLIAMLAAINFTHIMDFVIMAP-LSATLKIAMSITTKEFGYLVSIYTFAAAVGAIIAFFKIDKYD-RRTAIIFVYTGFIVANILCALAPQYKFFMLARLFAGLFGGVLNVLIMSVIGDVIPLERRGKAT--GMVMAAFSAASVIGIPSGLILADIfdYHAPFWLLSILSALVGFVLVFKFPSIKShgAKTPPMEIIKEYMQNSNVRRALLFIFLLMIAGFSVVPFISDYLVNNVGLDLKELKYVYLCGGLATVASSIFIGRLSDKLGKVKTFIIAALVSVAPIAIVTVLPVMPlvLLFNVLFFMCFGARFVPAMTLMTSCvpKRRGSFLSVSSAIQQLGSGVAVLIASAIieLHNFGWVGIVACVATVISILLSVRIKEV
     448 UniRef50_C6BZ87        Major facilitator superfami...   148     4e-34  1  15.5% 12:391   7:384     -----------NKNLQIVFAVTLMAIMGVSSIIPALPEMI-REFGISASTIGLIFTIFTLPGILFAPLAGIFADRLGRKK-ILVPSLIIFGLAGTACFFTKDFHSLLLVRFIQGIGAAAIGVINLTIIGDLFSGKDRIKAM--GLNAGVLSMGTAIFPAIGGILAQ-ISWEAPFLLSLVALPLAWVVAFKlnPEPSSSENFKRYMKAAFAGMRSKEVLSLFAISLLTFIILYgiVTYLPLLLNSRFHASPLMIGLVISSASFITALAASQMGRLAHFMSQPLMISLSAFAYGAAMIMLPAAESALWCILPVCMFGLGQGLNMPNSMSMLTAIApeQRAVFMSVNGMLLRAGQTIAPILMGLVYSGFSLEAVFYAGAVVAAAILVISTMFLR-
     449 UniRef50_Q97DH1        Predicted MDR-type permease...   148     4e-34  1  15.0% 11:390  14:389     ----------YRLQVIFLFIASICVGTGIYEWIP-LTNVLQQSFHVGQEQIIFIGSVFSLFYAIGFLIFGWLANYVEIKKLLIVGTLLLM-ISTFLIGFATNYKLMIVFRAIQGIFAASFAPLGFSIIVKMFPESKRIAG--ISAITTGFVMAGILGQLYGSIIANSYSWSVVFWLQALIYLMIIISMIFLVPKTDKVSERPTSFIglVKLLISKSLFPCYVITLTLLFCFVGMYTVMGMFFQKDFGLNNEKILWIRGIGIIGMIGSMVFA-KLSKKIGVGNILSLGLVCASIGVLIIGISNNVGLSVAMSVVFVFGITISLPMVVSSIGTLAGKKSGNAMTLYTFVLFIGATVGPIVCNRIIESGSYPLAFIFLAVVLGISFIASLIVR--
     450 UniRef50_C8QAG3        Major facilitator superfami...   148     4e-34  1  11.3% 14:392  23:424     -------------ILTVLSVGIAINYIDRAAMSVAIP-FMSQELHFSPTDSGLLLSAFFWSYVLFQLPGGWLVDKLGPRITFALSSL-GWGLATAACGLASSIAALVGFRFVLGAFEAPSYPASSSTVTRWFPRQERSFAA--ATFNNGSKIGGTLAIPIISFLIALVGWRMTFVISGLVAVVWALAWYLWYRDPREHKTVSAEEVAfrQLLAQRTVQAMMAGFFCINFVSYFFFTWFPTYLVETFHLSLMKFGLLGMLPGIAAIVGGWCGGLLSDSLVrrKIPLVGGMLGSATIGLAAFSPTVGLALSALCFANFAATFASAALWALPSDVAPNRaaTIGGIQNMAANLAGIISPILIGVIMQFTHSFVIPlaGVIGVVGALVYAFWLPRV
     451 UniRef50_A8U140        Permease of the major facil...   148     4e-34  1  15.7%  4:392   1:395     ---MNRPRPDSVAVAALLTMLVAFGPISTDMYLPSLPA-LVSDFGSDVPTVQLTLSVFLVAFAVSMLVYGPLSDRFG-RRPVLIGAIAIYVVASVACALAPTIEALIAARAMQAVGCCAGPVLARAVVRDVYGRER--AAAVLSYMGTAMALAPAIGPVLGGWLQVVYGWQATFWVLTAFSGVALVGVLTMLDETNAHRNprGMLHAYRTLLSHRGYVGYVATIAACYSIIFSFISGSSFVLIQVVGLTADVYGLCFAAMVIGYMSGTFISGRFGRRIGLDRLILTGATIATAAGVAMAGftHIETIVIPQVIAMLGVGLVFPNCQAGAIGPFPTMAGAASSLLGFSQMGVAAAVGLAIGLTFDGTARPMATAIAIAALMTLLSFRLIVWPV
     452 UniRef50_B5EPK8        Major facilitator superfami...   148     4e-34  1  15.2% 10:390  11:397     ---------RERRSIIALAGIFGLRLLGLFLVLPVFSVYAHGLHGAtpVLIGIALGAYGLTQAIFQIPFGRLSDKWG-RKPVIAAGLLIFAVGSVIAAQATSIEWLLAGRIIQ--GAGAIAAAIIALTADLVREERWTKAM--ATIGITIGISFSVSLVLSAPLAQWIGVQGIFWLTAALSILAIGVLYKVIPDVPARFHRDAepAALRDVLRNPNLLRLDFGIFSLHTGLTALFVVLPLVLIDPQhlSEADQWMLYLPVMLLSFIAMIPFIIVGekHRLREVFVLAIAILLAAVAWMALshSIWSIAIALFLFFVGFNVLEASLPSLVAKfhPGAKGTATGVYTTAEfaFTGGLLGGLLYLPGQHNYSDVFWAVAAIYLIWLIVALTMQ--
     453 UniRef50_C7R766        Major facilitator superfami...   148     5e-34  1  16.4%  2:392   1:391     -MKSSSLTTLEKKSAISLASIFALRMFGLFMLLPVIRVLGEGLEGATLPLLGLAIGIYGLSQAILQLPLGLLSDKIG-RKPVIYAGLLVFIVGSLVAANSETVWGLIAGRALQG--AGAIASAVMALAADLSRPHQRSK--VMAMIGASIGLAFALSLVLGPLLSNWLNLQGLFYVIAILAFLALLVAIFVVPSVRAVDMPtsFAERWRYVTAKGRIFVLALSVFVIHWALVAVFLVVPDKMIAS-GFELSQHSWIYLVVLALSIAVMLPMMINAEKKGWHRQVMQAAFVLLAMSLLTLLsqSLWFWLVVLTLFFAGFNLLEAKLPSTVSNLYGAqrGTALGIFSTSQFLGAFLGGSVTGYLLPSLGFTGVIWLNIGLMIIAGLALGWLGKL
     454 UniRef50_A0LZD2        Major facilitator superfami...   147     5e-34  1  14.2% 11:389   1:375     ----------MKKALLALAIGGFGIGMTEFVIMGILPE-VAEALSITIPQAGHFISAYALGVVVGAPLLTAFGNKWPPHKVLM-ALMIWFTIFNTLSAFSNSYTLLLITRFLSGLPHGAFFGIGAVVAGKLAKPGK--DAQAIAMMFTGLTVANVIGVPLGTWLGQNFEWGVAFLAVGVVGILAILSVKFWMPELPK--TKSNGFKKDIKVLKKPELWMVILLTTIGTGGFFAWYSYIAPLITDVAGHEENIVSYAMILAGLGMVAGNFIGAKLAEMFRPIYAVIIALVCMVIALIstFLAYDQIGVLIMTFILPLIAFCIATPIQMAVINSAKGSEMLGSSLNQSAFNMGNASGAYLAGliAYGYGIVSAQYVGAAMAGIGIFIGLGV---
     455 UniRef50_C3X9P9        MFS family transporter n=2 ...   147     5e-34  1  14.0%  6:390  17:408     -----AWTPMRHPVFRMLWIAILFVNIASWMQD-VGAGWLMTSLAPTPAMVSLVQAATSTPFFLLAIPAGALADIVDRRRFLIATQIWLACCAGALGFLttSSILLLVFTFCLGVGLAMMMPAWGAVIPELVPREELQSA--VALNSIAINIARSVGPAIAGIIVAAAGSGAVFLTNAAFYAIVTFLTIRWKreLPSEHLLSAIKAGLRYARHSEALIAVMIRGACFFIFASASWALMPLIVRQELKRGPDVYGLMLGCIGVGAICGAILMPRLIRLVSRDTIIRCASAVYGVGMLALAASDRVITACCAMLAIGISWMMTASALMTAAQITLPGwrARGLAFFWIVFTGGMAGGSVIWGQVAGLLNIQLALVIASACLFIGIGVSWRFY--
     456 UniRef50_O31577        Uncharacterized MFS-type tr...   147     5e-34  1  13.2%  4:388   1:380     ---MSIKNPSVKFIIFVLMICTFSIGYTEYAVMGILTS-IANDFHIQVSSAGLLVTAYAASVCLTGPLVTIISVKL-PRKPVLLGLMAIFILSNLMSALAPNFAVLAISRILSASIHGAFFAIAMVFASEMVPPEKRAAAA--ASMNGGLTVALMLGVPFGSYLGDVLNWRAVFSIITALGVIGFLGLMAAVPNRKPKVIP--MLMNEWGVFKHKQVLFSFAITILGYSGVFIAYTFIEPILRHSAGFSTVGITGALFAYGLGGVAGNFFAGKVPLPLLTRTMIGVMIGLIGVLAVFPYIAIYPAAAIVATFLFGACAFGTPPLLQTKVISSSEGGTTIAAAVSVSAFNLANALGAWIGGMILNGTgySWLFAGGALMTACGLVLSTF----
     457 UniRef50_B8FPH4        Major facilitator superfami...   147     5e-34  1  16.4% 15:387  24:388     --------------LLTGWFTLFIIGTDLFVISPLLP-FIAQEYAITPAVAGWLVTVFSLMYAISAPLFGWLSDRKG-RRLLIVCGLFSFGIANFLTAISQSFAMLITSRIFAGLSVASITPLVYAIIGDTALPERRG--VWLSIVVSGHLTALWAGAPLGTLLEQFLGWRSVFISLAVIAALLSILNFRVWASTNQAHPAEAQVKGSAL-----KIISAVSVTAFWAIAMYALYVFLGTGLVLDNHFSSSELAASITAYGIGAVAGSLFSGRVTDKIGARKVSIFSTVMLVGILALLGFFLSatWVYFLLFLWALIGYASFTSYQARLAEEFPETRGMALALNNTALYIGITLGSMMGGFIITKWGFFTLPLICSGAALISSLISA-----
     458 UniRef50_A9MXZ7        Putative uncharacterized pr...   147     5e-34  1  13.3% 13:389  49:426     ------------PILMILPLAGLAELASLYSIQALLPK-LSEVYNIPLNQVGMILSAEVGFLALAMLFSGTLSDRFG-RKPIIFYSLLAGGILTLLCATASSWPMLVVYRALLGIAVSGITAAVTVYISEEVSPAL--AGIVTGYFIFGNSLGSMSGRVFATLMMEHVSIDTIFFIFGGVLIAMALAVKLFLPTSRQFVPTpaVLKGGLEHFKNIRVSLCFVIGFILFGSFTSIFNFLAFYLHRpyELSYTWIGLIPVSFSLTFFL-APYAARVALNIGSMNALSMLIICMMVGAFLTLIAPSLWVFISGIVLLSVAFFSAHSTVLAWVSSRSPNAKGQATSFYLLCYYSGGAVMGYLNGYLFSWQGWNAIAASCLMMLGIGLFICRFI---
     459 UniRef50_C7PTJ2        Drug resistance transporter...   147     6e-34  1  12.0% 25:391  20:392     ------------------------SPFSIDMYLPAFPA-IASALKTDIAHVGYSLTSYYAGLCAGQLIYGILIDRLGRKKP-LYAGLLIYLTAAFACAFSLNINMLVAVRLFMALGGCVGMVTARAIVRDLFPPKD--TARVLSLLVLVMGIAPIIAPTIGSIVNTIAGWRWLFGVMALIALALLIATYTLLPETKTPDPdkDVLPEYIAVLKNPAFLVYTLAGGISYAGLYAYIAGSPFVFMTRFGFSDTAYSWAFAFNACGLISGSQINRLLLNRYDSIHISFYAAILLFITGLLLLISTALGIAGAPmfLFLFCLGFLNPNTTALALRPFTAAAGRASAVLGSIQMIAGVIASWTVNFFFNGTANVMAAVMFGCTALTLFLLVFFTGR-
     460 UniRef50_D2S0Y7        Major facilitator superfami...   147     6e-34  1  14.9%  8:390   7:396     -------ESIRWPMLITLVLIGFIPAFSGALINPTIPAIQETFShySETLAQLVSSMSAWIVIVVAPLTGYVLDKY-ARKPILIGAVIVYGAGTSIAFFLDSIYLILATRVLDGIAVGALMVTVPTLIADYYSGGRRE--SIMGYYSAVTAAGGAIAAVMGGYIAGTLGWRYIFLVFAG-ALLFVPPILRFLPEPDVEESARDDGVGRLEAIKkkLVAGIYAIVLVGMLVNNLVMIEVPYYLQSSLTVTDSQTGLVISGVMIGSFVSASMYGRIKQRMRHVTVMALGFVIAAMGFLLFTAADTLPVVIAGVIVSGagFGIIQPTANDWVASVVPGerGRALSGVTMMMYGGFALSPFAPIPLVDAFGRRGMLQTAGYVMLIVGGALLTVW--
     461 UniRef50_UPI00018742B6 permease of the major facil...   147     6e-34  1  14.0% 40:388  75:431     ---------------------------------------IASEFSTTESMVQLTLTTFMVGMATGQLVIGALSDSLGRKKLLLIATLV-FLGSSILCAVAPNIGTLIAMRLFQGLAGGSTIVLARSVVPDLLTGK--ASAKAFSTLMGISSIAPAVAPLVGGFLGPAFGWRSVFWFLAAINVAMVAIVVLMVPETLPPEKrrNLLPNIGRLLRRPVFVGYMLAFAGGFAVMFSYIAASPFIFQELLGLTPTQFSLVFASNAAMLTFVSILNGKMINRFHPHKSILIGLTVMLVTSIGllVGITFFTTWLLLFITVPMMPLIFANATALGIEEVRdgIGSGSGLMGFAQFLAAATVAPLVGLGSNllSMAISMLTCALIALIAVLTLTR----
     462 UniRef50_C8P5K7        Major facilitator superfami...   147     6e-34  1  15.7% 10:391   2:381     ---------KYRLQAILFVFIAFMLGCNEYMIVGVLPD-IAHEYHDSLSTLGLLVTVFAFVYAAFTPVITSLANRW-RRHHVLLWLMVIFLIGNTWTALATNLISLLLSRILTATVAGAIISLVLVMASFVAPYEKR--ASLVSWVFAGFSIASVIGIPIGTIISTSFSWHDSFWMVTIITVIAFCFLFWLVPRDTP--QFKSGLKKQFVLFKDYRVLLGVLFIVAICAADYTIYTYIRPLITSGMGFDNAWLNWLLFGMGIFFIIGNKFGGFLADRGGIHRLPIIYAAMTVLYLAFGPLLSFKWLAILIVALLCVAFSCYGSSTQLMFLDIapQSLDLASSLNSIFANIGISLGSFTASQAVQFTGLTRLGYVGSIYALLATVLVIVLSR-
     463 UniRef50_UPI0000DB7DF8 PREDICTED: hypothetical pro...   147     6e-34  1  15.9%  2:391   1:384     -MNNAKKRSQIWSSILCLAFAGFIFNTTEFVPVGLLPN-IAKSFSMDVAHAGLLLTIYAWAVSLLSLPLTVLTSRMERRKLLILLFCLFIG-SHLLAGFAWNFYSLMTARIGIACAHAVFWAITTPLAVQLAPNGK--KAKAMSFIVVGTSMATVLGIPIGTKIGELVGWRVTFLCIGGIAFGILVLLIYLLPKVPSINT--ISIKNLPKVLKRPALLNIYLLTAIIITGHFTAYTYITPFMMKVGGFSQEVVVHLLLVIGFSGMIGSVIFTRYASKYPTAILVVPVILLMACLLSLYFSSFSLYTAMIQGVIWGLAITIIGMVMQSKVIDAAPDATDIATSVYSGIYNIGIGGGAFVGSQVLVKLSTHYIGLVGAIFVLLALILFFLLSR-
     464 UniRef50_B2T6S7        Major facilitator superfami...   147     7e-34  1  14.0%  6:390   4:394     -----KFSRAQKTAVIAGLFLAWAVGYADRILMSVALVPISKEFMLTAQEGGMLLSAFYFSYAIMQLAGGWLSDKFGSR-IVVVACVVMWSIFTGVTSLGWSFASLLVIRFMFGLGEGSFSPASSVTVAEVFPKKQRARAK--SFLVSTTFLGSAVGSAIIAASVTKLGWRGAFDILSVVGFAVAVILWFSLRGDKRARQKtrPRVAWKPVLQSPLAWKLTAVWFFTSALHVGVNSWMPTYLMTSYHISLKHAGLALVVPNLIAFAGANTVGFFLDKLDKRfcLVAGSALSTVFLVLMITTTQIWLLLTYWTLFSLSFNLVYATVFATPLRRVPEQlgKTSGLMNFGGQLANSIFPAIMGALITAAnfFSAFYLLIGVGVLSVVAALVFK--
     465 UniRef50_B8CY87        Major facilitator superfami...   147     7e-34  1  15.8%  7:386   1:376     ------MESSKKYRITLYCIVTGLFWFSFYSYVPTLSPYI-ESLGASYKMIGIILGSFGFTQMLLRIPLGIISDKINRRKVFVVLGVFLGFASALGMWLFNDLILILIFRAMSG-AAAATWVTYVVLFSSYFDSNDTPKAM--GIINAFLRVGQVTAMLIGGQAAQYYGQKAPFLVAVVGGIIGLVLSTGVV-EKKNDHHKQVRLKSLILVMKEVELIKVSILAILFQIIIFATVFGFVPVAAKKIGATSLQLGMLTTLSTLPAIFSSALSGTLAERYGEKKTIMFGFLVIAFSCITVPYISSVLLLFIIQIIGGFARGFVFSLLMGliKNIEEDKRATAMGFYQAVYGIGMFLGPIIVGFLSDIGSLTLGFWFTGVIGLFAVVLT------
     466 UniRef50_C0ZEL8        Conserved hypothetical memb...   147     7e-34  1  11.5% 12:386   4:379     -----------KKVLYLLGITLMLGMFAQNLFMPILPA-MQKEFQTSAAMINWTVSIFTVMLAIMQIIYGPFIDRFGRKRVMIPA-LILFTIASIGCYLVDSIYGLLFFRALQGAGFAAIPIVAATIIGDIFTGVQR--ASAMGTYQMLLALSPALGPLLGGWIGGIGGHSAVFLFLAICAVFLVGINAIWLPETKKAQATSSgrGSFRNILLHPVGASVILIGFSQMYAYYCFLLFLPVQLTNHYAVSVEIIGLVFLLVSVVFIISSKLSAVLQNRWGARKTLLVTTGSNALAMFLFMTAasFLLLVLTSTLFALTLGVGMPAHTILLSEEFEAERATSIGVYNFIRYTGMAAGPVVGAMLLEWGGVWLDFGMAGILIALATLFA------
     467 UniRef50_C8WRQ0        Major facilitator superfami...   147     7e-34  1  16.3% 15:389  18:390     --------------IALFYAVTALYWFSTYTYVPLLSPYVVA-IGGSLSMAGMVVGSYGFSQMLVRVPIGVWSDKVRSRKPFVVAGGAVGMLSSLGFAVTHSVLWALVFRLLAGIAAGCWVVFTVLYASYHQPDE---APKAMGVLSFYTSIGQLAASTLGGVIAERYGWHAAFWLGAAGGLAATLLACFVVDKPPARDHGGIRVAEMLTVGRDRIVLGVSFLAVLAQVVTFTTMFGFTPEQATHLGANKADLSWLTLAATLPNAIASYFSGSLFSRwgERNVVASGFAIAALFTAAIPLCHALPLLYATQAVNGFGQGLCMPVLMGLAIriDASRRATAMGFYQAIYAVGMFGGPAVVGWLGDHVGLSRGFLAVAATSVVACALTFAL---
     468 UniRef50_D1YZL2        MFS transporter n=2 Tax=Eur...   147     7e-34  1  14.8%  9:392  10:398     --------SRFDRQVWGLVGAAIIAVMGSSLVMTFMSIYMYETLGMSMTQVGIADFITAIAGAGAAYIGGAACDAYGRKK-LLIAGLSLQIVSYLLISLaaAIPLFILALAFNSFNGGLYRAIPDVMVADVVEPSQRVEA--YGLLRIGSNLGWVVGPVLGGAFIMFTSYGNLFLITALTTFTYLLIAIFLLRDTKPKTRSEhsLKDVIVVASDRPFLAFCLIMLFMTIPYQQMYTLFSVYASSYVGLNEFWIGVLFALSGLMVALFQYPLSVRVGQHRMTSMLALAAVIFAFGFGLLSISTAFFVPFICMAIITLAEMIWAPSSSTLQANLSPEarGRYFGFSGLTGNIGWAVGPLFGGVLKDSmnVPSMWTVIGAMFIICAVAILGLKRL
     469 UniRef50_Q5YR88        Putative transporter n=1 Ta...   147     7e-34  1  16.5%  4:391   5:393     ---TRSGSRGLPGEIKVLVGAAFVIALGFGLVAPVLPQF-ARSFGVGMAAASAIVSAFALMRLLFAPFSGQLVQKLGER-WVYLGGLLIVAISTGASAFSQTYWQLLVLRSLGGIGSTMFTVSSLALVIRLSPVEQRGRVS--GLWSTSFLIGSVSGPLVGGALAG-LGLRAPFLIYAAALLVASGIVYVSLRHSQPIAAESgpVLTFRQGLAKPAYPALLWTHFANGAAVFGvmAFVPLIVVEVLAQPPGMAGVALTAFAAGNVAVLFASGRLSDRFGRRPFLIAGALVCGIGTVSIGFAPDLIWLLAASVVAGLGSGMLTPSEQAALADiaKARGGPMLAGFQMSADLGTVLGPVLIGAVVEATSYGVGLSITGSLLFAAAAIWLFVPE-
     470 UniRef50_B4B5P0        Major facilitator superfami...   147     8e-34  1  15.4% 13:389  18:392     ------------RNLQIIFLTILMAVLGATSITPAFPR-LARELSIPTEQVGWLTTAFMFPVFLATPITGLLADRWGTKK-IVVPSLILFAVAGTACAFIQDFKSLIELRFIQGIGAASLESLGLTSISKLYSGEKLTAAM--GYNSSVIGMGLVIYPLIGGALAT-LGWRFPFLllIAIPVGVIVLFKLKIPEKNNTQNFKEYLGSVGKSINNHQVIGLFVATflFVLLFGAFFTYIPMLVGTTLGASDLFIGTILSTMAVTIALVSAQLEKLIKFFSELILIKVSFILYAIALIIIPFIHYAWAVLISAVIFGCAHSLVFPCSQALLARLApdCRAGFMAVNATILTFGQAVGPLIAGAAFTLWGMNGVFYFSAIFSAVTLILLQWL---
     471 UniRef50_P54559        Uncharacterized MFS-type tr...   147     8e-34  1  14.3%  5:389   1:388     ----MKKWKDIHPISWTIIIGTIFGRMATSMSIPFLAIYLTAVQGASASYAGLVIAASSSVGILASFYGGYISDKFG-RKNMMLVSIFGWMLVFAGFAAASNLWVFFVVNALNGLCKSLFEPASKALLSDMT--EEKTRLLVFNLRYAAINIGVVFGPVLGLYFGSSQS-TTPFLVPAVIYGLYGIVLALQFKKHPSLSAPAQsrEAFMVTQKDYLFTIALVGITLCTFGYSQFSSTFPQYMAQNpgNGTKLYGLMLTLNAIVVLATQFPIVHFAKRFSPLCSLMLGNVMVSISMAIFTVSHGVPSIVMIVITFTIGEVLLFSMMDLYVDQIapGLKGTYFGAIGFSQ-LGNVIGPWVGGICIDLFGAGRPIYIFSVLSGITLLGLPFL---
     472 UniRef50_Q03P36        Arabinose efflux permease n...   147     9e-34  1  17.3% 10:391   3:382     ---------KYRWQASALVLVAFMLGCNEFMVVGVLSD-IARSLRVTVATAGYLVTIFAVVYAVSTPLITILTNRFGRY-PLLMTLMVIFLIGNTWSGFTSSYGWFLLTRMITAAVAGTIESLIIVFANDIAPREKR--AMLISWLAAGFSIASVVGVPVGTAISTAYSWHVAFHLISVVSLVTCLVMVGILP--RHIKHVSGTIKDQLVLLTDRRIYLGAALILFTAAAMYTYYTYIRPLLTTGLGFGTTALNWLLFVLGIMSILGNRLSGKIAERHGLTTMPRFYVMDIGLLLCLPVAMQSQVAGFGVFLVLTLIIMAVNSPIQVHFLDVapQSVALASSLNAIFFNIGISVGSATASVMLTRVGLGYLGWGAAVFAVISLVIVIGLNR-
     473 UniRef50_D1CHQ4        Major facilitator superfami...   147     9e-34  1  16.8% 18:391  17:393     -----------------LLLPIVLISLPFGAIGSFLPLY-AHSLGASAFEVGVVYGAFSLAGLVCRPLVGVGVDRLG-REQFVIAGMVAYTLSFAMFSLLDGVTMLVLARVLQGVASAAFWVALSVLAGDWSEGGLRGagALNQALNIGMALGTVLSYGLIAYMGIQSGWRWTMAAYALVSVCALLLMLRWLPRGVGLSGRGEPADKRPALDKRGVRVLSEVLLVLLVlcYSMITPLLLVYLEERFGVSEFVIGLAYAPAAVVYALAPAYLGRLSDRWGRRPVICLGLLSSGLVACFFPLAPSLWVLSLAWLVEALCSSAAVPAQDALVSDLTGGsrGRAYGVYAATTGLGSTVGPPLGGWLYDHVSMAAPFWVNAVVLVLGALALFYILR-
     474 UniRef50_Q2J5T8        Major facilitator superfami...   147     1e-33  1  15.8%  6:391  53:431     -----TRDRQRWGALITGWLALFVIGTDLFVVSPLLPIW-RSRFDVSLRTAGLTVTVFALAYVVAAPAWGRRAVKVSP-PAVLVLALSGFAVCNVLTALAPNFWTLLAARVGTGLFISGATATVFTLVASSAPNGRR--ASWLGIATSGLLSALWAGAPLGGLVARHTSWRAVFVILAAFAVLILVAARRIWPDTQAARAAAAPASRSAAWRAR-----AVAPTACWAAAVYGLYTYLSAGLGDRPGWSTAWLNASLIVYGLCAVAATFLGGRIADRHGAARTTWTALLLLAAADVAFSASLSSAAVTTCLAIALLAFAaaFPAKQAQLVSDHPADSAQLMSWNQSAMYLGITLGSLAGGRIADGHFRALPLACAAVAILGATTQVSTVRR-
     475 UniRef50_Q1IAY3        Putative multidrug transpor...   147     1e-33  1  14.1% 17:391  15:390     ----------------LLLALVCLPRVALDLYLPAWPQ-MAQALEVPPAQVQFSLTAYMLGYALCMLLAGPLCDLWG-RRPLLLAGLGLYGVATLGCLLAVDLPSLCVARFFQALGGCCGPLVARVMVRDRFAADEQ--ARLLGLLSSGMAIAPLLAPAFGSLLLEVLGWRGLFGGLLIIGLLSQVQAVRYLPETRPFDASPAHlqAWRQVLGSRVFWRSSLVIGCAYCSYFPFISESSLLLQHGLGLSPQVYGLVLGGTVAAYAAGSRCYGLLVRRLGNERVIILGCAisAALLALQLAGVSLWTLPLALLPVMLSVGLIIPACQWAVLQPFAAIAGTASGGFFFVQMLLTALSSALTGAWSDGSAWPMVGMTVVASALLPGVLWLTASR-
     476 UniRef50_B8KTP0        Major facilitator superfami...   147     1e-33  1  15.6% 12:388   9:391     -----------SLALWLVFVVVVIDLIGFGIIIPILP-FLAPKLGGNAVDIAAIIVVFSLCGALVTPLWGRLSDRIG-RKPVLMICLTGGALAYAMLGFADELWMVYLARAFAGVCSG-NLPVATALMADLSPPHRRARAM--GLIGTAFGLGLILGPVVGGVLaeQGDFRVPCLFAGFSSLLAVILGSFLIPREPreDTPAIKVLSSVQLLARDRSQLLVAQYILHTAAVTGALYLYPLWSAAMLDWGPREVGVFYGVVGIAMVLVqvLIGPLTTRFGVLPVLKVGMVVFAGSVLAAVFADEEWLIVTAGFLAFSGSTVCVPILNTVTSLLVseERGQMMGITASGAAVGRVLGPLVTGFVLSVGGFPVGWLAVLVPILLILYWAVT----
     477 UniRef50_A7BA35        Putative uncharacterized pr...   147     1e-33  1  13.7% 13:391  20:402     ------------ALLITLAVQNAVPPMATDMYSAAFPQ-ITADLATNSTMLGFTLTTFFVGYASGQVLGGAISDQIGRRRPIIAGG-IIALVGSMICVFTPNIWVLLVGRVFQGLGGGVASSVARAILVDVA--HGKTLARAMSLLQAIVGFAPMLAPVLGAFIITHATWRVVFWALAGFTLLMAALAWFVVPESLPEERRHPgfSGLVQVVRIRPFVGFMLTNAFSSFCMFGYISNATYVLQGPLGLSPMAFAWVFAFNALLSTGFALVNVRLISHFTPRTLIITGLTIAATGVVTLAIStpLILTCVGFALIMTATAFIFGNSGAQAMSEAREHAGTASSVMGVFQSIANGIAAPLAT--SGGDSAVPMVLVMIVGSVGAWFAFWVIAR-
     478 UniRef50_Q89EV3        MFS permease n=9 Tax=cellul...   147     1e-33  1  14.7%  2:390  15:411     -PDTSPWIAFRHTTFTVVWIATVVANVGTWMYNAA-SGWLMTSLDANPLTVSLVQVASSLPMFLFALPAGALADTVDKRRFLIGCEIVLTIIAAASAVLVgtPPILLLFTFLLGAGAAFTAPAWQSVVPQLVP--RQDLAAAVAGNGVGVNISRAIGPALGGAVIGGFGIAAPFWINALSNFAVIGALLWWRPAspPERLAGAMVIGFRHARFNPKLRATLVRAAAFFFFASAYWALLPLVARNQIAGGPALYGILLGAIGVGAVIGAFILPWMRTTFGPNGLVAAGTAGTALSLILLGIARHAEIGLAACLIAGISWIGVLATVNVSVQVSLPDwrGRGLAIFVTVFFGAMTAGSALWGQIASGLGLPTAHFLAAAGAVAGIALTWRWK--
     479 UniRef50_A6GZT6        Major facilitator superfami...   147     1e-33  1  11.9%  6:392   8:400     -----KFTSYQKLIIFVLAILQFTVVLDFTIISPI-GDILIKTLNITTKQFGFAVSSYAFSAAASGIIAAGFMDKFDRKKALIFF-YTGFIIGTLFCALSNTYISLLIARIFTGFFGGVISSIVLTIISDLFMPHQRGRAM--SFVQMAFAGSQILGIPFGLFIANKLGWHYTFFLIVILALIVLLIIIFKLkeHLKIVSDKKPILHLWHTVKNKKYQVGFLGITFLSIGGYMIMPFMTIYLVNNIHIASSNLPIIFMITGLSSLVMMPIVGKLSDKYSKLKIFLFGTFTSIIMIAIYTNLppLWSVVVINVIMFASIMSRMVPFQAlsMMPNKEGRGAYMSISSSLQQIAGGLGAVISGFVIIQKSKTSPlvLGYLAIAIAILCAYFVFRV
     480 UniRef50_Q07GL1        Major facilitator superfami...   147     1e-33  1  14.6% 14:390  23:406     -------------AFALLWTATLISNVGTWMHD-VGAGWLMTTLNSSPSVVTLVQAATTLPVFLFALFAGALADRLDKRRMLITINILLTIVISTLTVLVwtPLLLILFTLAIGTGAAFMAPAWQAIVPQLVPREKLKPA--IALNSMGINISRAIGPALAGILIASVGLAAPFALNAVSHLVIIVALLLWKPEPTTGTKYHGpaTGLRHVRNNEALKATAIRAGAFFIFASAYWSLLPLIARQAEGGGSQLYGTLVALIGGGAVTGALLLPRLQKRLDSDMAVRAGTLGTIAALLIMALSATPVALMAAAFLGGFSWITVLTSFNVSAQMALPNwrARGLAVFLMVFFGSMAAGSIIWGQVATATSIPVALMIAAAGLALGILVTRGFK--
     481 UniRef50_A0AX35        Major facilitator superfami...   147     1e-33  1  13.2%  6:391  12:429     -----NMKTRYRWWIGALLFGAGMLNYLDRAALSVVAPIIKRELGIDDAQMGILFSSFFIGYCVFCFVGGWAADRFGPRR-VFACAAGVWSLFCGATALAGSFAHLLIVRVAFGIGEGPMGTTTNKAISNWFP--RREAGRAVGWTNAGQPLGAAIAAPIVGLVALQFGWRVSFVVIATLGFVWLAAWWALFRDDPASHPRVSpaRPLLRDLLSRPVLGVALAFFSFNYVLYFFLSWLPSYLTDYQHLNIKQMSVVGILPWLGATVGFVAGGTVSDrfARKIVIVVGLAVAAACVLLASRVSSLGAAVTLIAIASLFAFMAPQACWSLLQEIVPRErgSAGGFVHLLANLAGILSPSLTGWLVQygGYASAFVLAGASALAGAVILTFAVR-
     482 UniRef50_C4L090        Major facilitator superfami...   146     1e-33  1  14.9%  8:389   7:382     -------QKLWTRDFLIISLINFFLTLIFFLLMVTIGVHAVESYGATTSQAGLVTGIFIIGTLTGRLFIGRLIDSIGRKKTLYI-GLVFFTATILLYFVHWGVGFLLLTRFVHGLGMGLSSTATGTIVAQVIPATRKGEG--IGYYSMSSTLATAIGPFVGLLLSQHTSFTVIFGLCFVIGVISLASTFFV--NVPEVDAPEVVRGFSLKSFVEPKALPIALIIGMAALSYSSVLSYINFYASELDLI--EAASIFFLVYSVAVLLSRPITGKLMDARGANVVMYPAIAIFAIGLLVLSQANSGWMLLLAGALIGLGFGNIQSGTQAIAVKASPPHrgMATSTFFIALDAGLGFGPYFIGLLIPLTGFSTLYLILSGVVLFTIFLYYVM---
     483 UniRef50_A1WQM4        Drug resistance transporter...   146     1e-33  1  17.2% 24:390  74:446     -----------------------IQPVTTDLYLPALPA-ITNSLAAPMAAAQLTLSGLLLAFGCSQMVWGPLSDRFG-RRPILLTGLCIYTLASLGSAFASTIAQLVLWRIAQGAAMGAAVMCARAIVRDLYTPLEGARAMSKAL--TGLGIVACVCAPLGGLLSQWLGWRAALLVLTGYALVTLALVAWRLPEtpQALQPRTLLRTWQQVLRNPTFWAFSLLTTTSYGGLFTFLAASPFVYIDVLGLTRTQYGWVMASACLAYFAGTLLCRRLLSRHGLLRTVAIAGGLSvlALVALLGWHQPWALLLPFYLFMLGHGMHQPCGQSGAVGPFPKAAGVASALSGCMTMLAAFAMGGWLGLRLDGSIWPLVNGIWFWSVLLALVAWTLVQ--
     484 UniRef50_Q0VSH1        Major facilitator family tr...   146     1e-33  1  17.1%  6:392   8:391     -----ALQRTELKATGYLATIFALRMFGLFMILPIFAVYGQALEGASPLLIGTAIGAYGLMQALLQIPFGMLSDRFG-RRPLLLIGLLLFIAGGAVAAMSDHIYGVIAGRALQG--AGAIASVIMALIGDVVTEKHRTRAM--ALIGMSVGGSFVLALILGPLLAGWLGLSGLFWMTSVLGGFALLVAFVVPAPKALQGEALPVSERFRRVLGSKTLLRFDVGIFSLHLIMTASFVVVPALLSDRLGLTLQSHSLLYLAVLVAGFVAMVPLIIRAERRGAVPMKRLAVVLLALSQLVLALAGalWHFVLALLVFFTAFNLLEALLPSLVGRAAPAgrGTAMGVYSTSQFLGVFVGGQMGGALYQWVGAEAVFYSCGVLALIWLLVLVGMKEL
     485 UniRef50_B8FM40        Major facilitator superfami...   146     1e-33  1  13.0% 11:388   1:377     ----------MKRIVPLLAFLTAFPALSTDMYLPAIP-MLVEQWNQPLVVVNLTLIAFFASFCTFIAVYGPLSDRYG-RRPLLLAGITIYIGASIGCALSPSVYTLIAARIGQGAGAASAQTLALAIIRDKFDGLERGR--ILAHMVGIMAVAPMLGPVFGGWMLKWRHWPWLFVSQACLGVIGFIGVYFMEekDPIKVSALQVFARYGVVFKNGRFMKLNVLMSLFGLPFFGFIASSSYLYIKVFGLTEQQFGYFFAFTSGGFMLGPMVLNRLANHMSYNKIIGIGLSGVTLGGLALAfhATPWHLALPIFLFVFSFGVFRPAATNMALEQVTTDVGSASSMLVFLYSMVGAVGMWMISLEWPDK-MTVLGSLAAGIGILSLIFWFL----
     486 UniRef50_B3E552        Major facilitator superfami...   146     1e-33  1  17.2% 13:390  10:388     ------------RRLAAACLISFSCFFAAYMRMPIVPL-LAASLGADPVQAGLINATFMITAALLSIPAGLVSDRLGRR-PLLLGGLAVMSLSSFLLSRSHGLGQMAVVYLVFGAGLATFSPALMSYVADVTPAERLGHA--YGRYTMALYCGMTLGPAAGGYVAALSGLQEVFVLVGGLFLIMLLLACRYLPAPPLkrRKTSAGPALLLILKNRPFLACLLATLGCCLGYGMFVTFMPLYMKD-MGMHTVQVGYVFTAQALANAVSRLPTGKLSDRISNkgLIGSGLALFSLAMAALAVCRSVTALTLVAVVMGGGMGVAFTVICARIAELvpQMRGLAVGCYNTCVYTGMMLSSVAMGPVIKLAGFAGAFVLNGMAGIVVLVLFTALY--
     487 UniRef50_A9VHC8        Major facilitator superfami...   146     1e-33  1  11.3%  7:387   1:375     ------MKKVNPLLILTLAIGVFGIITTEMGIVGVLPQ-ITEKFGISTTQAGFLVSIFALVVAISGPFLILLVSSI-NRKIILLTAIFAFVISNIIYAYTTQFEIMLIFRILPAALHPLFFSIALVTAAKLVPPEKSGQA--VTKVFMGITVGFALGVPLTSYLADQFSLEIAFLFGALVNTLAFIGILILLPSM--PVKEKMSFGKQIRILGKPGLWLNILTVTFLFAAMFSVYSYFAEYLAKVTSMNGSLISIMLFIFGIVMILGNHLFGSLLQKSIVNTVILFPILYSIVYILVYYLGSYLVPMIFIVFIWGIVHAGGLIVGQTWLISEAKEAPEFGNSLFVSFSNLGITLGTTIGGWFISNLGIHQLIWSGFIFTLLSFLLII-----
     488 UniRef50_D2PUM2        Major facilitator superfami...   146     1e-33  1  15.9% 11:388   1:373     ----------MPLAVYVLGLAIFAQGTSELMLAGLLPE-LSADLGVSIPDAGLLISAFAVGMLVGAPVLAVVTLRW-PRRTALLTFLAIFALTHVVGALTPNYEVLFATRVVGAFVYAGFWAVAAVTALNLVPADRRGRAM--SVVAGGLTLATIVGLPAGTVVGQHLGWRAAFWGVALLSTAAMAGVLATIPGGKPATAPR--IFDEVGAFANPRLWLAYSTTALSVGALIVSFSYFAPLLTEVTGLSAGWVPIVLALYGVGALIGITVGGRTSDRRPFGTLLVGLGGLVVLSVALALWAGQPAAVVAVIVLLGVFGFATNPAVNTRVFRLAESAPTLAAAVNVSAFNVGITVAPWLGGLAIEaaGYRSLGWIGAAIGALALLTVVV----
     489 UniRef50_B2S6M5        Drug resistance transporter...   146     1e-33  1  14.5%  7:288   1:283     ------MASSLVRNAIVLGLLSAIGPFAIDMYLPALPT-IATDLRAETGEVQMSLLAFFLALALAQLFCGPLSDMVGRKLP-LYGGLVLFAIGSIGSALAANIDVLVLFRFIQGLGAAAGMVIPRAIVRDL--HTGVEAARLMSLLMLVFSISPILAPLTGSIIISFFGWRGVFWAVLLAAGIGIILVATAQKETRSVEArsSALRGYGRLLKDRHFLGLVFVGGFGLASLFVYLANSAFVLIDHYGLTPIQYAVAFSANAVSFFGVSQLNGWLGARFGLGRVMRFAA--------------------------------------------------------------------------------------------------------
     490 UniRef50_Q0FEF9        Drug resistance transporter...   146     1e-33  1  14.2%  7:365   4:364     ------LAAKTNPHLVTLVVITAASIVSLNMFLPSLAN-MASEFNVSYRVMNISVAGYLAVTAILQIIIGPLSDRYG-RRIVLLSSVIIFCLSTIGCIFSSNIWWFLFFRILQGAMISG-TALSRAIVRDMMDSKE--AVKVLSIIAMAMAIVPMLAPMIGGFLDELYGWRTSFWVYLIMGLSLLILIWFDLGETNTKKSEtkQLSTYPKLFKSGQFWGYSICMSASVACFYGFLSGAPLVATKVLNLPPTELGLFIGTTSLGFFIGSFLSTKLNIYFNLTQMILFGRIIAVLGilVLMGYVSTLTIFGSMVFIGLGNGFSLPSSHVGIMNVRSDLAGSASGLSGAMAVGFGAVVATLMGLILTA---------------------------
     491 UniRef50_C5BCJ1        Inner membrane transport pr...   146     2e-33  1  13.8%  7:391   6:390     ------MTPDECKATWGLGTVFSLRMLGMFMVLPVLTTYGMSLSGASEPLIGLAIGIYGITQALFQIPFGIISDRIG-RKPLIVAGLLIFACGSAVAAMTDSIWGVILGRALQ--GAGAIAAALMALLSDLTREQNRTKAMAF--IGVSFGVTFAIAMVAGPLITHALGISGLFGLITLLALIGIAITLYLIPTPTThrDASMVRGAFGNVLIRPALLRLNAGIMCVHILLMSSFVALPP-LMEQAGLLRSEQWKVYLCTMLIAFITMVPFIIYAEkrRMKQIFQLCIVLMITAEVVLWYAghLWSIILGIQLFFFAFNMMEAMLPSLIseSPPGYKGTAMGVYSTCQFIGVAIGGILGGIIYARGGAEAIFTGCAVLAVMWFVISLTMKE-
     492 UniRef50_B8J477        Major facilitator superfami...   146     2e-33  1  14.8%  9:392  10:387     --------RRLWVPVFTLALAAFIFVTTEILPIGLLPE-IAADLGETEAFTGLLVAVYAWVVALLSLPLTALTARFERRK-LLLCLFGVFIAGHVLSAFAFNFTTLMIARICVANAHAVFWSIASPIVVRVTPPAL--KAKGLAIIIVGGSLATVLGVPFSTVIGQHFGWRAAFLIIGAMAFCIALILWRLLP--TLESKDTGSFKSVPALFRNKELSLLYLQTMLAVTGHFVAYTYLAPLLIQVGGFTEGAVPLFLLIMGLSGIAGSMLAARLVGNGAKFVFTVPPVAIFLCLLVLNVSIDSILLIVPLCIVWGGSMAVLGLLFQSRILEIAAHSADIATSIYSGIFNVGIGGGAFIGSMVFNKLGLGMTGYAGAAFFFATILVSLYAARI
     493 UniRef50_UPI0000510310 major facilitator superfami...   146     2e-33  1  13.7%  1:366   1:367     MTTSTHARVRVPAQVYLLAAVIFCLGTSEFMIAGIL-EPISADLQVSIPQAGLLITGFAVGMIVGAPAMALLTLKL-PRKATMIISIVAFSALHIVAALSPNYSILMVTRVLAAIACGGFWAVAAVHTTRIAPAEVHGRA--LASLVGGLTVANLIGVPVGTWVGTQFGWRATFWAVAIVTALAAVLIALTVRSATGERSgpTLFKAEIQAFKGPRIWLALATTALFQASVFAAFSYFSPLLTQVAGISHDLVPGVLAAFGIGAFIGVVVGGRFADRNIFGNIVGSLIALAISLFALWLVAENGWAAIVMIVLVGASGFSIAGALNARVFQIATQAPTLAASVNTSAFNVGNAIGPALGAAVIALG--------------------------
     494 UniRef50_B7R8I7        Transporter, major facilita...   146     2e-33  1  15.5% 17:390  19:394     ----------------VLGWVAFFGGLSQDMIVPILPTFYTQILGLSKEMVGLIEGSVTTVVSIMRIISGIISDKIGKRKSIVFIGYLFSAVGRVLLPLTNGAAMAFGLRLIDGIGKGTKDAPRDALIAKSS--KMKSMGFSFGFQRMLDTLGSFLGPLITAGLMILFayRLIFLIAGLVAFITIILIGLFVVEQKGERVSSSFKLDLS--VFKGKFLTFFVVMLVFTLGNSS--DAFLILRARSVGVKESTIPIIIAMFNLSYALLSVPSGVLSDRIGRVNVIRLGWIIYAVTYLGFALAKLPWHIWALYLIYGVYYSTTEGVAKSLVAHIVDenRGTAFGLYNASMGLLAIPASFIAGYLWDNVSPAAPFYFGAICSLVAVILITLFR--
     495 UniRef50_C7JAN7        Multidrug resistance transp...   146     2e-33  1  13.0% 21:390  26:404     --------------------VTAIGPLATDMYLPAFPD-VERDLGGGAGSAQFTLGAWFLGLAFGQFSQGPLSDRFGRKVP-LVIGLAVFAVASAMCAVVRDYHLFCIMRFMGAFGGSASAVIPRAIVRDVATGKKG--AHIMAQLTLVFGVMPVLAPSMGSLVLEFGNWRWIFWSGTLYAVLGMIGIICMLPDTLSPaaPFEIFTRYRTILREPVFLSNALITTFSTFVMFAYLGSAPVLFEQVLHFSPTAFGMFFGVNAAAFILGTQINGRLVHKFAMPALliMGGIFVVVACSGLAGLAHPWLTCGLITCITGALGFIGPNGTVMAFSRHAHQAGSASALLGTMQFSLGSLSSVLVGVLPGGGAIPTAIGMMTGVIGMVCANILRRR--
     496 UniRef50_A6VXJ7        Major facilitator superfami...   146     2e-33  1  11.5% 10:391   3:379     ---------AYQWGIFAIALGTFGIGTTEFMPMGLLPV-IADGVNASIPAAGLLISAYAVGVMIGAPLITLFLTRYSH-KTSLLALMVVFVVGNLLSAVSVNYETFLVSRIITSLSHGAFFGIGAVVAMNLAPFHKKGSA--VASIFLGLTIANIVGVPITTWLGQNFDWRISFAVTAILGIVAFIGISRSLP--VMPQAEKPDVKTELKAIMQPAALRAFATTVMCAGSMFTLYTYIAPIMQTLAQASDNAIATMLMLVGIGFTLGNYISGKVTDKSPDLALFAFLGLQVLVLLLFRFTSTTLIGASLTILLWGVVIFGSGPPLQMQVMKIADQAPGLASSINIGAFNLGNALGAALGGLVIsgFSFEWIPTAAAVLSFLALVMVWLNRR-
     497 UniRef50_B5JJ44        Transporter, major facilita...   146     2e-33  1  27.3% 10:390  12:396     ---------LRQPAFPGLLASTLTLGIAFSFVAPFLSKWGTEEVGMSPKAFGLFMTVVSLSAIAVSTYLARLSDSRFSRRQMLILGSLGGVFGFAGYAIIRNPIALVLIGSTLHAVASICFAQLFSHVRETYKPdgQNASFLMSVVRVCFSFAWTLGPAAGSLVLIAYGFRALFLAAAGLYLIFLLGIIRFVPetIQPQTGSQKIPSLWRTLKRPDLLLCFITFATVFAANAINMLNLPLAITRTLGGTERDFGIIFGIGPLVEIPLMLWFGHLAGKGYQLFLIRLGVAIMALYYFGLFFAYAPWHVYLLQILSGAGFAILTNVAILFFQDLVPGQMGLATSIFSNAGAVGNLLGMLSFGFIVEALGHQNAFSICAGLSLLALVMILTYR--
     498 UniRef50_D1YZD1        MFS transporter n=1 Tax=Met...   146     2e-33  1  15.0%  4:390   1:412     ---MAASMELKRQQILILAVANVIFTLGFGIIIPVLPYY-SRNLGADAFILGLLMASFSLMQFIFAPYWGMLSDRIG-RKPVLAIGLAGFGLSFIIFGLSTQLWMLFVSRIVGGILSAGIFPASFALIADITEPGERGK--IMGWMGAAAGLGIIFGPAICGVFVP-FGMSVPFFVAGAIALVTVVALYAVMPESRahAKKTSIADSFKAIATstPIGVFLLLTMLINFALACYEGTFSYFLMDRFHLtpTLMAFLFTAMGIVMLFGqiLVGMALKRLKEEKTVIAGLLLSCAGLVAVLVAPDFVTLLLAACVIGVGSGLVMPSLSSYIsrTDKDTQGSALGVMGSYNSLGRIVGPPVGGFAYDVNMIFPYISSSILLALGALSVVFIMR--
     499 UniRef50_B2JFU2        Major facilitator superfami...   145     2e-33  1  12.8%  9:391  32:438     --------RRIQRTALALLLLSGVINYIDRATLSIANPLIRHDLGLSVAEMGLLLSAFLWAYAFAQLPAGALVDRFGAR-VMLSVSLATWSVAQAFGGVVSNFSQFFAARMVLGIGEAPQFPTAAKVVRDWFGKKERGAAT--GIWNSSSTLGTAISAPLLTVLMLTVGWRWMFGVMGIAGLLVALGFFIMHRDPRqeAQSRPTWREWRRLFEFSTTWGMLLGFFGTIYVLWLYNAWLPSYLQMELHLTIAKSGWVAAVPYLFGVVGSLSGGKICDVLARRGvmAASLFGVAVFTVLTGLTHNVTLAVVFISISMLLLYVSSSAAWATASVAAPAntASIGAMQNFGGYFGGALAPVVTGFIVQQtsFAPALFVGAAVAAVAVIGYWLLVR-
     500 UniRef50_O34663        Uncharacterized MFS-type tr...   145     2e-33  1  13.5% 12:389   4:376     -----------TWKIYILAIVSFLVGTSEYIISGIL-DQIAHTLGITLAAAGQLITIFSLVYALSTPVLMALTASMDRRKLMMYA-LGLFVFGNVLAFVLPGYGWFIAARIIMAMGAGVVVVTALTIAAKIASEGKQGSA--IATVVMGFTASLIIGVPLGRMIAVALGWKSVFGAIALLGLIAMVVIFFTLPYT--EGDKPVPLLQQLALFKKRKVAMGLSITFFWLGGYSVAYTYLSPYLLNISGINGKLLSGVLLIFGIASLVGSKFGGYSTDKWGVPFTLVGGMTLHIVTLILLSLvhSYIGVLVILILWSFAAWSTGPTQQFHLATIEPEMSGVLLSMNQSMMQFAMAVGAGIGGVFVENVSLASITWVGALGVMIAIIASLLI---
     501 UniRef50_Q7NRP4        Probable multidrug resistan...   145     2e-33  1  14.9%  3:385   9:391     --RLSRPYRGLPPSVYIQVVCSFINNVG-GISKLFLPLYLRESYQLPYNQIGMLMAFYGAGMLAGSLKGGSLTDRFDSR-ALGVLALAVSGLCMVLLALRIPVWLFMPVLVLSGMADGGFRPINQRLALEPCAPQQRPVAQ--GMMRVAFNLGVAIAGVSSGFLAA-YGYQWVYAANAAGTLLGACWMarRVESTRPQRRRADDEDALAGPWRDASFLRSILALVLITLAFDQMYVTLALFLREHYQLGPQWVGYLFTLNGLMVVALQIPISRRILRWGLARSTQLGVLLTGCSFLWLNAGHGVPWAVLMMMTLTFGELLLSPSYAHLVMHRSEGrrGSYLGLYNAAWNGRTLVAPALGTALYGQFGGQMLWWLCALAACLGVAI-------
     502 UniRef50_UPI0001B4D736 putative drug resistance tr...   145     2e-33  1  14.1%  3:391  16:409     --STSPAPPRALRLLIVLGALSAFGPLSLDMYLPALPA-LARDFAVPDAAVQLTLTSCLIGLAVGQLIAGPLSDRWGRRVPLLI-GLAGYLVASVLCAVAPNVTALTGLRAVQGIAGAAGIVISRAIVRDLY--EGTAAARFFSLLMLVNGLAPILAPVVGGQLLRFTSWRGVFLVLAVIGALLLAATVVVVGETLPSARRRRGgrSFGVLLRDPGFLRPALAGGFAFAAMFAYISASSFVLQKTYGLDPQQFSIVFAANALGIALLGQGNARLLRRRSPSALLRAGLALCAAGGGALLLSvgVAAVLVSLFALVSSIGLIMPNSTALSMSGHPEMAGTASALLGLLQYALGGVAAPLTGLGANGAALPMALAIAACAAGAVVVHLWPVRR-
     503 UniRef50_C9W336        Putative transmembrane effl...   145     2e-33  1  17.3% 11:391   1:369     ----------MRSRLYPLAVGNFAVGTGMFVIAGVLPA-ISRDLGVSAAVAGQLVTVFALAYAVLSPLLAAVTARVPRKRLMLVA-LVLFVIGNVLTVLAPTYPLLLATRVVAAAGAALFTPTASAVAAELAEPERRGRA--LALVMGGLSMASALGVPLGTWLGGEYGWRVTIWLVVGLAVVGGAGVLAQVPEIRIQSSAR--LRDRFTPLADRGVLAVLTTQLLVFGGGFTAYTYIASLLDLPL-------AAVLWAWGIGGIVGNQVSGRLTDRYGPRRMVFIGIVVATAFIGLIPVAnaLPIALVWAFLWGMVGWLIAPAQQYRMLAALPGNVPVGLGLLSSAQYAGMFVAALGGGVALEQYGRAGVIGLAVALGAVGVVFTLVTYR-
     504 UniRef50_C8Q2T9        Major facilitator superfami...   145     2e-33  1  13.3%  6:388  33:407     -----STQKLPISALLALAMTGFICIITETLPAGLLPQ-IASGLSISASMAGQTVTAYALGSLLAAIPLTIATQSW-RRRNVLLLAIAGFFIFNSITALSTSYWLTLLARCFAGVAAGLSWSLLAGYARRMVAIQQQGKAMAIAMV--GTPIALSLGLPVGTWLGGIIGWRSAFGGISVLTLVLVLWVLVSVPDYPG--QSRHERLPLLRVLTTQGVRPVLSVVIAWMLAHNILYTYITPFL-DLAGLSA-QVDLILLVFGLAALLAIAVTGRLVDRHLRTCVLASLAIFALVSAAFMAFASVPAVIYVGVAIWGFTFGGAATLLQTALADTAGEGADIALSMNVVAWNGAIALGGIVGGILLKDWGAQAFPPVLILLLVIAMLVTWR----
     505 UniRef50_Q8DGS3        Tlr2241 protein n=1 Tax=The...   145     2e-33  1  17.3%  1:388   1:385     MVVLLKLAPPLRQTLLRLILAGLLFWSSIAAMLPTLPLYIAQK-GSTPHQVGFVMGAFAVGLLGSRSWLGPLADRRGRKITLLI-GLAVAAIAPLFYILSHNLPLLIAVRLLHGVSIAGFTTGYMALVTDIAPPQHRGE--IIGYTSLVHPIGVALGPSLGSWLQMHYGHDWVFIVASTLAAlmAAAGVRAVNRAQESGELPAETTLFWRLLLSERLRIPSLVMLSVGLTFGTIATFIPLFmaEQLGVSP---GLFYSVAAIASFIGRVLTGAASDRWGRGIFISASLAAYVVSMVLLAQAQTPLDVLWAAILEGLAGGVLIPMVAALMADRspQERGRVLSLSLGGFDLGMALAGPLLGGLVEHWGYRVIFRMGAVFSLLGLAFFLT----
     506 UniRef50_A3D098        Major facilitator superfami...   145     2e-33  1  14.7% 12:391  26:400     -----------WSGVLAMSLCVFALVASEFMPVSLLTP-IAADLNVSEGLVGQGIAISGFFAVLTSLSIASIA-KVTDRKSLLLGLTSLMLVSGIVIAYAPNYAVYMLGRSLIGVVIGGFWSLSGASAIRLVPTEKIPKA--LAIFNGGNALAMVIAAPLGSYLGAHIGWRGAFFGLVPVALIAFVWMWFSLPAMKP-EKRVAGSANVFSLLNKPLVRLGMLAIVLFFMGQFSLFTYVRPFLETAIHVESNNLSFILLVMGVAGFMGTLLVSVFLKNNLYRTLIFIPLVMAVIALALILFSDSSVAVTTLLALWGGVATAAPVAWWTWLARTMPEDSEVGGGLMVAVIQLAIGLGSTLGGVLFDFNGYHSTFMLSATLLAAAALLAYWTQR-
     507 UniRef50_D2Q5E1        AraJ-like protein probably ...   145     2e-33  1  15.3%  5:390   1:388     ----MKKDRFFNLPVTILVALSFMLGMSEFIMVGILPD-IAAGLKVSEVTVGNLVSLFALVYAPVTPLGSALSARF-PRFATHLTLVGVFLLGNVLCAFAPNYGVLVIARILIALVSGTLVAIAMTYAPDVTT--ERYRTKFIAWVFSGFSIASVVGVPVGTWVANVFGWRWAFHLVNVLTVVLIVLMVIVLP--RNSHIVKIGFLPQFRLFFDRRIQLGVLDVVFGAAASYVFYTYLTPIMRDEVHVPERYLSVGLVIFGAACLWSNLYGGKLADRGrpLTHIRPIYCAHAVLMASLIAAHWVPVyaLLLVVLGMFMYLQNSASQVLYMDVapGSLNLAASLNSMSFNIGIALGSAVGGVVNGHVGLMWLGPVGALFLLCAITITTMLR--
     508 UniRef50_A0JZZ8        Drug resistance transporter...   145     2e-33  1  15.1% 12:361  31:385     -----------RPLAVVLGLLTIFGPISMDLYLPVLPA-LTSELNSTTSVAQLTISACLLGLAIGQVVSGPLSDRFGRRPPLLI-GVIAYTVTSVLCALSPTVETLIAARFVQGLAGAVGIVIAQAAGRDVYSGGKLIR--YYGRLTVLGGLAAIIGPVIGGQLAAVTDWRGVFLFLAAVGVAILAACLMIFHETLPEGRRSTGGLsfRRLLADPMFVGAVLITGFTYSAIFAYLSGATYILQGMYGLSPQGYSFAFGLNSLGFVIFGFIAGRLAEHWSERGTLAAGLAMTLAGALGLLATapLIAIILSLFTMVSGVAVTSPPATSLALKGYPDIAGTASSLLGLARFAFGGLAAPLVGI-------------------------------
     509 UniRef50_C6RM61        Major facilitator superfami...   145     2e-33  1  14.8%  4:389   1:386     ---MKDSAPLWTRNFILASAINFQLILVFYLLIVVIVGYAVAELGASTAQAGLISGLYIVGTLFGRLLIGKFLSRFGHRLTLL-TGLIGFFLFSGLYFIEYGIGFLLFVRAIHGFTMGVASTVLGTLIAQILPVSRRGEG--IGYYSMSSTLGTAIGPFLGIWLSLNFDYNVIFIFSSIIAFCCLFTALGilVSRQETATAAPPKSSWITQFIEPRAVPIAIIVLLTSVCYSGVLSFINFYAKTL--DLAKAASIFFLMYALAILFSRPFTGPLMDRRGENIIMYPAILILAFGLFLLSQVQTASMLLICAGLLGLGFGNIQSVCQTIAVKSTseRMGLATSTFFIFLDAGLGFGPYILGKLLEYINYSQLYFISSLLALICIVLYYLL---
     510 UniRef50_C8NSU6        Major facilitator family tr...   145     2e-33  1  16.9%  2:391   8:392     -STTSKTPVNINLAITWMLLGVFGVGTVEYLVAGVLPQ-ISSDVAVTEATAGLLVTVYALTVVIGGPLLTIITSRV-RRIPLVLVLMALFIVGNILTAVAPNFPVLVIARVMTALPHATFFALCLVLATTLVEPEFQGR--VISRITLGLNLATVLGVPLGTLVGNQYGWRSSFLIIAGIQTLVTVALVLTTR--RAPERTSGSISAEVRVFGQGEVLKALGLTMLSQSGLFVLFTFIAPYLGQHAGFSPNVITVLLFVFGVGSIAGNMLGGYFSDRNMNATLYIALGSLALSLLLLFLFGNHTWFAAPWMFVVGAAGFSIIPPLTSKLIGAASNAPNLATTVNIAGFQLANAAGAWIGsaLSFGFGIGVLPAIGAVLALAAAALLWITNR-
     511 UniRef50_Q5HLN8        TcaB protein n=5 Tax=Staphy...   145     2e-33  1  13.6%  1:361   1:366     MKRVYQSENQSLLFIVILGSLTAFGPLAIDMFLPGLPN-ISHDFDISASTTQLTISFFMIGLALGNFLAGPISDITGRKKP-LIFSLIIFTIASLGIIFVTNIWIMIILRFIQGLTGGAGAVISRAIASDMYSGNALTK--FLSLLMLVNGIAPIIAPALGGIILNYGPWRIVFVILTMFGIVMLIGTLFKVPESLEKSLRESslINFKELFKTPRFVLPMLIQGVSFVLLFTYISASPFIVQTIYGLTPLNFSIMFAFIGVTLIISSQLTGKLVDYIDRLLLLRIMSTIQVIGVIIVSLtwTFWILSCGFVILVAPVTGIATLGFSIAMDESKGAKGSSSSLLGLFQTLLGGVISPLVGI-------------------------------
     512 UniRef50_Q0BZK8        Transporter, major facilita...   145     2e-33  1  11.8%  7:388  39:449     ------PQQRVRVTLWLLLIVNAFNFVDRQIVN-ILAEPIKNDLGLNDTQIGLMTgaFAVVYTSLGIPIARWADnkSNRVGIIAGSLAIWSGMTAICGVAQNFWQMLLARIGVGIGEAGCTPASHSLIGDTVPPEKRGSA--IAFFGLGIPIGSLFGMVIGGVLADAVGWRIAFMAVGVPGVILALLLWFLVKEPRkaAPRASIRETIAEVLSSKVFIYATLGASFVAFLGYGKGVWNGIFLIRTHGLSLTEVGLLYGvaGLGGVAGTWLGGWTSDKFGIRklAPAVAMLLTVPILLIGYAGPVWVAIPMLCLSAALSGVYYAPTFGCVQLlsPASRAVAVSLMLFTLNLIGLGLGplLAPMAGSESVRWSLYVAGCMGVIPAVLYWL----
     513 UniRef50_B9E9F2        Putative uncharacterized pr...   145     3e-33  1  12.3%  8:389   3:381     -------EKLWTKPFIMVSLINFILMLSMFLLLVTIGGYAVGEYHVSTSTAGLVSGIFIVGSLFGRFWAGKNIDILGQKK-VLVIGVLIFTITTALYFASFNLALLLAIRFLNGMGNGIASTATGTIAAFITPIKRRGEG--ISYFSMSTVMATAIGPFLGLSLLQFISYRQLFIFCLVLAVIGLLMvqVKVSHEVKSMTSHAPKGFHISDYIDINAIPISIVVLICCTAYSSVLSFISFFAEENNLITAG--SFFFLTYALVVLISRPITGKLMDSKGTNIVMYPALISFFLGLLCLSITHAAWTLILSAALLGFGYGNFQSIAQATAVKVTDHEkgLATSTYFIFLDFALGFGPYVLGLFIPVLGLHGLYRYMSILVIIGMVAYYML---
     514 UniRef50_C6XAP4        Drug resistance transporter...   145     3e-33  1  12.6% 11:391  21:407     ----------MPLLTLMLAGLAMLGPFTTDTYFPFFPD-IQTHFAISQAAAQQSLSVYLFTFTFMMLFHGAISDSVG-RKPVIVISLIGFVITSFGCAMADSYALLLAMRAGQGFFVGAGTVVGQAIIRDQFHGAEAQK--RIAMVTMLFGISPAIAPMVGGWLHVYFPWQSAFVFLAALGLILTWLCASRLPETLPKDQRrsLLRNYCAIAGNVRFMMLSLCIGTGFGGFLVYVAGAPDFVLHMMRLSELQFGWLFIPIVIGLITGSALAGRLVSTLPGRTIIRMAYGLLALASIgwLTTPELPYAVAPILIYTLGVTMLMPAVLTLALDIFPEKKGMAASVQGFVQSIIFTLISAFIVPFVLGNSLHYAVAMSGLFVLNLAAWCIYKKR-
     515 UniRef50_A1A3T8        Conserved hypothetical tran...   145     3e-33  1  14.1%  1:390   1:412     MMARMEKNkgLPLMFWGLWVTLLILWMGRF-VTSFLSMYLVSDMHVSAGVAGTIVSMYGFGGIFGCLYGGALSDRFG-RPAMIVIGNLGSAVMLVLLACIGNPWIMAITLLIYGAISSMPTPAVAAYVSDVVPFRKQKRA--YSLQTWAANFGFAIGPIIANQLV-KISYSLMFYAEAAVLVFATLLMMAFFKEaqSQQSKFSIWRSYRRACTDKALMSMVVLMFLYTLAYYQIVSGLPISMTQI-GLGTDEYSSLLTINGGILCLLQIPAIALFQRMSNTRVLVLGMSITAVGYAFQIGADSWVTFAIATVLWTLGELGTFPIAATTVANIApdVRGTYQGLYNLVWSLSNAFSPLVGGWILNAFGSHVLWTCCTVMFVIVAIGFYVTR--
     516 UniRef50_C2ETA1        Major facilitator transport...   145     3e-33  1  11.5%  8:389  13:395     -------RPKSYRTLVLVFLGFIVCFIDRSAMNIALA-YVGKSFTLTPAQLGVVGSAFFFSYSLMQVPGGWLVDRFGT-KWMTVLSLLAWSVFTVMTGFAWSFTSLIIIRVLFGIGEGSYPSAAMKQVRLAFPENKRGQASAVAI--SSNYIGNALAPFIVAPLIALLSWRGAFHVVGVLGLVYLAFYYFFERPLNREIPDYDTGDQKVKGKFDWRVLSFSVVVFGFSVITKGLDTWMPTYLLQARHINLKGIAWLVPLPSITAGIGSFIAGFIMVKfhEKWLISLSALVTMVFMYGMFHSLSLTGVITFEVLAYFTKSIGFAASYAFVAqvAKTNYGASIGVVNFGGQLAGFLAPILIGLVIQGtsYTAAFLVLTFFALLAFVASLTI---
     517 UniRef50_Q145U5        Major facilitator superfami...   145     3e-33  1  12.4%  3:390   5:411     --RRRSRFSATTGVLVVLCIMSFLMYVDRTNISTA-ALAIRRDLHLSNSQLGIVFSAFALTYALAMIPGGFIGDRLGARKMLAVCG-VLWGLGTLLTGFAGGLATLLLARFVVGLGESPIVPASARALTAWMEPERRG--FSQGITHACARLGNASTPILVAGLITAFSWHIAFILLGAASLAWVVLWVWYYRDNPapAKVGKTRVPMRWAPLLRALWPATVVSFCHGWILWFFLNWMPSFFAQAYHLNIRHSAVFSSGIFLSGVVGTTLGGWLSdrRSRQTLITIGFLAPIVFFVPMFLHPSATLAAFSLAAALFLSELVTAPLWAVAMDLAPNHAATSSSIMNTGLGIAASVSPPLVGWLVDthSWEPVFALSMFFLVLGPIAAHWIR--
     518 UniRef50_C2M2G9        Major facilitator family pr...   145     3e-33  1  13.2%  7:391   1:381     ------MNMKMIRQLFPLAIGGIALGSTEFIPMGLM-RTMGGDLHLSDDQVGNFIAAYAIGVVVGAPTLVGLSTRFQPKKVLIAF-MLLFTLFNGLFSLMPTYETLLVSRFCSGLPHGAFFGVGAIVAKQLAPREK--EAMAISVMFGGLTIANLLVIPLFTHLGGVIGWRPVVGMIAALGLVTALCVFFFLP--KVDSQRDMTLWKELQHFFSVPSMLLLVITALGCGGLFSWLSYIEPLMLDYAHLPREQMPTVMIVVGIGMVVGNFFGGWLTDKLHLVRaiIVFTSTICVLLIIFFFSDQLWLSWVLTFVCAIAAMSVGAPLNIMMFRVSPQAQMMGAAFMQAAFNLANTLGAYLGgpLKYGYTSNYPALVGATMALVGFLCALFLYR-
     519 UniRef50_D2LJS6        Drug resistance transporter...   145     3e-33  1  16.5%  2:389  22:414     -TATPINAPSQWHVLAILSALMGFASISTDFYLPAMPT-MARALNATTGSVEYTISGFLIGFSLGQLVWGAVSDRYGRRVP-LAAGLILFVIGSAGCALSGSVETIIIWRIVQALGACAGVVLSRAMVRDLYQGPR--AAQMLSTLIAIMAIAPLLGPILGGQIAELAGWRAIFWTLVGVGILTLAALFTLPETLPAARRQTAPlgEYGRLLLNRKILGYAGAGAFFYGGMYAYIAGTPFAFITYHHVAAEFYGFLFGAGILGIIATNILNTRLVLHYGIDRMLVSGTAAAALAGIIVAAtgGLWGLFVPLLLFVSVTGFIVANSIAGAMADFPEQAGAVSALVGALQYGAGIASSGLVGGFADGTPWPMGWVIAVTGIGSLLCAFLVV---
     520 UniRef50_B2HTU9        Arabinose efflux permease n...   145     3e-33  1  13.4% 13:377  18:377     ------------LAIFSLAVGGFCIGTTEFVAMGLI-QEIAHNLKITVPEAGHFISAYALGVVIGAPIIAILGAKV-PRKTLLLCLMLFYGIANACTALAHTPETVLVSRFIAGLPHGAYFGVGALVAAELAGPSRR--ASAVAQMMMGLTVATVIGVPLATWLGQHFGWRAGFEFSATIAFFTLIAVACFVPNI--PVQATASIKTELAGLKNINMWLTLAVGAIGFGGMFSVYSYVSPILTEYTKVNIQIVPIALALWGIGMVIGGLAAGWLADKNLNKTIVGVLISSAIAFVVASFLMSNIYSAIGSLFLIGLTVMGLGGALQTRLMDVAGDAQTLAASLNHSAFNLANALGAFLGGWVLShmGWIAPIWVGFV---------------
     521 UniRef50_C7MCT8        Drug resistance transporter...   145     3e-33  1  12.7% 14:390   2:384     -------------VILVLTTLSAIGPLATDMYIPAFPE-VAGELSTTASRMQLTITAFFLGTASGQIVAGPLSDRMGRRGPLL-FGIVLCLLASIGCALAPTVDFLLVLRVLQGIGGGFGMVLGRAVLIDMTDGPELFRIMNI--MQGVGGVAPIVAPLLGGIILIFGQWREIFFVIAAMSLISLLGVLFLIPESLPASRrrTFLRNCRTLLQRRTFVAYMLVNAFSAFALMAYVSASSFVVQEMLGFTSTEYSVSFAINSMGMMTMSLVSARLTRSIHPRKLIRVGLIVVSLASFSLLIgtPAWVVLPAFFFTVAPQGMIFGNGGALASDQAREIAGTGSAMLGLGFSFSASIAAPLVGIAGTHSSLPMAIAMVVGCLISSTFFVIAGR--
     522 UniRef50_B7VMU9        Multidrug resistance protei...   145     3e-33  1  16.3%  6:354  46:395     -----ALPTPSKLQVALLAMLVLFSPLAIDIYLPALPQ-ISTAFHVEHALAQDTITWFLFAMGVGQLFAGPLADKLG-RRTVALGGVSIYALSACLAWAAQSIDMMLMARLLQGLGACATSVAAFATVRDLFGPEKSGR--MISYLNGAICFIPALAPILGAWLTHQFGWRSNFSFMAGFAVVVGTILFFQMKESNPATEKVAVFkrYWSVLKTPSFLFHATLCLMAMAVILAYVTSAPVVLMENLGLTMKEFTFWFGVNAAINIAAAFTAPKFMDRFGTYKALVVglGLAGVIMLVLAEHASPIAFMLPIFLSSVGFAWILGAAAGKALEPFGDRAGTAAALLGLFQMSGSGL--------------------------------------
     523 UniRef50_B2TDI3        Major facilitator superfami...   145     3e-33  1  15.0%  5:390  16:410     ----TSVSQGRWLLVFILGYLALMADGADVMMYGLTLTRIKDDFGLSNVQAGALGSLTLLGMAVGGILGGWASDRIGRVRVV-VWALALFSLGAGLLGLTHSFVEFAIVRFIGSLGIG-SMVLVTTLVAEYVPTERRS--LILGALQTGISAGYIVVIALSSWILPHYGWRTLYYVSAIP-VVFALAIKFAVPEPASWRASQAIERTSQRRWRDSrfILWTLASVFILSGFYGLNNWLPTYLEKELHIKFSSLTGYMIGTYVVAFIGKIFAGWLGDRWSRRGVYVLGCVGAALFLPVIIFWHTRENIAVLMLFFGFLYGVPLGTIGTFMSESFATsrGTAVGGSYNLGRFCSGAAPIVIGFLATQFSIGLGFLVVGAVFFLSGVTALFIP--
     524 UniRef50_C6IYM1        Major facilitator superfami...   145     3e-33  1  15.8% 13:391   2:391     ------------RKTWLLGLGFFSISLTWALYNAFVPLFLDDYLK-SAAMIGFMMTIDNYFAIVLQPWIGHRSdrYGRRMPYLLIGMPLGAVFAALIPWHTGFVTLVLFMVLMNLSMSLFRAPTVALMPDITPEPQRTKA--NGIINFMGGIGSVLAFGIGSQLYGIGSY-MPFLFAGVVMLICLFVLKTVIREPAAaaGENPKPQIRIKDQLDKTTVLILGAIFFWFVAYQGVEALFTLYGTKQIGMSDAEASFSLTFFSLAFLLFALPSGWLGARYGKKAIISTGVAGLFVVFGVMIFVDSVLWLRLLLIVGGIFWACININSYPWVVSTGREEsgTRTGIYYFVSSLAAITSPPLLGWVIDVFGYPALFISASAGMLLALCCLFGIPR-
     525 UniRef50_Q8ENE2        Hypothetical conserved prot...   145     3e-33  1  15.7% 11:385  14:386     ----------FWRISFALALGSFFIFASLYAVQP-LSSVFVREFQVSVSQSTLTISMNIVGLIIGLIIFGFISDRIG-RTIFIKLSLIGAAIPFLLIPMVDHFILIIMLRFVQGLLLAGLPAAALAYISEEI--DQRSASIATALYISSNALGGMVGRVLTGSLAAEFSWEIGFYVLAGLGVIIFIIMTLLLPRSksKVSIGKDLQGMAYHLKDPSMIVVFGLGVILQYAFTSIWTFLPFHLedGFSMSLQGISNTFYAYGLG-IIGAPIAGWLASRLGISNVQVGGIVVLCLG-IALTFSSSVSIIVIGLCVICLGFFTTHSLTAASVTERATHHKGSASSLYLVSYYIGVTLGSS-AGPVWNIFGWGGIVTTALLLPLIYIIV-------
     526 UniRef50_Q67MU6        Putative multidrug efflux p...   145     3e-33  1  16.2% 10:391  12:397     ---------PWRRNVAVLWIAVFIAASAWTMVMPFMPVFLSEDLGVGAgwAGLLGAVNSGFSALTAPIWGALGDRWGRKAMMVRAGIFLGS-AYVLMAFVRNPYELLGVRVMIGALTGFIPTATA---LVATTTPERHMGQALSLVATGNQAGSILGPMLGGFLADLIGIRNTMALSGVAVFAATLLVVFAVREqrPARQPAHFLSDMRQVLQGGPLIVVLAMSLLLQMSQSAMEPVLIPHIRQLLGSGswMAGVIYSVPGIAFVLAAPSWARLGERWGYTTTVTIGLAGGALFTLPQALVQSGLGMGSFRLSAGLALAAVTPGISALIAASVpeQRGKAFGLNQSAFNVGAMLGPLLGGVLGDRVGIRWVFPATALLLLFAAGWCWSLVR-
     527 UniRef50_A6L2I2        Putative transmembrane tran...   145     3e-33  1  14.2%  7:386   2:384     ------KDKLITKNYIEILAANFLLFFGFWLLMPVLPFYLAEVFDANKTTIGAVLSCYTIAALCIRPFSGYLLDTF-ARKPLYLLAYFTFTAIFGGYLIAGTLTLFILFRIIHGVSFGMVTVSGNTIVIDIMPSSRRGEG--LGYYGLANNIAMSIGPMTGLFLHDaaDYTLIFCCSLGSCLIGFLCASLVKTTYKPPVKREPISLDRFILLKG---IPAGFSLLLLSIPYGMTTNYVAMYAKQIGIQSST--GFFFTFMALGMAVSRLFSGRLVDRGMVTQVIEAGLYLVCFCFFGlsLQWTTYFLFTIALLLGIGFGTMFPAYNTLFVNLApnQRGTATSTYLTSWDVGIGAGMLLGGYIAEIATFKMAYLFGAALTVISLFYF------
     528 UniRef50_Q1IQL5        Major facilitator superfami...   145     3e-33  1  12.8%  8:391  13:403     -------PAAARVTLLILTLLNFFNYIDRSILFAVQPQ-VQAEFHCSDRQIGLLTSAFFFTYMCFAPFVGPLADRF-TRKYIMAIGAIVWSVATLLTAVTHSYDVLLFRHAIVGIGEATFVTITPSFVSDLFPEEKR--ARIMAIFYMAIPVGTAIGYLVGGYLGHRHGWRMPFYVCAIPGMIMGLLLLLVPEPVRGShvATHERSSFLGLFRNGAFWTCSLGMAMMTFAVGGLQVWMPTFLNRMREIPLDAANFRFGLLTVvgLAAAFAGGWLGDRMLKrlVSGIGMAVCLPFMIVAITAKGPIMYVAILLAEFFILLNTAPLNAALVNSVSANIRSTAVAVNLFTIhlGDAFSPTIIGWISDKTNLQVGFIPTVVAVILSAVILFIGIR-
     529 UniRef50_A6W552        Major facilitator superfami...   145     3e-33  1  14.9% 11:366   1:349     ----------MPLAILALAVGAFAIGTTEFVAMGLLPQ-MADTFGVSIATAGWLITAYALGVVVGAPTLTALTHSWPRKR-VLTGLMALFVVGHAATALAPTFGALVGARFLSGLGHGAFFGASALVARKIAPPGRQGQAM--ALVFTGLTVANVVGVPAGTYVGQQLGWRLTFALVGLIGVATIAAILAIVPE---VETRAGSLRSEFAAFRRSQVWWTLLIVTVGFASMFTVLSYVSPLLTEVAGFSEGAVSWVLVLFGVGATLGNVLGGRLADWRPYRTLAVGFAAQAVVFTGLFLFAGNRVAAAVGVFLFAFVAFTMSAPIQTRGITAAGGGASMASAAMQAAFNIGNAMGAFLGGIVIDGG--------------------------
     530 UniRef50_Q7N0F3        Complete genome; segment 14...   145     3e-33  1  13.9% 21:388  38:404     --------------------ACGFAVANIYYNQPLLPT-IGTSFNVNGSISGWIATLTQIGYAAGLLFFGPLGDTISRRK-LIFCLLIGNIISLILCATAPNFTCLLTSSLIVGI-TSISAQIIIPAVSGWVIPEKRGQA--VGSLMSGLFAGALLARALSGAVGEYFGWREMFILAALIDICLFFLIWFVLPEIETPHtgQLLISLGKLVKQQPLLREAALSGFLLFAAFNTLWGSLALLLSQPPYGWGSDIAGLFGLMGIVGMLASPIIGSLTDRFGGRTIVATGALLVTLALCLigTSHNILFLFAGIILLDLGSRAGLVANQTRLYTLLPEARSRLNTVFMTCYFAGGAIGSSLGAVAAWHFSWYGVAFSGGGCALLAALWVLF----
     531 UniRef50_B8DV16        Multidrug transport protein...   145     3e-33  1  14.0%  6:391  43:429     -----ARERLITRDVALIMAATFFYMTSSMMGTPIIAGF-SQSLGASGALMGFLAGALSLSALICRPIAGNLSDRTSKRK-LAVIGALIFLASNLGYYFVPNTAWLLAARILNGVGFACISVCLSTWLSMLLPISRMGAGM--GLYGTMNALAQAVGPDLGIRASKAIGYRNTFLIAVGLTCCIVICVLLipRARLGRQQGGERHHIRLDSLFEPRVIPIALIFMLFAIPYFANQSFIVDYANARHAH--VIVSLFFPCYAITLLISRIVLRNWFDTKSFLFFMVTGTICQIVMLASLTVMRNNWFVMLAGLATVGAYGMMSSVTQARAVLIAGKArgMANTTYYAGIDLGMFLGPLIGGFLYGGLPIIWFYPALLLTMPVAWIVYAFAHR-
     532 UniRef50_C5CKV4        Major facilitator superfami...   145     3e-33  1  15.5%  5:391   1:381     ----MSRRAAPRGALWALLAGNFVIGTGVMVVPGTLNE-ISASLSVSVATAGQLITVAAVVMCLGAPLLAAAVAGWD-RRQLLALTLLWYAAGHAIAALMPSFGALLPVRMLTVVAPAIFTPQAAACAGMLVPPEHRGRAVTF--VFLGWSLASVLGLPIGALVGGHLGWRMAFGAIALLSIASAASIWLTLPQGIRPAA--LTAAAWARVLRSPVLMGIVSVTALQGAGQFVLFSYFGPILKRDFGADPTMLSLMWALFGVFGLAGNMLVSRFIDRVGAGRMVLLTSSLIALSLFLWPWAGTLPWLAAVLVPWGLGCFATNSAQQARLVGLAPALAPGSVALNSSGIYVGQAVGAGLGGWLLANDAVAWMNWAGFALLLAAIGLSVAIDR-
     533 UniRef50_C7I3R3        Major facilitator superfami...   145     4e-33  1  12.8%  6:373  17:383     -----AMTPAERRASSTLASIYGLRMLGLFFILPVFSIYAEHLPHgdKFLVGLALGIYGLTQAVLQIPFGVASDHFG-RKPVMAFGLLIFAIGSFVAGASDNLYLIIIGRAIQ--GAGAISAAISAMIADSTRDQHRTKAMAM--VGMTIGFSFILSLVLGPPIYHAISVPGMFDLTGILALLAIAVIIWVVPAAPMTTHSEEVQGHWAKAVFTPALLKLDFSIFVVNFLQVSMFVVVPVALVKYAGIPLLHHWMVYLPVTLISFAVSIPGIIYAEKYgmKPVFVGGVALLVLTMLGFAAgkNPVALIAALFFFFLSFNLMEALLPSLVSRTAPANrgLAMGVYNTGQSLGLFAGGAVGGWLSQYSSEDVFFV-------------------
     534 UniRef50_C0A726        Drug resistance transporter...   145     4e-33  1  16.0% 11:391  32:418     ----------RWPLIAILGALAAFGPLAIDMYLPALPA-IARDLRADDGAVQFTLSIFLVGVSLGQLIYGPLSDRIGRRGPLL-FGMALFTVASLGCALSRSVEALIGWRLVMALGGSAGMGLSRTVVRDRFEVHE--AADVFSMLMLVMGAAPILAPLIGGQMLLFTGWRGIFATLVAAGALVWVAVWRYLPESLPVERRTSalAGYGRLLVDRRFLGFALVMAFTSGAMFTYITCAAHVFIELNGVSPQVFAVFFGINAGGMIAGSQLNRWLLRRFTSRRILGGVLTVVACAGVLLAawGGFPALAGLLFVTLASGGLIGPNASALALAPFGRGAGSAAALMGTMQFGMGGLAGALAGMFAGDSALPMCATQAVCGIAAWCALRWLCAR-
     535 UniRef50_C0VPF8        Major facilitator transport...   145     4e-33  1  16.2%  3:390   6:389     --QLQTMNIRTWLALIILALSTFTIVTTELAPVGLLSP-MANGLNVSESQIGMTVSFYAWVGAISALIASIFLGNV-PKKWLLIILTLILFCSNILTALVDSYSILLIARVIGALAHGAFWAMIGATAVALVPSKYIGVAT--SIVFGGVSAASVFGVPLSNYIGINLGWREAFWFMSGLSLVTFIGILILVPNI--SSNSTIGLSSLKKVLKSSTLWKIYSATLLTITAHFAAFTYIEPLLHSQSLLKEQLIPLTLFIFGLAGLFGNFITGLIIDKNIKLTviSILLIFSVLTYIGIHTSpsLVSIVTLVIIWGLSVSGIFVGFQTWVLKLSGDDVFPASSMYVSFFNIAIGIGATLGAWIVAHYPISSLYLIAGIAIGLSLFLVALIP--
     536 UniRef50_C2G2T2        MFS family major facilitato...   145     4e-33  1  12.4% 10:389  28:403     ---------KMNKGLIALAFGGLAIGMTEFTMMGILPD-IAKDLKIEIPVAANLIAFYALGVVVGAPTLVAFSSKYSP-KSVLLFLMLLFFIFNGLFAISPDYNTLLLTRFVSGLPHGAFFGVGSVVAANLAKKGK--EAQAISVMFTGMTIANLAGVPIGTYIGHHFSWRITYAIISSLGLLTFLTLSIWLPRLK--ANKDSNILSQISYFKKWYSWLIIAIISIGTGGLFAWISYIAPLVTKVSDLDPDRVPYIMVLVGLGMFFGNLLGGKLADSILPTKASMASFAAMAVCLVILFFVSHiwLAYVMAFITGMISFTIGPCLQMMLINNAKGAETFAAAAGQAAFNIGNTFGAFFGAiiTMGLAYNYPSLVGAGMASIGALLTFVF---
     537 UniRef50_B6J7J7        Multidrug resistance transp...   145     4e-33  1  14.9%  9:391   4:389     --------PSIRKTVWTLAPMAMALALAMDVYVPAVP-HMATLFHVSAGQMQLTLSLFMFTCGIVQLVIGPLSDQYGRRRVSF-FSIVIFSIGSILCATAHSVPELIVYRIIQAIGAVGMMVCGFAIVRDRYHGEKSGKT--YSYLNGIIAFSPMFAPFVGSYLDVHLGWQSTFLILLLISLWAFLSLFFSLPESLPRNKrrRIFHEYKTIFTNRVFLNYTLSTAMGLSYLFIFCSISPYIIIQLLRIPELNYGYYFAFMGISFFVGSLLSGYFVGKIGIYKTVVVGFFISLIGGTIMALWYFITGLTipMLLIGIGGTFGLGAGSGGAMEPLGDTAGAAAALSGSFRFLFSAILGMV--VINKNISSTLPLALPAVLFSLVGLILFLSQR-
     538 UniRef50_Q03TC5        Arabinose efflux permease n...   145     4e-33  1  14.4%  5:392   1:387     ----MTKKISPTLTLLALAVSAFAIGSTEFISVGLIPMLI-QSFHVSLAQAGLTVSVYALGIMIGAPLMTLLTGQM-NRHTLMLMIMGLFIAGNLLAALAPTFSILLAGRVVAALAHGIFMTVASVIAADVVAPAKR--ASAIAVMFTGLTVATVTGVPLGTMIGQLGGWRWSFIFISVIGVIGLVADYILIPRQLPLPSRATA-KGILRVLKTPQLLLALLVTALGYGGTFVAYTYLSPLLETKMGWSAQAVVVILVVYGAMVALGNTLGGRWANAHPLPALLKMFVGLMVTLLVLTVTLHSQWLGLLTVLVMGFFAFMNVPGLQLYIVQVapQDITMASALNISAFNVGIALGSAIGGQVTSQFGLAWTPLFGALMVGLSIVATMGLIRL
     539 UniRef50_C8NJY5        Permease of the major facil...   144     4e-33  1  14.2%  7:387   5:390     ------KQRLTTPLLLGLALITATPALSTDMYLPALP-MIATDLDTTTPLVQLTLSAFMAGMAVGQLIIGPISDSLGRRR-LLLVGAVVSLVASIGCALAPSIGVLIGMRLLQGLGGGACVVIARAIVPDLARG--REAAQAFSLLMIIQAIAPVLAPVVGGVISAPFGWRAVFWALALINAAQLLVAVIGIRESRPVAERTgmLSNYLHVLRNPRFLAYAAVLAVTFGAMFSYISASPFVLQNQLGMTPLMFSVVFAVNSLALMISGFLNRRLLNSVHPHRIMAGAMVGfvLFLVQVALIRSTPLFLVLLFLIVAHVPLIMANATALGTAVVRERAGSGSAVMGFLQFSMGGLISPVVGLGADRALSMAVSMVGCALCAGIAVWFA-----
     540 UniRef50_C6BTC6        Major facilitator superfami...   144     4e-33  1  16.5%  2:388   5:385     -STILQDRPANWSAVLSLFVGVTSLVAAEFIPISLLTP-IAQDLAITEGMAGQTVTVVGIFAVLTSLLLAPLTKGINRRHILLIFSALL-VVSNIMVATANTYSFLLVGRGLLGICVGGFWSMAAAVTLQLVPANYVPRA--LSLIYAGVAAATVISLPIASYLGHMVGWRNVFLLEATLGATGLAWQFLSLPSIR--ADKNNDFKNMFRLLRQDWVILGILATIFSFGGYNIFFTYLRPYLELDLTLTPNSLSLVLGIFGLANCLGTFAAGILFERKFRSCMIVLQCILSVVAILLYQLQERIWIEVFFVIVWGFVWGFMPVGWTSWITRTLADRAEMAGGLSVASIQFSIGGAAAIGGVIYDGSGIEGIFLLAAGFLILSTILIWL----
     541 UniRef50_C6BHW2        Major facilitator superfami...   144     4e-33  1  15.1%  8:351   6:354     -------PSRERRLLWLLALTQFTVIMDFMVMMP-LGPQIMHTFGIGPAAFATAVSVYSLCSGASGLLAATYVDRFDRRR-LLLTVYGLFTLANLACALSGSYSMLLFARAFAGVTGGVLGSIIMAVLSDVIPPARRGAAT--GVVMSSFALAAMAGVPVGIAIGAHFGWSAPFFLLTALTVLIWLGARRTIPPLarSQTLGEVLSGLWRLLTNPRHLRAFVLTFVMMGSHMLVIPFISPVLVANHGVAPENLSWLYVAGGAASFFSSRAVGKLADRYGRRRVFVGAALLAFIPVLVMTHLPDWPFIGMLLFFPFFMVIlmVPMQALMTTVPAPQVRGAFLSANSAVMSVG-----------------------------------------
     542 UniRef50_C4KDJ0        Drug resistance transporter...   144     5e-33  1  16.9% 24:385  19:386     -----------------------LGPLSTDFYLPALPA-IARALHTDSAGVQLTLSVYLLGFGAGQLLVGPLSDRCG-RRPVMLWGMLVFLLSTLVCVFAESLAVLVGARLVQALGACAGPVLGRAVVRDLYGPAE--SARVLSHVSTATALAPLLAPLFGGWLTAAWGWRATFVALAIYAMVLMLAVAALLKETNRHprPARMLANYRTLLADPAYRGALLIGCGAFAALFAFISGSPFVFIEHFGMSPQQMGLAFGLNVTGFMIGSTLSARHSRRLGPARLIRYGVWIGAACGVLLAapQHPAAVMLPMWGVTAAIGLILPNATALGLAGYPKMAGAAASLMGFVQMGLGAGAGMLVGHGVQHGTAALGLTVAAGMLFALAAW-------
     543 UniRef50_C2FUD5        Major facilitator family tr...   144     5e-33  1  14.8%  9:392  13:400     --------SGLSPAAWLLALVMLINRMG-SMVIPFLGMYMTKQLGFDISHVGIVLTCYGCGSVAGSWLGGWLTDRIGNFK-VQSISLIMTAPLFLLMPMFRTFESMAAIVFVLSLVADTFRPANSVSVARYAKPENLTKA--YSLNRMAVNLGFSIGPALGGFLAA-FSYNWIFYgiAAVVFLYFFYNKKGNKIIKKSEKELQTEVKDRNPYTDGPFILFSILCCLFSMAFFQLISTLPLFYQDVHHMSEREIGMILGFSGFVIVVFEMLLVHIVerATITRILFYGTLCAGLSYLMLNFNFGIAWLYIAMFMLSLGEMLTLPFMATvaLRSTRNTQGAYMGMNSIAFASSNIFGPFLGTKTVALWGYQTLWYiaAILVLVAFGFIWALKRL
     544 UniRef50_B9DLQ3        TcaB protein n=115 Tax=Stap...   144     5e-33  1  13.5% 14:390  15:396     -------------LVIILGALTAIGALSIDMFLPGLPQ-IRSDFHTTTSAAQLTLTLFMVGLAFGNLFMGPISDALGRKQPLVIV-MIVYTLASLGIIFSINITMMVALRLVQGLCAGAVAVISRAIASDMYSGKELTK--FLAVLMLVNGIAPVIAPTLGGIILIFSNWHMVFIILTVFGIFMVMSSGLRIPESLSKEAREPalKQFKSLLQRPKFVLPMLLQGMTFVILFSYISASPFITQRIYSLSPQAFSWMFATIGIGLIISSQLAGKLVDYFEPLTIMRGYTAVQIIGVIMISTvlPIWILFISFLALVGPVTGIATISFSVAMDERTGGSGSASSLLGLVQTLIGGISTPLVGLMGENSYIPYLIIISIASVVLIILHLLIAK--
     545 UniRef50_C7LPJ1        Drug resistance transporter...   144     5e-33  1  15.6%  4:375   1:371     ---MTIPAPLKIRALLILALLAAFPPLSTDMYLPALPS-LTTDWGSTETIINLTLVGFFVSFSLALLFYGPLSDRYG-RKPVLLGGISLYILACLVCARAESPTALIVGRVLQGMGAASASTLSLAMTKDYFVGAERERA--LAHMAVIVSLAPMLAPVLGGLMLTFAHWSAIFYAQMLLGALAICGVLRLkpAPATTRTLGQVMGSYVRLMCNPRFMTLCTLIALGMTPLFCFIGGSSFIFVTYFGLSEQEYSYFFAFNSAALMLGFWICGRLLKRIPGFRIILIGYAGILIFATILALCsgPWGMALPMAAMTMSLGLTRPPSSNFLLEQVKNDAGSAASLIMFTYFVCGATAMWFIALPWDNKILTMALVGM-----------------
     546 UniRef50_D1P9H5        Putative transmembrane tran...   144     5e-33  1  14.6%  5:387   1:379     ----MMKEKLWNANYIKVMTTNFLLYFAFYLLTPLLPLYLSENFGATKDVIGIVLSGYTVAALIIRPFSGYVVDSFSRKKVLMV-CLSAFAIFFAGYIAASTILMFAICRTLHGGPFGAVTVANSTCAIDVLPASRRNEG--IGLYGLSNNFAMAIAPSIGIYLHNAVDSYMILFWIAFIVAIASVVIAGTVRLPEKEIVKNKEKLSLDRFFLTRA-WLLAINIAMFGFCWGVLSNYLAIYSKEELGITGGT-GTYFALLSMGLFLSRLQGRKALSQGKLTQNAAEGMLLSLVGFIIFVAIKHPVAYYLSACLIGLGNGHLYPAFLNMFINVARhqRGTANSSILTGWDLGFGIGCLLGGVVAEHFGYNGTFWMVAIENAASVLLFF-----
     547 UniRef50_Q65GU8        Sugar transporter superfami...   144     5e-33  1  14.4%  1:388   1:387     MTYIQPHSKDYHKASIALFISGFVTFATLYTTQPLMPLF-AEEFGISAAAASLTLSISTGILAFALLTAAALSDGFG-RKTIMAISLFATSVLGLLTAFSPNFAALLAMRGLLGFFLAGVPAIAMAYVGEEFDP--RGLGKMMGLYISGTSLGGMSGRLLTGLLTDLFSWRAALGIIGALSVLLSYLFWILLPRPQHSAKRKTSVkaYGAVLMNKRLLSIISLGFLLMGSFVTLFNYIGFQLMGPPYRLSQTVIGFIFIVYLAGTLSSVYMGKKADRFGSPLMLKIGIAIIAGGALLTLLPQ-LPLKIAGIAVFTFGFFGSHSIASSWVGQTAGEQRVQASSLYLLSYYLGSSLAGSFGGFFWTHFKWPGIISFIIGLLLIAYPVIFF----
     548 UniRef50_A1WI52        Major facilitator superfami...   144     5e-33  1  16.9%  5:389   1:389     ----MLSPSRERWLLLTLAGIQFTHILDFMIMMPLGPRF-TQLFAISDAQFGLLVSAYTLSAGVSGLLAGTYVDRFGRKR-LLLVLYGLFGLATLACGVAPGYALLMVARILAGAFGGVLSALSQTIVADVVPFERRGRAM--GIVMTSFSVSTVAGVPLGLLLAQYGGWHLPFFAIAALVALLALQAARTLpaHLQAARGRTALGGITQVLADHNHRWAFLFSALLMFTGFTVIPYITIYMQTNAGVRADQVPLLYLCGGLVTLFTARLFGRLTDRWGkyRRLALACTLPLLAITLVRGVPLWAVIAVSTLMFTFLSGRMIPGMAIVASAAQAPLRGTFMTLNTSVQSAAMGLASFVGGLLidAQGLVQHYWMAALVGIGASLLSMVV---
     549 UniRef50_A6GIA5        Transporter, major facilita...   144     5e-33  1  18.1%  5:386  14:396     ----VAAPTRVWPIVLVLWLVMFMSACQFLIVAPVLPR-IGAALHVREELLGTLVTGYSVSVAVFAVFAGPISDHYG-RRTILRAGSLFMGVALVLHAFADSFAVLLALRMLTGASSGILSGAAVAYIGDILPYERRGAA--LGWILSGMAFGQIAGVPLGTVLAGEVGFQSPFVVFGVVMLLAFGGTVVALVPGPARESsrSGLGNYAELLRRRDLLAVTLASTVMMVGVSVFIVYQPIWLETKFGATPNQIASLFLVGGLANAIAGPIAGRLSDRVGRKRLVVGSSVGMALLMGTVCWLPSFWQLYVSFFVVMCAVGTRISPLNAWMTALVgeRRGTLLSLTMASGQAGFAIGAAAAGWMYVSTGFLANSLAAAVTCVLTALLL------
     550 UniRef50_B1YHE0        Major facilitator superfami...   144     6e-33  1  16.6%  7:391   1:385     ------MQADQRKKLTVLMINMFIAVGSFGIIIPILPAYLA-SIGQGGTAAGLMIAIFAGAQLVMSPVAGKWADQYGRRK-MIIYGLIGLTLSMFVFYFSNSVTILYISRAIGGFGAALLIPAIFAYVADITTMDQR--AKGNSFVSAAMSLGIVIGPGIGGFLAE-FDLKLPLLVSALVSLLAVLFSVLLLQESDVhaPDEGSMWKKLGASFHKPYFVPLVITLVMSFGLMAYESVLGLFVDNQFGASPKDIAIMVTSTGIISVIAQIFVvkLSRSLGEGKVLNIFLLIATLGFLLSLLTASYGGFFAVTLVIFLATSILRPVLNTMISKLAGNEQGFAMGMNNAYMSIGNVLGPTLAGLLYD-VNILYPFMLGLVFLAVTLVGSVIWQR-
     551 UniRef50_C0VJ25        Major facilitator transport...   144     6e-33  1  12.5%  8:390  15:396     -------SKSFTAILWSLFFAGFASFSSLYCVQPMMPIF-AKFFQVSPTHSSFPLSFSTVALAIGLLFTGFISDRFG-RKPIMVFALFLVSLLLLISASFPIWEVFLTTRIFIGLAVSGVAAVAMTYIGEEI--AQQDIGFAMGLYISGTAIGGMGGRLIAGVLVDFISWQSATYIIGFLNLVIACLFYLLLPKSQHFQPYPFRFSRFKAalKDPKLRILFAQGFILMGCLVTVFNYISYHLLEafHLSQTWIGVI-SIAYLAGIYSSPKAAQWGFKYGRDKVL-PCLLLSMILGLFITLIPSLWAVLLGLTIFTFSFFAAHSTASSWVSVQAVQYRAVASSLYLFCYYVGSSLLGSSGGLIWEKFGWIGINLGVGIVLASGLVLALRLK--
     552 UniRef50_Q0W1K3        Putative permease (Major fa...   144     6e-33  1  17.3% 14:389   7:395     -------------QLIVLLVSMFIFTLGFGIVVPVFG-YLTKDMGASALDLGLLMATMSLMQFLCAPTWGKLSDRIG-RKPVMLIGLFGFALSFILTGFSTQLWMLFAAQILGGLLSAGIWPAVLAYVTDISSPEDRGK--LMGFMGAASGLGIIVGPAISSILAGW-GLTVPFFAAAAIALATMLMGAVLLPESLQKGKHISKGPKVALLDTLkpLGMIFFIMLMVSFAGACLDGTATYFIMDKFSLTEAamGIIFTIMGIMSVISQLAVGPLIQKYGEKNTMVFGLILVAVGMMCMPFSMGLATLVITVSVMGVGMNLVNPAVNTLVSKQapDRIGAMMGLLGSFNSIGRVLGPSVGGAAY-MISMTLPYIGSAVIAAGCAGAMALM---
     553 UniRef50_D1JB27        Putative uncharacterized pr...   144     6e-33  1  18.1% 13:387  17:395     ------------ANVVILGLVSLFTDLSSQMVFPLIPLFLTTAIGASAAVVGLIEGAAETTASLLKVFSGYWSDKIARRKPFVLFGYGLSSLMKPLFAFSYIWPSVLVIRIAERVGKGIRNAPRDAIIAESCDTDVRGKA--YGIHRAMDGLGSILGAVLGLILLIYLGFRNVFLVAGIPSLIAVLLIIFVREEKKTHIVTKSLQISLKTL--TPQLKCFIIVATVFTLGHFGYAFLMLRVLDLGLKIDGwtAMLLYAIFYVIYTLFTIPAGTLSDKIGRKPVIVIGYTLFGLTSLGLVFVSNLFSIIGLFMLYGVFYAMIDGVQRAFVVDLSpeLKATALGAFHTATGLAALPAGLIAGLLWDMVSPETTFIYGFVLSAIAIALFM-----
     554 UniRef50_B5GID1        Integral membrane transport...   144     6e-33  1  14.6%  9:391  16:398     --------AGLPRAFWWLWTSTLINRLGGFVY-TFMAIYLTVERGYSASYAGLVAALFGLGGVLASLIGGVLTDRWGRRPTMFTAQ-AGTALAVAVLGFVTHPVAIAGVAAVVGFVNNAARPAVRAMLADLVPPEDRVRA--FALNYWAINLGFAVSSVLAGFVAE-YSYLAGFLGDAALTMACAVVVFLKLPETRPEHaaRADEVGLRTVARDGRFMAVVGLSFLVALIFQEAQVGLP-IMMGQAGFSPADYGSAIALNGVLIVVLQIPLTRFIAHRSPGRLLVLSSLLAGYGLGLTAFADSMAVLLMTITVWTLAEMVNAPTQTGLVVQLSprGRGRYQGVYGLSWSAAALVAPLMAGAMIDHLGAGWLWGSCAVLGTVAGAGYGVVLR-
     555 UniRef50_A0LEE5        Major facilitator superfami...   144     6e-33  1  17.3% 14:388  17:404     -------------QLFGLCAVGFFARLSYALARSPVLPLFALYLGAAPEIIGWVVGISTVTGIFFKLPSGALSDVIGRRKTMLV-GLVVFALTPFAYFWVKDAALLLIVRFVHGFATAVYGPVAMAVVADVAGC---RKGEMLSWFSSVTIAGSLLGAPLGGFLLFTlhFHWVYLASGAFGCVALILGGKLLAGGDETVTqaQFGAGIREVVSDRRVVLTSSMEGLQNMTMGALEAFLPIYAVKVAGLNEFQAGLLWGAQVLVTIVSKPLMGRLSDRYGRKPAIVIGMLACAVAFAAIPLLTRFELLILASLLFGLGEAFVTSSSAALVADLCQERhgTAMGTFGTIFDVGHASGPILAGVLIASWGYLPAFSIMSAALVVALPVFIL----
     556 UniRef50_Q2WAN0        Permease of the major facil...   144     7e-33  1  15.0%  4:390   1:399     ---MLNTVSPSRRMAVLLTLLVAFGPVCTDLYLASLPD-MARDLATTTTMVQLTLSAFVGGFAVMQLVYGPLSDRFG-RRPLLLGGVAIYVVASVYCVFAPSIEALIAGRFFQAVGACCGPVLGRAVVRDLYARDQ--AAKVMSYMASAMALAPLVAPTVGGWFHTLFGWRSNFLLLALFGVILLVLVWRMLGETNQHKDPAamLENYREILTHRLFLGYVLTMTAAFGGLFSFISASSFVLIDVMGMEPRHFGLAFAFASAGFLVGGFIGARLTHRFGIERMVFTGTLGCTIAGVTLAAlaGIVMIMGPVMAFFASCALVLPNATAGAIAPFPRAAGAASSAMGFIQMSGGAVAGWLVGTLYDGSARPLAAMVAVMGLLSLLVYLRLVR--
     557 UniRef50_C3X9R5        Drug resistance transporter...   144     7e-33  1  14.7% 14:386  19:392     -------------LLIAMGMMSAFGPFVTDFYLPGLPA-LAAWFGTTTSWVQLSLTTSMMGLAGGQLIIGPASDKYG-RRGMLLISMALFIVSTVACLFSWNIESFVFFRVFQGIAGAGGVVISKSVAADLYQGKEL--ADFFSLLMVINGLAPIIAPVVGGFVMKYTDWQGIFLILLGIGVILFIVSLVFRESLPKERRIAGsfGNFIPIMKNGRFMNYVWIQMFAMGVFFTYIASSPFLIQEYFHLDAFMYSLCFAINASGMIVGSRLTPRFDRVFNALSTGVYWLAGSSLCfiVLVLGWSFYLLEALLFLMMVALGMILPTSTSLALTLERAKAGSASAIIGFFLFIFGAVVSPLTGFADMILSISVMTLVCCGLSLIFLVIA------
     558 UniRef50_Q21S94        Major facilitator superfami...   144     7e-33  1  15.4%  3:392  14:401     --SSPELRQRIHPDVLKLGLVSFLTDLSSEMIFSVFAIFFTTVAGASSALLGLIEGLADFSASSLNYLAGWLSDRSGRRKWLATAGYGFSTLAKLILLASSSVLGLSIFRVIERLGKGFRGPPRDAWLSSIAVKESRG--FAFGVHKALDKSGAVLGPLVAYGLLSWLgyRALFLVAFVPAVISVLVLTRIPDQPGVPHERESIGQNWQQL--SPGFKRFLIPAGVFALAYFSL--GFILLKAHAVGFGVTDIVLLYALFNITCVVSAPLVGKLGDKIGRSRIIVLSYAIYAVINLWLVVASSRWEMVALFAIYGLFYAIDESQSKAFIADLEPERRATAVGVYNFVTGLLYLPASLVAGALWALT-PGLAFAMAVALSLAAMVVFAVLRPV
     559 UniRef50_Q1QY09        Major facilitator superfami...   143     7e-33  1  14.9%  4:391   2:388     ---IEPRTRAWWRATLALCLGSFTVFINLYVAQPLLPA-IRESFEVSTLAAGSAMSVSMLTLALSLLFYGPLSDAIG-RAAIMRVTLVLASVCTLVMAFAPNFASLIALRALQGFLLGGLPAVAIAWMGDEFDKPALLLA--VGLYISGNTLGGIGGRVIGGAVAEHWNWHASFMVIACLSLVCTSIFWRALPPARQFRPSpkAVRDMGGHLRDPRLIAAYLIGGFNFFIFINQYSYVTFRLSEAPFSLTSQWLGLIFLTYLGGTLGSALSGRVAQRLSQPVCMMLGITTLMLGSLV-TLMPSLIAIIAGLTVNAVGFFLAHSMASSWVGRHAQRARGSASSLYLVFYYLGASLGGLYLEPFWARWQWGGVVAASWLVLAGTLSVAAWLWR-
     560 UniRef50_D2PV74        Major facilitator superfami...   143     7e-33  1  16.2%  8:389  11:388     -------APKLPRAFWALWVCQLVNRLGSF-VQPFLVLYLTQDRHLSPGTAGAVAAAVGAGSVVSQLVGGWLSDRIGRRRTMLI-GFLGTAAALILLGSAGSLEMIAVTAFTVGLLGDLFRPAVQATVADLLDP--RERVRAYGLLFWAINLGFSVSTVSAGVLAS-VGYSLLFWINAATSVVAALVIWRMVPETRPVLDEGPRRSLLPVALRDTTFVLMILIQIGYATIYFQGYSTLPLAMAAD-GLPSATYGLVIALNGVVIVVVQPFVGRRLAAFDRPRLLAGSMLLVGLGFGIGAVVHSWWGYGLSVVVWTIGEIGFAAVIGAVFADLApdLRGGYLGLAGSmfGLGSVIGPLIGTNALEHLGATATWLACAVLGVVLFLAQLGM---
     561 UniRef50_B2Q258        Putative uncharacterized pr...   143     7e-33  1  12.1%  9:388   2:377     --------QPYRYLLWVLATAVYLVGTTEFMLSATLTP-LAEVFSVSSAQASWLISAYALTYAVTAPVIGYFSDRIDRRKLLLVA-MFLFAIDSLAIIVSPNFTIAMFFRICGGLASAAIVPTIFALIADIFP--ERQQSTAMGMVMVGMTIGIVSGPVLAGVLTEYLTWYAPFIMTAVGSLIVWFCVCKILPSSKPHQDVRKQGGFQW--LQDIKIVRFISAKAIWNGTAVSVFLLSGEVLRLKFSIDSALIGVVVAAFGVGLFIGNLLVGRLNHFlsQRLLLVISLMAVAVLTFVLAYVP-LVVHTACLVIWGGFLGMAAPLSTTMVAMRSGENKGQVLAVSESFNNIVLFSMLPLLSWVLSYHGLVTMSVIIMLMLTIAIVLSVL----
     562 UniRef50_C1D9P5        Major facilitator superfami...   143     8e-33  1  15.9%  3:391  62:445     --QEPDTQRANWSGVFAMSLCVFALIASEFMPVSLLTP-IATDLHVTEGMAGQGIAISGAFAVLASLSIAWLAGDLD-RKMLLLGLTGLMAVSGAVVALAPGYAVYLTGRALIGVVIGGFWSLSAATAMRLVPADRVPRA--LAIFNGGNALATVIAAPLGSYLGAVMGWRGAFLCLVPVAALVLVWQWTSLPAM-PPQVRNPGPGTVFRMLKSRFITLGMVACGTFFMGQFALFTYVRPFLETVTQVNVSTLSLILLATGVTGVIGTILIGPALKRSLYGTLAVIPVLMAVIALGLLPLGASTGAVLVLLGCWGLLATSAPVGWWSWIARAMPHHAEAGGGLMVAVIQLSIALGSTTGGLLFDAAGYQATFATSAAILLLAALLAAMTAR-
     563 UniRef50_B0UI65        Major facilitator superfami...   143     8e-33  1  14.6%  5:374   1:371     ----MKMGNDRRNYLLFLVTCSGLVATARAMTLSFLVIKLHESFGLGSAIIGALLGAGPLVGAVVAPFAGSLSDRM-ERKPVLTLTLFMTAVALLGMAVAESVLTFCLAQIVSAVALAVYEPVSRALMSDVCPEEQRLR--FFSWRYTTNNVGWAIGPLIGVSAGATASI-LFFSASFLYAFFAIALLLVTVPYNQRhvQHTSVFSCVRAAIRDPRLAFFVLGGTLLIAVHGQYSATLAPYLSTSIENGNSIFAYLVSINGFVVLLGNPIARRFIESVGARHALVMGCGLFFIGEISFMFSNNLLTFSVAMTIFTLGEILVVPSEYMMVDDISNdnRGGYFGA-HSFSTIGNFIGPTLGGVLLGAYGGAAMFLL------------------
     564 UniRef50_C2ANS3        Drug resistance transporter...   143     8e-33  1  15.3%  1:386   1:390     MTPTERPAPPKLRIALILGSLSSFGPITTDLYLPGLPS-AAEDLGASQPAMQATLTACLVGLAIGQIVVGPLSDSIGRRRPMI-AGMALFIVSSLLCAVAPSVYLLDAARLLQGLAGAAGIVLSLAIVRDLF--HGVAAARMIAALMAVSGVAPIVAPLAGAQLLRVLDWRGLFVVLAVLGVALLAVAALLVPETLPTADRRPSgaGYYSLARDRRFVALTATSGLAFAVMFAYISTSSFVFQDHYGFTATQFSVVFAANAVGLLVTNLIGGRLVGRVSTSVLVWTGLAGMALgaVLALSADLLPLLVGSLFLAVSSLGLVMPTVAALALEDHGALAGTASAALGSARFVFGGLAALVAGIGGNPTVLGVVMVVCAVGALMAFVAA------
     565 UniRef50_B0TEA9        Quinolone resistance protei...   143     8e-33  1  15.6%  8:391  11:397     -------APLWTKSFLFICLTNLFMFTSFYFLLPTLPVFVTSGLGGDESSVGYIIGILSLTAVMVRPLSGYLLDVVGRKKVLFLA-LIAFCLATAAYYIVAGLTALFLLRALHGMAWGFTTTGASTVAADVVPAERRGEG--LGYYGLSNTLAMAAGPSLGLFVLDKGGFPALFGASLILAVLGLLSLGGVSYEDKTgdAKKKKAGLSLAALFEPAVFSLSAVMAFVAIVYGGIVSFITLLAKE---IGVPNAGVYFLVYALTLLVIRPWAGRAFDRQGPKRIMLIGFVSMAAAFALLFLAKGIVLFVLSAVVMGVGFGIVQPTLMAMAINRVPprRGAANGTLMSAFDLGIGLGSIALGYVSKLAGFSGMYLACAAIIVIPALLFFRLGE-
     566 UniRef50_C3JQY1        Major facilitator superfami...   143     8e-33  1  16.7%  7:377   1:373     ------MLRSTKVTVALLFVAYAIDYIDRLAINLALPL-LGEEFDLDYSQRGLIISTFFIAYTLAQLPGGLLADRYGAVR-MALIGLVAWSVFTGLTALAWSFGTLLIVRFLFGLAQGVFPAAAVKLVAERSIPEQR--ATATGWMNSSNAVGTLLAIVVAAALLPLIGWRGMFLAVAALGVLSLVSIKLWLPPALPAENDHGPDSSwrTVLRSRAMWLFALMFFGYDFVIWGMSSWVPSYLHDERGIALSSASLLLIPATVVAAVTTVIGGRISDRLasRVVVVPSMLACIVMLVSIPFVSNTALFVVLVTLGSAAASFAFMPCFALPLRSLPSsvGAASSMIIFGGMVAGIVAPLVFGFIVDHLSWSAAFVSLAL---------------
     567 UniRef50_D1RXR7        Putative uncharacterized pr...   143     8e-33  1  12.6% 11:391   1:375     ----------MPLALLALAISAFAIGTTEFVTTGLL-QDIARDLHITIPQAGYLTSGYALGVVISAPILTLLLARF-NRKHTLVFLILLFIVGSFVSARAATFEQLMLGRVLSAFCHGAFFGIGAVVATTVVAPNK--KASAIALMFTGLTLANVVGVPLGTYFGQHFGWRTAFWAIAALGVIGFAGLAALVPKQLAE---RSPILDEIAVFKRPQVWLALIVTAVGFSGLLASFAYISPMMTEVAGFAPTNLAWILSIYGVGLVVGNIVAAKFADRALVPTILTLLFLLALILALFTYTLHIKSLAIISVFLLGAIGFGTIPPLQMYVMETASGAPTLASAANISAFNLGASGGVWLGGVAIDayGFVSPNWVGAITTGIGLLIAVYALR-
     568 UniRef50_B4SND1        Major facilitator superfami...   143     9e-33  1  14.8%  8:386  24:396     -------PRQRTLIILALSLGGFAIGTSEFASMGLM-LEISRGLSISETQVGHLISAYAIGVVVGAPILAFVGASFPRRK-LLLALMGFYAVGNLASALAPNYGTMLIARFVAGLPHGAYFGVAMLVAAAISPAGQRGQAM--SRVLLGLSIAILIGNPLTTWLGQQLSWRTAFALVSLLAIATVAMIARFL--LPDPEEVRTSPMRELRAFNTTQVWLALAIGAVGFAGMFCVFTYLAPTLVQVTGVAESWMPLAVGVFGIGAIIGNIAGGWLVDKFHFKAAAVV-LLWSIVMLLLYPLAAQSVWTIGPMIITVGTMGALAAVLQTRLMDVAGEAQTLAAASNHAAFNTANALGPWLGGmiSAGFSPASTGYVGAATAIGGLLLW------
     569 UniRef50_A6SWB4        Transporter of the MFS supe...   143     9e-33  1  14.1%  2:390   6:399     -TSVKTTAAIPKLAIPALSLAAFGSAISLRVTDPLLPR-LAQEFSISLGNVSYVITAFSIAYGISQLFFGPVGDRFG-KYFVVACACVACALTSLLCALAPSYPLLLVARLMAGATAAAIIPLSMAWIGDVVPYDERQ--PVLAQFLIGQIVGISAGVLFGGLAADYFSWRVPFFGISSCFVLISITLFSFNRRLPAYALTKHKAEgfAQVLSTPWARVVLFTVFLEGGFLYGAFAFIATHLHHVHHLSLTNAASLVMLFGLGGLLYAGTSRRLVRDLGEKGLARWGCVVIAASFLTIGLAPSWWWAIPGCFAAGLGFYMLHNTLQINATQMAPERRGAAVSTFAACFYMGQSVGVGIAGLMVGFIGTTTVICIGAIGVLLTGLNFSRLK--
     570 UniRef50_A8T684        Major facilitator family pr...   143     9e-33  1  28.2%  7:389   1:382     ------MKSLLSGVSGKLFVVNSLTATAYAFILPIMSVFLVGDIGASPSFIAYYSVSFALSGMMFSQWFGSLSDRGVNDRWLFLTSMVCILVSAVCFSFITEPWQALMVGIILMGPGNACIPLILSMIKRYADQAGKNITSLNTQMRSGVSVVWIIGPALAFVVADTWGYQTNFYIAFVLSILVIIITAKYLPSFNQTTQASLTSDRQKSPVTMIAFL-LGLVIFLGNLANHVYLTAMPLYLTQELNIPLYFPGFLLGLTALFEIPVMLYAAKLSERYGKGQIMVFGLLCAMVYYGFMPFVTSIQLLLLLQVFNGLFYGVFVGLGITIIQDAFPKKGGFASAYYTNMMRIGMMFGTSIAGFIAQYFDFQTALFASLASILFALPLMLYV---
     571 UniRef50_C6HWS6        Major facilitator superfami...   143     9e-33  1  14.7%  1:389   1:387     MGEKDGMTALEKRTLAGLSLIFAIRMFGLFIVLPVISLYARTLPGADPLWLGLALGGYGLSQAIFQVPFGMLSDRFG-RKPVIVAGLLIFAGGSVMAATAHSVFGLFVGRLIQG--TGAVASVVIALMADLTREEYRTRAM--AGIGVSIGLSFAVGMVVGPIVGAAYGVSSLFWLTATLALLGIGIILFVVPSPKGAVHKNesFSQLGYVLKNPALLRIDISVFSLHLFLTAVFVSFPVLLKQY--IAPSAMWKVYLPVILGGMFLMVPAMIVAEKRKKLKTAFLIAVAFIVASFAIFLGgsETGLIAGLAVFFIGFNLLEPLMPSIMTRFVRTrrGTSSGVFNMSQFMGAFLGGVLGGGLATVSN-TALFSALLAISAVWFLIALGL---
     572 UniRef50_Q5FQ29        Putative transmembrane effl...   143     9e-33  1  14.8%  3:387  10:389     --ERVRPPHGVGPAMLSLMLATFTIGTGEFAMMGLLPEF-SHSLNITISQASWAISAYAMGVVIGAPLIAIIGARL-PRRTLLLCLLCLFIAGNIGSILMPGFAGIELMRFITGLPHGAFFGVSALIGASMVERARRGRA--VGQVLSGIMISTVIGSPLSTYAANHVGWRVAYGSIAALGVLCFAGIWFFAPRDRPH--PGASALSELGAFKRPQVLLTLLTSAVGFGGLFGIYTFLTTGLTQVTHLPGWLVAVYQVVWGLGMVAGNALGGTMADRSIDRTVIVSLTASIVFMLGFWLLLPSPYAMLPLTFLVPAGIIMLSPALQTRLMEVAGDAQTLAASLNHSAFNLANAFGAWLGAVLvsGFGLGSVGWGGAVFSALGLLIYF-----
     573 UniRef50_C5CVW8        Major facilitator superfami...   143     9e-33  1  14.1% 13:388  29:398     ------------RAVLALGVGGFAIGTGEFVIMGLLPE-VAKDIDVSIPQAGHVISAYALGVVIGAPVLAVLAAGW-RRRALLIALMAVFAAGNFASAMAPGYLSLNLLRFATGLPHGTYFGVAALVAATLAPPGRRARA--VGLVMLGLTGATLVGVPIAAWLGQLFGWRAAFVFVGLIALVAVALLRRDIPDLAPPAGASPWRE--LGALKRKQVWFTLGIGAIGFGGMFSVFSYIKPTLIEVAGLPLGGVPFVLALFGLGMVTGNLVGSRLADK-SLMRTIGGLLVYAALVLAMFSFAAHHVVAAAVNVFLIGTTVAIGPALQIRLMDVAGDAQTLAAALNHSAFNMANALGAWLGGviAAGLGWTSTGWVGALLALAGMGVFGW----
     574 UniRef50_D1BQV3        Major facilitator superfami...   143     9e-33  1  18.1%  7:388   1:390     ------MDSSWKRIIYLICTIQVGGGITIIGVLSFLPLFLAedPGEAAMWAGLVSGVTPCMVALSAPYWSRKANQLGPRKVMMFILFTLM-VTVGACAFTQTPWQLLMLRILQGVV-GGYVPIGLAIIILITPEDKVPWAM--GLYQASMVMGLVFGPLMGGLAADLLGYRAPFVMFSALTGLCMLGIYLFMPneHKVDARESQLSLIKSFLVIPRVRLLVGLLFLCNFGITGIGPILPLYIKHYMHMnaTIVGIIIFGAGLFSALASISIGKITERLTMPRIVFTATWAVGTLFILQYIMPSIWGLGIFRAIAGFFMGFITPIANTLISKAVpeRRGIVFGAVSSVAMMGNVLGPVLSGMIARAFGYGAVFWSTAAIFFVAALFIYR----
     575 UniRef50_A3JVE8        Drug resistance transporter...   143     1e-32  1  14.3%  7:335  38:368     ------LDRTTPPKLITLVLTAGLAALSLAIFVPSLPK-MAEHFGTDYAVMQLSIAGYFLVTGTLQLIIGPLSDRYG-RRPVLLWGILIFVIATIGAIYAPNVETFLAFRMAQG-GIATGMVLSRAVVRDLVPGP--SAASMIAYVTMGMAIFPMIGPIVGGYLGETFGWQTTFWFLATFGAVMLGLVFFDLGESNSNRSEskQFAECPELFGARRYWGFTLTSMFCSGTFFSYLGGAPQVANQVYALSETQTGAYLGLISLGYFFGNYYSGRNAERLGIFKMMIIGCWFATTGilVALGAASPLAFFGCVVAVGFGNGLALPSATVGLMSVRPS---------------------------------------------------------
     576 UniRef50_B6YXF4        Multidrug-efflux transporte...   143     1e-32  1  15.6% 14:391  28:412     -------------NVVLLAVSMFIANAAFGMAFPYLSVYM-KLLGGGMLMVGLLSVAFNLTSTVFQYPFGYLSDRTRNRKAFISFGLFSTGTFYALMAVVSTPLALLTLRTFQGALGSAIMPAHSALIAELSTR----VGSAYGLFGSIENAGYMLGNFIGGFLIKYVGIRGIFLIAGALLVLSSAIVLLLRERPRPKRAPRKLigAAFKRLMRGHLGLFYFTVLLVMIASGQVYSVVSVYFEEVFG--SEWVGILFGIDSLAAAVSGYYLGKLIDRYGAKKFYLLAIAGYAIAFLGYAFAKNLYLMIVVALFSGVKWSLTLNASSTYVakVRATERGQAMGLLNAMMSLGWVVGPLLGGYL-SAISFELNFMSTLVPLGVAFLFALRLPE-
     577 UniRef50_A4FF64        MFS transporter, phthalate ...   143     1e-32  1  11.6% 10:389  21:430     ---------RIRYVVLAVLFVSTAINYLDRTNLSVAAPHIQHDLGLSATELGVILSAFSWGYAFLQIPGGWLLDRIGPRLAF-GWALVLWSLATVATALARGFGSLFAVRASLGVLEAPAFPANGRLAASWFPSSERGRAT--AIYTAGEYVGLALAVPVLSMLVVAFGWQSVFVVTGVAGLVWAVVWFRQIRNTPQEDPRVDdwADLRYLLTRKRLWGIYLGQFAINSAMFFFLTWFPSYLTQSRGLELMEAGFYASIPYLAALAGVLLGGWWSDSMLRRGVSviTGLFLATVIVAANYVDDVGLIVAIMSVAFFAQGMAAISWLLPPEIAPSRMVGLTGGVFNFVGNLGGASTPIVIGMIVDATgfAGGLVFMSCVALMGALSYVFL---
     578 UniRef50_Q39QP0        Major facilitator superfami...   143     1e-32  1  12.4% 26:388  31:403     -------------------------YIDRQVLYAVFPL-IQHDFSLSDTALGLLGSGFMVTYMVSAPLFGWLGDRWSRTR-LAAAGLGIWSVATAAAGLAPTYPALLTARTTVGVGEASFGTVSPGLLAEFFDRERRGR--ILSYFYLAIPVGSALGYLLGGVIGQQWGWHAAFMMVGLPGLLLVLPVWLMREPPRSADAanPDNGGYRALFRNRSFIANTLAMAAMTFALGGLAQWIPTFLYREHGLSVSTGNTLfgLTVVTGICGTLTGGWLGDRLQRRtvSGWGFLLGTPAAAYAILTPSLNHCLGGMFLAEFFLFLNTGPLNTVIVNVtpAVRAMAFAVNIFFiaLGDAISPTILGRLSDIWGLRTALLSTPVAILVAALFAFV----
     579 UniRef50_Q4K578        Major facilitator family tr...   143     1e-32  1  12.9% 11:375   1:365     ----------MPIALLALTLSAFAIGTTEFVIVGLLPT-IGTDLGVSLPSAGLLVSLYALGVAIGAPVLTALSGKV-PRKLLLLSLMVLFTLGNLLAWKAPGYESLVLARIVTGLAHGVFFSIGSTIATSLVPKEK--AASAIAIMFTGLTVALVTGVPLGTFIGQHLGWRETFLAVSALGVIAFIGSLLFVPKNITHRPPASLLQQLQVLKQ-PRLLLVYAMTAVGYGGSFIAFTFLAPILQDISGFSAGTVSLVLLVYGVSVAVGNIWGGKLADRRGPIGAliIFALLAAVLLMLSLTAGNPWLALLTVLLWGAVAFGNVPGLQVYVVRQapQAVDVASGLNIAAFNLGIAGGAWLGGLIVAHLGLIHTAWIG-----------------
     580 UniRef50_B8D0I6        Major facilitator superfami...   143     1e-32  1  13.1%  7:389   1:389     ------MKSKYKLMMVAFSGVPFIMVLGNSMLIPEFPQ-IKAALDIDQFHVGLLITVFSISAGITIPFLGYLCDQIGRIKvlLLYGLGGIISGVAALIMDNPYNIILIGRVVQGVGAAGTAPIVMALVGDIFQSEQRSEA--LGIIEAANGIGKVVSPILGSAIG-LISWIALFFFYVFLAIPIAAGVWFWGKEVKEKGQqkKYLRNVGEIFKEKGLSLImlSGMLVLFILFGLLSYFSDFLEAKHNIKGFVKGLVIAIPILFMSTTSYINGYILKKVKkkASIITGLIIIPLALIILSFIKSLTTYLVLFSLLGIGTGLVLPAINTLVTSStaDQRGVITSIYGSARFVGVAIGPPAFSFL-EELSLKTMYYGGSLIAGIIMVLALIF---
     581 UniRef50_Q0W6V9        Putative permease (Major fa...   143     1e-32  1  13.5%  9:392   4:391     --------PQFDRRVWVLFAGMALNQFGMSIVMPFIAIYLFVYQGESPALVGFAMFFSAFAGAIFQFVGGEACDRLG-RRTVLIIGLILLIGSFLMLGWAVsyIYYLVLLSLTRVATGLFRPIPNVIAADIVPAEKRTEA--FALLRVAHNLGFATGPIIGG-LMAIVSYSSMFYLTAVTSTLYLALVLAFIGDTRrrPEKARARGGMGTILADRTFMVFSLLSFLVFVVYSQMYTPLSMYSKGYAGLSEPEIGVLLAINGIMVVTLQYFVTRVADRFRMTFSMTVGILFYAAGFALVSVSQGFAMLAICLFLITIGELWFIPAQITLATNLssETRGRYLGFSGLTTNMGSAVGPLIGGMLLSVfsPWAMWLVVATAGLLCAAGFLYLKKI
     582 UniRef50_B3E3Q4        Major facilitator superfami...   143     1e-32  1  14.1% 12:388   4:385     -----------RSLFRALFLINFAITLGFGIADAFFSMYVF-SLGARGILLVLPLVLYSLSKILFSPFMGACSDKIGPRR-IASISLGLYLLVSICYFFTTSLMLITIMRLFQGIGCAMFRPLVASLVGERTTSEKR--ATVLGTFDISFYGALSVGPVVGGILKDIWGFEGIFAVLTLLCIVALLVALFYIPAQRLSKNHAAErrTIFTMARQNSLRGLLAFIFGRACGISLLSAFLPILLTTKLGLSGIQTGLVMASGSLVFTLLLRPIGMLSDKTPRKPLIVAGGTIVSLLYFLIPVVSGFSQILFLGLGIGMFSVLSQPACTTLLIEevRHGMGLTVGIFNSVLNLGFIAGPLFGAGMQHTFGLSSVFYAAGILGFVAVGLFIT----
     583 UniRef50_D1BPG7        Drug resistance transporter...   143     1e-32  1  15.2% 14:389  13:392     -------------LVVFLGLLTAITPLATDLYLPALPI-MPSELNTSASNIQMTIGVMTFGVALGQLFGGPISDTMGRKLPLITGNLLC-VISSIICAYAPSIEILLLGRFLQGLTGSVGVVIAKAIARDFAFGQELTK--LFALLMMVNGLAPVIAPLIGGQLLLFTTWRVIFVILAIFSAILLVGSLLfpKEKRVTGGVATATKNYITLIKDKRFLGQTLIQFFAFGGFFAYISGSSFVYQNIFQLSAQEFSYLFGINSCGIILASAISARLSNVITVRQLLTFAliGSLLFLIAMLFEWPLIPVTAILFFTVCTVSLFGSASFSMAMAKYGKMAGSASAVLGFASMFSAGIVSPLVGIGGEYTGIPMGITMLVCAALSLLCLYRLV---
     584 UniRef50_D2B1R4        Major facilitator superfami...   143     1e-32  1  13.8% 11:387   1:372     ----------MPRAVHLMALGVFAMVTSEFAVAGLMPQ-MADGLSATIPQIGYLITAFAVAMAAGGPFLTIAVLKL-RPKPALMVLFAIFLVGNLLAATAPSYPIMMAARIITGIAAQAFFGVAISLAVRLTPPQSRGRA--IAVVMNGLMVGTLLGLPLSTLIGEHLGWRAAFWAVSAVAALAALATMIGVPRLERAEGDGGDFRQEMRVFTKPKLWLVFATSTLIIGATFSAFSYLNPILTQVTGFSAGTVPLLLIAYGAATVVGNNIVGRLADRHTVSVQLWGLALNLIFLTGFALLAHLSIPAVVLMLGIGLVGVTMNPAMVTRVQR-TGNARPLVNTVHSSFITLGVIIGSFAGGMAIDDFGLRAPLWLGAGLAALGILTLV-----
     585 UniRef50_C6WDC2        Drug resistance transporter...   143     1e-32  1  16.8%  5:390   3:393     ----VTAVQGRGKLVALLGVLCCLGPLSIDAYLPAFPD-MAKEFGAGESQIQLSLTTFIIGLSVGQLLIGPLSDSIGRRKPLL-FGIGSYVVLSLVCAMAPSAVALAAFRLLQGLGVAAGFVVAMAVARDRF--SGLAMAKFMSLIMLVNGLGPMLAPVLGGQVLRYASWRATFVVLAVIAVVLLVLMAVGLKETLPPEKRRPllRVFGGLLTDRVFVGYVLASAFALGAIFGYVSGSSFVLQGVFGLSPQEFSLVFALNSAGIFVAGVINTALTGRIMPRGLLRIGLSTAVLAGVAlaLGGGLVAFLVPLFLVTCSIGLLMPNAATLAMARHPEAAGSSSALLGVSQFLMGGLMAPVVGAGGSTSVLPLALVMAACTALALTSFLVLTR--
     586 UniRef50_B7RZM1        Transporter, major facilita...   143     1e-32  1  16.8% 17:390   3:382     ----------------ILFGVVLIDLIGFGIVIPILP-FLSPQLGADKVDIALIIVTYAACAGIFGPFWGKLSDRRG-RKPVIMICLAGASLSYVMLGLATELWMIFLARAFAGV-MAGNFGVASAMMADVTSPENRARGM--GLIGAAFGLGMVLGPLIGGLLadSGSFTLPCIFAGLMSVLAIIAAALTLPESLSPEKQAANRAHQKSLDRESTlrLFVFQYVVHNAGVSSATYLFPLWVADILGWTAREVGMVFGVQGVIMVVMqgALGALVKLLGEWRVLLFAICFFLSGMLLAVFAWSMPTMLASMFIGMTGATLCTPLLNTLVTHRTPAsrGRIMGTTAAASSWGRVFGPAFTGFNLAWFGYSAAWAACALIAACYLLWAFYER--
     587 UniRef50_D1R5H2        Putative uncharacterized pr...   143     1e-32  1  13.4% 13:384   8:385     ------------KLIGILTPFVFSFAFGLDIYIPIIPQ-MVQIFDTTPALIQLTLSLFLFITGFGQLFVGPLTDHFGRRK-ILYASVIFFTLGSLTCASSHHIYGLIFGRIVSAFGACGMLVTAFAIIRDLFSGNE--NAKMYSFLNGGIGISPLFAPILGGYLSLYFGWKSIFIFLALIGTFAFFINQILIQEtkRTKVSRSIFKRYVQIFSHKQFLVHAVIAGLAESVLFCFFSISPFIIINLLEVPTEEFGYYFAAFGCVIAFGGIASGKMSEKIGAHFTVRLGIHLMFIGGSSMLvsLSLAGFLIPMVIACTGAMFLLGSSASKAMEPFGHIAGTASAAFGSlfGIAALVGSILMIFPVNSTIPYAITILLIAFTAYSLF--------
     588 UniRef50_UPI000185C198 permease of the major facil...   143     1e-32  1  14.2%  9:387  19:395     --------PGFRRALIAVLFAGLASFQALYATQALLPT-LSDELSVDPATAALTVSATTGGLACAIIPVSILSERFGRRRVIVISAFVATLLGLVVS-IAPGIGSMIALRLLQGIVIAGVPAVAMAYVSEEVHADHVSR--VMGLYISGTTVGGLLGRIIPSIVLEFASWRMAIAVSATVAFIFAVLTWYFLPQQRRFTPKQLSFAgiARHLRDPRILALCALAFLFMGSFVSLYNYLGFRLGDKFGLSPALAGFVFILY-LSGTWSSARAGVWAKTVSRRRLIAIATLAACVG-LGLALLPWLPALIVGVLIFTASFFVAHSLSSSGVGLVAQRDRAEASSMYLFSYYAGSSIVGWVSGMVFSRFEWAGLIPWLVVLSFIAGACAV-----
     589 UniRef50_Q2KBF3        Tetracycline efflux transpo...   143     1e-32  1  16.4%  6:390  38:429     -----TRNAPMTRSLIVIFTAIVLDAVGIGLIFPILPSLLQEITHAqaPTIGAMTALYALMQFIFAPVLGALSDRLG-RRPVLLISLAGAAVNYLFLAFAPNLTLLFVGRAIAGL-TSANISVATAYITDISPEEKR--ARRFGLFNAMFGLGFIIGPVAGGVLGDHW-LRLPFIAAAVLNGANLLLAVFILPESRPGSREtnPLKPLRSVLEVKSLLPIVILFFIFSATGEAYGTCWALWGSDAFHWNGLSIGLSLGAFGICQTLAQALlgPAVRLLGERAAILVGVAGVSLALTVMAFAGQGWMIFAVMPIFTLGGIGVPALQSLATRQVDENSQGQFQGVLASVVSLASIAAPLGFSSLYFLvwPGAIWLSVVAVYALTVPLVLGLR--
     590 UniRef50_B0TTJ5        Major facilitator superfami...   143     1e-32  1  13.8%  5:389   6:384     ----MKQRLLNWAPVWLLALTAFVFVSTEFVPVGILAA-LGQSFNMSAVAVGPMLTVYAAVVALASLPAVLLFARFERKK-LLLGIMAVFIISHGICVWAPSYDILLSGRIGIALTHALFWAIAPALVVRLAPEGQG--AKALSIFATGCVLALVLGIPLGRVIGQLIGWRSIFALIGLLTFAMMLLLWRGLPNL--PATHGGSWRSLPALARNKALLWLYLLTMTLVTAHYSVYTYLEPLLQEHFGYSANITTMILLTFGGAGLIGSALFSRYQARNAQQLLMIAIASLGTCMAILPFIASQIWLLLPLCILWGTGMMLMCLSLQSKALKLAPDATDVAMAIYSGLFNVGIGSGALLGSIVAAQYGVVQNGTWATLLVLLALVPLFFL---
     591 UniRef50_Q11T42        Drug resistance transporter...   143     1e-32  1  12.8%  5:388   1:389     ----MRHTQNRHLITLILGMLATVSPFAIDFYLPAFSQ-IANELGTTTARISLSVSSYFIGMALGQLLYGPLLDRFGRKPP-LYAGLIIFIIASIGCCFSTGVEMLITLRFIQALGGSVAGVAAMAMVKDFFPPEQNHR--IFAMLILTIGLSPLLAPSIGGFVATAFNWKFVFVLLALIALFAITIVFLFLPEGQEPDKtkPMAKTYLSILSDTQFFTYTISGAFAFASLFIYVAGSPIVFIDLFHVSKQMYGAIFAFLSIGFIGASQLNILLVQKFSSASIFRFAMRLQVAAGMVFSIVAwlYTTILMLFVFLSCVGLINPNASALALAPFTKNIGSAAAMMGCSQIGIAAVASIAVGM-FDAASVLPMVLSMSATACIALALLMW----
     592 UniRef50_C0GJY1        Major facilitator superfami...   143     1e-32  1  12.7%  7:391   1:393     ------MRSQTKWKLTALSSVTFIMVFGNSMIIPVFTL-IRNALDISLFQVALLVTYYSVAASIFIPVFGFISDHIQRRSVIIVALALYGLGGSFIGFLahIFSIILASRVVQGIGAAGMSPIAMALVGDIFTTEER--AKALGLIEAANIFGKVISPILGAALA-LIAWFAPFFFYLGFAIPALLGVLFIipDNKPKTPFKKYFSDLKKIFTkkFLWVSYFTAWVSFLILFGVLAYLSDVLETRYDMTGIIKGIIIAIPVTAWTISSFGSGYYLQKkgLKYFVIAGIIMLGASAVAIPYMERIYFFLAAAFVMGLGGGLVIPSLTILVTNCApeERGGIMSLYGSIRFFGVAVGPPLFSYLLN-LSHHAPFWLSGALALIPLIILIRFKN-
     593 UniRef50_UPI0001B565C5 Bcr/CflA subfamily drug res...   143     1e-32  1  18.3%  5:391  16:407     ----PKKRPGALRMAVVLGLLEVFGPISMDLYLPALPR-LADDLRAGQSLAQATMSVCMLGLAFGQLVVGPLSDRFGRRRPLLI-GIGLFTVLSVVCAFAPSIEVLLAARFLQGLCGSAGIVLSLAVARDLA--EGVELVRLLALLTTVGALAPIVAPVLGGQLAAVIGWRGIFGVLAGIGAALLVVAATALPESLPPAARHpgRGEFRILLKDPLFLGFLLVSTCGGAAFFTYLASISFVLQDGFSLSPQLFSACFAANAVMSVLGAQVNRAAVRRAGPVRMYVLgaAAAVTMLGAVWFGAGLAALLIPLALLMFAGGTTQANGNALALANHGQRAGTAAALLGTSSFAIGPIVAplGGTTPLSMSLTMTVAYGIATVLLWLAVLPRLRR-
     594 UniRef50_Q0B5E9        Major facilitator superfami...   143     1e-32  1  12.9%  4:390   1:408     ---MPTDHRQRRHTLWLLCALSFILYVDR-VNLATAAGAIKAELGLSNTELGIAFSAFAYSYAICQIGGGWIADRFGARITLIGCGL-IWVASTFMTGLVHSLALLFAARLLLGIGEGATLPAQARAITHWFSRERRGVVQ--GFTHSFSRLGNAVTPPIVAALMTWLSWRAAFFVIGAVTMVWLVWWVVGFREYPRGESDGNGVGRTHTAATarRMAPTIFVYFCYGWTAWLFFTWLPTFFLNGQGLNLKSTALFASGVFFAGVVGDTLGGWLCDRisRQSVIVTSFTGALVCLLPLAFVHSTAGIALCLSGSFLCLELTIGPIWAVPSDIAPQHAGIASGMMNAGSAIAGILSPILFGYLVDRTgwTVPFVGSVAMLLIGIVAALRIR--
     595 UniRef50_B4VGF6        Transmembrane efflux protei...   143     1e-32  1  15.6% 11:375   1:360     ----------MPLALLALAIGAFGIGTTEFVIMGLLPE-VAADYGVTIPTAGFLVTGYALGVVLGAPLMTVLGTRVPRKR-MLMLLMGLFIAGNVLSALAPAFGVMLAGRVVASLAHGAFFGIGSVVAAGLVAPEK--KAGAIAMMFTGLTVANVVGVPLGTLVGQTAGWRLTFLIVAALGVLGLLGIARLVPELPRPEGVR--IRHELAAFRNVQVLLAMAMTVLGFGGVFAAITYITPMMTNVAGFADTSVTWLLVLFGLGMVAGNLIGGRFADRALMPMLYVSLGALAVVLAVFTLTAHTKAGAAVTVVLIGALGFATVPPLQKRVLDQAAGAPTLASAVNIGAFNLGNALAAWLGGliAAGLGWTAPNWVG-----------------
     596 UniRef50_B5JYB5        Major facilitator superfami...   143     1e-32  1  15.4%  7:390   1:386     ------MLPSERRAALSLALVYMFRMVGLFVVLPVLALYADGLRGATPLLLGLAVGTYGLTQAALQIPFGIMSDRWG-RKPVIVAGLLVFAVGSAVAATADSIYGVIAGRALQG--AGAVASAIMALAADLSRDSQRTK--VMAIIGASIGLAFMLSLMLGPVISAWVGVSGLFWLSLVLSLMGAALVWRAVPTPNSLSQSAgsVNELKRVLLEPSLLALNLSIFCLHGSLMALFVVVPFYLRDQLGLMSEQHWWVYLPVMLVSLLVALPLIMRSGRSGaaKALRIGVLVVGCGAAVMAAGQWlgLWLAAFALYFVGFNVLEASLPSLVSRLVpgHKGAALGAYSTSQFLGTFVGGAVGGWALGALGVAWVIAGIAVMVAIWAVLLWRAP--
     597 UniRef50_B9Z3Z9        Drug resistance transporter...   143     1e-32  1  19.0% 12:390  11:391     -----------TRLIVLLSALVAFGPLSIDMYLPSLPA-IARDLAAPVGLVQFTIGGFLTGFCLGMLLYGPLSDRFG-RRPVLLAGIALYLVASLACAFASSAEQLIALRVLQAVGGGAGSVMGRTVVRDVFPLDR--AAQVLSLMHLVTMIAPLVAPVLGGWLLLAAGWRSLFLALALFGAVCLALVALRLPETHPAERraSAFSAYGHLLTDTPTLGYMLALGLTFGAMFAYITGSPFVYIDYFGVAPQHYGWLFGLNIASVIVLTTLNKWLVKRVALDTLLQaaVIAAAGLALWLAGAHSLLAVVLPLLVSVGLTGSIGPNTMARLLQRHSERAGAAMALAVSGQFGLGMLASALVAALHDGT-PRAMCQVVALFGVAACLGLQLIR--
     598 UniRef50_A5FB16        Major facilitator superfami...   143     1e-32  1  15.1%  5:348   3:340     ----PKNKSIYTLQFILLCMSSLLFSSSFNMIIPELPSYLSSLGGAEYK--GFIISLFTLTAAISRPFSGKLTDKWG-RVPVMAVGSVVCLICGFLYPILSSVSGFLFLRLVHGFSTGFKPTATSAYVADIIPQERWGEA--LGMHGLCFSIGGALGPALGGMVVNAYGIDVMFYSSSFLAFLSIVIVMNMKETLAAKEkhKSMFYIGRKDIIDIGALPAGVITFFSYTAYGLILTLIPDWSE---HLGAENKGVFFTAFTIASVLVRFGAGKVSDRHGRTNVILAGLIVTSIALFVISTGNSITVLLTGAAIYGMGTGILSPAINAWTIDLspQHRGKAIATMYISM--------------------------------------------
     599 UniRef50_C4LG70        Permease of the major facil...   143     1e-32  1  12.5%  7:391  13:395     ------QSPMYRKVILAMVGAGLASFNALYCTQALLPV-LSEDLHVTPATASLTVSATTGMLALSIIPASIISERFGRKRVIMLSALS-ATLLGLLLPLSTSVGMLIILRGLQGIAVAGVPATAMAYLSEEIHPKHVP--QVMGLYVAGTSVGGLSGRVIPSGVLEFASWRWALAATVAVAIIFAFITSWALPDQQRFQPKrsEFSAIAQHVKNPRLSALFTLAFLFMGAFVSLYDYVGYRLTGHFGLSEGVAGAIFFLY-LSGTWSATQAGTMVHKFGRAHVLVGSIVGMMIGMAVL-FSPELISSILGILLFTACFFAAHSVASGWVGVVATTNRAEASSMYLFCYYMGSSIVGWLSGHVLHSWEWGGLVVWLLTGLAIATVIALFIAR-
     600 UniRef50_C4SHU7        Arabinose efflux permease n...   142     2e-32  1  11.9%  3:388  22:401     --ARPVPPSGILPAMLALGSGGLFIGTGEFAPMSLLPD-LAQATQVSIPSAGAYISAYAAGVVVGAPAFAIMAARWPRKKLL-ILLLIITMFGYIFSAGAQGYTSLLISRFISGLPHGAWYGVAALVAASMVPINQKNR--YIGYVMLGLAVANVVGVPLVTWIGQTFGWRISFAVIATGIVLTGLMVTFFIPSVPADKDASPIKE--LGALKSPQVLMTFATASVSFAGLFAVYSFITPALTEVSGFALSSVPWILVLWGMGMVFGNIVGGRLADKGLIPAIYGMILWNLLFLALFALVAQWKIPALICLFFLGSGC-CLVPALQSHMMNITGEAQTLASSLTHSAFNISNALGATFGGMAIsgWGWVSTGWVGVFFAFIALVFMYL----
     601 UniRef50_C6MFA3        Putative uncharacterized pr...   142     2e-32  1  14.2% 17:389   1:380     ----------------MLWAATLVSNIGTWMHD-IGASWLMTTLSPTPVMVALVQTATTLPIFLLAMPAGALADIVDRRSYLIGVQLWLALVAMLLGFITlsAWTLIALTFAMGIGTAMMMPAWAAITPELVPRNELQSA--IALNSLSINMARTMGPALAGIIISFAGTGAVFVLNAFSYFLVIFALMRWRRKAPISELPsaLRSGFRFARHAPDLQAAIIRGFGFFLFASASWALLPLLVKRLENGGPQTFGILMASIGAGAVIGALLLPKLREKISRDMLVALATIAYALTMFALAIVEQLIFLCLAMGVSGIAWIAVLSSLQIAAQMALPNwrSRGLAIFMAIFMGAMATGSLLWGKVAEMTSIPNALMTAAVGAVVTTLLTWRW---
     602 UniRef50_A4SLS0        Permease of the major facil...   142     2e-32  1  16.4%  8:392  31:415     -------SREWMRATLALSLGSFLVFLNLYQTHPLLPL-LANVFSVSSLSAGWTLAGCTAGLATSLLICARLADRFGRRRIML-WTLGGAILLSLLISLVNQFEQLLLLRILQGVLLAGLPATAIAYMGEEF--SKRALLSAVGVYIAANSLGGIAGRVVGGLLAGWFgwQHTFLGIGLISLILLPLVIWLLPAqpVVAEPGQFQRAISSHLGNPLLVGAYLIGGLNFMVFLNQYSYLTFLLAKAPFSLPTQWLGMLFLTYLSGTVASSLSGRCAHCWGAQRLLLAGISLMALGSALL-LHGSLAAILTGLLISSFGFFLAHACASAWVGQHVEHNRALASSLYLVGYYLGASLGGLYLHPFWERGGLGGLVLGIELVLVITAGLSLWLGHL
     603 UniRef50_A8SQH2        Putative uncharacterized pr...   142     2e-32  1  13.8%  7:389   5:382     ------LTRKEMLPLVGMTVSAFIFNTSEFMPIGLLTD-IAKSFSISESKAGMLITVYSWIVMLLSLPLILLVSKIDFRKLFM-GTIALFGICQIMSVLAPSYGVLMASRIGVACTHAIFWSIASPVAIRLVNEEHRS--FALSMVVTGTSIATIAGLPLGRLVGQYMGWRVTFLIVGIIAFAVLVYMAFVFPKI--ASGEQFHVKDLPALLKNPVLICLYVQTILFVLGYYTVYSYIEPFMQQVAKLQNNVITIVLLIFGATGLLGSYLFSKLYDRHRFAFIGTVMATLLAWLLLLLPASKSLATMVILCAFWGITAMAFNVTTQSEVIRSVDEkaAVATAIYSGLFNLGIGGGSWIGGIVCDKGAISYIGFVGAVFAVISVLFFAFV---
     604 UniRef50_UPI0001C4286D putative transport protein ...   142     2e-32  1  16.2%  4:392   2:389     ---IEEKTAQFRRTTFALGVAAFFIFANLHFPQPILPV-LAREFQVSDVMISLLVSVPLFVLAIAFFIYSPLSDALGRKK-IMNTAMVIACLLSLGLAVVPGFEGLLLIRTLQAIALAGIPTIALAYISEEYAKKAMTVA--IGVYISANSFGGMTGRFMSGVLTDLSSWRIAFLVMGLISVLSVILVLLFLPNSKQFTPQpeVIANYRHHLSDRQLQPAYIVGGLHFLIFIGFYSYVAFLlaEPFSLSTTVVGFVFITY-MAGTFSSTLAGKLAKKYSQAYCLKIGILIMAVG-ITLTLIMNLLLIVLGLLLLSFGFFFAHSCSSAWVSKYATTAKASASGLYLTAYYIGGGLGGIYLGWFWVHAGWIGVVAGSMMILVVTTYTSIQMKHL
     605 UniRef50_D1Z143        MFS transporter n=2 Tax=Eur...   142     2e-32  1  16.7%  7:389   1:381     ------MTGRKNLVFALVSAAIFMDMMVYTLVIPVLPSYAMK-LGADTVTIGAIYGAFSVSLLLFSIPFGILSDQLGRRSFMML-GMLTLAATNVAFALSSDVAVLILARLLQGMSGAATWSAGLSMLADTFGPEERGK--RLGMAMSAMSVGTLIGPTMGGILYDNLGYALTFIIPSVMACIVGLAFLAVSEPSGHAPSVPFRERLAPYLRSPRTFLAISLAVVIGAVTYGILEPFMPVYMYDVFSATPTMVGLAFGAMSLLSIVAQPLVGRLYDLHGGRLLITAGLASSAIVVAGCALTPSFALTAAVLSLLGMTMGFALTPMLPLLSDLYGgsSGMAYGIYNTLFSLGLAVGPFAGGVMVAALTLPATLYVVAVLLAIAGIIMFLF---
     606 UniRef50_A0JRG7        Major facilitator superfami...   142     2e-32  1  13.6%  7:389  20:430     ------MTRKRWVIIWLAFIGLSINYLDRSSLSVALP-FMGKDFELTATQQGLIFAAFFWAYDFCQLAAGWYVDKVGPRKSFSLAAL-WWSVFTMVTAAATSFWSLFAARFLLGVGESPAPSTAAKVVATWFPV--RERAFATSIWDSGSRVGAVIALPIVTLIVALTSWHAVFIIIGIAGVIWAAVWWKVYRSPQEHPgaNAAKLPWRSLFKYRTILSMMFGFFCLNSAIYFFITFFPSYLVKERGFDLLKLGFFGAIPGICAVLCGWLGGYLADRAVrrKTAIAGGLAGGSVIMFAALVPEAWMALALLSVAYSSLTVAATGIWSLPADVApkHVGSIGGLQNFASNLAGIFTPILIGVLVDQTgfVAPLAVIGAISLVGAANYLFV---
     607 UniRef50_UPI0001B58B47 MFS transporter n=1 Tax=Str...   142     2e-32  1  17.0%  8:390  22:410     -------RRTERTTLALLVGVFIIDYIDRVMIAVALPL-IGAEFGLSKTTQGLVVSAFAIAYLVGQMPGGLLADRVGAR-PLLVISLVAWSVFTAATGFAPGLVVLLVLRAAFGFAQALFPGAAFKALAERTTQEGRSRGA--GLLLASNSVGAGLGPLLVAPLVVAAGWRHTFWIVAVAGLVVGLALWRLLPatEPEARVAPVKVPVSQVLRNRLVIRCAAMFACFNMLAYGMITWVPSYLVETKGLSLVAAGISAAIPQLVSAAAVLLGGWLMSRyrPRWLVVPALVAAAGVLVAMLLSDSATGFTVLQTLAMFISGLASIGIVGLPLRVLpdLVGAGMGLVNTGGQLAGVLAPLVMGWLADRFGFAAAFGFLAVSTLAAAAISLTTR--
     608 UniRef50_B0T976        Major facilitator superfami...   142     2e-32  1  14.1%  5:366   6:361     ----PQPREALPLALFVLTLSIFAIGTSEFAIAGLLTE-VASDLSVSISAAGRLVAAYALGVAIGGPIMAVLTARL-PRKTSLMVLMAIFAVGNAACALAIHYEHLALARVVTSLGHGAFFGIGAVLAMSLVPDHR--KASAVAVMFAGLTIANILGVPLGTALGQWAGWRAPFWAITALSIAALVAILTMVPD--RRDDAPPNFADEARALADGGLWVALLTTVAFATSIFLLFSYVAPLLTQASGVSPGGLTLSLLSIGLSLAVGNILGGRLADWNLGRALVGIAVVIAAVSGLLAWSSAHLPAAEINWFAWGVVTFAAVPASQVNVMQLGHKAPNLVSTLNISAFNIGIATGSWLGGQLLDQG--------------------------
     609 UniRef50_A4W756        Major facilitator superfami...   142     2e-32  1  16.8% 10:391   9:398     ---------SWKVNLISVWFGCFFTGLAISQILPFLPLYVSQ-LGVSSHEagLTFSITFLVSAIVSPMWGSLADRKG-RKLMLLRASLGMAIAILLQAYATNVWQLFLLRGLMGL-TSGYIPNAMALVASQVPRERSGWA--ISTLSTAQISGVIGGPLMGGFLADHVGLRAVFFITALLLMVSFLVTFFLIKEGVRPTISKAERLSGKAVFAtgLMISLFVTTMVIQLCNGSIGPILTLFIKSMAPDsaFLSGMIAAVPGVSALMSAPKLGKLGDRIGTARILMATLIFAVVLFFAMSFVTSPLQLGVLRFLLGFADGAMLPAVQTLLVKYSSDQvgRIFGYNQSFMYLGNVIGPLIGASVSAMAGFRWVFAATAVVVLLNIIQLAIALR-
     610 UniRef50_Q07HC8        Drug resistance transporter...   142     2e-32  1  14.9%  8:390   7:395     -------KPSFARNAIVLGLLSAIGPFAIDMYLPALPA-IASDFRASAQAVQWSLVVYFFAFGLCQIVYGPASDMLGRKPP-LYFGLTLFALGAAGCSLAPDIHWLIAARLVQGIGAAAVTVIPRAVVRDL--HTGVEATKLMGLVMLVFSVSPIFAPLFGSALIVPFGWRAAFVAMTIAALIGLLLVATLLPETRPPALrrRALQNFAQLLSERRFVALSLVGGLGMASFFAFLANSSFIYINHFGLTPTQYSLAFALNAIGFIAGSQFAAPLGARFGITRVMLAGVALYalLALTLGGTDSLAVLIALLFVTYGCLGLTLPPIMVMLLENNGPIAGSASSLSGTLQMIVGGLVMASAGRFADGTALPMVSAIALCAVTAAAVAFVTLR--
     611 UniRef50_B9B7R7        Transporter, major facilita...   142     2e-32  1  13.5%  2:379   3:388     -KWYTDLSQSEKRTYWACFSGWGLDAMDTQMYALAIPTLIA-LWGMTRGQAGFLGTTVLIMASLGGWIAGILADRYGRVR-VLQITILWFSAFTLLSAFTDSFWQLTITRSLQGLGFGGEWAVGAVLISETIRPQVRGR--VVGSLQAGWAVGYGVAVLLSTLVFSTLgwRVLFAIGLVPTLLVLWIRRYIKEAprARLARPNDTPPVWAVFDRptTFKAILLTFGIYGGNYVMITWLPAYLKLVLHLSITNVGGYLAINILGSFSGAFLNGWMADRFGRRHTFVVIACLQAIAVATYTLAPLTLPVTLLlfVLGTLQSGTAAGTGAYLAELFPTrrASAQGLCGNAGRAIGAVMPAIVGVVSAHLDLGVAMGLCACAS-------------
     612 UniRef50_Q0C4X1        Tetracycline-efflux transpo...   142     2e-32  1  15.8%  1:367   1:374     MTDTAPARLPGKNAFFFVLVTVFIDHLAFGLIIPVLPTLIQDLANVPAswIGGLAATYAVMTFLFGPLIGALSDKFG-RRPVLLVSMAMLGLDFLLMALAPNIWILFLGRALAGI-SGATYSTANAYIADTTTPEERGRA--FGFIGASFGLGFIFGPVIGGLLGE-LGPRIPFFAAVGLAFLNFLYGVFVLPESLPKARRRnpLGAARHFSKLPKVSWFLIASGIFFLAHTVFPATWSVHGEIRYDWSPMQIGLSLGLVGVGAATVQalMGFILKRLGSVRTIMFGYCVTIIAMTGFAFAGQPLFAYLIIPFSALGGVTMPAANALMSSLTPPDAQGELQGAASSLNALGMIIGPLIMSGALFSFS-------------------------
     613 UniRef50_Q0W0C7        Putative permease (Major fa...   142     2e-32  1  14.8%  8:391   3:419     -------SKIKARQIIVLAVGMFIFTLGFGVIIPVMPYY-ANNLGATALDLGLLMATFSAMQFVCAPVWGAISDRIGRKPVMMIGLTGFGLAFTvwTGLSPHIGVLFISEVIGGTLSSGIWPATLAFIADITKPEERG--NLMGQMGAASGLGVIIGPAISGFLTSW-SLTLPFFATAGIGFLTAVLAYLLLPESRVPGQQPEVVKKVSMLSAIksLGFIFILTMLISFAGAMIDGTFGYFLMGKFGLspGVMGVVFAFMGITGVVCqlLVGKAISTLGEQKTIIAGLIIYSAGIIAIYFSVGIVTLALFTCLIEVGFGLIFPSLNTLVSKRtpDRQGEMLGVMGSFNSLGRVIGPPAGGLMFAVH-IGLPYFVSGILGFIAAGVMAMLTR-
     614 UniRef50_C3XKR8        Major facilitator superfami...   142     2e-32  1  15.0% 14:386  21:387     -------------AVIAIAFAAFIFNTSEFIPIGLLTL-IATDFGITEAKAGFLMSVYAWVVALASLPLMLACSRFDLRR-LLLFVMGLFIVSHIFSTFADNYYMLMASRLGVACAHALFWSIATPMAVRVAPKGKESVA--ISFVIVGTSIALLAGLPLGRVIGLYLGWRVSFFSIGIVAFLVFLVLLKTLP--QMPTSGAISLRSLPQLLKTPKLLGVYGITMCLVTAHFIAYSYIEPFLAQNAHFSQNAITATLIIFGAMGIVGGYLFSKYHDKYKETFLTFAIFGVFVALLLLKLLSFSGFGVVLVCLLWGLSIVMFGLAFQAKVLHLVPVGTSVAMSIFSGIYNVGIGSGAYFGGLITEYLSVGYVGYFGAFLAFFVCVYY------
     615 UniRef50_Q03DH0        Permease of the major facil...   142     2e-32  1  15.0% 10:390   9:394     ---------RKWWLVFFMGVVSATGPLSMDMYLPGLPE-MQRAFHSSASTLQLSITFCLIGLAVGQLIVGPISDRIGRRVP-LVVGFGLYAVTSLMLIFTTNIYLFIGIRLIQGLAGSTGQVLSRAVARDLFNGHELTK--FYAMLMAVNGAFPIIAPIIGGALLSIVQWQGIFVLLFVIGILVMVGVLCTLPETLKVTNngQTFKGLGAMFGKRQFILIALTQGLIFGALFSYISASSFVFQTYFHMTVGQFSLLYAINGLGIILGNNLPGYLPEQIKDSDILNGGLIGGMFAGVLLVGspMAILVIIPLFIVVFCVGVVNTVATSMAMSLGGrnAGAASAVLGLLMNIIGALASPLAG-IMGTQSYAPLAWLIFGFEFLGLILFQLTR--
     616 UniRef50_B8G5B0        Major facilitator superfami...   142     2e-32  1  17.1%  4:389   2:384     ---TIATAAATRRWLIPLYIAGVIVFSDMYLTQPILPQ-LSAEYGIAPATAGLSVSVVVLMIALGSLAVGPLSDRWG-RWPVMVGSVLVLSLPTLLCALAPSFGMLLVGRALQGLCIPGLTAVAVAYLGDRLPTAELGRA--VGSWIAANVAGGLSGRVVGGLISDSWGWRASFIVFAGLTLAAGFGLWLRLPRDRPVAGGgqAYWAMVMHLADRHLRSAYLIAGSLFFGFLGIFTYLPYYLSAPPFTLPSAIVALAYVSYLAGVIVSPWAGVLSARYARSRLITIGLLIAMGGIGLTLF-PHLPLIALGLWTLCSGMFIAQGVAPALVNQLAQHAKGAASALYLVAYYLGGTLGGVIPGLGWQIAGWPGVTIICLSALALALVATHRL---
     617 UniRef50_A4F7E6        Drug resistance transporter...   142     2e-32  1  15.0%  6:391  14:405     -----SSLSRKARFALILGGLTAFGPLSIDMYLPALPE-LTRELGATEAQAQLTLTAVLLGLAFGQLFAGPVSDAVGRRKPLL-AGLAVYIAATVLCALTESVHTLAVLRAVQGFGAAAGMVIARASVRDLYSGAE--AARFFSSLMLVVGLAPILAPVIGGQVLAHTTWRGVFVVLTAFGVVLMAVAAFALPETKppARIGSTFRTFGTLLAKPSFLGCALAAGLAMAAMFAYVSGSSFVMQNIYGMSPQTYAMVFGANAIGLVAAGQVNARLVGRVATEAQLLTTALLTASVAGAVLVTTalPVLLGALFVMISSLGFVMPNTTTLALAEHREVSGSASALLGVSQFVVGALAAPLVGMGGVGSALPMVSVMFGVILASAAVFLTLGRR-
     618 UniRef50_B3V5Q2        Multidrug resistance protei...   142     2e-32  1  19.0%  5:373   1:383     ----MTANNPYSWPIIALSLAVANMTFGFGIFFPYLPLF-AESLGASLgqIGLLTTGFMITRTITSLGLGSISDRIG-RKHSIVYGLFIYGVITILFYFSQDWKHVLILRTFQGITAGLIWPSARAFIYDLVETGARGRA--VSVLNVSAGIGMAIGPIFGAFLLTYfsFRIPFIFAGSFGILSSIFAFATLPSSKFSQQRTHLFKIliDAKYIYTFYSSLLMNFSHGFAFGMFRPVLVLYVYQVLGYsaSISAISFSLGAFSNSLSQIVGGRLADSKNRRLIITFAIIFGQLSTFSIIFVDNVFQLYFLVICRFSMIGIFLPSLVSLEGDIIPSarGQLSGLIEGFRGFGSAVGPIICFVFYDYVWTGSPFV-------------------
     619 UniRef50_A3CSK5        Major facilitator superfami...   142     2e-32  1  16.1% 12:389   5:380     -----------KRIYNVLFISVFATMLGLGIVSPLLPIY-AENLGATGIWLGIIFSAFALSRSVFMPVIGRISDRRG-RKWIILIGMFAYAVLSLAYIIVDSVYSLTAVRFAHGLASAMVVPIAMAYVADLSEKGR--EGSHMGNFSISMFLGMGMGPLLGGFLNDAFGLDSVFYVMAGLSAFATILVGISLPEAKRGtvQEGNPVPMRKILTLPVMRGVMVFAFISALGRGGMMVFIPVFGPLIA-ISPTEVGIVLSANTFLMALLQVPMGRITDTGNKVVLIVAGSAITALAIGAIPFSGSFGPLLAITSLVGIGGAIQQPAIMALTVDAGRtgMGTSMGAYNTVFGIGMIIAPLMGGVFMDYIGIDAVFYVGGAISLLGTGIFAVM---
     620 UniRef50_D2BHP6        Permease of the major facil...   142     2e-32  1  13.8% 13:389  19:408     ------------PNVFFLGLVSFLTDISSEIIFTLVPLFLANVLGATTTIIGFVGGLSDSTEAIFKIFSGYLSDKINRCKSLALFGYGFSALSKPFMLLANSWGVVTGVRFADRVGKGVRSSPRDALIANSVEVYERGR--SFGLHKAMDSLGATLGLGIAAAVIYFttYRTLVWWGIIPAFLAVVVLAVFVKEKRRTQTTKPVGERIRFNFrdSRFKLFLLVMFLFTLGNSS--DYFVILRAQDMSVSVLGISLMLVVFNITYSLVSLPAGMLSDKIGRRKVIAMGWLFYALVYLGFAVTQSQTGIWILFGCYGLYYGIVEGVAKAFVADMIpdKRGTAYGLYQGVVGLTLLPASLIAGILWDTIDSAAPFYFGAAMALLAVIGLLVF---
     621 UniRef50_C7XJS5        Major facilitator superfami...   142     2e-32  1  14.7%  2:389   4:406     -TKSAKLPAGWHMAFYTLWLGCFITGMGYSMTMPFISLFISDLGNYSKLQigLAFAMTFIAQAIVSPYWGSLADRKG-RKLMCMRASGVMALTITLTGFAPNAIYIIVMRFIQGSFSG-YINNATALMASETPHERSG--WVMSQMMTAGTAGNLVGPLLGGAlgGAWGYRIPFFITGVLMFIVFLGTTFLVHepISREKMKPMGEIMKSLPSVKLIVVMFITTMLVQSSTMSIDPIVSLYVKshGGDVAFVAGVVAATPGLGTLIAASRIGHKMDEVGPLRVLRIGLVVGAALFVPMALTNSPWVLAGLRFLLGIASAGMLPAAQTVLTLNTPSEsgRIFSYNQSFQAVGAVLGSLMGSTISGFSNYATVFWLTGFTLLINFVLVLIF---
     622 UniRef50_Q64C05        Multidrug resistance efflux...   142     2e-32  1  12.9% 18:390  13:386     -----------------IAISAFFVEFGTGMLMVLIPLYIRDLPAGMETSLalVFSIFGLFAAASYPVMGRLSDRLDSRKPFVLAGFAGFAVLAVACAEINTFEQLLIIRAAQGIMVGVMVPAILAMLAQVSTPYNRGR--SIGIYSTIRSIGPAAGPAVGGIIAGAWGYGAGFYACAILGLVSLLLVNSIVKETHETRGRGIGKNKTDRT-SNGEIKLFVYATFTTMLAIMIVATLLPVY-EVHLDASVGGLGVSLSAYFSARLLFQTPIGILSDRFGKRNMVAAGLSITAFLLLGMAHVTSVIQLFALMFVAGITSAAVnpALASGADLASPGMIGQQMSLFPMASAIGMVVGPMLGGIFATQFGFASPFYLCAGMMAAVGVLIMRLR--
     623 UniRef50_C3X464        AraJ protein n=33 Tax=Bacte...   142     2e-32  1  14.4% 11:391   1:377     ----------MKKSLVALAAGTFALGIAEFVMMGLLSD-VAADLGISIPAAGHFIAAYALGVCAGAPLL-VLIARTRPLKQILMGLAALIVLGNLCTAFAPGYEAMLATRFLSGLPHGAFFGVGSIVADRLADKGKG--AQAISIMVAGMTVANVLGVPLGTHISHAFSWRFTFMLVSVWALVLLWLIWRWIP--VMEALPDTGLLGQFRFLRRLPPWLILFATALGNGGAFCWLSYINPLMTEVSGFAPSDMTLLMMLAGLGMLAGNLAGGRLSDRFSPGEVAYLSQGLMCLALFSIFfaGNPVASVILMIVCTTCLFTVSAPQQLLLIRNAKGGEMLGAASVQIAFNLGNALGAWCGGliKAGFGYPYTALPASFLALAGCVLLLYFWR-
     624 UniRef50_A1HSG5        Major facilitator superfami...   142     2e-32  1  12.9% 11:391  15:423     ----------RHIVLIMLWLLYIINYFDRISVLTFLPL-IRKDLNLTHQEIGFAASIFFFAYALAQVSAGYLADKIGPKRVM-GIAIVVFTAVTFLTGMVRNYIQFVLLRLGLGLGEGHHFSPANKTIADWFPKSEKGRATAF--FSTTWAFAPAIIPVVITSIAAALgwRTIFYILAVPGVIGIFLLYYFVSDKPEedEAAVEKLGVSVILKDQSLWMYSAQLFCLLAVYWGSTTWISSFLFEQHGFSLAKMGALSALPYVVAIVSTMCGGWLMDkhRTKPVALISFLVSIPVLMYLGQVpnINLLIVMLILNGFFVNLIWGVIYAYPQVRYPKEvgSAIGLANGIGQLGAFLSPLLAGYLVEKTayDKVFFMFAACSALGALVTCLLKE-
     625 UniRef50_A9HWU1        Putative transmembrane tran...   142     2e-32  1  14.5%  6:392   5:396     -----SLSRSLPGWLILMGTLTAIGPFSIDMYLPAFPA-MADSLQVSRGEVERTLAAYLIGLALAQVVYGPLADRYGRKKPVL-AGLALYTVASLGCALAGSVQMLILWRVLQALGGAAGVVIPRAVIRDHY--ETQDAARAMSLLMLIMGLAPILAPLAGGQLLAVMGWRSLFWLMAAGALALMAATALIMQESLAPERVQPlaRNYAALLCHRGFMAHSLAGGFGQAGMFAYIISSPRLFIELYGVDPQHYGLLFGANAAGLIIGSQVSARLLRTYTPLQltALAVASLAALALALAGLMTLPLLMACLIGYMFSQGFVNPNSAALALSEQGARLGAGSALLGTLQLSCGAAAGFVVSA-WQAAGPLPLATVLACCATLSWLAGRVARNL
     626 UniRef50_D2Q5M6        AraJ-like protein probably ...   142     2e-32  1  15.0%  5:390   1:388     ----MASHRLFTLPVAILVFQSFLLGTSEFIIVGVLPD-IASDLNIAVTMVGNLVAIFAFVYAPLTPIGAAICSKFQRFRA-LIALLLVFLAGNVICTFAVNYPMLLLARVVTASVSGVLVAVALTFGPDVTSRENQPR--YMSWVFSGFSIASVFGMPMGTWIAGLAGWRTSFVVIDVLTVVMIGVMFVVLP--KRSVPSQVGILGQFKLFSDRRIILGVLTVVFGLASSYVWYTYLTPMFTNELHVPAAYVSVALVAFGACCLWSNLYSGKLATRGTGIWPLVgaYALQFVCMLLLPFATANAMLgvLLVVLGLTIYLQNSPSQVLYSYVapGCGTLASSLNSTSCNLGIALGSAVGGVAYDAAGLRWLGPVGAVFAALAVLMTVLLK--
     627 UniRef50_D2PLY5        Major facilitator superfami...   142     2e-32  1  15.1% 11:388   1:383     ----------MPPAVYIIGLAIFAQGTSELMLAGLLPE-LATDLGVSIPQAGLLISAFAVGMLVGAPVLAVVTLHWPRRNTLL-GFLAVFALTHVAGALTPNYEVLLATRVVGAFVYAGFWTVAAVTALALVPAGRRAKAM--SVVTGGLTVATIIGLPAGTVIGQHLGWRAAFWAVALMSALAMIGVLRTIPPGTpaGERAPRLRTELQVMANARLWLAYATTALVTAAILVVFSYLAPLLTEDTGLPSGAVPGVLALYGVGSLVGITLGGRTADAAPFGTLAIGIAGVVALSTVLALWAAQPVIAISAIFLLGGFGFALNPALNARVFTLAERAPTLATAVNFAAFNVGITVGPWLGGLAIDaaGYPALGWIAAALGVVALSTVAL----
     628 UniRef50_A8LRQ9        MFS transporter n=1 Tax=Din...   142     3e-32  1  17.1% 11:391   1:376     ----------MDARLYYLTLGNVMIGTGTMVVSGIL-DPIAADLAISVSAAGQVTTVYALAFALGAPVAAAFTGRFDRSR-VLALSLLVFAAASLLSAVAPNYTTLLIARGLGGLAAATFSPTAVAVAASLVPPAERGRA--IALVFGGMTIASVLGVPLGTWIGLNFGWRILLAGLGVLSLGAVIALWRGVPGGL--FLPAATLARWDEALRLPIIRALLGVTLFQIGGSFVLFAFFGPYLGTVTGVGTDGIASLLFLFGLASLIGNFAAGWAVDRVGAGPVAHGAIALTALSmaLLGTAGAPVLAGLAIILWGSAVFGINTAQQARLVDAAPGLATVVLPANSSILFAGQALGAALGGAVLAMGGLAALPLVGALVVGIALVLSLRAMR-
     629 UniRef50_Q58955        Uncharacterized MFS-type tr...   142     3e-32  1  16.0% 13:388   6:382     ------------KNVFVIWITTFTTMLGVGFIAPIMAIY-AQTLGATNLEIGLIFGSFALARTVAQIPVGVLSDIYG-KKFFIVCGTFFYGVSTLMYNFVSTVLGFLIVRIFTGIFSAFVTPVAGSYIAAIAPKTRLGE--YMGIFNSAITLGFGIGPFIGGILADMYGIKMPFYFCGFLGILAAIISYMKLEdkEKIDVKKISTLFSFEFLKNRNFSSSFIINVSNVMINAGIYAYLALYAIN-YNITISQVGFMIALTNILMALLQRSFGKLYDKLGNIMIIIGIFIISF-GMYLLSTSTTFLTILASLTIIAVGSSISSTATTSLAVKDIPTHrgEAMGLFTTSINIGMFIGAVSFGFLADILGIANMYKFSAIFSIVVGIISYL----
     630 UniRef50_Q4KIS8        Multidrug resistance transp...   141     3e-32  1  14.7% 13:392  15:398     ------------RTILILGALSAFGPLAIDFYLPAFPS-MALAFGTDEKHVQLTLAAYFLGLSIGQLAYGPVADRFGRRLPLL-AGVGLFTLASLACAYAPNLEWLIGARFVQALGGCAGMVISRAVVSDKCDA--VGSAKVFSQLMLVMGLAPILAPMLGGLLVNLYGWQSIFIMLTVFSALSGLAVALGLPESMPATRPrgALRQYGLLLSDRVFLGHALTGGIAIAGMFSYIAGSPFVFIKLYGVPAEHFGWFFGINAGGFILVAQINARLLAKRGPAFLLARTVWIYLAAGLTLLGvsALWPLLLPLFVCIASLGCIIPNAAACAMNGQGARAGSASAMLGCLQFSVAAGAAYLVGVLHDGSAMPMAMVIS-LCGVLAVSMAVMTRRL
     631 UniRef50_D1BK34        Drug resistance transporter...   141     3e-32  1  16.6% 15:388  24:403     --------------VLMLGALAALPAVTTDMYLPSLPT-VVQDLGTTDTAVQFTMSGMLIGGAVGQLVIGPFSDRYGRRLPLLI-GISLHVLTSLLCAIAPNIGALVALRVLQGFFNAAASVVAIAVIRDRFTGSE--AARLLSRLMLVIGVAPLLAPSLGQAIAGAFTWRAVFVALAIIGALLVVIVWFWMPETLPHERRrgALRSYLELLKDRHFLALAVLPGLGMAVIMSYVVGSPFVFQQEYGLSPTQFSLLFAVNGVALVLSAQLNASLVRRVAPIRILRVAIVVQLMLSLVLLVvgGVVGVLAALWLVLGMQGLIPANASVLALGGYGHMAGTAAALIGSMQAGIAGVVSPMVGVLGGDSLAMTTVIISVILVSLVVLATAT----
     632 UniRef50_Q2S7K5        Permease of the major facil...   141     3e-32  1  12.5%  9:391   7:388     --------RQFWLATLALCIGSFMTFANVYITQPLLP-MIADAFDLTVLEANGSFTITTLMLGLSLLIYGPLSDAVG-RKSIMLISLVGATVCTLLLTQVESYSALVALRAAQGFFLGGLPAVAIAYMGDEFSPKALL--FAVGLYIGGNSLGGIGGRLIGGFVGEAFSWRSAFVAMTIVSVLCLIVFALMLPNSRGFTrpRQMLADLGGHLRNPILLTCYLIGGLNFFIFINQYSYIIFVLEDAPFNLSAQYLGLLFLTYLAGTVGSSLSGKIVLKVPQPLCIALGVAILMSGT-LLTLAQTLPTIIVGLLINSFGFFLAHSSASSLVNRSARGAKASASSLYLVFYYLGASSGGFYLHPFWSAMGWDGVVLGSMLVLTGVLGAAIWLYR-
     633 UniRef50_Q0BE71        Major facilitator superfami...   141     3e-32  1  15.3%  7:391   1:386     ------MNERMPFVIYVFALCAFALGFTEFVTIGLVST-ISADLHASVAQVGTAVTAYALGAVIGAPGLTALATRWPRKRLLLVA-MGLFTLGNAVVSLSDALTPMLVARFASGLGHGVFLAVASSVATQLAGRHRAGAA--VAVVFGGLTLALALGVPLGTYLGSVLSWQVIFMAVAASGAVGFLGLLALMPTDRDDASAQANAMDGLKAMFNPRLLAGAGITVLAYAGSFALYTYISPILLQVTNVSESTASLLMLGYGVMAAIGNIWGGRLTDRKGAdaVMTVLVGLAVVLSAIWASAPSLPLMVLLTGLLGALTYAAVPALQARVIGlaPQAPAVAAGLNIAGFNGGIALGSLLGGASLEAMGLTSTAWVGAVAVGLGIVWMLWQMR-
     634 UniRef50_D1BEI5        Arabinose efflux permease f...   141     3e-32  1  15.4% 23:391  37:400     ----------------------FTIGTTEFATMGLLTD-IATDLDASIPAAGHTITAYALGVVLGAPLITVLAAKVERKR-LVVWLMVAYAIGNLLSAAAPNLETLMLGRFLTGLPHGVFFGTGAIVGTAVVGHARRGHA--VAMMMAGLTVANIVGVPLSSWVGQNLGWRVAFVGIGVLGLVTVVGLLALLPRT--PAATGASARKELGALRNGPLWIAFAGCAIGFGGMFAVYSYVKPTLTEVTGLSVASVPAILALFGIGMTLGVLVGGRLVDRDVLKTVYLGYVSTAVALVAFGLVGHSPVPAVIALFAIGVTSQILGIALQARLMDLSPAAPSLGAALCHSSLNAANANGAFLGGliAAGWGYLSLAWAGAVLTVLGLAVIMLFGR-
     635 UniRef50_C0VIP4        MFS family transporter n=1 ...   141     3e-32  1  16.8%  6:391  15:395     -----NPSQGNWFALLSVTLSAFALVTGEFLAVGVLNE-IARDFQVSVGTAGLTVSLTAIVGMFAAVLI-PISAKTLDRRTLLLLLTLLMILANFITAFASNFALLLFGRIILGIAIGGFWATAVALSGRLAPPH-LPIAKATAWVAFGVTLASVLGVPMGTWLAQYNGWRTSFTVISLMGILLFIFQYLYLPQLKPSSSLR--WKELPILVQHPAARKGLIIFIFMGFAHFAVYSYFSAFFKHQIDFSDGLISRLLLVYGIAGIFGNIFAGYLGQINIRYTFAVSGFAFFLAFLSLPMFGAHIMTAMVLTALWGFAYGIIPTAVNIWMFTHAPEAVEKGMPMVTLTFLILIALGSMFGGIIVDHFNGTILFFAMLPLVLCSLVLIFTLAR-
     636 UniRef50_C6CZF3        Major facilitator superfami...   141     3e-32  1  12.2%  7:390   1:394     ------MEKKKRLDLASIATIPLTMTLANSILIPVLPS-MQKAMGITTVQSSLLITAYAAVAILFIPIAGYLSDRIGRKKVILPGLLLVAAAGAFCGFAAVSfaLVMTGRLFQGLGAAGCFPVVLPLVGDLFKKEE-DVSNGLGLVETANTFGKVLAPIIGSALA-IWTWYMPFWFIPVFSLISFLLVAIWVKAPKDKKPAVPFGQFVRDVikGRWIWGVYVAGGINMFAIFASLFYLSEILEERGSHGILK-GCLVAIPLAALCSTSWAIGKWIgkKLMKWISVIGFIEAGGSLLFLAFGgsLWFIIIILFAGSIGLGAALPSLDALLTeiEKEQRGTVTSFYSSIRFLGVAAGPPLAALLIEHSKSSLFWLLTVCCAAAALIALFTIK--
     637 UniRef50_B3PK65        Major facilitator family tr...   141     3e-32  1  16.4%  7:389  31:416     ------PVPFERKVVLSLAALYSFRMFGLFMLLPVLSVYGSDYADHSPFLLGLALGAYGLSQALLQIPFGVMSDRFG-RKPLILAGLLLFALGSVVAAMADSVYGLILGRFLQGC--GAISAAVMALLTDLTSEENRTKAM--ATIGASIGMSFSVAMTLGPVLAAWGGVGAIFWLTAGLGLAGVYILLAVVPNVSVTAAPRREAValWHTLSHPELRRLNLGIFVLHFVLMANFVVLPLVLQNQLAIPRNYHGFVYFPLLALAFMLMLPFVIIAEKRRQIKPVFLAAIglVSELLLVWLSHSMIPALLVLFLFFVAFNLLEATQPSLVSKIApgAKGTATGIYATCQVLGVFGGGALGGWLlqQLGVAAVFMVNAALTLLWLLGAWGM---
     638 UniRef50_C1SLM4        Arabinose efflux permease f...   141     3e-32  1  14.9% 18:386  10:376     -----------------LFFINFCITLGFGVLDSFFSLYVIST-GVREVMLGIPFAFYAVTKIFFSVPLGALSDKIGRKR-VLSFAIITYSFVSVSYLFYPGLEAAVILRVIQGGACAMFRPVMLSYIGDMTESGKRS--TVTGTFDISFYGALGAGPVLGGFIRNYYGFNGVFVFLSLLCFISLLVTLFYIKDTGqtGNQSGGMNGLPVSALSRNTKALLVFIFGRACGISAIAAFMPVYFEKNLHFSSLETGFVLSVSMVFMTVCLRPLGKLGDVVPRSFLVVLGGFAVAVTYLFLPFAVNFTDVVFICIFTGVFGALSQPSSTALLLDEGGKamGRTFGYFNLFMNAGFAFGALTGSVLSGIFGVNAVFCFAGVVGILSTAVF------
     639 UniRef50_C5CRU0        Major facilitator superfami...   141     3e-32  1  15.4%  8:391  22:399     -------ARSAWLAVGSIAVGTFAMVSTEFMPIGLLTD-IARGLNVSDGTAGLMITMPGVLAAFAGPALIVASGRL-DRRTVLIALTTLLIASNLLAAFAPNFATMLVARLMLGLCVGGFWTFAPAAATQLVPDA--SKARAMSLVLAGVSAATVLGVPAGSFLGTQFGWRASFAVTGALAAAVLLVQLWLLPAIPPV--RAIGARDLLTPLTRRMAQVGLLAVLFFIAGHFAAYTYLKPLLQQVFGLAPNSVSTLLLVYGAVGFVGTFLGGSLVARSVRGTTLLAALMLATALLLSTVIGSGFVPGAVVVVIWGVAFGLIPVALTGWMMEAVPDAPEAGQALLVSGFQVAIASGALIGGVTVDNHGISSAMVLSGVLVLIAALIVSTLGR-
     640 UniRef50_Q01PG3        Putative uncharacterized pr...   141     3e-32  1  14.3%  7:390  13:409     ------WAPLRRPLYRYRWIASLVSNLGSWMQDTA-GTWLMTALTTSPLLIALMQTAASLPILFLGLPAGATADIFDRRRLLIFWQSWMLATVAILSALtvSPATLLVLTFLLNIGSAMNNPAWQAIVPELVPRSELPDA--IALNSAGFNLARAVGPALGGLAVGAfgAAVVFLLNSASFLAVIFVLYTWKRTppSERMFGSMRSGVRYVRHSPPVRAILLRAFLFTGFASAVWALLAVVAQQDLQTGAMGYGVLNGCLGAGAVIGAALLPRVRRTLPAEWMMAGTGLIFAGTLASLALTRSVPLIVVGLVAAGCAWTTTTSTLNIAVQTSVPDwqARALGTYQMVFAGGMAGGSALWGLVAEHFSNQTALLAAAAGMLIAVPIARRFP--
     641 UniRef50_P96709        Uncharacterized MFS-type tr...   141     3e-32  1  16.1%  9:392   8:398     --------KERLALAFLLGMLAILGPLNIDMYLPSFPE-IAKDLSASASLVQLSLTACLVGLTIGQLIVGPVSDAQGRRKPLLI-CIFLFALSSLFCALSPNITTLVAARFLQGFTASAGLVLSRAIVRDVFTG--RELSKFFSLLMVITAVAPMVAPMTGglLLPFATWHTIFHVLMIIGFLLVLLIALRLKETLPLEKrgTSVKTMGSLLKDRSFMGYALTVGFIHGGSFAYVSGTPFVYQDIYGVSPQVFSILFGINGLAIISGSFIIGRFGGIIHEKSLLRIAVITAMIATAVLLTMtpLATLVISIFIYMITIGMVLTSTFTLAMEKQGHRAGSASALLGMLPLLLGSIVSPLVGINETTAVPMGAIMFVTAVIGSLAFFGLTKERV
     642 UniRef50_A8FPY6        Arabinose efflux permease-l...   141     3e-32  1  14.7% 17:389  22:396     ----------------LLFVINFIVTLGFGICDTFFSVYVF-ELGGRGALLALPLISYSVAKAVFSPFMGRCSDTFGPEKIMLV-SLTIYLLVSVLFLVSTNLFILAISRLLQGVACAMFRPVIVSLVSESAIKEKRS--SIMGTFDISFYAALSFGPIVGGYMKDQLGFSAIFSGVTLLCILAILLCTCCVRDSSARVATTHSSRniQPIIRSRNLRGLLAFIFGRASCISLTGTFLPIILTEELKLTGTQIGIVMASSCLTITLLLRPMGMLADRVSHAILIILGGISVSIIYLIIPATLTFTQIIFATTLLGLFSALSQPACTAMLVEEGThgTGNTVGIFNGAMNLGFIFGPIFGAFILSGFGIDAVFYSAGVIGASTILLFALI---
     643 UniRef50_A8GB47        Major facilitator superfami...   141     3e-32  1  58.9% 11:392   1:381     ----------MNSIRLTFMVVAFFSGIAGALQIPTLSLFLTTEVRVTSLWVGFFYAVNAGVGIIVSFLLAKKSDRQRDRRHLILICYLLAAGNCLLFAFNRNYLTLITAGVLLTAIANTAIPQLFALAREYGERSSQNVAMFSAIMRAQLSLAWVFGPPLAFMLVVNYGFTAMFMFAAGIFLLVTLLAWWILPEVTRPPVGNEIAIPQKTVF-DKDVSRLFFASVLMWTCSAMYLIDVPLYITAELGLPQSLTGWMMGVAAAIEIPIMILVGRYVNRVGKRLMMAGAMVAGILFYAGMLWFTSAAGLLVWQLFNAIFIGIIATVGMLYFQDLMPERAGMATTLFTNSISTGVILAGILQGILTEYGPHSSVYLLAILLLCIALPVGFKTREV
     644 UniRef50_D1BKY2        Major facilitator superfami...   141     4e-32  1  13.9%  6:372   4:367     -----AKEALWTKSFVLDTLINFLVFLIYYLLIVIIAVVAKDNLHATASQAGLAVGIYIIGTVVARLLAGRFISILGCRK-MLYLGLLIYLISTAMYFYTPNLLMLDSVRFLNGFAYGITSTATSTIIAAIIPTSRRGEG--INYYGLSTSLAAAVGPFLGILMLHSLGYDFIIAFCVALIIFCGIGSVIMKFNEPKLGIESEAHKGIrsDYIEPRMNSISLVSILVGFAYSGVIGFMAAYTKD---LDLIMAgfFFVVYAVVITITRPLLGIVFDMKGENFVLYPCFVSLALGIFLLSIAHSTWLVLLSAVFVGLGYGTFMSNGQAVTVKIVphRIGVATSTYFIALDMGLGFGPYILGAVKEVVGYASMF--------------------
     645 UniRef50_Q4A0T1        Putative permease of the ma...   141     4e-32  1  13.1%  8:390  13:394     -------SQAYIKIIVALFISGFTIFSILYSVQPLIPHF-TNAFNVSETVASLALSAATITLAIAMLFFGALSEVLG-RKPIMIFSVISVSLLALVQPFILDFNTFLIVRLIQGICLAGLPSIAMAYIGEEISSHNLPEAM--GIYISGNAFGGAFGRIFTGFISSIYGYQTGLISIGIISVIAAILFTFLLPASNHFEKQraLLVSYSKHLKNIRLLKPFMIGFLLLGCNIAAFNYIGFVLADeyHLHDSVISFVYLLF-LIGMISSILNAKLRAQLGTLNALKFSILLLIFG-IWITLLPPLPFKILGLAFSVYAFFSGHAIASAVVTSRAEDHKAQASSLYLLFYYMGSSVGGTLAGIFYGAIQWPGVVLMITAFMIIAFIIALTIK--
     646 UniRef50_C6CWE1        Major facilitator superfami...   141     4e-32  1  13.7%  9:373   2:364     --------KKENLLIFTFTLLAFILGTTEYVIVGLLTP-IASSLGVSVAQTGIMVSGFAIAYAAGTPFVMMAAGYFTKRRALLLGASLV-VLFTMGSALSFSYPVLFLTRMATAIFCGLSISLAVSICSDYVSPERRGLA--LSYIIGGFTIANVLGVPIGTFVGLHFEWPAAFWLVAACGIISILLLYRIVPRNLPAVQ--SSLKNQVRLMRNPRVLLAFFIPIIGVAAIFVIYTYINPLMLEVMHISEGRTSTILLVYGAVTIVSNILGGKIASGTYMAKLKTLFLVHAVVYVIFGFTLSFTWLGIVSLMAIALISFSINAACQLYFIHlvPEAKDFASSLLPISANIGIAVGSSVGAFVTDHYGLRYLPW-------------------
     647 UniRef50_C8NNU0        Permease of the major facil...   141     4e-32  1  16.0%  3:390  30:411     --KTATQPRLFTPTFALGWLVNFLFFLVFYYLITVMALYAVREFAASDLAGGFASSSFVVGATIARLFAGYVVDRFGRRRILLI-SAVLAVLASSLYLVADSLVFLIAVRMLHGLAFSLASTSVMALVQSVIPAVRRAEGT--GYLALTTTLAAAVGPALALLLVDAYNYDVLFWVALATSVVSLLVALFL--RDPAGDGGNTSIRWSLKTVAHPAVFPIAMFMLIIALCYAGVLTYINPYAEERGLITGAA--FFFIAYAAAMLLTRPFLGRIQDRHGPTPVVVFGLIWMAVALVILAVAETDWLVILAGVCTGLGYGTLMPAAQAmvRAVAPHQLGTALSTLFLFVDLGFGLGPILLGVVLGWVGYGTLYLILSGGVVVAGCYYLAIR--
     648 UniRef50_B5JM03        Transporter, major facilita...   141     4e-32  1  13.3%  1:390   1:435     MSLATEKPPVKSLSLGVIFLTIFIDLVGFSVIFPLFPSMLDYYLELDGQHggVLGSLYAALQFFFAPLWGSLSDRKG-RRPILLITVSGTFLSYVLWLFAGNFALLIIARIVGG-AMSGNLSVATAAVADVTTKENRSKGM--GMIGAAFGLGFVVGPAIGgvMLNPLDwsTVAAVACLLSLVNIIWIRARFAESLPPEARGDANFVTNPVKrtPPVRRTNFAYLVYILAFSGMEFTLSFLGVERFGYTPVDITKMMIFIGFILIVVQgiVRRLAPKIGEKATALSGLVLVSIGLGFLSQASNQAILYTGLGFMALGAGLCSPTLTSLVSLYapQEQGRALGVFRSIGSLGRAVGPIGASFIFWWFGSDNLYLIGALIVAIAALLCLRLP--
     649 UniRef50_Q2RRA5        Major facilitator superfami...   141     4e-32  1  12.7% 11:389   1:373     ----------MPIAVVALTFATFGICTSEYVIMGLLPE-IAGDLAISIPQAGLLVSLYALGVVVGAPVLAVLTTSWPRRKT-LIGLSLVFLIGNLLCAIAPTYGLLMIARVITALCHGTYFGIASVVASGLVAPERRARA--IALVFMGVTLANMLGVPFGTAVGQALGWRATFLGICAINLVAILAQVLWIPKALP--TRPSSLGAEFRSLIDRRVALSLLLSMLSSVSLFIVFTYITPILRAVTGVSPQGVTYILLLYGVGLSIGSVIGGRLGDRSLMGALGWLMIGLTAILATLPFTLGLPVYAVASLFLWSVLTFAICPMLQTLVIDHAKGAPNLASTFNQSAFNLGNAIGAWVGGLLLNAGVTLDALPFASTLVAAFACLIIVV---
     650 UniRef50_B2T8G3        Major facilitator superfami...   141     4e-32  1  19.1%  8:389   7:392     -------TSALPAPIYWLALGAFAIGTEGFMISPLLPG-LAADLSVKIETAGQLVTVFALAYGLSSPVLTALSGNL-NRRTLLLASMIAFALSNVLAMVAPNFWALMGARVLLALSAGLYVPGANALASAIVPPERRGRA--IAVVNGGITIAIALGVPLGAVVGHALGWRMTFAGVAGLAMLAAAGLVVGLPRDIGAGIPVATLRERIAVGRNPVVLATLLTTTLWATGAYTVYTYLSPFLASVTGLAGAQIGMVMFMWGLAAAAGVVTGGNASDRFGPLAVIVPTIALSGLAFAMLSiaAALIPVLVAIALWGVAHWAFYPAQQARLIDIAgkVAPIVLSLNASFMYIGFSLGAALGALTLAHGGVGSLGWVAAASELAAVLLTLAI---
     651 UniRef50_A4AIK4        Sugar transporter n=1 Tax=m...   141     4e-32  1  15.2%  6:392  12:397     -----SSQAFPWAGLFTLSALIFTSVTSEWLPTGLLPE-IASELSVTESQVGLLITIFAATVVISTAPLAALT-RNYSRKSLVIAVLLVFVVGNLLAAAAPNYAVLVIARVIGGLSHGLFWAVVGAYSAHLVPAHQVGRA--VAVTSAGATAAFVLGVPVGTALGHALGWRLAFVVIAVIILALTIMVVRVLPPVDHRhsTAEISIPLRKDRSVPGVIYVCILVALVMLGHNLFYTYIVPYLIGPAGVEPGAVAGVLLVFGAAGAVGLALAGLLVDRFPRSIISVTVALVAICAALLAMFPSEPWIMFPVIAVWGMAFGGVPAMIQTRLLQLapRMRDVGSAYLTTSFNIGIGGGALVGGILLDQYGILSLPVVDAVILGGAVVFAIVGGEL
     652 UniRef50_C6AA50        Multidrug resistance transp...   141     4e-32  1  12.3% 13:387   8:386     ------------PFIILIVCLSTGGLISTDIFLPALGE-MRQYYQVTQSQIQNAVAVFLLALALGQLIYGPLSDNFGRKKTL-LLGLFLWLFTTFGAIYTVHIHAFLVLRFLQGLGACAGLVLSRAIINDLL--DKKAAGKLYLIVFPFIGMSPALAPFIGGLLIQAFHWQATFIFLSFFIFLTILLCCFVLTETLPPQKRqgLMKAYLGVFRNKQFIFYALIPCFSYIAYFAYIVESPFLLT-TLGLSPIHISYSYIGVSLPYILGNLLARWFFERESMEKTVCRGYIIFVIGGVLFAvpWPLVTSFMAIAVLTFGNGFLLPLGTALAISSHPKASGAASGVMGSLQLGSAALSAAVIGKISGH-SPRAMATLLAVCCVIGFIIYI-----
     653 UniRef50_Q03BY7        Permease of the major facil...   141     4e-32  1  18.8% 10:387   2:375     ---------KERRLSFLFFLVMFVIGTDTFLVSPLLPT-LTQYYGISTSLSGFIVSAYAVGYMISALLIGPISDRHDRKR-ILVIGLVVFTLATAGCGLANTFAMMLVARFVAGVAAATAGPQIWAAIPVLFPKTQVVKVMGYAT--AGLAVAQIVGVPLGSYLA-VWSWRFPFFFVGVIALMLTMLVVRFMPSLNEVTTSRLATGIYRKLFQNKTVLKLLGAYLLFQTANFCGFAFIGTWFAKSFHLSVGAIGSFILLIGVGQFVGSLLGNRLVTWLGQPHAFLLEFLLFIAGYLVLPFTNSPLTATVILAFIYTIGGALLPLFMSTLQEHAGSARSTISALANAVMYLGEAIGGVIGGILiqFTGFSGIAVFTAIGASLAMLLYA-----
     654 UniRef50_B1KMK8        Major facilitator superfami...   141     4e-32  1  15.2%  9:389  26:418     --------RSEVRLIWSLSIASIVVYINLYLVQGILPL-IANRFDVAVSHGTLLLSVTSFSMAFSLLFYAVLSDRIGRRTPLLISLYLLLLSDLLMVFVAD-FSQLVTLRLLQGVLLAAVPAIAMAYFKDELSKAAMLKAG--AIYIAANSLGGIAGRLIGGALSLHFPWQEVICVILLVSFIGVVTVHCLLPAKGKSRHLPsdLTGFWHHLKDSKLRSIYLVGGLAFLVMVNQFSYIQLHLMSsfHWGRFQVTLIFLCY-LSGTLASLYSSRWIGRFGRARLFNLAILAMFLGGLVTLLNTTL-AICIGFLMSSFGFFLLHSGCNAWVAQRARVHRAKATALYLCCYYLGASLGGPYLLPFWQHWGWSGVVAASSIVLLVLAWVLHRL---
     655 UniRef50_C7PJ34        Major facilitator superfami...   141     4e-32  1  13.5% 11:389   1:375     ----------MKKSLFPLMLGGLGIGTTEFVMMGLLPD-IALGMKITIPEAGHMISSYALGVVIGAPLLVLMSGSYPPKK-ILIGLMIVFTAFNGLSAFAPSPFTLLLARFFSGLPHGAFFGVGSVVASRLADKGKQ--AQAISMMFAGLTIANLLLVPVGTWVGHHFLWRYTFGIVALIGVITLIFLKAWLPAL--PAEQEGDTRSQFQIFRNPETWLIILITAIGTGGLFAWISYIAPLMTNISRFPADSVSGIMVLAGFGMVVGNFIGGRMADKFDPAKTCAGLLVAMAITLTCIYFFSAipVSLVLTFIAGALSIALAAPIQILMIGTAKGAEMLGAGVTQAAFNIGNSLGAFLGGllIAGYGYNSPVLVGSLMAVGGVLFAVIL---
     656 UniRef50_C8S752        Major facilitator superfami...   141     4e-32  1  14.1% 16:392   2:375     ---------------ISILLSLFSVMLGVGIISPLLPV-IAENLQATGVWIGLIFASFSISRVLSLPLFGYLADKFSRKK-IFSTGLILYTIIAILYAFSQTKEELLLVRILHGTSSAMVIPIAMAQVATISNKNELGK--NLGIVNSSIFLGMAFGPLIGGVFADKFGYSSAFFAMSAFSALSFLIALLKFPEGNVVKRREK-----KRIRITKSVFTAVIYRILSSMGRGSVMSFLPIYLSAI-GMSLTQIGAVLFANLISSSLIQMRSGILTDKYGFVKPVWFGSFIGAVSLFLIVRVENYFEVLFLSILLGVSTAITLPAVSSLVAHEGVKLsgSYMGVLSASKSIGRAIGPVISGIIYDlfGVRLIFEVAAILTIFAALIYKRGVEL
     657 UniRef50_A7H2C3        Multidrug resistance efflux...   141     5e-32  1  11.3% 10:389   3:383     ---------NFNRTLLVCWFGVFTTSMGLSQIAPILPFYIKELGHVDTSEigLAFGITPLFMAIFSPLWAFLGAKYGYKNMLLRASFGMSVL-TLWLSFAHSALEVVFVRGLTGI-ISGFTSAAVVFIAVIAPKEKV--AYALGTFSTASISGSLLGPLFGGFVAEFFSISAVFDVVAFLIACSFVTIYFFIHERKIQKEAKKNTQKVKE--NKTFIIVLFITTFVMQFGTFGVMPILSIYVEQIhgNLALWAGIVVAASGISNLFFAPKLGKIADKIGPSKIIFGALIFCGICFYLQAVASNVYTLIFVRLLIGIGLGGLLPCVNALLKkvSAKNLSVIFGFNQTCQFLGNFCGAFGGGLMASHFSVEFVFTFVCLIFIINAFIFLAF---
     658 UniRef50_Q1MR37        Permeases of the major faci...   141     5e-32  1  13.0% 16:391   6:378     ---------------VLFFSISLLVVMGVTIPLPVLPA-IAQRFMLTTEQVSWVTVAYTSPGIIMALIAGVLADRLG-RKAVLVPGVLLFGIGGLLCAFSLNFTMLIIFRVIQGMGGGVIGVLYATLPADMYHKEDLPK--IMGQISAVASIGIAIFPTVGGLLGEIV-WHAPFWVSILAFPVAWLSFYLPLVKGSSSVKWKKYFIDTKEIITNQKALILFSLTFLSYCIYYgvNTYFPMMAHIRFYVSPAEIGNIFIILAIGIGMSAFSLGWLNNHVQFNILLLMAGFGYFLAQFSFIIMPSMKWMIVPLIFEGLAQGITLPIVAERIAILApnNRAAVMAVNGSIFRFSQSVSPLIFGLAWTLWGWHGPYILGVLFSILIISIVLFIVR-
     659 UniRef50_Q2IPM1        Drug resistance transporter...   141     5e-32  1  15.1%  5:348  20:369     ----PATARTHGRLAVLLAALSALGPFSTDAYLPSFPE-IGRVFGAPAVLVQQTLTAYMVPFSVMTLWQGAISDALGRRRVTLV-MLALFALASVGCMLSWRVEALVAFRALQGATAGAGMVIGRAVVRDLLDGAEARR--LMSRIALVFAIAPALGPVVGGWLHVWLGWRAVFGFLALFSAALCAWCWRALPETLPPAQRRpmLRGYREVLSNRAFLALVAGVTCSFSAVFLYIVAAPVFLLRHLGVGETGFLWLFGPISGGMMIGNWASGALAGRMTNQRTVAWGFGAMAVAALaaLHAPALPWSVLPLVGYVLGTSLAMPSLTLMALDLFPERRGMASSCQAFMQ--------------------------------------------
     660 UniRef50_Q8DTP7        Putative permease; multidru...   141     5e-32  1  10.7% 16:389  15:386     ---------------ILLFWCGLIVVASNYITIPLMSAF-TQQFHVSAEQTAWLGTSFSFAYALSCLLVGVLSDRFGRKR-IMVGGLILLSVITLIIPFGNQLSWLIMGRIMQGIAASSFAPVAVVYISEKFSKEI--KGTVVGLVSASFLISAIVGQIMSAYISRLLNWQAVFCTFGIIYLLTALILYSYASPVSNQSKgsQLFRHYWEILRKKNLIKLYLIALTLLFAFVAFYTVLEGYSVHTFHLSKDNIFKIRAL-GVIGMLFAPFADKLARKFDIKCLLILSLLFSFVSLFIIAFCPYLNVLIIMSLLFVAGISIIVPTLIILVGRFGQNQAGIAVSFYTFILFLGASFGPIAGVQLLTVLGAKATFLTLALLLLFSMLVAFTL---
     661 UniRef50_C7JDG5        Arabinose transmembrane eff...   141     5e-32  1  10.5%  7:388  17:393     ------PPHGRAAALFILTFGTFVVGTGEFAIMGMLPEF-ARSLHLSAADAGYAITAYALGVVIGAPLITILGARLSR-RELLLSLLVLFCFGNFLSICMPTPELVEVARFITGLPHGALFGISALVAASMVERSRRGWA--VGRVLSGIAISTLVGAPFSTFAADHFGWRVAYLIIGIFGCITFLGVWRYIPADQPNRKNSPLKE--VSAMGNTQVLLTLLTAAIGFGGMFAIYTYLTSILQNVTHVPEWSVMVYMVIWGMGMLVGANLGAWLVDRKLDLAAILALGGSAIVMLGFSTVLHQPLLLALAVFLIPTFVNGLGPALQTRLMDFAGDAQTLAASLNHSAFNIANALGAALGSMLLAhfGYSALGVGGAVLSAGGLVVYLL----
     662 UniRef50_A8AI28        Multidrug resistance protei...   141     6e-32  1  16.2% 10:391   9:397     ---------NWKRNLTVAWLGCFLTGAAFSLVMPFLPLYV-EQLGVtnMWSGLVFSITFLFSAIASPFWGGLADRKG-RKIMLLRSALGMAIVMLLMGLAQNIWQFLLLRALL-GLLGGFVPNANALIATQVPRNKSGWA--LGTLSTGGVSGALLGPLAGGLLADQYGLRPVFFITASVLLVCFLLTLFFTRERFQPVSKKEMlrEVVGSLKNPKLVllFVTTLIIQVATGSIAPILTLYVRELAGNVSNIagMIASVPGVAALLSAPRLGKLGDRIGPEKILITALIISVLLLIPMSFVQTPWQLGVLRFLLGAADGALLPAVQTLLVYNASNqaGRIFSYNQSFRDIGNVTGPLMGAAISASYGFRAVFCVTAGVVLFNAIYSWNSLR-
     663 UniRef50_B0T980        Major facilitator superfami...   141     6e-32  1  14.8% 11:388  22:393     ----------RWAAVFSVAVASFALVTTEFLPVGLLSA-IAQDLGVSVGAAGLMISLPGATAALAAPILTVLS-RTLDRRVLLLAMTACLIGADVVSALTPNFALMLAARAVLGVAIGGFWAVGAAVGGRLVGETQAGRAT--AIIFSGISLGALLGVPVGVFLGALSGWRTAFWAAGGLSLVILIAQAVWLPKLPG--LRAVQVKDLFGIFANRNARVGLLAVFFAVAGQFAAYTFVNPVLLDVTRLTPTALSQVFFAYGVAGFFGNFLGGHGAGKNVRAAKFVVLLALGGVIIAFAQLAAHPPAAILLLTAWGLVWGGLPILHQAWAMRASPGMAEGGSALFVSVFQGSIAIGSGLGGAAVETVGLVWGLTLGGLSILIALVVSVL----
     664 UniRef50_Q6WSB5        Putative uncharacterized pr...   141     6e-32  1  13.8% 14:390  22:405     -------------TMVVMVFAWAVDYIDRFSIGMALP-MIGAEFDLSKTQQGWLVTVFALVYMVCQIPAGFLADRYGSRGPMLVTLLA-WSAFTAMTGMAGTFGMLLLVRGLFGVCQGLFPAASFKAIAERTTPGNR--ATVTGVMLSAGGIGAGLAPLIVGPLLMAVGWRHTFFWMAGIGAIIGVVVWTLLPksLPRTEASTPEVSRKQVLKSFVVWKFTLLFCATNMLNYGLITWVPSYLLEARGLTLNQTGVLAAIPMLVSIGTTILGGWLFDKyhGRWYLGSIALVTVVLLILMVSADSTAEFTLYETLALAVFGMATMAVFGLPLRVLPTAvgIGMGVMNFGGQVAGAVAPVAMGWLADAFSYTAAFGFLIVTTFLTAVMAFWVP--
     665 UniRef50_Q39X76        Major facilitator superfami...   140     6e-32  1  20.5%  7:367   1:357     ------MFRGISGNVLIFGLVSFLTDVSSEMIYPLLPLFLTTVLGAGPAFLGLIEGVAESTAAFLKLVSGILSDRVRSRKGLVLGGYALSSLARPLVAAATAPSAILAIRFADRVGKGIRTSPRDALIADSTDPAFRGKA--FGFHRAMDHAGALVGPLIATLLLAWfdLRTVFWLAAIPGFLAVVLIIWKVRET---ARVRTGDGTFLRIVPHGDLRRFLLILFLFTLGNSS--DAFLLLRAGELGVTPARIPLLWAFFHLVKMAGSTPFGALSDRIGRRGVIVVGWGVYALSYGGFALAETEVACWLLFAFYGLFYAMTEGAEKALLADLAPSrrGSAFGWYNFAVGAGALPASLLFGAVWEKAG-------------------------
     666 UniRef50_B1HNW2        Inner membrane transport pr...   140     6e-32  1  14.8%  2:392  22:409     -MHHTQLSKRHWLLILTLTSLTFVLGTSEFVIVGILTD-ISSSLEMTNAKAGTLVSAFAITFAVATPLVMSATSHFPKRKWML-FLIASFIVFNALCIISTNYIMLLILRIMTAIVTGVLISLAMIVASETMPINKRGLA--ISFVFGGFTLANVVGVPIGIVISNSYGWNAAFMLTTLLGGVAFMASFFALPNGL--SQVRSSIRDQFSLILKPRILMAFFIPALGFGATYTVFTYLVPILKG-MGAPHNSISFILFGYGFISIFSNILAGKIANHNPIGRLRFVFLLQAIVLICLFWTTNQFILGLANIGLMSLMAILLTTSTQLYLIDLapSAKGLAASLMPVASNVGIAFGSALGGIVYHQGNLMNVTWVGGLVAVCASLLTFFSHHL
     667 UniRef50_D1Z179        MFS transporter n=2 Tax=Eur...   140     6e-32  1  15.4%  9:391   2:400     --------KGKTRQIAILVFGMFFLTLGFSIIMPILPYY-TQKMGASALELGLLMASYSVMQLIVTPFWGEMSDRIG-RKPIFLIGLFGYGISFIIYGFATQLWMLFAARMLGGALAGGMYPASLAYIADVTEHSERGK--VMGLLGAASGLGMIFGPSISGIL-SVWGLTVPFFVTAVAAFIFGIIGYFALEESRAVDVHHPVRWEKVSLLarSSTGILFVMMLLVAFLMSGFQTIFAYYMGGRFSlgPTAMAVLFTVMGVVGVLCqvLVGVLIARIGEARTVLAGMAVSAAGFLLINVSWELLTIMLSSSLIAIGVGLATPCLNSLASKATdeHQGAVLGVLGSYGAMGRIVGPPLSGFGFDINVDLPYFTSALLSAAGALVLYVAIKR-
     668 UniRef50_B5XTA2        Drug resistance transporter...   140     7e-32  1  14.4%  7:361   1:356     ------MPRVSLSWALILGLLSGIGPLCTDFYLPALPE-ITQQLQATSTQTQLSLTAALIGLGLGQLFFGPLSDRIG-RLKPLALSLLLFIFASAMCALTRDINMLIVWRFLQGFAGAGGSVLSRSIARDKYQGTLLT--QFFALLMTVNGIAPVLSPVLGGYVITAFDWRILFWTMAAIGGVLLVMSLTILRETRPAAATHTARQQRGqvLKNRRFLRFCLIQAFMMAGLFSYIGSSSFVMQSEYGMSAMQFSLLFGLNGIGLIIAAMIFSRLARRFNAESLLRGGLTLaaAIMLLFAWLQLPVLALVGLFFTVSLMSGISTVAGAEAMSAVDAAqgTASALMGTLMFVFGGIAAPLAGF-------------------------------
     669 UniRef50_Q0GQS6        Purine efflux pump pbuE n=7...   140     7e-32  1  11.3% 11:389   1:374     ----------MNFKVFLLAASTIAVGLVELIVGGILPQ-IASDLDISIVSAGQLISVFALGYAVSGPLLLAVTAKAERKRLYLIA-LFVFFLSNLVAYFSPNFAVLMVSRVLASMSTGLIVVLSLTIAPKIVAPEYRARA--IGIIFMGFSSAIALGVPVGIIISNAFGWRVLFLGIGVLSLVSMLIISVFFE--KIPAEKMIPFREQIKTIGNAKIASAHLVTLFTLAGHYTLYAYFAPFLETTLHLSSVWVSVCYFLFGLSAVCGGPFGGWLYDRLGSFKSIMLVTVSFALILFILPLStsLIVFLPAMVIWGLLSWSLAPAQQSYLIKIAPESSDIQQSFNTSALQIGIALGSAIGGGVIGQTGSVTATAWCGGLIVIIAVSLAVF---
     670 UniRef50_D2LZ29        Major facilitator superfami...   140     7e-32  1  15.2%  8:389   3:391     -------KKRKGLVILAISSIPLIMTLGNSMLIPILPK-MQSELNLTAFQVSLTITIFSVSAALFIPILGYLSDRFSRkpSLILYGTGGLLAGIAAGWFTNPYLWIIFGRSLQGIGAAGTAPIAMALTGDLFKGGDQSK--VLGLVEASNGFGKVLSPIVGSLLALWF-WYAPFLGFPIFCLISVFLTLFFIREKKKKKEAPPIGKYVKGLFsgRWLFTAYLAGATCLFTLFGILFYLSDVLEAQYDIVGVLKGAILAIPLLCMMTTSYITGSKIGkkRMKAFIVIGLLLMTASFSTLVFFSALVPFISVLVVSSIGTGLVLPCLNSLITGSVgaRRGFVTSLYGSVRFLGVAAGPPIYGWLM-AWNRNGMFLVTAGLTLLVCILCIFL---
     671 UniRef50_Q17YP3        Major facilitator family tr...   140     7e-32  1  15.8% 10:389  19:399     ---------RMFKKIFPLALVSSLRFLGLFIVLPVISLYADSFHSSSPLLIGLAVGGAYLTQIIFQTPMGILSDKIG-RKVVVVVCLLLFLVGSLVCFVADDIVLLVIGRFIQGM--GALGGVVSAMVADEVKEEERTKAMTImfIFISFTISMAIGP---GVVAFFGGAKWLFLLTAILTLLSLLMLLKV---KDAPKISYQIKNKIAYQPNSKALYLLYLSSFFEKAFMTLIFVLIPLALVNEFHKDESFLILVYVPGALLGVLSMGIASVMAEKYnpKGVMLSGVFLFIVSYLCLFLADslWLFIVGVAFFFIGFATLEPIMQSLASKFArhEKGKVLGQFTTFGYLGSFVGGVSGGLSYHYLGISNTSLVVVILGLVWGLSLFFL---
     672 UniRef50_Q21E97        Major facilitator superfami...   140     7e-32  1  14.7% 10:390   3:387     ---------SSRTALRIIFFILLLDIMGVSLLWPV-AAFIVQQYSNDAIMLTVLTALYSAAQFFAAPFMGRLGDSYG-RRPVLIISLLGSCIGYIMFGVGGALWVLLISRLLDGF-TAGNQSVAGAYIADVSTPE--TRAKNFTLFGMAWGVALVAGPALGAVFGE-ISLAAPAFLAATLCLLAALLSYFYLPESLARENRNspFTTIIKLLSKPVLGSIFVVLILFNFVFNGFSSTESLYLVEKFSATPLQLGGLLTFAGLSLVAIQKILPPLIKRFGHQRVAVVSLIALAIMATITSITPAFNLLFGVVSLRTMAAGFLFPILGALMSSMvpKEQGALMGVNTALHSATYVFGPIWAGLVYDHLHASSPYWLGAVILLLTALYLSRVR--
     673 UniRef50_B3WA74        Permease of the major facil...   140     8e-32  1  14.8%  8:386   5:389     -------KSYQKKVLISSMLGLGLEGMDILLLSFALSSII-REFHISSAAGGVLPSITNIGMMVGGVIFGYWADRKGRIK-IFTYTIFIFAIATLLMAFARSIAEIYVLRFIVGLGAGGEYGIGMALVAEAFPKERRG--QMSAWITVGGQMGTLVAALLAAIVIPLAGWRAAFIF-GVIPVILAYFVRRHLPETKskHVRPRMTLLMNTPKTALITLGLTIMSAVQVAGYYGLMNWLPSLLEQKQGLSVSGSSLWMISTIIGMSLGMLSFGKLFDKFGSRTTYSVFLIMSGLSVTLYTFVHSAFLMLLIGAIVGFFANGMNAGYGALISSFYpeIRSFANNAIFNTGRAVGGLSPILVGYIIDRSGFSAALLCLGALYLISLVIV------
     674 UniRef50_Q5P2X2        Putative uncharacterized pr...   140     8e-32  1  14.3%  5:389   1:381     ----MQPTKLWTRDFVIVFAVNFFLALVFYMLIVVIGAHAMQEYGSSLSQAGLVAGIFVIGTLLGRLIIGQFVDALGRKKTMVI-GMIAFTITSGLYFLSDSIATLIAVRFVHGLALGVASTAAGTAVAHIIPRDRR--AEGISYYSLSTTLSAAIGPFLGVWLLQHTNFNWIFAACIAVAILGLLAAMWAQVPEGASHAGLRGFQFSLANLVEARAVPISVVTFLYGLCYASVLAFINGYAVELNLVTA--ASFFFIVYSAVVLLSRPLTGRLLDRKGSNMVVFPSCLLLALGLVVLANVQTGMGLLVAAVLIGIGFGNLQSALYAVAVkvAPQRMGLATSTFYISMDASLGFGPYLLGLAISEIGYRSLYGSMAALAVLGMPVFYLL---
     675 UniRef50_Q1QFJ1        Major facilitator superfami...   140     8e-32  1  14.1% 10:391  15:396     ---------RRERLLRMLAAATFIIFFQAYMVAPIIPA-LSNAFGTSVQTVGLIVPAYLIPYGIATLAYGILADRLGYPCVMFVSLMAFSAL-TMLTATAQSVEQLALWRTVTGIGASGVVPLALALVGRLYPYEQRGR--PLGWLFGAMAGGMAFGSPLGAMIVPFVGWQGLFVVVGAVGAVLLLVLLPYRSVIAATAQsrDLVRGYKDLLGTPRGQRTYGYVLINSIFHSGVFTWLGVYFEQRYGVGPIGIGLALLGYGVPGLLFGPLIGRAADRFGRARLIPIGLLLSTLAAAALMLGFPMVLAPVVAMVLSLGYDMTQPLFAGIVTSLGGKRAGQAMGLNVFMLFVGFGLGSLIFGELL-RYNFAAALGVFAVVEMILALLSLALFR-
     676 UniRef50_B9JRB5        MFS permease n=1 Tax=Agroba...   140     8e-32  1  13.0%  7:384   1:384     ------MNRKTLFLAISIGMICAIGPLATDMYLGAMPL-MATSLSTTAATIQLSVMTFFSGFTIGQMFYGPISDRTG-RKPIIYVALAIFCLSSFGCLTASTGEQLLVWRFMQGVGGSIGMVIGTAIIRDTHTGP--AATKLMSMVMLVIGVAPILAPFAGSLILKIANWQMIFVLLGCYAALCFVVVALWLPETRLPADRASSKPsyGGLLISRNFIPYAGTMALVQGGFFAYIAGSSFMLMTVYGLSAISYSIIFSTNAIGLGIGTQICNRFATRFGVKAAVRGSVLLYTVIALILVatDSLTVTCILMFILVMSIGGIMPGCNVLAMEAHGSIAGTAAALAGGLSFGAGALSSFVLGLLENGTALPLVCVMAGCGILAVLV--------
     677 UniRef50_B9M8N1        Major facilitator superfami...   140     8e-32  1  13.8%  1:391   1:384     MAHTGTKEILWSRTFTLTTLGMFFLFIPFALYLPVMPVYLLKELHSSMEAAGAVNGIFLIAAVLFRAQTARLEGRFGSRRVLLASG-FLFVATNLLYLSATTVAGVMLIRFFSGACFAVANTGIQAMGSRLIPRSRVGEG--LAYITTMVLAGGAIGPYLGLTLSQTLGYRAVFILSALVSLLGMLILCAM---TIPDERPQIKRGFSFHDLYEWKAVPVSLIILVIAIAYGGVLTFVAVYAAELR--LTAAANYFFVVMAAASVAARVTTGRMYDRFGPDAAIYPAIVLMAAGLLLMGCIHSAAGLLSAAALIGVGYGMAVPSIQTLAIQISPPHRAsvTATVFTCLDGGVGLGAYLLGGSILAFGYANVYLALGLLTLACTCFYYAMRR-
     678 UniRef50_Q4KEU2        Major facilitator superfami...   140     8e-32  1  13.6%  7:387   1:377     ------MNSRQHCARIALFLCGCAAFLNLYATQGILQEF-AQSFQVSIREAGWSITVTTLAVALTAPFVSRFTGRFDQRRVIVVAALLL-AVPAGLAAYAGSFTQLLVWRLVEGMLIPVVFATSVAYIGDRWSGGTVTEVT--SLYVAGTVLGGFAGRFVTGFMTEYVGWREAFALLAGLSLLIGVAIHLLLPANPptAPRASGGLSALRELCRRPLLAAYGVGFCVLFSQVATFTYAGLYlqAPFDLGAAALGAIYSVFLLALVVI-PIAGRLS-KSRPQAELLVAAALLGVCGSALTLLPSLWLIVLGLALSSTGVFLAQAAANSFTTATARHNKAGAVGLYLTCYYLGGSFGAVVPALLWSHWGWQGCVALIVLFQLLSLLIAW-----
     679 UniRef50_Q67KW6        Multidrug efflux protein n=...   140     9e-32  1  16.9% 17:389   1:390     ----------------MLWVGNFLTACSFSLVMPFLPRFIA-ELGVTatWSGLIFSVTFLSSSIMAPIWGNLADRYGRRPMLIRAGVAISIV-YLLMSFVTSHVQLFWLRLLNGAFSG-FIPSAVALVATNTPEDRVGR--YLAILQTGMATGTILGPLLGGTLAELLGIRWTMRVASVLVLISVLLVIFLVRERvaGKARTSVLSDLKLAVSNRRLLALMISALLIQASLQSLQPILSNflFGEGEATDFVVGFVFSLPAIATVLTAPRLARAGERIGFARLLSAGLLAAGLLILPQSLVQSIGWLILLRFVFGIATAAVQPSVNAALAEVvpSFRGRAYGINTSANNLGSVLGPSLGGWVADAFGPRAVFVVTGLVMLAASAWVQRM---
     680 UniRef50_Q3K5E1        MFS1-family membrane transp...   140     9e-32  1  16.8% 11:391   1:379     ----------MPLALLALAVAAFGIGTTEFVIMGLLPD-VARDLAVSIPHAGLLITGYALGVVFGAPIL-AIGTANMPRKATLLGMTLMFILGNVLCALAPNYATLMAARVVTALCHGAFFGIGSVVAAGLVAPNKR--AQAIAMMFTGLTLANVLGVPLGTALGQYAGWRSTFWAVSVIGVIAALAQWLWLPKHIPMD--KANLASEFKVLGKVNVLLALGMSVLASTSLFSVFTYIAPILQDITGVSPHGVTVMLLLFGVGLTGGSMLGGRLADSRLLPSLVGVALAVVVILAAFSQTSRSVVPAAITLVLWGIFAFALCPILQLLIIDQAHEAPNLGSTLNQSAFNLGNAAGAWIGGLvaDLADLPWTGALVGVLTVLTALFFIYLQR-
     681 UniRef50_A1SXQ3        Transporter major facilitat...   140     9e-32  1  34.3% 19:391  11:382     ------------------LLTCFFIGLSTAFIYPLLSLYLIEEVHATPISMGILITCMVLSGVLVSQYIAKKSDQGLSRKYIILAGQVGFIITTIFLAMSQHYYTLLFAVVFFMPFSAACLPQIFSMGRHFADKQLADKATvmTMMRATMSMSWVIGPPVAFLINDAFGFKQTFLLAGFFAVVVLIIVCVGISNVQIEKVKSAPKNVNWS--KISGVLFFLICIFFIFTANNMYITSISLYITQALDFDSKWVGYLMGTAAFVEIPIMLGAGYLAPRFGATRLINIAIISGLLFFAGLLVAEQLWQFILLQLFNGVFIGINASLGMLVVQDMMKKQIGLASTLFNNSLLLSVLLSSLLVGGIAQYFSYYAVFVVSALFCLIALFFMRLAER-
     682 UniRef50_UPI0001905CAE putative multidrug resistan...   140     9e-32  1  14.7%  9:390  34:417     --------SRKQPKLAVLIFLAALSVLPLNMFIPSLP-HIADALNSNYAVVNLAIAGYALMSALTHVVAGVLSDRFG-RKPVVLVALCVFCGASLICSFAPNVGIFLVFRTLQGVVIACY-AVSMASIRDTS--DEREATSRIAFVSSAWALAPMLGPAIGGTLDTLLGWRANFTAFAVLGLSGVVLVLRGFKETKASDLPAtrLSTYLAPMGSRIFWGYAICMVFSMSTLYIFLSGAPLAAKSFGVGSSIAVGALMGLVPAAFILGSMFAGRFGKKYAPPVLMAVgfGLSAGILLFFFDVHHVAAFFLPCAFVGLGNGITMPAANAGVLSLRSELSATALGLANATTVAGGAAIVSISGMFITAADAQwtIALMSATTFISLVAALIVR--
     683 UniRef50_C6D6Y9        Major facilitator superfami...   140     9e-32  1  18.2% 16:388   6:374     ---------------VLFFLVMFMIGTDTFLISPLLPT-LQAEYGVSTGIAGWMIGAYTLGSALFALVSGPLSDGW-NRRTVMICGLAAFSVSTALCGFADNYWMMLLFRFLAGVSAAFTAPQVWASIPAVMPPQRI--AKTMGVAFGGLAAAQALGVPIGSWLAAA-DWPVPFWSIGAFSLLLAVAAFLLLPDMKPNGQSrsIFSRYMPLITNGRTRGGFLAYLLLHLGSGTAMAFIGKWMADHFELSIGGIGNVMMGLGCGTLLGSIISSSVIRRLGSTRTVTAGMLLLALLYIVGPHTGLSPAVMIYFVIFTV-LGVIFPLVMSLLTALNASIRGTISSLANSTMNGANTLGAWLAGLLYVHfgYASIGIFSAVCIVLSLVTFRL----
     684 UniRef50_B5I8H9        Arabinose efflux permease n...   140     9e-32  1  15.7% 11:391   1:375     ----------MPFRLAALILAIFCVGTAELSPSGML-DDLSADLAVSIATAGLLVTAYALTMVVGGPAVTALTTRV-RRKTLLVALLAVFVLGNAVCALAPGFGVLMAGRVVTAAVHGTFMAVCVVTAGNMVGAGKGGGAVA--ATQLGINLATVLGVPMGSFLAQHYDWRAPFGVVAALATVAIGLVLAWVPDTPAPTVSAAHEA---RVFRRPSVWGTVGATVLCSAGMFTLITYMVPLLTGVGGLPRRWVPAVLLAYGLGSIVGNLLGGRFADRGIDRAVGQLSWALTAVCLLVWLLAPYGLAGAFALVLFSLATFALIPGLQAKVLTEASDAPTLSLTANMSAFGLGAALGSWLGGLLTeaAGTRAVPVGAAALTASGALLVLGLRR-
     685 UniRef50_B8IND3        Major facilitator superfami...   140     9e-32  1  13.7%  4:389   5:415     ---TPIPLPRQRWLIVLMCFLAVAINYIDRANLGVAVPMIQKEYGIDPALMGLILSAFFWSYVLMQLPGGWLIDRFGSRATYTVATL-IMSVATLATAFAGGVYSLIACRLVLGIGEAFCYPVNAKVTALWFRRSERGLAT--GIWASGSRVGSAMTLPLVAFLIANFGWREAFLVTGAIGLVWMVVWFLVYRDPARHPAVSPEQrgYAELFRHRTIWGMMIGFFCLNFVIYFYTTWFPSYLTESRGFSLAKLGTLGLLPGLVAIPAGWLGGYLSDRlaARKTCLVGGLLASSVVAIAPLVPGDAAALILLAVSYSGLAFAGANIWTLPGDVapAHVASISGIQNFASNLAGIALTTFTGVMVSLtsFVIPLAVAGCLSLVGAAAYLFI---
     686 UniRef50_Q6KYT7        Tetracycline resistance pro...   140     1e-31  1  15.2% 19:386   8:367     ------------------LFVTAMIDFIGFGIIIPIAPFYTRDLGATPFEFSILLVVYSLAQFIASPYLGRLSDRIG-RKNVLVLGLSGEIAGYLIFGLSPVLSLLYIGRAITG-ATSGNLPVIYSFVSDKTSSDNRTRA--IGMIGAAIGIGFVIGPFIGGSL-SIFGYRVPILFAAVLSFINMVLVLRIKEERKKTNYKKGSILKAFEI-----APYIFISITFIALGFVMLQTTLAYYGQALYSWGSLAVGIILGIVGMEQALFQLLLvrLTRRIGSIRTVMLGIISFTMAFLILSFRVNEYIAIFSLTLFSLGYSLFQTPVISIISDIApeIRGSTLGITQSAQSLSNIIGPLIAGYTFEFISIYSPYMLAAAFGILSLLFI------
     687 UniRef50_B4EPQ0        Putative transporter protei...   140     1e-31  1  10.9%  6:389   8:418     -----KPTKFRWFMVFLAFLAIVTNYMDRANLAVALP-YMNTELHLSSAESGLILGAFFWTYAACQIPAGMLVDRFGA-KLVFAGAVVWWSAFTMATSLARGGASLLGLRFLLGVGEAGAFPSATKFVERWFPPTERGLAS--GIYDCGARGGTLIALPICTAIITAYGWRASFIFTGAIGLVWVVVWLLvvDQDAPTEKHAPVRIKWGRLFTSRVVWAMSLGFACQGYVVYFFITWYPTYLVKERGFSLLQLGFYGILPGLAGLVGSWVGGWISDrfARKFCIVVGMALSA-TIGLAGLASQAWLALLLLSIAFFGVSVATSSILALPADVSARgaGTVAGFQNCISNLAGIASPAVIGLLKDATGSFTPGLISaiMAIIGCLIYIFM---
     688 UniRef50_Q01602        Transcription regulatory pr...   140     1e-31  1  13.8%  8:391  15:396     -------QSGSWSGVLAIAVCAFALVASEFLPVSLLTP-IANDLGTTEGMAGQGIAISGAFAVLTSLFISSVAGSL-NRKTLLLGLTAAMGMSGAIVALAPNYFVYMLGRALIGIVIGGFWSMSAATAMRLVPANDVPRA--LALVNGGNALATVVAAPLGAWLGTLIGWRGAFLCLVPVALVALAWQWTTLPSMRAGARAPGPGNVffALLKRPGVMLGMLASSLFFMGQFSLFTYVRPFLETVTGVHGAHVSLVLLVIGAAGFIGTLLIDRVLQRRFFQTLVAIPLLMALIALVLTVLGGWPAIVVVLLGLWGLTGTSAPVGWWAWIARVFPEDAEAGGGLFVAVVQLSIALGSTLGGLLFDRTGYQATFFASAAMLLIAAFLTILTAR-
     689 UniRef50_C7NKQ1        Arabinose efflux permease f...   140     1e-31  1  16.8% 11:391  13:394     ----------FPREIWILIGAAFVVAVGFGIVAPALPQF-ARSFGVGPTAAAAIISTFAAFRLFFAPVGGRLSEALGER-PVYLTGLVIVALSTGAAAFATNYWMLLIFRSLGGIGSTMFTVSAVALLVRMAPPTKRGRVS--AAYGSAFLLGNVFGPVLGGLLAGLG-LRAPFLIYGVALLIAAGVVAIGIPRDVGHAARKGTGPpvREAWADPVYKACLTSGFANGWANFGvvALVPLFVVEVLQSGPQMAGFALAAFAVGNVLVLNHSGRLSDRIGRRPLIIGGLVVCGVFTAFSGFITDVWVYLGVMAVAGVGAGMLNPAQQAAVADVVGNErgTVLAGFQMSQDVGAILGPIVVGMLAEQFGYGFAFAATGVIMAASVLVWIGRRE-
     690 UniRef50_A9CFW7        MFS permease n=26 Tax=Prote...   140     1e-31  1  13.6%  9:390  13:401     --------PLAQPVFAVLWAATVLGNTGSFMRDVA-SSWLMTDLSASPAAVALVQAAGTLPIFLLAIPAGVLTDILDRRKFLIAVQLLLASVSVTLMVLAhsVSALIGLTFLGGIGAALMGPTWQAIVPELVKREDIKSA--VALNSLGINIARSIGPAVGGILLAAFGAAFTYGADVASYFFVIAALLWWPRAKNANNALqaFRAGLRYTRASRPLHVVLLRAAIFFAFASAVWALLPLVARQLLGGDASFYGILLGAVGAGAIAGALVMPKLRARFDADGLLLGAAIVTALVMAGLSFAPPKWLAIIILLFLGGAWITALTTLNGAAQAILPNwrGRGLAVYLTVFNGAMTAGSIGWGAVGEAAGVPGTLLIGAAGLFIAGLIMHRLK--
     691 UniRef50_B8GJ43        Major facilitator superfami...   140     1e-31  1  14.4% 12:392   5:379     -----------RTLITILGLAGFISAADNWFISPVLPA-IASDFGIAIPLAGVILTAYLIPYGFMQPVFGVIGDRVG-KVQVLQCILAGFALGSGACAFAESLTSLTIWRACTGFFAAGIIAVSLALIGDTVPESERQR--YVGIFMGIVFFGQGLSVGVEGILATTLSWRIAFLIFSVIAVIVVLLLQR-IPKTLPESSVRSVQDELRSICKDRR-SRLFPMAFLIGLLLIGVYSFLGAFLHQIVGLDYLQIGCIVMFFGFSCLIGGTQAGFLEERIGRRAMVTGGAGVATLSTLLLALFPGWGTGWIAAAGLGLGYICMQSTIATLVFDIAPGSKGLPSALVGLGLFGGAGVGTALLGMIIPVCGYSAAFLLFALGMVGILILFIRAGEI
     692 UniRef50_B8GNI2        Bcr/CflA subfamily drug res...   140     1e-31  1  12.7%  5:389   1:391     ----MSPALPRWRVALLVASLAMLAPFTLDTYLPSFPD-IAEEFGAGPARMQQTLSIYLLGFAVMTLVYGPLSDAFGRRRVVLVA-LVGYMIASIGCALAQSMETFLLMRAAQGATAGAGTVIGRALVRDIYAGHEAQR--VMGLMMVMFGAAPALAPVIGGLLHDVAGWRSVFVFLSLFGAAVWLFTFRRMPETLPPVARVSvlASYGRALANARFMALVLVLALAFAGMFLYIAASPELIYGLLGYGVNDFWRLFAPLVCGIVLGGWLSSRLAERIPPVTMVTTGFAVMAVAVSLNLLQAHWltALAPLPLYSLGLALCMPNVTVLALDCYPHQRGMASALQAFLQLSANALVAALLVTVLSRSLAWLSLGMTGLYLAAAMLWGLWW---
     693 UniRef50_UPI0001826864 hypothetical protein EcanA3...   140     1e-31  1  14.2%  9:387   2:381     --------KSQSQMIFLLFIGYVVVYIDKT-VMGFALLPIEKEFGLSTAQLGYITGIFFLAYSLFQIPAGWLNDKIGYKTMLILSLCALGIFALCFGALGMSFGLLLVFRFLSGVGHSGYPCSCAKAVVSNFALEKRTFAQ--SVLLSSAGLAMTVGPIVAVWALEHLGWHASFVSLGIVACAIAVLIAVRVPYQKPAARQHAQGQS-GALWRNPTVVLLFISVFCVNIPSYGLLAWLPKFFVQSMGMPLEISGYIVAAGGAGIWLSSLGTGWLVGKyrEPQVILTCALVSAAAIFGIFHTSTALTASALLFVGEIFLMATFVTAFTLPMKRLPEnmGSAIGLINTGGTLGGFVSPVVIGYLvqSHSYESAFIFLSLAMVCAGVAIA-----
     694 UniRef50_C4K9T1        Major facilitator superfami...   140     1e-31  1  14.6%  3:392  38:426     --QLEAGTPGYRRANLAMFVGGFATFAMVYSTQPLLPL-LAAEFGVGAASASLTVSATTAGLALMLIPASVLADRLG-RQQVMKAALVIAALFALATAFAPDYGSLLVLRTLLGGVIAGLPAAAMAYIGEEIAPGAQARAM--GLYIAGNALGGMSGRFVAALLTDWSSWRVALGMIGVLGAVSALVFWRRLPASrrAATPARIFADTLAIYRDPGLPALFLVAFLAMGGFVGLYNFLGFRLLEPPYGLGQSAIGAIFLLYLVGTWASAASGRLAERRGRRKVLWPMVAVMGAGLAL-TLARPLWLIIAGVGVFTFGFFAAHALASGWVGRRAGERRALASALYLSSYYLGASVLGSLAGTAWADWRWAGVAALVGLCVLFTGACALWLRRL
     695 UniRef50_Q1D6T2        Putative multidrug resistan...   140     1e-31  1  16.0% 11:391   2:386     ----------QRRVRALVFVTVFLDLVGFGLIIPLLPFYV-ESMGGTATTAGVLLALFSFAQLVASPVLGRLSDRVG-RRPVILLSLLGNAISMALFAYSThlPWLFASRLLAG-ATAGNLAACQAAVADVTDES--GRAAGMGLVGAGIGLGMVLGPVIGSLLHVHGAWAPPLAGAVMAAAAMLGVLFFFppQAERHQEPGRPRVRLSDVLARPGLGAVLALTFLVFIGMTNLQVSLGLLAQARFGWGEQEIGRLFALMGLVTFVLqfVIGWLTSRVRDTTLVLVGAACMGAGLTCIAAAGHGAMLVLAMVLVGSGTGLLQPLMASLASGFAgeLRGGVLGVVQSAGGLARVVGPVWSGFLYSRLGPGAPFTSGAVAAGVALLVGASLLR-
     696 UniRef50_B4D0D8        Major facilitator superfami...   140     1e-31  1  13.1% 18:392   4:399     -----------------IFLTIFISMIGFGIVIPVLPVYAKSafKLGPTELGWLVGIFSLVQLFSGPIIGKISDRVGR-KPVLLVSIIGTAIGYFITGGASAAWMLFLGRIIDG-GSGGNIATAQACIADVTPPEQRSRAM--GQIGAAFGLGFILGPAIGGLL-SLYSPSLPFYFAGALSVLNAVLVWVRLPETLTEEKraSPLGEVFAEGRGRFIGLLLAATLLSTTGFAFIHLLFALFCQDHLHYDMRHTSYAFAYVGFIAVLVqgLLRRLPMDRIEKPVAALGAVLLAISLYLLPRADTTGAFLWVTALMALGNGLLVPTLTGMASrvHGRAQGRVLGLNASAGALGRFLGPALAalAIANHSYIVAFSASAGIMVVAFLIILAMKPL
     697 UniRef50_D0L8K6        Major facilitator superfami...   140     1e-31  1  15.6%  6:389  19:396     -----APSSVRRWAILALALGGFGIGTTEFVAMGLLPN-IASSLAVSEPTAGHVISAYALGVVVGAPLIAALTARM-SRRTLLIGLMVAFTVGNLATVLAPNYGLLIAARFIAGLPHGAYFGVAALVAAHLAGP--RHRAKAVGQVMLGLSVANVFGVPAATWLGESFGWRSAFAIVVVIGLATLVALVRSLPSLADMTVTNPM--TELGALRRGQVWFTLLIGIVGFGGMFAFYTYLNSTLTSLSGLSVSVVPFALMLFGTGMIVGNIIGGAAADRNVTLSILGGLVMTAVALGLFAAFAQNPWAALVLTFVVGVSATAMIPALQTRLMDVADDAQTLAAALNHSALNIANAAGAYLGGVVVGAGLGYRSPSALGVILAGAGMVVLGL---
     698 UniRef50_B9Z655        Major facilitator superfami...   140     1e-31  1  15.2%  4:392   1:392     ---MSSLDPHHRRAITLLSCAAFASSASARLCDPMLPN-LAKAFLATPADAAQVVSSFSVAYGLMQLFFGPLGDRFGKYR-MIAWTTLASLVGSLGAALSYSLGWLVLARLLTGVTAAGIIPLSMAWIGDTVPYEQRQAT--LARFLGGQIMGVIGGQFIGGLFTDTLGWRWAFAALALVYLLVGWRVLAESRANPLARPTPAPAGHTLGVLAQGraRVILLTVFLEGIVVFGALAFVPSYLHQRFGLSLTMAGALMAFFGVGGLSYILFARHFVRRFGEVGLAAGGGVLIGGAWLLLALGDAWAWAIPASYLVGLGYYMMHNTLQTNATQMAPQVRGTAVSLFASAFFLGQSLGVVLAAALLARSGATTVFIAAAAITPVLGTVFARRIRL
     699 UniRef50_Q49UW0        Putative sugar transporter ...   140     1e-31  1  11.0%  9:391   2:378     --------KNNKLIIFILTIGVFGILNTEMGFIGLIPQ-IAEHFNVSTSTAGWLVSVFAIGIAISGPIMPLLLSKIERKKVMIAV-LVIFIISNIVSLFTTSFSILLIARIIPAIFHPVYIALAFSVASDSVNSKDAPKA--VARVFIGVSAGIVVGVPIVNFLANQFNLYAALAFFALINMIVLILTIIFIPKM--PAKKAVTYGTQLRVLKRPLTWLSIIVSILFNAAVFGVYSYLTDFLNIVTNAPSHAVSIILFLYGASNILGNVIAGKLLTTIPKKAIFLLPFSLIIIYVAMFGIGSFLIPMMMISVLWGILAGISANITQYVIISVAPDAPDLSNGIFLSAVNSGTTIGTFLGGIFIASLGSNFVIFIGILACMINILFIYLRNR-
     700 UniRef50_Q15Q81        Major facilitator superfami...   140     1e-31  1  14.0%  4:388   1:409     ---MNAETRSYRRYVLFILTLVYIFNFVDRQILVILQEPIKAELGLSDTQLGLLTgaFALFYVVVGIPIARWAD-VGNRRNIVSLALVVWSGMTAVSGLAQNYTQLLLARIGVGIGEAGASPPSHSMISDYYAPEERGAAM--SIYSMGLYLGILVGLLLGGWLADKIGWRMAFFAVGLPGILMAVVVRLTLKEPPrvGEKYTFKQTLGFLWKSKPFRKAAFAAGFCAFTGYSTLTFIPSFLIRSHGMSIAEVGVSLGliGFSGVIGALSGGFLADKFGkmWVPAIGVLLSVPFSLLALSLDSLTLVLVCIFISNVFGSCYLGPTIAISHHLvpSMRATTSAILFFILNigLGCGPVVTGVVSDYfsLRYALVFSSLVILLAVVQYIR----
     701 UniRef50_B8KKX4        Major facilitator superfami...   140     1e-31  1  15.5% 12:366  52:422     -----------RYVIWLLFAVYVFNFLDRQIFTTLL-QPIKQEFQFSDTQMGLLGgaFALFYSTLGIPIARLADQR-NRVNIIAFSIAIWSAATAATGFAKSFSHLLIARICVGIGEAGCSPPAYSLISDYFEPQKRARAM--SIYSMGIGGGIFLGYLVSGVVAEQYGWRAAFFVVGIPGVLLALLLKLTLREPPraAKPPPVAEALTALWRRRSFRHLSLAAALHAFAGYGVGSFVPAFLIRSHGMTVSEVGFAlmISAVGIMGGIYFGGYLSDRVACQrvPGIATLLAVPIALCIYLLPNKLLILALILPSQLLGYMYLGPTFTMTQSLAgrERALAGAvlLIINLIGLGLGPTLAGWLSDMF--------------------------
     702 UniRef50_A5W3U8        Major facilitator superfami...   139     1e-31  1  15.3%  6:391  18:413     -----SIPRRYAWVVFALTFGVLISDYMSRQVLNAVFPLLKGEWALTDSQLGLLSGIVALMVGLLTFPLSLLADRFGRVRSLVLMA-VLWSLATLGCALAENYPQMFIARFLVGVGEAAYGSVGIAVVVAVFPRDMRS--TLAGAFMAGGMFGSVLGMALGGVLAQHLGWRWAFAGMALFGLVLAMLYPLIVKEGRIAPKCAQQahPLRTLYSSRSVIAAYVGSGLQLFVGGTLIVWMPSYLNRYYAMGTDRAGAIAAVIVLCSGIGMILCAMLCDRLGRQraIGYCLGSCALLSIAFALPAGTAQLVLICVGMMIAAGTNGPSSAMVANLTHAAVHGTAFATLTLANnlGLATGPLITGRVSDLIGLQAALQWVPLISIAAAAVFWVAKR-
     703 UniRef50_C9KKB9        Major facilitator family tr...   139     1e-31  1  13.2%  5:391   1:385     ----MQREKLWTPEFLGMGGSNLFLFMSQYIMVAALPIFIMDTLGGGDMEAGLAMTAFQIGAVSCRPLAGRIIDAVNKQK-LMRGATAAFFLVMFAFNWLHSEQAIYALRLLHGCIFALATTAAAAMAALVLPASRKGEG--IGYFALSTNLAMVVGPLIGLLIIGNLGGTALFVFMTALAILTFLTaaRRLPDEVIRPAKRPKKGFHLSDFIERRSLAPALLGGMVFFAYGGILTFIPLYAKSL--GLQAETSLFFVVFAFVIILTRPVIGRLFDEKGPDWTVWPGFAFFAAGMLFFSQVTTLVGLLGAAALLGIGFGALSPAFQTLAVQSAPASrgVATATYFWSLDISVGLAAVLLSIVAAQCGYPFMyvVSTAIIALNAALYFLWRR-
     704 UniRef50_A0NZ16        Putative transport protein ...   139     1e-31  1  13.7% 12:390  11:393     -----------RRTSLLGAGLVAIGPISMALYTPAMPA-LVEAFGTTDSAVKLTLTAYFAGFAVTQLVCGPLTDAFG-RKPVTIGFLILYLVSSVLATFSPTVEFMVFARALQGVGAAVGIAVSRAIVRDQFTGQ--ASAKIMNTIAMMLALGPAISPTIGGIVLELFGWQEVFWCMVIYGALLMVAVLVFQVETNPRPgpRQLAINYTTLLKDPRFLAPSLLIGFGLGNLYALATVLPFILIYEVGLTPSAFGLTMIIQSGSFISGTILTGRLLRFIEARKLVPYGLGMWVVASSLMCYvpTILTVMGPVALFTFALALVLPASFTESMAPFPHIAGSASSMLGFLQFGGGIVASLLIAALGE--PILGLAYILPGMPIVGIIVYLILR--
     705 UniRef50_A6LFS3        Putative transmembrane tran...   139     1e-31  1  14.8%  5:388   1:387     ----MNNDKIITPSFCYILAANFLLFFAFYLILPILPFYLKEEFMIGKSMIGFILSCYTLAALCIRPFAGYLLDTF-ARRPLYLVAYFIFTAIFGGYMVATALTLFIALRVVHGFAFGMVTVAGNTILIDILPSSRRGEG--IGYYGLANNIAMSFGPMIGLFMQGNFTYDVIFSCSLLSGSLGFIMAYMVKTPYKQPVKREPISLDRFFLVK----GTWAGISLLLLSIPYGMTTTYVAMYAAEIGISVNS-GLYFTFMAVGLAVSRLFSGRQVDKGRITLVISLGMYLAAVTFFLLAavFSSYLYIGIALSQGVAFGTMFPAFNTLFVNLAPnqRGTATSTYLTSWDVGIGIGLMAGGSIAqlGGFNYAYLSGACLTVLSTFFFLF----
     706 UniRef50_A5CMH4        Putative bicyclomycin efflu...   139     2e-31  1  15.3%  6:391  14:404     -----TSWTARRGPLLTVALIVGISPFATDLYIPGLPA-IAADLDASTASVQLTLTAFLVAFAVGQLVIGPISDGAGRRR-ILLAGTALFTLASIVCAISPDATTLILARVVQGLGGAAAAVSARAMVGDASTGALRSR--LFATLAVVNSVGPVVAPLVGGVVLTVWSWRAAFVVLAALGLALTIAAARLLPETLVRtsPRAVLGRMAELLRIPRFRWYLITGCAATIGFFSYIATSSFVFQEQYGFGEGLYTLVFASNASCMIASTLVFRRLIGRFDEDRLFTIGLLTCAVGSALVLVGagPAVVWPALALVTAGWGWVIPGSITLTQALGHRHPGTASALVGGLQFGLGGLATPLAGALGGTATAMGALMSGFIAVGLAAQLWASRAR-
     707 UniRef50_C7RLZ9        Drug resistance transporter...   139     2e-31  1  17.4%  5:390  10:401     ----LTAPPRSRGLAVLLTTLVALGPLSTDLYLPALPT-LARVFASDAARVQLTLSVFLAGFACGQIVYGPLSDRFGRRPAML-SGLAIYCAASLGCVFADSIEVLILARFVQALGACAGPVLGRAIVRDVWGATD--SARIIAYMGGAMAIAPLLGPTLGGFLTVLFGWQSNFVVLLLIGATQLIAVARLLRESNVHrhPRQMASTFLRLLADRHYLGNVLTFSFSYSALFAFISGSSFVLAERHGLTPQVYGMCFGVVVAGYLFGSLASGRLVRRLGSVRLLAGGAWLGAIAGAGmaGVHSIAALLGPMFLCTVATGLVMPNAIAGALAAYPTLAGSASALMGFVQMTLAALVGIAVGHGLAGGAGALASAVAICTALAPLSYLALIR--
     708 UniRef50_B1FU92        Major facilitator superfami...   139     2e-31  1  14.2% 11:391  36:443     ----------RWHVLIWLLIGGIINYMDRASLSIAAPGMIA-ELGLTRTQIGLLGSVFAWTYAVMQLPAGWVIDRFGAKRAYALA-MIWWSVATWLTGVVGSISGLLVMRALLAVGEAPCWPTSAKITAAWFPAKERGFAT--GVWDSSSKWGPAIAPAVLVALMVAFGWRSLFHVTGAVGVAFALLFLMLYRNPvhERSLANSSLRWRSLFARRSVWGMILGYFCTIWLWNIFLVFLPLYLLDRFHISFAQLGVYAGIPWAGGALGEIAIGYLAKKmaKRLLIACCAVGAAVCAIALPFSHTLNVTLALFTVGLAFIAAVVGSAWALAADIAPSSmaSVSAIQNFGGYFGGAFSPVVAGFIVDRTgyALAFISGGAIAGCAALFYWFMAR-
     709 UniRef50_C5BXV1        Major facilitator superfami...   139     2e-31  1  14.4% 11:391  28:417     ----------RWLRYAFLFFLGWVMMYADRSILSPVQDTVREQFGVSNATIGLLSSVFFVVYVATQIPSGILGDRVGRIR-LIFVGFVIFGIATALTGVahVFGMLVLMRAFAGFGEGLYYGPQYAKSGEETP--LRFRALGAAIINSGQGIGTAVGILAATFITYTLewGWTFVLFGGITLVVGLLIRTLIPDSRPSRPprGELGRFGTLLRNRVLLGTFVMLFCGVYAFFVMVTWLPTFLAHEWGMEPEAAGQLSSVAFWVAVPAGLLVGHLSDRIRARRPFVVVLvlTILAILTMAFTGQHAVLVAAIAMYGagKLALDPVLISVVAdiTNEMRSTAYGLYNCIGMAAAIVAPYVTGALVDVTgfQAAFLLSSVLLAIGASVFLLTFR-
     710 UniRef50_Q3A194        Drug resistance transporter...   139     2e-31  1  12.8%  1:390   1:396     MSAHTEIRTNMRLVVILLGVLTAIGPLTIDTYLPAFTA-IAADLHTDVATVSLSMSSYFIGIAVGQLIYGPLLDVFGRKGP-LVYGLVLYILASLGCALSYNVEWLIGLRLVLALGGCAGMVAARAVVRDLFPLHE--TARVFSSLMLVMGLAPIVAPTLGGLIVASLGWRYIFFLMGGSAVVMLAGVWWILPAIPGHGRrrSALRDYLAVLAVPGFTLRMVTGSFYIAGLFIYLTASPLIFMDMFGMSGPHYGWTMGGNALALVIGSQVNARLLKRFSLGGVLWRSNLLLLAVSALFVLGapLWMVLVFAALYLFCLGFLLPDVTALIMEPFgeQAGSASALLGAVQMMAGALAAALVSWGYDGT-VAVMAIGMPVCALGSVGLLWRER--
     711 UniRef50_D0WLC1        Putative multidrug resistan...   139     2e-31  1  17.0%  1:388   1:385     MTVPSQFTHASEPTMRLLSFSTLFVIGTDTFLTAPLLPLLQREFGVSVSRSGWLVSAYALGYALFALIAGPISDRLDRRK-VLLAGLVGFGVFTAACGCTWGFWSLFATRSLAGVAAAFVAPQIWASIPVTVPPKAIVKTMGYAT--AGLAIAQVVGIPIASFLSSM-GWRIPFFAIAASSAVLWTILYKGFPNVAPAASGGRLFAPYAHVARSRPLLMSLIAYLLFQTGNFTALSFIGSWLAKDFGADQNAIGTAMIIIGLGNAVGSLTGSRLVARLGERRSLLFGIIALGAIYLGTAFVSNMWVAVIVLAVAMLVGGFLFPVLMSELQSHTDLARGTVSSLASAAMYAGATIGGAIGGYLLSRfgYSGVAVFTVVAYAVSLGVYAL----
     712 UniRef50_Q5JHT0        Predicted permease, major f...   139     2e-31  1  17.5% 13:390   6:384     ------------RNIWLLNLSTFFFFLGISLTNPIVSPFAIT-LGASPFLVGLVAGVTSFVSLVSKPVGGLIGDR-GYRLEMMIAGNVLSLISGLLyaYTSNIVLFAFSRALHGFSMGIFFPSSLSTAVDLAPPGRVGET--LGWRGMMFSLGNIIGPALGGYLSDYLGFAGAFSFVSLFSLLGAGFVIPVWKEVGRITGDEESSGGSvrALLKVSFVFTSLALLFFSASYSGITTYLPAFYK-YLGFPQRTFGLYMMVVGASSFATRLVGGKTADRIGPVPVSFGGILVVITGYVFLNYRILPPESYISAVLIGAGFGLSVPAMQMMALAPLPGkrAMGSSIYTMFFDLGTLGGQVALGYVADLRGYEAVFPLLPFIAGVALISILITK--
     713 UniRef50_C8SSA0        Major facilitator superfami...   139     2e-31  1  11.9% 11:387   1:374     ----------MSLPLIALFIAAFAFGTTEFVIAGVLPQ-VAQGLGVSVPTSGYLVSGYACGIAIGGPLL-ALATKSISRKTLLLGLAIVFTIGQAACALAPDFTSMLLLRIAVAVAHGAYFGVAMVVAVGLVREDQRG--MAVAVILSGLTVSNVIGVPAGTAIGNIWGWRATFWVMCALGVAATFAMAALLPRTTGYQAKHAGLAREVRVLARQQVWTSLILMLMLMIGQFGLFTYITPTLLEITGLDEDLVPWVLLLNGVGATLGVFLGGKLSDWKLMPSLITMLALQAVTLAVIYAVSPYPLPMIVAIVIWGGLNFAIGTPIQTRILAWTADASNLASSLIPSGFNVGIALAASLGAAMlsGFGYRSLPLLGTFAMLVAVLVAL-----
     714 UniRef50_A0Z2H4        Putative transporter n=1 Ta...   139     2e-31  1  16.0%  8:344  27:381     -------TRYRNYVLGLLTLGYVFNFVDRQ-VMTILLEPIKAEFNASDTQMGLLSgaFALFYAVLGIPVARLADRW-SRRNVLAISMATWSAVTALCATAGSFAHLALLRVGVGIGEAGGTPPSQALITDYFPPERRALAQ--GILAAAPNLGILVGLFGGALLAEALGWRMVFLVFGIPGVLLALLLFFTVQEPKRQPRSEEGDESLlgIIRLPGFLWIAAGVGFAGIAGYGLGIWSPSFLVRVHAMSLVDAGLWLGLIGvgGTLGAVTGGLLVDRLARkrVPVIGLVIALPTQLAFVLWpgLPFALVFMGLSAVFASFWIAPSYAAVQNLvpHWRTQASALM------------------------------------------------
     715 UniRef50_Q67L14        Membrane transporter simila...   139     2e-31  1  14.1% 10:391  34:423     ---------NLWLQLAALCTVPLIMVLGNSMLIPVLPD-MGRVMGLSKATTGLAVTAFSLSAGIAIAVAGFLADRYG-RKLVVVPSLLVYGLGGIVSGLanGFAVVMAGRVIQGIGAAGTAPVAMAFVGDLFRGG--SRVTALGIFEASNGLGKVISPILGALIGQVLVWWAVFFAYAVLAVPFALAVWFLTREPPRRKAPPArfGQVLTIFRRkaLIACFWAGTVALFVLFGVLLFLSEHLETVHGIDGVPKGVRIMWPVLAMSATSFAAGLFLQRRglKPAVVLGLALAIAGTVLIAFVRADWAFYAGLVVAGIGTGLQLPGLNNLITSSAreQRAMITSVYGAVRFIGVAFGPPLYGALM-RNGEALPFWFSAGVLATSLAATLFLIR-
     716 UniRef50_A4TZ65        Major facilitator superfami...   139     2e-31  1  13.4%  7:380   1:381     ------MPAPSRLIVIILGIFTALAPLAIDMYLPALPQ-MQTDFAASSTQVQITLAAFLAGFALGPALYGPISDGWGRKGP-LYAGLIIHTLSSLACMMAPSVEIFTLARFFQAIGACAGGVIGRAMVRDLYPPQETHR--VYATLMLVMGAAPIIAPLAGAWLINLLGWRSIFATQAIMGGLCLVLLHRWLAESHPPHLRRRslVAYGRLLADRSFMAYALAGSFGMAGLFTYISGSPFVLIQYHNLPLEQFSWVFAANAFGFIIAGQINGRVLHGLDRHKVLAVAQWAQLALAAMLAAvaGVIGLSVALFATIACMGFIAPNSSVLVMAPRGGaaGTASALMGMLQFTIGAAASALVGLLHAHSALPMAMVMLGFAVL------------
     717 UniRef50_A3I0S1        Multidrug transporter, puta...   139     2e-31  1  12.5% 14:389  11:406     -------------PITAILLTVFLDMLGVGIIIPVMplPVMASEAYRSIMFGLLVGCYPLMQFFGAPILGALSDRFGRKK-MLILSIIGVLIGYLLFAWakNLWLLFFSRLLPGFA-GGNVSIAMSAISDIS--EEKEKTKNFGLAGMAFGIGFILGPALGGFLGdwFRSDTPFWFAAILALVNLIVVHFFFSETLITKRESkaLRNIVYSFSLPDLRGTFTVVLLLSIGFSLFTQFYAVFLIQKFAFTELDIGLLYCWIGLWFAFTqgIVRVLADRFRPQKLLSICVLLLGFSLLAVLLPSKASWLYLISPFIAIFQGIIMPNIASLVSSKADerQGEMLGINQSMQSLGEVIPPFIAGTLF-AINYNLPFITASLLIFIGWAIFLRI---
     718 UniRef50_C6QB01        Major facilitator superfami...   139     2e-31  1  15.6%  1:390   1:409     MHRAERLSRGAWAIVALLWLVATLNYLDRQLVVT-MPGPIKADLGIGNERFGLLSSVFLWIYGICSPIAGYVADRFG-KRPVIIASLLVWSAATFVTGMVTSFEGMLAARAMLGVSEAFYMPAAVALIVEYHRGPTRSRAT--GLHLSGVYAGSVLG-GLGGAFAEMYGWRTGFLVMGAIGVAYAMVLMIFFPRPSDGapSTPIAGAFKSLLTTRGFLFLLAMNLLNGAAYWPVRNWLPEFFRSELGVNQAWSGIYgmTFNGAAFIGMLIASNISDWWsrALVPAIGFMIAAPCLFAVGAVDYIPIILACVLVAGMSQGFLDANLMPAACTVTdrHRATAYGLLNFVGTTAGGVMTYVGGMLKEqvPFGTTFQVASLLIFVAGLCLFAVK--
     719 UniRef50_A5VFV6        Major facilitator superfami...   139     2e-31  1  14.6%  4:366   1:370     ---MSVSERGKSNATVFIVATILIDAIGFGIVIPVLPRLVMEVGQLDLPAagWLSVVYALMQFLCGPLAGNLGDRFG-RRPVLLLSLAGLAVDYVLMGFAHTLALLFLGRLIAGVFGASFSPATAAL-ADITAPEDR--AKRFGLVGAAFGIGFILGPALGGILGE-FGHRMPFYAAAICSALNFTFGFFFFPETLPPEKRRppVGALLQARKMRGVLGLSGILLLWNIASMVYPATWSFFAIAQYGWSNGMIGLSLALAGISMAVVqtVLGRVIKRFRERRTAMIGVAVAAFGYLGYALVPYAWFGMIVIVITAL-QALVQPSITALMSQRApdAQGEMQGFIGSLNAVGAIAAPLLLNPALAWF--------------------------
     720 UniRef50_A7NPL6        Major facilitator superfami...   139     2e-31  1  17.2% 10:388   3:389     ---------RWQRTLFILVAAQLVSAIGFGMFFPFLPLYVEQLGTNteFWAGMVFSGQALTMAITSPIWGSLADRYG-RKAMIERAMYGGAAIILLMGFARSAEELALLRTIQGAITG-TIAAINALAASLVPRERTGYAM--GMLQVGLWAGIAAGPLLGGIVADAFGFRAAFLVTSVLLLISGVVVTFGVQepPKGVKRPGILNDWRRILALPAVPAAYATRFLNWLGPNMLLPMLPLYVASLMRGGatLTGVIVGLSSAAGTVSALYLGRLGDRIGHRRVLLAGTLVAALCFVPQAFVTAGWQLLILQALTGAATGGMNPALSALLARYTNEgeGAVFGIDNSVNSAARAAAPLCGAMIAAWFGLPAIFIATALVLLGAAALVFR----
     721 UniRef50_C1XQE7        Arabinose efflux permease f...   139     2e-31  1  14.5% 12:391   3:398     -----------RSGLLVVLAILFVDVAGEGLVYPITPSFLQALGGGTVQEagWSLALYAALTLFFAPVWGMLSDRYG-RKPVLLLSMAGAAAGNLLTALAPGLELYFLGRVVAG-ATSANLVVINAYLIDVSPPEQR--ARNFGLVGAVFGVGFVIGPALGGLVGDW-GLRVPFWIVAGFSAFTFTLALTLLPESLKAEKRKrpFGALAALGRYPLLRSLTWTILLNGLAMNMLVAVWIPYVAYRYGFGPAENGLTLAAFGLMTALGqlVVPWLVPRLGERRAVVLGLVVSALSLVLYGLASAPWMLFAVLVVATLGAVDEPALQALISRSVRSDEQGTVQGALATVGSLMGVVGPVAGTYLFSRflPGAPFFAGAFCVALGLGIAYRALR-
     722 UniRef50_B2IJ56        Major facilitator superfami...   139     2e-31  1  14.6%  6:389   8:390     -----TSTPWLTRNTVLLALASLFADIATEMLYPILPVFLTQTLLASGSIIGLIDGIAQATQNIIQGFSGWLSDRLQQRKTIALAGYFLAAISKPLIGAASAWPAVLVARVFDRVGAGLRSAPRDALIASSVGDDHRGKA--FGLEGMGDNLGAFLGptVLLLTALAFDLRSIFALALAPGLLAFVMILLVREPPSAAQIEAKARIDVDPRQFPRAYWIYLLVTALFGLGNSS--NAFLILQTQDAGASLETTILIYAGFNLVAALISYPAGYFSDLWGRKTVLLLCFLIFTITYLGFALTRNTAGLGLLFIFYGLYQGIFRSVGKAFASDFapHLHASAIGWYSATIGLLQLFASLMAGVLWDRVGHQAVFFYGAFFAAIGSLALALL---
     723 UniRef50_A4E746        Putative uncharacterized pr...   139     2e-31  1  15.8%  9:388  22:425     --------KNKWAILFTVLIMTFMVCLDSTVVTVALPV-MQKELGVGLDRIQLVSSVYLLATCVAMLPFGRLGDVRG-KVGVFQLGVIVFTVGSLLCGLSASLEVLILARIVQGVGCAAAMANNMGIITESFPACERGRAM--GILATFVALGMMCGPVLGGMLVASFPWESIFLINLPIGVISFIVGLYTLPHVKPEAGERSmiEAARRCFANSAFTINLVCMLIVFVGIGASEFILPFYFQDAHGFGSDISGLLFLALPMVNAFIGPLSGTVSDRVGCEGPTAVGLGVYVCGLFAVSTlsSIPVIVCCAAFMSCGTSIFQSPNNSLYMGSAPREagFAGSLGSLARYAGMALGITVASNILYgfGFRSVFYVLMVVAAVGFALAVV----
     724 UniRef50_C8QGY6        Major facilitator superfami...   138     2e-31  1  13.3% 23:384  26:381     ----------------------FGVITTEIAIIGLLPKLVSQ-LQVTPTQVGFLVSVYAIIVAITGPFITLLLSGC-NKKTVLLSILLVFIVANLIYATSTAFNLILVFRILPALAHAVFFAVALVVAANSVPAEKRASAA--AKVFAGVAIGLVLGVPLSSMIAEHFSLAAAFYFGAAACIVAFIGVLFLMPSM--PATHKASFSSQLSVLRKGKLWLTISTVTFIFAAMFSSFSYVADYLSKVTQLDNNDISAMLILFGVCGFFGNFVFSSFLQTNLVKTTHLYPLFYALVFLLVWSFGFSVLAMCLLTIFWGAFHSSGLVISQTWLMREASEAPEFANSLYMSFSNLGITIGSLSGGWFIAHLGAHSVVLSSIIFALLAFI--------
     725 UniRef50_Q01X90        Major facilitator superfami...   138     2e-31  1  14.2%  9:367  43:424     --------SIQRWSIVLLVGGGALNYVDR-ATLSVANKLIQEDLGIPVVRMGLLLSAFLWAYAIAQLPVGGLIDRYGPRR-LLGLGLFGWSLAQAAGGLVTSFGPFIAARFALGVGEAPLFPGGARVVRDWF--GIRERGFATGLLQSASSLGNFIAVPLLTFLMLRLSWRWMFVIVGTAGVFLAAIWWAIHRDPAEVrtRPPSFAQWRQLFAHRTTWGMIAGFFGTIYTLWMYTGWLPFYLEHERHMSVARVGIVAAIPYFFGCVGAVLGGWLCDFlgRKLLISCALLGISACTLGTAFAESNAMALTFISISLFLIYIASSAAWATVPIAAPSqtASLGSIQNFGGYLGGALAPTVTGLILQRTG-------------------------
     726 UniRef50_UPI000050F813 putative efflux protein n=1...   138     2e-31  1  12.9%  1:387   1:382     MSDAPVSRRVYKFAVFALAIGAFAIGVTEFATMGLLP-HIARELGITVPQAGHAVSFYAIGVVVGAPLITTIAAHMD-RKLLLLCLMGLFALGNLASMLAPDATLFNIARFFSGLPHGAYLGVGAIVASSLVAPHRRGRAM--ARVMLGLTIANIVGVPIATALGNMFGWRSAYALVAALGVLTVIMVAVAVPKVKLAGVPSA--RGEMKALGRQQIILTLVAGSVGFGGMFAVYTYVTPTMTDVAGVPQVAIPWVLAVYGLGMTAGSLIAGPLVDKSIERSGIGGMILSAIVLAAFGAFTHIAAIAIIALFLIGIAGSMITTALQMRLLRDSHDAPSLSAAMNHAAFNLANALGAWLGGIVITalGYRAPAWVGVGLCLLGLIVLI-----
     727 UniRef50_A0LFP9        Major facilitator superfami...   138     2e-31  1  18.4% 13:386  16:390     ------------RLLFLCCIVCFFCYVGAYMRVPVVPLF-ALSLGADAFEVGLINSSFLFMAALLSLPLGIVSDRLG-RKSLILGGILLTSLSSFLLCLCRNPMQMVLVYLLFGVGLAAFAPTLMSYVADFAPATHLGR--SYGYYTMALYGGMSLGPALGGALAEVTGYPAVFAISGGFGFLMFCLVLVLLPRTPRTAAHSSRKLDSMAvlTNRPLLGCWMGTLGGCFGLGMFVTFVPLHAAEQ-GISVASIGLIFASQSLFNAVARIPFGHFTDRvdRGAVVVFGLIGFSIAVSGIAFSTGIFHFIGFSIALGITMSLTFTALGALISEVVPhsRGLAMGGYSTCIYLGMMLSAVSMGALARDLGFKSAFLVTAGVIALTGVVF------
     728 UniRef50_Q1CZY0        Major facilitator family pr...   138     2e-31  1  16.1% 10:364   8:361     ---------SERAVVALIGAVQFVNILDFVMVMPLGPDF-AKELGIASSHIGIIGGAYTAAASVAGLAGGYFLDRFDRRKA-LAVSMLGLVVATAAGGFATGMSTLMLARVVAGIFGGPATSLSLSIIADLVPVERRGRA--LGAVMGAFSVASVAGVPMALKLAEFGGWRVPFFAVAAMGLLVVLGAIFYLPPVRGhdAGPRKQAGVLELLANRDIQLSYVMTALVMMAGFVLIPNLSAYLQQNVGYPRDLLWLPYFIGGIASFATLRVAGPMVDRYGSFKVGTVGSALVLLsyVGFVHLPRWMPVPVIFTLFMVAMGTRNVAYNTLTSRVPDtvRARFMSLQSAVQHMAAAVGAFLSARLLT----------------------------
     729 UniRef50_C2BTZ3        Major facilitator superfami...   138     2e-31  1  13.7%  5:392  61:450     ----TSHDPEYRRIKFALFVAGFVTFAQIYEVQVLLPD-ISKFFSISPVTASLALSLTTLALAISMFFIGPSSERLG-RRPIILISLFVASLLGIILGFTPNWGLLMVGRFVQGMALAGLPAVATAYLAEEICPAELPKAA--GSYVAGTAIGGMLGRILSGFLSHLVGWDMTITVLGCIGVVGTLLVWLLLPQQEGFSKAEPGLKALLqvLTEPGLVLLFVVAGTALGAYQSILNMMPYRLTGAPYFLATWIVSLIFLVNLFGSVAASTAGSLASRFGRRAVVPLAGIIYLVGILMM-LARPLWAIFAGLVVFTIGFFGVHSVATGWVTARavGATGQASSAYSIVYYAGGSIFGTLAGFGWTALGWPGVVAISGSPAVVVIVLALILRHI
     730 UniRef50_P31122        Sugar efflux transporter n=...   138     2e-31  1  16.1%  1:391   1:385     MTTNTVSRKVAWLRVVTLAVAAFIFNTTEFVPVGLLSD-IAQSFHMQTAQVGIMLTIYAWVVALMSLPFMLMTSQVERRK-LLICLFVVFIASHVLSFLSWSFTVLVISRIGVAFAHAIFWSITASLAIRMAPAGKR--AQALSLIATGTALAMVLGLPLGRIVGQYFGWRMTFFAIGIGALITLLCLIKLL--PLLPSEHSGSLKSLPLLFRRPALMSIYLLTVVVVTAHYTAYSYIEPFVQNIAGFSANFATALLLLLGGAGIIGSVIFGKLGNQYASALVSTAIALLLVCLALLLPAANSEIHLGVLSIFWGIAMMIIGLGMQVKVLALAPDATDVAMALFSGIFNIGIGAGALVGNQVSLHWSMSMIGYVGAVPAFAALIWSIIIFR-
     731 UniRef50_A8VVW8        Arabinose efflux permease-l...   138     3e-31  1  13.0% 17:392   4:377     ----------------VLYFMIMVAFLDTFVQLPIITPY-AVSLGASNVLTGAIIAVYSLANMVGNIFTGHWIDRFGRKK-MLLISMFLVAFILLFYPLAQNGAQLFLIRLLHGLAGGALIPAAFAYVGDRTRREGRGRAM--AYTGGSIGFAAIIGPAFGGGVAAAGEIEWVFILISIIFVLTAVLVITNVEESFTPVERAKVKISDFSQLLKEPLIIQASLTAFALMISNGTLAFALPLKIDSIGLDSASTGMLLSIYGLTALLVFlpVNRLFDSINPVHLILSGLILIGSSMMMLTLFDAFALIILAMIVYGSGFAFVFPSMNKVVSDASSKvrGKAYGIFYAAFSLGVVSGSFIAGAVAEWFGLPFFFAASMIWILSGVLYAIYVRHL
     732 UniRef50_B0SH56        Sugar permease (Arabinose p...   138     3e-31  1  14.9%  9:363  13:371     --------QKERAIIFILAALQFLHVLDFVIMMPLGPVFM-ESFNIDAAAFGLLVSSYSISAGVFGLIGALFLDTFDRKLSLLV-LFFGFSFGTFLCAFANSYVFLLIARVIAGGFGGMIGATVLSIIGDIIPVFRRGTAT--GVVMGSFSVASVVGVPFGLELAERFGWHFPFLSLGIAGFLILPLGYKLLPSIRYhkVKQSQVKSLLLVLKKKEHFPPFIFMVFLMFGGFTVIPFLSPFLVSNVGLSTKQIPYIYFFGGLVTFFTSRYIGKLADRFGkyQIVTVLAIIPVILVVTMTKTALPMILVITTIFMVFVSGRMVPAFAMVTSAVEPRIRGSFMSVNSAIQQIASGAASYVAGLIL-----------------------------
     733 UniRef50_Q7NSL9        Probable MFS transporter n=...   138     3e-31  1  15.1%  8:392  28:411     -------TPAFRSTARAMFVGGFCTFAMVYGTQPLMPLF-AHDFSLTPAAASGVVSMSTGALALALIPASLLADRFG-RRALMNLALALGAVLMLLSAFVAGFGAFLQLRAVFGLVMAGLPAVAMAYLSEEVDA--RSLGHSMGLYIAGNALGGMCGRLLASLLADHVGWRGAVLALALIGCVGAWQFWRWLPASRHFQPRRHDFSRMGrmLRDGGLPWLFVTAFLLMGCFVSLYNYLGflLAAPFHLSQSALALVFSLY-VVGIWSSAWVGRLADGLGRRNVLWMMVAMMLAGLAL-TLADTLWLLVPGVALFTFGFFAAHSVASSWVGLRAREGRALASALYLTAYYLGSSVFGSMSGLMWGRGGWHGVASAVALALLVLLGISLWLRRL
     734 UniRef50_Q07GL6        Drug resistance transporter...   138     3e-31  1  15.2%  8:348   3:345     -------RPKTPPHLITLILLTGFSPMSLNMFLPSLAN-IAVDLETDYGTVSWAVSGYLAITAIIQLIIGPLSDRIG-RRPVLLGALLVFAFASVGCALAQSVEVFLFSRILQGGIIGGY-ALSLAIVRD--TRSEREAVSLIGYIGMTMAIAPLVGPMLGGVLDTFLGWRSIFAFYAVSGFGLFALCWLDLGETKTRSNSDtpVPGTTTLMREPLFWAYALCGTFSVGAFYIFLTGAPLVAQSVFDITTAELGFYIGTITVGFMLGGFIAGRFGKGFEPTTMMIAGRIIACIGLVGGLIvtSPQIFFASTIFVGLGNGITMPGSNAGAMSVRPDLAGSAAGLSGALI--------------------------------------------
     735 UniRef50_Q89WW9        MFS permease n=11 Tax=Alpha...   138     3e-31  1  13.8%  8:392  17:410     -------APLRYTVFRRIWLASLLSNLGL-LIQGVGAAWAMTQMAASADKVALVQTALMLPIMLISMPAGAIADMYDRRIVTLVSLMIALTGATALTILAgtPEALLAFCFVVGSGNALFGPAWQSSVSEQVPPEALPSA--VALNGISYNIARSFGPAVGGVIVAALGAVAAFACNAILYLPLLVVLLLWRRSTEPSRLPREKlsGFRYITNSPPIKIVLLRTLVMGLIGGAIMALMPLVARDLLHGGAQTYGIMLGAFGMGAVIGALNIHELRKRMSGESAIRACTISMAFAMAALAVSTEPVLTATALVLAGAVWMAAVALFNIGVQLSAPRwaGRSLAAFQASISGGIAIGAWGWGHLTDYAGVEVALLVAAGLMLIslGIWLTMPRV
     736 UniRef50_D0J374        Major facilitator superfami...   138     3e-31  1  13.8%  2:391   6:430     -TPPPAVSWRTHLSLALLALVYIFSFIDRQ-VLSILLEPVKQEFGASDTEMGLLTgaFGLIYAMLGVPVGRLADTR-NRRNIVALCCGIWSLATAACGVATQYWHMLLARMSVAVGEAGGMAPSVSIVSDLYPPKMRS--FAISLFMMGPNLGTLLGLVIGGMVAQHYGWRSVFLAFGIPGVILALLVYFFVKEPArsAPRESMFRQLRRLLGMASLRYICIACGVAGIAGYGYGVWAPSFFMRIHGMSISHAGLVFGLagLGAVFGAMFCGWLSDRLTQrrLAAMGTFCAVPAGVAVFFWpvPYAMAFALLFGFFASWFATLSYSAVSQMVTAAERSVASALLNLFMtlGVGLGPLVTGILSDYfgLRWALMGVTSLLVITSLFFALAIR-
     737 UniRef50_Q2JMV2        Transporter, major facilita...   138     3e-31  1  14.2%  2:389   1:398     -MWIPSWWPKLSFQVWLIFIGRLLSQTGTGFTLFYASLFFVNQVGLTATQVGLGLGIMAFAGVFGRILGGSMADGAWGRRSTLILSLAISTLGSFGFALSYDFWSFALANMAAGLGQGLYWPPAEAIVADLTTREQRNEA--YALNRLGDNLGLSLGVAMASTLVALTgyRLLFVIDGVTFLIFLAVLWFFIRETRAtpAAEPVLAGWKTALRDRSLLVFGLSNILFTTYVAQLSSSMPLYFRNGVGIPEVQIGILFALHGALIALLQMPVARWLNRRTRIQGLQGSALMWGVGFLLVWLSGLAAElvLALAVLSLALVSYNPSASALVADLAPDhrGVYLSVNSLCWAAGFALGPMIGGMALDlqPWASGLWIFWVITVSWVWGILRF---
     738 UniRef50_B4RF98        Major facilitator superfami...   138     3e-31  1  11.0% 14:385  19:415     -------------VVWLLAVVYTLNFLDRQIV-SILAEPIRKDLQLDDTQLGMLSgvFAIFYTGFGIPVGWLADR-ARRVWIISGACALWSLFTALCGTATNFVQLALYRMGVGIGEAGGSPPSYSLISDYFKPEERGTA--LAIYSLGVPAGSMFGSALGGWIAAEHGWRTAFYVMGVPGIILALVVLLFVKEPKrhDAAPPLWTAIGGFFSNRTLVLTAFAAGLSAFVGYAALTWNPPFLMRVKGMSLTEVAAYYSLvgITGMIGTFAAGWIADKLGAkwIPALAFFITIPFWFGIVYAPTWQIALICIAVPALLNNCYLAPALAVVQNAVPPNRRTISglLFVLNLIGLGAGPVYVGRISDMasLSIAFLALVPVIVITILA-------
     739 UniRef50_Q03WU3        Permease of the major facil...   138     3e-31  1  13.2%  7:386   5:389     ------KSEQRIRNFKIAWIGTFMAGMAFSEAMPFLALYIMQISHFNQAQvgISYAASYLVVILVSPIWGKIADQHG-RKPMLLRTAAGMGIVIILLSCVTNIWQIIILRLCQGLFDG-YTPSVIALIAAETPLEERS--VVISKLSTGYIIGGLMGPLIGGVLATIFSIRMTFFITGIILLCVAFISFYGIQekINTSPTEKLVSSKKESVWTVPILILLSATMLIQFVESAIIPYVSLMIKDLlhYLTIMTGIVSALPGVATAVFATFVGKMSSHFGTLKILKLCELAAIIIYALLGMTTSLMFFAGLRFLIGIANAGMTPMIQVLLSK-ASNRLSTVFSMSLSAQSLGSLAGSILGAYLSQFMPLNNLFYIASGALMISYVLL------
     740 UniRef50_A0KXB4        Drug resistance transporter...   138     3e-31  1  15.3% 25:389  31:394     ------------------------ASLGMDLYLPAIND-IRQSFSVSQGQMQLTLTLYMAILGLGQLLFGPLSDAIGRRRVVI-AGALVYAGSSLAMALTDSFSVFLLLRIVQALSASAVLVAAFATVRDVFADREEG-VVIYAIMGSVLAAVPVVAPFIGSLIDGLWHWRGIFYTLAIFAALVGLHALLKWPETRPAQTHPFEWSRCFNIIRAKAFLGYTLAYATAMGAFFVYFSASPSILMDKLGLDKVTFSLWFGSVAIVMIITTRFVKHLVKRWGTQGTVLRGLIGMMLSSGLLYGLesLLGFMLPMYFIGVHIALTCAVTANGALAAFSHSAGLATALYYAIESL---FLSALVSLLIWLLPSGTTLVICSYILISASLSLLFI---
     741 UniRef50_C1TRM4        Arabinose efflux permease f...   138     3e-31  1  16.4% 26:390   1:363     -------------------------MMGVGVISPILPLYAVQ-MGASGTLLGLVFGAFSMSRLFCSLVSGSMADRL-ERKTLILFGLSIYTISSLAYLFVESAWHLVAIRFFNGLGSAFVVPVAMSIGSDVSEEGE--EGAFFGSLQMALFAGIGAGPLISGLLTDWLGVQAPFLVMTAMTLVALTGIALWLPKGLppSGKGGDLSVYSALLKDPVLRRVYVYRFSTALGRGSMLMFLPLIATE-LDLSFVKVGVILSTVSIATSLFQKYTGGLADRFPKNRLVLVAGVLSSVTLFSMPLLRSFPALLLGALVFGIGTAIGAPSITSLAAIRGRdgTGRAMGFFNISFGLGMMSGPILAGYIRDAGILSSPFVPIGIILLTASSFFILDR--
     742 UniRef50_C2EC62        MFS family major facilitato...   138     3e-31  1  14.4%  2:389   1:383     -MNDEKMTTREWLPLIGLTVSAFLVNTSEFIPVGLLTD-IAKSLGVTEAKAGILITGYSWTVTLLSLPLMLVFSRMKPRK-LLLLTLFVFSLGQFLSVIAPGYAFLMIARICVASSHCIFWSIASPLAVRVVSRKHRSLA--LSAIVTGTSIAMVAGMPLGRLIGLQIGWRMTFMCVASVAVLTLVYLTAVFPDL--SSGAAFSVKNMPELLRNRRLMLIYVICALWATAYYTGYGYIEPFLRRVANLPDGTVTIVLMLFGGAGLVGSMLFYRFYDFHRHAFLCSTLALISAALLLLRVSASGAATVTGVCIAWGIAVLAFNVSFQSEVISCVKTSAAsaTAVFSSVINLGIGAGTLFGGIVCTNAGIGSIGYAGSFFSVAALIICFFF---
     743 UniRef50_B2GE68        Transpot protein n=14 Tax=L...   138     3e-31  1  17.5% 10:391   3:382     ---------KYRLQAVLFVMVAFMLGCNEYMIVGVLPD-IKGEFGTPLATLGYLVTVFAGVYALLTPVLTTIASRF-RRYDILLVYMAIFLVGNTWTALAGGFWSLLLSRILTASVSGAIISLVLILAAQLAPREKR--AGLVSWVFAGFSIASIIGIPIGTMISTTFSWHDSFWMVTGIATLVLIGLALLVP--REDTATKGSLLAQFSLLKDARILLGVGLVVSVCAGQYTFYTYIRPLLSTMMGFSISTLNWILLGMGVAFIIGNKFGGYLADMGGIKQLPHIYFMMTCLLLMMAPLFHFPWLDVLAIALICVAIACYGASTQLMFLDIapQSLELASSLNSIFANIGISLGSFTAAETVGFLGLTHVGNVGAVYGVLAVLAALFLRR-
     744 UniRef50_A4X9B2        Drug resistance transporter...   138     3e-31  1  17.1% 21:370  37:390     --------------------ITAIGPLSLDMYLPALPA-MARDLDASQAQIQLSLTTCLVGLALGQFVTGPLSDRWGRRRPVLI-GLVAYTVLALACAAAPSAPAFTALRFAQGFAGGMAAVVTRAVVRDL--HSGRAAAKYFSRLTLVFGLAPIAAPTVGSLVLRFGSWRTLFVLLAVVGALLTAVVATWLPETLPAHRRSRDgrSLRELLTDRVYLGYTLTQGLAFAGLFAYISGSSFVFQDVFHLSASTFGLLFGLNALAFVAVGQANARLLDRFPPRALLVGTlaVAAAGVLAGAIATSQLLLIGALLTFIGSLGMVMPNGTALALDRHAHHAGTAAALMGALQSVIGSLAAPLVGLGGEGSAVPM----------------------
     745 UniRef50_B1YKY7        Major facilitator superfami...   138     3e-31  1  13.7%  5:392   1:393     ----MQRLKQLHPLTVGVLLGTFFARLGTFITMPFFAIYLSVVLKFSPVDVGWILSISAIASLVMSFVGGTLSDRYG-RRTMMLSGTFGFVLVFIGLAQVETFWAFFILSALNGIFRSIFEPSARALISDTTEEENRL--FVFNIRYTCINIAAAIGPGIA-LLLSAGNTSITFYITAFVYFGYGVAIFILFRRHPITESHGGKKVSFGATVrdVAFTFALAGIIFGVFGYSQFNSTLPQftTTLLSGGTSLFALLITINAITVLVVQYPIMKFGVKTSPLVSITVGIATVAVGLFVMGTAGTVWLMIGAMFIFTCGEVMMFTMTDILTDSFapELRGSYFGAMG-LTSIGQSVGPVIGGQLLLYFGPepIFGILALLTVLGIPLLLLSQRV
     746 UniRef50_B7L180        Major facilitator superfami...   138     3e-31  1  13.6%  9:367   8:385     --------KATDRVLLIICLMYLVTYIDR-VNIGTAAPAMQKELGLSNFELGLAFSAFAYPYAFFQIAGGWLGDRLGPRMTLLICGT-IWSAATVAIGFVEGAVSLVIARFVLGVGEGSAFPTATRALANWMAADRRGFAQ--GITHAFARLGNALTPPLIAVLIVALSWRDSFVIVGLISFAWVALWFWYFRDDPRDHKhaGERKAVPWRRLLKRMLPVTITDFCYGWTLWLFLNWIPSYFLHQYQLDIKKSAIFASGVFFAGVVGDTVGGVVSDRILKKtvIVVGFLGAFVFMLPVLFATELVTITLCLSGAFFFAELIVAPIWAVPMDIAPQHSGTASGFMNFGFGLAGMISPVVFGAVIDATG-------------------------
     747 UniRef50_B8KNX8        Major facilitator superfami...   138     3e-31  1  16.5%  3:389  24:409     --TTNPMTGLERRVVAALALLYSFRMLGLFMALPLLALYAADMLGASPLMIGIALGAYGATQALLQIPLGWLSDRIG-RKPVIMGGLAMFVLGSVVAALADSVQIIALGRALQG--AGAISGSVMALAADLTSEEQRTKAM--AVIGISIGLSFALALICGPLLAAWGGLEAVFWMTAALALLGMAIVALGIPTATARTHegADRNMFRPVLADPVLRRLNGSVFLLHFMLTASFLVVPAVIEGSMGVPRESHWQVYLPVLVLSLLGMYPLLRLSERGGRTGLAliTVLMMPASLAVLFLGSNTLLLYAALCGFFTAVNYLEAALPSLVSkvFAHGKGTALGVYATCQFLGAFVGGTTGGLVYGSVGVTGLLWLVLIAAALWLVLIWRM---
     748 UniRef50_Q47P50        Drug resistance transporter...   138     3e-31  1  16.7%  5:388  34:425     ----VPRRRSTAFLAVVLGVLVSAGPLATDLYLPAFPA-IAEDLATTEARVQLTLTSSMLGLALGQLAVGPMSDAWGRRTPLLV-GTALFMVTSLLCMFVTSVEMFIAIRFVQGLAGAAGAVVSHAVVRDLYEGDE--AARFFSRLMLVSGMAPILGPLLGGQLLLVGSWPLSFALLALMNGVGFLAVLFFLPETLPRHDrrPLLATVGRLLRDPRFVGPMLALGLNFGMMFTYISCFSFVAQNELGASPQMFGMLFSVNAVGMVTGTQVNSLLIGRVSMVRRLMGGLVLGLGAVAAMVvtAGLVTISAALAVMMAGMGLVFPNATTLasSQPPSVAGTASALAGSARFvgGILAAVAGIAAGGEASLASMVWVMAVTGALALGIFAL----
     749 UniRef50_Q04NC9        Sugar permease (Arabinose p...   138     3e-31  1  14.8%  9:386  12:397     --------KSETMLVFLLAAVQFTHILDFVIMMP-LGTYFQEAFHINPREFSFLISAYTYSAFIAGIVGAFFIDRFD-RKSAAIFLYAGFIAGTTFCAIADSYFFLLIARIISGAFGGILSSVVFAIVGDVIAMDRRGRAT--GAIMGAFSVASVIGIPLGLKVAEYYGWNMSFAGIVLLSLPILVLMNYHLPNIPpqSAEVDPIWNFVRILTYRKYIASYMLIMFVILGGFTVIPFIAPYMERNVGILKDDIPWIYFFGGLVTFFSSRMIGIVSDKIGKHKVFYILVSLSFIPIFImgQTSLVNVLILTTVFMVVVSGRWIPALALITSATEPSDRGRFMTVISALQNLASGLGATIGGSILVAanYEVAGYLAMGFNVIALVLI------
     750 UniRef50_C5CAG2        Arabinose efflux permease f...   138     3e-31  1  13.1% 10:391  12:403     ---------PLPREIRVLVAAAFIIAIGFGIIAPLLPQYAAT-FDASAVGVAAVVSVFGLTRLLFAPVSGKLTNRLGE-TPVYMTGVLIVAASMFLVAFAQTFPQLLLFRALGGVGSTLFTVSAMAFLARKSPPTMRGRIS--GAYASAFLIGNIVGPIVGSAL-SVFGYRAPFLIYGSSLVVAAALVFFLLKDTrrAVRDVRPAMPVREALSNPSYRAALVSFFANGWATFGvnSVMPLFAATAFAGtaLMAGLALSVFALGNVTAVTFSSRLSDRHGRRPLILAGLLVMAATTGVIGWMTSPLSFLLACLLAGAGTGTLNAPQQAAIADVVGQRrgAVMSTAQMSADLGAISGPLLAGLVVDTAGYGWAFALTGGVILLGALAWWRAPE-
     751 UniRef50_C0ZSF4        Putative MFS transporter n=...   138     3e-31  1  14.1%  2:391   1:385     -MTTTARSTNANAAIIWMLLAVFGVGTVEYLVAGVLPD-ISTDLGVSTSTAGLLVTIYAVTVVIGGPLLTIATTRV-PRTPLIAALMALFVIGNIGTALAPNFATMVIFRIITALPHATFFALCLVLATSLVAPEFQGR--VIARVTLGLNLATVLGVPLGTLIGTQLGWRWSFAIIAVFQLLVTAALIASTRN-AAPSHQTGNVSSELRVFTRGPVLWAIGLTALSQAALFVVFTYISPYLTEHAGISVSTVTVVLFVFGVGSVVGNQLGGYYADKDLDKTLYIALTALALALLALFVFGGTSWFAFAWMFVLGATGFSIIPPLASKLIGAASEAPHLAATVNIAGFQLANAAGAWIGSIALSGGNSVAVLPAIGAVLAAGAVLLLFVSR-
     752 UniRef50_B5WAA9        Major facilitator superfami...   138     3e-31  1  12.5%  8:391   3:405     -------SAAQRRYILFLLFTVSVFNYVDRTILSILQIPIKKELGLTDAQLGMLTgaFAIFYAVLGVPIGRLADYWQRRR-LVAGALTVWTGFTALTGIATSFGALLGFRIGVAVGEAGSIPASHSIISDLYPPNKR--ATAIAIFGLSLPVGILLGYSSAGWLVTNVGWREAFSVIGLCGLIVVPFMWffDPVEVARAPAPSTGEALKILWSKRAYRWLVLAGGFHAWAWYSVNSWNAMFYVRVHQVPLSTVSYYLavNGIGSAIGIYAGARLADYfgRPRVVAISQFIMVPIAIVQYLVPSHAVSMVLGAITMTMMLVYYGPIVAVAHQMMPAnrGFTSGVLTLVVSlgLGLGPLVTGILSdaYGVQGLGYAICVTVCASLVSALMFWR-
     753 UniRef50_C6DK08        Major facilitator superfami...   138     4e-31  1  15.0% 11:389   1:376     ----------MPIALWALVIGAFGIGTTEFIIAGLLPA-IATDYGVTIPVAAYMATSYALGVFVGAPVLIILGSRL-PKKTMLVFLAGLFILGNLVTALAPSIGIAIVGRIITSLTHGAFFGIGSVLAAEMVPKEKRVSA--IAFMFSGLTVANLIGVPVGTWISHQFSWQATFYAITVIGVATAIGVIMLIPPTAKP--KAQHIGHEFAAFGNSKVLLSMGITILGPAAFFTSITYIAPMMTEVAHFSEGSITWLLMVFGLGLFVGNWLGGRFADRALMPMLYITLLGQAVILFIFHLTASSQTASIVCIFLMAAFGFATVSPIQKLVMdrAAGAPTLASAVNIGLFNLGNALGAWVGgvIASGFGFTAPNWAGGILSLSALILAIAV---
     754 UniRef50_A3N9X6        Transporter, major facilita...   138     4e-31  1  14.3%  4:388   1:388     ---MSQAKARHPLLVWLLIVGTGFVVMARAMSLPFLAIYLHERMGLDAATIGLLLGTGALVGTFGGFFGGHLSDVLGRRK-VLTGCLLVSSLSFAALHFAADAWQVFVINLFINLASSFYDPVSKATISDNLPPEQRLRA--FARRYVAINIGFAIGPLLGASLG-LLDKSPVFLITGAVYLLFSIAIyfGRAPHEAAASELPLAAKLRVIGTDRRLVLFTAGSMLAIAVHGEMSVTFSQYLIGAFDDGLKMFAWLMSTNAITVVLSQPLLNRIGERRGPFTSLTLGAILLAIGAAGFANSPNMIALVVSMVVFTWGEVLLIPSEYAVLDSITPEPLRGIYYGAHSLSNVGNLLGPWLGGLVLLHYGGAAMFYGMGFIALLSLLTFAV----
     755 UniRef50_A3ZVB6        D-galactonate transporter n...   138     4e-31  1  11.9%  5:391   1:398     ----MTMKSASSATLLTLMVIAIGVNYIDRGSLSIVKTDVAAEFELSSVQMGWLFSAFFWSYALSQVATGWLVDRFDV-KWLYAGGFLVWSLATVSMAMSGSFAIFLLLRLVLGVGESIAYPATSRMIVMNFP--ERRRGIANALIDAATKLGPMLALLFGGLLVANSGWRSLFVVVGLGGLLWLPAWLWLVPSQQKpaPKARTNVPFSELFKRQEVWGTSLGFFCLGYTWAFLLSWLPAYLEESRHFSKESMALFGSLPFAAMAVTSLCGGWLADRwaRKVFLIGGLVLCSVFMFASVLTPDPRACILLLCLACASLGFYTSNVWAVTQTLapNAAGQWTGLQNAIGNIGGAISPALTGWLVQETgyYSAFAAASVMLVVGVFAYVGLVR-
     756 UniRef50_Q3JX86        Major facilitator family tr...   138     4e-31  1  13.6%  8:390 146:529     -------SRGYWHASVALLFAGYATFSLLYYVQPLLPEF-SRAFGVSPAQSSLALSFATAALAAAVFVAGFVSEALSRHR-LMTASLTASSLLTLAAAFAPHWHQLLILRALTGLALGGVPAVAMAYLAEEVHPDGLGLAM--GLYVGGTAIGGMAGRVITGILTDLFSWRIAVGAIGVLGLASMLAFRMLLPPSRHFVPRRGlrTSLAHHLrqRELPVLFAMAFVLMGSFVTLYNYIGYRLLApySMGQATIGAIFVVY-LVGVVASPLSGRLADTLGRGRVLIASLAVM-LGGVALTLLHPVAAIVAGVACVTFGFFAGHAVASGWVGRLAQHGKGQAAALYLLAYYLGSSVVGSLGGRFWSTLGWPGVAALVGALLALGVVAAAWLR--
     757 UniRef50_Q0B8M3        Major facilitator superfami...   138     4e-31  1  15.8% 40:375  65:403     ---------------------------------------IARDLHADYGLVALALGGYAAVAASLEFVMGPLSDRFG-RRPIMLASLGVFTLGSLGCAMATDIRMFLACRLMQAAITSVY-PVSMATLRDTAGGER--AASRIGYAAMAAAFAPMIGPTLGGALDQTVGWRSSFWLLGAAGIALLGWCGFDLAETHTKRAtaHQLRAYPALLRARRFWAYALCMAFSTGAFYAFLAGAPLAAQAKFGIPPAEIGLYMGTITAGFVCGSFLAARHAHRYPLAATILCARVVaiALALLFGGATHAIAWFGPCVLIGVGNGLSNPGAHAGAMSVRPDLAGSASGLVGAMTIAGGAALSSLTGAVLTVRNAGYAPLVV-----------------
     758 UniRef50_C3JM80        Integral membrane transport...   138     4e-31  1  17.0% 12:388  26:396     -----------WAAVALIAASTFIVVAAEMMPVGLLTP-IGADLVESEGTIGLSLAITGLVAAATAPFVPVATRRFDRRST-LVVLMLLVAAANALTALSPSFVVLAVARVLLGVSMGGVWALAASLAPRLV--ETRSVGLATTIIFGGIAVASVLGVPAGTYIGAVAGWSVAFWTLSCAATLIAIAMIAVLP--TMPADRALSLGSLVAAFRNPGVRVGFAITALIVTAHFAAYTYVRPGLEFFAGLSPAQIGTMLLIYGALGVVGNFIAGPSAAKSPKTVVVILSAGVAVTLALFPISATTLITAALLMAAWGLFYGGVSVSTQTWIAQAAPVHREAASALWVAVFNASIALGAFSGGRIHDHSGSETVFWTAAGIATLAMLLATF----
     759 UniRef50_O34456        Hexuronate transporter n=4 ...   138     4e-31  1  12.7%  7:391   1:405     ------MFSKDKLPVILFLFLAGVINYLDRSALSIAAPFIQDDLTLSATQMGLIFSSFSIGYAIFNFLGGVASDRYGAKLTLFVA-MVVWSLFSGAVALAFGFVSLLIIRILFGMGEGPLSATINKMVNNWFPPTQR--ASVIGVTNSGTPLGGAISGPIVGMIAVAFSWKVSFVLIMIIGLIWAVLWFKFVKEKpkAETSPGEKIPLTFYLKQKTVLFTAFAFFAYNYILFFFLTWFPSYLVDERGLSVESMSVITVIPWILGFIGLAAGGFVSDyfSRKVVLVTCLFSSAVLIGFAGLVATTAGAVTLVALSVFFLYLTGAIYWAVIQDVVDqnVGSVGGFMHFLANTAGIIGPALTGFIVDQTgfSGAFLLAGGLAVFASLAVIRFVR-
     760 UniRef50_Q5N0B7        Multidrug-efflux transporte...   138     4e-31  1  15.5%  1:387   1:395     MAVFPPLMARQRLAFFSVALNVFMDALGVTLLL-PILPELLRPFGSNAFLLGAFASVYTLAQFISTPVLGSLSDRFGRRPPLILTLVFTGLAYVLLAvlVENLPLLFAARILAGLAGGVF-AIAQAYIADR-ESDPLKRSTQFGWIGAAFGLGFLFGPALGGLLSG-INLRLPIWFAAILAFINAALTVFTVVESLPPERRrnPLKQLWAVSRNPKLRRSLASAFIYNFAFAGFTSLFVLFVQNRFGWTPLQVAGVLIAGGFTSALGqlIFGRLLPYFQEKGLALIGLGGMAVGYLWLAQVPTPgqLYPAQILTALFGGFVIPALSGLFSRRvaEEQGQVLGSVQGWQSLAQVIGPLILGVVYDRGGADPFFWSLAALNAIAVLLLL-----
     761 UniRef50_A8LZG4        Major facilitator superfami...   138     4e-31  1  13.1% 11:385  15:389     ----------LPRTFWYLWTGTLINRLGSFVII-FLAIYLTQERNFSASQAGLVLGLWGVGGAAGTTIGGTLADRWGRRPTLLTAHLGATS-MMLALGFARDLWSVALGALLLGLFAEAARPAFGAMMIDVVPDKDRLRA--FSLNYWAINLGFACAAVLAGFATEA-GYLLLFVVNAATTLTTALIIFVKVSETRKpgRPTAPPRALRTILADRVYLGFVALNLFAALVFLQHISMLPIAMGDS-GLSPATYGSVIALNGVLIVVGQLFVPRLIKNRSRSHVLALSAVVLGVGFGLTAFAETAWFYGLTVLIWTLGEMLNSPSNATLIAELSpeLRGRYQGVFSLSWQVAGATAPVLGGVVRERAGDDILWLGCALIGGLVAAA-------
     762 UniRef50_A8W7E3        Transporter n=6 Tax=Bacteri...   138     4e-31  1  12.2% 28:387  17:371     ---------------------------TTEIMVAGLIQGISSDLGVSVAAVGYLVSVYAFGMVVGGPLLTIGLSRVPQKRS-LVWLLAVFVVGQAIGALAVDYWMLVVARVLTALAASAFFGVSAAVCIRLVGAERRGRAM--SALYGGIMVAQVVGLPAAAFIEQRVDWRASFWAVDLLALVCIAAVVLKVPA--GGDPDTLDLRAEIRGFRNLRLWGAYGTNALAIGSVVAGFTYLSPILTDAAHFTPSTVPVLFAVYGAATVVGNTVVGRFADRHTRPVLFGGLSTVTLVLVGFALTVSHQVPVAVFTVLLGLIGLPLNPALAARVMSVSNEGA-LVNTVNGSAINVGVVLGPWLGGmiSAGLGLAAPLWIGAAMALCALITLL-----
     763 UniRef50_Q6MN96        MFS family protein n=1 Tax=...   138     4e-31  1  15.9% 10:387   7:377     ---------KSWLPTVSISLASFIFVTSEFIPVGLLPE-ISAGLGKSEAFTGLLMTIYAWIVATMSLPMTVVSSHWDRRRLMLI-LLGTFVVANLASGLAASFGMLLVCRIIVAFAHAVFWSIAIPLAIRLGPAG--GRAKALSIIAMGASLGNILGIPLGTFLGQSFGWRMAFSLIALVAFVIYVILYRMLPSL--PSQSITTFKNVPSLFKRKSLVLVYLMTALTVTGHFTAFTYIKPFLLAVGGISTDFVVVLLLVFGASGVFGSILGSKIIYKHPKNALWISLGIVFSSLLLMTLAVHSQIWLMALAFVWGTALTLLCLIFQSAVLKEAPDVQDVAMSLYSGIFNIGIGGGALLGS-ISSTNHIGSVGYVGAIFVLASLMLSA-----
     764 UniRef50_Q89WG9        Bll0718 protein n=2 Tax=Bac...   138     5e-31  1  14.4%  9:390  21:411     --------SRYQALLIALLAFTQFTIILDFIIMSPLGAILMPALDITATQFGVAVSAYAFSAGLSGILAAGFADRFDRKR-LLLFFYVGFTLGTLLCAMAQTYHVLLLGRIVTGLFGGVIGSVVLAIITDLFPLHLRGR--VMGFVQTAFAASQVLGIPAGLFLANHWNWHVCFAAIVGLSIAAIAIIAFAMEPVDAhkQDRNPFHHLIATVAQKRYTLAFAVTTLLATGGYMLMPFSSAYTVNNLGIDMLHLPTIYLVSGLFSIVTGPLVGRASDAFGKYPTFVFGSVVSVIMVLIYTHLgsLATAILVNVLMFVGIFSRMIPSQALMSAIppSQRGSFSAISASLQQLSGGLGSMLAGAIIAQApfDRIGYVVVASAIVSLVAMYFVQ--
     765 UniRef50_A4T052        Major facilitator superfami...   138     5e-31  1  15.5%  7:392   1:380     ------MNPSELRSTLALAGIFGLRMLGLFLLLPIFSIHAHGLPGGeaLWVGLTLGIFNIVQACFYIPLGRLSDRIG-RKPVVLWGLSLFIAGALICAAKDDLLWIAIGRGVMG--AGAVSAAISAWVADLTREQVRTRAM--ALVGGSIALSFALSLVIAAPIYRAISLSGIFVVLAVLGVIAMFVTYYVLPTSKPEVRVQQ--ASLKEVFFRPELMRLNLGVFVLHATQVAMFLVVPRLLVQ-AGLPLSSHWEIYLPVVLLSFVFMAPAIIYGEKKQQLRTVLLVAIVLLLIamIFTQANSVMTIASALLVYFVGFNLLEALQPSLVSRFAKESKGTALGVYNTTQSIGLFSGAVIGGYLMDSHGDLSVFAMGAALLVCWLIIAWSMGEM
     766 UniRef50_Q1JWW0        Major facilitator superfami...   138     5e-31  1  15.2%  8:389  10:390     -------TSDYHRANLALFIAGFVTFSTLYTFQPLFPL-LVREFAISPATASLTLSVATFALAWMLPISGSISDSFGRKK-LMGWALILTSLISVLCATSTTLPSLLALRLLQGIVVAGVPAVAMAYLNDEMSP--RAIGAAMGLYIAGNACGGMTGRILTSWLVDLFAWQATIALIGFSAVVMSVLFWVLLPPSRHFERQPFHLksLIHHLRDPGLICLFLLAFLFMGSFVTVYNYVTFYLLApyDLSQSQVALIFFAYAFGAGGSSIIG-GLTDRYGRNRLMTLSVLIMIIG-ILLTLLTPLAAIVVGIVVLTIGFFAAHALASAWVGSRVPVARAQASSLYLLAYYLGSSISGTGGGYVWSAWGWPGIVGLVAILLIVAVVTIRVL---
     767 UniRef50_A5F1S3        Sugar efflux transporter A ...   138     5e-31  1  32.9% 11:375   3:370     ----------RDKTALLFIMSTLVTGLCGAFFYPLSSLFIVEALDASPMQLSLYMVLAVVSSVIVSQWLARQSDRHWQRKTILLVSLICYLITVVSFMFIRSYSLAIMVVVLFASVSGASFGQLFALGREYADQHLTDKTTFLSTMRAGIAIAWVFGPPAAFMLKASFGFNAAFAVSALIVFLGIVLIARFLPatASAVGTTPVELGQYSPRKRALIVLYCVTLVCTFGSNNLYITSMPLYLSRELMVPEHWLGLLFGTAALCEIPVMLMAGKLAERWGTNKLLMFGITSGILFYGVMLTHTGFVAMMAAQVLNGFFIGVCATLGMVVLQDMMQDRLGTASTLFSSMLSISTLVASLSVGVVGEFYNYFSTLYVS-----------------
     768 UniRef50_D2AR23        Major facilitator family tr...   138     5e-31  1  15.9% 11:375   1:360     ----------MPLALLALAIGAFGIGTTEFVIAGLLPE-VARDFGVSIPTAGYLISGYALGVAVGAAPMTVLGTRM-RRKHLLLALMVIFILGNVLSALAPTYGLMMTGRIVASFTHGAFFGVGAILAGDLVAPGRR--ASAIALMFTGLTLANVLGVPMGTFIGQAFGWRVTFWVVAGLGVVGLLSIAALVPVQPRPA--STDIGAELAVFRSPQVWLAIGMTVLGFGGVFASFTYIAPMMTEVAGFSEGAVSWLLVLFGIGLVIGNLLGGRLADRALMPSLYALLAGLALVLAVFTFTSHARIPAAITVFLLGAFGFATVPPLQKRVLDNAAAAPTLASAVNIGAFNLGNALAAWLGGLVITalGYTAPNWVG-----------------
     769 UniRef50_C3XI78        Sugar efflux transporter B ...   137     5e-31  1  12.5% 12:387  11:380     -----------WLPVLCVTFGAFIFNTSEFIPIGLLGA-IGNDFSMSDSEVGVMLTIYAWVVALASLPLMLYFAQ-SNLKSLMLGVIFVFVLSHFISALSQNFIMLVASRIGVALSHALFWSIASVMAVRAAPKGKQSSA--LGFVITGSSLAMIVGLPLGRMIGLYVDWRVSFLCIGLVALCVGIAFWRVFP--TMPNTQNISLKTLPTLLQNKAFMKICFLTLVFVSGHFSAYTYIEPFLENVAGFRASSVTFILCLFGLMGVVGSVLFARFYERFHLAFVRLSLFGLGFSMLLLYFVSESSAATTLLCAIWGLCFMLFGVIFQSQVIAAVPNATAVAMSIFSGIFNVGIGSGALIGGLAYTHFGIESIGFVASGICAVAALYFM-----
     770 UniRef50_Q9K7Z6        Multidrug resistance protei...   137     5e-31  1  13.2% 25:387   1:366     ------------------------MNIGFGMVVPYFAIYLGTYTGLDPVSIGLIVGTTSIGSLVGGFLGGTLSDQFGRKKIMLV-SLVVASAIYAGFMLQDYALLLVCLTLVMGFCTSFFEPCAKALMADFTESKKRMKA--FSLRYIGANIGFAIGPLIGIVAGVTASSRLPFIVVSTILLAYALFLQWLFRasIGEKEHVNLTGAFKAIQSDRVLLLFLFGGLLATVVHGQFSVILSQYFELEFQSGLAYLMLLWSVHSGVIVICGIPLVKVMERLSPLRAIVIGSLFFAVGVIGFAFSFNFMTFCLAMIVFTIGEMFLIPAEYSIVDEITphMRGTYYGSLNFT-SLGSFIGPWLSGILLVHFGGKFMFIGLALICALSLFFFI-----
     771 UniRef50_P32482        Chloramphenicol resistance ...   137     5e-31  1  12.6%  6:386   7:386     -----SWRYSLAATVLLLSPFDLLASLGMDMYLPAVP-FMPNALGTTASTIQLTLTTYLVMIGAGQLLFGPLSDRLG-RRPVLLGGGLAYVVASMGLALTSSAEVFLGLRILQACGASACLVSTFATVRDIY-AGREESNVIYGILGSMLAMVPAVGPLLGALVDMWLGWRAIFAFLGLGMIAASAAAWRFWPETRVQRVAGLQWSQLLLPVKCLNFWLYTLCYAAGMGSFFVFFSIAPGLMMGRQGVSQLGFSLLFATVAIAMVFTARFMGRVIPKWGSPSVLRMGMGCLIAGAVLLAItqSVLGFIAPMWLVGIGVATAVSVAPNGALRGFDHVAGTVTAVY---FCLGGVLLGSIGTLIISLLPRNTAWPVVVYCLTLATVVL------
     772 UniRef50_Q02A48        Major facilitator superfami...   137     5e-31  1  16.2%  1:390   1:388     MERMVSQASAPSKttAAVVFAGFCAFVTLFAPQPLLPL-LAREFRVSPAMISLVVTASTLAVALAAPFAGIVADRFGRKRVIVPAAFLL-AVPTLLAATATSFGQLLFWRFLQGVFTPGIFAVIIAYINEEW---EAGAGAATAAYVTGTVIGGFSGRALAALVASHANWRWAFVMLGALNLLGAFAIRAWLPAGRRFQRArsSGAAMLRHLRNPRLVATYAVGFCVMFSLLGTFTYVNFYLAAPPFLLSTAALGLLFVVYLVGAVVTPIAGRAIDRLGHRFALVMAFTGGATG-VTLTLVHSLPVVMLGLTLACTGVFIANSAGSSYVGSAATESRASAVGLYVTFYYVGGSGGSAVPGFFWARGGWPACVALIVAVQLLTITLALIFW--
     773 UniRef50_C4DSS7        Sugar phosphate permease n=...   137     6e-31  1  14.2% 10:389  23:431     ---------RMRWAIIWLAFVGLTVNYLDRASISVALPFLGEDIHLTKTQEGLILAAFFWTYDFFQLAAGWYVDKVGPRRAFTIAA-VWWSIFTAVTAAVHSFWTLVAARLLLGAGESPAPATSAKVVATWFPKRERGLAT--GIWDSGSRVGAVIAIPLVTGIIALAGWRVTFVIIGILGLAWALGWWKAYRDPAQHpaEGAAKLPWRKLFGYRTVRGMMLGFFCLNSVIYFFITFFPSYLVDERGFSLLKLGFFGMIPGICAVVSGWLGGWVADRAIrrKTVIVVGMVGGSVIIAAVLVPQAWMALALLSLSYASLTFAGTGIWSLPADVAPSSAHVAsgIQNFASNFAGILTPIMVGYLVDTTgfVIPLSVIGGIALLGALNYLFV---
     774 UniRef50_C2BLG8        MFS family major facilitato...   137     6e-31  1  16.7%  6:389  30:406     -----AKPPLITPTFVLAWVANFCQFLVFYLFVTTMALYAVESFGASDTVGGFASSAFVLGATCMRVFSGWIVDRVGHKKAAL-ASLAFVTLVAVAYFFAHNVAVLIIVRMVHGAAYALTSTALMAVAQSVIPHERRAEGT--GYFALGTTLATAFGPAIGLLLANNIGYTTLFAVALGANIVSLILALVLR---YPAEVSSEKPAFSLRNAVHPNVVPIGLFMLLVGIAYSGVVTYLNAYARKED--LATGAGLFFIGYAVTMLIMRFFLGRIQDHKGDNAVMYLGLAAFVVALLIMGFPTNDVMLVVAGACTGLGFGTLSPACQAivRSVSAAQLGAGISTMFLLMDLGIGLAPFGLGPIVAATGFDTMYLILAGLVVIAAIYYFFV---
     775 UniRef50_A4BBV9        Major facilitator family pr...   137     6e-31  1  28.2% 16:377  26:386     ---------------LILFIVNVITAMAYSFVLPIMSLFLIQNLNAPPAMIGFFTVTTALLSLVTNQQAGKFVDAGTNAKTLLIISLVALVTTGLLFSIFTHFWQAVLIGAPIFALGNTSIPILLSMIRQHADQSGLQSTKINAQMRSGVSLMWIIGPAMSFSVVGWLGFSATYLTASTIAFIALALTFFRLPDYTRPVTQRTTKETVHGPVPMR-FWLYSGVILFGNLANALYITAMPLVITESLNMAESWVGILMGITAALEIPAMLMAPRWSERFGRARLVTFAFLLAIIFYGCLLWTQHIILLMVLQLLNGLFFGIFVGLGISILQDELPQRVGWASAFHTNTMRIGSMAGSSTAGILAQWFGFQQAFAGSLI---------------
     776 UniRef50_Q1H218        Major facilitator superfami...   137     6e-31  1  13.6% 16:391   6:376     ---------------IALAAGAFCIGMTEFLPMGLLPD-IAHDLDVSIPATGNLVTVYALGVVIGGPLMVALT-INRPRKATLLGLMAIFTLGNMLCALAPNYLTLAAARIFTALSHGSFFGIAAVVALYLAPPGQGNRA--LALMFTGLTMANVLGVPLGTLLGQETSWRIPFWTVSVCGAVALYAIWRFIHDL--SAMPRPDIRREMRAVLKPSVLLAMAITAIGFAGVFTIFTYITPILEDMAGLSPRNVSAMLVAMGIAATIGLNIGGKMADWKLLPTIAISLTGMALLGMLFAWSMQFTLAAVLTAFAWGMVSFAVGPGLQTNAMAQAGDSPLMASTVNQSAFNLGNAGGAFLGGAVIhgFGLPAVALASAAVAVCGALLTVYSMR-
     777 UniRef50_D0XKC0        Drug resistance transporter...   137     6e-31  1  13.1% 24:390  27:399     -----------------------FGSLSIAMYLPGLPA-MAQEFHGSTTGVQDTVAAFSLGLCAGQLIYGPVSDRWGRRAPLL-FGIALYLVATLACIVASNLSTLVAFRFVQGLGGCAGVVISRAIVRDRFTPQE--SAGVYSTLMLILGVAPILSPLAGGWIIAGFGWRAVFWVLLAFGVVLGVVVWLRLREsrRRARSEHPFRSYLAILGDRQVAAFVACGGFGAAGTFIYMTMSAHLLIDGYGVPTTAFGWLYGAGSLAVLIGSQVNRVLLNRFSSHRLLVWSTRLNLAACLLMLATVSRwaFLIPLCLAFSMNGLSSPNAAAEAMGAAGWRAGAVAAVMGFAQFGMGALLATIAVRVLDGTAFEIAAMLCVTSACAVGCLLFAGK--
     778 UniRef50_C3KAD7        Probable transporter n=2 Ta...   137     6e-31  1  15.5%  7:392   1:391     ------MSRSIAHLALLLGLITAVGPFAIDIYLPALPT-LGASLQASPALVQMSLTVFFVIIGVCQLFYGPISDVFGRKPP-IYAGLVIFAVASVGCALAPTIESLIAFRALQAFGACAGMVIPRAIVRDLYTGHE--AAKLMALLMLVMSVSPILAPLAGSLVIALWSWREVFAVLAVVAVACLVMTIVQLPETHPAERrgNAFSSYGALLRDPVFIGLSVVCGFGLATFFVFIGSAPFVYIEHYGLTPTQFSLGFALNAASFFAMSQLTARLSARFGLAPLIRGSVVAVAAVMAvtLWVDSLALMMTMLFIGFGFLGLLLPAAGVLSLEDHGAVAGSASALLGAIQMITAAVSMTLVGVFADHTPAPMLIGIALCGIAAMLTTLWTLRRL
     779 UniRef50_A8TT91        Drug resistance transporter...   137     6e-31  1  17.8%  1:383   1:389     MTQTASPAAPGRSLIVLLGSLVMVGPLAVDMYLPSLPD-IAVGLSAHPAEVQQTITVFLLGFAVGMLVYGPISDRYG-RRPIIAAGLALFMLASILCAVADGIGMLTLGRVLQAIGGGAASALARAVAKDMFSTE--GAARVLSLMAMVMAVAPLAAPTVGGQILLVADWRAIFYVLAAFGAAGLFATVTLLPESLPPSARVgaFAAYGRILADRRALADLSSGSFNSAAMFAYITGTPFVYIEYYSVPAQWYGALFGINVVALVIASFLNARYVGRFGVLPLTRLSIAIGAVGGAGLLFagGLWGVALPLLLVIGVQAPVGANCTARLMGLFPASAGAASALFGAIRFGAGAVASALVGLLHDATPLAMCAVVAACCFLALV---------
     780 UniRef50_Q2T7X3        Major facilitator family tr...   137     6e-31  1  13.8% 13:388 111:487     ------------RSILPLALLTAVGLLATDLYLPAVPS-LPQQLGGSIESAQATLAAFSAALAVSQLVWGAAADRFGHRRT-LAFAVLLQLAAGAACALAPSMGALIGARVAQGFGAGAATVIVPALVRQSFGDG--GAVRALAWLGIVESAVPGLAPVAGAALLVVADWRMSFWIIVALSVVTAPLAFRVIPAARAMRPRTPARAgyRRLLRSPGYLGYALGHALCFAALLAFVASAPQVVEIWLGAGPSTFSLMQACGVAAFMLTAARSGKWSDALGLDRIISLGALLQFAASAAFLLLasTALVVATWMLFCGSLGLRGPASMARALAAEPAVAGRAAGLLMFFGLGGAALATQAVAPFL-HLGLAPVAWMCAGFTLASGAVVLW----
     781 UniRef50_C8RST1        Permease of the major facil...   137     7e-31  1  16.2%  9:391  25:405     --------KGYKMALIASLCSGLASYNALYATQAVLPA-LSEDFGISPSLAALTVSATTGGLAFMVIPLSVVSERFGRRRVIQASVLAATLLSIALVAL-PSIQSIIALRLLQGFAVAGVPAVTMAFLSEEIDRSYLPR--IMGFYIAGNSLGGLIGRLIPGIALEFTDWRIATLLSALFAFSMALVTTWVLPqtPKKITLSHEVHAFANHLRDPILLKLFLLPFLLMGSFVSMYNYMTFRLINTFGLPESLAALVFVIY-LSGTWTSTRTGKMVNRYGQAKVVVAC-IAMALAGLLLAFIPTVPTTLVAVLIFTATFFPAHSIASAWVGEVAEQDRAEASSLYILSYYLGSSLIGWVSGYFFAHGWGLFIGWLMLLTLIALVTALAAMRR-
     782 UniRef50_A8LSD4        Major facilitator superfami...   137     7e-31  1  13.1%  5:387   1:398     ----MSTPKSNRLPFVFILITLIIDAMGIGLILPVLPDLIGELEGGTLGQagVLATSYAVMQFLCGPTIGSLSDRFG-RRPILLVSLAVMAADYVVMAFAGSIWLLLAARIVGGIAA-ATQSTATAFIADISRPEDKSK--NFGLVGASFGIGFVVGPLIGGVLGE-FGTRAPFYAAAVLASFNLILGWYVLPETVTDKIRRppLGAFRHIGALPGLKRYLALFFLYEFAFFVYPAIWAYFTRAQFGWEPGMVGLSLGLFGIAIAFVQGVLIRVvpRLGETNAILYGFVFNFFAFIALGLVTSPTLALILTPMIALGAVVTPALQGCMSKIAGADQQGELQGLVSSFRSVAAILSPLVMTQIFFFStpGAPFFLSMCIMALCLAIFL-----
     783 UniRef50_C4LFU6        Major facilitator superfami...   137     7e-31  1  13.6% 12:392  18:393     -----------WGAVFAMSLCVFVLIASEFLPVSLLTP-IASDLMMTEGQTGQTISVSGIFAVITSLYVAVIT-RTMDRRVVMLTLTFIMILSGFVVTFAPNYFVLMVGRALLGIVIGGFWSLSTATLMRLLPAEALPKG--LAILNGGNALAATVAAPVGSFLGESIGWRGAFFTIVPLAIISLIWQMKTFPSMKPIHIRVISL-NVFKLFGRLEFSIGMAAILCLFMGQFSLSTYMRPFLETVTGMTVSRLSFTLLVLGVTGFIGTIVVGRLLSKTLFPILIGWPFIMSLIGLGFISFGSDEYSTIWVVAAWGFIGTSACVGWSVWLANVAPNDMEQGGGLMVAVIQLAITLGAGIGGVLYDHHGYKTTFSTSAFILLCAAALSFIAYRM
     784 UniRef50_C8PHE4        Drug resistance transporter...   137     7e-31  1  13.8% 13:390  11:394     ------------KLVIILAYMSALAPLSTDMYLPAL-EKVKASFATSEFYAQLSVASFFIAFALGQLVYGPLSDKFGRKKP-LYAGILLFICASLACVSFDNIYAFIFFRFLQALGGCAGVVLARAVINDKFELHE--AAAMFALMMVVGSLAPMLAPTLGGFVLDFFSWQAIFAILFALGILLFAFIFFGLDESAQIDevKGVLGEYGIILRNKEFMRYTLGFAVAMSALFAYITGSSFIFLGYYGLGEHAFGVIFGINALGMTLVSALNAKLVQNREPTALLNFGLIAMLVTSLILLACspFICFEVSLFILLSSLGFVAPNATTLAMALYKdnSGAASAVLGTAQFAIAGAISFIVGAVGANKPFLLASVMVICAFCANAVYFLLRK--
     785 UniRef50_D0L6X5        Major facilitator superfami...   137     8e-31  1  18.8%  9:391   2:385     --------KQIPRGIWVLLSANVVIALGYGLIAPALPSF-ARSFNVSFTAATAVVSAFAVMRLLFAPATGRLVTLFGERRIYLI-GLLIVAASTFACAFAQSYWQLLVFRAAGGVGSTMFTVSAMALLIRMSPNDIRGRVS--GFFSAGFLIGNITGPLIGAALVG-FGLRMPFVVYAVALLIASAVVATQLREVSAPEspAHGVISFRHALGDSAYRAIIASNFTQGWASMGvvAVVPLFITEGLGEGAGMAGVVLAVYAAGNVAAILTAGRLSDRFGRRPVMLPGLTLMAAATAALGFSSNIIVALVLSLIAGAGSGLFAPTHQAALADVLGNRrgSALAAFGMSSDVGAISGPVIVGFVADRVGFGPAFILTGVVAALALLMWVFARE-
     786 UniRef50_D2BN95        Sugar efflux transporter n=...   137     8e-31  1  14.8% 12:390   7:386     -----------SLTLLALAINAFAIGSTEFISVGLMP-MIVNTFNISLSQAGLTVSLYALGVTVGAPLLTILTGTW-NRKTLMVSIMGLFILGNLLSAFAPTFLLLLVGRVLASLAHGIFMSISTVIAADVVRPEKR--ASAIALMFTGLTVATVIGVPLGTFIGQHSNWHMSFVFIVVIGLIGLIATSILVPKGLPIPGK-INLSGLARIFTNKSILMSLFITAFGYGGTFAAYTYLTPILEGTFRFSASTVVIILVAYGVMVAIGNSLGGHLANklPALQKMFAALALSLLFLFISASLASQPLGLIATLLLGLFAFMNVPGLQLYVVQLapKDITLVSAFNIAAFNVGITLGSFVGGQISKGSSVVFTPLGGIIIILLAMFLIRLAQ--
     787 UniRef50_B8FKI6        Major facilitator superfami...   137     8e-31  1  14.3%  7:391   1:383     ------MAKSSSGILVLLSVSVGVSMIGLGIIWPLIPVY-AVELGAGGFMVGLIIASFNLSKAAFGPFMGRFSDSLGRKK-FITVGLIAYTCMSVMYVLAGSAETLIAVRIFHGMASVMVVPIAMALAADIAPKHELG--LYMGTLNMAVMLGLGAGPVLGGALRDHFGMDSAFIAMGLLALITCILVVIVIPSDAETrkENQARSSVGQIVRHRIALGIIFMRFLAASGQGAVYTFLPL-LGLKMDMSSSQVGILLSANIFLIAFLQRFSGRLADRVNPKYLVIFGTFLAGFAVLGMPMVKGFFLVLVLNIVMGAANGLALPGGLVITAQLGRTmmASLMSITDAAWSLGMIVSPILSGIILDVYGLPYVFLMGSALILTGGAAVSLFLR-
     788 UniRef50_A7IHQ8        Major facilitator superfami...   137     8e-31  1  15.6% 23:387  29:387     ----------------------FGIGTTEFVIMGLLPQ-VAGDLHVTIPQAGLLVTGYALSVTFGSPFLAVATARMDRRRALLV-LMGVFILGNLMCALAPSYWLLMGARVLTALCHGAFFGLGAVVASALVLPGR--KAQAIAMMFAGLTLANVLGVPAGTALGEAMGWRSPFFVVVGIGIAAALALAAFLPRTI--EVPPMNLKREAKSLGSPQVMFAMAMSIVSSASLFSVFTYITPILQNVTGISTQGVTMMLLLFGVGLTCGNFLGGWLADWRLMPSVIGIIAVIIPLLASFALTSHAVVPAALTLFVWGVLAFALIAPLQSRVVSEAAKAPNLASTLNQGAFNFGNAIGAWAGGLALTAGLPYADLPFMGATIATAGLALA-----
     789 UniRef50_A9AR07        Major facilitator superfami...   137     8e-31  1  17.8% 15:391  17:409     --------------LLLILFMTFGFVFFDRLALSFLFPFMAAELHLTNAQLGMVSSALALTWALSGAVTGAWSDARGTRKPLLIAAVLGFSVCSALSGFVGGFASLIAFRALMGIAEGPVLPLSQSLMIESSTPSRRGLNMGLLQGSAAGLLGAMIGPPVVIGIASAAGWREAFYVSCIPGIAIAFCIWRWVRETPpkDTAKGATVSRWALLKARNVLLCVLISCFFLTWFVVVISFAPTFLVSSRHFSASDMGVVMTCLGAAWVFWGFAVPAISDRIGRKPTMIVFALIAALCPLAMIHIASLWALCALVFATYTGLGCFTLFMATIPAevPPGAVASALGLIMGAGElgGFVAPTVAGFAADRFGLSFAMEMSAAGALVAGLLSIGLVE-
     790 UniRef50_A1BAU1        Major facilitator superfami...   137     8e-31  1  13.8%  2:391  60:449     -KSLQNPAPPIPPTVWMLGIVSLLMDVSSEMINTLLPLWLAGGLGASALAIGFIEGLSVAIATATRFLSGVFADWSRRAKPLAVLGYGLGALSRLIFPLAISIDQIVLAKALDRVGKGIRSTPRDAIIAAVAPPQIRGA--SFGLRKSLDTVGGFLGPlvGAMILLAGDIAAVFWIAAIPAALAMLVLVLAVHEPEPSRVAKRSGFRLADAFrnRAVWAVIGLAAIIMLARFS--EAFVLLKALEAGFAPTWVPLAMVVMHAAYGLTAWPVGRLSDRIGTAGLLSWSLVFLTIAHLTLAFAGTVWAYILGTVFWGLHMGFSQGLLGAMIAAATPDarGSAFGTFNLVAGVVMLVGNTAAGWFWHSAGSQAPFLIGAGLSGIAMLWIALRQR-
     791 UniRef50_C0QL33        Quinolone resistance protei...   137     8e-31  1  13.8% 10:386   2:376     ---------LKHRSIIALNVAIFFFMFGVGMIVPLLPQKIIALTG-SLQSVGYLASAFAVSFVLLQFPMGRLSDRFGFRR-FLLAGYLTCSASGLFYCFSDTPEMIFFGRMLQGIGEAPLWALAPALVSILYP---RSKGKVIGLYNASIHLGLTAGSAAGILVSPYWVNNESFLLFALSGLVGVLLIFVAVKNPDRKVSVTEgkVAFMALVKNSSTFAVFGGIILYGAGYGIFLTVLPGFLIQDVGFSHRDIGWFFMLFYVAISLSQAIIGPLSDRYGSGKTMVLGLMAVFMGVGMFP-GKGAWEIYSWLFAASFGLGGFCVSALAWLNNCVGDskGTVSGTFYLLWGIGFFLAPPLLGSFGKVLKTATGFSLLALCYLVQAVLL------
     792 UniRef50_D2BC33        Major facilitator transport...   137     8e-31  1  14.9%  3:391   6:389     --ERPSSPLKAWLGVAAITASLFVFLTTELMPIGLLTP-LSASLGISVGVAGLMVTLQGISAGLGVPFIVAWTRRV-NRRVLLSTLLAILALGNLITAVSPNYALILTTRLIMGFASGVFWAIGVSMAMRLVPERHASRAA--AVVMSGISIATVVGIPLGTILESLTDWRTTFLIWAGLSVLVFLAVTAVVP-SLPSANAVSVREVFGLPLKNVQLRLVLFIVVFFVLGHFGAYTFVRPFLEENASATPVFITVVLIIFGVGGAVGNFIAGYTVNKNLRGSFVVGIVGLVVSLLLLLTIGDGQAGSIVSLVLWGLSFGVVQLCQVNMTLAAAPKTFEAAMSLNTMAYNTSIALGALFGGLFADNAGVTSVVWFGVALTAASLLLRLATGR-
     793 UniRef50_B9QUJ0        Transporter, major facilita...   136     9e-31  1  13.4%  7:386  14:400     ------WSPFGYRAFALLWVATLISNIGTWMHD-VGAGWLMTTLNSSPAIVTLVQAATTLPFFLFALLAGALADRLDKRRMLITINLVLFGVISVLALLVwtPVLLILFTFVIGTGAAFMAPAWQAVVPQLIPRETLKPA--IALNSMGINISRAIGPALAGILIAGVGLAAPFALNAATHLVIIAALVFWRSEAAPSRTHHGsaTGLRHVRYNGPMLATLVRAVAFFVFASAYWSLLPLIARGVADGGSELYGMLMALIGAGAVTGALVLPRLTGKLTSNQTVQFGTLGTAAALTILALSAEPLALMAAAFLGGLSWIAVLTSFNVSAQLALPDwrARGLAVFLMGFFGSMALGSILWGQIATATSVPITLLIAATGLIAGMLLT------
     794 UniRef50_C9LY82        TcaB protein n=2 Tax=Seleno...   136     9e-31  1  14.1%  4:386  11:397     ---MKMTKRRRISLTIFLGIMSAMAPLATDMYLPALPE-LSAEFSASTSATQLTLTMTLFGMAIGQVFLGPLSDMYGRKRP-LFAGMVAFAIVSAGCFYASSIEPFLALRFLQGFAGASGIVIARAIARDVAEGVELTR--FLSILMLVNGLAPILAPVAGGQLLVFSSWRIVFAVLAAIGVLLAVWTLKtlAEGARQKSMTASFHAFPTLLRDRYFLGHCLVQCFVFGAFFSYIAGSSFVFQNIYGVSAQGYSLIFGGIGTGLFLAGLLPARLAGRIKDISMLKASLLVPLVSSALLLAsaPLALTIVLLFITVVPLSVMGTASFSLALSRQGRNAGAASALIGFFSMVLGGVMMPLVGIAGDHTAIPMAVLMLTGYTLGAIVFY------
     795 UniRef50_C8ZWF2        Major facilitator superfami...   136     9e-31  1  13.6%  1:390   1:386     MEKVNSSSRLWSKDFYLVMVVTVLAMTAITTQMGTMPLYVA-SLGGSKAVSGAIVGVLGLSALFCRLPIGVALDRYG-RKVLLCMGLAILLIDFSLLNLLQGLLMLFCLRILQGVGNSLQATAAATMAVDTIPEGKL--AVGLGYFSIAQAVPSAIGPLIGLAVVENYGFPVLFRMAVLLSGTAFLLSFFLkpFSRRNTHSGEAKSSLRELLRIKAVVFPSGILFLICFANSGVVAFIAQYALER---EIIGAGYYFTVMSIMTVTTRVVFPRLLAKIQTATLIYGSLLLILVSFCLLPFTTQLSSLLLAASCYGVGYAGLLPVMNTIVLESVSEarGQGTAVFSAALDVAYGGGAFLWGIIASLFGFDMMFFGCGLFACGAMIVYRYFQ--
     796 UniRef50_C7JHN9        Transporter n=8 Tax=Acetoba...   136     9e-31  1  14.2% 15:386  75:444     --------------IVALFSLGSCALLNIYATQPILPD-IARQFGVSLGTSAWTISASTLGVAVAAPLAGAISDRFG-RKCIMVMALIGLIVTTASCALAWNFMALFSLRFAQGLLVPFVFTAALAYITEEWSGS--TATTMNGVYVAGTAFGGFCGRFLAGAAATFTGWLSTFLVFAVLLFLVLVLTIFCLPTERQFKPSASLAGSLKSIAkdWRLLATCFIGASLLFQQVTSFTYLSLRLGApfSLTSLEVGSLFVVFLLPVTV-TPFFGRLINKIGRTRAFLLSQIIGIAG-IGLTLSFHLASIVVGLALSCMAVFSGQSCATGYTAQHAKTGRSAATGLYLTCYYLGGSIGAIAPAPFYAHHGWFGCAALICLVALASTVLA------
     797 UniRef50_A0QWM1        Permease of the major facil...   136     9e-31  1  15.4% 22:390  25:399     ---------------------NAVTPFSVDMYMSAFPA-MAVEFGTSASVVQLTLTTFLIGLATGQLFIGQLSDRLGRRGPLLV-GIVACLVASLLCAVSPSIEVLIMLRFVQGFAGAAGIVIARAIISDRSKGSQ--AAKLYSVMMVIGVLAPILAPVLGGQVVAGFGWRAVFLALAGLNLVMLLGALflPPEARRPAGLKAFAGSAASVLTNRRFMGYTLTLSCSGAAMFSYISASPFVLQNIIGLSPRAFSFTFGGCALAVAVSGVISARLVGRFGPRKLLLGGVSAMVVVAALMLLNVtpAVTVALMACFMGTVGFTFANATTLAIGEVRHAAGTGSAVIGFLQYGLGAVASPLVGLAGEHSAVPMGVAMFTCAALAATALLVLTR--
     798 UniRef50_C6CYJ9        Major facilitator superfami...   136     9e-31  1  13.4%  7:388   5:386     ------PDKLWSRSFVTLTVSYLLLFLSLQMLLSPFPTYAKEQFHPNNFALSLVTSLFALAAIVTRFATAALL-RKVHRNVILFVGLVIAAIATVLYPFASSMTSLLILRALFGIGFGMTSTIIPTLVSQIIPKKRTGEG--IGYFGLSTSIAMSLGPMIGLSVIKQFGFTTLAMIGTIALVLIIPLLIVMRsaKAAPPANKAESGEPASGSSTARMMVPAILNVLMSVTYGGILGFIALYGAQKH---IEQIGLFFLFIVFTVFIIRPISGKLFDRRGPMPIVIPGAIVVIASLIILSYAESLPLIIVSALLYGFGFGAIQPTTQAWMLraAPHQVSFANSLYYNTIDFGVAVGSMLLGIVASASSYSVMYRWAAVAMVLFMLVYLV----
     799 UniRef50_Q47P56        Drug resistance transporter...   136     9e-31  1  16.1%  7:361  35:398     ------PQRSAALLVFVLSLLTATSALATDLYLPAFPE-IAADLGATESQVQLTLTAIMVGLAVGQLVLGPLSDRWGRRLPLLI-GAAVFTLSSLASAVAPSTEVLSALRLLQGFSAAAGAVISRAVVRDIFHGED--SARFFSRLSLLTGVAPMVAPMLGGQLLLAGSWRLLFVVLALIGVANLVLVYVALPETLPRTprGSVLGALLRLQLDPRFMGPTLVMSLSFAMTFTYISAFSFVSESEFGTTPQQFSLIFGVNSLGMVLGNQVNTMLINRmgPRRLLAGLLGALASVAVLVGLaaNVVVVTAALFTMMFFTGLISPNATTLAIASQPSsaGTGSALLGALQFAIGGGLAATTGM-------------------------------
     800 UniRef50_B0CAE9        Major facilitator superfami...   136     9e-31  1  12.9%  3:390   8:406     --RWTRWIPSLDPQVWILAAGRLLSQMGTGFTLYFLQIFFVNKIGLTATSVGFAIGSASISGIVGRVLSGSMTdrWWGRRRTLLLSLFISAIAASIIAIAHSFWMLVVGNIVMGLGVGLYWPSTEAIIADLSEGEQRQEAFTITRfnAGLGLGVIFG---GSWIALTQAYRTLFIIDAVSFVIFLGVIYFTIAETSHPQTRghGWQGWVVALQDRRLRTYIIANILITTYLSQIHSTLPLYfqQGIGLSEVMITGLFSWHLGASVASQLPVARFLRRWPYPQGLMASAGFWGIGFLYIGItgVLIWASLGLGILAIATVAYMPIASSLVADLApeSRGVYLSINSLCWAVGYFIGPTLGGLALDQNQPFIDIYWGLLALSIGLVIIVLKR--
     801 UniRef50_Q07LA8        Major facilitator superfami...   136     1e-30  1  14.7% 10:389  19:405     ---------PRRAAVGFVFVTILLDMLSIGMILPILPKLVESFADNNTADagLFGTAWALMQLFASPVLGALSDRFG-RRPVILLSNFGLGLDYVLMALAPSLIWLFIGRMISGV-TSASIATSFAYIADVTPAEKR--AAVFGKIGAAFGLGFIFGPAIGGLLGG-YDPRLPFWVAAGLSLANAAWGYFVLPESLPKEKRSppLGAVRLLSSNRTLGAMAMVMFCAEVAHVALPATFVLYTTYRYGWDQTTVGLALAFVGVCTTIVQglVGPAIKRLGEFRAIVIGYSGGALGFLIYALAPNGTLFWIGIPVMTIWGIAGPATSSLMTRLVKPEQQGALQGANTSVNSIAELIGPFLFTMIFASFIGAGAPLDLPGAPFLVAGALLLV---
     802 UniRef50_C1DF27        Major facilitator transpote...   136     1e-30  1  15.8%  2:369   4:378     -PATSPWSPLRQTTFRWLWLASIASNIGTWMHE-VGAGWLMTTLSASPLNVALVQVAGSLPMFFLALPAGALADIVDKRRYLLGVQLWMATVATLLAALTlsVWLLLALTLCMGIGTALMMPAWSATTPELVDKDELPAAVALS--SVGVNLARAVGPAIAGVLVSLVGPWLTFALNALSFFAVIAVLLAWRRETEPAVLPaaLRAGWRYSRSSRPLQAVLVRALAFFLGASAGMSLLPLIVRGELQGSATDFGLLLGCVGIGAVLGAAFLPRLHERLGGDRLVLLASLLYALVLIALALLRDLYLLVPVMLLSGAAWIAVLSSLQVAAQTSVPGwrARALAVYILVFFGSMAAGGTLWGLVASRASIP-----------------------
     803 UniRef50_B5QU11        Purine ribonucleoside efflu...   136     1e-30  1  15.1%  8:392  15:393     -------ARPNWSAVFAVAFCVACLITVEFLPVSLLTP-MAQDLGISEGIAGQSVTVTAFVAMFSSLFITQIIQATDRRYIVILFAVLLTA-SCLMVSFANSFTLLLLGRACLGLALGGFWAMSASLTMRLVPA--RTVPKALSVIFGAVSIALVIAAPLGSFLGGIIGWRNVFNAAAVMGVLCVIWVVKSLPSLPGEPSHQ--KQNMFSLLQRPGVMAGMIAIFMSFAGQFAFFTYIRPVYMNLAGFDVDGLTLVLLSFGIASFVGTSFSSYVLKRSVKLALAGAPLLLALSALTLIVWGSDKTVAAVIAIIWGLAFALVPVGWSTWITRSLADQAEKAGSIQVAVIQLANTCGAAVGGYALDNFGLLSPLALSGCLMLLTALVVAAKVRI
     804 UniRef50_Q7VG70        Putative uncharacterized pr...   136     1e-30  1  13.6%  7:388   1:376     ------MIKTNPLLLPTLMLGVFALLSMELGMMGVLPI-VAEVYNVSVADAGWVVSIFALIVALVAPILPPLLTKYDAKK-VLLFCLLIFSVSSFLAAFCTNFIVLLILRAIPAFFHPIFCAFAFSMAADSVPHNESPKA--IAKIFIAVSAGMTLGVPLTSFIASNTSLEMSFIFFGALNALSLLATLLFIPNQKQEQKAPQN--EQFKVLAKPIVWVSVIVVMLLNGAMFGFYSYMSEFLLHFTQVSFNLISALLLIYGLSNVIGNFIAGKSLVSAPNATLRIVPLSLIVLYNALFFGGGNVWGASVILIILGIFAGIGNNMAQFVVTSPIPEAKELANGLFISAANIGITLGTSLCGLFISLNGSRFAVLAAVCLVVLSIIFLML----
     805 UniRef50_C7I2K9        Drug resistance transporter...   136     1e-30  1  13.8% 15:384  13:390     --------------ILTLGALTAFAPMSIDMYLPAFTA-LQHDLHTTPEAVQRTLVVFFVGLALGQAFWGPVSDRYGRKRPLLI-GIALYVLASLGCAMAASMDALMLWRLLQALGGCAGIVIARSMVRDLYAP--VDAARVFSRLTLVLGAAPILAPLAGAALVQAWGWRAIFLVLSAFGVACLLAALAllRSSAQQHPVRNALRIYFALLRDRRFIGFALSGALGQSAMFAYIAAAPFVFMQVFGLSSAQFAWVFGANALGLIAASQINHALLAHVGSGVLLRWALLSLAvlALAVLKVGGLWGVVIPLFIALSSLGFSFPNATALALAHQTGRVGSAAALMGSLQFTLAAASGSAVGVIAAHSALPMAAVFCAFAGLALWA--------
     806 UniRef50_B8G1S5        Major facilitator superfami...   136     1e-30  1  13.2% 12:391  12:391     -----------PRPILVLIIGGFIHSVGSSFMWPLNSIFMHNILGRSLTEAGALISLQALATLVGQFISGVLADRFGSRRVMIY-GLIGAILPLILISCFPIWEVYAPGLLFYGFAIAFIFVPINALVFTLWPEGGR---RGFNLLYVFNNAGVAVGTALGGFIAA-LSFKLVFLLNGLFFFIYLLMVLIFLPAKDIQSKPLSKSRVKVPIFKDRGfiALCAAIFLMWGAYIQINTVLPVTMTN-LGYSLPQYSILWTLNGVIIVAFQPVIHWIIRHWAPtrQFYVSCLFYAIGFLILLGNFPYPSYFIMMIIITLGEMLVLPGVPAAAALIAPEGkaTYQGVVGGAASGGRALGPILGGLAFDHYGGNMAWALALIFVSIALLPFYLYQR-
     807 UniRef50_C9KJ23        Transporter n=1 Tax=Mitsuok...   136     1e-30  1  13.9%  1:389   1:388     MADVAAPTRLWSRDYVFDIGVNFLVYSVHFLLMLWSTAYAIYTWNASISMAGLASGLFIVGALFARIPAGRFIDFVGRRK-MFLAGTLMFFLLVLCYELAPTLEVFMVVRFLHGLSFGTTSTAASTVVAALVPLKRMGTG--IGYFTLGVTMASAIGPFIAMNLTSAHEFTLAIEICSVATFVIFALSFFipERTILPEEKADLHKVSFDRFFSIKALAISCIALMAGVCYSTVLSFLGAY-TAHIGITGIGATGFFLCFAATSFISRPLTGYLLDHFGGNVVIYPALICMAIAMAFIGTASTDAAMLIGALFLGFGYGTTTASCHALAVHCAphQVGVATSTYFVLLDFGIGVGPYTLGSFVPSFGFSFVYLAAGAISLGGIALYYYL---
     808 UniRef50_B6QZ78        Drug resistance transporter...   136     1e-30  1  16.1% 10:388  18:401     ---------SLWEIVSLVAALMALNAVATSMMLPALPA-MSEALSVADNDRQLVITAYMIGLACASLFFGPLSDTIGRRTTLLI-GLSLYIIGGVYSTFAMSYEHMLAARALQGVGAAAPRVASISMIRDWY--SGRQMGKVMSLVMVAFQIAPVIAPFLGQVVLWFAPWQGVFAALTMFGVLLLVWCLMRLPESlrPLEARSILSAYRLALTTRVTVGYMMAMTFVFACLFAFINSAQQVFMERFAL-ADLFPIVFAAISIAMALSSYLNSQMVEKYGLRKMSHMALLGFTATSLLTAAIatIVSFIAIQSLAMFFFGFIGPNFNTMAMEPLGRVAGAGSAMIGFITTLIGALLGAGIGKLYDGTELPLVYGVALFSILGLICVLIT----
     809 UniRef50_Q7NKD3        Gll1545 protein n=1 Tax=Glo...   136     1e-30  1  12.1%  2:364   8:377     -TARPSFLPDLPAPVWILFAGRLLASLGLGFVLFYSAIFFTGALGISYTQLGLGLASSAVSGIFARLVGGTLTDrwGRRRTLL-AALVILSVGYVMFALADNFALFVAANVITGWGFGLYWPANEAVVADLTEGKQRAEA--YGLTRSGDSIGLGLGAVVGIAVIALTgyRLLFWLNACAFLGFFAVVARGVPETRPEheAHPSLGGYPEALRDRNLWLYAAANLVFTTIVAQLESTVPVYLRNFAGLSTEAVGACFTLHVALMAAIQLWVARGTSAWRRTRTLMLAAVVLAAALVIIWLAGTIAGSALGLAALALAVafMHPAAATLVAAMSPQnrGVYLSINSQCWALGYMIGPAVGGRILD----------------------------
     810 UniRef50_Q1CZ10        Major facilitator family tr...   136     1e-30  1  16.0% 15:389   7:376     --------------IYLLSFISFLIGTAEYIIAGIL-DQIAQDLNLPVPVIGQMITVFSIAFAVGTPLVITLTSSVDRKK-LLIFFMLVFAAANLVTLALSDYGWLNASRAASGLSAGVVEVIALTLAATLAAPGK--KAGAIAMVVIGFSAALVVGVPLGRVISGIMDWRYIFAGLGVLTLASLVLVVRAIPSTRGEAAV--PLKHQLKLLKNGQISIVYVMTFFWISAFSIIYSYISPYLANVARMADGTISIMLLICGIASIIGSRLGGWFTDKSGYAPTLLAGFAvcATLGLFFLFGQSAWIMYALLITWSLSAWSSGPALQFRLISLAPESTSIIFSCYTSMIQFGMAAGAIAGGVVIQIGSLDQLPSVGAASVLVSLVLLATV---
     811 UniRef50_UPI0001AF2ABB integral membrane transport...   136     1e-30  1  17.1% 12:391  20:393     -----------WLAVMAVTLGIFSLMTSELLPVGLLTP-VGQALDVSEGTAGLMVTVPGLVAAVSAPLVTVATGHL-DRRIVLVVLIGLMGAANLASAFATSFTVVLVARFLIGLSVGGFWSIAGGIALRLVPA--RHVARATAVIFGGVETASVLGVPSGTLIGDLSGWRTAFAAVGILGLVSLACMLFFMP--RVPAGRTVTFSALPQVFrnAGVRVGIALTFLVITGHFLAYTFVRPILQGD-GVADSSISVLLLTFGVAGICGNFIAGALVTRHLRRCVMGISVVLTAAMAVLALADTGAFSAGAILVLWGLGYGAVPVTFQTWILDAAPDATEAATSLYVSAFNLSIALGALLGGFAVDGIGTTSVLWAGAALTVLARFVVGGARR-
     812 UniRef50_D2C332        Major facilitator superfami...   136     1e-30  1  13.8% 13:389  23:399     ------------RVIFALAFSGLAELASLFFIQPLLPV-LAKDYDIPVSQVSIILSAETAMLAIGLLFTGTLADRYGRKR-LIVVSLLLGGLLTLICPLVKSWALLVMVRGVIGLSLSGIAAAATAYISEEVAP--VVAGVVTGYFVFGNSIGGMSGRVVASQLIGHVSIDVIFYGFALTLMFAALLVARVLPASKNFKASTSlvKGAQAHFKNKKLSLMYVVSFIIFGVFTSLYNYLAFYLAREPFNVSHANAGLISFSFIMSFFTAPQAGRLSQKYGALKVLSALFMIMIGGM-LLTLTANLPAFVIGAILFTGCFFGCHSIGLSWVSKNATHARGQATALYLFFYYMGGSVVGYCNGLIFSAAGWLGMTAFIITLLIGGILVATYL---
     813 UniRef50_C3HBM4        Major facilitator super n=5...   136     1e-30  1   9.5% 15:391   4:375     --------------VIFLAIGMFALGFDAYIIAGLVPG-ISDTYQKSASQVGQAVSIFTLCYAISAPLFASLLAGKPIKK-VLLTSIIVFGLANALTAVSPNFSIFLISRAIAGVGAGLFSPLAVAGSTMLVPVEKKGRA--LGLTIGGMSMGTVLGVPIGLYIADKFDWQSAMWFVVILSLIAAISILKFLPHVPVTAPPAMKER--LAMFLDKRVTITVLITFFASISSLGLYTYLSPLLQDLD--STSDLTIYLWAWGLGGLFGSITIGYLIDYfkPKTLMALILIILTVSVVCIPIMINLTIiyLPFFIWGAMGWASGAPQQHILLSYQPKHGSAAVALNSSINYLGSSVGATLGGVVISLggTMALIYFAIISMIISLGLQFYSMR-
     814 UniRef50_UPI0001B50E5E multidrug resistance protei...   136     1e-30  1  18.2% 15:388   2:380     --------------LLVAVASAFLVGLDSMITVPLVPA-IAEDTGTEARLGGLFVSAYALLFALAAPLCGAMSDRLG-RRTILTGGLVAFTLGNALTGITSDFTLLLACRALAGLGAAMIMPSVYAMIADTFPFERRGK--VMGIVVAGLLSSTVIGVPLGSYLAHLLGWRVAFFAVGGVAVLVCALVLALIPPVQPPAAQQQSAKsvGRAVTTPAVLCVLGCTLLWSFALYGMFSNIGIFYAERFGFNEAQTGLAIMGSGAGSMAGALLGGRIADKLGKRTVIVVAALVAAAGVTSVAlgDHIVPVLIVFIVWGTAVGVGQPSLSALVSELRPETRGTALALNGSAQYGGMMLATSIAALLLDNGVSFAVIGAICGACALAVLPLLV----
     815 UniRef50_A4BUQ4        Permease of the major facil...   136     1e-30  1  16.8% 10:390   5:391     ---------RSTAATLALASFVALGPLATDMYLPALPA-MATALNATPAQAQLTLSVYMIAIALAQLVYGPLSDRFGRKPPLLV-GLVLFTLASLACALAQSIEAVIAFRFLQALGGSAGPVLGRAAVRDVHGP--LEAARILSYLGAATALAPALAPIGGGYLLAAFGWPSVFIFLAAYGLAATALLWLALPEPLAPAQRQSivRNYRFLLRHREFVGYMLACAFTFAGLFAFLSGAAFVLIEFLGISAQHFGYYFTLAVGGYITGTLFAGRLSRRLGINRLLLIGGVIATLGGALMAALatALAVMLPMMLYMIGVGIVLPQSTAGAIGPFPQIAGSASALLGMVQMSIAAAAGILVGHLHSGTPLAMAAIIALMGTAGLASFFGLVW--
     816 UniRef50_Q392H5        Major facilitator superfami...   136     1e-30  1  15.9%  2:366   6:364     -SSVPRRGARLPLAVFVLGLTVFCIGTTEVMVSGLLPL-LARDFGVSIPSAALLISGYAAGVVVGGPAMTLAFLRT-RRKTALLVLLGVFIAGQALGALAQNYALLMTSRVVAALAQGAFFGIGSLLAIDLAGPDAKGRA--LAVMFGGLTIANIAGAPFGTLIGEQYGWRASFWVVTALAVLSLVATTLVVPMQGRPPYHGIARE--FASFRQPRLWAALGISALSQAGLFAAYSYFSPIFTEFGGFARAAVPALQALFGIGCFAGTVVGGRYTDRYPAGILVAGLVGLIVTMAAFGALAHSRTGTIVALAAFGIAAFSINPALQARAIAEAPHAPTLATTANTSAFNVGNTVGPWLGGVAINAG--------------------------
     817 UniRef50_B5H3A7        Putative uncharacterized pr...   136     1e-30  1  16.7% 10:387  24:400     ---------PLTRELTVLSLAAFATAIGIGILAPTLPL-LARDFGVSNTGAAAVVSAFALARLVCGAVMVRLAHRADTRRVML-WGLAVLAVSSALAGWATSYPVLLSLRIAGGVGSAMFSVSGMALVTRHAPA--TARARATGVYIGALLLGTALGPAAGIPFAG-ISLRAPLFCYAVLAALSFLLVLIGLPrrPAEQGTARKRTPLRQFLRGRPYLVVLTLNFAVTWCLGVRGSLIPLHMVENLGESASLVGWVLFSSAVFNILLLPLGGRISDREGWRPVLLTGCALAALGLLTTAAVPQLWALFLGLILFGAGAGILEPPSGAVLAEVSRDGDTTPVALHSTAGDLGMILGPLAMGALADGLSFTWAFAVTTAVMAAPLLLAL-----
     818 UniRef50_UPI0001B9ED41 drug resistance transporter...   136     1e-30  1  11.5% 16:390  14:393     ---------------LILATFSALGPFTVDMYLASLPQ-IAVFFGTSAAAVQASLTTSLLGLGLGQLIMGPLSDMYGRRPPLL-TSMILYILSSIGCAFAPSIEWFICLRFIQGVAASAGLVISRAIVRDRFRGVEMTK--FIALLTMISNVAPLISPTLGSAVMSYSSWGSVFLFLGALGIALTAITLGGLKESLPVQQRVPsiKNYNSLFRERSFMGYALVNGILFAGVFAYVAGTPFIYQNMYGVSPQMFSILFALNGLAIIAGSQFVKLFAGRVPESRLFRIGLIIAFISSAAVLFvgALSAMFISIFLFAFSIGIIGPISFTLAMESQGHIAGSASAVLGSLQFALGAVTSPLVGIAGENSAIPFGVVIFSTSVLSIAAYLILIQ--
     819 UniRef50_UPI00019F2159 putative sugar efflux trans...   136     1e-30  1  11.8%  2:390  18:398     -KYTVSGHHLPWSGLVALAMACFVTMLTEAMPAGLL-LWISPDLGVSVSYSGQLVTLYAVGTLISAIPLVSLTQSM-RRKPLLLVAIVGLVIINIITAFSHNYVLTLIARFFGGIFAGLVWSLAAGFAIRMSPPHLAGRAIAIA--MLGTPLALTIGIPAGAYLAEFIGWRSDFMMMSALTVILVAWIMVSVPDSPGAENDSSHL-TLLQVAKVKGLIAVLFVTLTFILAHNTLFTYVASFFAHA--GLSDNIDLVLLVFGVAALAGVWCAGITVDRWPRKSML-ASIAVFSVSILCLVFVRQHGVIYVSVAAWGLAFGGAPTLLQAALAKTAGNAIDVAQSMMVTVWNVAISGGGLLGGILLGRLGIQSLPFTVEGLLILTFVVAFNAR--
     820 UniRef50_Q3A1Q0        Putative transport protein ...   136     1e-30  1  14.3%  8:391   6:386     -------SQLYSRAFWAMSLANFSTAASFGVF--FLFPLFIEARGGSEADIGIIMGVFGLAATLCRPWVSGLVDRIGRRRSFTVGSLMMVGlmLLSGPLAGFYPGLMLLRILHGVGMALCFTAAFTFVADIVPPERLNEG--IGIFGISGLVGMAVGPALAEFALHRYGFFAMFVVASLLAGVGLVA-HLPLSEPVIERQARDVDTSFLDVLKRPKITTVALLAILFGLGQASTGNFVAPLAAARQ---VVHVSLFFVAYSVAAALVRIGGGRLADRVGELRVIPYALVITGGGLLALSVAYQAWSLTLAGAVTGCGHGLLFPSLNSLAVRDEPGgrGKITGIYTGALDGGNFCGSILLGYIGEWLGLQILFMVAGLALFSGLVVLPWGLR-
     821 UniRef50_Q21A62        Major facilitator superfami...   136     2e-30  1  13.1%  2:389  10:424     -SSLVKATKIRWIVAGLMWSAIAINYIDRTVLSAAAP-HLSAELSIPADQMGFILSAFFWSYALLQIPAGYFADRFGQ-KIGLGASVGLWSVATSATGLATGFYSLFAMRLGLGVGEAGAYPSNAGIASKWFP--DRERATISGLFDSASKFGGAVAMPLIVWLIALVGWRMTFVVIGAIGVVWAIIWWWFYTETPETHPMANKAerWYELLRYRNIWAMCLGFFTINYISYFFITWLPMYLVKEKGMGMIQMGFIAALPLLSGLVAEIVAGMLSDRVVrrKLFLIAGLSMALCIGLAAVAESVALTVALLCIAKAGTTIAASQVWALPGDVAPKNMTsvAGLQNMVSNFGGVVGPIVTGFIVAQTgfTAALVFSAGIGMLGILNYALL---
     822 UniRef50_D2SAZ8        Drug resistance transporter...   136     2e-30  1  16.5%  2:388  28:420     -PTTSSAPPSRALLALLLGAFVAIGPLTIDMYLPALPT-ITAELGTTSAMVQLTLTGTLIGLALGQLVLGPLSDAFGRRGPLL-AGTALYVVASALVLVAPTIEVLGALRVLQGVGTAAGAVVAMAIVRDLYTG--RAAATMLSRLFLVLGAAPVLAPTLGGELLRFTSWRGIFAVLAVYGLLLLAIGALGLRETLPPSRraGTLHTYRGLLRDRTLVGLVLVAGLTMAGLFSYVSGSSFVFQRQYGLDEQQFGLLFGAGAVWLIAATQLNPVVLKRWAPAQVLVAGVVAGALSGAVLLatGGLPGVVVPLWAMLFASGLALPNAPALALSRHGEAAGSAAALLGAVQFGVGAAVSPVVGLLGNDAAAMGTVILAALVLAIVVLATVV----
     823 UniRef50_B5ENK2        Major facilitator superfami...   136     2e-30  1  15.8%  7:392   1:385     ------MSPFEKRAVAGLSFIYVARMLGLFMLMPVLALDNDQLRHSTPVLLGLAIGIYGLAQAALQFPFGVASDRFGRKR-VLVFGLLIFVLGSLLGAVTHNIWGIILARLLQG--AGAVSSVLLATAGDLTGEQHRTKAM--AAIGGSIAIAYVLGMAMGPVFYGLSGLTGVFLVAAALGVLALLPLWKVIPPIPRnqQRMGNWRDALRIFRYPPVLTASVGIFILQMVLGASFVVLSPELVKAMHIPGSAVWEVYLPVMLLSVAGMLYPVIHAERHRQHGQMLvgLAIAAGALFMGLLAGHFWPVAVGAVIFFTGYNVASAILPSMMSRSTteQRGAASGVYSLMQFLGIFAGGVVGGWGLGMAGEQGVFYLLAVVGLLLALQSWNGKRV
     824 UniRef50_D0ICB3        Transporter major facilitat...   136     2e-30  1  31.6% 19:391  17:391     ------------------LLVSLFAGLSGGFFYPLLGIFVVDGLHASSLQMGIFMAISILSGVVVSQRIAKLSDVGWDRRQIILLAQSAFIVVMMLFMVIRDFYLALAVMIFISSFTAAALPQTFAIGREFADKNLGDKSTLfsLMRAMISLSWVIGPPLAFILYDAFGFNGAFMFAAANMMISLLIVWRWFPSTKLNETESSDGSAMRQPwkIPGAPLYLCAVFMLFMANNMYVMSIPLYVTKELEMAGAVAGQLLGLAAFVEIPVMVLAGLWAAKMAPQRLMVLSAAAACLFYTLLFHADTLWQMYALQLLNGLAVGISASLGMVVIQNKMPNQMGVATTLFNSAIMVASLASSMTVGVVAELYNYHSVMLAMLLAGAVAFGLLLLSAR-
     825 UniRef50_B1EKH7        Major facilitator superfami...   136     2e-30  1  13.8%  1:390   1:416     MTTGSGQWRVRNKMLLILWLIFLISYLDRVNFSVALPA-ISNELGLTAGEKGLVLSAFFIGYGLLQIGAGLMVDRFGGRVTMTLA-LFWWSLFTAFTGMVGGFIGLLLVRPLFGAGEAMHPPASWKLISQWFPKKEQVRA--NSLNLCSIALGPAFAPLLVVLLMQWVGWRGVFYIFAIPGFIVTWLCWKYMRDKPEDHpkEEKRLALAAAVREPGLWMLMCTYLLFGIAFWGFLSWLPSYLVDVRQFAMVKMGLVASIPFFASFVAMLIASWVCNHlgRKQIFVATCYLLGALFMWQAFAAADPNMCVLWLTLTAAFGIFMpvFWAISMEVLPTkmGFASGFINTGGQIGGFIAPIAIGYLIQYysYAAGFGLMVGCLIAAAILVLTIR--
     826 UniRef50_C6VJS3        Transport protein n=3 Tax=L...   136     2e-30  1  13.2%  5:383   1:378     ----MNSKSLNKSTVLLMAISAAIVVANINYIQPIEAD-IAQQFNLPNAVIGAVAMLTQLGYAFGLLLIVPMGD-IMNRRMLIMRLLVLAIISALLAFVAPNIWVYALASLLIGI-TSVAPQVIIPYAGFLAPRNQRG--QVLGNVLSGLLVGVLLSRTVSGVLASYLPWQMVYLIAAILIAGLWLVLWRKLPHDPVTTHTTNYKAMIQTVprYPVLRASAVNGFVLFGVSNIFWATLVFYLQHQYGWGSREAGL-LALLGVTGVLAAPLIGRLADRFRPRTIIGLGLVLSTLAYVVFWLstHLVGLIIGIVILDLGTQFGQVANQTRIQSIDVHASSRFNSVFMFGYFMGGALGSFCGNVLWDLAGWNGVCGLAVVVLMIGF---------
     827 UniRef50_A7IQ46        Major facilitator superfami...   136     2e-30  1  16.7%  7:389  10:395     ------QRPPIPKTVWALGFVSLFMDISSEMIHALLPLFLTATLGAGVAVVGLIEGVGESTAAIVKVFSGYLSDRIGRRKPLILIGYGLGAASKPFFALAGAPAMVFAARFADRIGKGMRGAPRDALVADVTPPSIRGRA--YGVRQALDTVGGFLGPLLAIALMALfdMRTVFWFALIPGALAVACVILGVEDRAIGEEGATGRPPPVRLADLRQFDGAFWGVVAIGVVFTFARFSEAFLVLKAhgLPLALAPLVLVAMNVVYSLGAYPAGAWSDQASPTRLLLVGLAVLIGADLMLAFAPGLWGAFFGIALWGAHMALTQGLLAKLVAQHAPalRGSAFGLFNLATGVAMLMASVVAGVLWERIGSAATFAAGAGFAVLAVLLVMVF---
     828 UniRef50_C5V8U8        Permease, major facilitator...   136     2e-30  1  15.3% 26:390  24:387     -------------------------PFSIDMYLPGLPQLGRD---LATTNAQLTLSGFMIGMATGQLIIGVLSDTFGRKR-FIVGGAALALITSLLCAIAPNIGVLIAARFLQGLGSGACVVLARSIIPDIT--SGVAAAKAFSWMGIISGIAPAAAPVLGSLLVSSLGWRGIFYVLAGIAAAQLLVALFVIPETRPPANRTpsFGSFTAVIKEPVFVRYALVVGFGFASMFAYISASSFVMQEIMGLSPQIFALVFGTNALGLMVGGALNTRLLDRFPAAAILKIALIIMTValVCALTGLPRIPFFLALFFAVMPLSLVMGNATALAVAAVRTRAGSASSVMGFGQFLLAGLVSPLVGMVGGSQAVGMGVCMVGAAVVAVMMFVLARR--
     829 UniRef50_B3TA26        Putative sugar (And other) ...   136     2e-30  1  13.1%  8:390  31:415     -------RRGRNKLAATVVLGHAFKHIYNSGLQTILLPEIKIGLGLSATQFGSLAFSRQATSWVTTMGAGYLGDRFANRalMLAASLVLTGVSYFVAGFAPNYWLMFAVMMLVGIGPSLYHPPAIGALSRRFPD---RRGFAISLHGTGGSVGEVLGPIITAGVLTLLMWRDVLHVSLIPALLAALVIWSMMrdVPGTASTRAYFTSVATLLRKRALLSLVLVTALRSMGQGVIITFLPVYLREDLEFSATRVALYLSMSQVVGIGAQPAMGFLSDRFGRKVVLMPAMACMGLLFMALAYADPGVQMVLTVLALGAFQYSLHTIFIAAAMDVAGGqqSTIVSLIYGAAIFG-TVAPILAGILADAYGVPSAFLFGGSVVLLSTFVLGLLK--
     830 UniRef50_B6J392        Multidrug resistance protei...   136     2e-30  1  17.9%  8:392  16:403     -------KQHMKKNLIVILTSVFVTvfAMALYLPALPA-LTTYFHTFPGVIQLSLTLFLIAFGFSQLFYGSLSDCYG-RKPLLLIGLVIVMIGFLIAVFARHLSLLLIARVVQGLGAGSVSVLARAVIRDRFEGKKLVQA--LSLLIMAASLAPMIAPFIGGHIQRRLGWHSIFIFLFFYSGLILLGIFFLLPETKKTESVpaLLNNYKLLLRHPIYIKYVVCIIMAYACQILYLSISPFIFQNGLKLNAAQYGTIITLPAIGYFVGNFLSTRLIRFFDSNHLVFVGALIVVMAGIALAlgLSAFSVITPIIFCVIGIGLIYPNVISGSLSPFPQMAGTAAALSGAIQMAGT---SSIAG-VTNALHVVSVLGLGISFLLCGAVVLLMIFRI
     831 UniRef50_C0GK28        Major facilitator superfami...   135     2e-30  1  12.5%  7:391   1:386     ------MKADSALKVGILSLSNYITVLVNTILFPVFPA-MARDLGINLTDLAILVGIVSFPAAVINLFGGVLADRFGRKLVMVVsgLGGLVAGLAILFVAKPYPLLLVGRFLQGLGSATPMFLSVALVGDIFQSIERSKA--VGFLETANGLGKVSSPVLGGAIG-LLAWQAIFFLYPLVAIPVAVATWVYIKEPKHDKSVedKHKEAFLLFTNRSRLLSLVAAFLVIFLLIGTMFWMSDFLGAKLEVNKLLRGVIIALPAVAMMLTTLAAGYISQRLHPRIIIALGMLLLAGSAVLLGFFFNALLFWPLIVLVGIGAGITLPAIDTVSTSvsKDIRGLTTTIYGSARSLGGALSPITFSFLL-HYGNRLTFASLGAAGLALTVIFYLLFR-
     832 UniRef50_A4IRY4        Multidrug resistance protei...   135     2e-30  1  15.6% 11:368   1:359     ----------MPRALWWLLIGMVLNVTGGSFLWPLNTIYLHEQLGQPLAVAGAVLMLNSGGSVIGSLVGGVLFDRIGGFRALLVGACS-TVVASAALSVWHGWPHYAVFLALLGIGSGIVFPVSSAYAGAIWPEGGR---RAFNALYVAQNLGVAVGSALGGFVAS-YSFSFVFFANLLLYVAFLLIVVVGLRrpPPKTKRAAEVKTSTSRAVGWALALLCVGYGLCWIGYVQWSTTIAVYMRE-FHLSVRQYSLLWTINGALIVLAQPLLSRVIRRfgMKRQMVIGFAIFAVSFAMLFGADSLGEFVASMVVITIAEMVVWPVIPTVVNELApgKAGFYQGIVNGTAMVGRMIGPVIGGWVADELGM------------------------
     833 UniRef50_B9JLQ9        Permease protein n=2 Tax=Rh...   135     2e-30  1  13.5%  3:386  14:392     --QTNGAARSKNLTLLALALGSFSIGTSEFASMGIIQLF-SNSLGISVPEATSAITAYAFGVVIGAPLITLAAARL-NRRTLLLALMGLFIAGNVLSAVASDLGLLMLARFISGLPQGAYFGAGAVVASYTVGPGQAGKA--FAIVMTGLTVATIVGSPLATFLGQTIGWRETYLAVAAFSLLALSAIRQWVPRTK--ALDGVPVIQELSALRKGPVWGVMLVAALGVASIFAVYTFIAPMATDTVRLAPAMIPVALTLFGIGMTAGNVYGGKLADRYPARGIALGFGSALVIMAILAVGGANPWIFFPAMFGVGGAMMAAIPTIQVRLTRFAPEAPSLMGAMNLASLNVANAIGAWAGGliAAGYGLLSAVWAGFALTLVGLGIF------
     834 UniRef50_Q2NXX4        MFS transporter n=21 Tax=Pr...   135     2e-30  1  15.3% 13:390  58:435     ------------RIRLALFLAGFATFSLLYSVQPVLPEF-ARAFQVDAATASLPLSLATGALALAIFCAGAVSENLG-RRGLMFASIAIAAVLNLIAAFLPHWGALVVIRTLSGIALGGVPAVAMVYLGEELPANKMGAAT--GLYVAGNAFGGMSGRIVMSVLTDHTDWRTALAVLSGFDLLCALAFFWLLPPSRNFVRRHghLSAWAGHLRDRNLPFLFALPFLLMGVFVCLYNYAGFRLGgeFGLSQSQIGMIFSAY-VFGIVSSSVAGAASDRFGRGPVVTAGIVLCVLG-VTLTLARVLAVVVAGIVLLTIGFFIAHSAASAWVSRLGGAHRSHAASLYLLAYYAGASTIGALGGWFWQHGGWGALVGMWLTLLAIAFAAAYILR--
     835 UniRef50_Q1V9Z1        Putative sugar transport pr...   135     2e-30  1  13.2%  9:388   2:375     --------KKQSLFIFALSLAVFGVITTELGIIGLLPQ-VMKDFNIDVQEAGLLVSVYAVVVAVSGPFITLLMSGW-NRKYVLIGILSLFVLSNLVYAITQDYTTMMIFRILPALMHAVFFSVALVAATSMVPAEEQSNAA--AKVFGGVAVGLVFGIPISAFLAEQYSLAYAFYFGLTACAIALVSVMFLMES--APVKEKMSFGSQVTILRSKSMWLSLSTVIFVFAAMFSSYSFITQYLSTVTNMNGTWISAMLMVFGVFGIFGNFIFGKLLGKNMKKTVMLYPVILGLIFVTVYFMGFSFSFMVAMVAFWGAVHSAGLVVSQTWVMDNAGDAKVFANSLYISFSNFGITIGSIVAGWFIAQFGVENLFLSSLAFTVLALISILL----
     836 UniRef50_Q47H29        Major facilitator superfami...   135     2e-30  1  16.3%  6:391   4:392     -----APEAQHRRAVMLLSVAAFASAAAARLCDPMLPD-LARSFTASPTAVASVISSFAIAYGLTQAMFGPLGDRLGKYR-LIALTTLLSTLGALGSAIAWSLDALVVSRVLLGATAAGIIPLSMAWIGDTVPYEQRQAT--LARFLGGQILGAIGGQFIGGVFTDTLGWRWAFAFLAGLYLIIGAVVLLESRANPSTHHRHAdlGQAAQVFAQPWARVILSIVFLEGMLVFGALAFVPSYLHEHFGLSLTMAGAAMAFFGLGGLSYILAARHFVRLLGEVGLATGGGILIALGWAMLAWGTTWLWALPASYFVGLGFYMLHNTLQTNATQMAPAVRGTAVSLFASSFFLGQSLGVTLAAHILAASGILPMLLIAAIGtlVGGTLAWLLSR-
     837 UniRef50_C6J037        Major facilitator family pr...   135     2e-30  1  15.9%  6:383  21:397     -----TPIRLSRFLVLTMAVTAGIAVANLYYIQPLLAE-IAASFGVTQSQVGYAATLTQVGYALGMLMILPLAD-IREKKSLILFMLVCSAGALLFLAFAWNSIILSVASFAVGF-TSIVPQLIVPLAAQLADPKEHGR--IIGTVMSGLLIGILVSRTFSGLVGEYLGWPTVYFIASGLMILLAFFLAFRLPKSPSVATAgdLFRSMASLIKdpLLREASLNGGMMFAAFSVFWTTLSFLLAEPHYGLGPDAAGLFSLIGVVGALAAPIAGRMADRRSPRFTIAIGMGAVILAYamLGFGYTLAGLVVGVILLDLGVQSTQISNQARIHAISDEYRNRINTIYMVSYFIGGALGSGIGSFSYAHFGWTGVCIAGLLTQLVAV---------
     838 UniRef50_UPI000187442B protein AraJ n=1 Tax=Capnoc...   135     2e-30  1  12.6% 11:392   1:378     ----------MIKKLWPLAIGGLALGATEFLIMGLL-RVIGEDMHLEDAITGRLISAYAIGVVVGAPTLIALAASYNPKK-ILLFFMFLFTLFNGLSAFSPNYTTLLLARFFSGLPHGAFFGVGAIVAKQLAPKGK--EAFAISIMFAGLTVANLIMVPLLTYIGAWIGWRTAMGCVSSLGLLTMLSIFFFLPNI--ENKRDLGIKREVRLFFNPRSLLVLGITALGCGGLFAWFSYIQPLMIETAHINPDMKSVVMIVAGVGMVVGNLLGGWITDRLSpkATIYISLMLISVLLLVFFFSHIQPIAWVLTFVCGAMSMSLGSPLNMLIFRCAPQSEMMGAAFMQAGFNTANSIGAYVGGllLYGLSTNYPSLMGAGLASLGLLLTFYLWRI
     839 UniRef50_A1VJV0        Major facilitator superfami...   135     2e-30  1  16.2% 14:390  24:405     -------------TLGLMAFGFALVNLDRFIMYPLFPV-MARELGLDYQDIGLISAAVALTWGLSSMVFGRLSDRLG-RRGILITSVLVFSILCGATGLAMGLGSLLLIRAVMGVFEGAFVPASIAAVVDSSPAGRVGRNTGLQQLMAPLVGSALAPVLAIGLLQVLPSWRWVFVVTALPGLLCAWLIFRKLAEppSPGQAPAIQAPLRTVLACPNVALCSVGFCFWLAPIVIFGSLMPSYLSDHLHLELGQMGLVMSSLGVGGAAGMLVFPALSDRWGRKKMMVSCLVMAMltWLLMQTGAEPLRLSLLMFLAAAFISGVIAMVHSVTADNVpqHVSTATGFIIGAgiVGGAIAPAVAGGLAKAMGIAAILPFSLGCMATGLLLAIMLR--
     840 UniRef50_B8GI30        Major facilitator superfami...   135     2e-30  1  14.9% 15:390   8:380     --------------ILILCLVAFFAMAGGALLAPVLPEMMGP-LGTTAQNVALLMSVFTISTAVFTLIIGHFIDRVNRKR-ILVPSLVLYGLTGLVSFFVADFSLLLVLRFLQGVGVAGMTSMAMLVIGDVYTGFDRVSAM--SKISISFALGSIFAPVIGGSLA-LLGWNYAFLFYA-LSLPFAIIVILSLPETKVQTDTRDHKGMIEAllRVLPIIYTIFMGFSIFFILFAMMIYVPFMLKSVFGYGSGESGLMLAIPGISCILFASRVGPLAGKHSLLMVIAAGFACVGLSMLFMPVLHSLAAVFLLLLLFGAGLVLAQTAIDVQIIQVspASRGGVISIHNCMKYVGQSASPIVLGIILAYYGLNAVFIAAGVFGLLIALTTYLMK--
     841 UniRef50_C3JSP3        Major facilitator superfami...   135     2e-30  1  12.9%  4:391   2:387     ---TARLPKATTLRLMTLAGAAFAYVTAEMLPVGLLSE-ISTDLDVTEGRVGLLLTFYAYGVAVLTLPLIGAVKTWPRRRVVVLT-VATLAVSQLVAALAVNYPMLVIGRLLCAATHGVFWAVVAPVAATLVPRGQQGKA--IAMVYAGTSLAFVLGGPLSSAIGQSWGWRTASAAIGVVAVGIAFSLHRALPEMPVDQHHRSKrkPKPTPAMKRALAVICAATLFAALGQFASYTFFTLLVEESLGSSGGIRTAMLLVYGAAGAVGVWVAGKYYDRRPRLFTLISIATVAGALAIFWLLAPSMGAfvVATILWGAAFTTVPICLQSSVLRAVPIGTDRASAIYVVVFQIAIATGALLGAAVVDSGGLSHLAGIGVALMIASLAIVGFGRR-
     842 UniRef50_Q3SQE5        Drug resistance transporter...   135     2e-30  1  15.1%  7:384  26:407     ------QPRGFPEFVALVACIMALNPIATDMMLPAMPDVRDAYAIVHPNHVQAVISVYLAGFGAGQFIMGPLSDRFG-RRPILIGGMLLYSAAGLLSVVASSFETMLLARVLQGIGSSAARVIATSIVRDCY--SGRRMASVMSLAMMIFISVPVLAPSLGQAILLFSEWRGIFVVLTAYGLLALLWCALRLPETLPPAGRKpvFDAFRQTVTNRQTIGYALAAGGVQSVLFAYVFCSQQIFTGIYGLG-DYFPLAFAAIATGLAAAGFLNARIVGRFGMRVISHGALTGSVVIAALTLLAasFPVYMVFAIGTMFAFGLMFSNFTALAMEPQGHIAGTASSLFGSITTL---IGSGVGAMIGQDFNGTMlfTASAFLCTIAAL--------
     843 UniRef50_UPI00016A85C7 Drug resistance transporter...   135     2e-30  1  16.9% 31:391   1:365     ------------------------------MYLPGFPA-ISIEFGVPHRLVQYTVTAFLTGVIIGQLLHGPVSDRVGRKIP-LCTGILLYIVASIGCGLAQNIWMLIAWRFVQGVGGCAGIVIGRAMVRDRFGPN--GSARAFSLMVTVVAVAPMIAPLIGGWMAGA-GWRVIFAILALFASLLLIGVFFTINETLPAERRvsIFGQYRALLSCSQLLAYTVVSGLMQSALFAYVVSAPFVLMEVYGIPAQYFGMVFFANTAGLIFASQVNAAIVERFPPDRILGVALLCPAVLSIMLITasSLFAVLAVLFGFLVGHGFISPNASALGLMKHGKHAGTASAVMGAVQN-GLGVATIFMTSLFKITSALPLALVMGSCSILAIACHRLIAR-
     844 UniRef50_Q2RM84        Major facilitator superfami...   135     2e-30  1  14.8%  7:390   1:393     ------MKASMKLPFAILCTVPFIMVLGNSMLVPLLPL-MRSSLNVTLVQVSLFITAFSLPAGIVIPFAGFLSDCYGRkpALIIYGAGGILAGLAAWLVASPYYLILGSRILQGIGAGGTYQLAMALASDIFQSNERTKA--LGLLEAANGLGKVVSPIAGAALGLLL-WFAPFFVYGILAIPIGLAVWFLVREPEQGNKNKTDFHSYFHNlkGLSLMASILAGMIVLFILFGVLSYVSDLLEGRYGVTGIRIGLLIAIPVGTMALTSYLSGSYLQKTalKIVIIAGLVLEAAALVIMGFFANIYIFFLAMILMGFGTGIVLPAVNTLITSASARERGGITCLYGSARFFGVALGPPAFGLAMTLGKLPLFLGAAVLVGIIAFLTIAFIQ--
     845 UniRef50_D1BTZ5        Major facilitator superfami...   135     2e-30  1  16.1%  8:391  19:394     -------PRRATIILVAMAVSTFLFVLVEGLPGGLLTL-MAPDLNTTTSRIGLLVTGYALVVLVTTVPLARITQHI-PRRWVLSATVLVAAAATLWAGLAGSYGSIMTARLVTALAQALFWVAVIPGTTGLFPP--RVRGRVVARLALGNSIAPVLGLPVGTWLAEQTHWRVTFWVVSALSTVIFVVVVMLFPTVRPSEGGASRAPFP----SRPRLLYQLVTTALIVTSAFGLITFVTQFLQDVAGYERADMPWLLVISGAAGVVGAFTVGRFLDRHSWGSLTVGIAVVAVAQVLLFATGAHPVAAIAGIALFGCAFSTVPPALSHRVMLVAPGSTDMGVAVSSATFNLGIAAGSALGAALTAAVGVRWVPFVGAVLAVLALGANLLENR-
     846 UniRef50_Q03P09        Permease of the major facil...   135     3e-30  1  11.9%  5:391   1:389     ----MKNVQKSGPSLGLVIVLVGFPQISESIFTPVLPQ-LQHVLAVSANQIQLTMSTYFVAFAIGVLVWGQLADYWGRRPAML-AGIGVYLVGNVGLLVSTQFTTLLIWRLVQAFGASTGSVVTQTIMRESFTGVRG--AKVFAKTSAAMALAPALGPLIGGIMQTISGYRGVFATLVTMAIVVGLLAQAGLPETRQLTTHAPIVKQRlrLLTDSVVWGYGLLIGGINGALFSYYAEAPFIFMTHFGYSAVAYGWLGLVLAAASLLGALIVGRLLNRWTPEQVTGGGLivMSAGLVGAAALHQATLMIIGIFLTFFGFNITLPNALNRALVGYEQVMGSASGWFSLGYYLLVSAVTYGMSWWHNGAINRLPLYLLVLSLGMGLAFWWLIRR-
     847 UniRef50_C4FS92        Putative uncharacterized pr...   135     3e-30  1  18.6%  7:388   1:390     ------MDSSWKRIIYLICIIQIGGGITIIGVLSFLPLFLIenPGEAAMWAGIVSGVTPCMVALSAPYWSRKANQLGPRKVMMFILFTLM-VTVGACAFTQTPSQLLVLRILQGVV-GGYVPIGLAIIVLITPEEKVPWAM--GLYQASMVMGLVFGPLMGGLAADLLGYRAPFFVFSGLTGICLLGIYFLMPnkHKVDAQESQISLIKSFLMIPRVRLLVAMQFLCNFGITGIGPILPLYIKHYMSVnaTIVGIIIFGAGLFSALASISISKVTQRLTMPRIIFTATWAVGSLFILQYLMPSIWGLGIFRAIAGFFMGFIAPIANTLISKAVpeRRGIVFGAVSSVAMMGNVLGPVISGVIARAFGYGAVFWSTAAIFFVASWFVYR----
     848 UniRef50_C7I2X5        Major facilitator superfami...   135     3e-30  1  15.4%  9:390  33:413     --------PPEWLRRAAVTAAGMCAFFTMYLTQGLLPS-LQSVFHASVAELSLTITFTTLAVAVAAPFSGIAADRFGRKRVLLV-SLAGLGLSTLLAATATSLHGLLVWRAIEGLCIPGVFTATVAYISEEWPPSEVPAVT--ALYISGSVAGGFSGRFIAGMVTAHAGWQAAFVVLGVINLLFLLLIARGLPASRRFAASraALSGFALHLRNPKLLGTYAIGFGILFSQVCTFTYVSFHLAApyGFDLKDLSLLFTVY-LVGMVATPLAGKLAWKFGKRRVFVVAVALGSGGMLLTLLSP-VWAIVLGLTLSSGGVFIAQSMATAQVPALAGQARSAAVGLYVLCYYVGGSVGAFGPAWVWAHAGWAGCVALVLIAQLAIGVAAWRIW--
     849 UniRef50_B8HY97        Major facilitator superfami...   135     3e-30  1  16.1% 11:390   1:386     ----------MSRTLWITLFVAFANGLSFTILIPILYPY-GRQFGLSNFETSLLFASYAAAQFFATPVIGKLSDRFG-RKPLLIVSLAGTVVANLLAGLAPYAAILFLARFLDGI-TGGNISVAQAIVSDITAPAER--AKAFGWFAAvfGLGFVLGPAV-SLLAQQISLGAGFLVSSVIALIALILTIVALPETLPTKTAQagLGKLITGLAWPKLGILFVINFLIGTTFTIFTFAFQPYFLHILGQDNKSLTLQFMLFGMVAIAMQagIPWLTRHLSLTRILFLGLLVRSLAFVLMPLLPNIIYFIGLSVVFSIFNALVQPMITTLISLNapEEQGTALGLNASYLNVSNAFGPIIAGTivDPRTYAYPLFLAGGLTFSVLVFAILTR--
     850 UniRef50_A8LGG3        Drug resistance transporter...   135     3e-30  1  14.5% 12:391   5:384     -----------RRTLLVLGFLVALGPFTVDFYIPAFPL-VQADFGTSAAAVQLTLTATTIGFALGQLAIGPWSDSIGRRRPLLVA-TALHVAGSLGVAAAPTVEVMLVFRLLQGAGAAGSGVVALAMVRDLFDGALFVR--MAARLAVVTGLAPVVAPFAGSLMLSHMSWRGLFVCIALYGLAVLAVAAFLVRETApvRRAGAPLGRYRVLVTDRGFVGAALAGGLLVSSVFTYMSSSSFLFQETYGLSAQRYSLVFAANAVGFVIGAQTSARLVTRIGPRRLLRYVlfLGFTLLLAAFAGENVVVVTFVTALYFLLAGAVGPCLQVIGMAPHGERAGTAAALMGAANFGLAGATAPVAGLL-GVGSIGPIGLVMGLTMTVAVVVFRVLAR-
     851 UniRef50_A3SNW7        MFS permease n=1 Tax=Roseov...   135     3e-30  1  14.3% 12:388  16:387     -----------NAALFALALGGFAIGTTEFASMALLPDF-AAHYGVSEARAADAISAYALGVVVGAPVLAVAGARL-RKRAMLIWLMLAFAVFNTLSALAPNYASFTFTRFLSGLPHGAYFGVSALVAASVVPPHKR--ATAVAWVMMGLTIATTIGVPAASLMSQITGWRSAYLLVGLLSLATAFAVWRKTPPSPADSAASPLRE--LSALRNRQVWLTLATGAVGFGGFFAVYTYIASTVQTTLGSSETAVAVMLGVAGLGMTVFNLLAGALADRHLNASAFFCLGLGTVLLLLYPTLAASGLWPMALGLFAICVLGGISTVLQIRLMSVAGEAQQLAASLHHAAFNVANAVGPFLAavLLAGYGFPASGYVGAGLSAAGLAIYML----
     852 UniRef50_Q2IWC5        Major facilitator superfami...   135     3e-30  1  14.6%  8:391  10:393     -------RPSLPPALKIIALSGFAASLSARALDPVLPR-IASEFSVSIATAAGLAAVTAFTFAVVQPAIGALADMFGKARLMIV-CLALLGFASLLGAVSSSFEVLFLCRILAGIGAGGVFPVALGLTSDLVEPGRRQVA--IGRVLGGSMTGNLLGASASGVIGDVLGWRGVLAVLGVLVIVAALAVSFGFRNKPMRPGaaALRRGYRTIFSNPNAPICFAAVLVEGTCVMGAFPFVAAFLHDQGQESLAVAGLVIAGFAVGGLLYTLTVARLLPRLGVRGMMIGGGALVGLQLAIIAFGPPWQAQAVAFVAMGMGFYMLHGCVQVFASELSETARGTAMSLHSFFFFLGQTTGPIAYGFGLAHAGKVPTMLIAAITMLALGFILAVVLR-
     853 UniRef50_C4XTW0        Major facilitator superfami...   135     3e-30  1  17.3% 12:386  30:398     -----------WSAVFSLFVGVTSLVAAEFIPISLLTP-IARDLAITEGMAGQTVTVVGIFAVLTSLLLAPLT-KGVNRRHILLAFSSMLLVSNILVAVAPNYPIMLIGRGLLGICVGGFWSMSAAVTLQLVPINYVPRA--LSIIYAGVAGATIISLPVASYFGHLLGWRNVFYLEALLGGVGLVWQFVSLPSL--SSDKSNDFRGMLRLFRQDWVLLGILATIFSFGGYNVFFTYLRPFLELDLFLRPNTLSIVLGVFGVANCVGTFAAGLLFNRQFRSCMILLQGVLAVVAVLLYLTDGFLRASIPLVVLWGFLWGFMPVGWSSWITRTLADRAEMAGGLSVASIQFSIGGAAAIGGFIFDRSGIQGIFLAAAGFLVIASILI------
     854 UniRef50_B8FMR8        Major facilitator superfami...   135     3e-30  1  15.5% 13:385   5:375     ------------RCIVALNIAVFLIMFGVGLIVSLLPHKIFTLTG-SFKTVGWLASFFAVSFVLLQFPIGRLSDRYGFKR-FLAGGYLICSLSGLLYWFSQSQETVFFGRMLQGAGEAPLWALAPALLCTLRPES---KGKAIGVYNASLHLGLTLGSGFGIVISSRWLNNEPFLLFALLCALGALLIIAFVQEPESRTLAPDGEIDYREliKRPETLAVLSGIILYGAGYGSFITVLPGFLMEYKGFSQAGVGWFFMFFYTAVSLSQIVAGPMSDRCGSGKIMLCGLAAAAAGLVIFPCMDG-WTVHPWLFLASWGLGMFCVSSLAWLNNAVGDskGTASGAFYLFWGLGYFGGPIILGACLGSAGGPAGFRILAGLYLITAML-------
     855 UniRef50_B8DCY4        Major facilitator family tr...   135     3e-30  1  13.8%  4:388   1:373     ---MENKTRLWTKDYVFLLLGSVLLYIGFMVFMPTLPARII-ELGGTQMEASLAVGLFSIVALLMRAIAGSWNDKFGP-KVLIIVGFLILILTTVNFYWSTAVAALLILRLFHGAGWGIGTTSIATGVSKLVPPSRTGEG--IGFYGLTTALGMSLAPIIAILIMNYFSFDVLVTFSLVLMVFILILM------TQVKIPKSEKIVHQKMKLFEKTALLPAGLCLLMAIPLGGIQTFMMVYGTE---LGISTTWIYFIGQAIMVLVSRLFAGRLYDTKGHRFVIIPGALSMIIGILILSFATGAISLFIASLFFGLGYGMSQPALQALAVdaAPHNKGTANGTFLSGMDIGMAVGSFGLSIVATYYNYAIMYRTAIIALVVFFAVYWF----
     856 UniRef50_B2KET1        Major facilitator superfami...   135     3e-30  1  11.1% 12:388   4:387     -----------KKIFWLLFAINLFNYIDRQVLFAVFPL-IKLDLSLTDAQLGSLASAFMLVYMIYAPLAGYFADR-SPRQHWMGLSAVLWSIATFFTGFMNNFKQLLAARSFIGIGEAGFTTVAQGFLAEQYPHEKR--ARILASFGLALPAGSALGYFLGGVLGDHFGWRIAFMIVGVPGLLLGLLAAFKIKDAraDKAEKPKLWAYVHLLKNKIFIFICLAQAFSTFIVGGLAAWLPTYFNRFYGYSVAKSSTIFGIMIVcgALGVFLGGQVADRLIKKTQKAYFITAGASFALAMPFAVLGImiFFLFFAIMFASAQTGPLSAAIVGYTSKKVRSMAFALNIFIiaLGDAISPMIIGKFSDIWNLRIAILFCLLMVVPACFFSAM----
     857 UniRef50_A5FFA6        Major facilitator superfami...   135     3e-30  1  16.9% 27:387  35:389     --------------------------TSEFLPVSLLTP-MAEDLQISEGAAGQAISITAAIAMLSSLLISSITKTLDRRRVLLI-LCVLQITSNLLVFCAPNFSVLLTGRVLLGIGLGGFWGMLAATAMRLVAEKEVQKA--LSIIYIAVSLATVIAAPMGSFLGNLFGWRNVFLIAAALGFIAFILQAITLPKM--PVDKITPLKTVIKVLQLPSVKSGMFATLFSFMAYAVLFTYLRPFLEQITGVGSNILSLILLGFGLTNLIGATVARHLLLWDLYRSLALMPLLMGISAVGLVLFGNISIVAALLIGLWGMALGVVQLGWTAWLTKTIPDEAESAGGIQIAVIQLAIMTGAASGGWVFDNLGAKGVFIFSSVVAFIAASVVF-----
     858 UniRef50_A2WII0        Arabinose efflux permease n...   135     3e-30  1  15.3% 11:390  32:411     ----------MPAAVFSLAFAAFAIGTTEFVIVGLLPD-IARAFGISVSTAGLLVSFYALAITVGTPVVSALT-ARLPRRALLLALMTFFTLCNLAAGLSSSFPALLAIRIVMAVSHGVFFGLGTTVAMALVPTQKSGRA--VAIMVSGLTVAMVTGVPGGTWLGDLMSWRLPFLVVAAMGALASIGLWRLLP-VVAAQRSAGTILSQLALLKDHTLMPLYAITALGMGATFAVFTYLSPLLVHTTGFGSKGVTLGLMVFGLGSVVGTSGGGRLSDRYGPKLSINIALAGIAASVAALWlaQHPVLVLVNLFVWGAFAFAVPPIMQATVvhVAPEAVGTAAGLNVATFNLGISGGSFLGGLTLAGVNVLTTVYAGVALAVVGIAVVATYR--
     859 UniRef50_Q6AD85        Sugar transporter n=3 Tax=M...   135     3e-30  1  16.0% 12:392  19:398     -----------WAGLIALAVAVFLSVTSEMIPTGLLPD-MSASLGVSEAQIGLLVSVFAFTVVVSSPPLTVLTRRW-PRHGMIVGVLVVLAVANALTAFAPDYAWVVVARVFGGLGHGMFWSVVGAYAGHLVPHRQIGRAVAITL--SGGTLAFVFGVPLGTFAGHLLGWQLTFGTLALLMLAGALLIAKLLPAVERDAGEPGRDRSQPRARDrpVVLMICLIAAVTMIGHYGFYTFVVPFLTGPMEVPPGDVGALLFLFGIAGAGGLLLAASVLGRSPQRGVLLGLAVTGVAVAVLAAFASLPVLGIGAFVLWGLAFGSLPPLLQTRLLHTSSArrDTASALYTSSFNIGIGGGALVGSLIFDAGGLGLLPVFYIGVLVVSVVLVVVMGRM
     860 UniRef50_A9IVS8        Transport transmembrane pro...   135     3e-30  1  13.2%  8:386  16:389     -------SRIRRLAILALAVGSFAIGTAEFVAMGLLPEMARSSY-VDIPTAGQYISAYALGVVIGAPLLAVATAQI-SRKTVLIGLMFFYALANIASAFFSDFSILVALRFLSGLPHGIYFGLAAMVAASMVEMNERSKA--VGSVMLGLTIATVLGAPGATWIGQLIGWQIAFILVGMIALLCCLLIWNFLPCDSSSPRTSPLRE--MGALKQKQVWLLLAMVSVGASGLFSVFTYIKSTLMHISGISLEWVPLIMPLVGLGMVGGNLLGPKLAIKIGISPMIFFSMLWSVFVFFLFFFLSYAPLTAAIGCFFVGTSFAAMPSIQTKIMDVALQGQILAGALMQSAFNIANALGAEAGALVLkgYSYEYTAVLGSVLTLCGLMIF------
     861 UniRef50_B9R147        Transporter, major facilita...   135     3e-30  1  14.0% 45:387  14:367     --------------------------------------------GEAALWGGWLSVVFALMQFLFGPTLGSLSDRFGRRPVLLISTLTV-AADYLLIALSWNLAVLFIARMISGIA-GATYSAGAAYIADISEKEDR--AKNFGLLGAAFGVGFVLGPVIGGLLGE-YGSRAPFYAGATLSFVNFLFGYFVLPETLKPekRANPFGALKHISSNKEVRVLLLALLLFDIAHYVYPAVWSYFTAEVFAWTPADIGLSLAVVGFGYAFVQGYLIRVLdrIGTGAILMIGLTCNLVAFVALSVAESGWVAYAFIGFAVTGALATPAFTGLMSNRVPDNAQGELQGLIASAAGLAMIISPFVMTQSFSFFtpGIPFVIAAVLISLSGLIAL-----
     862 UniRef50_B3E538        Major facilitator superfami...   135     3e-30  1  16.3%  7:392   1:387     ------MNGQHRNLFRVLFLINFLISLGFGVSDAFFPLYC-QSIGARGLLLGVAVGGYALSKIIFSPIMGSLADRFG-RRQLVITSLLVYLLVSCSYLVTENLVVVVSLRLLQGAGCAMFRPVVQTLIADHA--SSRQWGKAMGSFDISFYAALSSGPLIGGIIMDQAGFHGLFGVLIICSMAALGLALAAIPRQLQPPRIAQEVSAQPGIrqGGTLQGLLLFIFGRACGITACGTFLPILLSSKLGMSGVQVGIIMASATLIMTLLLRPAGRIADRVPRRMLVICGGTVVPLLYMLLPVAADFMQMLGVTLGIGAFSALSQPATSALLAEEGQrgMGTSIGTFHAFLNLGFVAGPLLGSLLQSSAGLQGVFIAIGLIGLCSVAGFILNKPV
     863 UniRef50_A8H6A1        Major facilitator superfami...   135     4e-30  1  13.5% 13:391   8:384     ------------KAILLACLIISVGQLSMGLVFPSLP-WIAKDFSVSHEQVQILVSIYLLGFGPSQFFYGPISDALGRKKVLLIGLMIAMLGLLMIIFLSHSFTGMVLGRFLQGLGTGCCAVLARASTRDNFSGAELPVAM--SYIAMVASITPLFAPVLGGFINFHFGWTMVFISLLGYLTLVWAVAALRFQepSPLPSPKKVLLQYRELLSSRYFMSFASIGWLNFSLMITTISVMPFIMQNQIGMTSDKYAMWAIIPALGMLIGASICNRIRPLIGSKKLLLYTPVLHLAAAVWLFFCPVEPllMLGQLLMILGNSIALPCVQAMVMQPYKKQAGAAAAMSGGGQ----MVVSSIVSMVLINLGLSQAWQLSLIIVVFAIITLINVMR-
     864 UniRef50_A9BZU5        Drug resistance transporter...   135     4e-30  1  15.2% 22:389  49:422     ---------------------SAIGPFAIDMYLPALPQ-IGSSLGAQVGAVQASLTAFFLSLGVGQLLYGPVSDMVGRKPP-LYFGLTVFALASVGCAMATSIETLVVLRFIQGLGAAAGMAVPRAVVRDLHTGH--AAARMMSLLMLVFSVSPILAPLAGSGVIAVSSWRGVFWAVAVAAVIGLVAVFMGLKETRGAAAraGALRAYGVLLRDWHYLGLVFIGGCAMAGFFVYLAGSPFVLINYYGLSSTQYSLAFGLNAIAFIGAAQFTGWLGQRFGLVRVVKVAATGSGLVMLSLLagERLAVLIGLYFVASALMGLVIPTTSVLALEEHGAIAGTASALLGTLQMLSGAAAMQIVGLFSTGKPLPMVVGMATGALIGVALAWITL---
     865 UniRef50_Q6MH66        Putative transport protein ...   135     4e-30  1  14.6%  7:389   2:378     ------KAASSWSGIWALTLGVSGLMIAEFLPAGLLTS-LASDLRISEGAAGQAVTATSIFAVIASLLVAYLTRKY-NRRTVLLWLSSCMAISSLVVAAAPNLPVLLAGRAFLGIALGGFWSMSTAIAIRLVPAESVPKA--LSIIFGGASFAALLAAPLGSFLGDFIGWRNVFTLAALMGAVAFIWQYVALPSLSPTGEVK--LRTTWDVLKIPNMLVGLVAINLAFGGRFASLTYMKPFLEQITMLKSSGVSLSFLIFDLAFFLGTLIAGRLITRSLRYGLTFAPLVLAASSLGLIAFGSQVVPTVLLLIIFGAAFAPIPVAWSTWTANTAPESTETAGGLYVASVQLSAAVGAMLGGVAFDSIGSKGVFWMSGLSWGLSALVVFLF---
     866 UniRef50_B2IHD0        Major facilitator superfami...   135     4e-30  1  15.9%  2:392  46:437     -TQIRRGTADYRRVNLALVAAGFSTFAILYCVQALLPIF-SRDFGLSPGAASLALSATSATLAVALLGAGQISDMRG-RKAMMALCLFSVGALTVLSAFAGTWGQLLAIRALEGLLLSGVPAVAMAYLAEEIHPSDLGGAM--GLYIAGNAYGGMTGRVLASLIVDYmsWRIALGIIGSLGVAAALAFTLLLPPSrpRPPLSSLHHPFLRHFKDPGLRWLFLTSFLLMGSFVTVYNYASYRLVEPPFSLGAGPAGAIFLVYLFGGWASASFGRWASRFERGRMLITG-VLLMLFGLLLTLSSSLWLTVAGITCVTIGFFGGHAVASGWVGQRAEIARAQAASLYLFNYYMGSSIIGSLGGWFYAGAGWTGLAILIGCLLLVALFVATRLARI
     867 UniRef50_A5W349        Drug resistance transporter...   135     4e-30  1  14.5% 13:391  25:407     ------------KVILLLAALAAISNLSTNIILPAFPE-MARQFNVSSQKLGLTLSSFFITFAFAQLLVGPLADRYGRKR-LVVGGLMIFVVGTFWAANAATFDMLILGRVIQAIGVCAAAVLARAIARDLYEGENLARALSLTMIAAAT--APGFSPLIGSMLNTTLGWRALFVVVGMSAILIALFYVRGIGETLPSRRrpAVLIAYGKLASNRLFILPALATSLLMSGLFASFAAAPSILMEGMGLNSLQVGLYFAATVFVVFAAGLAAPRLAHRWGSRAITLSGLATACLAGALLLIgpSFGWYSLSMVLFLWGMGIANPLGTALTMTPFGKEAGLASALLGFLTMAIGAVSTWMVSTPKFSTVAILGTTQTAVCLLAIMLFAWYAKR-
     868 UniRef50_Q55857        Slr0616 protein n=2 Tax=Chr...   135     4e-30  1  14.8%  9:387  24:403     --------RQHDRLFGLLAIAAGLIFLQGYMIAPLIPR-LAEIFDVSAQEIGFIVPAYMLAYALAALFYGILSDRFG-RWPVIQISIIVFITCTALTATAQTAAQMTFWRLLTGLGASGVIPLTFALIGDMFPYNQRGA--KLGLVFAAMEGGMAAGSAGGAILEPFLGWQLLFIGTATAPVIVLwgALFDAPKATKIPALATVFAGYWAVLSNFRGMRTYGYVLCNGIYHSGVYTWLGLYLSQRYEMDTLSIGLNILGYGVPGLIFSPLIGKAVDRWGRRWLIPPGLAMAAIAGLTMVPFIPPLAVTMAILVMSLGYDLTQPLFVGIVTDLAEEDtgQTMGLKVFTLFTGFGIGSWLFGEVL-HWGFEVALVAFGVMQLLSAIAAI-----
     869 UniRef50_A1AWF8        Major facilitator superfami...   135     4e-30  1  13.8%  7:375   1:365     ------MNKQERAFAFKISLIMATRMLGLFMIFPIFSVYASEYTSTTPYLIGLSIGIYGLTQALLQIPFGYLSDKYG-RKPMLIIGLIIFFIGSVVAAKSTDIIGIVIGRALQG--AGAISAVLMAFLADFVSENQHSKANAF--VGVQIGIAFMLALLLGPIISSNLSISGLFWVIALLSVIALIIVS-TLPNAKPKEQYSLSIANIKKVI-NIDLLRLDFSVFALHLILTCAFIAIPIFLRENNIVEIKDSWQMYLPIIILSFIGMLPMIILISKYQkkPIFLSAIALLIISQILFYQIqtYTLFFILLTLFFIAFNTLEAILPSLIASSasDKRGLAMGLYATSQFLGAFVGGIVGGWIYNISNLNNVFLLT-----------------
     870 UniRef50_Q2G331        Major facilitator superfami...   135     4e-30  1  14.6% 12:387   4:395     -----------RASFGIVFAIVMIDMLGFGIVTPVLPGLIIedIGTAAEYAGWLGAGYATMQFVFAPVIGNLSDRFG-RRPVLLAAILMLGLDYLLQAMAPHFWWLIIGRLLAGV-TGASFSAAYAYIADVTPPEKR--AANFGMMGLAFGFGFVVGPAMGGLLGA-ISPRLPFYAASALALTNFVFGMFFLRESLAPENRRPFDWRRANAlrSRTVLWFVAALGAWQLAHVVYPAVWPYFAIAAYGFSTRDVGLALAMVGFSSALVQGFGLRFapRLGERRAVVLGVAGLCASAVLYNLAQHTWQVYLAIAVGALQGFVQPPIAAFNSRAVDARSQGELQGAVQSIGSIAAIVGPPLYTQTLARFspGMPMLLSAAISLMTLALFW-----
     871 UniRef50_B0T1H4        Drug resistance transporter...   134     4e-30  1  15.2% 12:386  14:394     -----------WRLVLMLGALTAFAPMSIDMYLSSMPE-IGRRLHAGADDVQATLAAFFAGMAIGQFLYGPASDRFGRRPPLLL-GIGIYVAASVVCALAPSIEVLIAARFVQALGGCAGAVVARAVVRDRF--NHADTARVLSLMTLIMGLAPVLAPQLGGVIQFFAGWRGVFWSLVVFGLLIGLWIALGLSESRSEarSENPFKAYGALLSQKRLVGYGLAGALNGATLFTYISTAPDLVMGTYGHTPLVFNLIFAFNAVGIIGASQVNRLLLRRATPDRVLVRASIASIVAAFLLAavGGQFTVLPLLFAALSSYGLMAGNTMAGALSVDPKRAGSISALMGGASFAAGALAAWIGGLLHDGTARPVAAVMFACLIGSSLAIF------
     872 UniRef50_B1YJZ4        Major facilitator superfami...   134     4e-30  1  15.8%  7:391   2:382     ------KNRLFHRHYVLTLLINLLLFITFYLLNASLPLLAAKQFDVSQAALGWVVTSFILATVCSRPLIGHWLDRHDVKRMLLISASLfmSVLYLLVLPLNSFLYLIIVRIFHGFSFGMLSSSISLAVTTLIPKTRQGEGM--GYFVLSMNLASVLGPVIGLSLIQHDAFFLYFITVASLAFVSFVLMIRLPLTSQHVPNTRVFRLHQSLFLSRP---LLLFATVLAGVAISSTAAFISLYTDSIGHIS--YASYFYALVALGMVAIRPLAGKWFDQKGPGFVLFPSFLLYSLGFILLGVFPSLPGLLLAALIIGIGSASIFPGLQtmLTYAAPHQKGKAISTFFLAYDSGFGLGALLLSGLAAKIGYSNMFLFCSIIVLTSGFIYFIFNR-
     873 UniRef50_C7T9R7        Putative transporter protei...   134     4e-30  1  11.6%  2:389   4:398     -TQSAVKTHRGTITFIMVYIGYIICFIDRSAISIALS-YIGQDLHLSTATLGVVASAFFFSYAFMQIPGGWLTDKFGTYRTIIVA-ITMWSLFTILTGFAWSLASLIIIRILFGIGEGTYPSASLKQISETMPYNKRASAT--SATISSNYVGAAIAPVVIAPVIAYAGWRTAFHLMGLLGIVFIVVYAIILRPRKQArhATQKRVPWKTVLTNGVLWQFFLIVFGLSSVTKGLDSWMPTYLLAARHINLAGISWLVPLPSLAAGAGSLISGYIMARfkEKLFIGVASLLATGLMFGMYKSTALPAVIIFEILTYFCKSIAFAGTFALFAELVSKKagSSVGIVNFGGQLSGFLAPIIIGILVQISgyATAFLFLVFTAGVAFIAALTL---
     874 UniRef50_A7HQL1        Drug resistance transporter...   134     5e-30  1  13.6%  2:384   1:389     -MNASSPRGSRIGFVVILGALIAFAPLSIDMYLPAFPA-IAAHFNTTAGAVQMTLAVFFIGLSVGQGVVGPITDRVGRLPPLLI-GIGLYVGASIWAALAPDIESLTAARLFQALGGCAGIVVSRAMVRDLF--DERGSAQVYSLLMLVMGLAPILAPMIGGFIILHHDWHMIFWVLAAFGLACVPAVIFGLGETLPRERrrPVLGAYLALFADRPFMGFALANAFISAAMFAYITGSPFVFIELHGLDPSGYAMLFGANAAGLIFASQVNAFLLRRISGRLILKIAmaVVALLGFTIFMPGAFYPLAACIFVAVGCLGFVGANATAAAMARADSHIGSASALTGILQFALAAVSGGLVGAFNDGTALPMALIIAGASIAATLA--------
     875 UniRef50_C6VMI0        Multidrug transport protein...   134     5e-30  1  15.2%  5:391   1:382     ----MMKTRLYTPDVKLVLMASFFFLMSPMLINPVIAGF-AHGIGASSVLAGTIAGLTNLTSLVLRPLAGNLTDRVSKYRLTFVGGCLL-LLASLGYSLTTNVTLIMLLRILNGLGYTLCSVCMATWMASLLPPDRIGSGM--GIYGLANALGMACGPAISVFLYQHYSYQSVFWLAAGCSLLLVIMIQFVGDHGEPIVTPQTATTKHHIRIVQPRVIPVALILLLFSLPYFATQTYIVSYVAARHFH--VAAGVFFPVYAGILLVLRIILRDWFDRVPFKRFIWLCLIFNLLGLIGLTDMNNWAMLLLGAAGLAAGYGLMFSICQAKALMLVPKahGLANSTFYIGVDLGMSLGPIIGGLISSQLPMAWFYPVMMVTLPLIIVVYLVSRR-
     876 UniRef50_B9JBF1        Multi-drug resistance efflu...   134     5e-30  1  15.8% 11:389  19:402     ----------WMRNLIICLVGSFTTIVAMTLLLPFLPLYV-EELGVTdqWSGIAYGATFFAAAFVAPLWGRLGDIYG-RKLMLVRASLGMTVAISLMGMAGSVWQLVALRLFTGLA-GGYASGSMVLVATQTP--KLRSAWALGVLSSGIMAGNLVGPLMGGALPPIIGIRGTFLLAGGVIFFTFLATTFLIKEEKSPARKKAAKAswASIPDKRPAIAMLSIGLLLMLANMSIEPIITVYVAQFVENAHVTmgVVMAAAALGSIMSASWLGKLADRIGHWTVIMTALAVAALLLIPQAFVTSAWQLIALRFLMGIALGGLLPCITAVIRHNVPdaAGSILGLSISSQYVGQVVGPVMGGFVGGHIGMRAVFLGTCVLLAIGAVYCWWV---
     877 UniRef50_Q7X358        Putative major facilitator ...   134     5e-30  1  18.8% 31:386   1:361     ------------------------------MYLPSLPD-ISSRLEATTAQTQLTISTYLIVFALGQLFYGPASDRFG-RRPVLMTGLVIYCAASFLCAFAWSVELLMLGRALQAVGACSGIVLARAIVRDLYSGARAGR--ELSLMGMVMALAPVLAPLIGGVLQTFFGWRANFVVLTAAGLVIVLTIWFLLPETLAKRSPagMLRSFGGFLRDGSFLAHTGLVVFVFAGLFAWISGASFVLQDVYGQSAFDFGVAFAVASGGYMVGTALAAKFVGKYGIDAVSGFGAAAAVSGGLLMVGapSGFALVLPMALYLAGMGGVLGQAIAGALQPYHDRAGAASSLLGFLQQGVSAVVGIIIGHMLGDSAMPMAAGVAMCGAITFMIWL------
     878 UniRef50_A4BEE3        Major facilitator superfami...   134     5e-30  1  15.8%  5:389   1:383     ----MSFNSIERKALTGLSLLYASRMLGLFMVLPILTLYGQDLQDASPASLGLALGIYGLTQAFLQIPFGAASDRYG-RKPLIVIGLLLFMVGSIVAAMADSVTSLIIGRALQG--GGAISSVVLALLADYTREDQRSK--SMAVIGAVIGASFVVAVMLGPWIAGFGGLSGLFWFTSALALAGLVITFWlvPSLQVHKERQFRPADLWDVLTDRNVTILSLGIFLLHMTMTALFVALPVVLVAR-GFASDGLGQIYAPVMILSFIGMAPLMMIsrRLAQVQFLRLAAGIVIGALLLLWQVPQWAASAVALLIFFVGFNFMEATLPSLLSRKARAqrGTSMGVFSTAQFTGAAAGGAVGGLLFSDMAFGPVVFLGVAAQAIWLLSLFAV---
     879 UniRef50_B2UD63        Major facilitator superfami...   134     5e-30  1  18.1% 11:391   1:382     ----------MPASLWWLCLGAFAIGTEGFMIAGLLPV-LAADLGVSVPAAGQLVTVFAVTYAVGSPVMATLLGNVDRRR-VLIGALAIFAAGNLLAATAHGFGQLMAARVLLALAAGVFLPTANAVATSLVPASRSGSA--LAIITGGGTVAVALGVPLGAWIAAQGDWRSTFIACGVLSALATAGLAFGLPRALPH--SVTTLAQRLSVARRTGMLGALAVSALWAAGGFTFYTYVAPFFVQGLGFAPQHVGIVLFLVGSFAALGTGLGGHLTDRAGVARVLAVSSAGIVLAFSVLSLSAQvaVAIGAVVLWGMAGWGFGPAQATRLIRLAPDVSPITLSLHASAVYAGIALGSSVGALALAHGGPGMLGWAAAACHVVAVVLWRMGGR-
     880 UniRef50_B6VLU6        Mfs family, multidrug tranp...   134     5e-30  1  12.1% 27:391  25:392     --------------------------MTQTIYVPVIAD-IAKDFNMPTGSVQRVMAAYLFSYGLSQLFYGPLSDQIG-RRPVILAGMMIFLFSTVCALFSPNLDVLVVASALQGLGTGVAGVMSRTMPRDLYMGTALRYA--NSLLNMGILVSPLLAPMIGGVIAHFFGWRSCYLFLLILCAGVVYYVFRKLPETRPQqeKRKMFTSFCHLLSNGPFISYLIMLIGGLSGIAVFEASSGVLMGGVLGLNSIAVSILFILPIPAAFFGAWRAGR--EGKSFYNLMWHSVICCLLAGVLMWLPgnIWTLLVPAALFFFGAGMLFPLATTGAMEPFPYLAGAAGALVGGLQNVGSGVATWLSAMLPQNGQFslMFLMSVLILLCWLPLAHRMQR-
     881 UniRef50_C6IWG6        Major facilitator superfami...   134     5e-30  1  16.8%  1:387   1:391     MNLYKESDRLWTRSFISLTISAFLLFLNLQMLLSSLSSYAKNELAASDLEVSLVTSIFAVSAILTRFLAAAMLRKFSP-NVLLFAGLIIAAIMTELNDWVGSVGGLLLVRAGYGFGFGIGSTILPTLVSRIIPPSRMGEG--IGYFGLSSSLAMSIGPMIGLNLLQKFGFGTLTltMAVLVVIPLLLLTRALPRSnkTTPGAGDSTPKRRAPFNRKLLFPAFLNTLLSITYSGLLSFIALFGE---FLHLEQVGLFFLFNAVTVIIIRPISGRIFDAKGHVAVLIPAALLVVASMVVLSFTQSLPMLIVSALLYGLGFGATQPTLQAWMLRTspEQYGVANSMFFNTTDFGVAIGAIILGAIASATDYAVMYRYSAGVMGLFLVVYV-----
     882 UniRef50_B6R5M9        Drug resistance transporter...   134     5e-30  1  16.0% 13:388  17:397     ------------RTAVFGALLVTIGPLSMALYTPALPT-LAEVFGTTEAVAKLTLTVYFAGFTLAQLLCGPLSDAFG-RRPIILGFFSCYLLGSLLAWLAPNIEMLLLGRLIQGIGASSGIAVARAIVRDQFSGEAG--ARIMNLLAVMLGIGPAISPTIGALTLSAFGWQAIFVLMVAYAGFILLLTLTILPETNAYrrPKQILASYWRLLRSFEFMQPSLILGFTIGVIYTLSTVLPFVLIERIGLTPLQFGMGMVLQSGSFFMGGVVTRLLLRRFSTEALLAPALICCGLGGLALFVVtsFLSIMIPIGVFAFGASMAMPALSMRGMEPFPEIAGAASALMGFIQMAGGFFGSLVTAVVVPD-PVTALGVVMPGMAFIALFLLIL----
     883 UniRef50_Q6SGC7        Drug resistance transporter...   134     5e-30  1  14.3% 10:386  29:412     ---------KERITFATLVALVAYAAIATDLYLPAIPAMVA-EFGATASDGQLTLSTFMLGIAVGQLIFGPLSDYYG-RLPVVKIGTVLFLGTSIACALASSMEFMWLARLAQGLAAASGPVIARAIVRDRYEGPR--AAQIMAILSGAMAVVPLMAPTLGAWLLILVSWRATYIALAIFAGVVLLGLRSFEESAPHIRKGapVLKHFSTCLKNRRFVGYQICGTAAFSAIVAYLSTVSFFMQDVFALPIKYFGYAFAVTVAGFMVGALLCSRIVIHLGINRTLALGTTLSLLGALGQSLGASlaLLAGCSFVMFLGVGFTSANATMGALSLFPDHAGSASAVFGFTQSSVAALVGVYAGHLYDgvSVTNIMLVCAGAGMLGLPLA------
     884 UniRef50_Q0RV66        Multidrug resistance transp...   134     5e-30  1  17.2% 13:390   8:391     ------------PMLLVLALLSATSPVATGVYLPGLPS-IASALGTSNIGVQLTLTTFMVGLGLGQLLAGALSDSWGRRR-LLLGGSVAFTVASAVCALAPTIGVLTVARLIAGFSGGIGVVLARAVISDRARGIE--AARLFSVMMIIGGVAPVIAPVLGGMLLGPIGWRGTFWVLTAIGGIMTFGVATAIPETLPPETRHTGgqNFRQVVGDRRFVGYAAAMAIGAGAMFSYIAASPFVVQKIFGFTPTQFSLVFAFNALSLVTAMTINSRLVSRISVRRLLIFGVGVVWVSGLGLLAvtTPWPLLALLLTMMFGMGLTMGNAVALAQDQVPSVAGTGSAVIGAAQFAVAAIVSPLVGLGGESTSVPMAVSIAVCGTIALTALLTLTR--
     885 UniRef50_B0RSC5        MFS family drug efflux tran...   134     5e-30  1  14.8%  6:390  13:404     -----AWAPLRQPIFRALWLAILGSNIGTWINDVAASWVMAEQTG-SPLMVAAVQSATTLPVVLFALAAGTLADIVDRRRYLMLTqlVAASLSLLSHLQLLTPWVLVALTFAMGMGAAMAMPAQAAIVSELVPRPLL--ASAVALNSIGMNIARSIGPAIGGLIVAQFGPPWAFLLNGLTFGLMMWVLWRWRREtpPESFGAGLRAGLRYAARAGRLQAVLIKAAGFFLFASALTALLPLVVRRDMQLGAGSYGLLLGCIGIGAISGALVLPRLRARYDRDLLVFVATLICAASLLGLALSRQIGVLCVVMVVNGLAWITVLSSLQIAAQTSVPAwrARALSLYIVVFSLGMASGSLLWGALAQRTSIAIALQIAAAGAVIAALLVKRAR--
     886 UniRef50_A9D5W8        Tetracycline resistance pro...   134     6e-30  1  13.0% 21:390   1:387     --------------------MVTIDMMGVGLAYPLLPKLIQGVGSYTLSEagLIAILYALAQFAFSPLLGNLSDAYGRRPVLLTAQTGL-ALDYFLMALAPSLWWIAVARFVSGVF-GATVSTATAYVADVSTPE--TRARNFGFIGMAFGIGFVIGPFLGGLLGE-IDIQLPFLVSGLLVCANVVFGFFVLPESLPKANRRppFSALRMLTRLPHLTPYLVCFFLVFMAQRGLESIWVLYADFRFEWGVRQAAFSLAFVGLMYIIVqfLVGKLVSRFGERPVIDAGYLLAAASLLVFAMTDNGLIAVPLIGLFILGAASAEPALKSLSSQAVgdEQGLLQGAIGSVNSLVIILAPLSANMVLSNVspGAWFYFGAALFLIAWLVFRRSR--
     887 UniRef50_Q1IEZ1        Putative transporter, MFS s...   134     6e-30  1  15.1% 11:388   1:373     ----------MSPRIWLLALATFVTGMAENITVGILPA-LADGLDVPLGVAGQLTTVFSLSFALAAPFSPLLTTRLPLR-GLLCATLALFALCNLLAAWAPGYTALLIARIGMAATSALTCLTCTLMATRMAPEALRGRA--IGVIFMGICSSLILGVPAGMLLCDALGWRGVFVGLSGLAVAVLLMAWRGLP--TLQSNERIALASYVRHLRDSRLTAAQGVSLLMIAGHFTVFAYLAPYAQQVAHVPPQWLAAVFAAFGIAGVSGGYVGGWMADRLGVAKAILLAPLLYLASLLMLPlaGTPWLFLPAMMLWGGLSWTTSPVVQSYLAKRGEGTFPAGMSLNMSAMHLGVGLGSAIGGVVITGSALEATPWAGALLTTVAAGLAIW----
     888 UniRef50_C7N6T2        Arabinose efflux permease f...   134     6e-30  1  18.8%  6:389   9:391     -----TEETIWSAPFVILMASNFFQSLAAFTANTTLPLYI-DRMGASAGMVGVIIGAFAITALLIRPFAGPAFDSFSRKR-ILLAAQGIIALAFLLYSFARTSWALFAVRLLHGLGIGCAGPVAMSLVSEYLPMSK--FASGVSIYMLSQSFAQVIGPAAGLWMADAFGFQVTYRIAACMLLFSVLAITRVRETPRERPPYQLRLDRMFA----REAVGKAIVLTLFAAAFACVGSYLVLYANR---LGIADIGSYFVVYAICLLGTRPLFGRLADNFGAERVLLAGVACFALSYVVLSQAATLPGFLVAAVIGAAGFGSCVPLVQTLAMASvaERRGAASNTSFTGMDLGFLVGPAVAGAVIELLdySLVWLVMLVPLACAFAIILRW---
     889 UniRef50_A0NTY9        MFS permease (Drug) n=1 Tax...   134     6e-30  1  16.7% 40:387  11:363     ---------------------------------------MMLVFSATAGEIQLSMSAFFIAVAVFQLFWGPLSDQFG-RRPVIILGSVLFVIGTVFCLFAQSIEALIAARVIQAAGGCTGLVLGRAILRDLYSPKQ--AASMIGYVTMGMAVMPTVGPAIGGLLDHYYGWQGGFMLLLVFGVATLWASVFLLPEtrNEVGGRQILRAYATLCREPLYWCYTLTAAFSALAYFAYLGGAPFIAADLLSLSAGEMGFYFMFVALGYIAGNFISGRYSERVGLFRMMLAGTLIAIVCVAVIAGFtsAPSLFLPMFLLGLGNGICLPSALSGAASVRPELTGAASGMTASFQVSMGAIAGSLVASLYAHGILAGSPWGMILVMGVGVGFSL-----
     890 UniRef50_C8WQB2        Major facilitator superfami...   134     6e-30  1  13.3%  8:391  17:399     -------TPIYRRVSIAFLAAGLVTFANLYAVQPLIPAF-SSDFARSPAAASLALSASTFTLALSLPIFASLSDRFG-RKPIMLFSLFSSSVLQFAVGLVPTFWGIVAARALEGFTLAGLPAVAMTYLSEEIDSSSLGFAM--GLYISGNTLGGLLGRVLISLVADGASWRIGMMAFGAVSLALSAYVAWSLPASRHFVPRRDrlSRFAHAVKRPELDALYLVGGLLMGGFVSLYTYMGFRLaaPYHLSTSVIGLLFFAY-LAGTFSSSFMGSLADRIGRHRVLPLNIAIMAAG-AALTCARGLAAIVLGMVVFTFGFFGAHSTASSSVGSLGGAHRAQASALYLFCYYTGSSVIGSLGGLFWTDMGWRGVIGMILAAQAAAALAFLFAKR-
     891 UniRef50_O34546        Uncharacterized MFS-type tr...   134     7e-30  1  12.8% 11:370   1:360     ----------MPRALKILVIGMFINVTGASFLWPLNTIYIHNHLGKSLTVAGLVLMLNSGASVAGNLCGGFLFDKIGGFKSIML-GIAITLASLMGLVFFHDWPAYIVLLTIVGFGSGVVFPASYAMAGSVWPEGGR---KAFNAIYVAQNAGVAVGSALGGVVAS-FSFSYVFLANAVLYLIFFFIVYFGFRNIQTGDASQTSVLDYDAVNSKAKFAALIILSGGYVLGWLAYSQWSTTiyTQSIGISLSLYSVLWTVNGILIVLGQPLVSFVVKKwsLKAQMVIGFIIFIVSFSMLLTAKQFPMFLAAMVILTIGEMLVWPAVPTIANQLAPKGkgFYQGFVNSAATGGRMIGPLFGGVLVDHYGIRA----------------------
     892 UniRef50_C5AND2        Major facilitator superfami...   134     7e-30  1  17.1% 10:378   8:380     ---------KQNASLYFLALGAFAIGTEGFMLAGLLPI-IAKDLSISLAAAGQLVTVFSLSYAISSPILTTVSAGVSRRRFLIVALLCFTAANFAACA-SPGYLSLLAARVLLAVSAGLYMPSANALAGSLVAPERRGRA--LATVHGGITIAVALGVPLGAWIGGHFGWRATFAGIGMLSAIVTLGVLTGLPHGIGASLSVPSLSQRIAVGRQPAVLVTLLITTLWATGIWTIYPYLAPFLTGSPGFSDAEVGAVLLLYGVFAGIGVFVSGRAIDRLGSGKVLIVCLVVMMLSYESLTavPARVAILIAIGAWGAAGWAFNPAQQAKLIGIAgdVAPVSLSLNSSFTYLGFALGAALGSLIVAYSSVANIGAIGGLC--------------
     893 UniRef50_B9ZL41        Major facilitator superfami...   134     7e-30  1  14.6%  7:390   1:388     ------MTPRELRATSGLAAIYGVRMAGLFMVLPVFMLHLDTLAGATPFLMGLALGIYGLTQALLQIPFGLLSDRLG-RKPLILGGLVLFVLGSLVAALAETVHGVILGRALQG--AGAVAAVILALTADLVGEERRMRA--LAVIGLTIGLTFTASMALGPVVDRAAGLSGVFGLSALLGVLAIVILLFWVPNPERARQHppIWSALPQVLREPELLRLNVGIFVLHLVLAANFLVIPLLLVEYLGLAGAEHWRFYVPVLLAGFALMLPGIILGERRRRVHTVMRGAIASLALVQLLLALvgMWFFVALMVVFFAAFNLLEAGLPSLVAREApaHKGTAMGGFATAQFLGIFAGGLLGGGVLTLAGPASVFLAAVPLLLIWFVVAWRMQ--
     894 UniRef50_Q2RQ29        Drug resistance transporter...   134     7e-30  1  14.3% 15:391  20:401     --------------VGLMAMLMALTALSIDVMLVALADISSDYFLADANDRQLVITAYLLGFAVGQPVWGPLSDRIG-RKPVLIAGLVIYGLGCLGAMVSPSFETLLAARLVQGLGGASPRVMTMAVVRDRYAGS--GMARVMSLLMMIFIIVPILAPTMGSAVMAFAPWHWLFGFMMVFDLIVLVWTLTRLRETHRPQRqgGLLETLRVVVSNRQTVGYTVAFGFMMGSLMGYVGTAQQVFVEVYH-EVELFPILFGAIASAIAAASIINARFVTRIGSRRMSHAALLGFVaaAFGFPAKPPLALFMAALGIQFFCFGLIGPNFNAMAMEPMGRVAGAASSFVGFYSTAASAFLGWAVGQQFDD-SVRPLMMGFAGFGILALVCVLVTER-
     895 UniRef50_B5ZLT7        Drug resistance transporter...   134     7e-30  1  15.7% 13:387  22:405     ------------WLVILLGLVTAIGPLATDMYLPAFPA-VDRDLGGGPGSAQITLASWFAGLAIGQFSQGPLSDRLGRRVPLL-GGLTLFSIASAGCALSYSYHMFCVWRFLAALGGSAGVVVPRAIVRDVATGMQG--ARIMAQLTLVFGLMPILAPSLGSLVLSVGHWRWIFWFAVVYGALGVVAIAWTLPDTMPRDRrpTVLWRYVTIAREPMFLSAALLLGFSAFVMFGYLASAPTLFEHILSFTPGQFGLFFGVNAALFITGAQVNGRLVHRvgVTVVTMAAVLFLALSLAGIAGPRHPALVCCLIGLITGSLGFVNPNATVLAFTRHGHHAGSASALLGTLQFTIGSLSGVLLGYLPLDTTVPIAGTMAAGIVGMLFCTVW-----
     896 UniRef50_D2B4P0        Major facilitator transport...   133     7e-30  1  13.8% 11:387  25:398     ----------LPPAFWALWTGTLVNRVGM-MVQPFIGVYLTQARGMSYAAAGAVMAVFGVGSLLSQIIAGWLADRFGRRIT-LTGGMVATAATMVALGYSTSLPAIVATMFVLGMTVDVYRPASNALVADLIPPLDRPRA--YGLLFWALNLGFAVAMVAGGWLA-RAGYGWMFGVNAATSLAFGLLVWRAVPETLPArpGGQRRGGFADVLKDRLMVAFSVITLISTVAYSQAFTTLPLAMTHE-GFTTVDYGMVIAVNGVLIVLVQPLTGDWFGRLDHSTVLAVGLAVIGAGFALTAAVSSIIGYTVSVILWTAGEIVTAGIPGAIVAALapHLRGRYSGMYGFAWSGGALLAPLLGTGLLEVSPAALWPAIGAISLVAAGGLLA-----
     897 UniRef50_B1YX06        Major facilitator superfami...   133     7e-30  1  14.1%  8:391  46:429     -------SAAYKRIALALFLAGFSTFSLLYCVQPLLPAF-AREFHIGAASSSLSLSLSTGLLAVSILCAGALSERVG-RRGLMFASMTLAALFNVLAAISPNWNLLLIWRALEGFALGGVPAVAMAYLAEEIAPD--GLGLSMGLYVGGTAFGGMIGRIGMSALEEYFSWRTAMLTIGVVDLVAAIAFVMLLPQSRRFVKrrHHLRLWNAQLHHARLQFVFAIGFLVMGSFVTVYNYAAFRLTAAPFNLSATACGLIFGAYLFGMVSSSSAGALADRLGRAPVLVSGILVFAAGLAL-TLSHSLVAIIVGIVLITIGFFVAHAVASGWVGQLAGSAKGHAASLYLLAYYLGSSVLGSAGGTVWQHGAWGAVVAYVAVLLALSLVAARRIIR-
     898 UniRef50_A3ZLR9        Major facilitator family tr...   133     8e-30  1  15.9%  8:391  21:404     -------PRNSGAALLALCMGAFAIGTTEFLPVALLPT-IGADLEVSLPAAGLLVSGYALGVTLLTPILSAMFSGL-PRKGMLISLMGLFFVTNLLCALAPSYGILLGVRFFTAISHGVFLAAATTVATSLVPKGK--EAHAIGVIFAGLSVAMATIVPLGSLLGQTLGWRVAFAGTAFLGLFAMIAQARYLPK-LPAPTKRLTLAGQAMVLKQPRVLLALSMTTLGYAGTFATFTYLTAILEEISGFHAVAVTLILGVLGVCITIGNIIGGKAADRNIYPALAGLFALVVVAMLGLWLAAPFKIGMIVAVIFFGLFMFSPGAGLQMLVVNQARRWKsvAAGLNQSAFNLGIALGAVIGGQVVAslGLGATPLVSAGVVVLAIGLIALGWR-
     899 UniRef50_C4F9M7        Putative uncharacterized pr...   133     8e-30  1  14.9%  3:392  34:422     --DTVHLTPYALLCIGLLIALGFSLGCSEFIVIGIQPE-IARDFGVPLSQAGMLMSAFSITYAIATPVLALSTGRIPHR-TLLIGYSVLFCAGNSAAVLATSFEMLLAARVLIGLVSGALLAIGATYIPELAGMKRIS--ICISLVYAAFSIAMVISTSAGKFIAATWEWHYAVIGTLVMSLVVCAALILVLPRTGATDIPATAREQMP-LLRDPRIIAGTAIFMFGVGSIYVFYGYVTPYLENILGMGTLEASGALMAYGGMCFASNLLSGWCDARFGVKTMLVSFPIQAVLLFGLWAVGPAMPWALAIILGIALTMYVVSTPCISLFMTTapQALTLASSLEPTAFNVGIAFGTAVGGAVISGPGMPYVGLVGAAFSLVAWALAALTVRL
     900 UniRef50_B9E9R9        Putative uncharacterized pr...   133     8e-30  1  15.4% 11:392   1:377     ----------MKVNLFLLAMMAFLAGLNELVLAGILP-FVMDYFNINTQEAGYLITVFALIFGLAGPVLMSVTMNV-NRKTLLLVFLSIFIVGNLMSVFAQFYWMMMLSRIVLAASVSMLIGLALSLSVKVVPEYMQARA--IGIIMMSISGSLVLGTPIGIYIAELTDWKVIFILISVLSAILMLLLMKYFPKNIQVERVSMARD--WKFILKKEILSVHLFSFLFFVGQGMFFVYLTPYLMDR-GHSIAVVGLIYLVFGLAGILGSGIGGYMTDKFGSTNLLVVQSFLYVFLMLMVNFTasAVLVCINIAIWAMTGWMVNAPTQTYLIQAAPKFSSINQTVSTSSTQFGISLGALLGGiiTQTNSYPALIYYGCCVLVIAFLVTLYIRRL
     901 UniRef50_Q1CVH5        Drug resistance transporter...   133     8e-30  1  15.2% 23:390  25:394     ----------------------AFAPLSIDMYLPALPR-IAEDLQSTAPAIQLTLASCFAGLALGQLFTGPLIDRFGRTRP-LYAGLALYVLGSLGCALAPSASMLVAMRFVQALGGSVALVVPRAVVRDLWSGAN--AARTMSRLMLVMGVAPILAPLLGGMVLQYSGWRAIFVVLAAVGAVALAFVLKSLPETAPPhgAQSMRSRMGALMKDPDFVGPALAGGFAQAGMFAYIAGSPFVFISLYGIPEEHFGWFFGVNAMGLIAVAQLNRKLVTHLPLHRLLRLALSLCVVAAVAVLAVagLWGIAVTLFFFVSAMGLVGPNAAAIALERHATRAGMASAALGALQFTAAAGASWAVSTFNNGTAMPMAGVMTAMALLAWLAAFFGLR--
     902 UniRef50_Q0RCM4        Putative Drug resistance tr...   133     8e-30  1  15.5% 14:386  43:419     -------------TMVLLGAMTGLGPFSMSVHLPGLPR-MADDLATSQSSVQLTMTACVVGIAVGQVVAGPLSDAYGRRRPLLVA-MALYCATSAVCAAAWTVPMLAGLRFAQGMFAAFGMTIARAVIRDVADGQRLVR--LFARMALVSGLTPIIAPNLGSALLVVTDWRGIFVVLAALGALFAALSVGSLRETLPPARraSTARTYAALATDGAFLAPSLVVGLAYGAMFSYVSSSSFVLSDAYGVSQTVFGVLFAANAVGFMAGGQLGAALAGRRGTIRALRiaAATAAAGITLAALAGSGPAVVGTLFLTVASIGACMPIASAEAMRTRPDSSGTASGLLGLTQFALGGLIGPIVGAFGSTSALPLGIGMCLCLLAAFALCL------
     903 UniRef50_C6D6N0        Major facilitator superfami...   133     8e-30  1  13.2% 10:387  27:402     ---------NQPRAVWAVFFAGIIAFMGIGLVDPIL-KAIAEEMHASASEVSLLFTSYNAVMAVAMLITGVVTSRIGIKWTLLL-GVVIIAVFSLLGGMSNDIWALVGYRAGWGLGNAFFVATALTAIVSL---SKSGVTKAIILYEAAIGIGISVGPLLGGELGS-ISWRGPFIGVAGLMVIAFLAIIFMMPKTAGAPKAstSLLDPFRALRHRPLVVFGLTACFYNFGFFTLMAYAPFVM----GLGIHQLGYVFLGWGILLAVTSVfaPWLQRRFGTVKSMAVMLTLFGLTLLAMAIWTNtwVIIASVIFAGALLGNNNTLITTGVMNAAPVERSTASAAYSFLRFIGGAIAPYFAGKLAEWFNPHIPFYVGAGFVIVSVLFIL-----
     904 UniRef50_Q02CL1        Major facilitator superfami...   133     9e-30  1  16.0% 15:389   2:387     --------------VGVLWVVALLNYVDRQVIFSLFPL-LARDLSLSPLQLGLLSTVFLWVYGLLSPFAGFAADRFGRGR-LITVSLLVWSAVTLATGVSRSYGQLVAARAVMGLSEACYLPAALARIAQH--HGSRTRSLAVGIHQSGLYVGLILGGVAGGWAGERFGWRAPFLVLGAIGLVYVGVVAVFFRADPaeDQRAEFRAAVAALCRLPGFGTMTAVFSAMAVANWLVYTWLPLYLYERFGMSLTAAGFTATFYigASVGGIVLGGWVADRWGARstQAAGLLLASPFLFLLGYADTRVLLLSALVVFGVGRGFYDCNTMPVLCQVArdLRSTGYGIFNFAGCLAGGVVAALAGALKGVLGLAAAFQIAAGILCLSGLLLLRI---
     905 UniRef50_Q67MA0        Membrane transport protein ...   133     9e-30  1  16.6%  1:392   1:391     MPRIQRGTREYQLVTLALFLSALSIYASLYVTQPILPL-LSADFGIIPAQASLSVSTATISMAISQMLVGPVADSLG-RKPIMTVAVLATGVIGLVASRTVAFGPFLFTRFLQGLVMAGLPATAMAYLAEEIDPQHLGAAM--GLYISGNSLGGLGGRIISGSVAEFWGWRGAVAAIGVVSLVCALWFARALPPSRNFRAqrRLVHSLFGAVRDPLLRALYLVGFMAMGSFVALYNYVSYHLMApySLSAALMGWIFLLY-LAGTFSSALMGRLSDQYGRAPMLALSLGIELAGAAIALAGP-LLVKIGGIAVFTFGFFGAHSIASSWVGQRARHDKGAASALYLFTYYMGASIAGTVAGLFWMRFGWPGVVGFIACLLATAVGLAALARKL
     906 UniRef50_A0LW56        Major facilitator superfami...   133     9e-30  1  19.1% 10:385  22:412     ---------ALPRPVLVLSVVAFCVAVGFGLVVPALPLF-ARDFGANKAAVGAVISTFAAMRLAAALGVGKVVDILGER-VVLALGIAIVAVSSAATGFSENYPQLLVLRGAGGIGSAMFTVSALALVLRVSDVTVRGRAA--GIFQGGFLLGGIFGPVLGGPLISW-SIRAPFFCYAGTLVVAGGVGLIGLRQVERPPGISPHRRsiGAALRQRPYQAALAANAAISWAALGvnSLIPLFVIEALHAPAVWIGVGLTLMAAANAAVLLPAGRSADRRGRRSLLVAGCAVSGVALVMLAVMGHIAGYLAAMVVFGVGSGLLDVAPAAIVGDIAGGRGGTVVAGYQMAGDLGSVLGPVTAGWIADAAGDRAAFWTTAVVLLGAALL-------
     907 UniRef50_C8WN39        Major facilitator superfami...   133     9e-30  1  16.6%  6:391   5:406     -----AREKLWTRDFVFGTAVNFLIMVNYYGLMVVVADYAMKTYDAPAATAGLAASIFVIGALIARLFSGRIMDRVGRKR-LLIIGAVLEVAFSALYLTGLGLWLLFALRLLHGIAFGTCSTAIGTIVTALVPDNRKGEG--VGYYMLSVTLGAAIGPFLGMFLTQNAGFQTL-FLVAAAVALACLLAATQLRVPKNPVSAETVARKASDIARDErvIPIGAVCALLFFCYSSLLAFLTPFAAENGLETP--ASFFFVVYAIATFVTRPFTGKLFDRKGDRVVMVPAFIAFIVGMGLLATVYQPTAMLIAAALLGFGVGTVQASGLALAVRLAPDDrsLANSTFYILLDIGVGVGPLLLGIVQPLWGYRGLFEAMSLVAIVALAAYLLVSR-
     908 UniRef50_A1ANY9        Major facilitator superfami...   133     9e-30  1  14.1% 11:392  23:402     ----------YHRANLAFFAAGFVTFVTLYDMQPLLPEF-AREFRVSPALSSLPLSVATATLSIAMLFAGTLSETLG-RKQVMTAALFLSSLLTMLTSVCHDFGALLGLRLLQGAVLAGLPAVAMAYLSEEMETSALGAAM--GLYISGNAVGGMAGRLYTAAATDLWNWQSALASIGVFCLALSCFFVKSLPPSHLRKRprYLFSSLARHLGDPLLLCLYGIAFMVMGSFVTLFNYLTFRLLAphGLSQSQVSLVFLVYLLGS-LSASLAGRMVNRFGRRAIIRVSLLAMAAG-VLVTLAGSLLGIVSGVGIFTIGFFGVHSVASSWVGRRASTAKAQASALYLFFYYLGSSISGTAGGIFWLHWGWWGVVGLIVLLVLLAMILLVPLSRL
     909 UniRef50_C6CXQ3        Major facilitator superfami...   133     1e-29  1  14.6% 12:389   3:375     -----------RVVIYVLMIAVFFTATSELVIAGILNV-LAVQMNISVSLAGQLITVYSLAFAIGTPVIIALSARIPRKRLLLLA-IVVFIAGNILSIVSTDFMVLMAARMLLGVSSGVFIVAAFSAAAKVVPVEKIGSA--IGTIILGFSSAMILGVPLGVALTNMYSWQTIFLFLGIGGVVILIGLALLLPQIEGDAPV--PFKQQAGVLANPVIFYALLLVLFREAGNSLMFTYIASFLGDILHRSSAEIGLMMLLFGLAGAVGSRIGGSAVDKWGSAKLILIGVTIHVIALLLLPLahSFPVAITLLSLWIMSMFTLGPATQTYFIERAPQASNLIISLNISVTQVGIAAGASVGGLVVNWQDTVLYNPLAAGLVLILALASAAV---
     910 UniRef50_C6ATB7        Major facilitator superfami...   133     1e-29  1  12.7% 16:392  28:398     ---------------LALACGGFGIGTGEFAIMGLLPN-VAETFSVTTPQAGYVISAYALGVVVGAPVIAVLAAKM-ARRTLLLMLMLIFAAGNISSAMAPTFESFTLLRFVSGLPHGAYFGVAALVAASMVPVHRRARA--VGRVMLGLTVATLLGTPLTTFFGQSLDWQVAFFSVGVLGLLTVALIWFYVPKDRVSEE--AGFLRELGAFRRPQVWLTLGIAAVGYGGMFAMFSYIASTTTEVAMLPETAVPIMLVLFGVGMNAGNFIGSWLADK-SLLGTIGGSLIYNVVVLTTFSLTAANPYMLGLCVFLVGCGFAAGPALQTRLMDVAADAQTLAAASNHSAFNIANAIGAWLGGliAGGYGFAATGYVGAALSFLGLFVFAASLRL
     911 UniRef50_B0T5Q9        Major facilitator superfami...   133     1e-29  1  11.2%  8:391  15:433     -------SRYRWLVLAVLTAVHSTHHIDRN-VLSVVVEPIRQEFHLSDSQMGMLGSlyALAFAIAAIPMGYLVDRV-NRRNMLVGILALWSVMTAVCASANSYVHLLLARMGVGIAESGGAPTAMSMVSDYFPPKQRSTAIGIWYLSSAIGTGIIF--LVGGFLAQSFGWRTVFLVAGVPGLVMGLILFLVVREPPrpEKAATPREAFAYVIRRPAILSMMAGIVLAAAMSSAFALWSVSFLVRVHHMPLALAGviAAAFSVFGIIIPLISGVMGDRLSNAklSATTMTGVVLCGVAAALSGSAPVAVAMMCLWCGLMLAHNGPANALVLSLlpRMRGVVVATLQTVAtvGTALGPFLVGVLSDVYglRWAIMTGMSLNVVAVLCFLNAAR-
     912 UniRef50_A0JUL5        Drug resistance transporter...   133     1e-29  1  16.5% 26:364  31:373     -------------------------PFTIDLYLPAFPA-LEASLGVSEAEVQLTLTGTTVGFALGQLVVGPLSDKFGRRLPLILA-TALHITASLGAALSTDLATLGLFRVVMGIGAAGGGVVAMAMVRDLFTGY--AMVRMFSRMALVNGLAPILAPVIGSQLLLVMPWPGIFYFLAGYGTLVITAAILLVRETLPRELRGKSgqRYKLLFSDRIFVGLLLLGGMNFAGLFAYLSASPFLFQDVYGFSPQEYGLLFGINSLGIVAGVQTSSRVIRRVPPQWILACSTAWMFLMAVLIvlGLGLWGVMVPLWFYILGTGFTFPCVQVLALSKHGAQAGTAASLLGAATFMMAGIVSPVVGWFGD----------------------------
     913 UniRef50_Q0ARP1        Drug resistance transporter...   133     1e-29  1  13.7%  5:390  10:402     ----TTMPISLTELVALLVAMTAVVALAIDMMLPALDDIAGDLGVRSENDQQFVIGVYLTGFGFAQLFYGPLSDRFG-RKIVIQFALAFFIVTSLVCTLTPTFDMLLVARFFQGAAAAACRVIATAIARDLT--SGRRMAEVMSMVMTAFMAVPVLAPMMGQAILTFAPWRWIFAFLVLFGLGLMVWLQLRLPETLHPqrVKPLLAAFRETFSHRLMLGYTLAGAPFFGGLYGFLGSSQQIFVGHFGLSDDAFPFAFAAIAGGIGLSSYANSRLVMRLGQRRLSHWALIAFTvaGILWSGIDNFVLFLVLLSAAMAFLGLIAANFSALALEPVGHIAGTASAVYGFVTGVIGAAIGSYVGQLYDGTATPLIVSQALMAGTALAIVFWTER--
     914 UniRef50_UPI0001B53F4A putative integral membrane ...   133     1e-29  1  20.9% 17:390  14:382     ----------------VLAFGAFGVGTSGYIVAGLLPA-LTSELHVSATAAAQLVTSFAIAYAVGSPLFAAATGRW-ERRTLLVAALAVAAVGNIFAAVAPGYTTLLIARVVTAIGAAVYTPAATAVAAELTTPERRGRA--VSLVFGGLTIALIFGVPLGSVISQQFGYEGAFLFVGLLSLLGALGVRVALPKVAPP--PVVGLAERFAVARDKRVVALLVTTTLACLAAFMVYTLVSPVLSATAGVSGGTITVLLFCYGIGGAVGNFAGGRAADRWGARKPLLVVLIGFTAVMVLLPfaTTVVGAGITLFVWGLANWSFSPPLQHRLIELSPGHAGLALSLNASAIYLGVGLSGVVGGAVLTSAGPTVLPEVAAALAAASMLVVVFFW--
     915 UniRef50_Q48KU6        Carbohydrate transporter, p...   133     1e-29  1  15.4%  8:391  13:390     -------KPASWWAVGSVSLGSFATVTTEFLPVGLLPD-IARDLGTSISQAGLMMAVPGILAAISAPSCIALFSHVDRKRLL-LGLLSILLASNLIVALSTHFWLTLAGRVLLGFALGGFWTIAGSLGPRLRPGKEGVKAT--AYVLAGVSIGTVAGIPAGTLIGEAFGWRAAFETAAVVTVAIGLLIAAFLPALPGE--RSAGISQMLSLAGKQRIRRMFAAALLIYVGHFAAYTYLAPFVQEFAHIQGQALGALLFAFGLAAVAGNLAGGALAARSAPSSVLIMTLLMLGSLTALLMFVSNPWLLWPVILVWGFAFGMIPITTQIWCFEASNDRVEGVQALLVCVVNLSIGGGAFIGGVVSGRAGFTAAIVIGAVCAALSMFTVALAIR-
     916 UniRef50_D2BS05        Drug resistance transporter...   133     1e-29  1  16.9%  4:388   2:391     ---TEKSSRSQLEYALILGSLAALGPLCIDLYLPALPQ-MANAFATSTSVTQLSLTAGLLGLGAGQLVFGPLSDKLG-RRLPLLLSLAMLLLTSIWCALAQDIGQLIVARLLQGIAGAGGAVLSRAIARDLYIGHALTR--FFSLLMLINGLAPILSPVFGGLLLSITSWRGIFALLAVIACLLLTMSALRLNETLPAERrgSMLSSLGSLLRERTFMGLCLAQGLCGAGMFAYIGASPFVLQEVYGLSPQAFSVCFAVNGIGLIAAGQLAAHFSLRFGEQRVLRAGLTIAVTAALALTVAgpLIGILIPLFFAIAMIGIVGPCASSLAMQSQGDKAGSASALIGLNMFMFGALSVPFTGLGGNTSALSMALVILGCYLLAVTAYLLL----
     917 UniRef50_B4RX34        MFS permease n=1 Tax=Altero...   133     1e-29  1  12.7% 36:389   3:351     -----------------------------------LLPYFAEDFGITENVAGHAISAYAIGVVVGAPLITIFFSRL-ARRTMLISMMIFYAGGNLLTALAWSEWTMNIARFIAGLPHGAYFGIAMLFAADIAGKNKR--AQAVSNVIMGLAIANIIGVPSISGIGQMFGWRTGFFMISAFALATALMVWKTAPYRGPNPDAKPLTE--LKALKNKDVLLVLLMGAIGFGGMFSVYSYFSASYLNTTSAPEWGISATLLIYGIGVTLGNIIAGRYSEGRLLTSAIVFQVLLGLSAAAYAASMGQPYLMAASLFFIGIGGGMVVP-LQTRLMDVAGEAQTLAGAMNHAAFNTANALGPWLAGmlSAGYGYASTGWVGLALAGGGVLVWLAI---
     918 UniRef50_D1AA13        Drug resistance transporter...   133     1e-29  1  15.1% 24:387  27:394     -----------------------VAPFATDMYLPAFTD-MADDLGAGASSVQLTLTAFLIGLAVGQLTIGPLSDRFGRRVPLLIAT-CAATAAAVVCALSPNVWVLVAARFVQGFAGAAGIVIGRAVAADRT--GGQAAAKVFSLLTSISGIAPVVAPLAGGLLVPA-GWRMEFWALTGISALMLLGALLVVPESLPPERraATGRTMRHLLADRGYLGYILTFGLGFTGLMGYISASPFVIKNVLGLSTSAYSADFAVNALGMVTAGLINARLIGRFTPQGLLGFglTGSAVLLAMLAAGAPAAAVLPVLFLTVSCVAFVMGNSAALALGRARHASGTGAAMMGALQFACGALVSPLVGLGGEETGVPMGIALVTAAVLGIGAHLL-----
     919 UniRef50_C9PMQ3        Major facilitator family tr...   133     1e-29  1  13.4%  1:389   1:383     MLTIETVKRIKFARVLTLAAAGFIFNTTEFIPVALLSD-IAASFEMPISQTGLMITVYAWIVSLLSLPFMLMTANL-ERRSLLLKLVALFFVSHVISVIAWDFWVLLIGRIGVACAHAIFWAIMTSLIVRVAPKDK--KAQAIGLLAIGCSLAMVLGLPLGRIIGQSLGWRATFAAITLISFIILILLYKLLP--HLPSKNAGSLKSIPMLFKRPLLVGLYTLTIIIISAHFTAYSYVEPFMLKIGQMTGNMTTIILLVFGFSGITASLLFNRFHNYGPAKFLTISMVILVLSLALLHLFRGNQWSMFLLTFLWGIGISGIGLSLQIRVLQLAPDATDVAMAIYSGIYNIGIGGGALLGNLVMQQVGLENIGLSGALFALCGLVIFLTI---
     920 UniRef50_C4V2K6        MFS family major facilitato...   133     1e-29  1  12.2%  8:392   5:392     -------ARTRLWLTIFLGVMTAIAPVSTDMYLPALPE-VQEAFSVPTSLVQMTLTMTTLGMALGQILAGPWSDLWGRRRPLLI-GMLVFVGATLGCVLAQNIYLFLFFRFFAGFAGASGIVISRAIARDVCEGSELTR--FFSVLMMVNGFAPIIAPVIGGQILLFAKWRATFILLTLIGVVLAGATLAylPKEQRSKNVMDSLKKFPILLHDRYFLGHCLLQCFVFGAFFSYLSGSSFVFQNIYGVSPQGFSMIFAVIGAGLLLAGILPARFAGRVplKYAVLVPLIGSSLLLIGFFVSAPLPVIFILLFITIIPLSVMGAASFSLALSRQGKNAGSASALIGCFSMLLGACMMPVVGIAGDYTAIPMGVIMLTCYGLGIFVFYRMIASV
     921 UniRef50_C6C991        Drug resistance transporter...   133     1e-29  1  15.9%  2:390   1:394     -MSKSTSNRSRFGYALILGSLAALGPLCTDLYLPALPQ-LASELSTSTATAQFSLTAGLLGLGFGQLIFGPLSDKRGRRGPL-LWSLIMLLLTSAWCALASDIGQLIIARLLQGIAGAGGAVLSRAVARDLYAGHELTR--FFTLLMLVNGLAPILSPVLGGALMTLTNWRGIFVTLTLIAILLLLMSALRLPETLPAKRrgAMLASLGSLLQARQFMGLCLTQGFSGAGMFAYIGGSPFVLQEIYGLSPQAFSLCFAVNSIGLIIAGQLAERLCRRWGENGVLRLGLGIAIVASLALALAgpLIGILLPLFLAISMIGFIGPCASALAMQSQGGKAGSASALLGLSMFALGALSVPLTGLSGGTSALSMGVVILTCYLLATFCWWRSLQ--
     922 UniRef50_A1VNZ5        Major facilitator superfami...   133     1e-29  1  15.9%  9:391  15:403     --------PATRRSILLLSLGTFASMAAQRICDAMLPE-LSRVFAVSLAQAAQVVSVFAITYGASQLFYGPLGDRLGKFR-VITFATLGCSVGSILAVFAGTLEALVFARLLMALGAAALIPLAMAWVGDSVPSDQLQE--MLTRTGLGSTLGIVGGQLAGGLLTDALGWRWAFVFMTLLFGVVGALMHADLRRQQARParHGFARQALLIVTGPWSRVILLMALVEGAAGFGVLAIWASHLHRSLGLSLSMAGAIVALFGLGGMLYMAVGRHLIRRFGQQGLVLIGGAIVGVCALVLAYTPHWGPALPASLLAGFGFFMFHNTMQANATQMAPHARGTAVSLFSSFLFLGQSIGVVLAASLIDRIGTGAVVALGGGVMAVEGVFFAWVLR-
     923 UniRef50_B5GNT8        Major facilitator superfami...   133     1e-29  1  15.2%  1:389   1:386     MVRLKSLTGGFDRSFWSVCAGLFTNQIG-AMVLTYLGYYLTQEQGLSVTAAGTVLTAAGIGGVVCQWVGGILVDRLGYR-SVMAGSMSLTGFALLFLASSDQIGPIVVCTFLVGATAEMYRPAVAALVAHQFSPQDLPRA--YSFVYWAVNVGYGCSMILGGVLVRH-GYTSLFYVNSATCVAAGLLVWRSLprSGAVPGEAPPKGGFLGILRDRLMLGYLMVTLCYGVVFRQAGTTLPL-AMSLDGLSPSLFGFIMGVNAVVVVVFQPLSVPVVSRMDPHRVLMLGMVLLGTGFGLTSLASSALEYCATVIVWSLGEIAFSAVNQAIVAPLAPAhrGRYYGLYGMVWATAMLAAPLLGTRLLEH-GAALLWGVCAGLCAIAVCAQLLL---
     924 UniRef50_B0KHJ2        Major facilitator superfami...   133     1e-29  1  16.0% 10:391  26:402     ---------QQWLAILSVAVGAFALVTSEFLPVGVLND-VASDLGISAGLAGLMVTLPGIMAALAAPLISVGVGALD-RRYLLIGLTLIMIIANAIVAYAGDFNLLLVGRVLLGVSIGGFWATAIALSGRLAPDGM-GVAKANSIIMAGVTLATVVGVPVGTWLSGLMGWRMTFLVTALVGVPVLLAQVLLLPRLMPEKAIR--ISDLPALFVNPQARVGLIAVLLIGLAHFAAYTYVAPFFKQNAGFDGPTIGSLLLLYGVAGFMGNIFAGFAANRSVRHTLMLVALMIAVSTALFPHFATSMTGAAMLIALWGFAFGAFPACANIWMFVVAPKDVERGMPLFVAMFQVIIAVGSFFGGQVVDHMGTAVLLSLATALVGCGFVTVLVLGR-
     925 UniRef50_Q1QAK4        Major facilitator superfami...   133     1e-29  1  13.6%  6:388  25:402     -----SPSWVLKLTIGLIGMFAFLQVYSIQAVLPVL----MVDFSATEVQAGMVVGATVMAIAIMSPFLGMLSDAVG-RKSFIVGALLFLAIPTALIAQSPSIGWLGMWRFMQGLSVPGITVVTIAYIGEEF--EGRAVTELMSFYVSGSVLGGFMGRFLLGHLHEFIGWRAGYYVMAAMTLIGALWVGKMLPSSRHFVAnrSAMQTLGEHLTNRYVVTACLLGACVLFSLVGCFTFINLHLAGTPYELSTGALANIFAVYLIGVIITPLSTTLLRRFGAARTVRVAVIFSMLG-ALLTLVTPLWGIIIGLAIMSSGVFVTQAATISYIAVNVKNGRSLASGLYYMAYYAGGTMGAWLCGIVYARGQWSLTVWLLLFVQVLALLVASF----
     926 UniRef50_C6CDC7        Major facilitator superfami...   133     1e-29  1  14.6%  8:370   6:371     -------RKKSYWVLFLLYIGWCVAFIDR-VVLSMGSTQMAKELSLSPSEIGLVLSAFYFGFWLMQLPGGWLADRFGA-KVVVAMAIAMWSLFTFLTGIAWSLTALLVIRFLFGLGEGAYPSASVKNAAEQFPPSDKPRMT--SLLMSSNYVGSMIAPLLIAPLILALGWRHAFMVIGLFGIAFVLVYTLTvpAWVSNEPERLSGADWREVMKNPLLWRLAAVWFGLSLINKGLDSWMPIYLMTERHLDLKAVGVLLPIPYVMAGVATASGGWVMTRfrERVMLMGCALLTALFLYLMYSASSITAVVVAQSCAYFFKSFVLAIAVALPTKvaSRMVGSGIGVINVGGQAAGFIAPLVIGAMVEHFGYPS----------------------
     927 UniRef50_A9QSK8        Transporter, MF superfamily...   133     1e-29  1  14.6%  7:389   2:384     ------KEKLWTTTFVVNMLLNFIFYLVFYLPTVVIGTMAMERYHASASIAGILSGIFIVGGFIARLWAGNNMKRLGAKKLLYIGTLIYFLL-TFAYFFVHSVVLLLILRLVHGLGFGIAATASGTLAGAIVPSSRRGEG--IGYYALSVTLSSAVGPFLSMFLYRTSGFYSLIWLSALLLFIALVGIFFIHVEKTTDSSnkVHKKFAWSNYFEKEALPISLIAFLIGISYSSILSFMDAYARNIH--LSEAASFFFLVYAITVLLSRPITGRVFDGFGDNFVMYPTYLFFALGLLLIGFAHSGWMLLLAAIFIGLGYGSFSPFGQAIAIRNSEAHrgITTSTFFGFMDMGVGFGPFILGMFMPLLGYRNLYFASAILALLIAVIYHFV---
     928 UniRef50_Q01QX5        Major facilitator superfami...   133     1e-29  1  13.9%  7:388   2:391     ------KTRYKWTVVGLLWFVCLFNYADRQAIFSVFPL-LKAEMHLSDVQLGYVASSFMWVYAAAAPFAGLAGDRF-RRKSVILGGLIFWSLITLATALATRYWHLVLFRALEGLGEAFYFPASMSLISSWHGKETRSRAM--SWHQSSVYAGTIAGGTAAGFLAERFGWRSGFYLFGSLGVVLGLVLLVLLKEPPEEAPReqFGSAWRDVLRNPMAGALMAVFICANFVAVVFLTWLPSYLNRNFHMSLTMAGFSATAYlvASVLGVLTGGMVAdrRGRMFTQAVGLFAGVPFLLLTGWAFQVTVFVFATIGFGFFKGMYDANIWASLHDVvpGRRATAVGLMNSIGWLGGGVAPVAIASASGVWGMGACLSATSAVYALAGSLLVL----
     929 UniRef50_B1VHN6        Putative permease of the ma...   133     1e-29  1  17.9% 13:387  11:394     ------------LTLAGFALLSAGGPLGTDMYLPALPL-IGRDLGASPAVVQLSITAYMVGMAMGQLLIGPLSDGRG-RRGLLCFGMVLGLIASVVCAIAPTAAVLIAARFFQGVAGGTGVVLTRAMIADKLRGS--AAAQALSVMMLIIGVAPILAPLLGGVINQAAGWRAIFFTLALIALTQILVASrlPVERRHGGGPVRMYRNMLGLFRRPAFVGYAMAFAFGFGTMFAFISGSSFVYQEVFGLSSVGFSVMFALNAVALLSANSLNIRLVGRIGARRLQRVAVCVIAAGAVAVLLCALVlaLAAAVFVATFGVGLNMSNSTALAQGLAADRAGAGSAVLGAGQFVVAGVMSPLVGLGSDRMLALGLCMVASVAVAIAGTLLA-----
     930 UniRef50_Q7MK22        Permease n=41 Tax=Gammaprot...   133     1e-29  1  12.7%  5:390  15:403     ----MSASFPLAKLTFLIAILTAVGQMTQTMYVPSIG-HMASEFLVSPAALQAVMACYLIPYGLSQFVYGPLSDRLG-RKPIIIAGLLIYIAGTMLSLFAHEYTWFLVGSFVQGLGIGCGGAMSRTLTRDCFEGAELHRA--NSLISMCVIFSPLMAPVLGGLLTETFGWRslFLALFAIAVIITMMTSMIETLPKEKRKHESVARSYHYVLSNKRFQGYLLCLVATFAGVAVFEAAAGVLLGGVLGLPATIVSILFVLPIPGYLIGAGLSSYIAQRRSQKRALNVGLVAILIGAAVVLIptTALTLVGGATIYFLGAGILFPAATTGALAPFPYHAGTGGAILGGMQNLGAGIATLIASLFPAQDQLPLGCLMLAMSILAMLGLRLVYR--
     931 UniRef50_Q28U05        Major facilitator superfami...   133     1e-29  1  15.8% 11:389   1:373     ----------MKRPILALAAAGFAVVTTEFVIIGVLPR-LAADLGVTIAQAGLLATIFAFTVAIAAPFLTALVAKIERKK-LFAALLAMIAISNLLTAIAPTFEIFAAARVVGALALPVFWAVGTASAAQLGGPEGGGK--SVAILYASISAGTVIGIPLGTLLADLMGWRVMFGAIGVLAAIMSLALLAFFPTTPPDA--APSLLKQASILKRGSFLAHLVLTAFAFTSMFVAYTYLADILQTLASLPTSQVAWVLMGFGIVGLFGNWLAGQYVDRSPMGVTVVSLAALSIASFATVALTGQGILFLIPLAIWGAAQSAGFIGNQLRVMKEAPEAQEFASALSVTIARVGIGLGALIGGKVIDARGLAALGSENALIGIAGLVVAMLI---
     932 UniRef50_Q1H0P2        Drug resistance transporter...   133     1e-29  1  13.6%  9:384   2:382     --------RHSIFLVYVLAGLTALAPFAIDTYLPAFP-MMERDLGASTVEIQHSLTLYLLPYALMTLFHGAISDAIG-RLTTIRWGLVIFIFASIGGMLAPNVETLWAMRILQGLSAGAGNVVARAMVRDLFQGVEAQRAM--ATVQMLFGIAPAVAPIIGGWLLG-IHWQAIFAFLALYALLIALAAARYLPETMPKERRVSLsrNYQVVFSHREFSLLVLAIGANFSAFFLYVLASPVFLIQHLGLSSQQFAWMFIPTVCGTVLGSWLAKRAAGKYGAQHILRFAYGWMSTMAVLNLAVSLLPFiiLPVALFNIGLALAMPLLSISALDCHPRIRGTAASGQVFMQMLLSTLSAGLVAPLVWHHPAGLALAMLGYLLLGWLA--------
     933 UniRef50_Q3SKZ4        Major facilitator superfami...   133     2e-29  1  16.4%  7:372   1:365     ------MKSARPSFFVLIALVGGLAIFSSTLSKTPVLPLFAQALDATPAEIGWIVMASTIPGILISYPAGALSDQLGKRR-VLLASLVVFATAPFLYLIISTAWQLMAVRFYHGFATAIFGTVASAAIAERYTAD---RAQRLSTYSSVTIVGRSVAPFLGGTLISLGSFGAVYIACAISGVLALVVGLALRDHAPPAATkpKFWTSLATVLRDRGIMLVSLVEAAQYLVFGAIEAFLALF-ASSLGIPAWQIGVILGVQLVSIVFAKPIAGKVSDRLGRRRVILPGLMIGAASVALLPYFPSFAGLSVLSLVFGLGFATVTSSTAALVADLTRDGrgSSMGVLRTIMDVGQSIGPVLTGFLVGAAGYPSAF--------------------
     934 UniRef50_B7DPZ6        Major facilitator superfami...   133     2e-29  1  15.7% 14:375  16:378     -------------LVTTLAFMILLVGSDEMVLSPILSQ-ISNAFRVSVSQAALAVSAYGLALALGAPVLARVGDRKGA-GAALWLGLAGFVGASILCAYATSFLEFLLARFLSGLAAGLTVPSAYALAGASVSDEFRGQA--LGWVVSGWSWSFILGVPLATWVDRDLGWRWMFMAFGIAAILLLLFMAWSLKRRhrNAAEAGKRTAAADLFRLQGVAALLIATLGNMFGFYGMYALFGAAWHLQASATHAESGTLLLAYGIG-FATSIVTGRWADRWGRQRTLVISLVVLTAVILMLPYSMNQIGLaiALFVWGVFQSLTVTLLTASLSEYSEVHRHQIMGWYSFATNMAVILAPAVMGWLDVRVGYATVAMLC-----------------
     935 UniRef50_B2J7N2        Major facilitator superfami...   133     2e-29  1  13.0%  2:387  12:423     -SQLSSWLPSIHPQVWIFAIGRFLSEVGTGCTLFYAPIFFVNEVGLSATSVGVALGSASISGIVGRIVGGSLAdhWGRRRTLLLA-TAISAIASLVLAATNDFTILVIGSLISGLGIGFYWPAAEAVVADASQIDNRRETFAIA--RLADNLGLAIGIALAGFLIAVIgyRWLFVIDAISFLMFFGVVYVGISKTEQQQMGESEKTAHFavARHRRFLVYIAVNIFFTIYISQIHSTLPLYLKNFvgFAQTTISVLFAWHLVLAIIFQLPVTSFLKRCSHTLALTVSAILWGVGFGLIWVSgnLAWVALALGVFAVAIVSYTPSAASLVTELAPeqRGVYFSVNAVCWAIGSFIGHPLGGWALDQPpiTNTFWLGFPLSVLIVVVIL-----
     936 UniRef50_D2EJ58        Major facilitator superfami...   133     2e-29  1  13.6%  4:392   1:387     ---MIRKMKNKKLLIFTLAFGTFSILNTEVGILGILPL-IGSRFGVSVATAGLFVSLFALVIAVFGSIMPVALKRFDRKKVM-LLTLLLFTLANVIGGMVTSFNLALFFRLLPAILHPVYCSLAFTIAAETADNGQASKA--VSRVMVGVSAGTVLGTPLTTLIANNISYSAAMYFFALVNFVALVLNFVVLPSFKNGEDSVEESANatGVLKRGSLWVSGLGTILIGSTLFIVYGYVSDLLTQLSSFSSTQLSISLFVFGLMSMVGNTIAGNLLSKAPRKLVSMYPFLLMAVYLLVAFFESHTLMMFPVIVLWGMIYGIGNNIQQYLISAALPDALDLANGLFISLGNVGTSLGTSLGGVLLSSVGLGMLPIGGISILILTFIVVLVRNRM
     937 UniRef50_Q39AI2        Drug resistance transporter...   132     2e-29  1  15.9% 14:390   6:386     -------------LILVVSLLSAFGLIASDVYLPAMPS-MAHAFSIGAWQMPQTVSAYLIALACAQLFYGPLSDRWG-RKPVLTVGILVYILGSIGCASASGFASFLGWRVLEALGAASGLVIGRAIIADTCDKH--ASAKVYSIVYPLVSLSPAIAPAIGGYLAAWFGWRSDFIFVAAFGGVALVLVQLLLKETRPpqQRAVPLAGFADVLGDRAFIRYTLVVCAIYCAWFVYLTQSPFIFSG-LGLSEQQSGWLYLPLTAGIISANLLSRRMLDRMSYDAIVAAGVGCFVAGGIAFALCEsiIAIVMPMFLVSLSNGSSLSLAVSGAIASEHGRAATASGLVGFFQIGSASLAATVSSSLLGTGSHVLATAMPFFAIVAAVAIVPRWY--
     938 UniRef50_B7GPD1        Major facilitator superfami...   132     2e-29  1  14.8% 11:375   5:371     ----------LSPLYWGLWLAILILWMGRF-VTSFLSIYLVSALHLDEGVVGAVVAMYGFGAIIGCLFGGALSDRFG-RQSMIIIGEIGAAAALLVVSVLADPVALGAALFVYGAFASLPSPAIAAYIADVVPPKRQQRAYV--LQSWAINFGYAIGPIVANQLI-KISYSLMFYVEAAVMIAVTILLIVFFReaPAARPEGAMSRNWRRVLTDTPFLGFSLLMFGYFLVYFQSTSGLPIAMTD-LGLGLGEYSVLLTINGGMLCLLQIPAMKLFARMGNSRVLVMGLAVTAIGYAVQAVAHSWGGFAIAVVLWTLGELGTFPIATTTVAAMAPaaRGTYQGVYNVVWSVSIALAPLIGGWVIGGFGGRMLWIAC-----------------
     939 UniRef50_Q65FX6        Major facilitator superfami...   132     2e-29  1  13.4% 11:391   1:382     ----------MPRTLWLLVIGMFINVTGASFLWPLNTIYIHQHLGKSLTAAGFVLMLNSGANVLGNLFGGYLFDKIGGFKTVVLGIVITFASLSGLVFF-HDWFQYILFLTLAGFGSGIVFPACYAMAGSVWPEGGR---KPFNSVYVAQNAGVAVGSALGGIVAS-FSFTYVFLANAMLYAVFFMIAFFGFKRIRSEKAMQSSVLDHADSVSGkaLLVICTGYLLGWIAYSQWSSTIASH-TQELGISLGQYSVLWTVNGALIVFGQPLIGFFVKRfsLKNQIVIGFVIFMMAYGILFGAERFPAFLAAMVVLTIGEMLVWPAVPTIANRLAPRGkgFYQGFVNSMATGGRMIGPLFGGMLVDYFSMQLLLAVLLALLLIAIGTAFLYNR-
     940 UniRef50_B2JMQ5        Major facilitator superfami...   132     2e-29  1  15.0%  5:390  18:396     ----TSSPLRAWLAVASVTVGAFAFVTTEFLPVGLLPQ-VAQTFDVLPGTAGLMVTIPGIMAAISAP-GMMLAARRVNRRLILILLSVMLLASNLMSAFAPSFSVMLVGRAMLGAALGGFWTLALAAAGRLVKAHEAPRAT--ATILAGVTCATVIGVPLGTFIASFASWRMSFVATAVLVTVALIAQFALLPSLPSKAALR--FADLVTLVRRPFPRKSLLMVALIFGAHFSSYTYIAPFLQD-AHFNASTITAVLLGFGIIGFVSNFTVSTFVARRLRGSLASMTMLLLFALLTMPLLKDMAPVVTAVVLAWGVAFGAIPLCVSVWMQEAAPDLPEAGSALFVGIIQVAIAVGSSAGGTIVDHAGIPVDFWFGSVLAILGLVTLASFR--
     941 UniRef50_B1YE91        Major facilitator superfami...   132     2e-29  1  13.4%  4:391   1:403     ---MFTALKQLDRNIWIRFVGETITGVMMFMIAPFLVLYYSEQLD-SYFLVGLIMATGPITSLFGSFLGGYLADLYG-RKPLMVISIVGDVIALIGFSFADSFWPLLLMNALLGLTNSLFHPAASAMVADVTPPERLNE--SFGLLRMGHNVGAAFGPLIGSAVL-FIDRSLIFYAAAAVFFLYALVLLVFIQETKphTHDEPKLSAFTVLRKDHVFVIFIAAGVFISMGFALVESMLPVFLKEALPGLPNdfPYLMGLNGIMVVLFQFPVAARLSGKAFGKVMLLGASIFGLGMILLAFIPsvTILLVIYALYTLGEMIMSPVQMTFIALIAPEhrGTYNGAASIQWLIGGVTAPLLGSLFLDSGNGQYALAGVGVACCLSGLVYLALDR-
     942 UniRef50_B6J4F7        Multidrug resistance transp...   132     2e-29  1  12.5%  9:384   2:383     --------SSNKLLFFVIALAACLTQFAADIYAPSLPA-VALSLNTTIDLAQWSMAIYLFGVALTLLIYGPLSDAVGRKQPMVI-GLCIMAAGSVVAMLAPNIKLLILGRFIQGCGAGACAGLWRSIFRDVFTGEEL--AKYGSYFAILVMFIVPLAPALGGFLQHYFDWRANFVFMTIYTLFALLTVAFGFKETSRHHHLENLRLpfRRLVKSPIFMGITVSTFLSYGAFFAWITSGSVLLIHVLGMSPLAYGlvFFGGGIAYALAGFLNGRLVSRFSMPTMMRFGWSVMVLSGILMALGknVWVIAIPIILFYFGSTFIWPNAFATAFTPFGDIAGYAGALYGFMQLSGGAVIGSLMAYLPHADQLPLALVIIGASLLAWII--------
     943 UniRef50_D2PVD1        Major facilitator superfami...   132     2e-29  1  14.6% 15:391   4:375     --------------LGVLMFCVFGITTGEFVVAGILPA-VATDLQVTVGTAGLLVTAYAVGMILGGPVLTALTAGTDRKR-LMLALLAVAVAGNAISALAPGFSLLLAARVATALVTSTFFAQAIVIAVRSAPPER--AATMVARLAFGMNLAIILGAPIGTQIGGHWGWRATFAAIAVACLIGFGLVLLLL--TTPPDEHRRSAVSELRVLRRRPVLIALAITAVGNVGVLMVFSYLAPLLTNLGGHPATRLPVLLLAYGVGATIGNLLGGALYDRNPRVSQPALLGALAAALVGTWFVAGSTTLTAVAVVVIGLLAFAIIPGMQARVMTTATEAPTLAVAVNASGYQLAAACAGLFGGLIADStgPRPIYLTAAVLTTCALLITLVATR-
     944 UniRef50_C1F4X8        Transporter, major facilita...   132     2e-29  1  12.9% 12:391  31:413     -----------PWTLAAVCLCGIFAFLNLYVTQPMLPMF-EHVFHASKSLVSLTVSASTLGVAISAPFLGAIAERMSRKR-VIVLGLLLLAIPTLLAATAPGLPLLILWRFLQGLVMPAIFASVITYIGEEWSP--LSIALVMSIYVSGTAMGGFLGRLIAGLTAEYLNWRASFLLLGLATAAGAALIALILPREKRPLPQHPHprGTLAHFANPRLLATYTVGFGMLFALVSTFTYVTFYLAAPPFSLSTAALSYLFAIYLIGLLVTPAGGYLITRIGMRRGIVFAILLCLLGEGLTLSHHLWIVVFGGLGLVCTGVFMAQSTAASFVRLAAPDgrVSAAGLYLSCYYLGGTAGGVLPSAAWNLGQWPACVALTSTVLLLIVGIGWAGFR-
     945 UniRef50_B5H5E7        Integral membrane transport...   132     2e-29  1  14.2%  6:391  12:399     -----TTVSGLPPGFWWLWTSTLVNRTGAF-VLTFLSLYLTQELGYSAWYAGLVIALHGLGGVAGSPLGGMLTDRWGRRPTMI-SMHLAGAACAAALAVVSSAWGIAVVVLLMGVAMQAVRPAISAMIADMVPESELRRAYALNYWALNLGFAVAALGGGAAI---FLGYRTLFVADAVATALCAVIVFMRLGETRPAARveEERVTVLDVLKDAPFRTLVLLNLLVCLIFTAPWVGLPLTMAGE-GLSADSYGMVIAVNGVVIVALQLLVNRITDKRSPAALLTVSSLLFAVGTGATALAGTPLVFAATVVVWTLGEMVHVPTNAAATARLAPEhrGRYQGVMGMSWAVAGFVAPILAGWVVDGPGPDVLWMGCAVVGAVAAVGYSLLLR-
     946 UniRef50_C7N8A6        Drug resistance transporter...   132     2e-29  1  11.7% 14:390  21:399     -------------LIVFITLLSVFPPLATDMYMPSLPE-LREDLGTSSAVASASIIAFFFMFGVGQLLFGTISDKFG-RKPILLAGLGVFVASSIGCALAPNIAVLLALRALQGLGGGAGGAIAMAITKDCFPEERRARVLIVT--QAAGALGPVVAPVIGGWISTFATWRVVFWVLAGTGLAAFALAIVypPEMRYTGSLAGNFGRLAVVARNKGFTLLLVTLALVSAPFMGYVTTSSYVYMDFFGLSSGAYSLFFAGTALIMVAAPFVYLIVSRYFKTKTLIEATMVGAFVFAGLMLLFasPWMFVLTIAPFLMMSSAIRPGTTNVLLMQHETDTGSASSLINFTFTAFGSLGSVVAALSWPDFVTADAGTILVFFTAAVALWVVLLK--
     947 UniRef50_B7KA29        Major facilitator superfami...   132     2e-29  1  15.2%  1:387   1:386     MLSVLRSPAKQIVQCLVLLAAGCLTTMTGGIVAPVFPEIL-QHLHLEPRWAGMLISIHALMIALFTPILGILADRIGKLK-VLIAALIFYAVFGISGAFIGHFLPLLADRALLGIASGGISAACIGLLSNMFEGEARL--QVLGYATSAMTTASIFVPLLGGWVGS-YNWKFAFFIYGVSLPIALAAALMLQEADRSENSALsmGNQLIKAITKPQVIRLFITLALAAAIVYSVVIYTPVYLNETIGADAKLNGIVLTARAIGavVSALAANWIGKRLGRNVTIALGFILMASMLATIPVLKDISLILYAAVFFGAGFGVAVPHMYNGLAEFspELRSSVMAIGTGFNSLGQFICPIFLGAVWQSWGLTNVFYVTAGVGLMIAVWIV-----
     948 UniRef50_B9QTF4        Drug resistance transporter...   132     2e-29  1  13.6%  1:390   1:394     MTAAPATLMSARRTALLGAGLVAVGPISMALYTPAMPA-LVEFFGTTDGAVKLTLTSYFAGFAATQLVCGPLTDAFG-RKPVTILFLGIYLISSVLATFSPTVEFMVAARALQGVGAAIGISVSRAIVRDQFTGQ--ASARIMNTIAMMLALGPAISPTIGGFVLELFGWREVFWCMVIYGVALMVAVTVFQVETNPSPgpRQLAINYTTLLKDPRFLAPAILIGCGLGNIYALATVLPFVLIYEVGLSPSVFGLTMILQSGSFILGTVITGQLLKVTDAHKLVPFGLAMLVVASVLMCAmpSVASVMAPVGLFVFALAFVLPASFTDSMAPFPHIAGAASSMLGFLQFGGGVAASLIVAMVGD--PVLGLAFVLPAMPVAGVVCYLLLR--
     949 UniRef50_Q480G3        Major facilitator superfami...   132     2e-29  1  13.0%  7:391   5:388     ------KTSAYRRASFALALGSFLVFCNLYMFQPMLPL-MAEKFNASAIEINWLLASCTFTLALTLVPWAIGSEIFGRRNVMML-SLFLLPFAGLAMLLTDSLLMLTLVRGVMGISIAGFAAVAVAYMAEEFTPKALMLA--VGSYISANSLGGITGRLYGGFITEYWGWEIAVIGMAVASLLGAVLVNRLLPEQLYFTQKKGQFRSHNrhLKQKKLWLAMLIGGLNFAIFVNLYTVMGFRLVAAPYSLSISLTSMIFLCYLSGTITAKISGRWSQVYSPIKGMLLGTTVSALGMWVAAY-DSLYTMLIGLLLISSGSFFTHSLAYAWVSQKAETAKATATALYLVHYYVGGSLGGFYLIACWQYGTWNGVLAGGMVIYGLIYLLCWLLQR-
     950 UniRef50_C3DZQ3        Drug resistance transporter...   167     5e-40  1  12.1% 12:391   7:392     -----------NLLLITLICLVCIPQLSISLYLPSLP-HMSNDFNTGNDLMQLTLSIYMVGYAISTLACGIFSDRYGN-KPVITFGLFLYLLATVICLYTSNIYVLILGRFLQALGGGCGTVLARVIAKEKFKDKEQLNVLTN--LSTAIAVTPAIAPAIGSFIQTYLNWRYCFVFLLVLVSIVLILTLCILEKEKNVQGKksIFNNYKLLLTHKIFLAYSVAIGLAWCAYYTFIQSSSFVLQGFFHVSPKSYSLMYALVIIGYIMGTTFTRRNGSRVGLNKVImiALFSSILMVIAVWIIpnPFGIIFPMMLLMIGVGGIFPACQAAVMKPFNEIVGTASGLFFFIQMIFGFCCGLILSAFNMTSQLPMVLTILVCCILLVASFYQLIYR-
     951 UniRef50_B5XQW0        Transporter, major facilita...   161     5e-38  1  11.8%  1:389   1:416     MNTTANTTRIRWWIAGLMWLAIAINYIDRTVLSAAAPHLI-DELKLDPEMMGFIMAAFFWSYSLLQIPAGWFADRFGQKKG-LGLAVAWWSIATSMMGVATGFKSLLALRLALGVGEAAAYPSNAGIAARWFPDKER--ATVSGLFDSASKFGGAVAMPLIVWMIYTFDWRLTFLIIGSVGILWVIAWYFIYAENPEEHKRISPSekWYKLLRYRNIWAMCIGFFTINYTSYFFITWLPTYLVKEKGMDFIKMGMVAALPLLCGMVIEVFAGWASDRlaTRKLFLTIGLLMALCIGFAPFTDSVFMTVFLLCVAKSGTTVAASQVWALPGDVAPKnvSIVAGLQNTVSNMGGAVGPIITGAIVAATgfNWALIFSAILVVIGIINYLFL---
     952 UniRef50_B2JWD4        Major facilitator superfami...   156     2e-36  1  12.3%  1:389   1:412     MEKHTRRVKTRHIILAVMCVMYFISYIDR-VNIAVAGPLIRHEMGLTSAELGLVFSAFAYPYAIMQIIGGWLSDKYGP-KLVLTVLSIIWGAATLATGFAGSVAMLVALRFTLGIGEGGAFPTATRAFTYWMPVSERGFAQ--GITHSFARLGGAVTPPLVLAVVAAGGWRDAFVLLGVASLAWTVLYLCVFTNSPEQNKRITpaKRMPTPWRkrRMWLVTFVDFCYGWLLWVYLTWLPSYLKESRGFDLKHLALFTALPLLAGVIGDTLGGVVSdrFARCAVLVVGMGGSLAFLLPMVSASNPLTAVWYLSASFFFLEITNPVLWTLPLDIAGKYAGTAGGMMNTGFGVAGMVSPVVFGYLIQTTgyNVPFSISAGLLAVGVVAACFI---
     953 UniRef50_D1PB05        Major facilitator family tr...   153     7e-36  1  12.0%  8:389  48:424     -------SKQMKKGLFALALGTFTLGIAEFIIEGIITD-IANNMNVSIPEAGHLISIYALGVCAGAFSL-ILMHKY-RPKNILMFLTSLITFGAVIASVAPNYWLLLCARFIEGLPHGAYFGTGTIVAVKIAKEGKGTNA--VAMMCAGMPVANLLGVPVGTFLSHMFSWRVPFVSCIVLGLITLYMIHRWVPDV--EALPNNGMKAQFHFLRNKAPWLIIAATFLGNGGILCWFSYISPLLQMEGGFSAASISLLMILAGGGMVVGNQVSALLADRIKPGRFtyLQFLAAAALLLTFFLAPFGWVSVVLMFICCACLFGIGSPEQFLIVKHAKGGEMLGGCCIQGAFNLGNAMGAFLGGivAMGLGYNFPALIGVPMALAGAICLLIF---
     954 UniRef50_P39398        Inner membrane transport pr...   150     7e-35  1   9.9%  8:391  37:444     -------KRIQTTAMLLLFFAAVINYLDRSS-LSVANLTIREELGLSATEIGALLSVFSLAYGIAQLPCGPLLDRKGPR-LMLGLGMFFWSLFQAMSGMVHNFTQFVLVRIGMGIGEAPMNPCGVKVINDWFNIKERGR--PMGFFNAASTIGVAVSPPILAAMMLVMGWRGMFITIGVLGIFLAIGWYMLYRnsVNARRDPLSFAEWRSLFRNRTMWGMMLGFSGINYTAWLYLAWLPGYLQTAYNLDLKSTGLMAAIPFLFGAAGMLVNGYVTDWlsRKICIIAGMFCSAAFTLIVPQATTSMTAVLLIGMALFCIHFAGTSCWGLivAVASRMTASVGSIQNFASFICASFAPIITGFIVDTtsFRLALIICGCVTAAGALAYIFLVR-
     955 UniRef50_A5N6X3        Predicted transporter prote...   150     7e-35  1  10.7%  6:389  12:423     -----KPTGKRWFILFLVCAITFINYLDR-ANLSVAAPFISKEFMLDPAKMGLIFSALSWSYTVMQIPSGWFLDRLGPR-LVYGVALCGWSAFTGIVAFTFNFTSMIFCRLGLGFFEAPAFPANGRIVTTWFPSKERGSA--IGAYTASEYVGLALCTPILTWLLVTFGWRVIFIVTGILGLLFAFIWFTHYNDPAhsEQKKITKKEIKYLFTSRQLWGMYIGGFAITAILFFFMTWFPSYLVNEKNMAILKVGIYGALPYLAAIAGVLVAGKWSDwlSRKLPVIVGLLLSSVIMVA-NYTTNVNVVITFMSISFFGQGMASAISWALLSEIApdLVGLCGGTYNFVANMGGALSPAIVGYLISRTgySSALVFVSCMALIGALSYIFI---
     956 UniRef50_C6PT89        Major facilitator superfami...   149     2e-34  1  12.1%  2:389   8:423     -KEKSKATGKRWFILLLVCVITFVNYLDR-ANLSVASTSISKEFALNPAVMGLIFSAMSWAYTCMQIPCGWFLDTFGPR-LVYGIALLGWSLVTGIMSLASGVSSLIACRIGLGFFEAPAFPANNRIVTTWFPSHERGLA--IGAYTGSEYVGLALCTPILTWLLVTFGWRSIFITTGVLGVLCFIGWIAFYHDPASaeKRKISLRELKYLFSNRQLWGMYIGGFSIASILFFFMTWFPSYLVNEKHMAILKFGIYGAIPYFAAIAGVFVAGRWSDWMlsRKMPVIIGLLLSAMIIGGNYTNNISLVITFMCIGFFGQGMASTVSWALLSEIMPKnvGLCGATYNFITNMGGALSPLIVGYLIARTgySSALVFISIMGIIGAVSYIFI---
     957 UniRef50_C8QBB2        Major facilitator superfami...   148     3e-34  1  11.9%  5:389   1:412     ----MRNYPKIRWFMIIMCFIAMAINYIDRVNLSVAAPHIKHDLGLDDVSMGLIMGAFFWTYALMQIPVGRLLDRFGERIG-LTIAVAWWSVFTVLTAFGRGLVSMMGLRMLLGIGEAGGHPGCAKVVYSWFPKKDR--ATASGIFNAGPRAGSALALPLVAWIITTWDWETSFIVTGVLGIIWAVAWYIIYRTPepAKKQGTEKKAWLFLFRYRTMWGMMLSFFCLNIALSFFLTWFPSYLMASQGFSLKQLGTLGMIPPLVGIPASMLGGYLSDwfARKSCLVFGLLLSSVISFA-TYTNSIPLIITLLSISYASIAFAAAVVWSLPADVApeYVGTIGGIQNFAGNLAGIISSSFTGIMLSlgSFEVPLIATGVICLIGALSYIFI---
     958 UniRef50_Q5ZSL6        Multidrug resistance protei...   148     4e-34  1  15.1%  9:392   6:394     --------PKSHNSIIFLGLLSAFSLLTFDLYQPSLP-FITNYFNITPSMGQLTLSIYLLVYGITHLLWGPLIDHFGRRRLL-PGNLLLALIGSLMCAFAPNITMLICGRALQGFALCCANLIAYSAARDF--EDTIVRAKVLSYISMTVSVSPIIAPVIGALIFHHFGWQANFIVMAIVACILLIQTKLSLLESPFWTPPQERFseYKSILNIPSLWCASFILMFGISAVMLTVINSSYLIIEVLNYSPLAYGLIFILNGLNIIFGNYLGIWLRDRLPIITTIYLGNWFIVLGGTAMLVTSKLFGFSLLALSFslGISVSAAPTISIALTDFKQNAGIVMAFMNTIRLIGPSLLTILTGYLLTR-NLDALPLGLIGSGIGALFFSWHFSRL
     959 UniRef50_D1B0Q6        Drug resistance transporter...   147     7e-34  1  10.6%  5:390   1:384     ----MPHTLTERQIVLILASLSAITPLAIDMYLPAFPA-IALDLHSAIPHVEFSLSLYFFGMAMGQLFGGPISDAYG-RRPMILIGLSVFALSSFMLSIANSIEMFWILRALQSFGGGVATVNVSAIVRDKFDGKE--SARIFSMISMIMLMAPLLAPTLGSAILKLLDWEAIFIGLGSYTLITLGVYLFCFPKTKQIRTKITPIQNYKTVLSHKLAMVFVISQILCTSGMYTFITSSSFIYMEHFQLSAAQFALFFSSNVTMMMFFGWLNASLVKRREPLSLLRFGMSVQALLGILLFTfgSLYLIFPLIGLYIGILGFIFSNSIALTLEFFPTISASANAIIGVLQYSVGALMGFVASSFHDGTLFPITTVMMSVSLCGIILLLTGSR--
     960 UniRef50_Q0BNA9        MFS family major facilitato...   147     8e-34  1  13.1% 40:390  62:425     ---------------------------------------IANAFNITPTEMGILLSAFMWSYAIASLPAGYMVDRLGVNKVMLI-SMIAWSVACILGGFVIGFYSILLTRILLGLAEAPFFIVATRIIQHRFPSSQRG--LMSSIIALGPRLANILAPLILVGLMLLIDWRGMFIILGVVGLIAAIGWKLLHTKETLEHtkKSQKISISETLRNKNVVYLCIGNLCSSYAYWLFLTWLPFYFIKVKHLTLSQMSIATSASFISGVASVMLGGIISdvFARLTPIIAGCLVASIAILALPFIDNIFVIVCVIGVTIFYLGLRISPTWALVADISpsLVGTIGGLQNFANFVGAGLAPLITGIILQStnFMIIFIFSGIICLFGSIIYMLIR--
     961 UniRef50_C0Q9N6        Drug resistance transporter...   146     1e-33  1  11.1% 12:391  11:389     -----------KGMFILLAFISAFPPLSTDLYLPALPQ-MKEILNTTQSQVNLTLSMFFVFYAIGLLFWGPLSEKYG-RKPILLIGMVIYTISSIICGFSQYVEQLIVGRIIQAIGGSAATAVSTAMVKDLYSGRKREK--VMAMVMSMVIIAPIVAPVIGAFLLEYVSWEIIFFVLAGVGA-TALMAGALLEETIENRYTGSVWRSWGrvLKNPNFSILLAIFSTISMSIMTFLAASSFIYINGFGLNEREFSYFLAFNAVFAMIGPMLYVKLSQHFKSQAIISAGFPIFILCGIAVATvgSVWAFALAAALATLIVDGMRVPGVNLMLEQQQNDTGSASALINFFGMLLGSLGMHLVSLNPNDL-ILALGCIQIMIGLISGILWFLIRN-
     962 UniRef50_A8H4F5        Major facilitator superfami...   146     1e-33  1  14.9%  5:387   6:424     ----PSVTWRTHSTLVLLALVYVFSFIDRNVIAIVL-EPIKQEFGASDTLMGFLSgaFAILYAGLSLPLSRLADRGGNRRNIIAVCCGLWSIATMACGMAQHFWQLMIARMTVAVGEAGGIAPSISMVSDLYPPHRRSLA--ISVLMIGPHLGLLAAMVAGGWIAQEYGWRSVFLFFGAPGILLALLLFCFTKDPGhkNKQESFFKQLKGIMKVKGFIWIAMGCALAGMAGYGYGIWVPTFMVRNYDMSLAHAGISFGLagIFAAIGTIFSGVFCDKLSKrpIIGILISLPMGVAFMLWPADAFWMviVFAALFSFFNCWWPSLSYAAISHlsSQRATGAASLNLFLTLFGAGLGPLLTGTLSDVfgLKYALVATMMLLLVSAWFYY-----
     963 UniRef50_B5CWD9        Putative uncharacterized pr...   146     1e-33  1  11.8%  7:386   2:376     ------MQTKNWMALVGLTCAAFIFNTSEFIPIGLLTD-IANDFLTTEAQAGMIISIYAFVVMLLSLPLMIVVSRFEMKK-LLSTVIFVFVGFQLLSAVSTSYYMLMLSRIGVACAHAIFWSIVSPLAVRTVPEKYKSLA--LSMIVTGTSVAMIFGLPIGRIIGLHIGWRMTFLCIGIFAFVLMIYLMLMLP--KVPSRGTFSLQKLPFLFRKSILLDFFIISFAIATSYYTGYSYIEPFLKQVAGLQDNWITVTLVIFGAMGILGSLAFSRFYNKNPYKFTDFVLLGIFGCLMLLQAAACCCLTIILLCALWGMVFTASNVVLQAETINNSpeATSVSMSIFSGIFNLGIACGTYIGGQVCTHFSMSDIGYAGAVLAFLTFIYW------
     964 UniRef50_D2YUM8        Inner membrane transport pr...   146     2e-33  1  12.0%  5:387   1:378     ----MTMRSRLPGSIYLLSVGIFLMVCCELQVLG-MTQQLTRDLDISVAKVGYLVSAFAAAMAIGGPILTLLFNKLPP-KTFVIRLYGVFVFGEIMGALTHQYWVLMLSRLITGAVAGAFFGVAISMCQQLTDKTRQLDA--VALVLSGIMLGTIIGLPMAKIISESFAWPMSFYILALLALIFAILSALKLPNIQPEQPRA--MQQEIAALKNAKLWWLYATSFFVISAAYAPFSYIVPMLSDYSSMSQHSITLLLLVYGIAMLVGNQIVAKLATNHAKGVIITGLSLVSAALGVFYLLGHNPYIASAATLAIGFCGVSLNPALVARIMQLPQGQRTFTHTVHSSLITMGIMFGSFIAALGLdgFSVVSPLLVGLGFAFVAMLIVL-----
     965 UniRef50_D2TK31        Major Facilitator Superfami...   145     3e-33  1  12.4%  5:390   1:410     ----MNMMKNKSTKILALFCALSFLMYVDRVNLSASAALIKEEIGLDNTELGIVFSAFAYTYLVFQIIGGWFCDRFGAKRTIIICGS-IWVVATICTGFVGGFASLFFSRLLLGIGEGAALPSQARAISFWFKKEKRG--FVQGLTHSFSRFGNAVTPSLVALLVLAHSWRFSFIALGVLTAIWLLMWIAWFRDTPhpDVSEKVKEPTPWGALLKRMGPTMGVYFCYGWTGWLFFTWLPTFFMSGRGMDIKSSALFTSGVFLSGVVGNTVGGVLSDYiaRRNVIIFSFLSALLLLIPVILSSSMTVITLCLAVAFFCLELTIGPIWAVPMDITPKHVGIASGLMNAGSAVAGIISPILFGVIIDRTgwSLPFYGSVVLLMVGIILTFFMR--
     966 UniRef50_D1VYV7        Transporter, major facilita...   145     4e-33  1  11.3%  1:390   1:383     MIHQNKTTEIFPWILIILMSSVTFVGILSELLPSGVLQQIMEDLNINEVEGGRLIGLYALSSAIFCIPLISLSMQFNRKK-VLLFLLIGFAVCNTFSGLVHNYYLILALRFLGGISAGVMWPMISAFGLRLVPSCYQGRA--VAVIMAGNTLGISLGMPLMTFIGNRFGWRIEFIVLGLLVVLIAVLSILMLPSTPGEKLTSTT--SPFVMLKNKSIVLIILLTFLGVCAHYGVYTYITQLVVEVGIKGGVEMALF--IFGIGSLISVVVVTKYIDKYLRELSVLTFSLLGIVMLLFFFFRGVNVITQLGFFLWGLLYGPLVTLFQAAVGNQVEHAKDVAMSVQSCMFNLSIMITTWIAGLLLIHFGTCSLLWYATLLVIPGIIISIFAR--
     967 UniRef50_A0B668        Drug resistance transporter...   144     4e-33  1  14.2% 12:385  27:400     -----------KGLIVLISLLSAFVPLSTDLYLPALPG-MADYFCVSSDLANLTLTMFFLSFGAGTLLWGPLSDRYG-RRPMLLIGLSLYSIASLACAFSTDIHLLIAFRALEGIGGSSGFAVATAMIKDVYDV--RSREPILAVVQTMVLISPVSAPVIGAILLKFTTWRGLFEALAFIGLLALAGSIA-LQETLERRCSGSLLHSLGrvARNPAFASLLLLFSLPSICALAFIASSSYIYIRGFGLSELEYSYFFAFNAIGMISSPTIYLKLSRRMCRRSFVTMCFGVMILslILILGTWSPWIFAVALLPSTIAAGAVRTPGTNLMLEQQREDTGSAAALMSCFGIIAGSIGMTLISMTRENMIPALGMMYMLIGTICAILW-------
     968 UniRef50_C8Q1P0        Major facilitator superfami...   144     5e-33  1  13.3%  1:391   1:420     MPSHQVVGKQRWFVAFVLLIGGFINYLDRASLAVAAPSMMS-DLHLTNTDIGLMGSVFSLFFAFSQFPAGWLADRFGPRK-VYASAASLWGVSTMITGLCSTLPALLCARALLGMTEAPGWPTSAKITSIWFPRKER--ALASSIWDASSRWGLAFAPPLLVLMSVHFGWGALFYLAGSLGVIFGLIFFCIYRHPEQHQgpSGKRVKWRELFRYQSMWGMMLGWFCYIWLFNIFVTFLPLYLMKTQHLSLSSMGVYASIPYLAGIVGAALGGYAVKWlaKKVVIMVAALISGATTIAVPFCDSLIGALSMMTVAMFFLSTVSCTCWAIPGDVAsdIVGSVCGIQNFGGFFAGALSPLVTGYIADVTgyALAFISGGVIAALTGLCYWLLVR-
     969 UniRef50_Q20Y82        Major facilitator superfami...   143     1e-32  1  11.9%  3:390   9:420     --ARPIPSARWWRIIPPAILVYIFSFMDRTNIGFAMAGGMNESLQMTASMSGLAAGIFFIGYVMLQAPAGHWAEHRSA-KNFIGWSILVWGGLSILCGFVQNSTQLLIIRFLIGVAEGGVWPAMLVILSHWFPNEERGRA--NAYFIMNIAIASIITGPLSGWIISSFGWRWVFIGEGVLSLLLILVWFPLISDSPATAkkDRAPISYGAVMRDPNMWKLILLYLFYQMGIYGFAMWLPTLLKELTNTGMTGIGFLSMFPYIAMIFGLYGFAQLSDRSGNRrtALPILGFAICFLLSTLLKDHIWVSFGFLVACGLFMQSASSIFWTIPPLLFpeVAGGVRGIINALGNLGGFVGPFAVGWLRTSfsYDVGVYFLVGMLVIGFFIALSLP--
     970 UniRef50_B2H6N7        Transporter, major facilita...   142     2e-32  1  14.1%  8:390  13:403     -------EKRKYLVLGSLFVAWIMSYTDRVAFTVAI-IPISREFGLTTPQAGYLLSAFYAGYAVMQLGGGSLSDRFGGR-VVLIGCVLAWSLFTSLTGGAWSLSSLLVLRFMFGMGEGGFSPASSVTIADNFKREERGRAKAF--LLSTDYLGSAIGSGVIALFIVTYGWHTSYQYLGVVGALVAALLFWCLPpsVAHDARAPARPTLLSLMKLPAVLKIFSIWFFTRMLWIGVVSWMPSYLIKSRGISLGELGFATILPYCLAFIFANIVGYGLDKLleKVLMTTGTLLAALSLFLCINSQSLAMTVVYWAGCMLAFNLVYVSLFSIPIKYFQEaaGRVTGIMNFGGQLSGTIAPTLIGyaADKNSYVPAFLFLSVCGVVAAAIAMTWK--
     971 UniRef50_B2JWX0        Major facilitator superfami...   142     2e-32  1  15.6%  7:390   5:408     ------LPKATTMVLATLCLMYFITYVDRVNISTAAGQF-KSELGLTNTQLGLIFSAFAYPYVMFQFIGGWVSDRFGARRT-LIACATVWAAATALTGFAGGFLSLIAARLLLGLGEGATFPASTSAMAAWVTKDKRGMAQ--GITHSCARLGNAIAPMLVLALMTAFKWRFSFYLLGALSAGWLMLWYFTYTERppPPKVRLADAPGTWMRLYRRMAPVSAVYFCYNWILWLMLDWMPLYFMHSFHLNIKKAVVFTSGVFIAGVVGDLAGGLVSDRLLRKslVACCMALTGLSLIPVVLLHDPMYSLIFLAAAMFFNEMNIGPMWAIPMDIAYDRAGTASGIMSGNGFVAAIASPVVAGYVVDRLgwNVTFMLSIGVMVCGIALSFVMK--
     972 UniRef50_D1R7Z6        Putative uncharacterized pr...   141     3e-32  1  14.6%  5:381   1:389     ----MLEVRKKVPSFLLLTLLLGFPQISETIYTPSLPD-IAHSLQTTEHLVELTLSVFFIGFAMGVFLWGILADFLGRRTSIL-CGLGVYLIGTLLCSLAPSIYYLLAFRWIQALGSSVGSVVTQTMIRDTYEGKERN--QLFSALGAPLAISPAIGPFLGGYIDQLFGWNANFYALLVLGICILLYAWKALPETRPMHCRVQGWSVMTLVAkdCKIWGYVLLIGGSNGILFSYYAEAPFLFIDLLKLTPGQYGLMGIAVATPFFLASFVSHHLNKQWQGEGIIFLGCAIVFVGSCSLAfgTAFMALILPLLFLFFGIGLVISNSLSLALVDYQEARGIAGSLLGLFYYFVIAALTAIMGLIHTGTPYPLPCYFIVMSLLL-----------
     973 UniRef50_Q5LHE8        Putative efflux transporter...   141     4e-32  1  11.4%  4:379   1:377     ---MTDRQNSRRFLLLFLGVLSAFGPFIMDMYLPTLPA-MADFFHTSSSMVQLGLTTSMIGLAAGQLIFGPLSDKYGRRPPL-LLAMILFLLATVGCIFSHTISQFVTSRFLQGIAGAGGVVISRSIATDEYSGQQL--AGMLAVIGGINGIATVIAPIGGGILAQITSWQGIFICLFFMGVVLLSGSLHLNESLPAKHRQTVSWqsFGEVLHNRRYVGYVLQYGFTMGILFVNISSAPFIMQQHYGLSPLSFSLCFGINAIAMVISSAISIKLP---TMERALYIglSVSALLMVFLSLRCDFWIYELLIFALLSMIGMTFTASNTLAMECERRNAGIASALLGATGFAFGGIVSPLVSLGDMMTSTGILFLAGSACA-------------
     974 UniRef50_C6CDT6        Major facilitator superfami...   140     6e-32  1  12.3% 10:390   7:415     ---------NRRWGIVVLLIIDYFVMFVARSGMSMCGPALMQEYGWSATQFGWVSTAFFIGYAITMLPAGMLADRFGG-GIVLMTGTLWWAIFTFLTPLGTTLGTMMALRILVGIGQGLLVPANFSLLSNWVTRNESGKGT--GLLQIGCPAGIAAAMVIAAWIIQTWGWQHVFYLLAAPGLVWCLLWWRmqKPDAHAADDEAHPITRRDILSTPSVWCCSLCYFCTNYLFFLFMTWLPTYFAMGRGINLKQSAILSMLPYLVAILAYPLGgrLGQSAGRKLTPMVGLLLAGIFLILGTRANSLWNAAALISASNFFLCFTMGAHFSIPMVFSRRNTGMLVGLNGVFGTTAGILAPVFSGLIIDLTgyEYALYLGATLAIIGALFMWMAR--
     975 UniRef50_UPI0001B4F4CA Major Facilitator Superfami...   140     6e-32  1  14.4% 11:392  35:453     ----------RWLMAFLCFLGMTVNYVDRATISISLP-YMTDDLHIGPEWQGVILSMFFVTYALGQLPAGAMIDRYGEKKMFAIGGL-IWSLVTVATGFVRGIGSLLIARLALGAGEAPAYPSCAKSVSRWFPV--RERALANSVWDNGARAGTAVAAPVVTALIAWQGWRMAFWVTGGVALLWVALWLKAYREPSAaaAPEGPAVRWRDLFRYRTVWGMMIGFFCLNYVIYFFITWFPSYLVDARGFDLLKLGFYGALPGLVAIGGSLLGGWTSDTLLrrKTCLVCGMLFSSVIAFAVLVPSAMWALTLLSVSYASLAFSAASVASLPADVAPTPRHVAsgIQNFASNLAGVLGSTTTGLLLGFFnvAPLMLSGALCVVGALTYGLVIKRV
     976 UniRef50_C5RB83        MFS family major facilitato...   140     8e-32  1  15.0% 16:389  11:382     ---------------FVLILISLILGFSEFIIIGIL-DDLSKEFSVSVATTGYLVTIFALVYAISTPIIT--STLRSNLYHAMLVLALVFTFGNALTIIAPNYTVLVISRIIVAIVSGALVSLSMTFATVIAPMAKR--AWLVSWIFSGFSVASVFGVPLGTWISTTFGWRFTFITITLLSIITVLLIIKTLPHNLMQKKQGHILQQFV-IFKDARIYLSVFIQTCSLAGVYVFYTYLRPIFSKTLSFDAGLITILLTIFGVMSLISNQASGRIADNKGLRLMPVLYLIEFIVLITMPMLLGNVWSGTIDIMLVGVLMYLVNSPLQLHIMGVapHSLVLASSINSIFSNLGISLGSAAGGLVVSNFGLNNVGIGGAIFTAFALISTIML---
     977 UniRef50_C7TLV6        Transporter, major facilita...   140     8e-32  1  13.8%  4:386   1:389     ---MQEAESYRKKILVSSMLGLGLEGMDILLLSFALSSII-NEFHISSAAGGVLPSVTNIGMLVGGVIFGYWADKKGRIK-IFTYTIFIFAIATLLMAFARSIGEIYILRFVVGLGAGGEYGIGMALVAEAFPKERRG--QMSSWITVGGQMGTLIAALIAATVIPLAGWRAAFIF-GVIPVFLAYFVRRHLPEthKSGAEKSDHPRISLLFNQPKivGLTIMSAIQVAGYYGLMNWLPSLLEKQQGLSVSGSSLWMISTIIGMSLGMLSFGKLFDKFGSRLTYSVFLIMSGMSVTLYAFVHSAFLMLIIGAIVGFFANGMNAGYGALISSFYpeIRSLANNAIFNTGRAIGGLSPILIGYIIDEKGFSVALLVLGSFYLISLVIV------
     978 UniRef50_A7G927        Major facilitator family pr...   140     1e-31  1  12.6%  6:385  20:398     -----AKPILTNLLILVMSIACGLTVANLYYIQPLLAD-IAKTFHVSQLSIGFAAMLTQIGYAIGMIFILPLGDIKEKRK-LIVIMLLCSIISLMSMFFASNIYILTISSFAVGF-TSIIPQLIITLAAQLSTPQQRGQT--IGTIMSGLLIGILLSRTIGGILGGYFGWRAVYLIAAIMMLTLMLILRKLIpePISDIKYTQLLKSMIHLIKTEQILraSINGALMFSAFSAFWTSLIFLLESSYYNIGAEAAGLFGLVGIIGALAAPIVGKLADKKGSRFAIDICIIVVIIAYLFFFLFGfiWGLILGIILLDLGVQSCNVSNQARVHFLNEETRNRLNTVYMVSFFLGGALGSFLGSYSYSHFGWYGVCTFGMATQIIAIIL-------
     979 UniRef50_A1S6I3        Drug resistance transporter...   140     1e-31  1  12.6%  1:389   1:385     MISNSLTKRRSLVFFPYLALLSMLGFLATDMYLPAF-NQIESSLNTSASLVAMTLTCFLGGLAIGQLAYGSLCDKFGKRNTLM-AGLGVFAVSSILLGFTENISVFFVLRVIQAFGACSAAVIWQALVMEKFDEGEARK--VFSSIMPLVALSPALAPLMGAWVSEQFGWRAIFIILAIVGLLLAAMTPALAKESRTRSQSEPIL--VKNILKNRAFQNNVAIFGACSAAFFCYLTLWPAVM-QHHGYAAAEIGLSFIPQTLAFMLGGFACKKALHSHSPEalITGFVVLSLVLFLLTQLGAGILAVLWVFAALAAINGAVYPLLVTDALAPFSNNATKAAGWQNFLQLGMAFIASAAVALIAHWF-EKAIGTGILVCAAIVLVAWWRM---
     980 UniRef50_C8WSL6        Major facilitator superfami...   139     2e-31  1  15.4%  8:389   3:421     -------TRFRWVIIGLLFFITVVNYIDRSAISYAIGD-IAQVLHLNDSQVGMILGAFGIGYMITTFFGGIWVDHVGARWALFFASL-LWSLSIGLTGVAASFTVIYLMRILLGVAEGPNFPAVNRAVGDWLSPRERAIALSNSLV--AVPLALAIGAPIVTSLILGVGWRGMFIILGIVGLLWVPVWFFLFRDFprQAHHVSSGTLWKYLLVNRTLMANNWSFFVFGYYLFFFMTWLPSYLKSEYHLNLKSVGAFSILPWALATVLLWLVGYLSDWILRRtpIWISQLLSALCVVPLTFTHDLTTAIVFITLAVGFGMSANSTFYAMNVDLMRERTGTALGLMDTFFAAAGFLAPVITGWIVNATgfKSAFWLMAVLSATSVLAVLIF---
     981 UniRef50_Q397G2        Drug resistance transporter...   139     2e-31  1  14.4%  1:390  53:449     MNATLTPARESNSPRFLLFLICLFAslAIDIYVPALPD-MARSFATTPQAIQSSVSGYMAAYALGQLIFGPVADAYGRKR-VLAFGLVIYTIGCLLSLGAQNLETFVLARCLQGFGIATTNLLAKAIITDSFSGQALMHA--FTYMSIAWGLAPIVAPVIGAHLQEWFGWRACLVFLLVYSLVMWALLWRYRETLPKPVhpRTLMTNAGKVLASPVFQSCFLAQGLCYSILLVFNIVGPFMVQTTLHKPPTFFGYLALGIGLMYFLGGLSNRIHRPGLprLRIGARVMAGASVAMLVLALTVGlwTLATPVLVMGFCAGAMYPTLMAKGNSLFPHIAGLTSAILGCALLLVSSAMMGLAGFVSIHVLTPLAVFFVVLSCIVVWMVTKLLR--
     982 UniRef50_Q2G4Y0        Drug resistance transporter...   139     2e-31  1  16.6%  2:387  11:402     -TSTSARFMGERETIAMMALVMALQALAVDSMLPALGDIARELAVTDPNERQLVVGTFLLASGFASLVPGSLADRYG-RRPVLLSCIGLYILFSLACALATTFDMLLGMRVLQAVGCGGLAVLPGTIIRDRFAGDQ--MAKQMSIISVVFLVVPMLAPSIGQVVLLFAGWRWIFVFLAVMALAMGVWVAVRLPETLHPEYRQPIRPamLGAATNRSAIGYVLGGALTFGAMIGYVNCSQQLVGEHFGAG-KMFPVLFGFSALMMAVANFSNSRIVERFGARRVSHTAVILFICVSALQAWFSslWQFMPLMIANMILIGFIGANFGSIALQPFARTAGTANSMHAFLRMVIGSIIGIVVGQAYDGTAHPLGLALLASGILSLALVLF-----
     983 UniRef50_C8Q2N4        Major facilitator superfami...   138     2e-31  1  12.9%  2:389  10:428     -SSTMKPQGRQRWGVLGLLCLLAIINNIDRLTLSIAAPVMQTEMHITATDIGLLGSAFALAYAFGQLPSGWFVDRFSPR-ILLGTSVIIWSAATVAMGLSYTLTGFILARIWLGLAEAPSLPATNKIVTRWFPKKEQGIA--NASWDAALKVGPAFFTFLLIWIVSEIGWREMYFIAGGAGIIAAVIFFAFYRDIEKHKSLTKEErpWRELFKHQTMWGMMAGFFCNMWVYQIFLVFIPLYIINQFGIKFSSLGLVASIPWIGAIIGDLVSGVISGKLSErvTIIGALVLQAIVLALLPfgAGLTVAVILMAFALGFNGGVVAHAWSIPAEvaPGTVASVAAVQNFGGFLGATVSPLVAGAIVDAtsFTLVFLISAVVSVIGAGIYFWF---
     984 UniRef50_B1ZUY3        Major facilitator superfami...   138     3e-31  1  12.8%  6:389  14:419     -----TPPTRARYWVVVFAITLAVIQYIDRVCISQAAPSVSSALDLSKEQMGWVFSAFTLAYALFEIPTGYWGDRNGPRRVLLRV-VLWWSFFTAATGWVWNWSSLVVTRFLFGAGEAGCFPNLTKAFEAWLPTRERIRAQGIMWMSARW--GGAVTPYLVFLVLSVMNWRLAFLVFGLLGVVWAILFARWFRDNPREHPSVNAAepWRKLITAPSVWCVCGQYFACSYAWYFFITWFPTYLLEVHKfsALLAGLPLLLGGAGCFLAGALVPRFTRRFGHGGLivVGQGGAALCLIAATFFSQPLLAVTAIALASFSNDLSIPCSWTTCMDVGGRYVGTLSGMMNMVGNIGGFLSPIVLGYIVGRTgwNLTFYVTAAVYLLGALCWWLI---
     985 UniRef50_Q31HA1        Major facilitator superfami...   138     3e-31  1  16.5% 18:350  13:354     -----------------LGALVALTPFAVDTYLPAIPE-MATDLSSTVNHVSLTVPLFLIGFALGQLIGGPLSDRYGRKRIALL-GLLIFFVSSLLIMFSIQIEQLYIMRVLQAVGGGFATVVSAAIVRDLYSGKE--SARVFSMIALVMLIAPLVAPGVGAFIVNLSGWHQVFAFLAFYAVLLSFLVKKGLPETVTIERKQKMRSqyRQVITHWQGLGFLIAQGFASSVLFVYITESPFIYMEKFAIDSASFPFYFGIVVLGVMFFNRMNLGLLKRFEPRQIVFYALLAQVILSfiLLATESVYVVLVFQFFILGLLGAITPNVQSCYMDYFPDFSGTANALMGTSIFA------------------------------------------
     986 UniRef50_Q8CN60        Bicyclomycin resistance pro...   138     4e-31  1  12.3%  1:390   1:394     MMMTTSSKHLSKILIVILGVMTAFGPLTIDMYGPSLPK-VQHAFGSSISEIQLTLSFAMIGLAIGQFVFGPLSDVLGRKK-MALILLIGYLIASLLSVFTVHLTIFLIIRLIQGLAGGGAIVIAKASIGDNYDGDEL--AKFLTSLMVINGIITIIAPLLGGLALSIASWRMIFIFLTIITLIVILGILLKMPVGPHQEQSqaIFKDFGLLLTKPTFVIPMLLQGLTYVMLFSYSSAAPFISQKMYHMTPLQYSAMFAINGVGLIVVSQITAIIVEKVSRYAMLIYLTIIQMLGVVILIFTLtlYVLLIGFFINICPVTSIAPLCFSMAMAERTGGSGNASSLLGLFQFILGGLISPLVGLNGQHDMSPYLIIISATAVLLIALQIIYFK--
     987 UniRef50_A4TM16        Sugar transporter n=57 Tax=...   137     5e-31  1  11.7%  7:390   6:413     ------PNARWFRVIVPIMIACIISFMDRVNISFALPGGMESDLAITSQMAGLAGGIFFIGYLFLQVPGGRIAVHGSGRK-FIAYSLAVWAIVSILTGFVTHHYQLLFLRFVLGVSEGGMLPVVLTMVSNWFPEREIGRANAF--VMMFAPIGGMFTAPLSGFIINTLDWRWLFFLEGGLSALVLVMWWFVISDRPEEAkkPVTNAPLKAVFLNKGLMKLVALNFFYQTGDYGYTLWLPTILKNLTGGNMASVGILAVLPFVATTAGIYVISALADKTGKRRLLIMISLFCFAAALVAsfRHNVLVSYLALVVCGFFLKAATSPFWSIPGRIapEVAGGARGGINGLGNLGGFCGPYLVGVMIFFYGQSAAVCMLAGSLIIAGLITLTLP--
     988 UniRef50_A4Y718        Major facilitator superfami...   136     1e-30  1  13.7% 14:385  33:404     -------------LIFMLVFMVACGQMAQTIFVPALPQ-IALSLNVDASQLQAVMACYLIAYGLFQFVYGPLSDRIGRKTPLLI-GIGIFILGAFMAARAQHFNQLIFASLIQGLGTASAGALCRSIPRDHYFGDNL--VKFNSYVSMAVVFLPLIAPFLGSIMTAYFGWQAVYWVLAGFGVFVWLLLLVGFKESLpkREHNPIIASYRHVLRHRGFRAYLSSLIATFAGIAAFEAIAGVLYGQYLGLPPFMVSCYFVAPIPGYLLGALIAGKQTkrTVYQGVALLGTGALFMLIPGIFLLVSTWSLLVGSVLFFSGAGMLFPTLTSAALEPFPRQAGIAGALLGGLQNFGAGLAALSMSVMPMGGQLSIGLLSTMMVILVIASL-------
     989 UniRef50_B9NI90        Predicted protein n=36 Tax=...   135     2e-30  1  15.7% 17:386 249:621     ----------------LLATACGMIVANLYYAQPLVGP-IARALELSPEIAGLIVTLIQIGYCVGLLLLVPLGDIVENRKLVL-ALIAGCAVALVAAALATHASVFLIAGCAIGLCSVAVQVLV-PFAAHLAPEHARGRA--VGNVTSGLLMGIMLARPVSSLVADLFGWHTIFAASAVAMVLLGVVLSRKLPQRQPAPGVneMLGSMGHLLrqPVLRRRAMYQASMFGVFSLFWTTTPLYLAGPAFHMSQTGIAVFALVGVAGAIAAPMAGRYADRGHSRQMTAIALALGAGSFLLsgSLMSLAALTVAAVVLDFAVSANLVIGQRAIFSLSAEHRSRLNGLYMAIFFVGGAIGSSVGAWAYARAGWPLASWIGFALPAIALLYF------
     990 UniRef50_D0J772        Major facilitator superfami...   135     3e-30  1  15.3% 31:389  15:379     ------------------------------LILGFMLSAISKDLNLTPGQAGSLVTWTLIGAVFGGIVFGMLSDKYGRIR-VLTWTIVLFAVFTGLCAFAQGYWDLLIYRTIAGIGLGGEFGIGMALAAEAWPA--RHRARVSSYVALGWQLGVLGAAMLTPLLLPSIGWRGMFLVGVIPAVVAWVivFVARSKKEQPSAMQCLKLLMKDKATRKISLGVIVLTSVQNFGYYGIMIWMPSFLSKQMGFSLTKSSMWTAVTIIGMSLGIWVFGQLADRIGRKPTFLIFQLGSVISVLAYSQLTDATAMLWVGAIMGLCVNGMMGGYGAVISEAYpeARATAQNVLFNIGRAVGGLGPVVIGALAMAYSFQVAIALLAAIYVLDMLATVFL---
     991 UniRef50_C4L8J7        Drug resistance transporter...   135     3e-30  1  15.4%  8:390  30:412     -------RREKWIPVIYACLLIAVGQTGMSLLLPALPA-MQQDLHVSSQMTQWLVSAYLLGFGPSQLFYGPLSDMYGRRPVLLAGLMITFSGILLCLFAHESATLIILGRVLQGIGAGCTSVIARVSLRDRYEGAHLRQAM--AYFGIVMAFVPTITPLAGGYLTTHFSWISIFFTMAGYLGLLWVLLFYRFEETHAPEPAEDRAHayWLLLKSDHFRCYSGVVSIQYALNIFSISVMPFIMQIMVGMSADTYGRWTLLPAVSLVLGGVLASKTRHYFSKESVLQAAAALQLigLSMLLLPHTALLMMLGLSLFAFGNGVAFPNALSSLLEPYKRTAGTATALAGASQMLIASFSS----ALLVSLGITSILGLGMVILLGSSVLLYLTR--
     992 UniRef50_Q1JW92        Drug resistance transporter...   134     5e-30  1  13.1% 18:392  16:386     -----------------LALLAATPPLSTDMYLAALPE-IASSWGVGKDLINLTLVLWFASFSVSILISGSLSDKYG-RKPLLLWGLSLFVVTSFLCAGAGSAQMLILFRIFQGLGAGAPAAIVLAIIRDRFTGKERHQA--IAYVMTIVAVAPMVAPIIGAMLLEFFNWRFIFVMQGVMVSITLLVTFAFKeaDPLNISLKRLMTRYTVHFRNKEFMFASISMGILVLPFYGFIAFSPIYYITIHGLSEKMFSLLFGLNALSSMCGAFSSSFIVKWVSDKTVITVSIYGCVIAGIGLMVLGsfLYFFVFMAFFSFCTGISRPISGNMILGLVKTDVGSASSFLVFYQFISGALCMAFVTLQWSY----PVLVYGSLTTIVSILVLILWARI
     993 UniRef50_B7VRB1        Multidrug resistance protei...   134     7e-30  1  13.2% 13:330   8:327     ------------KSILLACLVISIGQLSMGLVFPSLP-WIAKDFDVSLEQAQLLVSVYLLGFGPSQFIYGPISDALGRKKVLLSGLLIAMLGLLMIIFFSHSFTSMVMGRFLQGLGTGCCAVLARASTRDRFSGADLPLAM--SYIAMVASITPLIAPVIGGFINFHFGWSMVFISLLGYVSLAWVVLAFKFKETVTqpSPKKMVSQYKELLTSRYFMSFASIGWLNFSLMITTVSVMPFIMQNQIGMTSDEYAMWAVIPALGMLGGTSLCNRIRPMLGNKKTLLCTPVLHIFAALWLFFCPLEPllMLGQFLMILGNGIALPCAQALVM--------------------------------------------------------------
     994 UniRef50_C3XB23        Drug resistance transporter...   134     7e-30  1  12.4% 12:391  18:397     -----------KGLIAFLAFLNAFVPLSIDLYLPAMPT-MAEYFSATPELTNFTLSFFMLFFAISMLLWGPFTDKFG-RKPILYIGIVLYILGSLTCVLSQSIYHLIAGRAIQAIGSGAIQAVSMAIVKDNFKGLVMERVLV--WIQTLTILCPMLAPIIGAFLLEFISWRGLFVVLILCGILGLILC-FFLKETLTNATEGSALRSLTrvLKNKGILILLFTFSLIIMPVMSFLSTSSFIYMDLFKLSAQEYSYFFALNGCFAMLAPILYLRVLRKIPRVLFLTICFASVAaaMILIFGTLSPYAFAFLYIPVTFFGSASRPAGTMLIMNQIDTDNGTVGSLWGCIALLFGSLSMMLCSLDWPNLTMAVGTISLVSGSLCALLWLFAWSR-
     995 UniRef50_C0WM86        MFS family major facilitato...   133     9e-30  1  10.6% 15:390  16:392     --------------IIFLALLSAFVPLSTDLYLPALPT-MTTFFNVSEITMNLTLILFFVFYSVATLIWGPLSDRYG-RRPILLIGLTIYMLAGILCGVATSAFEIILFRVLQAIGGGVATTIATAVIKDVYTG--RKQETTLAIVQSMVVISPALAPVLGSLLLTFISWRGIFFTQALLGLIVVLGAVIFQETHDTSKESISVLHSLGrlMKNPPFSAMLINFSAVSIISLSFISSSSYIFQVHFGLSSQAFSYFFAFNAIGMLVGPLLYIRLSKYIDRMVILYAclGIIGGILILGFGLNNPYLFAITELPATLASSASRPPATYLILKQQENDNGSASSLYSAGGTIMGSIGMVVVSFANHWPVLIIAIIDIVINVLCAIGLYVTLR--
     996 UniRef50_A3YHL5        Drug resistance transporter...   133     1e-29  1  15.4% 26:388  30:397     -------------------------PLAADAYLPALSL-MSDYFETSDSMLKFSVTAYFIGFALAQIVFGPLSDAKGRRK-VILLGLLIGILGALICFVSQSIWQFLIGRCILGIGMASGIPVARAVLKDLFNGVELSKAA--SSINMVLALMPLIAPLFGAYLASYYQWQQIFQLVFALSLVVLVLTYYLLPETNPKIDpkPLLQTFIRVLKDRAVFTYSMTTLCAFGCAVAYMVSAPFVFLDVFGFSMIEFGWLAGLITLSYILGGFLNNYLLKKLSPDHIIFAALIGLLVTGliILFGPNLIIITLNVFLLTLSSRMVFPNALAGAFSSPIKEVGVISSVYGIYHTLGAIIASGIMSLL-NINPISAMASTMIGFACFGIGVFYL----
     997 UniRef50_B3PEY1        Bicyclomycin resistance pro...   132     2e-29  1  11.8% 15:387  23:401     --------------IVLIALLMSVVAISIDALLPALGFIANDIPLAHPNQAQYLISILFLGMAIGQLVCGPLSDATGRKK-ILYAGIVLILLGSLICFMAQDINTLLLGRFIQGLGVAGPYVSAISIVRDKYTGNE--MARIMSLVMLIFILVPAIAPSLGQAVLLVSSWRYIFVLYIVYALIIGVWIFLRLEETLPRDYrrGFVDGFKEVISNYTTMCYTLCMGLFFGSFLGYLNSSQQIFQELFN-TGQLFTLYFGILALVFGASSLVNARFVQKWGMDYlaVLGIVLSSALFLALQLvpNLWAFLVYAAVLFFCFGLVFGNVNAMAMEPMGHVAGIAAAIIGAFSSIMSMTIGTVIGQLYNGTLMPITCGFLILGMMAYGILLL-----
     998 UniRef50_D2TP69        Major Facilitator Superfami...   132     2e-29  1  12.3%  7:389   1:414     ------MAKNIRWIIVLLLFLVYMINYLDRVALSITVPMIEKDLMLNAEQFGMIFGSFFFGYAIFNFIGGLAVDRFGA-TLVLGVAVGLWSLFCGLTAFATGFYSMLILRVLFGMAEGPICSSANKMINGWFPKKQ--AATAVGFLSAGSPLGGAVAGPIVGYLALALGWRPAFLIIFTIGIVWMIVWFFIAANSPEKHKrnETAHSLGYYLKQPIILVTAFAFFCYNYILFFFLSWFPSYLVQQHHLDIKSMSLTTMIPWIVGFVGLALGGYISDKisRKIVLVVCLMMAAICVGLAGTVSSVVPAVILMSVSIFFLYVTGAIYWAIIQDVVHKSrgGTSGFIHLIGSISGIVGPIVTGYIVQSTgfDSAFILAGSVAALGALLVLFV---
     999 UniRef50_A8EWW6        Major facilitator superfami...   132     2e-29  1  10.9%  5:390   1:388     ----MKKRLINFKFILTIALIEVLCYMAVDMYLASMPN-IASYFGTSYSKVQLTLTFYLFSMGIGQLFFGPIIDYFGRKIPLIL-GVLLYSLCSILITLSTNIELFLLFRIIQGLSVALIYVCIISMVRDVS--KGRVAANIFAILITIGAITPILAPTFGGYIEQEFGWKTVFYTLFSLAILLSIMSFFTLQETLKEEKkkNIFIIYFKIIKDRKFLTPAITACLMYMFVFAYIAGASFAYQEIYKLDSKTFGLIFGLTGSALLFGALLSTKLLKVFNMKQLSISGAFILVIGSIISFFSANItgIVAGFFISFFGLGLCEASLFSMAMSSQEKSVGATAALLGSLQLLLPASATLVAGYLVEI----SIIYWLGIILFLGILSFLFTY--
    1000 UniRef50_B8FQK7        Major facilitator superfami...   132     2e-29  1  14.8% 25:390  33:428     ------------------------DGYDMGIYGVTLPS-VMKELNLNATQTGLLASAGMFGMMFGALLFGMLSDVIGRKKTIII-GIFVYSVFNGIVAFIHSASIFAVVRFIAGMGMGALTPVVISLLSEYTPRSRRT--LLLTMVMVGIPLGQLVASLAGVAFLESIGWR-VLYLATLIALIMIAFVVWNVPESMKFYVPRGETKTIKKVLAkkNTIYIWIAFFCNLYLFFGISTWLPK-LMTMLGYPLKSSVMFLAIFLLGGVLTTPFVGMLGDKYGYKKVMPVLYAMSAVLVSLLSFQMSTFIFYTLLFLAGCAVTLVQSMTLAAAPDFYpaFRGTAMGWGSAVSRLGSAVAPTVVGVLLTalPVRGVFLTFIIPAVIACIAILLTK--
         consensus/100%                                                                                     ........................................................................................................................................................................................................................................................................................................................................................................................................
         consensus/90%                                                                                       ................h....hh..hs..h..shhs..h.t.hths...hthhhshh.h..hh....hs.h.sth..+h.hhh..hhhh.h..hh.hhs.sh..hhhhRhh.uh..s...s...shh.p.h..t........uhh.....hu.hhu..hu.hh...hsht..ahh.shh.hh.hhhhhhhh..................hh....hh...hh.hh..h....h.sh.s.hh.t...h....hshhh.h..hh.hh......hh.tth....hhh..hhh.hh.hhhh.h......hhh.hhhhhh...h..s....hh.t...t..s.h.uh......hh..hss.hhu.h.............................
         consensus/80%                                                                                         ...........hhhhhhh.hh..hs..hhhshhs..htp.hths...hshhhshhhhshhhht.hhu.hs-phs.++.hhhh.hhhhhhs.hhhshs.sh..hhhhRhh.uhs.uhh.shs.shhtphh..tt...s...uhh.hs.shu.hhus.lushlht.hshph.Fhhhshhshhhhhhhhhhh.p....t..t..h.thhthhtp..hhhhhhhhhhh.hshhshhshhs.hh.p.hths...hshhhhh.shshhhst.h.shh.pphs..hhhhhshhhhhhhhhhh.hh.t.hhhhhhhhhhhhh.hhh.s.h.shh.t..st.tu.s.uh...h..hu.hhushhhuhhht.hsh...hhhhhhhhhh.hhh......
         consensus/70%                                                                                           .......h.hhhlhhhshhh.hsh.hhhshls..htpthshs.s.huhhhssahhshslht.hhG.luD+hu.++.llhhshhhhslsshhhuhussh.hlhhhRhltGhstushhshshshhschhs.pphttu..huhhhhshslu.hlushlGshlhthhuaphhFhhhuhhshlhhhhhhhhl.p....ttttt.htthhthhpp.thhhhhhhhhhhhhshhshhshhshhh.p.hths.tthuhhhhhhulshhhsthhsuthsc+hs.tthhhhuhhhhhhhhhhhhhstshhhhhhhhhlhshshshh.sshtshhhphsspttuhs.uhhthhh.huhhhushlsGhhhthhsh.hhhhhsshhhhhshhhhhh...

MView 1.51.1, Copyright © 1997-2009 Nigel P. Brown